data_1b4r_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1b4r _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.663 ' HA ' ' CB ' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.393 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -81.49 144.66 31.19 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.214 -0.929 . . . . 0.0 108.95 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.686 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.8 mp -94.27 86.7 5.0 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.215 -178.164 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.561 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 32.9 t -94.88 102.39 13.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 120.873 -1.142 . . . . 0.0 108.386 178.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.506 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.95 76.72 0.28 Allowed Glycine 0 N--CA 1.488 2.113 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.038 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.52 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 31.4 Cg_endo -71.73 146.85 49.48 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.438 2.092 . . . . 0.0 111.401 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 174.51 164.17 0.22 Allowed 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 -179.664 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -89.29 -125.91 2.77 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 107.363 -2.295 . . . . 0.0 107.363 178.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -80.06 147.06 18.52 Favored 'Trans proline' 0 C--N 1.302 -1.875 0 C-N-CA 121.839 1.693 . . . . 0.0 108.293 177.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.549 ' HB3' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -114.15 80.13 1.35 Allowed 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.922 -1.111 . . . . 0.0 109.158 -179.633 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -91.61 172.29 8.6 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.2 t -59.39 117.85 5.31 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.2 -0.938 . . . . 0.0 109.325 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.81 46.71 3.09 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . 0.429 ' HB3' HD12 ' A' ' 17' ' ' LEU . 0.0 OUTLIER -122.27 152.27 40.22 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.386 -1.067 . . . . 0.0 110.559 -179.627 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.429 HD12 ' O ' ' A' ' 23' ' ' ALA . 2.0 tm? -109.99 94.58 5.09 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.739 -0.6 . . . . 0.0 109.65 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.429 ' O ' HD12 ' A' ' 22' ' ' LEU . . . -75.66 158.9 31.76 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.52 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -124.71 117.81 25.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.463 -1.398 . . . . 0.0 108.573 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.769 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.8 m-85 -105.55 170.96 7.59 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 122.085 0.945 . . . . 0.0 111.828 -177.318 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.561 ' CE1' ' CG1' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.8 138.98 3.51 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 178.105 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.678 HD13 ' HG ' ' A' ' 79' ' ' LEU . 0.3 OUTLIER -105.32 152.52 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.085 -1.009 . . . . 0.0 109.47 -178.276 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -134.66 116.83 15.4 Favored 'General case' 0 N--CA 1.5 2.046 0 C-N-CA 118.823 -1.151 . . . . 0.0 111.644 -179.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.688 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 176.56 -62.26 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.915 0 O-C-N 121.076 -1.015 . . . . 0.0 109.952 178.173 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.688 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.4 Cg_endo -80.11 63.55 8.76 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.32 2.013 . . . . 0.0 109.711 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.629 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -13.13 -64.58 0.02 OUTLIER Pre-proline 0 N--CA 1.504 2.266 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 -178.902 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.629 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.2 Cg_endo -77.69 72.5 6.05 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 121.724 1.616 . . . . 0.0 111.282 -179.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.483 ' CG2' ' O ' ' A' ' 30' ' ' PRO . 2.7 t -98.77 127.26 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.996 -1.065 . . . . 0.0 109.341 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 p -111.21 -14.87 13.77 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.417 -0.802 . . . . 0.0 109.219 178.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -163.46 148.34 11.02 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.224 -0.922 . . . . 0.0 109.824 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.418 ' CG2' ' HB2' ' A' ' 49' ' ' ALA . 1.4 t -140.38 162.66 34.78 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.43 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.545 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -127.31 100.5 6.08 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.101 -0.999 . . . . 0.0 109.217 179.586 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.769 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 36.4 m95 -87.59 179.02 6.61 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.218 -0.926 . . . . 0.0 109.453 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.461 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.3 OUTLIER -146.84 103.14 3.6 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.862 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.63 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 3.5 m-30 -81.16 -59.1 2.77 Favored 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.314 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.28 8.48 68.44 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.497 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 10.4 p30 -98.49 35.7 1.76 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.372 -1.075 . . . . 0.0 108.111 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 108.33 -38.35 3.37 Favored Glycine 0 N--CA 1.483 1.785 0 N-CA-C 105.356 -3.098 . . . . 0.0 105.356 -175.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 74.6 m -101.86 95.06 6.14 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.2 -90.7 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -0.919 . . . . 0.0 110.151 -178.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.4 ' C ' HG21 ' A' ' 47' ' ' VAL . 72.9 mm-40 -55.9 146.81 20.97 Favored 'General case' 0 N--CA 1.493 1.688 0 CA-C-O 121.251 0.548 . . . . 0.0 109.758 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.616 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 63.8 t -135.01 106.36 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.377 -0.827 . . . . 0.0 110.972 -178.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.8 94.12 9.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.988 -1.07 . . . . 0.0 108.211 178.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.421 ' CB ' ' HB1' ' A' ' 54' ' ' ALA . . . -101.65 166.6 10.6 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.258 -0.901 . . . . 0.0 110.801 -178.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.61 150.09 21.53 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.725 -0.61 . . . . 0.0 109.595 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 44.14 -153.26 0.41 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.461 ' HD3' ' HB ' ' A' ' 33' ' ' VAL . 38.8 Cg_endo -88.43 40.09 0.54 Allowed 'Trans proline' 0 C--N 1.301 -1.943 0 C-N-CA 122.372 2.048 . . . . 0.0 110.282 178.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.533 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -143.38 154.39 43.68 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.135 -1.603 . . . . 0.0 112.011 -178.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.45 ' HB1' ' NE1' ' A' ' 38' ' ' TRP . . . -165.88 -168.86 1.37 Allowed 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.362 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.473 ' HB3' ' HA ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -157.32 146.59 20.08 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.133 -0.979 . . . . 0.0 109.131 179.236 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.63 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 7.5 m80 -100.08 133.76 44.0 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.352 -0.843 . . . . 0.0 110.915 -178.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -107.5 88.63 2.78 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.418 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.659 ' CE2' HG12 ' A' ' 83' ' ' VAL . 13.8 m-85 -88.71 135.14 33.66 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.389 -0.819 . . . . 0.0 109.294 -178.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.9 p -127.96 -12.93 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.235 -0.916 . . . . 0.0 111.314 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.405 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -110.23 144.63 30.49 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 120.527 -1.358 . . . . 0.0 109.584 -179.767 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.405 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.0 Cg_endo -77.78 115.54 3.85 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.408 2.072 . . . . 0.0 109.868 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 163.97 -142.76 8.04 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.69 159.74 22.46 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.221 -1.164 . . . . 0.0 109.215 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.526 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 57.9 m-85 -140.68 160.85 39.14 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.413 -0.805 . . . . 0.0 109.297 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 49.2 t60 -122.0 142.09 50.68 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.496 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 21.7 t -125.17 149.6 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.862 -1.148 . . . . 0.0 110.991 -178.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.415 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -150.28 160.65 43.55 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 107.448 -1.315 . . . . 0.0 107.448 178.129 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.713 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -151.79 153.66 34.7 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.843 -1.16 . . . . 0.0 111.292 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 37' ' ' ARG . 0.8 OUTLIER -126.0 121.99 60.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.58 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.623 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.6 OUTLIER -88.36 141.54 28.46 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 120.596 -1.315 . . . . 0.0 109.103 -178.406 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.66 109.12 10.4 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 118.679 -1.209 . . . . 0.0 109.694 178.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.504 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -104.07 -11.03 17.59 Favored 'General case' 0 C--N 1.288 -2.069 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.73 -49.46 0.84 Allowed Glycine 0 N--CA 1.487 2.074 0 N-CA-C 107.729 -2.148 . . . . 0.0 107.729 -178.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -118.41 -5.56 10.8 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.678 -0.895 . . . . 0.0 109.877 179.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.55 164.09 26.04 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.447 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 6.8 p -151.18 -177.23 5.92 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.344 -1.092 . . . . 0.0 109.684 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.571 ' HB1' ' HG ' ' A' ' 70' ' ' LEU . . . -153.17 154.81 35.5 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 179.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -112.94 124.79 53.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.141 -0.974 . . . . 0.0 109.938 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.713 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -114.53 155.24 26.81 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.416 -0.802 . . . . 0.0 110.032 -179.643 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.452 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -164.66 91.59 0.11 Allowed Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.271 -1.531 . . . . 0.0 109.271 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.452 HG21 HD22 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -106.88 175.84 5.37 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.127 -1.219 . . . . 0.0 109.895 -179.683 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -122.12 160.34 25.28 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.378 -0.826 . . . . 0.0 108.99 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.659 HG12 ' CE2' ' A' ' 58' ' ' TYR . 25.9 t -144.17 147.51 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.011 -1.055 . . . . 0.0 110.448 -179.022 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.6 ' N ' HG11 ' A' ' 83' ' ' VAL . 0.8 OUTLIER -137.14 98.98 3.87 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.385 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.549 HG21 ' HB3' ' A' ' 17' ' ' LEU . 29.1 t -96.93 139.83 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.111 -0.993 . . . . 0.0 110.658 -179.004 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 23.6 mm-40 -110.59 -159.41 0.68 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.512 -0.743 . . . . 0.0 109.62 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.123 -0.986 . . . . 0.0 109.243 179.811 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.645 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.549 HG22 HG21 ' A' ' 11' ' ' VAL . 1.3 t -70.62 149.44 47.05 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.196 -0.94 . . . . 0.0 109.336 -179.203 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.718 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 4.9 mp -84.62 108.18 17.22 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.088 -178.359 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.549 HG21 HG22 ' A' ' 9' ' ' THR . 0.7 OUTLIER -123.53 104.28 14.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 120.777 -1.202 . . . . 0.0 108.912 178.708 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.55 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.85 76.52 0.3 Allowed Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.508 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.6 Cg_endo -73.26 150.43 47.28 Favored 'Trans proline' 0 C--N 1.308 -1.567 0 C-N-CA 122.728 2.285 . . . . 0.0 111.918 179.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.518 ' CD2' ' HA ' ' A' ' 23' ' ' ALA . 32.6 t-80 161.94 -36.82 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.796 0 CA-C-O 121.782 0.801 . . . . 0.0 108.944 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.97 -138.04 14.52 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 107.942 -2.063 . . . . 0.0 107.942 -178.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -77.74 147.83 25.03 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 122.027 1.818 . . . . 0.0 109.313 178.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.567 HD23 ' HB3' ' A' ' 23' ' ' ALA . 0.6 OUTLIER -110.59 115.73 30.12 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.251 -0.906 . . . . 0.0 109.486 -179.441 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -106.24 160.01 15.67 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 45.7 t -56.3 119.34 5.82 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.316 -0.865 . . . . 0.0 109.471 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.42 46.92 3.92 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 7.5 mm100 -127.4 153.52 46.15 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.145 -1.209 . . . . 0.0 110.543 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.448 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 1.8 tm? -108.81 92.31 4.0 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.567 ' HB3' HD23 ' A' ' 17' ' ' LEU . . . -71.21 156.33 39.68 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 178.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.508 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -122.74 112.49 17.99 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.26 -1.525 . . . . 0.0 108.341 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.764 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.6 m-85 -100.64 173.84 6.35 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 122.512 1.148 . . . . 0.0 112.415 -177.19 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.54 ' HA ' ' HA ' ' A' ' 53' ' ' ALA . 5.9 p80 -172.47 147.61 1.91 Allowed 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.19 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.724 HD13 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.82 156.88 12.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.961 -1.087 . . . . 0.0 108.198 -178.484 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -132.66 122.34 24.52 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.442 -1.303 . . . . 0.0 112.702 -177.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.716 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 172.8 -70.06 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.797 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.716 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.1 Cg_endo -77.62 77.76 3.76 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 121.592 1.528 . . . . 0.0 108.718 178.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.557 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.3 OUTLIER -35.16 -55.57 1.01 Allowed Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.817 -0.552 . . . . 0.0 111.284 -178.795 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.557 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.8 Cg_endo -80.62 81.29 2.78 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.141 1.894 . . . . 0.0 111.236 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.537 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 40.1 t -111.89 150.3 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 120.908 -1.12 . . . . 0.0 109.0 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 18.5 p -116.91 -28.92 6.16 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.203 -0.936 . . . . 0.0 110.593 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.93 143.7 17.15 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.088 -1.008 . . . . 0.0 110.274 -179.569 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.66 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.8 t -130.79 157.37 43.05 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.508 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -125.05 104.25 8.45 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.305 -0.872 . . . . 0.0 108.669 179.102 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.764 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 32.7 m95 -88.85 -178.6 5.78 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 109.276 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.516 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -148.24 102.73 3.38 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 178.085 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.598 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 4.7 m-30 -81.61 -66.03 0.94 Allowed 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 119.182 -1.007 . . . . 0.0 110.561 -177.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.89 11.12 47.55 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.532 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 12.6 p30 -97.04 33.07 1.99 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.249 -1.148 . . . . 0.0 108.224 179.043 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.24 -34.84 5.08 Favored Glycine 0 N--CA 1.48 1.603 0 N-CA-C 105.449 -3.06 . . . . 0.0 105.449 -175.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 50.2 m -108.35 100.78 10.04 Favored 'General case' 0 N--CA 1.485 1.305 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.516 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -75.3 -86.96 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.166 -0.959 . . . . 0.0 109.773 -178.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -50.89 144.77 8.04 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.308 0.575 . . . . 0.0 109.806 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.639 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 91.9 t -133.84 105.91 8.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.36 -0.838 . . . . 0.0 110.764 -178.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -83.12 115.75 22.03 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.479 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.489 ' HB2' ' CG2' ' A' ' 36' ' ' THR . . . -129.26 164.08 24.25 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.028 -1.045 . . . . 0.0 110.74 -178.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.18 151.02 19.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.659 -0.65 . . . . 0.0 109.574 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.471 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 45.65 -155.31 0.51 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -88.5 38.91 0.47 Allowed 'Trans proline' 0 C--N 1.298 -2.1 0 C-N-CA 122.269 1.979 . . . . 0.0 110.191 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.54 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -139.55 155.57 47.42 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 120.227 -1.546 . . . . 0.0 111.895 -178.705 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.554 ' HB1' ' CE2' ' A' ' 38' ' ' TRP . . . -165.18 -169.64 1.69 Allowed 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.448 ' HB2' ' CD1' ' A' ' 22' ' ' LEU . 0.0 OUTLIER -154.0 144.09 22.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.018 -1.051 . . . . 0.0 109.816 179.407 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.598 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 0.3 OUTLIER -94.48 129.89 41.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.705 -0.622 . . . . 0.0 111.031 -178.797 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.434 ' HA ' HD21 ' A' ' 22' ' ' LEU . 2.1 ptp180 -105.47 85.57 2.27 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.12 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.532 ' CD1' ' HB3' ' A' ' 42' ' ' ASP . 13.0 m-85 -92.29 134.2 35.12 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.986 -1.071 . . . . 0.0 110.073 -178.544 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.4 m -127.3 -3.12 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.605 -0.685 . . . . 0.0 111.046 -179.083 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.417 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.2 OUTLIER -117.61 140.5 27.6 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 120.651 -1.281 . . . . 0.0 109.36 -179.944 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.417 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.1 Cg_endo -77.65 109.47 2.76 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 122.479 2.119 . . . . 0.0 110.155 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 169.81 -144.23 8.41 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.89 162.25 15.0 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.166 -1.196 . . . . 0.0 109.826 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.48 ' HB2' ' HB ' ' A' ' 83' ' ' VAL . 61.5 m-85 -146.91 165.28 30.26 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -124.87 153.9 41.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.151 -0.968 . . . . 0.0 108.503 179.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.524 ' CG1' ' NE2' ' A' ' 56' ' ' HIS . 12.5 t -134.19 145.19 33.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 120.839 -1.163 . . . . 0.0 110.764 -179.057 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.427 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -150.63 159.03 44.79 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 178.129 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.712 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -152.03 157.26 41.43 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.868 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.427 ' HA ' ' O ' ' A' ' 77' ' ' ALA . 7.3 p -150.14 108.19 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.66 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -89.16 151.11 22.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.931 -1.106 . . . . 0.0 109.154 -179.156 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.42 119.7 23.09 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.362 -0.935 . . . . 0.0 109.708 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 7.4 mt -109.23 -12.97 14.73 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-O 121.518 0.675 . . . . 0.0 109.492 179.511 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.07 -47.41 1.05 Allowed Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -178.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -113.87 -6.24 13.22 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.574 -0.956 . . . . 0.0 109.696 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.65 158.84 27.83 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -150.8 168.34 24.73 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.199 -1.177 . . . . 0.0 109.395 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.555 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -141.74 132.62 25.87 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.199 -0.938 . . . . 0.0 109.358 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.2 mp -101.76 147.06 26.92 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.15 -0.969 . . . . 0.0 110.45 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.724 ' HG ' HD13 ' A' ' 27' ' ' ILE . 0.1 OUTLIER -133.26 160.11 38.25 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.655 -0.653 . . . . 0.0 109.886 -179.292 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.42 88.91 0.09 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.456 HG23 HD11 ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.48 175.8 5.28 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.087 -1.243 . . . . 0.0 109.976 -179.755 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -117.87 155.37 30.27 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.243 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.536 HG11 ' N ' ' A' ' 84' ' ' GLN . 25.1 t -134.82 143.42 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.172 -0.955 . . . . 0.0 110.049 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.536 ' N ' HG11 ' A' ' 83' ' ' VAL . 2.1 mt-30 -131.83 104.0 6.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.37 -0.832 . . . . 0.0 109.038 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.423 HG21 ' HB3' ' A' ' 17' ' ' LEU . 86.0 t -102.43 132.19 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.345 -0.847 . . . . 0.0 109.964 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.45 -160.98 0.81 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.201 -0.937 . . . . 0.0 109.391 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.632 0 O-C-N 121.064 -1.022 . . . . 0.0 109.427 179.909 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.652 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.443 ' CG2' HG22 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.79 139.68 30.22 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.77 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.594 ' N ' ' CD1' ' A' ' 10' ' ' LEU . 5.6 mp -97.19 89.55 4.81 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.148 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.495 ' CB ' ' CE1' ' A' ' 26' ' ' HIS . 65.3 t -99.08 112.34 30.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.885 -1.134 . . . . 0.0 109.092 179.521 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.497 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -124.1 71.18 0.44 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.541 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.4 Cg_endo -73.64 150.4 45.22 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.803 2.336 . . . . 0.0 112.153 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.454 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.9 t-80 168.9 -38.87 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.681 0.753 . . . . 0.0 109.208 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.29 -138.05 14.56 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 -178.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.62 147.0 24.57 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 121.972 1.782 . . . . 0.0 109.166 178.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 2.7 mt -117.26 98.56 6.5 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.2 -0.937 . . . . 0.0 109.779 -179.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.09 165.66 14.98 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 t -60.85 114.74 3.22 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.243 -0.91 . . . . 0.0 109.272 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.68 39.52 2.72 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.84 154.58 51.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.152 -1.205 . . . . 0.0 110.015 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.606 HD12 ' HB2' ' A' ' 55' ' ' SER . 0.1 OUTLIER -115.82 128.14 55.59 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.805 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.692 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -92.69 148.37 22.12 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.541 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -105.25 121.9 44.81 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.067 -1.645 . . . . 0.0 108.04 179.012 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.692 ' CE1' ' HB2' ' A' ' 23' ' ' ALA . 5.2 m-85 -105.39 170.53 7.83 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 121.914 0.864 . . . . 0.0 111.721 -177.009 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.567 ' CD2' ' C ' ' A' ' 26' ' ' HIS . 0.0 OUTLIER -166.72 140.14 3.84 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.793 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.679 ' CD1' ' CH2' ' A' ' 38' ' ' TRP . 4.6 mm -109.42 148.67 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.279 -0.888 . . . . 0.0 109.309 -178.345 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -133.33 122.6 24.07 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.989 -178.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.679 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 175.25 -61.86 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.078 -1.014 . . . . 0.0 109.552 178.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.679 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 35.3 Cg_endo -79.17 68.49 8.27 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.209 1.939 . . . . 0.0 109.699 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.621 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.0 OUTLIER -15.42 -64.03 0.03 OUTLIER Pre-proline 0 N--CA 1.506 2.327 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.83 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.621 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.4 Cg_endo -78.52 73.39 5.9 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 C-N-CA 121.774 1.65 . . . . 0.0 111.202 -179.513 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.49 HG21 ' HG2' ' A' ' 30' ' ' PRO . 2.8 t -96.41 136.64 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.894 -1.129 . . . . 0.0 109.656 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.5 t -115.89 -15.33 11.25 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.48 -0.763 . . . . 0.0 109.331 179.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.6 149.43 0.48 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.311 -0.868 . . . . 0.0 109.667 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.459 HG23 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -136.93 139.68 41.73 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.59 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.511 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 10.2 mtm-85 -93.33 109.04 20.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.138 -0.976 . . . . 0.0 109.136 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.679 ' CH2' ' CD1' ' A' ' 27' ' ' ILE . 18.7 m95 -93.85 179.81 5.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.918 -1.114 . . . . 0.0 109.621 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.482 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.76 106.61 3.41 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.328 -1.731 . . . . 0.0 106.328 177.369 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.616 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 3.7 m-30 -81.37 -66.44 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 118.451 -1.3 . . . . 0.0 111.37 -176.892 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.11 -4.91 59.03 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.1 p30 -90.41 23.71 2.86 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.335 -1.097 . . . . 0.0 109.164 179.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 122.56 -38.11 2.64 Favored Glycine 0 C--N 1.298 -1.576 0 N-CA-C 106.129 -2.788 . . . . 0.0 106.129 -176.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.77 101.52 12.96 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 177.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.38 -98.28 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 0.0 109.958 -178.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.436 ' C ' HG21 ' A' ' 47' ' ' VAL . 1.6 mm-40 -56.92 150.1 17.33 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.286 0.565 . . . . 0.0 109.927 -179.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.668 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 70.8 t -138.9 132.97 40.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.47 -0.769 . . . . 0.0 110.591 -178.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -112.89 89.8 3.18 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.529 ' HB1' ' CD1' ' A' ' 38' ' ' TRP . . . -92.84 152.53 19.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.373 -0.829 . . . . 0.0 111.423 -178.135 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.72 150.2 23.75 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.459 ' O ' HG23 ' A' ' 36' ' ' THR . . . 46.08 -156.4 0.49 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.24 -1.944 . . . . 0.0 108.24 -179.27 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -88.43 42.63 0.7 Allowed 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.122 1.881 . . . . 0.0 110.479 178.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.494 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -146.87 144.38 29.24 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.072 -1.642 . . . . 0.0 112.009 -179.089 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.463 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -149.54 -169.6 3.42 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.606 ' HB2' HD12 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -152.64 138.8 18.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.249 -0.907 . . . . 0.0 109.174 179.558 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.616 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 11.1 m80 -102.91 135.45 44.57 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.231 -0.918 . . . . 0.0 111.101 -178.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -100.44 95.06 6.49 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 177.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.592 ' CZ ' HG12 ' A' ' 83' ' ' VAL . 23.8 m-85 -95.5 120.24 35.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.225 -0.922 . . . . 0.0 109.232 -179.232 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.6 p -118.17 -29.71 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.241 -0.912 . . . . 0.0 111.165 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -90.71 143.35 28.82 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 120.619 -1.3 . . . . 0.0 109.376 -179.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.405 ' HA ' HG13 ' A' ' 85' ' ' VAL . 34.0 Cg_endo -76.26 133.04 14.34 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.575 2.183 . . . . 0.0 110.281 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.59 -135.05 5.93 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 -179.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -127.27 164.51 21.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -1.193 . . . . 0.0 109.651 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.509 ' HB2' HG12 ' A' ' 83' ' ' VAL . 59.7 m-85 -142.98 152.84 42.39 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.466 -0.771 . . . . 0.0 109.205 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -112.99 130.37 56.16 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.514 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 59.2 t -116.0 150.58 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 110.821 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.79 155.51 42.42 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.756 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -150.53 158.57 44.31 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.853 -1.155 . . . . 0.0 111.518 -179.538 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -129.84 127.17 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.423 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.645 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.3 OUTLIER -89.07 141.87 28.12 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 120.656 -1.277 . . . . 0.0 109.015 -178.743 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.3 110.48 11.56 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.589 -1.245 . . . . 0.0 109.698 178.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.602 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 5.9 mp -105.49 -11.1 16.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.072 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.66 -49.62 0.83 Allowed Glycine 0 N--CA 1.486 2.011 0 N-CA-C 107.669 -2.173 . . . . 0.0 107.669 -178.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.44 -5.76 11.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.58 -0.953 . . . . 0.0 109.884 178.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -140.04 162.5 26.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.465 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.8 p -151.44 -179.23 7.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.306 -1.114 . . . . 0.0 109.579 -179.598 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.595 ' CB ' ' HG ' ' A' ' 70' ' ' LEU . . . -154.17 166.39 33.25 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.2 mt -119.93 132.75 55.62 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.068 -1.02 . . . . 0.0 110.227 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.756 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -117.4 157.14 26.7 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.524 -0.735 . . . . 0.0 109.769 -179.879 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.65 95.12 0.11 Allowed Glycine 0 N--CA 1.485 1.938 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.467 HG21 HD21 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -116.38 -173.33 2.35 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.232 -1.158 . . . . 0.0 109.937 179.932 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -150.74 153.7 36.0 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.435 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.592 HG12 ' CZ ' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.0 154.25 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.66 -1.275 . . . . 0.0 109.845 -179.519 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.45 ' N ' HG21 ' A' ' 83' ' ' VAL . 12.0 tt0 -123.07 99.81 6.56 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.464 -0.773 . . . . 0.0 108.985 179.073 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.405 HG13 ' HA ' ' A' ' 61' ' ' PRO . 41.6 t -86.15 137.71 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.24 -0.912 . . . . 0.0 109.846 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -113.15 154.41 26.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.101 -0.999 . . . . 0.0 109.667 179.711 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.64 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.435 HG22 HG21 ' A' ' 11' ' ' VAL . 0.8 OUTLIER -71.47 149.87 45.44 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.178 -0.951 . . . . 0.0 109.253 -179.427 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.597 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.0 mp -92.29 98.28 11.41 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.315 -178.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.563 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 11.1 t -108.81 101.3 12.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 120.873 -1.142 . . . . 0.0 108.273 178.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.56 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -115.64 75.49 0.26 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.459 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.521 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 32.8 Cg_endo -72.63 148.7 47.78 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.59 2.194 . . . . 0.0 111.694 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.485 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 54.3 t60 159.11 -35.63 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.659 0.742 . . . . 0.0 109.003 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.81 -141.52 15.25 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 108.437 -1.865 . . . . 0.0 108.437 -179.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -77.2 149.19 27.95 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 122.288 1.992 . . . . 0.0 109.434 179.106 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.426 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 1.4 mt -117.74 117.51 29.53 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.161 -0.962 . . . . 0.0 109.888 -179.39 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.408 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -94.06 168.77 10.73 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.137 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.2 t -56.79 118.72 5.19 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.25 -0.906 . . . . 0.0 109.01 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.63 43.22 6.19 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.22 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . 0.408 ' HB2' ' O ' ' A' ' 18' ' ' ALA . 7.9 tp-100 -111.6 150.77 29.6 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.42 -1.047 . . . . 0.0 110.869 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.437 HD12 ' O ' ' A' ' 23' ' ' ALA . 2.1 tm? -111.52 102.68 11.0 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.573 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.485 ' HA ' ' CG ' ' A' ' 14' ' ' HIS . . . -86.68 156.34 20.02 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.521 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -118.97 108.78 15.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.367 -1.458 . . . . 0.0 108.474 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.657 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.2 m-85 -96.02 168.18 10.78 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 122.428 1.109 . . . . 0.0 112.394 -177.343 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.563 ' CE1' ' CG1' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.0 142.44 5.13 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.808 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.754 HD13 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -107.42 156.95 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 120.88 -1.138 . . . . 0.0 109.34 -178.467 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.402 ' CB ' HG21 ' A' ' 9' ' ' THR . . . -134.76 120.6 19.62 Favored 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 118.738 -1.185 . . . . 0.0 112.472 -178.639 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.745 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 172.56 -71.85 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.211 -0.931 . . . . 0.0 109.263 177.663 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.745 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -76.27 78.24 3.3 Favored 'Trans proline' 0 C--N 1.313 -1.312 0 C-N-CA 121.766 1.644 . . . . 0.0 109.465 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.511 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -35.47 -54.0 1.25 Allowed Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.859 -0.526 . . . . 0.0 111.768 -179.145 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.511 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.1 Cg_endo -78.74 60.85 7.84 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.192 1.928 . . . . 0.0 111.819 -179.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.624 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 55.6 t -89.51 145.28 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 120.798 -1.189 . . . . 0.0 109.358 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.7 t -116.63 -31.97 5.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.306 -0.871 . . . . 0.0 109.914 179.506 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.0 138.71 14.17 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.322 -0.861 . . . . 0.0 109.152 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.593 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.1 t -124.19 151.93 43.48 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.553 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -118.22 101.43 8.2 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.206 -0.934 . . . . 0.0 108.921 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.657 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 25.9 m95 -87.88 -179.59 6.27 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.124 -0.985 . . . . 0.0 109.162 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.406 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.8 OUTLIER -148.96 101.7 3.19 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 177.834 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.611 ' CD1' ' NE2' ' A' ' 56' ' ' HIS . 2.6 m-30 -80.35 -59.92 2.52 Favored 'General case' 0 C--N 1.301 -1.503 0 C-N-CA 119.028 -1.069 . . . . 0.0 110.111 -177.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.1 19.72 49.33 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -178.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -109.06 -104.71 0.36 Allowed 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 178.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -80.33 -21.03 65.59 Favored Glycine 0 N--CA 1.479 1.507 0 N-CA-C 107.852 -2.099 . . . . 0.0 107.852 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.16 130.17 30.69 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.347 -1.09 . . . . 0.0 109.557 179.549 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.2 -85.01 0.1 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.983 -1.073 . . . . 0.0 109.668 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.462 ' C ' HG21 ' A' ' 47' ' ' VAL . 2.9 mt-10 -57.64 150.61 18.99 Favored 'General case' 0 N--CA 1.493 1.711 0 CA-C-O 121.132 0.492 . . . . 0.0 109.684 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.62 ' CB ' ' HB2' ' A' ' 38' ' ' TRP . 32.5 t -137.1 112.33 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 O-C-N 121.288 -0.882 . . . . 0.0 111.03 -178.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -96.09 95.75 8.39 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.528 ' CB ' ' HB1' ' A' ' 54' ' ' ALA . . . -107.63 171.37 7.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.455 -0.778 . . . . 0.0 111.06 -178.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.06 153.18 21.82 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.802 -0.561 . . . . 0.0 109.702 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.521 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 46.61 -156.42 0.59 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.776 -1.729 . . . . 0.0 108.776 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -88.45 41.75 0.63 Allowed 'Trans proline' 0 C--N 1.294 -2.298 0 C-N-CA 122.201 1.934 . . . . 0.0 110.277 178.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.458 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -142.8 152.88 42.7 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 119.933 -1.729 . . . . 0.0 112.508 -178.794 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.528 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -175.7 154.41 1.56 Allowed 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.457 ' O ' ' CZ ' ' A' ' 40' ' ' PHE . 0.2 OUTLIER -113.34 161.83 16.79 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.742 -1.224 . . . . 0.0 110.327 -179.744 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.611 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 2.3 m80 -113.11 141.2 47.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.506 -0.746 . . . . 0.0 110.578 -179.228 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.03 93.28 4.18 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.566 ' CE1' ' CG ' ' A' ' 64' ' ' TYR . 39.6 m-85 -95.91 133.56 39.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.024 -1.047 . . . . 0.0 109.553 -179.143 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 58.5 t -116.31 -41.65 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.319 -0.863 . . . . 0.0 111.029 -178.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -87.64 145.52 37.28 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.607 -1.308 . . . . 0.0 109.768 -179.117 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.482 ' HA ' HG13 ' A' ' 85' ' ' VAL . 34.6 Cg_endo -78.39 129.66 9.56 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 122.551 2.167 . . . . 0.0 110.232 179.379 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.88 -136.91 5.28 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 3.5 mtp180 -131.51 126.3 34.6 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -1.173 . . . . 0.0 109.739 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.566 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 44.8 m-85 -110.62 158.81 18.17 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.217 -0.927 . . . . 0.0 109.393 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.434 ' CD2' HG21 ' A' ' 67' ' ' THR . 70.4 t60 -111.02 132.12 54.49 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.506 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 67.5 t -114.23 152.13 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.272 -0.892 . . . . 0.0 110.352 -179.092 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.434 HG21 ' CD2' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -147.88 158.84 44.24 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.707 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.741 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -154.71 120.44 5.15 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 120.871 -1.143 . . . . 0.0 111.679 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -112.68 110.91 33.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 177.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.593 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -88.9 146.75 24.74 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.755 -1.216 . . . . 0.0 109.441 -178.944 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -125.52 116.06 21.19 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.24 -0.912 . . . . 0.0 109.206 178.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.406 ' N ' HD13 ' A' ' 72' ' ' LEU . 5.7 mp -103.43 -13.75 16.51 Favored 'General case' 0 C--N 1.292 -1.906 0 CA-C-O 121.53 0.681 . . . . 0.0 109.33 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.56 -49.7 0.83 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -118.19 -5.76 10.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.674 -0.898 . . . . 0.0 109.857 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -143.03 161.49 27.56 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.422 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 3.2 p -151.45 168.82 23.68 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.291 -1.123 . . . . 0.0 109.362 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.517 ' CB ' HD13 ' A' ' 70' ' ' LEU . . . -140.69 136.1 32.29 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.13 -0.981 . . . . 0.0 109.066 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 13.6 mt -101.78 133.46 46.49 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.308 -0.87 . . . . 0.0 110.269 -179.182 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.754 ' HG ' HD13 ' A' ' 27' ' ' ILE . 0.0 OUTLIER -122.13 156.16 34.23 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.593 -0.692 . . . . 0.0 109.952 -179.335 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -161.68 88.66 0.11 Allowed Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.564 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.458 HG21 HD21 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -105.82 -175.35 2.77 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.937 -1.331 . . . . 0.0 110.289 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -150.83 143.48 24.44 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.274 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.566 ' CG1' ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -129.07 149.13 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 120.779 -1.201 . . . . 0.0 110.059 -179.43 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 72.2 mt-30 -114.7 98.7 7.01 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.462 -0.774 . . . . 0.0 108.97 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.482 HG13 ' HA ' ' A' ' 61' ' ' PRO . 96.4 t -83.74 144.65 9.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.087 -1.008 . . . . 0.0 109.945 -179.456 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -126.58 -154.87 0.65 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.489 -0.757 . . . . 0.0 109.343 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.454 -0.779 . . . . 0.0 110.579 179.35 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.634 ' HA ' ' HB1' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.517 HG22 HG21 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -70.06 149.48 47.61 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.219 -0.926 . . . . 0.0 109.346 -179.229 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.687 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 4.2 mp -83.59 110.42 18.23 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.902 -178.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.543 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 0.5 OUTLIER -124.65 101.52 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 120.753 -1.217 . . . . 0.0 109.216 179.116 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.639 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.88 76.12 0.28 Allowed Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.591 ' O ' ' HB2' ' A' ' 14' ' ' HIS . 35.1 Cg_endo -72.9 149.7 47.9 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.774 2.316 . . . . 0.0 112.778 -179.464 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.591 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 152.25 175.28 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.908 0 CA-C-N 114.85 -1.068 . . . . 0.0 108.388 178.743 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.99 -141.6 2.11 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -76.91 150.06 29.8 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 122.123 1.882 . . . . 0.0 109.552 179.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.528 ' HA ' ' HG2' ' A' ' 21' ' ' GLN . 4.6 mm? -99.75 85.01 3.01 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.122 -0.986 . . . . 0.0 108.867 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -82.32 166.13 19.76 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.104 -0.997 . . . . 0.0 108.664 179.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.1 t -54.83 117.32 3.31 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.408 -0.808 . . . . 0.0 109.123 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.17 43.21 5.69 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 -179.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . 0.528 ' HG2' ' HA ' ' A' ' 17' ' ' LEU . 19.6 tp60 -112.54 145.82 39.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.448 -1.031 . . . . 0.0 110.696 -179.116 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.453 HD12 ' O ' ' A' ' 23' ' ' ALA . 2.3 tm? -106.51 93.95 4.87 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.254 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.453 ' O ' HD12 ' A' ' 22' ' ' LEU . . . -76.88 159.05 30.34 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.077 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.555 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.53 118.2 28.69 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.132 -1.605 . . . . 0.0 108.004 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.721 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 8.3 m-85 -103.95 174.65 5.78 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 122.705 1.24 . . . . 0.0 112.592 -176.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 53' ' ' ALA . 0.3 OUTLIER -174.93 149.52 1.14 Allowed 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 177.992 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.718 ' CD1' ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -113.98 156.33 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.806 -1.184 . . . . 0.0 108.63 -178.258 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -129.95 121.16 26.05 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.704 -1.247 . . . . 0.0 112.559 -178.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.732 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 170.88 -72.36 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.406 -0.808 . . . . 0.0 108.955 177.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.732 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 35.7 Cg_endo -77.09 78.82 3.31 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 C-N-CA 121.616 1.544 . . . . 0.0 108.593 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.71 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 13.0 mt -40.51 -50.36 6.85 Favored Pre-proline 0 N--CA 1.497 1.891 0 O-C-N 121.782 -0.574 . . . . 0.0 111.653 -178.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.71 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 36.8 Cg_endo -80.99 60.05 7.71 Favored 'Trans proline' 0 C--N 1.315 -1.185 0 C-N-CA 122.024 1.816 . . . . 0.0 112.001 -179.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.579 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 38.7 t -90.94 147.82 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 120.708 -1.245 . . . . 0.0 109.288 179.006 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.12 -30.57 6.62 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.334 -0.854 . . . . 0.0 110.171 179.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.36 145.06 18.85 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.245 -0.909 . . . . 0.0 109.334 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.676 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.3 t -129.22 158.72 38.23 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.469 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 2.9 mtm-85 -123.12 101.67 7.53 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.298 -0.877 . . . . 0.0 108.895 179.546 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.721 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 37.6 m95 -89.17 178.66 6.31 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.124 -0.985 . . . . 0.0 109.619 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.464 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.33 102.34 3.06 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 177.515 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.609 ' CE1' ' CG2' ' A' ' 47' ' ' VAL . 2.2 m-30 -79.66 -60.03 2.51 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 118.794 -1.162 . . . . 0.0 109.76 -177.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.13 18.32 47.06 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.42 -103.32 0.32 Allowed 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 178.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.64 -20.26 60.27 Favored Glycine 0 C--N 1.297 -1.618 0 N-CA-C 107.805 -2.118 . . . . 0.0 107.805 176.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 12.9 p -135.91 130.06 33.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.353 -1.086 . . . . 0.0 109.342 179.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.49 -85.37 0.1 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.047 -1.033 . . . . 0.0 109.877 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.487 ' C ' HG21 ' A' ' 47' ' ' VAL . 3.1 pm0 -56.07 152.05 11.12 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.303 0.573 . . . . 0.0 110.306 -179.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.661 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 26.1 t -140.8 121.87 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 111.047 -179.004 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 62.1 m-20 -104.58 107.81 18.94 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.429 ' HB2' ' CG2' ' A' ' 36' ' ' THR . . . -120.99 170.87 9.09 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.055 -1.028 . . . . 0.0 111.092 -178.475 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.48 152.4 20.05 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.648 -0.657 . . . . 0.0 109.643 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.516 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 46.51 -156.08 0.61 Allowed Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.842 -1.703 . . . . 0.0 108.842 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -88.83 40.79 0.54 Allowed 'Trans proline' 0 C--N 1.297 -2.151 0 C-N-CA 122.244 1.963 . . . . 0.0 110.24 178.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.548 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -140.0 157.59 45.42 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 119.936 -1.727 . . . . 0.0 112.307 -178.681 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.525 ' HB1' ' CE2' ' A' ' 38' ' ' TRP . . . -171.59 -167.67 0.53 Allowed 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.506 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.504 ' O ' ' CZ ' ' A' ' 40' ' ' PHE . 0.0 OUTLIER -146.74 175.99 10.2 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.096 -1.003 . . . . 0.0 109.186 179.29 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.575 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 4.6 m80 -133.92 132.95 40.85 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.927 -1.108 . . . . 0.0 110.408 -179.139 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.53 89.17 2.92 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.566 ' CE2' ' CG1' ' A' ' 83' ' ' VAL . 32.7 m-85 -92.41 126.85 37.67 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.206 -0.934 . . . . 0.0 109.122 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 9.8 p -114.44 -28.41 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.407 -0.808 . . . . 0.0 111.514 -178.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -98.63 145.86 30.63 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 120.512 -1.367 . . . . 0.0 109.429 -179.36 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.36 119.28 4.89 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 122.383 2.055 . . . . 0.0 109.814 179.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 161.49 -162.14 33.65 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -107.09 130.17 54.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.221 -1.164 . . . . 0.0 110.12 -179.756 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.563 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 73.1 m-85 -112.87 161.1 17.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.465 -0.772 . . . . 0.0 109.07 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 70.0 t60 -115.23 122.22 45.33 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.462 -0.774 . . . . 0.0 109.069 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.536 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 66.1 t -102.74 152.01 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.38 -0.825 . . . . 0.0 109.899 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.57 158.52 44.25 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 178.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.7 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -149.51 156.67 42.35 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.92 -1.113 . . . . 0.0 110.989 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.413 HG22 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -147.07 104.68 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.385 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 179.224 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.676 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -88.84 150.44 22.9 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.734 -1.229 . . . . 0.0 109.703 -179.181 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.45 117.04 20.66 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.588 -0.845 . . . . 0.0 109.309 178.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 5.2 mp -105.36 -13.13 15.75 Favored 'General case' 0 C--N 1.293 -1.881 0 CA-C-O 121.52 0.676 . . . . 0.0 109.239 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.33 -56.21 0.59 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -114.63 -7.25 12.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.576 -0.955 . . . . 0.0 109.759 179.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -137.47 161.13 25.29 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.0 p -151.2 170.06 20.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.411 -1.053 . . . . 0.0 109.409 -179.724 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.545 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -144.16 126.63 15.9 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.882 . . . . 0.0 109.198 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -95.25 152.14 18.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.224 -0.923 . . . . 0.0 110.639 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.718 ' HG ' ' CD1' ' A' ' 27' ' ' ILE . 0.1 OUTLIER -135.7 158.53 44.17 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.747 -0.596 . . . . 0.0 109.472 179.878 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.536 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.96 88.54 0.1 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.544 HG21 HD22 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -110.83 -171.91 1.92 Allowed 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.05 -1.265 . . . . 0.0 109.965 -179.893 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -149.54 149.56 30.9 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.566 ' CG1' ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -132.29 138.29 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.76 -1.213 . . . . 0.0 110.056 -179.654 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.46 83.33 2.43 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.408 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 53.4 t -72.62 134.3 30.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.148 -0.97 . . . . 0.0 109.627 -179.418 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -110.77 -179.1 3.65 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.386 -0.821 . . . . 0.0 109.643 -179.592 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.919 . . . . 0.0 109.185 179.603 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.658 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.418 ' O ' ' HA ' ' A' ' 27' ' ' ILE . 1.2 t -75.44 155.83 35.89 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.199 -0.938 . . . . 0.0 108.873 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.622 HD11 ' CD2' ' A' ' 79' ' ' LEU . 0.0 OUTLIER -96.8 90.96 5.45 Favored 'General case' 0 N--CA 1.49 1.553 0 C-N-CA 119.961 -0.696 . . . . 0.0 110.141 -178.854 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.574 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 25.3 t -93.96 96.23 5.88 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.622 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -114.74 75.69 0.25 Allowed Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.716 -1.231 . . . . 0.0 110.545 -178.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.557 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 32.7 Cg_endo -73.01 149.38 46.7 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.5 2.133 . . . . 0.0 111.494 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.559 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 69.6 t60 163.16 -37.5 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 CA-C-O 121.771 0.796 . . . . 0.0 109.06 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.77 -137.62 13.49 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.133 -1.987 . . . . 0.0 108.133 -178.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.25 147.08 25.68 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 C-N-CA 122.138 1.892 . . . . 0.0 109.351 178.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.426 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 12.1 mt -113.15 85.85 2.26 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.264 -0.897 . . . . 0.0 109.967 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.56 160.78 32.1 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.9 t -54.41 123.47 13.08 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.237 -0.914 . . . . 0.0 109.466 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.47 48.41 4.53 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 19.9 mm-40 -123.94 150.83 44.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.434 -1.039 . . . . 0.0 110.313 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.436 HD21 ' HA ' ' A' ' 22' ' ' LEU . 2.3 tm? -108.48 93.26 4.43 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.829 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.559 ' HA ' ' CG ' ' A' ' 14' ' ' HIS . . . -76.42 155.75 33.72 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.557 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.49 121.09 37.72 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.689 -1.257 . . . . 0.0 108.426 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.756 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.2 m-85 -108.33 171.07 7.62 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-O 122.204 1.002 . . . . 0.0 111.397 -177.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.574 ' CE1' ' CG1' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -168.64 135.79 1.96 Allowed 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 177.803 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.692 ' CD1' ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -101.48 149.64 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.882 -1.136 . . . . 0.0 108.692 -178.509 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -128.75 126.71 40.56 Favored 'General case' 0 N--CA 1.5 2.068 0 C-N-CA 118.775 -1.17 . . . . 0.0 112.501 -177.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.726 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 169.18 -69.6 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.532 -0.73 . . . . 0.0 109.081 177.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.726 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 34.8 Cg_endo -76.96 79.59 3.08 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 121.654 1.569 . . . . 0.0 109.144 179.061 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.507 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -34.89 -54.34 1.02 Allowed Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.989 -0.444 . . . . 0.0 112.004 -178.921 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.507 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.5 Cg_endo -79.48 69.4 7.95 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.23 1.954 . . . . 0.0 111.775 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.578 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 47.8 t -98.34 148.24 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.834 -1.166 . . . . 0.0 109.327 179.018 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 24.3 p -119.14 -29.15 5.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.307 -0.871 . . . . 0.0 110.26 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -159.29 145.05 16.17 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.221 -0.924 . . . . 0.0 109.619 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.675 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.8 t -130.75 151.44 51.18 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.51 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.7 OUTLIER -120.56 104.73 10.18 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.202 -0.936 . . . . 0.0 108.713 179.173 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.756 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 37.5 m95 -89.6 -178.6 5.59 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-O 122.079 0.942 . . . . 0.0 109.432 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.407 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.3 OUTLIER -150.45 101.03 2.93 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 106.329 -1.73 . . . . 0.0 106.329 177.45 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.678 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 3.3 m-30 -80.37 -56.08 4.44 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.121 -177.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.6 20.41 54.25 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.133 -1.587 . . . . 0.0 109.133 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.55 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 1.1 p30 -104.25 -104.48 0.3 Allowed 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 178.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.24 -15.91 68.15 Favored Glycine 0 C--N 1.296 -1.646 0 N-CA-C 107.754 -2.138 . . . . 0.0 107.754 176.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.7 p -138.29 130.97 29.39 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.489 -1.007 . . . . 0.0 108.892 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.407 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.74 -85.4 0.09 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.941 -1.099 . . . . 0.0 109.752 -179.602 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.473 ' C ' HG21 ' A' ' 47' ' ' VAL . 1.3 pt-20 -57.16 154.09 10.68 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.332 0.587 . . . . 0.0 110.121 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.654 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 52.6 t -140.01 121.63 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.431 -0.793 . . . . 0.0 110.689 -178.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -104.21 118.97 37.93 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 178.007 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.437 ' HB2' ' CG2' ' A' ' 36' ' ' THR . . . -132.75 166.06 23.1 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.031 -1.043 . . . . 0.0 111.042 -178.513 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.31 153.47 18.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.672 -0.642 . . . . 0.0 109.796 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.462 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 45.35 -155.93 0.39 Allowed Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -88.96 38.99 0.44 Allowed 'Trans proline' 0 C--N 1.298 -2.118 0 C-N-CA 122.544 2.163 . . . . 0.0 110.149 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.52 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -138.16 152.63 48.87 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.115 -1.616 . . . . 0.0 112.054 -178.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.551 ' HB1' ' CE2' ' A' ' 38' ' ' TRP . . . -163.61 -166.79 1.26 Allowed 'General case' 0 N--CA 1.494 1.775 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.469 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.4 p -158.49 141.1 14.42 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.11 -0.994 . . . . 0.0 109.79 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.678 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 9.7 m80 -94.02 136.7 34.03 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.476 -0.765 . . . . 0.0 111.081 -178.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -110.89 87.71 2.6 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 178.396 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.668 ' CE2' HG12 ' A' ' 83' ' ' VAL . 15.1 m-85 -87.73 138.55 31.37 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.202 -0.936 . . . . 0.0 109.704 -178.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 12.0 p -129.51 -26.83 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.362 -0.836 . . . . 0.0 111.257 -178.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -98.36 144.6 28.38 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 120.507 -1.371 . . . . 0.0 109.718 -179.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.64 116.39 4.04 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.55 2.167 . . . . 0.0 109.929 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 160.54 -154.78 25.84 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.93 165.41 11.56 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.022 -1.281 . . . . 0.0 109.817 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.604 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 47.2 m-85 -149.17 166.43 28.86 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 28.0 t60 -127.88 142.18 51.34 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.317 -0.864 . . . . 0.0 108.858 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.541 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 30.3 t -122.64 146.0 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 120.997 -1.064 . . . . 0.0 110.712 -179.236 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -151.44 156.28 40.32 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.541 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.71 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -149.92 161.17 42.82 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 120.849 -1.157 . . . . 0.0 111.128 -179.76 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -150.78 105.58 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.675 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -89.4 144.85 25.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.754 -1.216 . . . . 0.0 109.811 -178.845 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -118.74 119.97 36.0 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.38 -0.928 . . . . 0.0 109.247 178.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.489 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 6.4 mp -114.16 -9.33 12.91 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 121.479 0.657 . . . . 0.0 109.485 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.428 ' O ' ' CB ' ' A' ' 74' ' ' ALA . . . 102.19 101.43 2.57 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 107.495 -2.242 . . . . 0.0 107.495 -178.235 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.428 ' CB ' ' O ' ' A' ' 73' ' ' GLY . . . 71.53 -0.38 3.17 Favored 'General case' 0 N--CA 1.485 1.292 0 O-C-N 121.714 -0.874 . . . . 0.0 110.372 -178.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -145.71 142.41 10.63 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.421 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -150.28 163.95 37.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.098 -1.236 . . . . 0.0 109.973 -179.382 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.643 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -132.15 119.81 21.42 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -89.75 149.69 22.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.911 . . . . 0.0 110.407 -179.202 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.71 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.2 OUTLIER -131.75 160.29 35.95 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.451 0.643 . . . . 0.0 110.103 -179.583 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.493 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.21 92.52 0.1 OUTLIER Glycine 0 N--CA 1.483 1.814 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.598 HG23 ' HB3' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -113.07 175.39 5.46 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.034 -1.274 . . . . 0.0 109.377 179.524 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -117.68 156.17 28.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.309 -0.869 . . . . 0.0 108.851 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.668 HG12 ' CE2' ' A' ' 58' ' ' TYR . 25.1 t -137.25 139.87 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 120.983 -1.073 . . . . 0.0 110.635 -178.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.494 ' N ' HG11 ' A' ' 83' ' ' VAL . 5.4 mt-30 -123.5 93.81 4.06 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.168 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 40.8 t -87.16 135.36 25.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.237 -0.914 . . . . 0.0 110.058 -179.303 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -107.66 -157.32 0.61 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.447 -0.783 . . . . 0.0 109.424 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.005 -1.059 . . . . 0.0 109.107 179.691 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.691 ' HA ' ' HB1' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.533 HG22 HG21 ' A' ' 11' ' ' VAL . 1.1 t -69.2 150.44 47.48 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.19 -0.944 . . . . 0.0 109.584 -178.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.716 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 4.6 mp -83.19 107.18 15.56 Favored 'General case' 0 N--CA 1.489 1.516 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.648 -178.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.533 HG21 HG22 ' A' ' 9' ' ' THR . 0.4 OUTLIER -120.79 96.26 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 120.823 -1.173 . . . . 0.0 108.977 179.088 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.624 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -115.95 80.03 0.29 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.021 -1.231 . . . . 0.0 110.021 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.554 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 32.2 Cg_endo -71.94 147.58 49.73 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.513 2.142 . . . . 0.0 112.018 179.598 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.501 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 32.7 t-80 158.87 -33.98 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.08 -141.32 15.23 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -77.07 148.4 27.52 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.082 1.855 . . . . 0.0 109.209 178.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 4.4 mm? -105.59 109.89 22.02 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.111 -0.993 . . . . 0.0 109.681 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -89.18 161.17 16.61 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.2 t -57.82 116.74 3.65 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.151 -0.968 . . . . 0.0 109.389 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 89.8 44.74 4.75 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -121.22 152.87 38.33 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.252 -1.146 . . . . 0.0 110.609 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.478 HD21 ' HA ' ' A' ' 22' ' ' LEU . 2.5 tm? -107.39 99.07 8.61 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.852 -0.795 . . . . 0.0 108.852 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.503 ' HB2' ' HE1' ' A' ' 25' ' ' PHE . . . -80.34 153.71 28.21 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.554 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -116.03 125.14 52.05 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.479 -1.388 . . . . 0.0 108.081 179.411 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.723 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.6 m-85 -112.57 172.44 6.92 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 122.526 1.155 . . . . 0.0 112.285 -177.188 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.533 ' HA ' ' HA ' ' A' ' 53' ' ' ALA . 4.1 p80 -173.95 148.51 1.41 Allowed 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 177.175 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.73 ' CD1' ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.21 157.51 12.05 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 120.733 -1.229 . . . . 0.0 108.599 -178.166 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -132.41 121.63 23.74 Favored 'General case' 0 N--CA 1.5 2.058 0 C-N-CA 118.698 -1.201 . . . . 0.0 112.542 -177.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.723 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 172.31 -71.54 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.402 -0.811 . . . . 0.0 108.867 177.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.723 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.6 Cg_endo -77.39 76.86 4.05 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 C-N-CA 121.708 1.605 . . . . 0.0 108.725 178.522 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.551 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -35.45 -55.78 1.08 Allowed Pre-proline 0 N--CA 1.497 1.921 0 O-C-N 121.956 -0.465 . . . . 0.0 111.472 -178.746 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.551 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.7 Cg_endo -80.16 75.1 5.23 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.125 1.884 . . . . 0.0 111.332 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.56 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 20.5 t -106.03 149.22 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.024 -1.048 . . . . 0.0 109.131 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.1 p -114.59 -28.85 7.01 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.285 -0.884 . . . . 0.0 110.626 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -158.72 143.08 15.72 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.073 -1.017 . . . . 0.0 110.164 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.664 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.8 t -129.99 155.55 45.91 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.481 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.513 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 2.6 ttm180 -122.72 104.06 9.06 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.248 -0.907 . . . . 0.0 108.713 179.059 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.723 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 32.1 m95 -88.78 179.89 6.13 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.306 -0.871 . . . . 0.0 109.324 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.499 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.21 103.1 3.14 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 106.811 -1.551 . . . . 0.0 106.811 177.889 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.623 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 2.5 m-30 -81.16 -67.0 0.82 Allowed 'General case' 0 N--CA 1.493 1.683 0 C-N-CA 119.001 -1.079 . . . . 0.0 110.738 -177.502 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.64 7.58 56.62 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -178.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.6 p30 -98.34 35.6 1.75 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.415 -1.05 . . . . 0.0 108.317 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.88 -39.19 2.96 Favored Glycine 0 C--N 1.295 -1.699 0 N-CA-C 105.773 -2.931 . . . . 0.0 105.773 -176.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 87.7 p -107.27 101.82 11.17 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 177.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.499 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -75.58 -89.99 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -0.944 . . . . 0.0 110.189 -178.602 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.428 ' C ' HG21 ' A' ' 47' ' ' VAL . 0.8 OUTLIER -52.21 145.74 10.25 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-O 121.296 0.57 . . . . 0.0 109.884 -179.416 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.628 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 47.7 t -135.9 110.79 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.299 -0.875 . . . . 0.0 110.851 -178.703 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.23 107.41 19.18 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.368 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.45 ' HB2' ' CG2' ' A' ' 36' ' ' THR . . . -120.02 165.79 14.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.198 -0.939 . . . . 0.0 110.98 -178.432 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.07 152.59 18.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.598 -0.689 . . . . 0.0 109.446 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.554 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 45.53 -156.12 0.41 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -88.97 40.99 0.54 Allowed 'Trans proline' 0 C--N 1.295 -2.242 0 C-N-CA 122.209 1.94 . . . . 0.0 110.381 178.465 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.533 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -139.52 159.26 42.57 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 119.953 -1.717 . . . . 0.0 112.509 -178.659 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.508 ' HB1' ' CE2' ' A' ' 38' ' ' TRP . . . -171.55 -167.05 0.48 Allowed 'General case' 0 N--CA 1.495 1.823 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.3 p -156.52 144.32 19.38 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.011 -1.056 . . . . 0.0 109.536 179.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.623 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 9.1 m80 -102.4 146.25 28.35 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.595 0.712 . . . . 0.0 111.327 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.402 ' HA ' HD21 ' A' ' 22' ' ' LEU . 0.4 OUTLIER -118.26 90.47 3.34 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 178.626 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.556 ' CE2' ' CG1' ' A' ' 83' ' ' VAL . 30.2 m-85 -92.63 128.76 38.6 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.067 -1.02 . . . . 0.0 110.012 -178.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.0 p -117.62 -27.84 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.484 -0.76 . . . . 0.0 111.108 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.45 ' CD2' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -101.77 146.44 32.25 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 120.561 -1.337 . . . . 0.0 109.483 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.45 ' HD2' ' CD2' ' A' ' 60' ' ' LEU . 34.3 Cg_endo -77.6 121.74 5.69 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 C-N-CA 122.286 1.991 . . . . 0.0 109.849 179.481 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 162.45 -163.31 35.0 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.446 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.3 OUTLIER -105.92 121.26 43.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.107 -1.231 . . . . 0.0 110.052 -179.805 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.509 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 64.6 m-85 -104.2 151.29 23.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 0.0 109.091 179.49 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.1 t60 -108.37 125.33 51.61 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.352 -0.842 . . . . 0.0 109.154 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.525 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 64.8 t -108.3 151.59 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.921 . . . . 0.0 110.185 -179.401 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.81 158.4 44.13 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.686 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -151.23 155.28 38.5 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.011 -1.056 . . . . 0.0 110.768 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.427 ' HA ' ' O ' ' A' ' 77' ' ' ALA . 8.1 p -148.35 108.09 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.664 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -89.13 149.99 22.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.818 -1.176 . . . . 0.0 109.367 -179.112 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.19 119.97 20.57 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.372 -0.931 . . . . 0.0 109.93 179.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.45 HD22 ' HA ' ' A' ' 33' ' ' VAL . 11.6 mt -110.86 -12.21 14.28 Favored 'General case' 0 C--N 1.295 -1.776 0 CA-C-O 121.498 0.666 . . . . 0.0 109.406 179.35 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.43 -49.65 0.86 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 -178.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -112.17 -7.71 14.03 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.517 -0.99 . . . . 0.0 109.71 179.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -145.84 153.48 25.33 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.407 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 1.7 p -150.89 169.37 21.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.191 -1.182 . . . . 0.0 109.691 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.53 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -144.2 154.02 42.69 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.394 -0.816 . . . . 0.0 108.997 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 5.1 mp -122.65 150.51 42.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.143 -0.973 . . . . 0.0 109.89 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.73 ' HG ' ' CD1' ' A' ' 27' ' ' ILE . 0.1 OUTLIER -136.06 158.92 43.25 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.552 -0.718 . . . . 0.0 110.013 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.525 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -167.2 87.54 0.1 OUTLIER Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.768 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.432 HG21 HD21 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -107.46 -174.51 2.55 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.126 -1.22 . . . . 0.0 110.353 -179.491 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -150.88 143.0 24.09 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.246 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.556 ' CG1' ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -128.82 145.02 36.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 120.683 -1.261 . . . . 0.0 109.636 -179.539 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -109.6 84.33 1.91 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.45 -0.781 . . . . 0.0 109.246 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 48.1 t -69.51 133.47 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.01 -1.056 . . . . 0.0 109.394 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -114.9 162.71 16.56 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.456 -0.777 . . . . 0.0 109.845 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.324 -0.86 . . . . 0.0 109.388 179.533 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.63 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.487 1.415 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.493 HG22 HG21 ' A' ' 11' ' ' VAL . 1.2 t -70.44 148.53 48.22 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.222 -0.924 . . . . 0.0 109.272 -179.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.697 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.1 mp -85.59 103.86 14.81 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.083 -178.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.593 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 4.7 t -117.08 104.79 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 120.772 -1.205 . . . . 0.0 108.829 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.556 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -117.77 73.99 0.29 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.523 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 35.0 Cg_endo -73.17 151.96 49.95 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.874 2.383 . . . . 0.0 112.462 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.551 ' CE1' ' HG2' ' A' ' 21' ' ' GLN . 26.8 t-80 158.52 -39.78 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.27 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.14 -137.0 13.73 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.074 -2.01 . . . . 0.0 108.074 -179.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.15 148.44 24.38 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 C-N-CA 122.152 1.901 . . . . 0.0 109.521 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 4.0 mm? -112.16 102.42 10.61 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.097 -1.002 . . . . 0.0 109.465 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.51 165.05 15.14 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.164 -0.96 . . . . 0.0 108.848 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.7 t -56.41 122.16 11.26 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.321 -0.862 . . . . 0.0 109.363 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 83.26 47.62 5.68 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . 0.551 ' HG2' ' CE1' ' A' ' 14' ' ' HIS . 1.6 tp60 -120.26 150.66 40.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.345 -1.091 . . . . 0.0 110.622 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.44 HD21 ' HA ' ' A' ' 22' ' ' LEU . 2.3 tm? -107.27 96.67 6.58 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.428 ' O ' HD12 ' A' ' 22' ' ' LEU . . . -79.31 156.59 27.97 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 178.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.523 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.97 117.49 27.42 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.516 -1.365 . . . . 0.0 108.094 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.734 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.8 m-85 -101.95 176.55 5.17 Favored 'General case' 0 N--CA 1.488 1.459 0 CA-C-O 122.459 1.124 . . . . 0.0 112.223 -177.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.593 ' CE1' ' CG1' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -174.3 143.41 0.86 Allowed 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.502 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.744 ' CD1' ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.72 153.55 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.911 -1.118 . . . . 0.0 108.388 -179.067 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -131.62 123.43 27.86 Favored 'General case' 0 N--CA 1.501 2.101 0 C-N-CA 118.429 -1.308 . . . . 0.0 112.781 -177.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.707 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 173.3 -68.56 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.948 0 O-C-N 121.296 -0.877 . . . . 0.0 109.525 177.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.707 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -76.17 78.44 3.21 Favored 'Trans proline' 0 C--N 1.312 -1.395 0 C-N-CA 121.787 1.658 . . . . 0.0 109.497 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.521 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -32.86 -55.06 0.59 Allowed Pre-proline 0 N--CA 1.499 2.014 0 O-C-N 121.966 -0.459 . . . . 0.0 112.103 -179.16 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.521 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.3 Cg_endo -79.27 61.13 8.07 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 C-N-CA 122.324 2.016 . . . . 0.0 112.084 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.57 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 90.2 t -85.86 152.21 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 120.593 -1.317 . . . . 0.0 109.564 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.6 t -126.07 -33.14 2.69 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.489 -0.757 . . . . 0.0 109.783 179.294 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.53 140.69 15.31 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.395 -0.816 . . . . 0.0 109.296 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.607 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 0.8 OUTLIER -127.5 150.78 49.52 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.666 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.491 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -116.96 103.88 10.72 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.216 -0.928 . . . . 0.0 108.788 179.257 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.734 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 33.7 m95 -89.12 -179.74 5.96 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.24 -0.912 . . . . 0.0 109.383 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.409 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.48 101.84 2.99 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 177.686 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.626 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 2.6 m-30 -79.9 -62.55 1.65 Allowed 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 118.834 -1.146 . . . . 0.0 109.992 -177.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.57 16.94 43.9 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.35 -102.95 0.32 Allowed 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -85.5 -18.33 60.52 Favored Glycine 0 C--N 1.297 -1.585 0 N-CA-C 107.872 -2.091 . . . . 0.0 107.872 176.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.5 m -135.18 126.24 27.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.455 -1.027 . . . . 0.0 108.996 179.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.409 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.43 -85.91 0.09 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.02 -1.05 . . . . 0.0 109.692 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.469 ' C ' HG21 ' A' ' 47' ' ' VAL . 2.1 pt-20 -57.95 152.94 15.23 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.239 0.542 . . . . 0.0 109.679 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.644 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 27.5 t -139.22 118.46 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.295 -0.878 . . . . 0.0 110.943 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -101.53 101.28 11.82 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.438 ' HB2' HG22 ' A' ' 36' ' ' THR . . . -113.2 168.61 9.58 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.265 -0.897 . . . . 0.0 111.082 -178.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.65 155.01 18.37 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 121.422 0.63 . . . . 0.0 109.618 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.472 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 45.96 -156.26 0.48 Allowed Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -88.93 40.44 0.51 Allowed 'Trans proline' 0 C--N 1.296 -2.198 0 C-N-CA 122.194 1.929 . . . . 0.0 110.356 178.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.557 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -142.06 156.64 45.41 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 119.99 -1.694 . . . . 0.0 112.357 -178.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.5 ' HB1' ' CE2' ' A' ' 38' ' ' TRP . . . -167.41 -168.34 1.03 Allowed 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 11.5 p -156.24 141.61 17.57 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.023 -1.048 . . . . 0.0 109.678 179.494 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.626 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 12.0 m80 -99.01 143.86 28.81 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-O 121.743 0.783 . . . . 0.0 111.614 -178.328 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -114.6 90.63 3.39 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.459 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.573 ' CE1' ' CG ' ' A' ' 64' ' ' TYR . 37.0 m-85 -93.59 136.95 33.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.955 -1.091 . . . . 0.0 109.762 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 8.4 p -123.62 -33.12 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.283 -0.886 . . . . 0.0 111.356 -178.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.413 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -95.03 147.36 32.91 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 120.526 -1.359 . . . . 0.0 109.478 -179.431 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.413 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.4 Cg_endo -78.75 116.59 3.8 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.545 2.163 . . . . 0.0 109.972 179.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 166.68 -155.17 26.16 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.468 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 8.2 mtm-85 -115.1 123.08 48.06 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.261 -1.14 . . . . 0.0 109.715 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.573 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 62.5 m-85 -106.45 157.63 17.5 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.441 -0.787 . . . . 0.0 109.367 179.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 67.2 t60 -109.85 129.39 55.65 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.519 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 83.0 t -110.36 151.49 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.385 -0.822 . . . . 0.0 109.969 -179.439 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.46 157.12 42.66 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.133 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.673 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -150.43 156.41 41.41 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 120.889 -1.132 . . . . 0.0 110.979 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -147.32 107.66 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.607 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -90.19 153.19 20.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.896 -1.128 . . . . 0.0 110.445 -178.39 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -131.13 117.91 19.75 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.303 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.507 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 6.1 mp -106.05 -12.86 15.64 Favored 'General case' 0 C--N 1.293 -1.85 0 CA-C-O 121.495 0.664 . . . . 0.0 109.29 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.15 -45.76 1.26 Allowed Glycine 0 N--CA 1.488 2.116 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -178.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.13 -6.76 12.48 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.59 -0.947 . . . . 0.0 109.704 179.082 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -150.02 165.23 29.76 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.35 168.75 23.83 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.246 -1.149 . . . . 0.0 109.512 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.531 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -145.14 140.68 28.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.487 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -107.16 150.88 26.11 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.067 -1.02 . . . . 0.0 110.3 -179.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.744 ' HG ' ' CD1' ' A' ' 27' ' ' ILE . 0.1 OUTLIER -134.96 158.53 44.08 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.467 -0.771 . . . . 0.0 109.842 -179.751 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -167.72 91.47 0.1 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.26 -171.57 1.94 Allowed 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.08 -1.247 . . . . 0.0 110.165 -179.7 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -150.15 147.96 28.37 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 179.201 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.569 HG13 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -129.86 140.81 48.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 120.617 -1.302 . . . . 0.0 110.027 -179.271 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.428 ' HG2' ' HG2' ' A' ' 63' ' ' ARG . 0.8 OUTLIER -104.07 85.55 2.41 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.381 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 98.4 t -77.74 136.99 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.151 -0.968 . . . . 0.0 109.644 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -124.05 142.55 51.09 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.278 -0.889 . . . . 0.0 109.579 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.168 -0.957 . . . . 0.0 109.648 179.809 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.63 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.484 HG22 ' CG2' ' A' ' 11' ' ' VAL . 1.0 OUTLIER -73.48 149.21 42.49 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.282 -0.886 . . . . 0.0 109.209 -179.442 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.662 ' HG ' ' CD2' ' A' ' 79' ' ' LEU . 5.2 mp -91.38 103.81 16.4 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.322 -178.315 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.52 ' HB ' ' CE1' ' A' ' 26' ' ' HIS . 3.1 t -117.12 105.47 18.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 O-C-N 120.776 -1.203 . . . . 0.0 108.782 178.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.572 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.93 74.17 0.3 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.518 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 35.3 Cg_endo -73.14 152.54 50.9 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.752 2.301 . . . . 0.0 111.983 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.475 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.2 t-80 163.74 -37.99 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 CA-C-O 121.698 0.761 . . . . 0.0 108.961 179.58 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.5 -136.54 13.57 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.308 -1.917 . . . . 0.0 108.308 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -78.01 149.18 25.46 Favored 'Trans proline' 0 C--N 1.304 -1.797 0 C-N-CA 122.246 1.964 . . . . 0.0 109.352 179.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.501 HD22 ' HB3' ' A' ' 23' ' ' ALA . 22.7 mt -120.75 93.37 4.01 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.041 -1.037 . . . . 0.0 110.102 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.554 ' HA ' ' HG3' ' A' ' 86' ' ' GLU . . . -87.42 164.03 16.42 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.082 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.427 ' CB ' ' HA ' ' A' ' 87' ' ' ALA . 40.6 t -49.96 121.27 5.17 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.564 -0.71 . . . . 0.0 110.085 -179.406 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.31 47.47 4.35 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . 0.499 ' HB3' HD21 ' A' ' 17' ' ' LEU . 4.4 mm-40 -122.4 149.57 43.64 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.23 -1.159 . . . . 0.0 110.94 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.46 HD21 ' HA ' ' A' ' 22' ' ' LEU . 2.4 tm? -108.49 98.55 8.06 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.501 ' HB3' HD22 ' A' ' 17' ' ' LEU . . . -81.93 154.63 25.68 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.518 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -117.4 121.37 40.9 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.611 -1.306 . . . . 0.0 107.981 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.725 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 7.3 m-85 -108.15 173.5 6.29 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 122.425 1.107 . . . . 0.0 112.362 -176.813 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.543 ' HA ' ' HA ' ' A' ' 53' ' ' ALA . 3.4 p80 -171.27 144.51 2.03 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 177.286 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.722 HD13 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.54 158.33 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.095 -1.003 . . . . 0.0 108.571 -178.578 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -136.91 122.41 19.59 Favored 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 118.445 -1.302 . . . . 0.0 112.627 -178.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.702 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 172.01 -68.24 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 121.201 -0.937 . . . . 0.0 109.595 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.702 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -76.41 78.39 3.29 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 C-N-CA 121.758 1.639 . . . . 0.0 109.374 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.512 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 3.7 mp -32.5 -54.97 0.56 Allowed Pre-proline 0 N--CA 1.499 2.019 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.512 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.7 Cg_endo -79.85 60.77 7.96 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 C-N-CA 122.249 1.966 . . . . 0.0 111.994 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.575 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 94.2 t -84.14 149.0 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.633 -1.292 . . . . 0.0 109.708 179.283 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 31.9 p -122.11 -36.62 2.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.41 -0.806 . . . . 0.0 109.611 179.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -154.04 136.36 14.92 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.515 -0.741 . . . . 0.0 109.257 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.522 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.2 t -123.59 140.05 53.38 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.506 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.506 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 1.2 ttp180 -107.68 106.05 16.19 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.816 179.285 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.725 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 36.1 m95 -89.08 179.55 6.12 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.998 0.904 . . . . 0.0 109.111 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.424 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.78 100.23 2.8 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 177.445 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.611 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 2.7 m-30 -80.01 -59.79 2.58 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.787 -1.165 . . . . 0.0 110.011 -177.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.54 17.27 53.06 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -104.35 -103.75 0.31 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 178.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.61 -21.63 59.63 Favored Glycine 0 C--N 1.297 -1.631 0 N-CA-C 107.717 -2.153 . . . . 0.0 107.717 176.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 11.6 p -134.58 129.8 35.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.427 -1.043 . . . . 0.0 109.148 179.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.424 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.25 -84.22 0.11 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.074 -1.016 . . . . 0.0 109.686 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.472 ' C ' HG21 ' A' ' 47' ' ' VAL . 4.0 mp0 -58.78 149.27 26.92 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.153 0.501 . . . . 0.0 109.848 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.681 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 42.3 t -137.72 121.05 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.385 -0.822 . . . . 0.0 110.755 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 61.8 m-20 -104.17 97.26 7.25 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.451 ' HB2' HG22 ' A' ' 36' ' ' THR . . . -107.89 166.35 10.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.251 -0.905 . . . . 0.0 111.239 -178.292 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.58 154.58 18.15 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 121.275 0.56 . . . . 0.0 109.533 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.441 ' O ' HG21 ' A' ' 36' ' ' THR . . . 45.88 -155.65 0.53 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.788 -1.725 . . . . 0.0 108.788 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -89.53 40.74 0.48 Allowed 'Trans proline' 0 C--N 1.295 -2.252 0 C-N-CA 122.256 1.971 . . . . 0.0 110.486 178.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -143.43 156.42 44.65 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 119.882 -1.762 . . . . 0.0 112.581 -178.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.467 ' HB1' ' CE2' ' A' ' 38' ' ' TRP . . . -168.06 -167.69 0.86 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.3 p -155.52 141.38 18.12 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.959 -1.088 . . . . 0.0 109.738 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.611 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 12.9 m80 -97.98 142.83 29.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.499 -0.75 . . . . 0.0 111.442 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.436 ' HA ' HD21 ' A' ' 22' ' ' LEU . 0.9 OUTLIER -114.52 90.52 3.36 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.697 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.586 ' CE1' ' CG ' ' A' ' 64' ' ' TYR . 31.2 m-85 -94.15 122.3 36.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.11 -0.994 . . . . 0.0 109.751 -178.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.0 m -115.83 -26.02 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.487 -0.758 . . . . 0.0 111.104 -178.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.429 ' CG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -98.04 146.31 31.28 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 120.647 -1.283 . . . . 0.0 109.227 -179.636 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.429 ' HD2' ' CG ' ' A' ' 60' ' ' LEU . 34.1 Cg_endo -77.19 123.8 6.87 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 122.41 2.073 . . . . 0.0 110.018 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 156.47 -169.8 33.92 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.411 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -103.84 121.74 43.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.285 -1.127 . . . . 0.0 109.884 -179.823 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.586 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 79.9 m-85 -100.2 160.76 14.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.391 -0.818 . . . . 0.0 109.645 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.471 ' CD2' HG23 ' A' ' 67' ' ' THR . 35.8 t60 -115.18 121.88 44.34 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 178.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.474 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 64.5 t -102.86 151.57 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.265 -0.897 . . . . 0.0 110.648 -179.051 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.471 HG23 ' CD2' ' A' ' 65' ' ' HIS . 0.1 OUTLIER -150.61 160.2 43.97 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 178.427 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.715 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -153.3 157.97 40.89 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.094 -1.004 . . . . 0.0 110.695 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.2 p -147.07 107.8 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.61 HD13 ' HB1' ' A' ' 77' ' ' ALA . 0.2 OUTLIER -88.94 147.86 24.11 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.849 -1.157 . . . . 0.0 110.147 -178.043 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.47 113.88 16.08 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 121.932 0.872 . . . . 0.0 108.808 178.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.539 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 6.0 mp -103.36 -12.57 17.13 Favored 'General case' 0 C--N 1.289 -2.027 0 CA-C-O 121.553 0.692 . . . . 0.0 109.194 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 112.3 -49.84 0.82 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 -178.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.1 -5.66 11.92 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.577 -0.955 . . . . 0.0 109.815 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.16 160.78 27.87 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.414 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.2 p -151.04 173.31 14.48 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.398 -1.06 . . . . 0.0 109.218 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.61 ' HB1' HD13 ' A' ' 70' ' ' LEU . . . -149.88 129.63 13.25 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.261 -0.899 . . . . 0.0 109.651 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.3 tt -94.33 140.0 30.35 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.424 -0.798 . . . . 0.0 110.007 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.722 ' HG ' HD13 ' A' ' 27' ' ' ILE . 0.0 OUTLIER -126.23 155.25 42.13 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.449 -0.782 . . . . 0.0 110.275 -179.336 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.467 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -162.65 87.05 0.11 Allowed Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.413 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.612 HG21 HD22 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -105.31 -175.6 2.84 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.028 -1.278 . . . . 0.0 109.633 179.904 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . 0.406 ' N ' ' OG1' ' A' ' 81' ' ' THR . 0.7 OUTLIER -150.96 146.49 26.28 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 179.258 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.569 ' CG1' ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -131.69 141.49 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 120.602 -1.311 . . . . 0.0 110.239 -179.474 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 17.9 tt0 -104.37 89.37 3.21 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.47 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 43.4 t -82.07 133.79 28.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.204 -0.935 . . . . 0.0 110.115 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.554 ' HG3' ' HA ' ' A' ' 18' ' ' ALA . 11.2 pt-20 -103.56 -147.97 0.39 Allowed 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.427 ' HA ' ' CB ' ' A' ' 19' ' ' SER . . . . . . . . 0 N--CA 1.489 1.508 0 O-C-N 120.952 -1.092 . . . . 0.0 109.335 179.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.638 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.467 HG22 HG21 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -68.93 147.39 51.73 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.277 -0.889 . . . . 0.0 109.278 -179.147 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.619 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.0 mp -92.63 109.16 20.57 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.261 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.547 ' HB ' ' CE1' ' A' ' 26' ' ' HIS . 2.5 t -123.88 106.11 16.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.9 -1.125 . . . . 0.0 108.738 178.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.581 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.91 76.24 0.3 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.881 -1.287 . . . . 0.0 109.881 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.522 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.0 Cg_endo -73.38 150.25 46.33 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.729 2.286 . . . . 0.0 112.064 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.52 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 40.0 t-80 165.84 -38.77 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.701 0 CA-C-O 121.696 0.76 . . . . 0.0 109.114 179.623 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.01 -137.63 14.29 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 108.221 -1.952 . . . . 0.0 108.221 -179.106 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.83 148.86 25.71 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 C-N-CA 122.237 1.958 . . . . 0.0 109.371 179.053 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.547 HD21 ' HB3' ' A' ' 21' ' ' GLN . 34.5 mt -118.3 100.08 7.26 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.066 -1.021 . . . . 0.0 109.987 -179.539 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.461 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -86.5 171.3 11.19 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.149 -0.969 . . . . 0.0 108.432 179.144 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 37.4 t -54.59 126.26 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.189 -0.944 . . . . 0.0 109.851 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 77.45 51.61 5.97 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . 0.547 ' HB3' HD21 ' A' ' 17' ' ' LEU . 0.4 OUTLIER -115.55 149.78 37.65 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.392 -1.064 . . . . 0.0 110.838 -179.426 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.412 ' C ' ' CD1' ' A' ' 22' ' ' LEU . 2.1 tm? -109.46 96.67 6.43 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.52 ' HA ' ' CG ' ' A' ' 14' ' ' HIS . . . -81.21 155.97 25.88 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.949 -1.094 . . . . 0.0 108.123 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.522 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.61 116.6 26.35 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.523 -1.361 . . . . 0.0 108.11 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.581 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 4.4 m-85 -104.53 170.38 7.92 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-O 122.319 1.057 . . . . 0.0 112.229 -176.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.547 ' CE1' ' HB ' ' A' ' 11' ' ' VAL . 4.6 p80 -167.08 149.04 6.0 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.098 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.788 HD11 ' HG ' ' A' ' 79' ' ' LEU . 0.2 OUTLIER -112.96 161.85 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.095 -1.003 . . . . 0.0 109.216 -178.294 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -138.97 118.96 13.33 Favored 'General case' 0 N--CA 1.501 2.086 0 C-N-CA 118.629 -1.228 . . . . 0.0 112.463 -178.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.707 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 173.43 -68.67 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.206 -0.934 . . . . 0.0 109.634 177.688 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.707 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 33.5 Cg_endo -76.64 78.19 3.41 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 121.716 1.611 . . . . 0.0 109.362 179.616 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.497 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -33.27 -54.43 0.68 Allowed Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.946 -0.471 . . . . 0.0 112.186 -179.008 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.497 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.3 Cg_endo -79.69 58.53 7.01 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.113 1.875 . . . . 0.0 112.055 -179.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.56 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 93.9 t -81.78 147.44 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 120.724 -1.235 . . . . 0.0 109.42 179.05 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 74.0 p -122.27 -37.06 2.86 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.313 -0.867 . . . . 0.0 109.614 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -154.34 136.34 14.64 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.582 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.5 t -123.11 150.07 43.69 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.569 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.7 OUTLIER -115.54 103.44 10.74 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.351 -0.94 . . . . 0.0 108.847 179.155 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.698 ' CH2' ' CD1' ' A' ' 27' ' ' ILE . 31.7 m95 -87.66 179.13 6.57 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.158 -0.964 . . . . 0.0 109.113 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.513 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.5 OUTLIER -149.03 103.08 3.31 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 177.835 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.62 ' CD1' ' NE2' ' A' ' 56' ' ' HIS . 2.4 m-30 -81.13 -63.72 1.34 Allowed 'General case' 0 N--CA 1.491 1.597 0 C-N-CA 118.83 -1.148 . . . . 0.0 110.275 -177.782 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.59 7.05 62.0 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.479 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 13.6 p30 -98.79 31.15 3.04 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.324 -1.103 . . . . 0.0 108.647 179.367 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 117.94 -40.74 2.23 Favored Glycine 0 C--N 1.295 -1.742 0 N-CA-C 105.409 -3.077 . . . . 0.0 105.409 -176.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -106.57 100.29 9.82 Favored 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 177.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.513 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -76.21 -89.84 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.029 -1.044 . . . . 0.0 109.943 -178.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -51.48 142.15 14.43 Favored 'General case' 0 N--CA 1.495 1.825 0 CA-C-O 121.287 0.565 . . . . 0.0 109.736 -179.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.621 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 95.8 t -134.92 113.77 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.345 -0.847 . . . . 0.0 110.813 -178.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -94.84 99.46 11.52 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.534 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -110.64 167.7 10.03 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.368 -0.832 . . . . 0.0 111.015 -178.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.33 153.65 19.14 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.695 -0.628 . . . . 0.0 109.564 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.446 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 46.28 -156.51 0.52 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -89.08 40.14 0.49 Allowed 'Trans proline' 0 C--N 1.294 -2.336 0 C-N-CA 122.279 1.986 . . . . 0.0 110.285 178.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -142.73 156.32 44.99 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.889 -1.757 . . . . 0.0 112.62 -178.525 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.465 ' HB2' ' CE2' ' A' ' 38' ' ' TRP . . . -170.64 -171.76 1.1 Allowed 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 179.229 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -148.98 150.2 32.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.94 -1.1 . . . . 0.0 109.637 179.494 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.62 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 8.5 m80 -105.89 143.54 33.89 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.39 -0.819 . . . . 0.0 111.006 -178.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -118.16 89.4 3.12 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.709 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.583 ' CZ ' HG12 ' A' ' 83' ' ' VAL . 43.0 m-85 -91.49 138.97 31.15 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.914 . . . . 0.0 109.898 -178.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.1 p -124.27 -35.85 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.336 -0.852 . . . . 0.0 111.355 -178.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -86.77 146.5 41.3 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 120.511 -1.368 . . . . 0.0 109.607 -179.446 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.18 117.55 4.14 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 122.477 2.118 . . . . 0.0 110.013 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 162.11 -147.61 13.98 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.415 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -123.39 140.75 52.69 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.096 -1.237 . . . . 0.0 109.671 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.535 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 66.9 m-85 -119.98 164.37 16.19 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.322 -0.861 . . . . 0.0 109.906 -179.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 64.1 t60 -115.77 127.42 55.08 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.501 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 66.7 t -110.06 152.48 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 110.488 -179.1 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -146.93 158.62 43.97 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.75 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -155.12 117.89 4.32 Favored 'General case' 0 N--CA 1.498 1.94 0 C-N-CA 118.885 -1.126 . . . . 0.0 111.689 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.2 p -108.49 110.43 31.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.582 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -89.04 154.51 20.14 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.762 -1.211 . . . . 0.0 110.038 -178.801 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.18 116.65 16.5 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.779 0.799 . . . . 0.0 108.883 178.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.561 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 5.8 mp -105.43 -12.88 15.83 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 121.539 0.685 . . . . 0.0 109.26 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.67 -44.59 1.44 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.906 -2.077 . . . . 0.0 107.906 -178.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -113.89 -5.82 13.21 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.557 -0.966 . . . . 0.0 109.847 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -153.63 166.06 31.69 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.421 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 1.4 p -150.9 170.79 18.46 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.272 -1.134 . . . . 0.0 109.404 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.51 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -145.72 135.02 22.97 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.271 -0.893 . . . . 0.0 109.541 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 4.1 mp -101.04 131.11 47.09 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.148 -0.97 . . . . 0.0 109.992 -179.572 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.788 ' HG ' HD11 ' A' ' 27' ' ' ILE . 0.0 OUTLIER -118.11 155.17 30.86 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 121.451 -0.781 . . . . 0.0 110.208 -179.149 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.501 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -161.58 86.7 0.11 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.417 HG21 ' CD2' ' A' ' 10' ' ' LEU . 0.1 OUTLIER -106.04 -172.78 2.15 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.015 -1.285 . . . . 0.0 109.888 -179.808 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -151.25 152.88 33.87 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 179.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.583 HG12 ' CZ ' ' A' ' 58' ' ' TYR . 0.5 OUTLIER -132.77 155.48 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.781 -1.2 . . . . 0.0 109.88 -179.822 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.438 ' N ' HG21 ' A' ' 83' ' ' VAL . 31.6 tt0 -122.17 88.27 2.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.494 -0.754 . . . . 0.0 109.231 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 80.0 t -81.8 139.87 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.216 -0.927 . . . . 0.0 109.613 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -117.29 170.65 8.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.291 -0.88 . . . . 0.0 109.666 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.553 0 O-C-N 121.12 -0.988 . . . . 0.0 109.352 179.638 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.64 ' HA ' ' CB ' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.45 ' CG2' HG22 ' A' ' 11' ' ' VAL . 0.4 OUTLIER -81.66 140.24 34.49 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 179.807 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.622 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.5 mp -100.26 100.33 11.13 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -178.246 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.535 ' HB ' ' CE1' ' A' ' 26' ' ' HIS . 21.8 t -113.81 116.35 52.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 120.654 -1.279 . . . . 0.0 109.177 178.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.534 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -120.87 72.58 0.35 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 108.901 -1.679 . . . . 0.0 108.901 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.569 ' O ' ' HB2' ' A' ' 14' ' ' HIS . 32.5 Cg_endo -71.27 147.46 53.4 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.83 2.353 . . . . 0.0 113.069 -179.067 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.569 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 151.58 170.76 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 114.639 -1.164 . . . . 0.0 108.122 179.102 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.46 -141.34 1.15 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -76.74 151.91 32.35 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 C-N-CA 122.225 1.95 . . . . 0.0 109.464 179.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.496 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 51.3 mt -104.74 91.51 3.88 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.001 -1.062 . . . . 0.0 109.427 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.87 169.17 11.82 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.9 t -55.02 113.55 1.39 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.259 -0.9 . . . . 0.0 109.34 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.17 38.29 5.15 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . 0.495 ' HG2' ' HA ' ' A' ' 17' ' ' LEU . 3.1 tp-100 -107.89 146.33 32.49 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.286 -1.126 . . . . 0.0 110.609 -179.447 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.448 HD12 ' O ' ' A' ' 23' ' ' ALA . 2.8 tm? -108.65 94.43 5.05 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.531 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.548 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -77.68 158.62 29.62 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.027 -1.046 . . . . 0.0 108.266 179.238 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.547 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.92 119.3 31.14 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.566 -1.334 . . . . 0.0 107.869 179.293 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.548 ' CE1' ' HB2' ' A' ' 23' ' ' ALA . 3.1 m-85 -106.09 170.35 7.96 Favored 'General case' 0 N--CA 1.489 1.517 0 CA-C-O 121.96 0.886 . . . . 0.0 111.583 -177.006 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.535 ' CE1' ' HB ' ' A' ' 11' ' ' VAL . 2.3 p80 -164.66 143.65 7.03 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 107.813 -1.181 . . . . 0.0 107.813 176.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.664 ' CD1' ' CH2' ' A' ' 38' ' ' TRP . 6.0 mm -109.14 154.05 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.34 -0.85 . . . . 0.0 109.997 -177.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -136.69 113.38 10.24 Favored 'General case' 0 N--CA 1.498 1.962 0 C-N-CA 118.933 -1.107 . . . . 0.0 111.629 -179.443 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.689 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . -178.39 -61.7 0.0 OUTLIER Pre-proline 0 N--CA 1.494 1.766 0 O-C-N 120.936 -1.102 . . . . 0.0 109.791 178.36 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.689 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.0 Cg_endo -80.19 63.06 8.71 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.14 1.893 . . . . 0.0 109.874 179.693 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.625 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -12.96 -64.32 0.02 OUTLIER Pre-proline 0 N--CA 1.506 2.37 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -179.101 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.625 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 35.5 Cg_endo -77.34 71.58 6.32 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 C-N-CA 121.788 1.659 . . . . 0.0 110.926 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.502 HG21 ' HG2' ' A' ' 30' ' ' PRO . 3.0 t -96.7 135.14 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 120.853 -1.155 . . . . 0.0 109.919 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.4 t -111.58 -16.72 13.2 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.414 -0.804 . . . . 0.0 109.375 178.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.83 150.54 0.5 Allowed 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.372 -0.83 . . . . 0.0 109.827 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.496 HG23 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -137.98 137.64 38.11 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.374 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.526 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.3 OUTLIER -89.61 104.26 16.84 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.192 -0.942 . . . . 0.0 108.7 179.555 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.672 ' HB2' ' HB ' ' A' ' 47' ' ' VAL . 26.1 m95 -87.65 178.73 6.68 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.906 -1.121 . . . . 0.0 109.45 -179.589 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.449 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.7 OUTLIER -149.8 102.27 3.13 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 178.359 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.581 ' CE1' HG22 ' A' ' 47' ' ' VAL . 2.1 m-30 -80.51 -58.58 3.05 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.696 -1.202 . . . . 0.0 109.966 -178.134 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.87 15.82 57.3 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.079 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -104.63 -105.72 0.3 Allowed 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 178.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.13 -17.41 67.17 Favored Glycine 0 C--N 1.296 -1.669 0 N-CA-C 107.982 -2.047 . . . . 0.0 107.982 177.042 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.4 m -135.88 125.42 25.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.413 -1.051 . . . . 0.0 109.042 179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.24 -84.59 0.1 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.053 -1.029 . . . . 0.0 109.849 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.479 ' C ' HG21 ' A' ' 47' ' ' VAL . 39.9 mt-10 -58.42 149.78 24.09 Favored 'General case' 0 N--CA 1.495 1.809 0 CA-C-O 121.272 0.558 . . . . 0.0 110.105 -179.685 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.672 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 21.1 t -139.68 128.98 28.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.26 -0.9 . . . . 0.0 111.263 -178.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -108.15 91.4 3.63 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 177.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.551 ' HB1' ' CD1' ' A' ' 38' ' ' TRP . . . -97.35 155.67 16.79 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.347 -0.845 . . . . 0.0 111.517 -177.796 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.56 151.01 20.38 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.778 -0.576 . . . . 0.0 109.477 179.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.496 ' O ' HG23 ' A' ' 36' ' ' THR . . . 47.84 -159.11 0.61 Allowed Glycine 0 N--CA 1.489 2.181 0 N-CA-C 107.997 -2.041 . . . . 0.0 107.997 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.474 ' HB3' HG23 ' A' ' 33' ' ' VAL . 37.8 Cg_endo -87.43 41.2 0.69 Allowed 'Trans proline' 0 C--N 1.297 -2.14 0 C-N-CA 122.017 1.811 . . . . 0.0 109.99 178.265 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.48 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -143.46 150.44 39.0 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.152 -1.592 . . . . 0.0 112.097 -178.654 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.478 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -160.02 -168.32 2.19 Favored 'General case' 0 N--CA 1.495 1.778 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 179.045 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.468 ' O ' ' CZ ' ' A' ' 40' ' ' PHE . 0.1 OUTLIER -152.67 154.31 35.06 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.219 -0.926 . . . . 0.0 109.09 179.491 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.581 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 13.3 m80 -113.63 133.86 55.05 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.043 -1.036 . . . . 0.0 111.411 -178.63 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.423 ' HA ' HD21 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -104.75 87.17 2.61 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 178.723 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.609 ' CE1' ' CG ' ' A' ' 64' ' ' TYR . 31.7 m-85 -89.44 125.37 35.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.199 -0.938 . . . . 0.0 109.684 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 86.0 t -114.58 -34.52 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.428 -0.795 . . . . 0.0 110.928 -178.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.452 ' CD2' ' HD2' ' A' ' 61' ' ' PRO . 0.2 OUTLIER -90.78 145.94 33.02 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 120.542 -1.349 . . . . 0.0 109.487 -179.367 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.452 ' HD2' ' CD2' ' A' ' 60' ' ' LEU . 34.8 Cg_endo -77.66 125.52 7.58 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.44 2.093 . . . . 0.0 109.937 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.87 -154.57 25.63 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.457 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 3.9 mpt_? -114.68 133.85 55.55 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.101 -1.234 . . . . 0.0 109.65 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.609 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 82.2 m-85 -115.92 150.13 37.6 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.313 -0.867 . . . . 0.0 109.714 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.429 ' CD2' HG21 ' A' ' 67' ' ' THR . 58.9 t60 -103.95 129.63 51.52 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.482 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.573 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 92.0 t -111.03 155.18 12.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.255 -0.903 . . . . 0.0 110.236 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.429 HG21 ' CD2' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -149.84 158.6 44.32 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.658 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.706 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -154.04 123.47 6.58 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.752 -1.179 . . . . 0.0 111.709 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -95.89 126.59 48.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.732 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.636 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.6 OUTLIER -88.61 142.35 27.76 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 120.727 -1.233 . . . . 0.0 108.722 -178.738 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.75 110.39 11.3 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 120.739 -1.225 . . . . 0.0 109.832 178.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.505 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -105.39 -10.84 16.73 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.137 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.38 -45.51 1.3 Allowed Glycine 0 N--CA 1.486 2.029 0 N-CA-C 107.895 -2.082 . . . . 0.0 107.895 -178.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -119.84 -5.13 10.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.605 -0.938 . . . . 0.0 109.839 179.178 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.14 165.58 27.34 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.444 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 6.8 p -151.09 -176.88 5.72 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.391 -1.064 . . . . 0.0 109.741 -179.467 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.566 ' CB ' ' HG ' ' A' ' 70' ' ' LEU . . . -155.18 164.33 38.97 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.5 tp -120.82 119.85 33.89 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.147 -0.971 . . . . 0.0 110.067 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.706 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -105.53 156.12 18.53 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.603 -0.686 . . . . 0.0 109.392 -179.702 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.573 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.14 99.34 0.16 Allowed Glycine 0 N--CA 1.485 1.905 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.408 ' OG1' ' HB ' ' A' ' 66' ' ' VAL . 0.7 OUTLIER -115.65 -173.43 2.34 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 120.923 -1.34 . . . . 0.0 110.216 179.993 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -149.79 140.07 22.25 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.572 ' CG1' ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -125.77 152.04 32.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.916 -1.115 . . . . 0.0 109.916 -179.455 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.74 86.44 2.52 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 78.8 t -77.85 140.79 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.04 -1.038 . . . . 0.0 110.355 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -114.99 -173.93 2.4 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.426 -0.797 . . . . 0.0 109.361 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.553 0 O-C-N 120.895 -1.128 . . . . 0.0 109.701 179.865 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.686 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.412 ' CG2' HG22 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -90.19 141.91 28.23 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.664 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.595 ' N ' ' CD1' ' A' ' 10' ' ' LEU . 5.3 mp -97.05 95.33 7.71 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -178.283 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.494 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 47.5 t -105.65 118.12 52.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 120.894 -1.129 . . . . 0.0 109.186 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.516 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -123.75 71.42 0.43 Allowed Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.595 ' O ' ' HB2' ' A' ' 14' ' ' HIS . 34.5 Cg_endo -72.81 150.81 50.42 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 123.136 2.557 . . . . 0.0 113.517 -178.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.595 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 145.74 179.04 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.091 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.283 178.717 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.81 -144.52 4.63 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -75.99 150.98 34.69 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.32 2.013 . . . . 0.0 109.51 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.481 HD23 ' CB ' ' A' ' 23' ' ' ALA . 17.2 mt -102.04 82.53 2.24 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.038 -1.039 . . . . 0.0 109.759 -179.578 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -75.3 165.5 25.08 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.037 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 18.1 t -58.49 114.12 2.31 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.043 -1.035 . . . . 0.0 109.187 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.404 ' HA2' ' HA ' ' A' ' 59' ' ' VAL . . . 96.54 44.28 2.98 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -120.69 155.38 33.99 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.337 -1.096 . . . . 0.0 110.879 -179.509 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.472 HD21 ' HA ' ' A' ' 57' ' ' ARG . 2.8 tm? -112.33 97.7 6.8 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.519 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -79.44 157.55 27.5 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.557 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.75 120.25 36.01 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.497 -1.377 . . . . 0.0 108.167 179.414 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.519 ' CE1' ' HB2' ' A' ' 23' ' ' ALA . 3.4 m-85 -105.16 173.55 6.26 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.987 0.899 . . . . 0.0 111.542 -177.162 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.544 ' CD2' ' C ' ' A' ' 26' ' ' HIS . 0.0 OUTLIER -168.26 138.7 2.61 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.06 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.686 HG23 ' CB ' ' A' ' 8' ' ' ALA . 5.0 mm -107.43 149.53 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.401 -0.812 . . . . 0.0 109.154 -178.282 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -134.42 124.56 25.88 Favored 'General case' 0 N--CA 1.502 2.156 0 C-N-CA 118.57 -1.252 . . . . 0.0 112.281 -178.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.72 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . -178.8 -66.0 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.101 -0.999 . . . . 0.0 109.116 177.742 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.72 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.7 Cg_endo -81.01 66.71 8.81 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.056 1.838 . . . . 0.0 109.314 179.174 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.696 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -9.93 -66.56 0.01 OUTLIER Pre-proline 0 N--CA 1.513 2.688 0 N-CA-C 112.77 0.656 . . . . 0.0 112.77 -178.427 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.696 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 37.1 Cg_endo -79.35 90.52 1.26 Allowed 'Trans proline' 0 C--N 1.314 -1.261 0 C-N-CA 121.709 1.606 . . . . 0.0 110.577 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.431 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 8.7 t -112.59 145.62 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.948 -1.095 . . . . 0.0 109.637 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -113.7 -19.08 11.7 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.515 -0.741 . . . . 0.0 110.257 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.13 151.23 0.8 Allowed 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.094 -1.004 . . . . 0.0 110.431 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.475 HG23 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -139.1 137.96 36.64 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.382 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.512 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 7.0 ttm180 -92.61 112.67 24.7 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.145 -0.972 . . . . 0.0 108.836 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.678 ' CH2' ' CD1' ' A' ' 27' ' ' ILE . 17.8 m95 -95.77 -178.97 4.56 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -0.894 . . . . 0.0 109.454 -179.812 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.496 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.57 103.06 3.08 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 177.598 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.63 ' CD1' ' NE2' ' A' ' 56' ' ' HIS . 3.1 m-30 -80.84 -65.35 1.02 Allowed 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 118.896 -1.122 . . . . 0.0 110.697 -177.369 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.51 6.82 58.36 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.509 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 12.1 p30 -98.03 31.47 2.7 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.354 -1.086 . . . . 0.0 108.777 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 116.18 -39.95 2.56 Favored Glycine 0 C--N 1.295 -1.705 0 N-CA-C 105.626 -2.99 . . . . 0.0 105.626 -176.251 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 63.8 p -105.99 103.58 13.1 Favored 'General case' 0 N--CA 1.487 1.386 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 177.452 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.496 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -77.98 -88.97 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.115 -0.991 . . . . 0.0 110.429 -178.373 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -52.67 142.85 17.4 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.311 0.576 . . . . 0.0 109.992 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.652 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 90.4 t -135.67 132.61 51.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.346 -0.847 . . . . 0.0 110.953 -178.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -111.65 92.66 4.12 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.032 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.529 ' HB1' ' CD1' ' A' ' 38' ' ' TRP . . . -97.26 151.51 19.8 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.305 -0.872 . . . . 0.0 111.283 -177.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.17 150.48 23.92 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.475 ' O ' HG23 ' A' ' 36' ' ' THR . . . 47.25 -157.44 0.63 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 108.395 -1.882 . . . . 0.0 108.395 -179.168 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -87.92 39.75 0.56 Allowed 'Trans proline' 0 C--N 1.296 -2.193 0 C-N-CA 122.037 1.825 . . . . 0.0 110.128 178.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.54 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -145.13 149.38 34.91 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.124 -1.61 . . . . 0.0 112.029 -178.54 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.498 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -154.6 -167.18 2.53 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -153.89 145.47 23.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.246 -0.909 . . . . 0.0 109.016 179.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.63 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 10.8 m80 -105.02 138.98 40.39 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.091 -1.006 . . . . 0.0 110.91 -178.804 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.472 ' HA ' HD21 ' A' ' 22' ' ' LEU . 0.3 OUTLIER -110.07 90.16 3.23 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.889 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.613 ' CZ ' HG12 ' A' ' 83' ' ' VAL . 30.9 m-85 -92.48 124.49 36.56 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 109.786 -178.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.404 ' HA ' ' HA2' ' A' ' 20' ' ' GLY . 11.4 m -119.1 -13.93 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.486 -0.759 . . . . 0.0 111.385 -178.776 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -102.7 148.41 35.49 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 120.663 -1.273 . . . . 0.0 109.618 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -78.21 116.45 3.91 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.453 2.102 . . . . 0.0 109.782 179.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.71 -156.92 27.38 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 2.3 ptt-85 -112.49 159.69 18.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.179 -1.189 . . . . 0.0 110.135 -179.779 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.499 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 87.4 m-85 -136.05 159.74 40.79 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.455 -0.778 . . . . 0.0 109.328 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -116.52 115.99 26.8 Favored 'General case' 0 N--CA 1.486 1.372 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.521 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 83.3 t -97.77 148.48 5.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.373 -0.83 . . . . 0.0 110.551 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.437 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 2.1 p -145.38 156.0 43.51 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 178.322 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.727 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -152.44 164.79 36.83 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.741 -1.224 . . . . 0.0 110.955 -179.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 9.5 p -139.69 129.26 29.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 N-CA-C 107.146 -1.428 . . . . 0.0 107.146 178.251 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.612 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.1 OUTLIER -88.03 142.03 28.1 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.845 -1.159 . . . . 0.0 108.749 -178.358 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.61 107.4 9.16 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 118.585 -1.246 . . . . 0.0 109.935 178.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.415 HD13 ' HB2' ' A' ' 30' ' ' PRO . 0.5 OUTLIER -105.39 -9.98 17.24 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.832 179.159 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.47 -49.5 0.87 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 107.734 -2.146 . . . . 0.0 107.734 -178.413 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.52 -5.91 11.19 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.626 -0.926 . . . . 0.0 109.692 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.65 154.73 23.84 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 29.7 p -149.53 -179.86 7.42 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.291 -1.123 . . . . 0.0 109.421 -179.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.596 ' CB ' ' HG ' ' A' ' 70' ' ' LEU . . . -154.79 162.9 40.94 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.622 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -116.67 131.41 56.96 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.098 -1.001 . . . . 0.0 110.128 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.727 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -115.48 157.68 23.66 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.555 -0.715 . . . . 0.0 109.717 -179.809 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.509 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.29 89.28 0.09 OUTLIER Glycine 0 N--CA 1.483 1.822 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.454 HG21 HD21 ' A' ' 10' ' ' LEU . 0.2 OUTLIER -109.14 -171.71 1.9 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.04 -1.27 . . . . 0.0 109.55 179.675 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -150.81 155.69 39.74 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 179.398 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.613 HG12 ' CZ ' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.24 151.65 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.659 -1.276 . . . . 0.0 109.776 -179.868 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.412 ' N ' HG21 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -117.05 85.93 2.42 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.031 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 47.3 t -77.52 136.71 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.791 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -123.25 141.08 52.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.425 -0.797 . . . . 0.0 109.959 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.911 . . . . 0.0 109.433 179.658 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.625 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.526 HG22 HG21 ' A' ' 11' ' ' VAL . 1.0 OUTLIER -73.51 148.95 42.61 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.182 -0.949 . . . . 0.0 109.157 -179.374 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.668 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.3 mp -91.17 103.13 15.85 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.339 -178.413 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.545 ' HB ' ' CE1' ' A' ' 26' ' ' HIS . 2.6 t -115.38 104.54 16.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 120.928 -1.108 . . . . 0.0 108.682 178.497 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.571 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.37 76.51 0.29 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -179.348 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.541 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 31.1 Cg_endo -71.42 148.24 54.12 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.674 2.249 . . . . 0.0 111.973 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.452 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 41.4 t60 161.13 -37.19 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.3 -139.4 14.81 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 107.952 -2.059 . . . . 0.0 107.952 -179.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -76.66 145.78 26.29 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 122.02 1.813 . . . . 0.0 109.064 178.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.497 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 3.3 mm? -104.53 92.94 4.52 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.167 -0.958 . . . . 0.0 109.871 -179.074 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.9 160.2 30.92 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.165 -0.96 . . . . 0.0 108.515 179.104 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.3 t -56.14 125.17 20.51 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.223 -0.923 . . . . 0.0 109.937 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 80.69 49.15 5.86 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -123.4 151.82 42.21 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.35 -1.088 . . . . 0.0 110.744 -179.517 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.463 HD21 ' HA ' ' A' ' 22' ' ' LEU . 2.2 tm? -105.97 98.65 8.31 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.502 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.454 ' HB2' ' HE1' ' A' ' 25' ' ' PHE . . . -78.83 153.09 30.93 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.159 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.541 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -116.66 118.16 31.8 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.469 -1.395 . . . . 0.0 108.44 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.684 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 7.4 m-85 -107.79 168.35 9.33 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 122.417 1.103 . . . . 0.0 112.262 -177.183 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.545 ' CE1' ' HB ' ' A' ' 11' ' ' VAL . 4.1 p80 -167.92 145.52 4.36 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 176.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.74 HD13 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.2 161.25 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.868 -1.145 . . . . 0.0 108.906 -178.336 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -139.43 119.55 13.61 Favored 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.556 -1.258 . . . . 0.0 112.433 -178.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.72 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 174.24 -68.87 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 177.614 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.72 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -77.6 78.21 3.6 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 121.779 1.653 . . . . 0.0 109.34 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.484 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -33.52 -53.95 0.74 Allowed Pre-proline 0 N--CA 1.5 2.029 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -178.913 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.484 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.7 Cg_endo -79.81 58.57 7.04 Favored 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.183 1.922 . . . . 0.0 111.877 -179.283 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.583 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 73.3 t -82.23 148.43 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 120.843 -1.16 . . . . 0.0 109.273 179.11 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.3 t -120.95 -36.79 3.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.318 -0.864 . . . . 0.0 109.661 179.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -152.06 139.19 19.22 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.453 -0.78 . . . . 0.0 109.156 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.547 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.2 t -127.52 134.92 49.75 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.535 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 2.8 tpp180 -104.07 104.06 13.95 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.042 -1.036 . . . . 0.0 109.174 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.684 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 29.4 m95 -87.82 -179.76 6.32 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.078 -1.014 . . . . 0.0 109.172 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -148.31 100.55 3.16 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 177.724 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.592 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 2.8 m-30 -80.01 -60.72 2.23 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 118.733 -1.187 . . . . 0.0 109.746 -178.122 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.98 15.93 55.27 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -178.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.25 -104.22 0.25 Allowed 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 178.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.08 -23.92 50.26 Favored Glycine 0 C--N 1.296 -1.649 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 176.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.8 m -128.62 127.69 42.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.501 -1.0 . . . . 0.0 109.04 179.426 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -81.11 -83.91 0.11 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.063 -1.023 . . . . 0.0 109.644 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.456 ' C ' HG21 ' A' ' 47' ' ' VAL . 2.4 pm0 -58.48 152.2 18.56 Favored 'General case' 0 N--CA 1.495 1.799 0 CA-C-O 121.222 0.534 . . . . 0.0 109.567 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.639 ' CB ' ' HB2' ' A' ' 38' ' ' TRP . 43.9 t -138.07 113.9 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.069 -1.019 . . . . 0.0 111.444 -178.444 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.19 105.18 17.09 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 177.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.493 ' CB ' ' HB1' ' A' ' 54' ' ' ALA . . . -118.74 168.34 10.82 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.143 -0.973 . . . . 0.0 111.042 -178.671 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.05 155.32 18.47 Favored 'General case' 0 N--CA 1.49 1.532 0 CA-C-O 121.503 0.668 . . . . 0.0 109.796 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.43 ' O ' HG21 ' A' ' 36' ' ' THR . . . 46.29 -155.42 0.64 Allowed Glycine 0 N--CA 1.488 2.159 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -89.77 40.48 0.45 Allowed 'Trans proline' 0 C--N 1.295 -2.284 0 C-N-CA 122.464 2.11 . . . . 0.0 110.484 178.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.516 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -143.75 154.09 43.1 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 119.899 -1.751 . . . . 0.0 112.658 -178.629 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.524 ' HB2' ' CE2' ' A' ' 38' ' ' TRP . . . -174.36 155.36 2.32 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -115.61 155.03 28.38 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.591 -1.318 . . . . 0.0 110.768 -179.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.592 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 5.3 m80 -105.36 143.31 33.7 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.465 0.65 . . . . 0.0 110.791 -179.221 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -115.05 94.57 4.8 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.57 ' CE2' ' CG1' ' A' ' 83' ' ' VAL . 25.9 m-85 -99.1 126.98 44.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.148 -0.97 . . . . 0.0 109.747 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 8.2 m -119.46 -31.06 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.362 -0.836 . . . . 0.0 111.553 -178.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.512 ' HB3' ' OH ' ' A' ' 64' ' ' TYR . 0.6 OUTLIER -96.49 140.56 22.24 Favored Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 120.579 -1.325 . . . . 0.0 109.165 -179.49 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.468 ' N ' ' HG ' ' A' ' 60' ' ' LEU . 32.5 Cg_endo -73.1 135.78 23.55 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.293 1.995 . . . . 0.0 110.567 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 148.36 -140.01 8.04 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -179.538 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -129.54 137.64 50.88 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.211 -1.17 . . . . 0.0 109.61 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.552 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 79.0 m-85 -117.36 159.68 22.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.313 -0.867 . . . . 0.0 109.449 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.426 ' CD2' HG23 ' A' ' 67' ' ' THR . 11.2 t60 -114.13 126.27 54.9 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.838 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.509 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 60.1 t -108.94 151.41 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.295 -0.878 . . . . 0.0 110.559 -179.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.426 HG23 ' CD2' ' A' ' 65' ' ' HIS . 0.1 OUTLIER -148.92 161.23 42.29 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.459 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.761 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -157.96 122.48 4.25 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.869 -1.144 . . . . 0.0 111.609 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.1 p -112.96 109.15 27.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 177.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -88.89 147.27 24.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.787 -1.196 . . . . 0.0 109.791 -179.12 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -126.76 116.5 21.02 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.353 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.492 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 5.6 mp -103.53 -13.42 16.58 Favored 'General case' 0 C--N 1.292 -1.92 0 CA-C-O 121.495 0.664 . . . . 0.0 109.417 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 114.78 -51.55 0.71 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 107.9 -2.08 . . . . 0.0 107.9 -178.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.35 -5.73 12.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.576 -0.955 . . . . 0.0 109.894 179.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.3 162.98 27.88 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.7 p -151.24 169.48 21.82 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.393 -1.063 . . . . 0.0 109.59 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.533 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -142.85 136.15 28.43 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 109.463 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.5 tt -101.65 132.41 47.35 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.287 -0.883 . . . . 0.0 110.335 -179.426 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.761 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -121.06 155.01 35.34 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.561 -0.712 . . . . 0.0 110.21 -179.372 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.509 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -162.21 88.05 0.11 Allowed Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.437 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.483 HG21 HD22 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -104.98 -176.65 3.14 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.112 -1.228 . . . . 0.0 109.903 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -150.47 143.76 24.95 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.57 ' CG1' ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -130.43 153.08 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 120.567 -1.333 . . . . 0.0 110.22 -179.331 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.421 ' N ' HG21 ' A' ' 83' ' ' VAL . 32.4 tt0 -118.59 100.79 7.66 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 42.9 t -80.9 136.42 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.148 -0.97 . . . . 0.0 109.854 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -121.21 -156.61 0.69 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.619 -0.676 . . . . 0.0 109.54 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.406 0 O-C-N 121.484 -0.76 . . . . 0.0 110.325 179.464 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.711 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.432 0 CA-C-O 121.457 0.646 . . . . 0.0 109.412 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.415 ' CG2' HG22 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -87.3 141.04 28.94 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.857 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.628 ' HG ' ' CD2' ' A' ' 79' ' ' LEU . 5.4 mp -97.22 94.85 7.34 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.003 -177.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.497 ' CB ' ' CE1' ' A' ' 26' ' ' HIS . 41.1 t -107.1 115.99 49.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.89 -1.131 . . . . 0.0 108.568 178.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.452 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -121.98 71.78 0.39 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.363 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.537 ' O ' ' CB ' ' A' ' 14' ' ' HIS . 34.4 Cg_endo -73.63 150.79 45.93 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.942 2.428 . . . . 0.0 112.036 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.537 ' CB ' ' O ' ' A' ' 13' ' ' PRO . 16.0 t-80 150.29 -39.52 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 CA-C-N 115.44 -0.8 . . . . 0.0 108.935 179.53 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 116.4 -142.97 17.88 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.49 -1.844 . . . . 0.0 108.49 -179.218 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.82 149.01 25.9 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 122.306 2.004 . . . . 0.0 109.779 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.597 HD11 ' HB3' ' A' ' 21' ' ' GLN . 4.4 mm? -105.2 106.74 17.37 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.181 -0.949 . . . . 0.0 109.207 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.402 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -93.44 168.72 10.87 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.01 -1.057 . . . . 0.0 108.905 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 28.1 t -56.42 120.81 8.29 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.364 -0.835 . . . . 0.0 109.045 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 80.3 44.14 9.0 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . 0.597 ' HB3' HD11 ' A' ' 17' ' ' LEU . 23.0 tp60 -113.35 147.3 37.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.523 -0.986 . . . . 0.0 110.697 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.427 HD21 ' HA ' ' A' ' 22' ' ' LEU . 1.8 tm? -108.35 96.32 6.27 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.565 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.495 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -78.86 156.59 28.6 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 178.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.516 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.63 108.85 14.05 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.415 -1.428 . . . . 0.0 108.224 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.544 ' CE1' ' HB2' ' A' ' 56' ' ' HIS . 2.6 m-85 -95.19 166.7 11.78 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 122.098 0.952 . . . . 0.0 111.57 -177.282 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.559 ' CD2' ' C ' ' A' ' 26' ' ' HIS . 0.0 OUTLIER -159.74 135.89 8.82 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 177.864 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.711 HG23 ' CB ' ' A' ' 8' ' ' ALA . 5.0 mm -108.97 152.01 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.368 -0.833 . . . . 0.0 109.526 -177.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -136.93 136.12 38.32 Favored 'General case' 0 N--CA 1.506 2.354 0 C-N-CA 118.439 -1.305 . . . . 0.0 113.045 -178.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.762 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 174.05 -71.4 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.951 0 O-C-N 121.002 -1.061 . . . . 0.0 108.963 177.352 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.762 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -79.44 72.89 6.28 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 C-N-CA 121.778 1.652 . . . . 0.0 109.13 178.486 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.633 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -13.81 -63.79 0.03 OUTLIER Pre-proline 0 N--CA 1.512 2.661 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -178.437 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.633 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 36.4 Cg_endo -78.22 63.43 8.29 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 C-N-CA 121.889 1.726 . . . . 0.0 111.187 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.658 HG21 ' HG2' ' A' ' 30' ' ' PRO . 62.1 t -80.95 148.26 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.901 -1.124 . . . . 0.0 109.635 179.616 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 t -120.49 -18.33 7.88 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.345 -0.847 . . . . 0.0 110.648 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -176.48 139.27 0.33 Allowed 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.013 -1.055 . . . . 0.0 110.329 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.664 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 0.5 OUTLIER -126.73 134.22 50.71 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.356 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.476 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 1.1 mtm180 -93.11 113.83 26.18 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.295 -0.878 . . . . 0.0 108.736 179.462 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.666 ' CH2' ' CD1' ' A' ' 27' ' ' ILE . 11.8 m95 -99.19 -179.25 4.18 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 121.976 0.893 . . . . 0.0 109.853 -179.403 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.5 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.62 103.3 3.1 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 177.245 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.637 ' CD1' ' NE2' ' A' ' 56' ' ' HIS . 2.7 m-30 -80.78 -65.14 1.05 Allowed 'General case' 0 N--CA 1.492 1.656 0 C-N-CA 118.784 -1.166 . . . . 0.0 110.809 -177.378 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.37 1.47 59.22 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -178.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.4 p30 -95.57 34.97 1.4 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.293 -1.122 . . . . 0.0 108.403 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.43 -36.46 4.25 Favored Glycine 0 C--N 1.296 -1.677 0 N-CA-C 105.845 -2.902 . . . . 0.0 105.845 -176.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.406 ' O ' ' HB2' ' A' ' 40' ' ' PHE . 18.1 m -104.05 94.05 5.18 Favored 'General case' 0 N--CA 1.487 1.375 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.057 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.49 -95.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.22 -0.925 . . . . 0.0 110.066 -178.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -52.22 146.67 8.78 Favored 'General case' 0 N--CA 1.496 1.87 0 CA-C-O 121.194 0.521 . . . . 0.0 109.879 -179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.618 HG23 ' CZ ' ' A' ' 40' ' ' PHE . 95.6 t -138.49 130.69 38.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.347 -0.846 . . . . 0.0 110.969 -178.823 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -111.37 94.71 5.11 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.528 ' CB ' ' HB1' ' A' ' 54' ' ' ALA . . . -100.45 147.9 25.35 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.226 -0.921 . . . . 0.0 111.146 -178.373 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.7 151.8 26.07 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.731 -0.605 . . . . 0.0 109.499 179.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.501 ' O ' HG23 ' A' ' 36' ' ' THR . . . 46.82 -156.55 0.61 Allowed Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.64 -1.784 . . . . 0.0 108.64 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . 0.47 ' HA ' HG23 ' A' ' 36' ' ' THR . 38.2 Cg_endo -88.05 39.33 0.52 Allowed 'Trans proline' 0 C--N 1.296 -2.191 0 C-N-CA 122.406 2.071 . . . . 0.0 110.438 178.374 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -145.38 146.65 31.65 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 119.93 -1.731 . . . . 0.0 112.156 -178.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.528 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -156.15 -178.81 7.59 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 178.558 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -141.62 152.49 44.04 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.735 -1.228 . . . . 0.0 109.477 179.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.637 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 5.4 m80 -108.16 138.82 43.78 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.473 -0.767 . . . . 0.0 110.618 -178.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -111.95 89.71 3.14 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.565 ' CZ ' HG12 ' A' ' 83' ' ' VAL . 34.5 m-85 -90.25 130.34 36.38 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.172 -0.955 . . . . 0.0 109.307 -179.172 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 9.4 p -116.58 -30.8 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.252 -0.905 . . . . 0.0 111.283 -178.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.413 ' CG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -100.91 146.7 32.58 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 120.703 -1.248 . . . . 0.0 109.453 -179.226 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.413 ' HD2' ' CG ' ' A' ' 60' ' ' LEU . 34.7 Cg_endo -76.91 121.46 5.86 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.255 1.97 . . . . 0.0 109.944 179.601 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 164.46 -157.05 29.28 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -112.47 120.76 42.73 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.022 -1.281 . . . . 0.0 109.986 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.477 ' CB ' ' CE1' ' A' ' 58' ' ' TYR . 86.4 m-85 -105.07 147.13 28.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.492 -0.755 . . . . 0.0 109.349 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -104.24 132.35 50.58 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.494 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 79.6 t -113.57 149.4 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.153 -0.967 . . . . 0.0 110.462 -179.128 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.5 p -148.15 153.91 39.46 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 178.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.728 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -150.94 163.03 39.67 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.946 -1.096 . . . . 0.0 110.883 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.429 ' HA ' ' O ' ' A' ' 77' ' ' ALA . 12.1 p -150.9 112.27 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.664 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -89.01 143.17 27.04 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 120.481 -1.387 . . . . 0.0 110.287 -178.205 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -122.63 117.74 26.51 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -105.88 -13.98 15.35 Favored 'General case' 0 C--N 1.29 -2.003 0 CA-C-O 121.587 0.708 . . . . 0.0 109.388 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 110.72 -51.42 0.7 Allowed Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 -179.09 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -110.77 -6.08 14.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.6 -0.941 . . . . 0.0 109.628 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.87 160.37 28.48 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 2.0 p -150.58 164.06 36.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.247 -1.149 . . . . 0.0 109.712 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.536 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -138.47 163.71 31.25 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.446 -0.783 . . . . 0.0 109.111 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 15.3 mt -122.9 150.35 43.03 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.173 -0.954 . . . . 0.0 109.939 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.728 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -132.43 160.43 36.44 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.436 -0.79 . . . . 0.0 109.885 -179.44 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.486 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -172.14 99.82 0.15 Allowed Glycine 0 N--CA 1.485 1.965 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.414 HG21 HD21 ' A' ' 10' ' ' LEU . 1.2 p -120.85 -172.42 2.38 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.137 -1.213 . . . . 0.0 110.167 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -151.01 145.31 25.46 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.565 HG12 ' CZ ' ' A' ' 58' ' ' TYR . 0.2 OUTLIER -132.64 144.23 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 120.749 -1.219 . . . . 0.0 109.906 -179.502 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -107.69 85.88 2.2 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.512 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 75.6 t -70.46 132.46 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.279 -0.888 . . . . 0.0 110.118 -179.254 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -114.14 -162.96 0.84 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.018 -1.051 . . . . 0.0 109.479 179.734 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.652 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.443 ' CG2' HG22 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.79 139.68 30.22 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.77 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.594 ' N ' ' CD1' ' A' ' 10' ' ' LEU . 5.6 mp -97.19 89.55 4.81 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.148 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.495 ' CB ' ' CE1' ' A' ' 26' ' ' HIS . 65.3 t -99.08 112.34 30.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.885 -1.134 . . . . 0.0 109.092 179.521 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.497 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -124.1 71.18 0.44 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.541 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.4 Cg_endo -73.64 150.4 45.22 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.803 2.336 . . . . 0.0 112.153 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.454 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.9 t-80 168.9 -38.87 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.681 0.753 . . . . 0.0 109.208 179.353 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.29 -138.05 14.56 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 -178.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.62 147.0 24.57 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 121.972 1.782 . . . . 0.0 109.166 178.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 2.7 mt -117.26 98.56 6.5 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.2 -0.937 . . . . 0.0 109.779 -179.301 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.09 165.66 14.98 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 t -60.85 114.74 3.22 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.243 -0.91 . . . . 0.0 109.272 -179.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.68 39.52 2.72 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.84 154.58 51.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.152 -1.205 . . . . 0.0 110.015 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.606 HD12 ' HB2' ' A' ' 55' ' ' SER . 0.1 OUTLIER -115.82 128.14 55.59 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.805 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.692 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -92.69 148.37 22.12 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.252 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.541 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -105.25 121.9 44.81 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.067 -1.645 . . . . 0.0 108.04 179.012 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.692 ' CE1' ' HB2' ' A' ' 23' ' ' ALA . 5.2 m-85 -105.39 170.53 7.83 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 121.914 0.864 . . . . 0.0 111.721 -177.009 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.567 ' CD2' ' C ' ' A' ' 26' ' ' HIS . 0.0 OUTLIER -166.72 140.14 3.84 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.793 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.679 ' CD1' ' CH2' ' A' ' 38' ' ' TRP . 4.6 mm -109.42 148.67 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.279 -0.888 . . . . 0.0 109.309 -178.345 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -133.33 122.6 24.07 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.989 -178.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.679 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 175.25 -61.86 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.078 -1.014 . . . . 0.0 109.552 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.679 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 35.3 Cg_endo -79.17 68.49 8.27 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.209 1.939 . . . . 0.0 109.699 179.551 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.621 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.0 OUTLIER -15.42 -64.03 0.03 OUTLIER Pre-proline 0 N--CA 1.506 2.327 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.83 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.621 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.4 Cg_endo -78.52 73.39 5.9 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 C-N-CA 121.774 1.65 . . . . 0.0 111.202 -179.513 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.49 HG21 ' HG2' ' A' ' 30' ' ' PRO . 2.8 t -96.41 136.64 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.894 -1.129 . . . . 0.0 109.656 179.338 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.5 t -115.89 -15.33 11.25 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.48 -0.763 . . . . 0.0 109.331 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.6 149.43 0.48 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.311 -0.868 . . . . 0.0 109.667 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.459 HG23 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -136.93 139.68 41.73 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.59 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.511 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 10.2 mtm-85 -93.33 109.04 20.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.138 -0.976 . . . . 0.0 109.136 179.657 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.679 ' CH2' ' CD1' ' A' ' 27' ' ' ILE . 18.7 m95 -93.85 179.81 5.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.918 -1.114 . . . . 0.0 109.621 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.482 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.76 106.61 3.41 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.328 -1.731 . . . . 0.0 106.328 177.369 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.616 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 3.7 m-30 -81.37 -66.44 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 118.451 -1.3 . . . . 0.0 111.37 -176.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.11 -4.91 59.03 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.1 p30 -90.41 23.71 2.86 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.335 -1.097 . . . . 0.0 109.164 179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 122.56 -38.11 2.64 Favored Glycine 0 C--N 1.298 -1.576 0 N-CA-C 106.129 -2.788 . . . . 0.0 106.129 -176.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.77 101.52 12.96 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 177.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.38 -98.28 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 0.0 109.958 -178.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.436 ' C ' HG21 ' A' ' 47' ' ' VAL . 1.6 mm-40 -56.92 150.1 17.33 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.286 0.565 . . . . 0.0 109.927 -179.588 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.668 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 70.8 t -138.9 132.97 40.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.47 -0.769 . . . . 0.0 110.591 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -112.89 89.8 3.18 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.283 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.529 ' HB1' ' CD1' ' A' ' 38' ' ' TRP . . . -92.84 152.53 19.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.373 -0.829 . . . . 0.0 111.423 -178.135 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.72 150.2 23.75 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.459 ' O ' HG23 ' A' ' 36' ' ' THR . . . 46.08 -156.4 0.49 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.24 -1.944 . . . . 0.0 108.24 -179.27 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -88.43 42.63 0.7 Allowed 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.122 1.881 . . . . 0.0 110.479 178.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.494 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -146.87 144.38 29.24 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.072 -1.642 . . . . 0.0 112.009 -179.089 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.463 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -149.54 -169.6 3.42 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.606 ' HB2' HD12 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -152.64 138.8 18.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.249 -0.907 . . . . 0.0 109.174 179.558 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.616 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 11.1 m80 -102.91 135.45 44.57 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.231 -0.918 . . . . 0.0 111.101 -178.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -100.44 95.06 6.49 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 177.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.592 ' CZ ' HG12 ' A' ' 83' ' ' VAL . 23.8 m-85 -95.5 120.24 35.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.225 -0.922 . . . . 0.0 109.232 -179.232 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.6 p -118.17 -29.71 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.241 -0.912 . . . . 0.0 111.165 -178.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -90.71 143.35 28.82 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 120.619 -1.3 . . . . 0.0 109.376 -179.678 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.405 ' HA ' HG13 ' A' ' 85' ' ' VAL . 34.0 Cg_endo -76.26 133.04 14.34 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.575 2.183 . . . . 0.0 110.281 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.59 -135.05 5.93 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 -179.616 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -127.27 164.51 21.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -1.193 . . . . 0.0 109.651 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.509 ' HB2' HG12 ' A' ' 83' ' ' VAL . 59.7 m-85 -142.98 152.84 42.39 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.466 -0.771 . . . . 0.0 109.205 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -112.99 130.37 56.16 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.514 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 59.2 t -116.0 150.58 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 110.821 -178.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.79 155.51 42.42 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.85 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.756 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -150.53 158.57 44.31 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.853 -1.155 . . . . 0.0 111.518 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -129.84 127.17 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.423 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.645 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.3 OUTLIER -89.07 141.87 28.12 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 120.656 -1.277 . . . . 0.0 109.015 -178.743 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.3 110.48 11.56 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.589 -1.245 . . . . 0.0 109.698 178.425 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.602 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 5.9 mp -105.49 -11.1 16.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.072 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.66 -49.62 0.83 Allowed Glycine 0 N--CA 1.486 2.011 0 N-CA-C 107.669 -2.173 . . . . 0.0 107.669 -178.128 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.44 -5.76 11.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.58 -0.953 . . . . 0.0 109.884 178.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -140.04 162.5 26.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.465 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.8 p -151.44 -179.23 7.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.306 -1.114 . . . . 0.0 109.579 -179.598 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.595 ' CB ' ' HG ' ' A' ' 70' ' ' LEU . . . -154.17 166.39 33.25 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.2 mt -119.93 132.75 55.62 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.068 -1.02 . . . . 0.0 110.227 -179.401 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.756 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -117.4 157.14 26.7 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.524 -0.735 . . . . 0.0 109.769 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.65 95.12 0.11 Allowed Glycine 0 N--CA 1.485 1.938 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.467 HG21 HD21 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -116.38 -173.33 2.35 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.232 -1.158 . . . . 0.0 109.937 179.932 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -150.74 153.7 36.0 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.435 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.592 HG12 ' CZ ' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.0 154.25 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.66 -1.275 . . . . 0.0 109.845 -179.519 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.45 ' N ' HG21 ' A' ' 83' ' ' VAL . 12.0 tt0 -123.07 99.81 6.56 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.464 -0.773 . . . . 0.0 108.985 179.073 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.405 HG13 ' HA ' ' A' ' 61' ' ' PRO . 41.6 t -86.15 137.71 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.24 -0.912 . . . . 0.0 109.846 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -113.15 154.41 26.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 -179.473 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.101 -0.999 . . . . 0.0 109.667 179.711 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.675 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.43 ' CG2' HG22 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -90.12 141.62 28.51 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.636 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.595 ' HG ' ' CD2' ' A' ' 79' ' ' LEU . 5.3 mp -98.01 97.96 9.36 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -178.188 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.481 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 47.2 t -109.69 115.92 50.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 120.875 -1.141 . . . . 0.0 109.189 179.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -125.67 68.68 0.51 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.634 ' O ' ' HB2' ' A' ' 14' ' ' HIS . 36.7 Cg_endo -75.16 151.05 38.34 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 123.082 2.521 . . . . 0.0 112.655 -179.252 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.634 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 21.6 t60 162.61 -36.36 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.881 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.472 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.85 -138.6 14.93 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -179.377 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.8 151.74 28.31 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.42 2.08 . . . . 0.0 109.878 179.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.456 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 65.8 mt -120.87 99.74 6.69 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.113 -0.992 . . . . 0.0 109.917 -179.717 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.402 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -91.78 170.94 9.49 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.7 t -53.15 120.06 5.47 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.914 . . . . 0.0 109.818 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.74 48.3 4.5 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . 0.456 ' HB3' ' CD2' ' A' ' 17' ' ' LEU . 1.6 mm-40 -115.78 143.81 44.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.432 -1.04 . . . . 0.0 110.449 -179.535 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.438 HD21 ' HA ' ' A' ' 57' ' ' ARG . 2.5 tm? -108.35 93.26 4.43 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.175 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.537 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -75.49 155.21 36.4 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.94 -1.1 . . . . 0.0 108.089 179.341 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.547 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.08 114.5 22.59 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.475 -1.39 . . . . 0.0 108.076 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.537 ' CE1' ' HB2' ' A' ' 23' ' ' ALA . 3.8 m-85 -100.15 174.65 6.05 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 122.135 0.969 . . . . 0.0 111.805 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.549 ' HA ' ' HA ' ' A' ' 53' ' ' ALA . 0.0 OUTLIER -168.53 139.09 2.52 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 177.997 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.7 ' CD1' ' CH2' ' A' ' 38' ' ' TRP . 4.7 mm -107.95 149.33 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.37 -0.831 . . . . 0.0 109.063 -178.37 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -133.35 125.09 28.41 Favored 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 118.598 -1.241 . . . . 0.0 112.274 -178.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.727 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . -179.8 -67.3 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 120.978 -1.076 . . . . 0.0 109.297 177.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.727 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.5 Cg_endo -79.89 69.58 7.88 Favored 'Trans proline' 0 C--N 1.314 -1.275 0 C-N-CA 121.944 1.763 . . . . 0.0 109.314 179.162 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.665 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -11.82 -66.21 0.02 OUTLIER Pre-proline 0 N--CA 1.51 2.546 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -178.707 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.665 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.6 Cg_endo -79.29 95.32 1.05 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 121.728 1.619 . . . . 0.0 110.424 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.448 ' CG2' ' O ' ' A' ' 30' ' ' PRO . 5.1 t -118.06 145.01 24.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 120.866 -1.146 . . . . 0.0 109.565 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.2 t -113.15 -18.64 12.09 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.495 -0.753 . . . . 0.0 110.209 179.736 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.22 152.3 0.86 Allowed 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.049 -1.032 . . . . 0.0 110.456 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.482 HG23 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -139.05 137.04 35.9 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.428 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.46 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 4.8 ttp180 -92.78 114.2 26.69 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.07 -1.019 . . . . 0.0 108.838 179.512 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.7 ' CH2' ' CD1' ' A' ' 27' ' ' ILE . 15.6 m95 -97.68 -178.61 4.17 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 -179.8 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.43 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -151.37 101.99 2.87 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 177.34 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.612 ' CD1' ' NE2' ' A' ' 56' ' ' HIS . 2.9 m-30 -80.19 -61.33 2.01 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 118.756 -1.178 . . . . 0.0 110.267 -177.52 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.62 14.63 52.59 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.068 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.06 -103.05 0.25 Allowed 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.662 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -86.63 -17.15 60.58 Favored Glycine 0 C--N 1.297 -1.59 0 N-CA-C 108.05 -2.02 . . . . 0.0 108.05 176.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 17.0 p -135.8 129.26 32.21 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.308 -1.113 . . . . 0.0 109.309 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.43 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.34 -87.66 0.08 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.024 -1.048 . . . . 0.0 109.96 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.465 ' C ' HG21 ' A' ' 47' ' ' VAL . 1.1 pt-20 -56.48 151.24 13.69 Favored 'General case' 0 N--CA 1.497 1.877 0 CA-C-O 121.358 0.599 . . . . 0.0 110.123 -179.716 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.669 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 61.5 t -140.14 134.44 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.287 -0.883 . . . . 0.0 111.019 -178.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -115.0 90.8 3.43 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 177.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.511 ' CB ' ' HB1' ' A' ' 54' ' ' ALA . . . -94.31 153.57 17.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.339 -0.85 . . . . 0.0 111.488 -177.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -89.33 150.52 22.54 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 179.283 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.482 ' O ' HG23 ' A' ' 36' ' ' THR . . . 47.84 -158.11 0.73 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 108.075 -2.01 . . . . 0.0 108.075 -179.188 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -87.69 41.0 0.65 Allowed 'Trans proline' 0 C--N 1.298 -2.101 0 C-N-CA 122.135 1.89 . . . . 0.0 110.013 178.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.549 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -145.25 147.55 32.52 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 120.232 -1.542 . . . . 0.0 111.891 -178.87 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.511 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -153.83 -169.56 3.31 Favored 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.863 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -151.87 145.24 24.77 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.135 -0.978 . . . . 0.0 109.184 179.433 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.612 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 10.6 m80 -104.33 137.67 41.89 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.259 -0.901 . . . . 0.0 111.228 -178.762 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.438 ' HA ' HD21 ' A' ' 22' ' ' LEU . 0.7 OUTLIER -108.46 88.67 2.78 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.589 ' CE2' ' CG1' ' A' ' 83' ' ' VAL . 34.2 m-85 -92.06 118.39 30.76 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.237 -0.915 . . . . 0.0 109.602 -179.296 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.2 t -106.96 -28.94 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.411 -0.806 . . . . 0.0 111.089 -178.678 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.413 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -97.21 146.92 32.17 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 120.628 -1.295 . . . . 0.0 109.617 -179.364 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.413 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.6 Cg_endo -78.28 123.81 6.26 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 C-N-CA 122.473 2.116 . . . . 0.0 109.837 179.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 158.6 -159.68 30.4 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.631 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.437 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 15.1 mtp-105 -111.34 125.97 54.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.073 -1.251 . . . . 0.0 110.152 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.573 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 82.9 m-85 -108.75 157.92 18.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.34 -0.85 . . . . 0.0 109.481 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 72.1 t60 -112.81 126.99 56.04 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.526 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.506 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 84.3 t -107.62 150.06 10.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.099 -1.001 . . . . 0.0 110.675 -179.054 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.404 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 1.2 p -147.75 155.64 41.91 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.258 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.749 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -152.5 165.96 33.47 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.822 -1.174 . . . . 0.0 110.751 -179.674 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.3 p -141.81 130.6 22.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 107.197 -1.409 . . . . 0.0 107.197 178.315 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.598 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.1 OUTLIER -88.16 140.7 29.22 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 120.947 -1.096 . . . . 0.0 108.821 -178.302 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.02 108.18 9.9 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 118.555 -1.258 . . . . 0.0 109.933 178.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -106.88 -9.66 16.26 Favored 'General case' 0 C--N 1.286 -2.188 0 CA-C-N 115.415 -0.811 . . . . 0.0 108.838 178.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 102.94 -48.39 1.04 Allowed Glycine 0 N--CA 1.487 2.057 0 N-CA-C 107.599 -2.2 . . . . 0.0 107.599 -178.19 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.04 -5.51 11.95 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.687 -0.89 . . . . 0.0 109.627 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -142.35 155.73 25.79 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.425 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 17.1 p -151.05 179.71 8.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.224 -1.162 . . . . 0.0 109.598 -179.533 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.586 ' CB ' ' HG ' ' A' ' 70' ' ' LEU . . . -156.02 170.41 22.23 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.458 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -124.31 136.39 54.08 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.107 -0.996 . . . . 0.0 109.906 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.749 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -119.5 158.44 26.27 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.566 -0.709 . . . . 0.0 109.711 -179.631 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.94 94.62 0.1 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.432 HG21 HD21 ' A' ' 10' ' ' LEU . 0.5 OUTLIER -115.03 -172.12 2.07 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.088 -1.242 . . . . 0.0 110.117 -179.878 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -150.64 148.37 28.53 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.589 ' CG1' ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -132.95 153.66 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 120.842 -1.161 . . . . 0.0 109.972 -179.725 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.413 ' N ' HG22 ' A' ' 83' ' ' VAL . 30.1 tt0 -122.57 89.29 3.09 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.309 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 92.9 t -79.63 143.56 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.253 -0.904 . . . . 0.0 109.82 -179.428 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -115.84 173.3 6.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.387 -0.821 . . . . 0.0 109.667 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.149 -0.969 . . . . 0.0 109.782 -179.944 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.654 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.474 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.544 HG22 HG21 ' A' ' 11' ' ' VAL . 1.1 t -70.79 148.89 47.42 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.224 -0.923 . . . . 0.0 109.299 -179.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.565 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.6 mp -88.16 109.84 20.22 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.325 -178.312 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.574 ' HB ' ' CE1' ' A' ' 26' ' ' HIS . 1.2 t -126.21 103.91 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.01 -1.056 . . . . 0.0 108.863 178.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.599 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.8 80.52 0.3 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 -179.33 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.585 ' O ' ' HB2' ' A' ' 14' ' ' HIS . 33.2 Cg_endo -73.07 146.65 41.67 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.612 2.208 . . . . 0.0 112.538 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.592 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 62.4 t60 164.62 171.09 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -93.31 -124.16 3.67 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 178.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.86 151.07 21.4 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.314 2.01 . . . . 0.0 109.938 179.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.596 ' HB3' HG21 ' A' ' 85' ' ' VAL . 22.1 mt -121.65 89.13 3.06 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.057 -1.027 . . . . 0.0 109.469 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -90.29 167.04 12.97 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 179.214 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.3 t -51.95 118.42 3.43 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.331 -0.855 . . . . 0.0 109.403 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.71 47.86 3.58 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.1 mm-40 -119.81 155.97 31.55 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.281 -1.129 . . . . 0.0 110.868 -179.396 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.432 HD12 ' O ' ' A' ' 23' ' ' ALA . 1.8 tm? -114.52 96.62 5.85 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.757 -0.589 . . . . 0.0 109.565 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.592 ' HA ' ' CG ' ' A' ' 14' ' ' HIS . . . -81.59 160.96 23.69 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 178.552 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.518 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -122.79 111.37 16.61 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.39 -1.444 . . . . 0.0 108.744 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.599 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 4.4 m-85 -100.7 166.38 10.91 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 122.172 0.987 . . . . 0.0 112.277 -177.176 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.574 ' CE1' ' HB ' ' A' ' 11' ' ' VAL . 7.5 p80 -163.45 151.77 13.65 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 176.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.754 HD11 ' HG ' ' A' ' 79' ' ' LEU . 0.3 OUTLIER -114.51 160.94 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.0 -1.062 . . . . 0.0 108.884 -178.33 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -138.05 120.17 15.63 Favored 'General case' 0 N--CA 1.499 2.008 0 C-N-CA 118.453 -1.299 . . . . 0.0 112.653 -178.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.746 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 176.44 -72.1 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.228 -0.92 . . . . 0.0 108.963 177.57 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.746 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 35.9 Cg_endo -77.57 77.93 3.7 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 C-N-CA 121.569 1.513 . . . . 0.0 108.745 178.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.559 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 2.6 mp -33.3 -56.34 0.61 Allowed Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 122.127 -0.358 . . . . 0.0 111.631 -178.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.559 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.9 Cg_endo -80.62 75.96 4.77 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.165 1.91 . . . . 0.0 111.328 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.629 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 36.8 t -103.46 148.53 8.34 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 120.984 -1.073 . . . . 0.0 109.098 179.102 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 15.4 t -113.59 -29.06 7.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.131 -0.981 . . . . 0.0 110.256 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -162.35 144.17 10.77 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.319 -0.863 . . . . 0.0 109.91 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.633 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.8 t -127.33 162.16 26.91 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 179.539 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.493 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 13.1 mtp85 -123.89 103.12 8.15 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.721 ' CH2' HD12 ' A' ' 27' ' ' ILE . 35.1 m95 -88.55 179.94 6.18 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.05 -1.031 . . . . 0.0 109.837 -179.462 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.465 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -148.71 100.7 3.13 Favored 'General case' 0 C--N 1.291 -1.939 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 177.44 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.602 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 4.1 m-30 -80.27 -50.69 9.85 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 118.869 -1.132 . . . . 0.0 109.829 -177.748 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 80.27 21.77 64.25 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.519 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 1.2 p30 -106.96 -104.87 0.34 Allowed 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 178.483 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.88 -15.41 72.87 Favored Glycine 0 N--CA 1.48 1.607 0 N-CA-C 107.715 -2.154 . . . . 0.0 107.715 176.508 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -140.26 130.62 25.27 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.396 -1.061 . . . . 0.0 109.035 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.465 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.17 -85.48 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.956 -1.09 . . . . 0.0 109.624 -179.796 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.457 ' C ' HG21 ' A' ' 47' ' ' VAL . 10.2 pt-20 -56.5 151.2 13.82 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-O 121.268 0.556 . . . . 0.0 109.878 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.689 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 61.6 t -139.28 125.02 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.428 -0.795 . . . . 0.0 110.737 -178.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -104.67 109.72 21.76 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.227 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.545 ' CB ' ' HB1' ' A' ' 54' ' ' ALA . . . -123.33 167.83 13.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.157 -0.964 . . . . 0.0 111.024 -178.487 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.64 153.34 17.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.68 -0.638 . . . . 0.0 109.641 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.558 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 46.33 -156.33 0.55 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -89.52 39.0 0.41 Allowed 'Trans proline' 0 C--N 1.297 -2.152 0 C-N-CA 122.484 2.123 . . . . 0.0 110.25 178.468 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -140.8 151.6 44.52 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 119.976 -1.703 . . . . 0.0 112.458 -178.368 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.552 ' HB2' ' CE2' ' A' ' 38' ' ' TRP . . . -172.2 153.24 3.0 Favored 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.029 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.43 ' HB2' ' CD1' ' A' ' 22' ' ' LEU . 0.0 OUTLIER -109.84 161.09 15.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.939 -1.1 . . . . 0.0 110.237 -179.82 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.602 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 2.9 m80 -109.24 134.04 52.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.457 -0.777 . . . . 0.0 110.298 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -110.8 92.13 3.93 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.617 ' CE1' ' CG ' ' A' ' 64' ' ' TYR . 22.0 m-85 -92.33 133.49 35.81 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.136 -0.978 . . . . 0.0 109.596 -179.39 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 53.6 t -117.86 -28.15 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.418 -0.801 . . . . 0.0 110.973 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.413 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -97.78 143.28 25.94 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 120.592 -1.317 . . . . 0.0 109.611 -179.545 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.44 ' HB3' ' CB ' ' A' ' 87' ' ' ALA . 36.0 Cg_endo -79.06 120.78 4.7 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.616 2.211 . . . . 0.0 110.152 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 159.08 -143.68 9.48 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 18.5 ttm-85 -112.39 154.26 26.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -1.171 . . . . 0.0 109.572 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.617 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 54.0 m-85 -139.1 167.52 21.88 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.526 -0.734 . . . . 0.0 109.06 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 65.6 t60 -125.84 144.59 50.59 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.501 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 39.1 t -126.97 148.63 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.09 -1.006 . . . . 0.0 110.751 -179.133 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.24 161.12 43.05 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.605 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.694 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -149.48 157.55 43.39 Favored 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 119.182 -1.007 . . . . 0.0 110.92 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.407 HG22 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -145.81 106.03 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 179.16 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.633 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -87.62 143.27 27.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.652 -1.28 . . . . 0.0 109.288 -179.254 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.64 115.12 17.55 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.211 -0.996 . . . . 0.0 109.639 179.077 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.1 mt -105.88 -12.62 15.78 Favored 'General case' 0 C--N 1.289 -2.058 0 CA-C-O 121.526 0.679 . . . . 0.0 109.215 179.437 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.42 -47.32 1.05 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -178.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.23 -5.82 11.85 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.581 -0.952 . . . . 0.0 109.801 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -146.19 154.67 26.1 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 18.4 p -150.62 174.23 13.23 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.177 -1.19 . . . . 0.0 109.675 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.609 ' HB1' HD13 ' A' ' 70' ' ' LEU . . . -151.81 134.59 15.59 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.182 -0.949 . . . . 0.0 109.397 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -99.69 143.01 30.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.252 -0.905 . . . . 0.0 110.311 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.754 ' HG ' HD11 ' A' ' 27' ' ' ILE . 0.0 OUTLIER -127.53 157.91 38.85 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 121.662 -0.649 . . . . 0.0 109.966 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.459 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.03 84.59 0.1 Allowed Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.442 HG21 HD21 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -103.2 178.01 4.68 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.204 -1.174 . . . . 0.0 110.055 -179.766 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -121.43 157.78 29.81 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.31 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.617 HG12 ' CE2' ' A' ' 58' ' ' TYR . 16.4 t -137.45 143.39 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 120.997 -1.064 . . . . 0.0 110.264 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.573 ' N ' HG11 ' A' ' 83' ' ' VAL . 3.5 tt0 -132.69 101.77 5.42 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.467 -0.77 . . . . 0.0 109.27 179.448 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.596 HG21 ' HB3' ' A' ' 17' ' ' LEU . 79.5 t -103.52 140.52 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.333 -0.855 . . . . 0.0 109.714 -179.473 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -104.9 -174.71 2.6 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.158 -0.964 . . . . 0.0 109.872 -179.479 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.44 ' CB ' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.158 -0.963 . . . . 0.0 109.848 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.693 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.487 1.389 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.447 ' CG2' HG22 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.15 141.72 28.34 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.693 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.587 ' HG ' ' CD2' ' A' ' 79' ' ' LEU . 5.8 mp -97.88 91.24 5.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 -178.121 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.509 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 57.0 t -101.14 117.76 46.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.953 -1.092 . . . . 0.0 108.653 179.171 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -125.08 72.6 0.43 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.588 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.508 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 32.7 Cg_endo -73.01 147.97 44.25 Favored 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.701 2.267 . . . . 0.0 111.758 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.494 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 23.6 t-80 157.52 -33.86 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.791 0 CA-C-N 115.442 -0.799 . . . . 0.0 108.965 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.95 -143.35 15.63 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.123 -1.991 . . . . 0.0 108.123 -179.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -77.16 147.79 26.64 Favored 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.049 1.833 . . . . 0.0 108.947 179.032 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.487 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 5.6 mt -112.27 110.63 20.98 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.201 -0.937 . . . . 0.0 109.89 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -93.09 168.61 11.0 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 179.214 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.6 t -60.83 122.16 14.14 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.209 -0.932 . . . . 0.0 109.456 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.91 47.42 4.78 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.0 mm100 -125.62 157.89 36.05 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.252 -1.146 . . . . 0.0 110.934 -179.515 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.423 HD21 ' HA ' ' A' ' 22' ' ' LEU . 1.8 tm? -113.27 103.58 11.46 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.545 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -85.61 156.22 20.8 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.508 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.51 107.7 13.18 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.506 -1.371 . . . . 0.0 108.63 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.563 ' CE1' ' HB2' ' A' ' 56' ' ' HIS . 1.9 m-85 -95.36 168.78 10.51 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 121.976 0.893 . . . . 0.0 111.779 -177.53 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.541 ' CD2' ' C ' ' A' ' 26' ' ' HIS . 0.0 OUTLIER -163.72 141.21 7.28 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.502 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.693 HG23 ' CB ' ' A' ' 8' ' ' ALA . 4.9 mm -108.01 152.5 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.292 -0.88 . . . . 0.0 109.435 -178.216 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -135.28 121.7 20.5 Favored 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.781 -1.168 . . . . 0.0 112.133 -179.045 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.739 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . -177.72 -66.34 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.002 -1.061 . . . . 0.0 109.222 177.721 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.739 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.3 Cg_endo -81.72 61.7 8.02 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 C-N-CA 122.129 1.886 . . . . 0.0 109.15 178.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.664 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.1 mp -8.81 -67.09 0.01 OUTLIER Pre-proline 0 N--CA 1.508 2.45 0 N-CA-C 113.299 0.851 . . . . 0.0 113.299 -178.55 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.664 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.3 Cg_endo -77.72 68.42 7.67 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 121.892 1.728 . . . . 0.0 111.076 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.557 HG21 ' HG2' ' A' ' 30' ' ' PRO . 3.4 t -91.22 148.06 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 120.757 -1.214 . . . . 0.0 109.875 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.9 p -114.28 -18.11 11.67 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.603 -0.686 . . . . 0.0 110.045 179.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.95 152.53 0.75 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.26 -0.9 . . . . 0.0 110.284 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.48 HG23 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -140.7 140.66 34.94 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.318 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.487 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 18.3 mtm-85 -93.74 107.35 19.24 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.101 -0.999 . . . . 0.0 109.369 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.679 ' CH2' ' CD1' ' A' ' 27' ' ' ILE . 22.8 m95 -90.73 179.56 5.77 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.212 -0.93 . . . . 0.0 109.502 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.42 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.95 102.3 2.96 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 177.36 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.592 ' CD1' ' NE2' ' A' ' 56' ' ' HIS . 2.4 m-30 -80.37 -59.66 2.61 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 118.853 -1.139 . . . . 0.0 110.086 -177.722 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.03 20.06 40.63 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -107.15 -104.52 0.34 Allowed 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.619 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.91 -19.69 62.69 Favored Glycine 0 C--N 1.296 -1.67 0 N-CA-C 107.749 -2.141 . . . . 0.0 107.749 176.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 11.0 p -135.22 130.4 35.21 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.427 -1.043 . . . . 0.0 109.3 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.42 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.36 -86.65 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.115 -0.991 . . . . 0.0 109.936 -179.658 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.511 ' C ' HG21 ' A' ' 47' ' ' VAL . 4.3 pt-20 -57.62 152.84 14.32 Favored 'General case' 0 N--CA 1.497 1.89 0 CA-C-O 121.176 0.512 . . . . 0.0 110.112 -179.618 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.671 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 34.3 t -140.99 126.96 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.416 -0.803 . . . . 0.0 111.242 -178.745 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -105.44 91.78 3.92 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.345 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.526 ' CB ' ' HB1' ' A' ' 54' ' ' ALA . . . -96.03 154.97 16.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.244 -0.91 . . . . 0.0 111.677 -177.624 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.84 153.18 19.0 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.48 ' O ' HG23 ' A' ' 36' ' ' THR . . . 47.26 -158.23 0.55 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 108.248 -1.941 . . . . 0.0 108.248 -179.229 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -88.37 40.03 0.54 Allowed 'Trans proline' 0 C--N 1.297 -2.157 0 C-N-CA 122.029 1.819 . . . . 0.0 109.932 178.118 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.472 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -145.27 152.02 39.28 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 120.096 -1.628 . . . . 0.0 112.187 -178.651 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.564 ' HB1' ' NE1' ' A' ' 38' ' ' TRP . . . -165.12 155.91 14.15 Favored 'General case' 0 N--CA 1.498 1.941 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -114.41 160.71 18.84 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.932 -1.105 . . . . 0.0 110.192 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.592 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 5.8 m80 -114.54 139.34 49.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.538 -0.726 . . . . 0.0 110.489 -179.15 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -111.89 95.64 5.6 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 178.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.58 ' CE2' HG13 ' A' ' 83' ' ' VAL . 36.3 m-85 -99.02 129.86 45.32 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.161 -0.962 . . . . 0.0 109.432 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.7 t -117.91 -27.89 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.352 -0.842 . . . . 0.0 111.25 -178.433 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.459 HD22 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -99.51 146.39 31.71 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 120.511 -1.368 . . . . 0.0 109.596 -179.381 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.476 ' HA ' HG13 ' A' ' 85' ' ' VAL . 34.8 Cg_endo -77.73 124.42 6.89 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.404 2.069 . . . . 0.0 109.888 179.352 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 160.81 -151.78 22.31 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.609 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.17 120.11 33.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.113 -1.228 . . . . 0.0 109.82 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.558 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 81.6 m-85 -103.6 153.64 20.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.353 -0.842 . . . . 0.0 109.541 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.9 t60 -107.89 132.51 53.38 Favored 'General case' 0 N--CA 1.488 1.475 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.521 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 90.7 t -113.42 150.82 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 110.569 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 6.0 p -147.54 156.43 42.83 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 178.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.749 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -149.94 156.09 41.14 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.855 -1.153 . . . . 0.0 111.186 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -128.49 125.82 64.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 178.502 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.579 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.2 OUTLIER -87.76 144.58 26.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 120.535 -1.353 . . . . 0.0 109.007 -178.865 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.21 106.7 7.72 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 118.783 -1.167 . . . . 0.0 109.627 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -103.62 -10.62 18.28 Favored 'General case' 0 C--N 1.284 -2.28 0 CA-C-N 115.317 -0.856 . . . . 0.0 108.697 179.055 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.81 -47.27 1.07 Allowed Glycine 0 N--CA 1.488 2.125 0 N-CA-C 107.627 -2.189 . . . . 0.0 107.627 -178.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.31 -5.09 11.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.741 -0.858 . . . . 0.0 109.68 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.55 158.4 27.52 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.726 -1.349 . . . . 0.0 109.726 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.414 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 25.7 p -148.03 -177.71 5.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.364 -1.08 . . . . 0.0 109.405 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.578 ' CB ' ' HG ' ' A' ' 70' ' ' LEU . . . -156.55 162.69 39.9 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.8 mp -116.8 132.38 56.71 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.065 -1.022 . . . . 0.0 109.976 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.749 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -116.46 157.36 25.29 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.548 -0.72 . . . . 0.0 109.497 -179.752 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.521 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -168.24 96.3 0.12 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.407 HG21 HD21 ' A' ' 10' ' ' LEU . 0.7 OUTLIER -116.34 -171.74 2.05 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.044 -1.268 . . . . 0.0 109.732 179.791 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -151.55 147.63 27.03 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.408 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.58 HG13 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -131.77 138.44 52.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 120.68 -1.262 . . . . 0.0 110.018 -179.466 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 30.9 tt0 -105.22 90.47 3.44 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 178.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 52.9 t -76.54 130.92 35.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.307 -0.871 . . . . 0.0 109.352 -179.575 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -114.46 144.16 43.77 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.467 -0.771 . . . . 0.0 109.768 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.241 -0.912 . . . . 0.0 109.301 179.676 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.733 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.469 HG22 ' CG2' ' A' ' 11' ' ' VAL . 1.1 t -94.26 147.23 23.39 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.65 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.3 mp -91.99 88.83 6.73 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.162 -178.215 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.534 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 22.1 t -97.76 100.15 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 120.702 -1.249 . . . . 0.0 108.561 178.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.53 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -117.96 78.73 0.3 Allowed Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.276 -179.304 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.532 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.1 Cg_endo -74.99 148.11 34.88 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.404 2.069 . . . . 0.0 111.635 179.412 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 3.3 p-80 174.35 162.01 0.19 Allowed 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.5 -130.0 1.36 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 179.354 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -78.87 147.3 21.36 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 C-N-CA 121.978 1.786 . . . . 0.0 109.145 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.472 ' HB3' HG21 ' A' ' 85' ' ' VAL . 0.4 OUTLIER -113.41 84.21 1.97 Allowed 'General case' 0 C--N 1.298 -1.671 0 O-C-N 121.194 -0.941 . . . . 0.0 109.046 -179.815 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -95.53 168.16 10.86 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.58 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 39.0 t -56.71 108.52 0.51 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.294 -0.879 . . . . 0.0 109.521 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.94 37.67 2.49 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -128.21 154.42 45.85 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.227 -1.161 . . . . 0.0 109.79 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.561 HD11 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -118.66 130.01 55.61 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.118 -0.988 . . . . 0.0 109.662 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.593 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -94.92 146.01 24.53 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.014 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.532 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -101.82 129.6 48.07 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 119.978 -1.701 . . . . 0.0 108.014 178.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.7 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 16.6 m-85 -112.22 166.39 11.31 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 121.959 0.885 . . . . 0.0 111.942 -176.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.571 ' CD2' ' C ' ' A' ' 26' ' ' HIS . 0.0 OUTLIER -164.5 134.41 3.92 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 178.22 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.745 HD13 ' HG ' ' A' ' 79' ' ' LEU . 0.4 OUTLIER -103.38 149.43 7.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.17 -0.956 . . . . 0.0 109.036 -178.437 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.429 ' CB ' HG21 ' A' ' 9' ' ' THR . . . -133.73 124.31 26.44 Favored 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.545 -1.262 . . . . 0.0 112.225 -178.856 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.724 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 179.15 -66.38 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 121.118 -0.989 . . . . 0.0 109.199 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.724 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.4 Cg_endo -80.51 68.64 8.25 Favored 'Trans proline' 0 C--N 1.314 -1.281 0 C-N-CA 121.983 1.788 . . . . 0.0 109.102 178.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.66 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -10.81 -66.52 0.01 OUTLIER Pre-proline 0 N--CA 1.507 2.42 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -178.664 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.66 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 37.0 Cg_endo -79.58 83.86 2.16 Favored 'Trans proline' 0 C--N 1.314 -1.257 0 C-N-CA 121.667 1.578 . . . . 0.0 111.001 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.495 HG21 ' HG2' ' A' ' 30' ' ' PRO . 6.3 t -106.12 143.22 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.836 -1.165 . . . . 0.0 109.384 179.365 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.5 t -118.62 -14.18 9.61 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.406 -0.809 . . . . 0.0 110.412 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -174.2 146.82 1.16 Allowed 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.898 -1.126 . . . . 0.0 110.532 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.521 HG23 ' O ' ' A' ' 51' ' ' GLY . 0.4 OUTLIER -142.96 136.94 29.02 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.69 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.519 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 7.5 mtm180 -94.28 112.36 24.15 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.19 -0.944 . . . . 0.0 108.872 179.448 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.73 ' CH2' HD12 ' A' ' 27' ' ' ILE . 18.6 m95 -94.32 -177.09 4.16 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.898 0.856 . . . . 0.0 109.079 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.436 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -151.39 103.77 3.02 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 106.282 -1.748 . . . . 0.0 106.282 177.424 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.655 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 4.1 m-30 -80.04 -63.65 1.36 Allowed 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.822 -1.151 . . . . 0.0 110.31 -177.586 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.26 9.32 55.68 Favored Glycine 0 N--CA 1.486 1.974 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -178.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -93.47 -101.72 0.13 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 178.471 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -89.02 -28.92 19.38 Favored Glycine 0 C--N 1.293 -1.826 0 N-CA-C 107.507 -2.237 . . . . 0.0 107.507 177.056 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.31 130.26 55.93 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.546 -0.973 . . . . 0.0 109.38 179.438 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.436 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.3 -85.02 0.1 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.202 -0.936 . . . . 0.0 109.541 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.489 ' C ' HG21 ' A' ' 47' ' ' VAL . 0.2 OUTLIER -59.77 155.26 16.39 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.265 0.555 . . . . 0.0 110.065 -179.775 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.667 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 60.6 t -142.01 136.16 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.469 -0.769 . . . . 0.0 111.076 -178.79 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -116.16 93.2 4.14 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 177.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.516 ' HB1' ' CD1' ' A' ' 38' ' ' TRP . . . -96.35 150.13 20.92 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.359 -0.838 . . . . 0.0 111.661 -177.841 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.69 146.71 27.3 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.521 ' O ' HG23 ' A' ' 36' ' ' THR . . . 47.73 -159.16 0.58 Allowed Glycine 0 N--CA 1.492 2.385 0 N-CA-C 107.91 -2.076 . . . . 0.0 107.91 -179.03 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -86.55 41.6 0.82 Allowed 'Trans proline' 0 C--N 1.299 -2.049 0 C-N-CA 121.909 1.739 . . . . 0.0 110.12 178.253 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.502 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -144.07 141.01 29.82 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.314 -1.491 . . . . 0.0 111.65 -178.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.484 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -146.26 -166.16 2.4 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.03 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.536 ' HB2' ' CD1' ' A' ' 22' ' ' LEU . 5.4 p -156.38 136.45 12.79 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.364 -0.835 . . . . 0.0 108.919 179.391 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.655 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 9.4 m80 -99.46 131.62 45.34 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.291 -0.881 . . . . 0.0 111.329 -178.26 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -97.08 96.06 8.2 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 178.23 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.592 ' CZ ' HG12 ' A' ' 83' ' ' VAL . 16.6 m-85 -100.1 105.16 16.76 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.905 -1.122 . . . . 0.0 109.547 -179.086 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.0 m -107.73 -9.32 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.488 -0.758 . . . . 0.0 111.292 -178.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.425 ' CD2' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -105.83 145.86 31.72 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 120.46 -1.4 . . . . 0.0 109.462 -179.818 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.47 ' HB3' ' CB ' ' A' ' 87' ' ' ALA . 35.5 Cg_endo -77.56 123.78 6.65 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.614 2.209 . . . . 0.0 110.133 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 150.37 -142.97 10.12 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 -179.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.26 158.54 37.87 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.204 -1.174 . . . . 0.0 109.475 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.562 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 92.5 m-85 -135.78 155.46 50.33 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.307 -0.87 . . . . 0.0 109.683 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 9.8 t60 -111.46 114.31 27.33 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.034 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.52 HG11 ' NE2' ' A' ' 56' ' ' HIS . 62.7 t -95.06 150.64 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.228 -0.92 . . . . 0.0 110.527 -178.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.408 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.8 OUTLIER -146.42 157.96 43.83 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.388 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.719 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -156.36 164.57 38.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.603 -1.311 . . . . 0.0 111.224 -179.457 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.421 ' CG1' ' HB2' ' A' ' 37' ' ' ARG . 9.8 p -142.16 127.29 17.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 178.427 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.586 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.1 OUTLIER -88.2 142.23 27.92 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.932 -1.105 . . . . 0.0 108.769 -178.471 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -131.41 106.23 8.11 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.551 -1.26 . . . . 0.0 109.949 178.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -104.6 -9.82 18.0 Favored 'General case' 0 C--N 1.284 -2.261 0 CA-C-N 115.218 -0.901 . . . . 0.0 108.701 178.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.11 -48.52 0.97 Allowed Glycine 0 N--CA 1.487 2.094 0 N-CA-C 107.776 -2.13 . . . . 0.0 107.776 -178.457 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.59 -5.52 11.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.633 -0.922 . . . . 0.0 109.61 179.089 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.94 156.66 26.07 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.0 p -150.38 -178.65 6.65 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.304 -1.115 . . . . 0.0 109.421 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.572 ' CB ' ' HG ' ' A' ' 70' ' ' LEU . . . -158.98 141.4 14.03 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.36 -0.837 . . . . 0.0 108.744 179.577 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -99.85 135.37 41.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.984 -1.073 . . . . 0.0 110.101 -179.211 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.745 ' HG ' HD13 ' A' ' 27' ' ' ILE . 0.0 OUTLIER -119.82 156.91 29.75 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.492 -0.755 . . . . 0.0 110.026 -179.569 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.511 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.46 89.73 0.1 Allowed Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.49 -172.7 2.12 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.991 -1.3 . . . . 0.0 110.267 -179.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -150.72 146.28 26.34 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.592 HG12 ' CZ ' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -131.2 157.59 43.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.856 -1.152 . . . . 0.0 109.93 -179.702 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . 0.45 ' N ' HG22 ' A' ' 83' ' ' VAL . 8.1 mt-30 -130.45 92.14 3.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.595 -0.691 . . . . 0.0 109.165 179.466 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.472 HG21 ' HB3' ' A' ' 17' ' ' LEU . 40.9 t -86.58 141.92 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.253 -0.904 . . . . 0.0 109.734 -179.663 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -108.34 175.69 5.38 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.29 -0.881 . . . . 0.0 110.309 -179.29 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.47 ' CB ' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.659 0 O-C-N 121.347 -0.846 . . . . 0.0 109.693 179.5 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.635 ' HA ' ' HB1' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.521 HG22 HG21 ' A' ' 11' ' ' VAL . 1.6 t -74.95 150.73 38.97 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.13 -0.982 . . . . 0.0 109.408 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.676 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.3 mp -87.15 105.6 17.31 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.977 -178.636 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.59 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 2.3 t -119.36 91.6 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.976 -1.078 . . . . 0.0 109.009 178.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.687 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -113.7 81.14 0.29 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.492 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.546 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.5 Cg_endo -73.34 149.04 44.45 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.662 2.242 . . . . 0.0 111.92 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.471 ' CD2' HD21 ' A' ' 17' ' ' LEU . 45.6 t60 166.96 -39.13 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.49 -138.86 14.76 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.057 -2.017 . . . . 0.0 108.057 -178.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -77.42 147.65 25.75 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 C-N-CA 122.096 1.864 . . . . 0.0 109.043 178.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.471 HD21 ' CD2' ' A' ' 14' ' ' HIS . 0.2 OUTLIER -106.31 109.84 21.9 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.098 -1.001 . . . . 0.0 109.721 -179.285 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -92.34 153.35 19.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 179.269 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.0 t -59.29 111.08 1.23 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -0.875 . . . . 0.0 109.37 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.47 35.44 3.09 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 13.6 mm100 -133.65 160.54 37.23 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.192 -1.181 . . . . 0.0 109.88 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.527 HD11 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -117.06 126.66 53.2 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.186 -0.946 . . . . 0.0 109.414 179.672 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.605 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -90.06 145.42 25.08 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.084 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.546 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -99.89 129.78 46.01 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 119.918 -1.739 . . . . 0.0 108.165 179.111 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.75 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 16.8 m-85 -113.88 163.26 15.32 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 122.102 0.954 . . . . 0.0 111.977 -177.335 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . 0.59 ' CE1' ' CG1' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -165.9 139.77 4.43 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.079 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.707 HD13 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.31 154.69 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.868 -1.145 . . . . 0.0 108.777 -178.331 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -133.87 123.43 24.73 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 120.693 -1.255 . . . . 0.0 112.732 -178.08 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.724 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 171.45 -69.22 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.399 -0.813 . . . . 0.0 109.305 177.659 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.724 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -76.66 78.7 3.26 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 121.796 1.664 . . . . 0.0 109.486 179.198 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.712 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 6.0 mt -34.05 -53.82 0.86 Allowed Pre-proline 0 N--CA 1.504 2.251 0 O-C-N 121.944 -0.472 . . . . 0.0 111.703 -178.792 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' PRO . . . . . 0.712 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 36.8 Cg_endo -81.3 63.12 8.61 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 C-N-CA 122.077 1.851 . . . . 0.0 112.198 -179.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.608 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 74.4 t -87.59 148.02 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 120.595 -1.316 . . . . 0.0 109.696 179.118 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 70.7 p -119.53 -35.82 3.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.422 -0.798 . . . . 0.0 109.665 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -155.13 144.37 21.04 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.461 -0.774 . . . . 0.0 109.007 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.644 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 0.5 OUTLIER -129.29 156.44 44.0 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.976 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.542 ' HB2' HG22 ' A' ' 69' ' ' VAL . 49.1 mtp85 -119.51 101.06 7.67 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 109.044 179.82 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.75 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 30.3 m95 -89.24 178.77 6.27 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.123 -0.985 . . . . 0.0 109.476 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . 0.453 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.51 101.58 2.97 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 177.49 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.616 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 2.9 m-30 -79.75 -61.26 2.05 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.989 -177.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.77 15.86 47.68 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -178.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.27 -104.52 0.27 Allowed 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 178.607 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.31 -20.28 59.09 Favored Glycine 0 C--N 1.296 -1.649 0 N-CA-C 107.708 -2.157 . . . . 0.0 107.708 177.028 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 m -132.58 127.59 35.35 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.432 -1.04 . . . . 0.0 109.304 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.89 -85.96 0.09 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.17 -0.956 . . . . 0.0 109.72 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLU . . . . . 0.474 ' C ' HG21 ' A' ' 47' ' ' VAL . 0.9 OUTLIER -57.73 153.37 13.69 Favored 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 121.112 0.482 . . . . 0.0 109.71 -179.918 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.694 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 57.7 t -140.16 124.12 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.384 -0.823 . . . . 0.0 111.1 -178.445 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -104.61 99.47 9.14 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.074 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.424 ' HB2' ' CG2' ' A' ' 36' ' ' THR . . . -109.91 167.8 9.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.203 -0.936 . . . . 0.0 111.02 -178.596 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.97 151.94 21.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.715 -0.615 . . . . 0.0 109.352 179.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.467 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 45.92 -155.2 0.58 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -89.06 41.63 0.57 Allowed 'Trans proline' 0 C--N 1.295 -2.255 0 C-N-CA 122.272 1.981 . . . . 0.0 110.515 178.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . 0.44 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -143.58 154.02 43.14 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.928 -1.733 . . . . 0.0 112.602 -178.716 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.406 ' HB1' ' NE1' ' A' ' 38' ' ' TRP . . . -166.56 -171.17 1.81 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.074 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.501 ' HB2' HD12 ' A' ' 22' ' ' LEU . 0.3 OUTLIER -150.45 143.25 24.65 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.116 -0.99 . . . . 0.0 109.263 179.449 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' HIS . . . . . 0.616 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 7.3 m80 -102.41 134.64 45.4 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.197 -0.94 . . . . 0.0 111.515 -178.686 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.15 95.47 6.57 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.331 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.6 ' CE1' ' CG ' ' A' ' 64' ' ' TYR . 18.6 m-85 -102.58 112.84 25.77 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.079 -1.013 . . . . 0.0 109.403 -179.285 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.6 p -110.85 -10.56 11.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.417 -0.802 . . . . 0.0 111.525 -178.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . 0.446 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -114.73 146.14 35.4 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 120.478 -1.389 . . . . 0.0 109.673 -179.743 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.446 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.1 Cg_endo -77.06 122.85 6.41 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.403 2.069 . . . . 0.0 109.935 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 161.77 -157.05 28.73 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.418 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -116.93 121.2 40.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.144 -1.21 . . . . 0.0 109.771 -179.824 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.6 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 90.3 m-85 -103.71 155.95 18.18 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.314 -0.867 . . . . 0.0 109.315 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 80.8 t60 -111.94 123.34 50.04 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.504 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 62.4 t -106.22 150.5 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.163 -0.961 . . . . 0.0 110.594 -178.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.53 159.56 44.2 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 178.664 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.718 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -151.09 154.52 37.13 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.939 -1.101 . . . . 0.0 110.921 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.542 HG22 ' HB2' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -144.75 104.3 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.102 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.644 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -88.74 150.73 22.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.757 -1.215 . . . . 0.0 110.204 -178.663 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.99 116.16 18.91 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.826 0.822 . . . . 0.0 108.937 178.453 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.477 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 5.6 mp -104.36 -12.96 16.29 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-O 121.508 0.671 . . . . 0.0 109.212 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.74 -53.75 0.62 Allowed Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.135 -1.986 . . . . 0.0 108.135 -178.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.71 -5.33 12.13 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.584 -0.95 . . . . 0.0 109.777 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.43 161.4 26.95 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.413 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 3.4 p -150.87 170.36 19.47 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.371 -1.076 . . . . 0.0 109.359 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.498 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -143.42 128.75 18.88 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.245 -0.91 . . . . 0.0 109.57 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.3 tp -95.11 140.79 29.55 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.471 -0.768 . . . . 0.0 110.029 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . 0.718 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -128.72 157.52 41.15 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.604 -0.685 . . . . 0.0 109.919 -179.464 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -164.88 86.48 0.1 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 179.589 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.401 HG21 HD11 ' A' ' 79' ' ' LEU . 0.0 OUTLIER -104.34 -176.32 3.05 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.122 -1.222 . . . . 0.0 109.762 -179.854 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -150.76 147.53 27.42 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.575 HG12 ' CZ ' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -131.83 149.78 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 O-C-N 120.768 -1.208 . . . . 0.0 109.618 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -119.22 87.46 2.74 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.441 HG13 ' HA ' ' A' ' 61' ' ' PRO . 84.5 t -75.01 134.84 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.312 -0.867 . . . . 0.0 109.815 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 -109.26 177.52 4.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.363 -0.835 . . . . 0.0 109.591 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.364 -0.835 . . . . 0.0 109.515 179.874 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.663 ' HA ' ' CB ' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.393 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -81.49 144.66 31.19 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.214 -0.929 . . . . 0.0 108.95 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.686 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.8 mp -94.27 86.7 5.0 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.215 -178.164 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.561 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 32.9 t -94.88 102.39 13.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 120.873 -1.142 . . . . 0.0 108.386 178.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.506 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.95 76.72 0.28 Allowed Glycine 0 N--CA 1.488 2.113 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.038 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.52 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 31.4 Cg_endo -71.73 146.85 49.48 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.438 2.092 . . . . 0.0 111.401 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 174.51 164.17 0.22 Allowed 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 -179.664 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -89.29 -125.91 2.77 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 107.363 -2.295 . . . . 0.0 107.363 178.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -80.06 147.06 18.52 Favored 'Trans proline' 0 C--N 1.302 -1.875 0 C-N-CA 121.839 1.693 . . . . 0.0 108.293 177.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.549 ' HB3' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -114.15 80.13 1.35 Allowed 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.922 -1.111 . . . . 0.0 109.158 -179.633 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -91.61 172.29 8.6 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.2 t -59.39 117.85 5.31 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.2 -0.938 . . . . 0.0 109.325 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.81 46.71 3.09 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . 0.429 ' HB3' HD12 ' A' ' 17' ' ' LEU . 0.0 OUTLIER -122.27 152.27 40.22 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.386 -1.067 . . . . 0.0 110.559 -179.627 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.429 HD12 ' O ' ' A' ' 23' ' ' ALA . 2.0 tm? -109.99 94.58 5.09 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.739 -0.6 . . . . 0.0 109.65 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.429 ' O ' HD12 ' A' ' 22' ' ' LEU . . . -75.66 158.9 31.76 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.52 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -124.71 117.81 25.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.463 -1.398 . . . . 0.0 108.573 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.769 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.8 m-85 -105.55 170.96 7.59 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 122.085 0.945 . . . . 0.0 111.828 -177.318 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.561 ' CE1' ' CG1' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.8 138.98 3.51 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 178.105 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.678 HD13 ' HG ' ' A' ' 79' ' ' LEU . 0.3 OUTLIER -105.32 152.52 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.085 -1.009 . . . . 0.0 109.47 -178.276 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -134.66 116.83 15.4 Favored 'General case' 0 N--CA 1.5 2.046 0 C-N-CA 118.823 -1.151 . . . . 0.0 111.644 -179.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.688 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 176.56 -62.26 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.915 0 O-C-N 121.076 -1.015 . . . . 0.0 109.952 178.173 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.688 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.4 Cg_endo -80.11 63.55 8.76 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.32 2.013 . . . . 0.0 109.711 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.629 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -13.13 -64.58 0.02 OUTLIER Pre-proline 0 N--CA 1.504 2.266 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 -178.902 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.629 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.2 Cg_endo -77.69 72.5 6.05 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 121.724 1.616 . . . . 0.0 111.282 -179.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.483 ' CG2' ' O ' ' A' ' 30' ' ' PRO . 2.7 t -98.77 127.26 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.996 -1.065 . . . . 0.0 109.341 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 p -111.21 -14.87 13.77 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.417 -0.802 . . . . 0.0 109.219 178.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -163.46 148.34 11.02 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.224 -0.922 . . . . 0.0 109.824 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.418 ' CG2' ' HB2' ' A' ' 49' ' ' ALA . 1.4 t -140.38 162.66 34.78 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.43 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.545 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -127.31 100.5 6.08 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.101 -0.999 . . . . 0.0 109.217 179.586 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.769 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 36.4 m95 -87.59 179.02 6.61 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.218 -0.926 . . . . 0.0 109.453 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.461 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.3 OUTLIER -146.84 103.14 3.6 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.862 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.63 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 3.5 m-30 -81.16 -59.1 2.77 Favored 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.314 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.28 8.48 68.44 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.497 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 10.4 p30 -98.49 35.7 1.76 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.372 -1.075 . . . . 0.0 108.111 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 108.33 -38.35 3.37 Favored Glycine 0 N--CA 1.483 1.785 0 N-CA-C 105.356 -3.098 . . . . 0.0 105.356 -175.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 74.6 m -101.86 95.06 6.14 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.2 -90.7 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -0.919 . . . . 0.0 110.151 -178.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.4 ' C ' HG21 ' A' ' 47' ' ' VAL . 72.9 mm-40 -55.9 146.81 20.97 Favored 'General case' 0 N--CA 1.493 1.688 0 CA-C-O 121.251 0.548 . . . . 0.0 109.758 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.616 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 63.8 t -135.01 106.36 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.377 -0.827 . . . . 0.0 110.972 -178.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.8 94.12 9.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.988 -1.07 . . . . 0.0 108.211 178.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.421 ' CB ' ' HB1' ' A' ' 54' ' ' ALA . . . -101.65 166.6 10.6 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.258 -0.901 . . . . 0.0 110.801 -178.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.61 150.09 21.53 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.725 -0.61 . . . . 0.0 109.595 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 44.14 -153.26 0.41 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.461 ' HD3' ' HB ' ' A' ' 33' ' ' VAL . 38.8 Cg_endo -88.43 40.09 0.54 Allowed 'Trans proline' 0 C--N 1.301 -1.943 0 C-N-CA 122.372 2.048 . . . . 0.0 110.282 178.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.533 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -143.38 154.39 43.68 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.135 -1.603 . . . . 0.0 112.011 -178.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.45 ' HB1' ' NE1' ' A' ' 38' ' ' TRP . . . -165.88 -168.86 1.37 Allowed 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.362 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.473 ' HB3' ' HA ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -157.32 146.59 20.08 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.133 -0.979 . . . . 0.0 109.131 179.236 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.63 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 7.5 m80 -100.08 133.76 44.0 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.352 -0.843 . . . . 0.0 110.915 -178.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -107.5 88.63 2.78 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.418 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.659 ' CE2' HG12 ' A' ' 83' ' ' VAL . 13.8 m-85 -88.71 135.14 33.66 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.389 -0.819 . . . . 0.0 109.294 -178.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.9 p -127.96 -12.93 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.235 -0.916 . . . . 0.0 111.314 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.405 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -110.23 144.63 30.49 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 120.527 -1.358 . . . . 0.0 109.584 -179.767 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.405 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.0 Cg_endo -77.78 115.54 3.85 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.408 2.072 . . . . 0.0 109.868 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 163.97 -142.76 8.04 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.69 159.74 22.46 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.221 -1.164 . . . . 0.0 109.215 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.526 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 57.9 m-85 -140.68 160.85 39.14 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.413 -0.805 . . . . 0.0 109.297 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 49.2 t60 -122.0 142.09 50.68 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.496 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 21.7 t -125.17 149.6 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.862 -1.148 . . . . 0.0 110.991 -178.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.415 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -150.28 160.65 43.55 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 107.448 -1.315 . . . . 0.0 107.448 178.129 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.713 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -151.79 153.66 34.7 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.843 -1.16 . . . . 0.0 111.292 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 37' ' ' ARG . 0.8 OUTLIER -126.0 121.99 60.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.58 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.623 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.6 OUTLIER -88.36 141.54 28.46 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 120.596 -1.315 . . . . 0.0 109.103 -178.406 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.66 109.12 10.4 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 118.679 -1.209 . . . . 0.0 109.694 178.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.504 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -104.07 -11.03 17.59 Favored 'General case' 0 C--N 1.288 -2.069 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.73 -49.46 0.84 Allowed Glycine 0 N--CA 1.487 2.074 0 N-CA-C 107.729 -2.148 . . . . 0.0 107.729 -178.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -118.41 -5.56 10.8 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.678 -0.895 . . . . 0.0 109.877 179.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.55 164.09 26.04 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.447 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 6.8 p -151.18 -177.23 5.92 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.344 -1.092 . . . . 0.0 109.684 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.571 ' HB1' ' HG ' ' A' ' 70' ' ' LEU . . . -153.17 154.81 35.5 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 179.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -112.94 124.79 53.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.141 -0.974 . . . . 0.0 109.938 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.713 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -114.53 155.24 26.81 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.416 -0.802 . . . . 0.0 110.032 -179.643 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.452 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -164.66 91.59 0.11 Allowed Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.271 -1.531 . . . . 0.0 109.271 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.452 HG21 HD22 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -106.88 175.84 5.37 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.127 -1.219 . . . . 0.0 109.895 -179.683 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -122.12 160.34 25.28 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.378 -0.826 . . . . 0.0 108.99 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.659 HG12 ' CE2' ' A' ' 58' ' ' TYR . 25.9 t -144.17 147.51 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.011 -1.055 . . . . 0.0 110.448 -179.022 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.6 ' N ' HG11 ' A' ' 83' ' ' VAL . 0.8 OUTLIER -137.14 98.98 3.87 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.385 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.549 HG21 ' HB3' ' A' ' 17' ' ' LEU . 29.1 t -96.93 139.83 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.111 -0.993 . . . . 0.0 110.658 -179.004 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 23.6 mm-40 -110.59 -159.41 0.68 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.512 -0.743 . . . . 0.0 109.62 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.123 -0.986 . . . . 0.0 109.243 179.811 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.645 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.549 HG22 HG21 ' A' ' 11' ' ' VAL . 1.3 t -70.62 149.44 47.05 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.196 -0.94 . . . . 0.0 109.336 -179.203 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.718 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 4.9 mp -84.62 108.18 17.22 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.088 -178.359 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.549 HG21 HG22 ' A' ' 9' ' ' THR . 0.7 OUTLIER -123.53 104.28 14.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 120.777 -1.202 . . . . 0.0 108.912 178.708 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.55 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.85 76.52 0.3 Allowed Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.508 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.6 Cg_endo -73.26 150.43 47.28 Favored 'Trans proline' 0 C--N 1.308 -1.567 0 C-N-CA 122.728 2.285 . . . . 0.0 111.918 179.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.518 ' CD2' ' HA ' ' A' ' 23' ' ' ALA . 32.6 t-80 161.94 -36.82 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.796 0 CA-C-O 121.782 0.801 . . . . 0.0 108.944 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.97 -138.04 14.52 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 107.942 -2.063 . . . . 0.0 107.942 -178.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -77.74 147.83 25.03 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 122.027 1.818 . . . . 0.0 109.313 178.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.567 HD23 ' HB3' ' A' ' 23' ' ' ALA . 0.6 OUTLIER -110.59 115.73 30.12 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.251 -0.906 . . . . 0.0 109.486 -179.441 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -106.24 160.01 15.67 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 45.7 t -56.3 119.34 5.82 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.316 -0.865 . . . . 0.0 109.471 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.42 46.92 3.92 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 7.5 mm100 -127.4 153.52 46.15 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.145 -1.209 . . . . 0.0 110.543 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.448 ' CD1' ' HB2' ' A' ' 55' ' ' SER . 1.8 tm? -108.81 92.31 4.0 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.567 ' HB3' HD23 ' A' ' 17' ' ' LEU . . . -71.21 156.33 39.68 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 178.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.508 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -122.74 112.49 17.99 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.26 -1.525 . . . . 0.0 108.341 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.764 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.6 m-85 -100.64 173.84 6.35 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 122.512 1.148 . . . . 0.0 112.415 -177.19 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.54 ' HA ' ' HA ' ' A' ' 53' ' ' ALA . 5.9 p80 -172.47 147.61 1.91 Allowed 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.19 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.724 HD13 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.82 156.88 12.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.961 -1.087 . . . . 0.0 108.198 -178.484 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -132.66 122.34 24.52 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.442 -1.303 . . . . 0.0 112.702 -177.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.716 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 172.8 -70.06 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.797 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.716 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.1 Cg_endo -77.62 77.76 3.76 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 121.592 1.528 . . . . 0.0 108.718 178.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.557 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.3 OUTLIER -35.16 -55.57 1.01 Allowed Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.817 -0.552 . . . . 0.0 111.284 -178.795 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.557 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.8 Cg_endo -80.62 81.29 2.78 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.141 1.894 . . . . 0.0 111.236 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.537 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 40.1 t -111.89 150.3 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 120.908 -1.12 . . . . 0.0 109.0 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 18.5 p -116.91 -28.92 6.16 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.203 -0.936 . . . . 0.0 110.593 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.93 143.7 17.15 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.088 -1.008 . . . . 0.0 110.274 -179.569 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.66 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.8 t -130.79 157.37 43.05 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.508 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -125.05 104.25 8.45 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.305 -0.872 . . . . 0.0 108.669 179.102 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.764 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 32.7 m95 -88.85 -178.6 5.78 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 109.276 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.516 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -148.24 102.73 3.38 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 178.085 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.598 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 4.7 m-30 -81.61 -66.03 0.94 Allowed 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 119.182 -1.007 . . . . 0.0 110.561 -177.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.89 11.12 47.55 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.532 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 12.6 p30 -97.04 33.07 1.99 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.249 -1.148 . . . . 0.0 108.224 179.043 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.24 -34.84 5.08 Favored Glycine 0 N--CA 1.48 1.603 0 N-CA-C 105.449 -3.06 . . . . 0.0 105.449 -175.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 50.2 m -108.35 100.78 10.04 Favored 'General case' 0 N--CA 1.485 1.305 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.516 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -75.3 -86.96 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.166 -0.959 . . . . 0.0 109.773 -178.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -50.89 144.77 8.04 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.308 0.575 . . . . 0.0 109.806 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.639 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 91.9 t -133.84 105.91 8.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.36 -0.838 . . . . 0.0 110.764 -178.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -83.12 115.75 22.03 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.479 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.489 ' HB2' ' CG2' ' A' ' 36' ' ' THR . . . -129.26 164.08 24.25 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.028 -1.045 . . . . 0.0 110.74 -178.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.18 151.02 19.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.659 -0.65 . . . . 0.0 109.574 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.471 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 45.65 -155.31 0.51 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -88.5 38.91 0.47 Allowed 'Trans proline' 0 C--N 1.298 -2.1 0 C-N-CA 122.269 1.979 . . . . 0.0 110.191 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.54 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -139.55 155.57 47.42 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 120.227 -1.546 . . . . 0.0 111.895 -178.705 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.554 ' HB1' ' CE2' ' A' ' 38' ' ' TRP . . . -165.18 -169.64 1.69 Allowed 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.448 ' HB2' ' CD1' ' A' ' 22' ' ' LEU . 0.0 OUTLIER -154.0 144.09 22.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.018 -1.051 . . . . 0.0 109.816 179.407 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.598 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 0.3 OUTLIER -94.48 129.89 41.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.705 -0.622 . . . . 0.0 111.031 -178.797 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.434 ' HA ' HD21 ' A' ' 22' ' ' LEU . 2.1 ptp180 -105.47 85.57 2.27 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.12 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.532 ' CD1' ' HB3' ' A' ' 42' ' ' ASP . 13.0 m-85 -92.29 134.2 35.12 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.986 -1.071 . . . . 0.0 110.073 -178.544 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.4 m -127.3 -3.12 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.605 -0.685 . . . . 0.0 111.046 -179.083 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.417 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.2 OUTLIER -117.61 140.5 27.6 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 120.651 -1.281 . . . . 0.0 109.36 -179.944 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.417 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.1 Cg_endo -77.65 109.47 2.76 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 122.479 2.119 . . . . 0.0 110.155 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 169.81 -144.23 8.41 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.89 162.25 15.0 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.166 -1.196 . . . . 0.0 109.826 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.48 ' HB2' ' HB ' ' A' ' 83' ' ' VAL . 61.5 m-85 -146.91 165.28 30.26 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -124.87 153.9 41.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.151 -0.968 . . . . 0.0 108.503 179.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.524 ' CG1' ' NE2' ' A' ' 56' ' ' HIS . 12.5 t -134.19 145.19 33.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 120.839 -1.163 . . . . 0.0 110.764 -179.057 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.427 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -150.63 159.03 44.79 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 178.129 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.712 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -152.03 157.26 41.43 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.868 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.427 ' HA ' ' O ' ' A' ' 77' ' ' ALA . 7.3 p -150.14 108.19 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.66 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -89.16 151.11 22.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.931 -1.106 . . . . 0.0 109.154 -179.156 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.42 119.7 23.09 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.362 -0.935 . . . . 0.0 109.708 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 7.4 mt -109.23 -12.97 14.73 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-O 121.518 0.675 . . . . 0.0 109.492 179.511 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.07 -47.41 1.05 Allowed Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -178.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -113.87 -6.24 13.22 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.574 -0.956 . . . . 0.0 109.696 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.65 158.84 27.83 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -150.8 168.34 24.73 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.199 -1.177 . . . . 0.0 109.395 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.555 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -141.74 132.62 25.87 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.199 -0.938 . . . . 0.0 109.358 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.2 mp -101.76 147.06 26.92 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.15 -0.969 . . . . 0.0 110.45 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.724 ' HG ' HD13 ' A' ' 27' ' ' ILE . 0.1 OUTLIER -133.26 160.11 38.25 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.655 -0.653 . . . . 0.0 109.886 -179.292 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.42 88.91 0.09 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.456 HG23 HD11 ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.48 175.8 5.28 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.087 -1.243 . . . . 0.0 109.976 -179.755 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -117.87 155.37 30.27 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.243 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.536 HG11 ' N ' ' A' ' 84' ' ' GLN . 25.1 t -134.82 143.42 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.172 -0.955 . . . . 0.0 110.049 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.536 ' N ' HG11 ' A' ' 83' ' ' VAL . 2.1 mt-30 -131.83 104.0 6.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.37 -0.832 . . . . 0.0 109.038 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.423 HG21 ' HB3' ' A' ' 17' ' ' LEU . 86.0 t -102.43 132.19 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.345 -0.847 . . . . 0.0 109.964 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.45 -160.98 0.81 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.201 -0.937 . . . . 0.0 109.391 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.632 0 O-C-N 121.064 -1.022 . . . . 0.0 109.427 179.909 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.652 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.443 ' CG2' HG22 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.79 139.68 30.22 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.77 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.594 ' N ' ' CD1' ' A' ' 10' ' ' LEU . 5.6 mp -97.19 89.55 4.81 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.148 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.495 ' CB ' ' CE1' ' A' ' 26' ' ' HIS . 65.3 t -99.08 112.34 30.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.885 -1.134 . . . . 0.0 109.092 179.521 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.497 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -124.1 71.18 0.44 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.541 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.4 Cg_endo -73.64 150.4 45.22 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.803 2.336 . . . . 0.0 112.153 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.454 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.9 t-80 168.9 -38.87 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.681 0.753 . . . . 0.0 109.208 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.29 -138.05 14.56 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 -178.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.62 147.0 24.57 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 121.972 1.782 . . . . 0.0 109.166 178.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 2.7 mt -117.26 98.56 6.5 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.2 -0.937 . . . . 0.0 109.779 -179.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.09 165.66 14.98 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 t -60.85 114.74 3.22 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.243 -0.91 . . . . 0.0 109.272 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.68 39.52 2.72 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.84 154.58 51.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.152 -1.205 . . . . 0.0 110.015 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.606 HD12 ' HB2' ' A' ' 55' ' ' SER . 0.1 OUTLIER -115.82 128.14 55.59 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.805 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.692 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -92.69 148.37 22.12 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.541 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -105.25 121.9 44.81 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.067 -1.645 . . . . 0.0 108.04 179.012 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.692 ' CE1' ' HB2' ' A' ' 23' ' ' ALA . 5.2 m-85 -105.39 170.53 7.83 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 121.914 0.864 . . . . 0.0 111.721 -177.009 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.567 ' CD2' ' C ' ' A' ' 26' ' ' HIS . 0.0 OUTLIER -166.72 140.14 3.84 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.793 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.679 ' CD1' ' CH2' ' A' ' 38' ' ' TRP . 4.6 mm -109.42 148.67 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.279 -0.888 . . . . 0.0 109.309 -178.345 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -133.33 122.6 24.07 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.989 -178.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.679 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 175.25 -61.86 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.078 -1.014 . . . . 0.0 109.552 178.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.679 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 35.3 Cg_endo -79.17 68.49 8.27 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.209 1.939 . . . . 0.0 109.699 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.621 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.0 OUTLIER -15.42 -64.03 0.03 OUTLIER Pre-proline 0 N--CA 1.506 2.327 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.83 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.621 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.4 Cg_endo -78.52 73.39 5.9 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 C-N-CA 121.774 1.65 . . . . 0.0 111.202 -179.513 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.49 HG21 ' HG2' ' A' ' 30' ' ' PRO . 2.8 t -96.41 136.64 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.894 -1.129 . . . . 0.0 109.656 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.5 t -115.89 -15.33 11.25 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.48 -0.763 . . . . 0.0 109.331 179.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.6 149.43 0.48 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.311 -0.868 . . . . 0.0 109.667 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.459 HG23 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -136.93 139.68 41.73 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.59 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.511 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 10.2 mtm-85 -93.33 109.04 20.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.138 -0.976 . . . . 0.0 109.136 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.679 ' CH2' ' CD1' ' A' ' 27' ' ' ILE . 18.7 m95 -93.85 179.81 5.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.918 -1.114 . . . . 0.0 109.621 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.482 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.76 106.61 3.41 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.328 -1.731 . . . . 0.0 106.328 177.369 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.616 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 3.7 m-30 -81.37 -66.44 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 118.451 -1.3 . . . . 0.0 111.37 -176.892 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.11 -4.91 59.03 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.1 p30 -90.41 23.71 2.86 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.335 -1.097 . . . . 0.0 109.164 179.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 122.56 -38.11 2.64 Favored Glycine 0 C--N 1.298 -1.576 0 N-CA-C 106.129 -2.788 . . . . 0.0 106.129 -176.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.77 101.52 12.96 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 177.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.38 -98.28 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 0.0 109.958 -178.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.436 ' C ' HG21 ' A' ' 47' ' ' VAL . 1.6 mm-40 -56.92 150.1 17.33 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.286 0.565 . . . . 0.0 109.927 -179.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.668 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 70.8 t -138.9 132.97 40.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.47 -0.769 . . . . 0.0 110.591 -178.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -112.89 89.8 3.18 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.529 ' HB1' ' CD1' ' A' ' 38' ' ' TRP . . . -92.84 152.53 19.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.373 -0.829 . . . . 0.0 111.423 -178.135 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.72 150.2 23.75 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.459 ' O ' HG23 ' A' ' 36' ' ' THR . . . 46.08 -156.4 0.49 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.24 -1.944 . . . . 0.0 108.24 -179.27 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -88.43 42.63 0.7 Allowed 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.122 1.881 . . . . 0.0 110.479 178.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.494 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -146.87 144.38 29.24 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.072 -1.642 . . . . 0.0 112.009 -179.089 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.463 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -149.54 -169.6 3.42 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.606 ' HB2' HD12 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -152.64 138.8 18.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.249 -0.907 . . . . 0.0 109.174 179.558 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.616 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 11.1 m80 -102.91 135.45 44.57 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.231 -0.918 . . . . 0.0 111.101 -178.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -100.44 95.06 6.49 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 177.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.592 ' CZ ' HG12 ' A' ' 83' ' ' VAL . 23.8 m-85 -95.5 120.24 35.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.225 -0.922 . . . . 0.0 109.232 -179.232 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.6 p -118.17 -29.71 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.241 -0.912 . . . . 0.0 111.165 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -90.71 143.35 28.82 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 120.619 -1.3 . . . . 0.0 109.376 -179.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.405 ' HA ' HG13 ' A' ' 85' ' ' VAL . 34.0 Cg_endo -76.26 133.04 14.34 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.575 2.183 . . . . 0.0 110.281 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.59 -135.05 5.93 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 -179.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -127.27 164.51 21.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -1.193 . . . . 0.0 109.651 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.509 ' HB2' HG12 ' A' ' 83' ' ' VAL . 59.7 m-85 -142.98 152.84 42.39 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.466 -0.771 . . . . 0.0 109.205 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -112.99 130.37 56.16 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.514 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 59.2 t -116.0 150.58 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 110.821 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.79 155.51 42.42 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.756 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -150.53 158.57 44.31 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.853 -1.155 . . . . 0.0 111.518 -179.538 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -129.84 127.17 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.423 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.645 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.3 OUTLIER -89.07 141.87 28.12 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 120.656 -1.277 . . . . 0.0 109.015 -178.743 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.3 110.48 11.56 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.589 -1.245 . . . . 0.0 109.698 178.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.602 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 5.9 mp -105.49 -11.1 16.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.072 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.66 -49.62 0.83 Allowed Glycine 0 N--CA 1.486 2.011 0 N-CA-C 107.669 -2.173 . . . . 0.0 107.669 -178.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.44 -5.76 11.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.58 -0.953 . . . . 0.0 109.884 178.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -140.04 162.5 26.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.465 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.8 p -151.44 -179.23 7.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.306 -1.114 . . . . 0.0 109.579 -179.598 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.595 ' CB ' ' HG ' ' A' ' 70' ' ' LEU . . . -154.17 166.39 33.25 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.2 mt -119.93 132.75 55.62 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.068 -1.02 . . . . 0.0 110.227 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.756 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -117.4 157.14 26.7 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.524 -0.735 . . . . 0.0 109.769 -179.879 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.65 95.12 0.11 Allowed Glycine 0 N--CA 1.485 1.938 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.467 HG21 HD21 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -116.38 -173.33 2.35 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.232 -1.158 . . . . 0.0 109.937 179.932 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -150.74 153.7 36.0 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.435 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.592 HG12 ' CZ ' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.0 154.25 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.66 -1.275 . . . . 0.0 109.845 -179.519 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.45 ' N ' HG21 ' A' ' 83' ' ' VAL . 12.0 tt0 -123.07 99.81 6.56 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.464 -0.773 . . . . 0.0 108.985 179.073 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.405 HG13 ' HA ' ' A' ' 61' ' ' PRO . 41.6 t -86.15 137.71 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.24 -0.912 . . . . 0.0 109.846 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -113.15 154.41 26.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.101 -0.999 . . . . 0.0 109.667 179.711 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.64 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.435 HG22 HG21 ' A' ' 11' ' ' VAL . 0.8 OUTLIER -71.47 149.87 45.44 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.178 -0.951 . . . . 0.0 109.253 -179.427 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.597 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.0 mp -92.29 98.28 11.41 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.315 -178.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.563 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 11.1 t -108.81 101.3 12.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 120.873 -1.142 . . . . 0.0 108.273 178.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.56 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -115.64 75.49 0.26 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.459 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.521 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 32.8 Cg_endo -72.63 148.7 47.78 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.59 2.194 . . . . 0.0 111.694 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.485 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 54.3 t60 159.11 -35.63 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.659 0.742 . . . . 0.0 109.003 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.81 -141.52 15.25 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 108.437 -1.865 . . . . 0.0 108.437 -179.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -77.2 149.19 27.95 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 122.288 1.992 . . . . 0.0 109.434 179.106 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.426 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 1.4 mt -117.74 117.51 29.53 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.161 -0.962 . . . . 0.0 109.888 -179.39 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.408 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -94.06 168.77 10.73 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.137 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.2 t -56.79 118.72 5.19 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.25 -0.906 . . . . 0.0 109.01 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.63 43.22 6.19 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.22 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . 0.408 ' HB2' ' O ' ' A' ' 18' ' ' ALA . 7.9 tp-100 -111.6 150.77 29.6 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.42 -1.047 . . . . 0.0 110.869 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.437 HD12 ' O ' ' A' ' 23' ' ' ALA . 2.1 tm? -111.52 102.68 11.0 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.573 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.485 ' HA ' ' CG ' ' A' ' 14' ' ' HIS . . . -86.68 156.34 20.02 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.521 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -118.97 108.78 15.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.367 -1.458 . . . . 0.0 108.474 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.657 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.2 m-85 -96.02 168.18 10.78 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 122.428 1.109 . . . . 0.0 112.394 -177.343 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.563 ' CE1' ' CG1' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.0 142.44 5.13 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.808 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.754 HD13 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -107.42 156.95 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 120.88 -1.138 . . . . 0.0 109.34 -178.467 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.402 ' CB ' HG21 ' A' ' 9' ' ' THR . . . -134.76 120.6 19.62 Favored 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 118.738 -1.185 . . . . 0.0 112.472 -178.639 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.745 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 172.56 -71.85 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.211 -0.931 . . . . 0.0 109.263 177.663 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.745 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -76.27 78.24 3.3 Favored 'Trans proline' 0 C--N 1.313 -1.312 0 C-N-CA 121.766 1.644 . . . . 0.0 109.465 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.511 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -35.47 -54.0 1.25 Allowed Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.859 -0.526 . . . . 0.0 111.768 -179.145 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.511 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.1 Cg_endo -78.74 60.85 7.84 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.192 1.928 . . . . 0.0 111.819 -179.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.624 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 55.6 t -89.51 145.28 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 120.798 -1.189 . . . . 0.0 109.358 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.7 t -116.63 -31.97 5.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.306 -0.871 . . . . 0.0 109.914 179.506 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.0 138.71 14.17 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.322 -0.861 . . . . 0.0 109.152 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.593 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.1 t -124.19 151.93 43.48 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.553 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -118.22 101.43 8.2 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.206 -0.934 . . . . 0.0 108.921 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.657 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 25.9 m95 -87.88 -179.59 6.27 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.124 -0.985 . . . . 0.0 109.162 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.406 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.8 OUTLIER -148.96 101.7 3.19 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 177.834 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.611 ' CD1' ' NE2' ' A' ' 56' ' ' HIS . 2.6 m-30 -80.35 -59.92 2.52 Favored 'General case' 0 C--N 1.301 -1.503 0 C-N-CA 119.028 -1.069 . . . . 0.0 110.111 -177.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.1 19.72 49.33 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -178.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -109.06 -104.71 0.36 Allowed 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 178.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -80.33 -21.03 65.59 Favored Glycine 0 N--CA 1.479 1.507 0 N-CA-C 107.852 -2.099 . . . . 0.0 107.852 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.16 130.17 30.69 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.347 -1.09 . . . . 0.0 109.557 179.549 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.2 -85.01 0.1 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.983 -1.073 . . . . 0.0 109.668 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.462 ' C ' HG21 ' A' ' 47' ' ' VAL . 2.9 mt-10 -57.64 150.61 18.99 Favored 'General case' 0 N--CA 1.493 1.711 0 CA-C-O 121.132 0.492 . . . . 0.0 109.684 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.62 ' CB ' ' HB2' ' A' ' 38' ' ' TRP . 32.5 t -137.1 112.33 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 O-C-N 121.288 -0.882 . . . . 0.0 111.03 -178.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -96.09 95.75 8.39 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.528 ' CB ' ' HB1' ' A' ' 54' ' ' ALA . . . -107.63 171.37 7.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.455 -0.778 . . . . 0.0 111.06 -178.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.06 153.18 21.82 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.802 -0.561 . . . . 0.0 109.702 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.521 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 46.61 -156.42 0.59 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.776 -1.729 . . . . 0.0 108.776 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -88.45 41.75 0.63 Allowed 'Trans proline' 0 C--N 1.294 -2.298 0 C-N-CA 122.201 1.934 . . . . 0.0 110.277 178.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.458 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -142.8 152.88 42.7 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 119.933 -1.729 . . . . 0.0 112.508 -178.794 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.528 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -175.7 154.41 1.56 Allowed 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.457 ' O ' ' CZ ' ' A' ' 40' ' ' PHE . 0.2 OUTLIER -113.34 161.83 16.79 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.742 -1.224 . . . . 0.0 110.327 -179.744 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.611 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 2.3 m80 -113.11 141.2 47.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.506 -0.746 . . . . 0.0 110.578 -179.228 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.03 93.28 4.18 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.566 ' CE1' ' CG ' ' A' ' 64' ' ' TYR . 39.6 m-85 -95.91 133.56 39.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.024 -1.047 . . . . 0.0 109.553 -179.143 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 58.5 t -116.31 -41.65 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.319 -0.863 . . . . 0.0 111.029 -178.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -87.64 145.52 37.28 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.607 -1.308 . . . . 0.0 109.768 -179.117 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.482 ' HA ' HG13 ' A' ' 85' ' ' VAL . 34.6 Cg_endo -78.39 129.66 9.56 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 122.551 2.167 . . . . 0.0 110.232 179.379 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.88 -136.91 5.28 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 3.5 mtp180 -131.51 126.3 34.6 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -1.173 . . . . 0.0 109.739 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.566 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 44.8 m-85 -110.62 158.81 18.17 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.217 -0.927 . . . . 0.0 109.393 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.434 ' CD2' HG21 ' A' ' 67' ' ' THR . 70.4 t60 -111.02 132.12 54.49 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.506 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 67.5 t -114.23 152.13 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.272 -0.892 . . . . 0.0 110.352 -179.092 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.434 HG21 ' CD2' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -147.88 158.84 44.24 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.707 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.741 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -154.71 120.44 5.15 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 120.871 -1.143 . . . . 0.0 111.679 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -112.68 110.91 33.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 177.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.593 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -88.9 146.75 24.74 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.755 -1.216 . . . . 0.0 109.441 -178.944 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -125.52 116.06 21.19 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.24 -0.912 . . . . 0.0 109.206 178.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.406 ' N ' HD13 ' A' ' 72' ' ' LEU . 5.7 mp -103.43 -13.75 16.51 Favored 'General case' 0 C--N 1.292 -1.906 0 CA-C-O 121.53 0.681 . . . . 0.0 109.33 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.56 -49.7 0.83 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -118.19 -5.76 10.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.674 -0.898 . . . . 0.0 109.857 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -143.03 161.49 27.56 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.422 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 3.2 p -151.45 168.82 23.68 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.291 -1.123 . . . . 0.0 109.362 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.517 ' CB ' HD13 ' A' ' 70' ' ' LEU . . . -140.69 136.1 32.29 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.13 -0.981 . . . . 0.0 109.066 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 13.6 mt -101.78 133.46 46.49 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.308 -0.87 . . . . 0.0 110.269 -179.182 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.754 ' HG ' HD13 ' A' ' 27' ' ' ILE . 0.0 OUTLIER -122.13 156.16 34.23 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.593 -0.692 . . . . 0.0 109.952 -179.335 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -161.68 88.66 0.11 Allowed Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.564 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.458 HG21 HD21 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -105.82 -175.35 2.77 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.937 -1.331 . . . . 0.0 110.289 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -150.83 143.48 24.44 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.274 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.566 ' CG1' ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -129.07 149.13 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 120.779 -1.201 . . . . 0.0 110.059 -179.43 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 72.2 mt-30 -114.7 98.7 7.01 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.462 -0.774 . . . . 0.0 108.97 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.482 HG13 ' HA ' ' A' ' 61' ' ' PRO . 96.4 t -83.74 144.65 9.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.087 -1.008 . . . . 0.0 109.945 -179.456 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -126.58 -154.87 0.65 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.489 -0.757 . . . . 0.0 109.343 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.454 -0.779 . . . . 0.0 110.579 179.35 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.634 ' HA ' ' HB1' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.517 HG22 HG21 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -70.06 149.48 47.61 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.219 -0.926 . . . . 0.0 109.346 -179.229 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.687 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 4.2 mp -83.59 110.42 18.23 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.902 -178.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.543 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 0.5 OUTLIER -124.65 101.52 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 120.753 -1.217 . . . . 0.0 109.216 179.116 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.639 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.88 76.12 0.28 Allowed Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.591 ' O ' ' HB2' ' A' ' 14' ' ' HIS . 35.1 Cg_endo -72.9 149.7 47.9 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.774 2.316 . . . . 0.0 112.778 -179.464 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.591 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 152.25 175.28 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.908 0 CA-C-N 114.85 -1.068 . . . . 0.0 108.388 178.743 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.99 -141.6 2.11 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -76.91 150.06 29.8 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 122.123 1.882 . . . . 0.0 109.552 179.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.528 ' HA ' ' HG2' ' A' ' 21' ' ' GLN . 4.6 mm? -99.75 85.01 3.01 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.122 -0.986 . . . . 0.0 108.867 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -82.32 166.13 19.76 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.104 -0.997 . . . . 0.0 108.664 179.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.1 t -54.83 117.32 3.31 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.408 -0.808 . . . . 0.0 109.123 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.17 43.21 5.69 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 -179.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . 0.528 ' HG2' ' HA ' ' A' ' 17' ' ' LEU . 19.6 tp60 -112.54 145.82 39.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.448 -1.031 . . . . 0.0 110.696 -179.116 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.453 HD12 ' O ' ' A' ' 23' ' ' ALA . 2.3 tm? -106.51 93.95 4.87 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.254 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.453 ' O ' HD12 ' A' ' 22' ' ' LEU . . . -76.88 159.05 30.34 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.077 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.555 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.53 118.2 28.69 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.132 -1.605 . . . . 0.0 108.004 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.721 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 8.3 m-85 -103.95 174.65 5.78 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 122.705 1.24 . . . . 0.0 112.592 -176.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 53' ' ' ALA . 0.3 OUTLIER -174.93 149.52 1.14 Allowed 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 177.992 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.718 ' CD1' ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -113.98 156.33 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.806 -1.184 . . . . 0.0 108.63 -178.258 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -129.95 121.16 26.05 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.704 -1.247 . . . . 0.0 112.559 -178.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.732 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 170.88 -72.36 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.406 -0.808 . . . . 0.0 108.955 177.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.732 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 35.7 Cg_endo -77.09 78.82 3.31 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 C-N-CA 121.616 1.544 . . . . 0.0 108.593 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.71 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 13.0 mt -40.51 -50.36 6.85 Favored Pre-proline 0 N--CA 1.497 1.891 0 O-C-N 121.782 -0.574 . . . . 0.0 111.653 -178.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.71 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 36.8 Cg_endo -80.99 60.05 7.71 Favored 'Trans proline' 0 C--N 1.315 -1.185 0 C-N-CA 122.024 1.816 . . . . 0.0 112.001 -179.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.579 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 38.7 t -90.94 147.82 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 120.708 -1.245 . . . . 0.0 109.288 179.006 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.12 -30.57 6.62 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.334 -0.854 . . . . 0.0 110.171 179.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.36 145.06 18.85 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.245 -0.909 . . . . 0.0 109.334 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.676 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.3 t -129.22 158.72 38.23 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.469 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 2.9 mtm-85 -123.12 101.67 7.53 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.298 -0.877 . . . . 0.0 108.895 179.546 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.721 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 37.6 m95 -89.17 178.66 6.31 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.124 -0.985 . . . . 0.0 109.619 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.464 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.33 102.34 3.06 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 177.515 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.609 ' CE1' ' CG2' ' A' ' 47' ' ' VAL . 2.2 m-30 -79.66 -60.03 2.51 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 118.794 -1.162 . . . . 0.0 109.76 -177.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.13 18.32 47.06 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.42 -103.32 0.32 Allowed 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 178.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.64 -20.26 60.27 Favored Glycine 0 C--N 1.297 -1.618 0 N-CA-C 107.805 -2.118 . . . . 0.0 107.805 176.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 12.9 p -135.91 130.06 33.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.353 -1.086 . . . . 0.0 109.342 179.421 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.49 -85.37 0.1 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.047 -1.033 . . . . 0.0 109.877 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.487 ' C ' HG21 ' A' ' 47' ' ' VAL . 3.1 pm0 -56.07 152.05 11.12 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.303 0.573 . . . . 0.0 110.306 -179.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.661 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 26.1 t -140.8 121.87 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 111.047 -179.004 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 62.1 m-20 -104.58 107.81 18.94 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.429 ' HB2' ' CG2' ' A' ' 36' ' ' THR . . . -120.99 170.87 9.09 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.055 -1.028 . . . . 0.0 111.092 -178.475 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.48 152.4 20.05 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.648 -0.657 . . . . 0.0 109.643 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.516 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 46.51 -156.08 0.61 Allowed Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.842 -1.703 . . . . 0.0 108.842 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -88.83 40.79 0.54 Allowed 'Trans proline' 0 C--N 1.297 -2.151 0 C-N-CA 122.244 1.963 . . . . 0.0 110.24 178.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.548 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -140.0 157.59 45.42 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 119.936 -1.727 . . . . 0.0 112.307 -178.681 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.525 ' HB1' ' CE2' ' A' ' 38' ' ' TRP . . . -171.59 -167.67 0.53 Allowed 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.506 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.504 ' O ' ' CZ ' ' A' ' 40' ' ' PHE . 0.0 OUTLIER -146.74 175.99 10.2 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.096 -1.003 . . . . 0.0 109.186 179.29 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.575 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 4.6 m80 -133.92 132.95 40.85 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.927 -1.108 . . . . 0.0 110.408 -179.139 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.53 89.17 2.92 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.566 ' CE2' ' CG1' ' A' ' 83' ' ' VAL . 32.7 m-85 -92.41 126.85 37.67 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.206 -0.934 . . . . 0.0 109.122 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 9.8 p -114.44 -28.41 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.407 -0.808 . . . . 0.0 111.514 -178.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -98.63 145.86 30.63 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 120.512 -1.367 . . . . 0.0 109.429 -179.36 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.36 119.28 4.89 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 122.383 2.055 . . . . 0.0 109.814 179.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 161.49 -162.14 33.65 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -107.09 130.17 54.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.221 -1.164 . . . . 0.0 110.12 -179.756 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.563 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 73.1 m-85 -112.87 161.1 17.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.465 -0.772 . . . . 0.0 109.07 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 70.0 t60 -115.23 122.22 45.33 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.462 -0.774 . . . . 0.0 109.069 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.536 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 66.1 t -102.74 152.01 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.38 -0.825 . . . . 0.0 109.899 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.57 158.52 44.25 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 178.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.7 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -149.51 156.67 42.35 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.92 -1.113 . . . . 0.0 110.989 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.413 HG22 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -147.07 104.68 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.385 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 179.224 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.676 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -88.84 150.44 22.9 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.734 -1.229 . . . . 0.0 109.703 -179.181 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.45 117.04 20.66 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.588 -0.845 . . . . 0.0 109.309 178.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 5.2 mp -105.36 -13.13 15.75 Favored 'General case' 0 C--N 1.293 -1.881 0 CA-C-O 121.52 0.676 . . . . 0.0 109.239 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.33 -56.21 0.59 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -114.63 -7.25 12.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.576 -0.955 . . . . 0.0 109.759 179.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -137.47 161.13 25.29 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.0 p -151.2 170.06 20.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.411 -1.053 . . . . 0.0 109.409 -179.724 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.545 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -144.16 126.63 15.9 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.882 . . . . 0.0 109.198 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -95.25 152.14 18.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.224 -0.923 . . . . 0.0 110.639 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.718 ' HG ' ' CD1' ' A' ' 27' ' ' ILE . 0.1 OUTLIER -135.7 158.53 44.17 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.747 -0.596 . . . . 0.0 109.472 179.878 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.536 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.96 88.54 0.1 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.544 HG21 HD22 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -110.83 -171.91 1.92 Allowed 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.05 -1.265 . . . . 0.0 109.965 -179.893 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -149.54 149.56 30.9 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.566 ' CG1' ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -132.29 138.29 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.76 -1.213 . . . . 0.0 110.056 -179.654 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.46 83.33 2.43 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.408 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.489 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 53.4 t -72.62 134.3 30.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.148 -0.97 . . . . 0.0 109.627 -179.418 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -110.77 -179.1 3.65 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.386 -0.821 . . . . 0.0 109.643 -179.592 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.919 . . . . 0.0 109.185 179.603 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.658 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.418 ' O ' ' HA ' ' A' ' 27' ' ' ILE . 1.2 t -75.44 155.83 35.89 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.199 -0.938 . . . . 0.0 108.873 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.622 HD11 ' CD2' ' A' ' 79' ' ' LEU . 0.0 OUTLIER -96.8 90.96 5.45 Favored 'General case' 0 N--CA 1.49 1.553 0 C-N-CA 119.961 -0.696 . . . . 0.0 110.141 -178.854 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.574 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 25.3 t -93.96 96.23 5.88 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.622 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -114.74 75.69 0.25 Allowed Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.716 -1.231 . . . . 0.0 110.545 -178.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.557 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 32.7 Cg_endo -73.01 149.38 46.7 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.5 2.133 . . . . 0.0 111.494 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.559 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 69.6 t60 163.16 -37.5 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 CA-C-O 121.771 0.796 . . . . 0.0 109.06 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.77 -137.62 13.49 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.133 -1.987 . . . . 0.0 108.133 -178.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.25 147.08 25.68 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 C-N-CA 122.138 1.892 . . . . 0.0 109.351 178.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.426 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 12.1 mt -113.15 85.85 2.26 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.264 -0.897 . . . . 0.0 109.967 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.56 160.78 32.1 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.9 t -54.41 123.47 13.08 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.237 -0.914 . . . . 0.0 109.466 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.47 48.41 4.53 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 19.9 mm-40 -123.94 150.83 44.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.434 -1.039 . . . . 0.0 110.313 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.436 HD21 ' HA ' ' A' ' 22' ' ' LEU . 2.3 tm? -108.48 93.26 4.43 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.829 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.559 ' HA ' ' CG ' ' A' ' 14' ' ' HIS . . . -76.42 155.75 33.72 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.557 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.49 121.09 37.72 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.689 -1.257 . . . . 0.0 108.426 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.756 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.2 m-85 -108.33 171.07 7.62 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-O 122.204 1.002 . . . . 0.0 111.397 -177.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.574 ' CE1' ' CG1' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -168.64 135.79 1.96 Allowed 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 177.803 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.692 ' CD1' ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -101.48 149.64 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.882 -1.136 . . . . 0.0 108.692 -178.509 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -128.75 126.71 40.56 Favored 'General case' 0 N--CA 1.5 2.068 0 C-N-CA 118.775 -1.17 . . . . 0.0 112.501 -177.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.726 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 169.18 -69.6 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.532 -0.73 . . . . 0.0 109.081 177.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.726 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 34.8 Cg_endo -76.96 79.59 3.08 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 121.654 1.569 . . . . 0.0 109.144 179.061 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.507 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -34.89 -54.34 1.02 Allowed Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.989 -0.444 . . . . 0.0 112.004 -178.921 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.507 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.5 Cg_endo -79.48 69.4 7.95 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.23 1.954 . . . . 0.0 111.775 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.578 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 47.8 t -98.34 148.24 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.834 -1.166 . . . . 0.0 109.327 179.018 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 24.3 p -119.14 -29.15 5.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.307 -0.871 . . . . 0.0 110.26 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -159.29 145.05 16.17 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.221 -0.924 . . . . 0.0 109.619 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.675 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.8 t -130.75 151.44 51.18 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.51 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.7 OUTLIER -120.56 104.73 10.18 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.202 -0.936 . . . . 0.0 108.713 179.173 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.756 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 37.5 m95 -89.6 -178.6 5.59 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-O 122.079 0.942 . . . . 0.0 109.432 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.407 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.3 OUTLIER -150.45 101.03 2.93 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 106.329 -1.73 . . . . 0.0 106.329 177.45 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.678 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 3.3 m-30 -80.37 -56.08 4.44 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.121 -177.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.6 20.41 54.25 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.133 -1.587 . . . . 0.0 109.133 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.55 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 1.1 p30 -104.25 -104.48 0.3 Allowed 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 178.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.24 -15.91 68.15 Favored Glycine 0 C--N 1.296 -1.646 0 N-CA-C 107.754 -2.138 . . . . 0.0 107.754 176.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.7 p -138.29 130.97 29.39 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.489 -1.007 . . . . 0.0 108.892 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.407 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.74 -85.4 0.09 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.941 -1.099 . . . . 0.0 109.752 -179.602 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.473 ' C ' HG21 ' A' ' 47' ' ' VAL . 1.3 pt-20 -57.16 154.09 10.68 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.332 0.587 . . . . 0.0 110.121 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.654 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 52.6 t -140.01 121.63 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.431 -0.793 . . . . 0.0 110.689 -178.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -104.21 118.97 37.93 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 178.007 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.437 ' HB2' ' CG2' ' A' ' 36' ' ' THR . . . -132.75 166.06 23.1 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.031 -1.043 . . . . 0.0 111.042 -178.513 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.31 153.47 18.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.672 -0.642 . . . . 0.0 109.796 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.462 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 45.35 -155.93 0.39 Allowed Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -88.96 38.99 0.44 Allowed 'Trans proline' 0 C--N 1.298 -2.118 0 C-N-CA 122.544 2.163 . . . . 0.0 110.149 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.52 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -138.16 152.63 48.87 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.115 -1.616 . . . . 0.0 112.054 -178.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.551 ' HB1' ' CE2' ' A' ' 38' ' ' TRP . . . -163.61 -166.79 1.26 Allowed 'General case' 0 N--CA 1.494 1.775 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.469 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 1.4 p -158.49 141.1 14.42 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.11 -0.994 . . . . 0.0 109.79 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.678 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 9.7 m80 -94.02 136.7 34.03 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.476 -0.765 . . . . 0.0 111.081 -178.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -110.89 87.71 2.6 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 178.396 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.668 ' CE2' HG12 ' A' ' 83' ' ' VAL . 15.1 m-85 -87.73 138.55 31.37 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.202 -0.936 . . . . 0.0 109.704 -178.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 12.0 p -129.51 -26.83 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.362 -0.836 . . . . 0.0 111.257 -178.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -98.36 144.6 28.38 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 120.507 -1.371 . . . . 0.0 109.718 -179.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.64 116.39 4.04 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.55 2.167 . . . . 0.0 109.929 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 160.54 -154.78 25.84 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.93 165.41 11.56 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.022 -1.281 . . . . 0.0 109.817 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.604 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 47.2 m-85 -149.17 166.43 28.86 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 28.0 t60 -127.88 142.18 51.34 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.317 -0.864 . . . . 0.0 108.858 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.541 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 30.3 t -122.64 146.0 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 120.997 -1.064 . . . . 0.0 110.712 -179.236 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -151.44 156.28 40.32 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.541 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.71 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -149.92 161.17 42.82 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 120.849 -1.157 . . . . 0.0 111.128 -179.76 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.5 p -150.78 105.58 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.675 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -89.4 144.85 25.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.754 -1.216 . . . . 0.0 109.811 -178.845 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -118.74 119.97 36.0 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.38 -0.928 . . . . 0.0 109.247 178.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.489 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 6.4 mp -114.16 -9.33 12.91 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 121.479 0.657 . . . . 0.0 109.485 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.428 ' O ' ' CB ' ' A' ' 74' ' ' ALA . . . 102.19 101.43 2.57 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 107.495 -2.242 . . . . 0.0 107.495 -178.235 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.428 ' CB ' ' O ' ' A' ' 73' ' ' GLY . . . 71.53 -0.38 3.17 Favored 'General case' 0 N--CA 1.485 1.292 0 O-C-N 121.714 -0.874 . . . . 0.0 110.372 -178.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -145.71 142.41 10.63 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.421 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -150.28 163.95 37.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.098 -1.236 . . . . 0.0 109.973 -179.382 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.643 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -132.15 119.81 21.42 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -89.75 149.69 22.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.911 . . . . 0.0 110.407 -179.202 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.71 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.2 OUTLIER -131.75 160.29 35.95 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.451 0.643 . . . . 0.0 110.103 -179.583 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.493 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.21 92.52 0.1 OUTLIER Glycine 0 N--CA 1.483 1.814 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.598 HG23 ' HB3' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -113.07 175.39 5.46 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.034 -1.274 . . . . 0.0 109.377 179.524 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -117.68 156.17 28.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.309 -0.869 . . . . 0.0 108.851 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.668 HG12 ' CE2' ' A' ' 58' ' ' TYR . 25.1 t -137.25 139.87 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 120.983 -1.073 . . . . 0.0 110.635 -178.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.494 ' N ' HG11 ' A' ' 83' ' ' VAL . 5.4 mt-30 -123.5 93.81 4.06 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.168 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 40.8 t -87.16 135.36 25.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.237 -0.914 . . . . 0.0 110.058 -179.303 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -107.66 -157.32 0.61 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.447 -0.783 . . . . 0.0 109.424 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.005 -1.059 . . . . 0.0 109.107 179.691 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.691 ' HA ' ' HB1' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.533 HG22 HG21 ' A' ' 11' ' ' VAL . 1.1 t -69.2 150.44 47.48 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.19 -0.944 . . . . 0.0 109.584 -178.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.716 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 4.6 mp -83.19 107.18 15.56 Favored 'General case' 0 N--CA 1.489 1.516 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.648 -178.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.533 HG21 HG22 ' A' ' 9' ' ' THR . 0.4 OUTLIER -120.79 96.26 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 120.823 -1.173 . . . . 0.0 108.977 179.088 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.624 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -115.95 80.03 0.29 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.021 -1.231 . . . . 0.0 110.021 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.554 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 32.2 Cg_endo -71.94 147.58 49.73 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.513 2.142 . . . . 0.0 112.018 179.598 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.501 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 32.7 t-80 158.87 -33.98 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.08 -141.32 15.23 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -77.07 148.4 27.52 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.082 1.855 . . . . 0.0 109.209 178.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.467 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 4.4 mm? -105.59 109.89 22.02 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.111 -0.993 . . . . 0.0 109.681 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -89.18 161.17 16.61 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.2 t -57.82 116.74 3.65 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.151 -0.968 . . . . 0.0 109.389 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 89.8 44.74 4.75 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -121.22 152.87 38.33 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.252 -1.146 . . . . 0.0 110.609 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.478 HD21 ' HA ' ' A' ' 22' ' ' LEU . 2.5 tm? -107.39 99.07 8.61 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.852 -0.795 . . . . 0.0 108.852 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.503 ' HB2' ' HE1' ' A' ' 25' ' ' PHE . . . -80.34 153.71 28.21 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.554 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -116.03 125.14 52.05 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.479 -1.388 . . . . 0.0 108.081 179.411 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.723 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.6 m-85 -112.57 172.44 6.92 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 122.526 1.155 . . . . 0.0 112.285 -177.188 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.533 ' HA ' ' HA ' ' A' ' 53' ' ' ALA . 4.1 p80 -173.95 148.51 1.41 Allowed 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 177.175 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.73 ' CD1' ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.21 157.51 12.05 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 120.733 -1.229 . . . . 0.0 108.599 -178.166 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -132.41 121.63 23.74 Favored 'General case' 0 N--CA 1.5 2.058 0 C-N-CA 118.698 -1.201 . . . . 0.0 112.542 -177.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.723 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 172.31 -71.54 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.402 -0.811 . . . . 0.0 108.867 177.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.723 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.6 Cg_endo -77.39 76.86 4.05 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 C-N-CA 121.708 1.605 . . . . 0.0 108.725 178.522 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.551 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -35.45 -55.78 1.08 Allowed Pre-proline 0 N--CA 1.497 1.921 0 O-C-N 121.956 -0.465 . . . . 0.0 111.472 -178.746 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.551 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.7 Cg_endo -80.16 75.1 5.23 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.125 1.884 . . . . 0.0 111.332 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.56 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 20.5 t -106.03 149.22 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.024 -1.048 . . . . 0.0 109.131 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.1 p -114.59 -28.85 7.01 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.285 -0.884 . . . . 0.0 110.626 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -158.72 143.08 15.72 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.073 -1.017 . . . . 0.0 110.164 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.664 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.8 t -129.99 155.55 45.91 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.481 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.513 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 2.6 ttm180 -122.72 104.06 9.06 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.248 -0.907 . . . . 0.0 108.713 179.059 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.723 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 32.1 m95 -88.78 179.89 6.13 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.306 -0.871 . . . . 0.0 109.324 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.499 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.21 103.1 3.14 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 106.811 -1.551 . . . . 0.0 106.811 177.889 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.623 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 2.5 m-30 -81.16 -67.0 0.82 Allowed 'General case' 0 N--CA 1.493 1.683 0 C-N-CA 119.001 -1.079 . . . . 0.0 110.738 -177.502 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.64 7.58 56.62 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -178.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.6 p30 -98.34 35.6 1.75 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.415 -1.05 . . . . 0.0 108.317 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.88 -39.19 2.96 Favored Glycine 0 C--N 1.295 -1.699 0 N-CA-C 105.773 -2.931 . . . . 0.0 105.773 -176.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 87.7 p -107.27 101.82 11.17 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 177.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.499 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -75.58 -89.99 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -0.944 . . . . 0.0 110.189 -178.602 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.428 ' C ' HG21 ' A' ' 47' ' ' VAL . 0.8 OUTLIER -52.21 145.74 10.25 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-O 121.296 0.57 . . . . 0.0 109.884 -179.416 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.628 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 47.7 t -135.9 110.79 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.299 -0.875 . . . . 0.0 110.851 -178.703 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.23 107.41 19.18 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.368 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.45 ' HB2' ' CG2' ' A' ' 36' ' ' THR . . . -120.02 165.79 14.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.198 -0.939 . . . . 0.0 110.98 -178.432 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.07 152.59 18.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.598 -0.689 . . . . 0.0 109.446 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.554 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 45.53 -156.12 0.41 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -88.97 40.99 0.54 Allowed 'Trans proline' 0 C--N 1.295 -2.242 0 C-N-CA 122.209 1.94 . . . . 0.0 110.381 178.465 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.533 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -139.52 159.26 42.57 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 119.953 -1.717 . . . . 0.0 112.509 -178.659 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.508 ' HB1' ' CE2' ' A' ' 38' ' ' TRP . . . -171.55 -167.05 0.48 Allowed 'General case' 0 N--CA 1.495 1.823 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.3 p -156.52 144.32 19.38 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.011 -1.056 . . . . 0.0 109.536 179.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.623 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 9.1 m80 -102.4 146.25 28.35 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.595 0.712 . . . . 0.0 111.327 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.402 ' HA ' HD21 ' A' ' 22' ' ' LEU . 0.4 OUTLIER -118.26 90.47 3.34 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 178.626 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.556 ' CE2' ' CG1' ' A' ' 83' ' ' VAL . 30.2 m-85 -92.63 128.76 38.6 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.067 -1.02 . . . . 0.0 110.012 -178.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.0 p -117.62 -27.84 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.484 -0.76 . . . . 0.0 111.108 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.45 ' CD2' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -101.77 146.44 32.25 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 120.561 -1.337 . . . . 0.0 109.483 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.45 ' HD2' ' CD2' ' A' ' 60' ' ' LEU . 34.3 Cg_endo -77.6 121.74 5.69 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 C-N-CA 122.286 1.991 . . . . 0.0 109.849 179.481 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 162.45 -163.31 35.0 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.446 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.3 OUTLIER -105.92 121.26 43.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.107 -1.231 . . . . 0.0 110.052 -179.805 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.509 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 64.6 m-85 -104.2 151.29 23.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 0.0 109.091 179.49 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.1 t60 -108.37 125.33 51.61 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.352 -0.842 . . . . 0.0 109.154 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.525 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 64.8 t -108.3 151.59 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.921 . . . . 0.0 110.185 -179.401 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.81 158.4 44.13 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.686 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -151.23 155.28 38.5 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.011 -1.056 . . . . 0.0 110.768 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.427 ' HA ' ' O ' ' A' ' 77' ' ' ALA . 8.1 p -148.35 108.09 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.664 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -89.13 149.99 22.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.818 -1.176 . . . . 0.0 109.367 -179.112 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.19 119.97 20.57 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.372 -0.931 . . . . 0.0 109.93 179.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.45 HD22 ' HA ' ' A' ' 33' ' ' VAL . 11.6 mt -110.86 -12.21 14.28 Favored 'General case' 0 C--N 1.295 -1.776 0 CA-C-O 121.498 0.666 . . . . 0.0 109.406 179.35 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.43 -49.65 0.86 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 -178.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -112.17 -7.71 14.03 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.517 -0.99 . . . . 0.0 109.71 179.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -145.84 153.48 25.33 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.407 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 1.7 p -150.89 169.37 21.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.191 -1.182 . . . . 0.0 109.691 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.53 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -144.2 154.02 42.69 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.394 -0.816 . . . . 0.0 108.997 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 5.1 mp -122.65 150.51 42.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.143 -0.973 . . . . 0.0 109.89 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.73 ' HG ' ' CD1' ' A' ' 27' ' ' ILE . 0.1 OUTLIER -136.06 158.92 43.25 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.552 -0.718 . . . . 0.0 110.013 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.525 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -167.2 87.54 0.1 OUTLIER Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.768 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.432 HG21 HD21 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -107.46 -174.51 2.55 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.126 -1.22 . . . . 0.0 110.353 -179.491 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -150.88 143.0 24.09 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.246 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.556 ' CG1' ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -128.82 145.02 36.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 120.683 -1.261 . . . . 0.0 109.636 -179.539 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -109.6 84.33 1.91 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.45 -0.781 . . . . 0.0 109.246 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 48.1 t -69.51 133.47 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.01 -1.056 . . . . 0.0 109.394 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -114.9 162.71 16.56 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.456 -0.777 . . . . 0.0 109.845 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.324 -0.86 . . . . 0.0 109.388 179.533 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.63 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.487 1.415 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.493 HG22 HG21 ' A' ' 11' ' ' VAL . 1.2 t -70.44 148.53 48.22 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.222 -0.924 . . . . 0.0 109.272 -179.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.697 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.1 mp -85.59 103.86 14.81 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.083 -178.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.593 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 4.7 t -117.08 104.79 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 120.772 -1.205 . . . . 0.0 108.829 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.556 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -117.77 73.99 0.29 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.523 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 35.0 Cg_endo -73.17 151.96 49.95 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.874 2.383 . . . . 0.0 112.462 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.551 ' CE1' ' HG2' ' A' ' 21' ' ' GLN . 26.8 t-80 158.52 -39.78 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.27 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.14 -137.0 13.73 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.074 -2.01 . . . . 0.0 108.074 -179.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -78.15 148.44 24.38 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 C-N-CA 122.152 1.901 . . . . 0.0 109.521 178.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 4.0 mm? -112.16 102.42 10.61 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.097 -1.002 . . . . 0.0 109.465 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.51 165.05 15.14 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.164 -0.96 . . . . 0.0 108.848 179.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.7 t -56.41 122.16 11.26 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.321 -0.862 . . . . 0.0 109.363 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 83.26 47.62 5.68 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . 0.551 ' HG2' ' CE1' ' A' ' 14' ' ' HIS . 1.6 tp60 -120.26 150.66 40.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.345 -1.091 . . . . 0.0 110.622 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.44 HD21 ' HA ' ' A' ' 22' ' ' LEU . 2.3 tm? -107.27 96.67 6.58 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.428 ' O ' HD12 ' A' ' 22' ' ' LEU . . . -79.31 156.59 27.97 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 178.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.523 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.97 117.49 27.42 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.516 -1.365 . . . . 0.0 108.094 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.734 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.8 m-85 -101.95 176.55 5.17 Favored 'General case' 0 N--CA 1.488 1.459 0 CA-C-O 122.459 1.124 . . . . 0.0 112.223 -177.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.593 ' CE1' ' CG1' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -174.3 143.41 0.86 Allowed 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.502 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.744 ' CD1' ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.72 153.55 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.911 -1.118 . . . . 0.0 108.388 -179.067 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -131.62 123.43 27.86 Favored 'General case' 0 N--CA 1.501 2.101 0 C-N-CA 118.429 -1.308 . . . . 0.0 112.781 -177.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.707 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 173.3 -68.56 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.948 0 O-C-N 121.296 -0.877 . . . . 0.0 109.525 177.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.707 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -76.17 78.44 3.21 Favored 'Trans proline' 0 C--N 1.312 -1.395 0 C-N-CA 121.787 1.658 . . . . 0.0 109.497 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.521 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -32.86 -55.06 0.59 Allowed Pre-proline 0 N--CA 1.499 2.014 0 O-C-N 121.966 -0.459 . . . . 0.0 112.103 -179.16 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.521 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.3 Cg_endo -79.27 61.13 8.07 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 C-N-CA 122.324 2.016 . . . . 0.0 112.084 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.57 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 90.2 t -85.86 152.21 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 120.593 -1.317 . . . . 0.0 109.564 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.6 t -126.07 -33.14 2.69 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.489 -0.757 . . . . 0.0 109.783 179.294 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.53 140.69 15.31 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.395 -0.816 . . . . 0.0 109.296 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.607 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 0.8 OUTLIER -127.5 150.78 49.52 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.666 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.491 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -116.96 103.88 10.72 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.216 -0.928 . . . . 0.0 108.788 179.257 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.734 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 33.7 m95 -89.12 -179.74 5.96 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.24 -0.912 . . . . 0.0 109.383 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.409 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.48 101.84 2.99 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 177.686 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.626 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 2.6 m-30 -79.9 -62.55 1.65 Allowed 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 118.834 -1.146 . . . . 0.0 109.992 -177.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.57 16.94 43.9 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.35 -102.95 0.32 Allowed 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -85.5 -18.33 60.52 Favored Glycine 0 C--N 1.297 -1.585 0 N-CA-C 107.872 -2.091 . . . . 0.0 107.872 176.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.5 m -135.18 126.24 27.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.455 -1.027 . . . . 0.0 108.996 179.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.409 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.43 -85.91 0.09 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.02 -1.05 . . . . 0.0 109.692 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.469 ' C ' HG21 ' A' ' 47' ' ' VAL . 2.1 pt-20 -57.95 152.94 15.23 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.239 0.542 . . . . 0.0 109.679 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.644 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 27.5 t -139.22 118.46 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.295 -0.878 . . . . 0.0 110.943 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -101.53 101.28 11.82 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.438 ' HB2' HG22 ' A' ' 36' ' ' THR . . . -113.2 168.61 9.58 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.265 -0.897 . . . . 0.0 111.082 -178.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.65 155.01 18.37 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 121.422 0.63 . . . . 0.0 109.618 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.472 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 45.96 -156.26 0.48 Allowed Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -88.93 40.44 0.51 Allowed 'Trans proline' 0 C--N 1.296 -2.198 0 C-N-CA 122.194 1.929 . . . . 0.0 110.356 178.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.557 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -142.06 156.64 45.41 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 119.99 -1.694 . . . . 0.0 112.357 -178.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.5 ' HB1' ' CE2' ' A' ' 38' ' ' TRP . . . -167.41 -168.34 1.03 Allowed 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 11.5 p -156.24 141.61 17.57 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.023 -1.048 . . . . 0.0 109.678 179.494 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.626 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 12.0 m80 -99.01 143.86 28.81 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-O 121.743 0.783 . . . . 0.0 111.614 -178.328 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -114.6 90.63 3.39 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.459 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.573 ' CE1' ' CG ' ' A' ' 64' ' ' TYR . 37.0 m-85 -93.59 136.95 33.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.955 -1.091 . . . . 0.0 109.762 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 8.4 p -123.62 -33.12 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.283 -0.886 . . . . 0.0 111.356 -178.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.413 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -95.03 147.36 32.91 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 120.526 -1.359 . . . . 0.0 109.478 -179.431 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.413 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.4 Cg_endo -78.75 116.59 3.8 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.545 2.163 . . . . 0.0 109.972 179.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 166.68 -155.17 26.16 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.468 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 8.2 mtm-85 -115.1 123.08 48.06 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.261 -1.14 . . . . 0.0 109.715 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.573 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 62.5 m-85 -106.45 157.63 17.5 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.441 -0.787 . . . . 0.0 109.367 179.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 67.2 t60 -109.85 129.39 55.65 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.519 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 83.0 t -110.36 151.49 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.385 -0.822 . . . . 0.0 109.969 -179.439 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.46 157.12 42.66 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.133 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.673 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -150.43 156.41 41.41 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 120.889 -1.132 . . . . 0.0 110.979 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.4 p -147.32 107.66 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.607 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -90.19 153.19 20.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.896 -1.128 . . . . 0.0 110.445 -178.39 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -131.13 117.91 19.75 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.303 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.507 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 6.1 mp -106.05 -12.86 15.64 Favored 'General case' 0 C--N 1.293 -1.85 0 CA-C-O 121.495 0.664 . . . . 0.0 109.29 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.15 -45.76 1.26 Allowed Glycine 0 N--CA 1.488 2.116 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -178.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.13 -6.76 12.48 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.59 -0.947 . . . . 0.0 109.704 179.082 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -150.02 165.23 29.76 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.35 168.75 23.83 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.246 -1.149 . . . . 0.0 109.512 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.531 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -145.14 140.68 28.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.487 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -107.16 150.88 26.11 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.067 -1.02 . . . . 0.0 110.3 -179.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.744 ' HG ' ' CD1' ' A' ' 27' ' ' ILE . 0.1 OUTLIER -134.96 158.53 44.08 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.467 -0.771 . . . . 0.0 109.842 -179.751 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -167.72 91.47 0.1 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.26 -171.57 1.94 Allowed 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.08 -1.247 . . . . 0.0 110.165 -179.7 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -150.15 147.96 28.37 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 179.201 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.569 HG13 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -129.86 140.81 48.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 120.617 -1.302 . . . . 0.0 110.027 -179.271 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.428 ' HG2' ' HG2' ' A' ' 63' ' ' ARG . 0.8 OUTLIER -104.07 85.55 2.41 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.381 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 98.4 t -77.74 136.99 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.151 -0.968 . . . . 0.0 109.644 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -124.05 142.55 51.09 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.278 -0.889 . . . . 0.0 109.579 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.168 -0.957 . . . . 0.0 109.648 179.809 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.63 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.484 HG22 ' CG2' ' A' ' 11' ' ' VAL . 1.0 OUTLIER -73.48 149.21 42.49 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.282 -0.886 . . . . 0.0 109.209 -179.442 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.662 ' HG ' ' CD2' ' A' ' 79' ' ' LEU . 5.2 mp -91.38 103.81 16.4 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.322 -178.315 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.52 ' HB ' ' CE1' ' A' ' 26' ' ' HIS . 3.1 t -117.12 105.47 18.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 O-C-N 120.776 -1.203 . . . . 0.0 108.782 178.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.572 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.93 74.17 0.3 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.518 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 35.3 Cg_endo -73.14 152.54 50.9 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.752 2.301 . . . . 0.0 111.983 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.475 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.2 t-80 163.74 -37.99 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 CA-C-O 121.698 0.761 . . . . 0.0 108.961 179.58 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.5 -136.54 13.57 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.308 -1.917 . . . . 0.0 108.308 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -78.01 149.18 25.46 Favored 'Trans proline' 0 C--N 1.304 -1.797 0 C-N-CA 122.246 1.964 . . . . 0.0 109.352 179.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.501 HD22 ' HB3' ' A' ' 23' ' ' ALA . 22.7 mt -120.75 93.37 4.01 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.041 -1.037 . . . . 0.0 110.102 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.554 ' HA ' ' HG3' ' A' ' 86' ' ' GLU . . . -87.42 164.03 16.42 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.082 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.427 ' CB ' ' HA ' ' A' ' 87' ' ' ALA . 40.6 t -49.96 121.27 5.17 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.564 -0.71 . . . . 0.0 110.085 -179.406 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.31 47.47 4.35 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . 0.499 ' HB3' HD21 ' A' ' 17' ' ' LEU . 4.4 mm-40 -122.4 149.57 43.64 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.23 -1.159 . . . . 0.0 110.94 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.46 HD21 ' HA ' ' A' ' 22' ' ' LEU . 2.4 tm? -108.49 98.55 8.06 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.501 ' HB3' HD22 ' A' ' 17' ' ' LEU . . . -81.93 154.63 25.68 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.518 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -117.4 121.37 40.9 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.611 -1.306 . . . . 0.0 107.981 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.725 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 7.3 m-85 -108.15 173.5 6.29 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 122.425 1.107 . . . . 0.0 112.362 -176.813 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.543 ' HA ' ' HA ' ' A' ' 53' ' ' ALA . 3.4 p80 -171.27 144.51 2.03 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 177.286 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.722 HD13 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.54 158.33 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.095 -1.003 . . . . 0.0 108.571 -178.578 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -136.91 122.41 19.59 Favored 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 118.445 -1.302 . . . . 0.0 112.627 -178.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.702 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 172.01 -68.24 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 121.201 -0.937 . . . . 0.0 109.595 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.702 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -76.41 78.39 3.29 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 C-N-CA 121.758 1.639 . . . . 0.0 109.374 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.512 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 3.7 mp -32.5 -54.97 0.56 Allowed Pre-proline 0 N--CA 1.499 2.019 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.512 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.7 Cg_endo -79.85 60.77 7.96 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 C-N-CA 122.249 1.966 . . . . 0.0 111.994 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.575 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 94.2 t -84.14 149.0 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.633 -1.292 . . . . 0.0 109.708 179.283 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 31.9 p -122.11 -36.62 2.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.41 -0.806 . . . . 0.0 109.611 179.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -154.04 136.36 14.92 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.515 -0.741 . . . . 0.0 109.257 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.522 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.2 t -123.59 140.05 53.38 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.506 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.506 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 1.2 ttp180 -107.68 106.05 16.19 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.816 179.285 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.725 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 36.1 m95 -89.08 179.55 6.12 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.998 0.904 . . . . 0.0 109.111 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.424 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.78 100.23 2.8 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 177.445 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.611 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 2.7 m-30 -80.01 -59.79 2.58 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.787 -1.165 . . . . 0.0 110.011 -177.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.54 17.27 53.06 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -104.35 -103.75 0.31 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 178.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.61 -21.63 59.63 Favored Glycine 0 C--N 1.297 -1.631 0 N-CA-C 107.717 -2.153 . . . . 0.0 107.717 176.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 11.6 p -134.58 129.8 35.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.427 -1.043 . . . . 0.0 109.148 179.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.424 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.25 -84.22 0.11 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.074 -1.016 . . . . 0.0 109.686 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.472 ' C ' HG21 ' A' ' 47' ' ' VAL . 4.0 mp0 -58.78 149.27 26.92 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.153 0.501 . . . . 0.0 109.848 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.681 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 42.3 t -137.72 121.05 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.385 -0.822 . . . . 0.0 110.755 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 61.8 m-20 -104.17 97.26 7.25 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.451 ' HB2' HG22 ' A' ' 36' ' ' THR . . . -107.89 166.35 10.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.251 -0.905 . . . . 0.0 111.239 -178.292 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.58 154.58 18.15 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 121.275 0.56 . . . . 0.0 109.533 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.441 ' O ' HG21 ' A' ' 36' ' ' THR . . . 45.88 -155.65 0.53 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.788 -1.725 . . . . 0.0 108.788 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -89.53 40.74 0.48 Allowed 'Trans proline' 0 C--N 1.295 -2.252 0 C-N-CA 122.256 1.971 . . . . 0.0 110.486 178.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -143.43 156.42 44.65 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 119.882 -1.762 . . . . 0.0 112.581 -178.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.467 ' HB1' ' CE2' ' A' ' 38' ' ' TRP . . . -168.06 -167.69 0.86 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.3 p -155.52 141.38 18.12 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.959 -1.088 . . . . 0.0 109.738 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.611 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 12.9 m80 -97.98 142.83 29.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.499 -0.75 . . . . 0.0 111.442 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.436 ' HA ' HD21 ' A' ' 22' ' ' LEU . 0.9 OUTLIER -114.52 90.52 3.36 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.697 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.586 ' CE1' ' CG ' ' A' ' 64' ' ' TYR . 31.2 m-85 -94.15 122.3 36.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.11 -0.994 . . . . 0.0 109.751 -178.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.0 m -115.83 -26.02 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.487 -0.758 . . . . 0.0 111.104 -178.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.429 ' CG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -98.04 146.31 31.28 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 120.647 -1.283 . . . . 0.0 109.227 -179.636 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.429 ' HD2' ' CG ' ' A' ' 60' ' ' LEU . 34.1 Cg_endo -77.19 123.8 6.87 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 122.41 2.073 . . . . 0.0 110.018 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 156.47 -169.8 33.92 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.411 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -103.84 121.74 43.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.285 -1.127 . . . . 0.0 109.884 -179.823 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.586 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 79.9 m-85 -100.2 160.76 14.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.391 -0.818 . . . . 0.0 109.645 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.471 ' CD2' HG23 ' A' ' 67' ' ' THR . 35.8 t60 -115.18 121.88 44.34 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 178.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.474 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 64.5 t -102.86 151.57 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.265 -0.897 . . . . 0.0 110.648 -179.051 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.471 HG23 ' CD2' ' A' ' 65' ' ' HIS . 0.1 OUTLIER -150.61 160.2 43.97 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 178.427 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.715 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -153.3 157.97 40.89 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.094 -1.004 . . . . 0.0 110.695 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.2 p -147.07 107.8 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.61 HD13 ' HB1' ' A' ' 77' ' ' ALA . 0.2 OUTLIER -88.94 147.86 24.11 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.849 -1.157 . . . . 0.0 110.147 -178.043 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.47 113.88 16.08 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 121.932 0.872 . . . . 0.0 108.808 178.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.539 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 6.0 mp -103.36 -12.57 17.13 Favored 'General case' 0 C--N 1.289 -2.027 0 CA-C-O 121.553 0.692 . . . . 0.0 109.194 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 112.3 -49.84 0.82 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 -178.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.1 -5.66 11.92 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.577 -0.955 . . . . 0.0 109.815 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.16 160.78 27.87 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.414 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.2 p -151.04 173.31 14.48 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.398 -1.06 . . . . 0.0 109.218 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.61 ' HB1' HD13 ' A' ' 70' ' ' LEU . . . -149.88 129.63 13.25 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.261 -0.899 . . . . 0.0 109.651 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.3 tt -94.33 140.0 30.35 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.424 -0.798 . . . . 0.0 110.007 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.722 ' HG ' HD13 ' A' ' 27' ' ' ILE . 0.0 OUTLIER -126.23 155.25 42.13 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.449 -0.782 . . . . 0.0 110.275 -179.336 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.467 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -162.65 87.05 0.11 Allowed Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.413 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.612 HG21 HD22 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -105.31 -175.6 2.84 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.028 -1.278 . . . . 0.0 109.633 179.904 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . 0.406 ' N ' ' OG1' ' A' ' 81' ' ' THR . 0.7 OUTLIER -150.96 146.49 26.28 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 179.258 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.569 ' CG1' ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -131.69 141.49 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 120.602 -1.311 . . . . 0.0 110.239 -179.474 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 17.9 tt0 -104.37 89.37 3.21 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.47 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 43.4 t -82.07 133.79 28.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.204 -0.935 . . . . 0.0 110.115 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.554 ' HG3' ' HA ' ' A' ' 18' ' ' ALA . 11.2 pt-20 -103.56 -147.97 0.39 Allowed 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.427 ' HA ' ' CB ' ' A' ' 19' ' ' SER . . . . . . . . 0 N--CA 1.489 1.508 0 O-C-N 120.952 -1.092 . . . . 0.0 109.335 179.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.638 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.467 HG22 HG21 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -68.93 147.39 51.73 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.277 -0.889 . . . . 0.0 109.278 -179.147 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.619 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.0 mp -92.63 109.16 20.57 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.261 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.547 ' HB ' ' CE1' ' A' ' 26' ' ' HIS . 2.5 t -123.88 106.11 16.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.9 -1.125 . . . . 0.0 108.738 178.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.581 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.91 76.24 0.3 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.881 -1.287 . . . . 0.0 109.881 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.522 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.0 Cg_endo -73.38 150.25 46.33 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.729 2.286 . . . . 0.0 112.064 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.52 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 40.0 t-80 165.84 -38.77 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.701 0 CA-C-O 121.696 0.76 . . . . 0.0 109.114 179.623 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.01 -137.63 14.29 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 108.221 -1.952 . . . . 0.0 108.221 -179.106 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.83 148.86 25.71 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 C-N-CA 122.237 1.958 . . . . 0.0 109.371 179.053 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.547 HD21 ' HB3' ' A' ' 21' ' ' GLN . 34.5 mt -118.3 100.08 7.26 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.066 -1.021 . . . . 0.0 109.987 -179.539 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.461 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -86.5 171.3 11.19 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.149 -0.969 . . . . 0.0 108.432 179.144 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 37.4 t -54.59 126.26 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.189 -0.944 . . . . 0.0 109.851 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 77.45 51.61 5.97 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . 0.547 ' HB3' HD21 ' A' ' 17' ' ' LEU . 0.4 OUTLIER -115.55 149.78 37.65 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.392 -1.064 . . . . 0.0 110.838 -179.426 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.412 ' C ' ' CD1' ' A' ' 22' ' ' LEU . 2.1 tm? -109.46 96.67 6.43 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.52 ' HA ' ' CG ' ' A' ' 14' ' ' HIS . . . -81.21 155.97 25.88 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.949 -1.094 . . . . 0.0 108.123 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.522 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.61 116.6 26.35 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.523 -1.361 . . . . 0.0 108.11 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.581 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 4.4 m-85 -104.53 170.38 7.92 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-O 122.319 1.057 . . . . 0.0 112.229 -176.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.547 ' CE1' ' HB ' ' A' ' 11' ' ' VAL . 4.6 p80 -167.08 149.04 6.0 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.098 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.788 HD11 ' HG ' ' A' ' 79' ' ' LEU . 0.2 OUTLIER -112.96 161.85 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.095 -1.003 . . . . 0.0 109.216 -178.294 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -138.97 118.96 13.33 Favored 'General case' 0 N--CA 1.501 2.086 0 C-N-CA 118.629 -1.228 . . . . 0.0 112.463 -178.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.707 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 173.43 -68.67 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.206 -0.934 . . . . 0.0 109.634 177.688 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.707 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 33.5 Cg_endo -76.64 78.19 3.41 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 121.716 1.611 . . . . 0.0 109.362 179.616 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.497 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -33.27 -54.43 0.68 Allowed Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.946 -0.471 . . . . 0.0 112.186 -179.008 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.497 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.3 Cg_endo -79.69 58.53 7.01 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.113 1.875 . . . . 0.0 112.055 -179.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.56 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 93.9 t -81.78 147.44 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 120.724 -1.235 . . . . 0.0 109.42 179.05 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 74.0 p -122.27 -37.06 2.86 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.313 -0.867 . . . . 0.0 109.614 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -154.34 136.34 14.64 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.582 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.5 t -123.11 150.07 43.69 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.569 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.7 OUTLIER -115.54 103.44 10.74 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.351 -0.94 . . . . 0.0 108.847 179.155 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.698 ' CH2' ' CD1' ' A' ' 27' ' ' ILE . 31.7 m95 -87.66 179.13 6.57 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.158 -0.964 . . . . 0.0 109.113 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.513 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.5 OUTLIER -149.03 103.08 3.31 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 177.835 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.62 ' CD1' ' NE2' ' A' ' 56' ' ' HIS . 2.4 m-30 -81.13 -63.72 1.34 Allowed 'General case' 0 N--CA 1.491 1.597 0 C-N-CA 118.83 -1.148 . . . . 0.0 110.275 -177.782 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.59 7.05 62.0 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.479 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 13.6 p30 -98.79 31.15 3.04 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.324 -1.103 . . . . 0.0 108.647 179.367 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 117.94 -40.74 2.23 Favored Glycine 0 C--N 1.295 -1.742 0 N-CA-C 105.409 -3.077 . . . . 0.0 105.409 -176.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -106.57 100.29 9.82 Favored 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 177.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.513 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -76.21 -89.84 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.029 -1.044 . . . . 0.0 109.943 -178.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -51.48 142.15 14.43 Favored 'General case' 0 N--CA 1.495 1.825 0 CA-C-O 121.287 0.565 . . . . 0.0 109.736 -179.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.621 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 95.8 t -134.92 113.77 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.345 -0.847 . . . . 0.0 110.813 -178.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -94.84 99.46 11.52 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.534 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -110.64 167.7 10.03 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.368 -0.832 . . . . 0.0 111.015 -178.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.33 153.65 19.14 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.695 -0.628 . . . . 0.0 109.564 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.446 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 46.28 -156.51 0.52 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -89.08 40.14 0.49 Allowed 'Trans proline' 0 C--N 1.294 -2.336 0 C-N-CA 122.279 1.986 . . . . 0.0 110.285 178.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -142.73 156.32 44.99 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.889 -1.757 . . . . 0.0 112.62 -178.525 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.465 ' HB2' ' CE2' ' A' ' 38' ' ' TRP . . . -170.64 -171.76 1.1 Allowed 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 179.229 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -148.98 150.2 32.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.94 -1.1 . . . . 0.0 109.637 179.494 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.62 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 8.5 m80 -105.89 143.54 33.89 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.39 -0.819 . . . . 0.0 111.006 -178.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -118.16 89.4 3.12 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.709 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.583 ' CZ ' HG12 ' A' ' 83' ' ' VAL . 43.0 m-85 -91.49 138.97 31.15 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.914 . . . . 0.0 109.898 -178.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.1 p -124.27 -35.85 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.336 -0.852 . . . . 0.0 111.355 -178.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -86.77 146.5 41.3 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 120.511 -1.368 . . . . 0.0 109.607 -179.446 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.18 117.55 4.14 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 122.477 2.118 . . . . 0.0 110.013 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 162.11 -147.61 13.98 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.415 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -123.39 140.75 52.69 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.096 -1.237 . . . . 0.0 109.671 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.535 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 66.9 m-85 -119.98 164.37 16.19 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.322 -0.861 . . . . 0.0 109.906 -179.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 64.1 t60 -115.77 127.42 55.08 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.501 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 66.7 t -110.06 152.48 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 110.488 -179.1 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -146.93 158.62 43.97 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.75 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -155.12 117.89 4.32 Favored 'General case' 0 N--CA 1.498 1.94 0 C-N-CA 118.885 -1.126 . . . . 0.0 111.689 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 7.2 p -108.49 110.43 31.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.582 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -89.04 154.51 20.14 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.762 -1.211 . . . . 0.0 110.038 -178.801 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.18 116.65 16.5 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.779 0.799 . . . . 0.0 108.883 178.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.561 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 5.8 mp -105.43 -12.88 15.83 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 121.539 0.685 . . . . 0.0 109.26 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.67 -44.59 1.44 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.906 -2.077 . . . . 0.0 107.906 -178.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -113.89 -5.82 13.21 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.557 -0.966 . . . . 0.0 109.847 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -153.63 166.06 31.69 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.421 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 1.4 p -150.9 170.79 18.46 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.272 -1.134 . . . . 0.0 109.404 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.51 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -145.72 135.02 22.97 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.271 -0.893 . . . . 0.0 109.541 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 4.1 mp -101.04 131.11 47.09 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.148 -0.97 . . . . 0.0 109.992 -179.572 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.788 ' HG ' HD11 ' A' ' 27' ' ' ILE . 0.0 OUTLIER -118.11 155.17 30.86 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 121.451 -0.781 . . . . 0.0 110.208 -179.149 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.501 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -161.58 86.7 0.11 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.417 HG21 ' CD2' ' A' ' 10' ' ' LEU . 0.1 OUTLIER -106.04 -172.78 2.15 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.015 -1.285 . . . . 0.0 109.888 -179.808 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -151.25 152.88 33.87 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 179.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.583 HG12 ' CZ ' ' A' ' 58' ' ' TYR . 0.5 OUTLIER -132.77 155.48 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.781 -1.2 . . . . 0.0 109.88 -179.822 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.438 ' N ' HG21 ' A' ' 83' ' ' VAL . 31.6 tt0 -122.17 88.27 2.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.494 -0.754 . . . . 0.0 109.231 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 80.0 t -81.8 139.87 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.216 -0.927 . . . . 0.0 109.613 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -117.29 170.65 8.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.291 -0.88 . . . . 0.0 109.666 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.553 0 O-C-N 121.12 -0.988 . . . . 0.0 109.352 179.638 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.64 ' HA ' ' CB ' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.45 ' CG2' HG22 ' A' ' 11' ' ' VAL . 0.4 OUTLIER -81.66 140.24 34.49 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 179.807 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.622 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.5 mp -100.26 100.33 11.13 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -178.246 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.535 ' HB ' ' CE1' ' A' ' 26' ' ' HIS . 21.8 t -113.81 116.35 52.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 120.654 -1.279 . . . . 0.0 109.177 178.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.534 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -120.87 72.58 0.35 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 108.901 -1.679 . . . . 0.0 108.901 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.569 ' O ' ' HB2' ' A' ' 14' ' ' HIS . 32.5 Cg_endo -71.27 147.46 53.4 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.83 2.353 . . . . 0.0 113.069 -179.067 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.569 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 151.58 170.76 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 114.639 -1.164 . . . . 0.0 108.122 179.102 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.46 -141.34 1.15 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -76.74 151.91 32.35 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 C-N-CA 122.225 1.95 . . . . 0.0 109.464 179.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.496 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 51.3 mt -104.74 91.51 3.88 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.001 -1.062 . . . . 0.0 109.427 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.87 169.17 11.82 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.9 t -55.02 113.55 1.39 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.259 -0.9 . . . . 0.0 109.34 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.17 38.29 5.15 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . 0.495 ' HG2' ' HA ' ' A' ' 17' ' ' LEU . 3.1 tp-100 -107.89 146.33 32.49 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.286 -1.126 . . . . 0.0 110.609 -179.447 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.448 HD12 ' O ' ' A' ' 23' ' ' ALA . 2.8 tm? -108.65 94.43 5.05 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.531 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.548 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -77.68 158.62 29.62 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.027 -1.046 . . . . 0.0 108.266 179.238 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.547 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.92 119.3 31.14 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.566 -1.334 . . . . 0.0 107.869 179.293 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.548 ' CE1' ' HB2' ' A' ' 23' ' ' ALA . 3.1 m-85 -106.09 170.35 7.96 Favored 'General case' 0 N--CA 1.489 1.517 0 CA-C-O 121.96 0.886 . . . . 0.0 111.583 -177.006 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.535 ' CE1' ' HB ' ' A' ' 11' ' ' VAL . 2.3 p80 -164.66 143.65 7.03 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 107.813 -1.181 . . . . 0.0 107.813 176.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.664 ' CD1' ' CH2' ' A' ' 38' ' ' TRP . 6.0 mm -109.14 154.05 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.34 -0.85 . . . . 0.0 109.997 -177.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -136.69 113.38 10.24 Favored 'General case' 0 N--CA 1.498 1.962 0 C-N-CA 118.933 -1.107 . . . . 0.0 111.629 -179.443 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.689 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . -178.39 -61.7 0.0 OUTLIER Pre-proline 0 N--CA 1.494 1.766 0 O-C-N 120.936 -1.102 . . . . 0.0 109.791 178.36 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.689 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.0 Cg_endo -80.19 63.06 8.71 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.14 1.893 . . . . 0.0 109.874 179.693 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.625 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -12.96 -64.32 0.02 OUTLIER Pre-proline 0 N--CA 1.506 2.37 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -179.101 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.625 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 35.5 Cg_endo -77.34 71.58 6.32 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 C-N-CA 121.788 1.659 . . . . 0.0 110.926 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.502 HG21 ' HG2' ' A' ' 30' ' ' PRO . 3.0 t -96.7 135.14 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 120.853 -1.155 . . . . 0.0 109.919 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.4 t -111.58 -16.72 13.2 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.414 -0.804 . . . . 0.0 109.375 178.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.83 150.54 0.5 Allowed 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.372 -0.83 . . . . 0.0 109.827 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.496 HG23 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -137.98 137.64 38.11 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.374 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.526 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.3 OUTLIER -89.61 104.26 16.84 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.192 -0.942 . . . . 0.0 108.7 179.555 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.672 ' HB2' ' HB ' ' A' ' 47' ' ' VAL . 26.1 m95 -87.65 178.73 6.68 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.906 -1.121 . . . . 0.0 109.45 -179.589 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.449 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.7 OUTLIER -149.8 102.27 3.13 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 178.359 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.581 ' CE1' HG22 ' A' ' 47' ' ' VAL . 2.1 m-30 -80.51 -58.58 3.05 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.696 -1.202 . . . . 0.0 109.966 -178.134 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.87 15.82 57.3 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.079 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -104.63 -105.72 0.3 Allowed 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 178.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.13 -17.41 67.17 Favored Glycine 0 C--N 1.296 -1.669 0 N-CA-C 107.982 -2.047 . . . . 0.0 107.982 177.042 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.4 m -135.88 125.42 25.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.413 -1.051 . . . . 0.0 109.042 179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.24 -84.59 0.1 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.053 -1.029 . . . . 0.0 109.849 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.479 ' C ' HG21 ' A' ' 47' ' ' VAL . 39.9 mt-10 -58.42 149.78 24.09 Favored 'General case' 0 N--CA 1.495 1.809 0 CA-C-O 121.272 0.558 . . . . 0.0 110.105 -179.685 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.672 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 21.1 t -139.68 128.98 28.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.26 -0.9 . . . . 0.0 111.263 -178.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -108.15 91.4 3.63 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 177.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.551 ' HB1' ' CD1' ' A' ' 38' ' ' TRP . . . -97.35 155.67 16.79 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.347 -0.845 . . . . 0.0 111.517 -177.796 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.56 151.01 20.38 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.778 -0.576 . . . . 0.0 109.477 179.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.496 ' O ' HG23 ' A' ' 36' ' ' THR . . . 47.84 -159.11 0.61 Allowed Glycine 0 N--CA 1.489 2.181 0 N-CA-C 107.997 -2.041 . . . . 0.0 107.997 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.474 ' HB3' HG23 ' A' ' 33' ' ' VAL . 37.8 Cg_endo -87.43 41.2 0.69 Allowed 'Trans proline' 0 C--N 1.297 -2.14 0 C-N-CA 122.017 1.811 . . . . 0.0 109.99 178.265 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.48 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -143.46 150.44 39.0 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.152 -1.592 . . . . 0.0 112.097 -178.654 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.478 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -160.02 -168.32 2.19 Favored 'General case' 0 N--CA 1.495 1.778 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 179.045 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.468 ' O ' ' CZ ' ' A' ' 40' ' ' PHE . 0.1 OUTLIER -152.67 154.31 35.06 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.219 -0.926 . . . . 0.0 109.09 179.491 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.581 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 13.3 m80 -113.63 133.86 55.05 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.043 -1.036 . . . . 0.0 111.411 -178.63 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.423 ' HA ' HD21 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -104.75 87.17 2.61 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 178.723 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.609 ' CE1' ' CG ' ' A' ' 64' ' ' TYR . 31.7 m-85 -89.44 125.37 35.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.199 -0.938 . . . . 0.0 109.684 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 86.0 t -114.58 -34.52 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.428 -0.795 . . . . 0.0 110.928 -178.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.452 ' CD2' ' HD2' ' A' ' 61' ' ' PRO . 0.2 OUTLIER -90.78 145.94 33.02 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 120.542 -1.349 . . . . 0.0 109.487 -179.367 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.452 ' HD2' ' CD2' ' A' ' 60' ' ' LEU . 34.8 Cg_endo -77.66 125.52 7.58 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.44 2.093 . . . . 0.0 109.937 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.87 -154.57 25.63 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.457 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 3.9 mpt_? -114.68 133.85 55.55 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.101 -1.234 . . . . 0.0 109.65 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.609 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 82.2 m-85 -115.92 150.13 37.6 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.313 -0.867 . . . . 0.0 109.714 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.429 ' CD2' HG21 ' A' ' 67' ' ' THR . 58.9 t60 -103.95 129.63 51.52 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.482 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.573 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 92.0 t -111.03 155.18 12.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.255 -0.903 . . . . 0.0 110.236 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.429 HG21 ' CD2' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -149.84 158.6 44.32 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.658 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.706 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -154.04 123.47 6.58 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.752 -1.179 . . . . 0.0 111.709 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -95.89 126.59 48.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.732 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.636 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.6 OUTLIER -88.61 142.35 27.76 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 120.727 -1.233 . . . . 0.0 108.722 -178.738 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.75 110.39 11.3 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 120.739 -1.225 . . . . 0.0 109.832 178.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.505 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -105.39 -10.84 16.73 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.137 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.38 -45.51 1.3 Allowed Glycine 0 N--CA 1.486 2.029 0 N-CA-C 107.895 -2.082 . . . . 0.0 107.895 -178.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -119.84 -5.13 10.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.605 -0.938 . . . . 0.0 109.839 179.178 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.14 165.58 27.34 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.444 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 6.8 p -151.09 -176.88 5.72 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.391 -1.064 . . . . 0.0 109.741 -179.467 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.566 ' CB ' ' HG ' ' A' ' 70' ' ' LEU . . . -155.18 164.33 38.97 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.5 tp -120.82 119.85 33.89 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.147 -0.971 . . . . 0.0 110.067 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.706 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -105.53 156.12 18.53 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.603 -0.686 . . . . 0.0 109.392 -179.702 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.573 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.14 99.34 0.16 Allowed Glycine 0 N--CA 1.485 1.905 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.408 ' OG1' ' HB ' ' A' ' 66' ' ' VAL . 0.7 OUTLIER -115.65 -173.43 2.34 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 120.923 -1.34 . . . . 0.0 110.216 179.993 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -149.79 140.07 22.25 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.572 ' CG1' ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -125.77 152.04 32.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.916 -1.115 . . . . 0.0 109.916 -179.455 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.74 86.44 2.52 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 78.8 t -77.85 140.79 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.04 -1.038 . . . . 0.0 110.355 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -114.99 -173.93 2.4 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.426 -0.797 . . . . 0.0 109.361 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.553 0 O-C-N 120.895 -1.128 . . . . 0.0 109.701 179.865 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.686 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.412 ' CG2' HG22 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -90.19 141.91 28.23 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.664 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.595 ' N ' ' CD1' ' A' ' 10' ' ' LEU . 5.3 mp -97.05 95.33 7.71 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -178.283 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.494 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 47.5 t -105.65 118.12 52.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 120.894 -1.129 . . . . 0.0 109.186 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.516 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -123.75 71.42 0.43 Allowed Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.595 ' O ' ' HB2' ' A' ' 14' ' ' HIS . 34.5 Cg_endo -72.81 150.81 50.42 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 123.136 2.557 . . . . 0.0 113.517 -178.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.595 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 145.74 179.04 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.091 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.283 178.717 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.81 -144.52 4.63 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -75.99 150.98 34.69 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.32 2.013 . . . . 0.0 109.51 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.481 HD23 ' CB ' ' A' ' 23' ' ' ALA . 17.2 mt -102.04 82.53 2.24 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.038 -1.039 . . . . 0.0 109.759 -179.578 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -75.3 165.5 25.08 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.037 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 18.1 t -58.49 114.12 2.31 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.043 -1.035 . . . . 0.0 109.187 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.404 ' HA2' ' HA ' ' A' ' 59' ' ' VAL . . . 96.54 44.28 2.98 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -120.69 155.38 33.99 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.337 -1.096 . . . . 0.0 110.879 -179.509 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.472 HD21 ' HA ' ' A' ' 57' ' ' ARG . 2.8 tm? -112.33 97.7 6.8 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.519 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -79.44 157.55 27.5 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.557 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.75 120.25 36.01 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.497 -1.377 . . . . 0.0 108.167 179.414 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.519 ' CE1' ' HB2' ' A' ' 23' ' ' ALA . 3.4 m-85 -105.16 173.55 6.26 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.987 0.899 . . . . 0.0 111.542 -177.162 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.544 ' CD2' ' C ' ' A' ' 26' ' ' HIS . 0.0 OUTLIER -168.26 138.7 2.61 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.06 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.686 HG23 ' CB ' ' A' ' 8' ' ' ALA . 5.0 mm -107.43 149.53 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.401 -0.812 . . . . 0.0 109.154 -178.282 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -134.42 124.56 25.88 Favored 'General case' 0 N--CA 1.502 2.156 0 C-N-CA 118.57 -1.252 . . . . 0.0 112.281 -178.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.72 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . -178.8 -66.0 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.101 -0.999 . . . . 0.0 109.116 177.742 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.72 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.7 Cg_endo -81.01 66.71 8.81 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.056 1.838 . . . . 0.0 109.314 179.174 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.696 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -9.93 -66.56 0.01 OUTLIER Pre-proline 0 N--CA 1.513 2.688 0 N-CA-C 112.77 0.656 . . . . 0.0 112.77 -178.427 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.696 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 37.1 Cg_endo -79.35 90.52 1.26 Allowed 'Trans proline' 0 C--N 1.314 -1.261 0 C-N-CA 121.709 1.606 . . . . 0.0 110.577 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.431 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 8.7 t -112.59 145.62 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.948 -1.095 . . . . 0.0 109.637 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -113.7 -19.08 11.7 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.515 -0.741 . . . . 0.0 110.257 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.13 151.23 0.8 Allowed 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.094 -1.004 . . . . 0.0 110.431 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.475 HG23 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -139.1 137.96 36.64 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.382 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.512 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 7.0 ttm180 -92.61 112.67 24.7 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.145 -0.972 . . . . 0.0 108.836 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.678 ' CH2' ' CD1' ' A' ' 27' ' ' ILE . 17.8 m95 -95.77 -178.97 4.56 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -0.894 . . . . 0.0 109.454 -179.812 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.496 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.57 103.06 3.08 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 177.598 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.63 ' CD1' ' NE2' ' A' ' 56' ' ' HIS . 3.1 m-30 -80.84 -65.35 1.02 Allowed 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 118.896 -1.122 . . . . 0.0 110.697 -177.369 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.51 6.82 58.36 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.509 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 12.1 p30 -98.03 31.47 2.7 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.354 -1.086 . . . . 0.0 108.777 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 116.18 -39.95 2.56 Favored Glycine 0 C--N 1.295 -1.705 0 N-CA-C 105.626 -2.99 . . . . 0.0 105.626 -176.251 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 63.8 p -105.99 103.58 13.1 Favored 'General case' 0 N--CA 1.487 1.386 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 177.452 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.496 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -77.98 -88.97 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.115 -0.991 . . . . 0.0 110.429 -178.373 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -52.67 142.85 17.4 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.311 0.576 . . . . 0.0 109.992 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.652 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 90.4 t -135.67 132.61 51.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.346 -0.847 . . . . 0.0 110.953 -178.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -111.65 92.66 4.12 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.032 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.529 ' HB1' ' CD1' ' A' ' 38' ' ' TRP . . . -97.26 151.51 19.8 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.305 -0.872 . . . . 0.0 111.283 -177.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.17 150.48 23.92 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.475 ' O ' HG23 ' A' ' 36' ' ' THR . . . 47.25 -157.44 0.63 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 108.395 -1.882 . . . . 0.0 108.395 -179.168 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -87.92 39.75 0.56 Allowed 'Trans proline' 0 C--N 1.296 -2.193 0 C-N-CA 122.037 1.825 . . . . 0.0 110.128 178.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.54 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -145.13 149.38 34.91 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.124 -1.61 . . . . 0.0 112.029 -178.54 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.498 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -154.6 -167.18 2.53 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -153.89 145.47 23.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.246 -0.909 . . . . 0.0 109.016 179.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.63 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 10.8 m80 -105.02 138.98 40.39 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.091 -1.006 . . . . 0.0 110.91 -178.804 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.472 ' HA ' HD21 ' A' ' 22' ' ' LEU . 0.3 OUTLIER -110.07 90.16 3.23 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.889 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.613 ' CZ ' HG12 ' A' ' 83' ' ' VAL . 30.9 m-85 -92.48 124.49 36.56 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 109.786 -178.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.404 ' HA ' ' HA2' ' A' ' 20' ' ' GLY . 11.4 m -119.1 -13.93 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.486 -0.759 . . . . 0.0 111.385 -178.776 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -102.7 148.41 35.49 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 120.663 -1.273 . . . . 0.0 109.618 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -78.21 116.45 3.91 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.453 2.102 . . . . 0.0 109.782 179.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.71 -156.92 27.38 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 2.3 ptt-85 -112.49 159.69 18.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.179 -1.189 . . . . 0.0 110.135 -179.779 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.499 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 87.4 m-85 -136.05 159.74 40.79 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.455 -0.778 . . . . 0.0 109.328 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -116.52 115.99 26.8 Favored 'General case' 0 N--CA 1.486 1.372 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.521 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 83.3 t -97.77 148.48 5.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.373 -0.83 . . . . 0.0 110.551 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.437 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 2.1 p -145.38 156.0 43.51 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 178.322 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.727 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -152.44 164.79 36.83 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.741 -1.224 . . . . 0.0 110.955 -179.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 9.5 p -139.69 129.26 29.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 N-CA-C 107.146 -1.428 . . . . 0.0 107.146 178.251 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.612 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.1 OUTLIER -88.03 142.03 28.1 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.845 -1.159 . . . . 0.0 108.749 -178.358 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.61 107.4 9.16 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 118.585 -1.246 . . . . 0.0 109.935 178.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.415 HD13 ' HB2' ' A' ' 30' ' ' PRO . 0.5 OUTLIER -105.39 -9.98 17.24 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.832 179.159 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.47 -49.5 0.87 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 107.734 -2.146 . . . . 0.0 107.734 -178.413 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.52 -5.91 11.19 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.626 -0.926 . . . . 0.0 109.692 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.65 154.73 23.84 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 29.7 p -149.53 -179.86 7.42 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.291 -1.123 . . . . 0.0 109.421 -179.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.596 ' CB ' ' HG ' ' A' ' 70' ' ' LEU . . . -154.79 162.9 40.94 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.622 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -116.67 131.41 56.96 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.098 -1.001 . . . . 0.0 110.128 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.727 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -115.48 157.68 23.66 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.555 -0.715 . . . . 0.0 109.717 -179.809 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.509 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.29 89.28 0.09 OUTLIER Glycine 0 N--CA 1.483 1.822 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.454 HG21 HD21 ' A' ' 10' ' ' LEU . 0.2 OUTLIER -109.14 -171.71 1.9 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.04 -1.27 . . . . 0.0 109.55 179.675 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -150.81 155.69 39.74 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 179.398 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.613 HG12 ' CZ ' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.24 151.65 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.659 -1.276 . . . . 0.0 109.776 -179.868 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.412 ' N ' HG21 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -117.05 85.93 2.42 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.031 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 47.3 t -77.52 136.71 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.791 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -123.25 141.08 52.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.425 -0.797 . . . . 0.0 109.959 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.911 . . . . 0.0 109.433 179.658 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.625 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.526 HG22 HG21 ' A' ' 11' ' ' VAL . 1.0 OUTLIER -73.51 148.95 42.61 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.182 -0.949 . . . . 0.0 109.157 -179.374 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.668 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.3 mp -91.17 103.13 15.85 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.339 -178.413 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.545 ' HB ' ' CE1' ' A' ' 26' ' ' HIS . 2.6 t -115.38 104.54 16.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 120.928 -1.108 . . . . 0.0 108.682 178.497 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.571 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.37 76.51 0.29 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -179.348 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.541 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 31.1 Cg_endo -71.42 148.24 54.12 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.674 2.249 . . . . 0.0 111.973 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.452 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 41.4 t60 161.13 -37.19 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.3 -139.4 14.81 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 107.952 -2.059 . . . . 0.0 107.952 -179.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -76.66 145.78 26.29 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 122.02 1.813 . . . . 0.0 109.064 178.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.497 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 3.3 mm? -104.53 92.94 4.52 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.167 -0.958 . . . . 0.0 109.871 -179.074 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.9 160.2 30.92 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.165 -0.96 . . . . 0.0 108.515 179.104 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.3 t -56.14 125.17 20.51 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.223 -0.923 . . . . 0.0 109.937 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 80.69 49.15 5.86 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -123.4 151.82 42.21 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.35 -1.088 . . . . 0.0 110.744 -179.517 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.463 HD21 ' HA ' ' A' ' 22' ' ' LEU . 2.2 tm? -105.97 98.65 8.31 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.502 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.454 ' HB2' ' HE1' ' A' ' 25' ' ' PHE . . . -78.83 153.09 30.93 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.159 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.541 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -116.66 118.16 31.8 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.469 -1.395 . . . . 0.0 108.44 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.684 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 7.4 m-85 -107.79 168.35 9.33 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 122.417 1.103 . . . . 0.0 112.262 -177.183 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.545 ' CE1' ' HB ' ' A' ' 11' ' ' VAL . 4.1 p80 -167.92 145.52 4.36 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 176.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.74 HD13 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.2 161.25 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.868 -1.145 . . . . 0.0 108.906 -178.336 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -139.43 119.55 13.61 Favored 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.556 -1.258 . . . . 0.0 112.433 -178.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.72 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 174.24 -68.87 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 177.614 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.72 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -77.6 78.21 3.6 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 121.779 1.653 . . . . 0.0 109.34 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.484 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -33.52 -53.95 0.74 Allowed Pre-proline 0 N--CA 1.5 2.029 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -178.913 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.484 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.7 Cg_endo -79.81 58.57 7.04 Favored 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.183 1.922 . . . . 0.0 111.877 -179.283 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.583 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 73.3 t -82.23 148.43 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 120.843 -1.16 . . . . 0.0 109.273 179.11 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.3 t -120.95 -36.79 3.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.318 -0.864 . . . . 0.0 109.661 179.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -152.06 139.19 19.22 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.453 -0.78 . . . . 0.0 109.156 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.547 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.2 t -127.52 134.92 49.75 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.535 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 2.8 tpp180 -104.07 104.06 13.95 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.042 -1.036 . . . . 0.0 109.174 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.684 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 29.4 m95 -87.82 -179.76 6.32 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.078 -1.014 . . . . 0.0 109.172 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -148.31 100.55 3.16 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 177.724 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.592 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 2.8 m-30 -80.01 -60.72 2.23 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 118.733 -1.187 . . . . 0.0 109.746 -178.122 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.98 15.93 55.27 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -178.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.25 -104.22 0.25 Allowed 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 178.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.08 -23.92 50.26 Favored Glycine 0 C--N 1.296 -1.649 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 176.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.8 m -128.62 127.69 42.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.501 -1.0 . . . . 0.0 109.04 179.426 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -81.11 -83.91 0.11 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.063 -1.023 . . . . 0.0 109.644 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.456 ' C ' HG21 ' A' ' 47' ' ' VAL . 2.4 pm0 -58.48 152.2 18.56 Favored 'General case' 0 N--CA 1.495 1.799 0 CA-C-O 121.222 0.534 . . . . 0.0 109.567 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.639 ' CB ' ' HB2' ' A' ' 38' ' ' TRP . 43.9 t -138.07 113.9 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.069 -1.019 . . . . 0.0 111.444 -178.444 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.19 105.18 17.09 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 177.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.493 ' CB ' ' HB1' ' A' ' 54' ' ' ALA . . . -118.74 168.34 10.82 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.143 -0.973 . . . . 0.0 111.042 -178.671 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.05 155.32 18.47 Favored 'General case' 0 N--CA 1.49 1.532 0 CA-C-O 121.503 0.668 . . . . 0.0 109.796 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.43 ' O ' HG21 ' A' ' 36' ' ' THR . . . 46.29 -155.42 0.64 Allowed Glycine 0 N--CA 1.488 2.159 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -89.77 40.48 0.45 Allowed 'Trans proline' 0 C--N 1.295 -2.284 0 C-N-CA 122.464 2.11 . . . . 0.0 110.484 178.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.516 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -143.75 154.09 43.1 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 119.899 -1.751 . . . . 0.0 112.658 -178.629 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.524 ' HB2' ' CE2' ' A' ' 38' ' ' TRP . . . -174.36 155.36 2.32 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -115.61 155.03 28.38 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.591 -1.318 . . . . 0.0 110.768 -179.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.592 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 5.3 m80 -105.36 143.31 33.7 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.465 0.65 . . . . 0.0 110.791 -179.221 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -115.05 94.57 4.8 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.57 ' CE2' ' CG1' ' A' ' 83' ' ' VAL . 25.9 m-85 -99.1 126.98 44.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.148 -0.97 . . . . 0.0 109.747 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 8.2 m -119.46 -31.06 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.362 -0.836 . . . . 0.0 111.553 -178.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.512 ' HB3' ' OH ' ' A' ' 64' ' ' TYR . 0.6 OUTLIER -96.49 140.56 22.24 Favored Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 120.579 -1.325 . . . . 0.0 109.165 -179.49 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.468 ' N ' ' HG ' ' A' ' 60' ' ' LEU . 32.5 Cg_endo -73.1 135.78 23.55 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.293 1.995 . . . . 0.0 110.567 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 148.36 -140.01 8.04 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -179.538 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -129.54 137.64 50.88 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.211 -1.17 . . . . 0.0 109.61 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.552 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 79.0 m-85 -117.36 159.68 22.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.313 -0.867 . . . . 0.0 109.449 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.426 ' CD2' HG23 ' A' ' 67' ' ' THR . 11.2 t60 -114.13 126.27 54.9 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.838 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.509 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 60.1 t -108.94 151.41 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.295 -0.878 . . . . 0.0 110.559 -179.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.426 HG23 ' CD2' ' A' ' 65' ' ' HIS . 0.1 OUTLIER -148.92 161.23 42.29 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.459 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.761 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -157.96 122.48 4.25 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.869 -1.144 . . . . 0.0 111.609 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 2.1 p -112.96 109.15 27.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 177.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -88.89 147.27 24.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.787 -1.196 . . . . 0.0 109.791 -179.12 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -126.76 116.5 21.02 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.353 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.492 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 5.6 mp -103.53 -13.42 16.58 Favored 'General case' 0 C--N 1.292 -1.92 0 CA-C-O 121.495 0.664 . . . . 0.0 109.417 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 114.78 -51.55 0.71 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 107.9 -2.08 . . . . 0.0 107.9 -178.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.35 -5.73 12.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.576 -0.955 . . . . 0.0 109.894 179.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.3 162.98 27.88 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.7 p -151.24 169.48 21.82 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.393 -1.063 . . . . 0.0 109.59 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.533 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -142.85 136.15 28.43 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 109.463 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.5 tt -101.65 132.41 47.35 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.287 -0.883 . . . . 0.0 110.335 -179.426 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.761 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -121.06 155.01 35.34 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.561 -0.712 . . . . 0.0 110.21 -179.372 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.509 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -162.21 88.05 0.11 Allowed Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.437 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.483 HG21 HD22 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -104.98 -176.65 3.14 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.112 -1.228 . . . . 0.0 109.903 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -150.47 143.76 24.95 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.57 ' CG1' ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -130.43 153.08 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 120.567 -1.333 . . . . 0.0 110.22 -179.331 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.421 ' N ' HG21 ' A' ' 83' ' ' VAL . 32.4 tt0 -118.59 100.79 7.66 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 42.9 t -80.9 136.42 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.148 -0.97 . . . . 0.0 109.854 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -121.21 -156.61 0.69 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.619 -0.676 . . . . 0.0 109.54 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.406 0 O-C-N 121.484 -0.76 . . . . 0.0 110.325 179.464 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.711 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.432 0 CA-C-O 121.457 0.646 . . . . 0.0 109.412 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.415 ' CG2' HG22 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -87.3 141.04 28.94 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.857 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.628 ' HG ' ' CD2' ' A' ' 79' ' ' LEU . 5.4 mp -97.22 94.85 7.34 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.003 -177.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.497 ' CB ' ' CE1' ' A' ' 26' ' ' HIS . 41.1 t -107.1 115.99 49.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.89 -1.131 . . . . 0.0 108.568 178.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.452 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -121.98 71.78 0.39 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.363 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.537 ' O ' ' CB ' ' A' ' 14' ' ' HIS . 34.4 Cg_endo -73.63 150.79 45.93 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.942 2.428 . . . . 0.0 112.036 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.537 ' CB ' ' O ' ' A' ' 13' ' ' PRO . 16.0 t-80 150.29 -39.52 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 CA-C-N 115.44 -0.8 . . . . 0.0 108.935 179.53 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 116.4 -142.97 17.88 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.49 -1.844 . . . . 0.0 108.49 -179.218 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.82 149.01 25.9 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 122.306 2.004 . . . . 0.0 109.779 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.597 HD11 ' HB3' ' A' ' 21' ' ' GLN . 4.4 mm? -105.2 106.74 17.37 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.181 -0.949 . . . . 0.0 109.207 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.402 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -93.44 168.72 10.87 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.01 -1.057 . . . . 0.0 108.905 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 28.1 t -56.42 120.81 8.29 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.364 -0.835 . . . . 0.0 109.045 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 80.3 44.14 9.0 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . 0.597 ' HB3' HD11 ' A' ' 17' ' ' LEU . 23.0 tp60 -113.35 147.3 37.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.523 -0.986 . . . . 0.0 110.697 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.427 HD21 ' HA ' ' A' ' 22' ' ' LEU . 1.8 tm? -108.35 96.32 6.27 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.565 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.495 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -78.86 156.59 28.6 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 178.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.516 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.63 108.85 14.05 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.415 -1.428 . . . . 0.0 108.224 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.544 ' CE1' ' HB2' ' A' ' 56' ' ' HIS . 2.6 m-85 -95.19 166.7 11.78 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 122.098 0.952 . . . . 0.0 111.57 -177.282 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.559 ' CD2' ' C ' ' A' ' 26' ' ' HIS . 0.0 OUTLIER -159.74 135.89 8.82 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 177.864 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.711 HG23 ' CB ' ' A' ' 8' ' ' ALA . 5.0 mm -108.97 152.01 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.368 -0.833 . . . . 0.0 109.526 -177.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -136.93 136.12 38.32 Favored 'General case' 0 N--CA 1.506 2.354 0 C-N-CA 118.439 -1.305 . . . . 0.0 113.045 -178.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.762 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 174.05 -71.4 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.951 0 O-C-N 121.002 -1.061 . . . . 0.0 108.963 177.352 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.762 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -79.44 72.89 6.28 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 C-N-CA 121.778 1.652 . . . . 0.0 109.13 178.486 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.633 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -13.81 -63.79 0.03 OUTLIER Pre-proline 0 N--CA 1.512 2.661 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -178.437 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.633 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 36.4 Cg_endo -78.22 63.43 8.29 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 C-N-CA 121.889 1.726 . . . . 0.0 111.187 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.658 HG21 ' HG2' ' A' ' 30' ' ' PRO . 62.1 t -80.95 148.26 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.901 -1.124 . . . . 0.0 109.635 179.616 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 t -120.49 -18.33 7.88 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.345 -0.847 . . . . 0.0 110.648 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -176.48 139.27 0.33 Allowed 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.013 -1.055 . . . . 0.0 110.329 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.664 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 0.5 OUTLIER -126.73 134.22 50.71 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.356 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.476 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 1.1 mtm180 -93.11 113.83 26.18 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.295 -0.878 . . . . 0.0 108.736 179.462 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.666 ' CH2' ' CD1' ' A' ' 27' ' ' ILE . 11.8 m95 -99.19 -179.25 4.18 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 121.976 0.893 . . . . 0.0 109.853 -179.403 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.5 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.62 103.3 3.1 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 177.245 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.637 ' CD1' ' NE2' ' A' ' 56' ' ' HIS . 2.7 m-30 -80.78 -65.14 1.05 Allowed 'General case' 0 N--CA 1.492 1.656 0 C-N-CA 118.784 -1.166 . . . . 0.0 110.809 -177.378 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.37 1.47 59.22 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -178.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.4 p30 -95.57 34.97 1.4 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.293 -1.122 . . . . 0.0 108.403 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.43 -36.46 4.25 Favored Glycine 0 C--N 1.296 -1.677 0 N-CA-C 105.845 -2.902 . . . . 0.0 105.845 -176.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.406 ' O ' ' HB2' ' A' ' 40' ' ' PHE . 18.1 m -104.05 94.05 5.18 Favored 'General case' 0 N--CA 1.487 1.375 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.057 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.49 -95.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.22 -0.925 . . . . 0.0 110.066 -178.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -52.22 146.67 8.78 Favored 'General case' 0 N--CA 1.496 1.87 0 CA-C-O 121.194 0.521 . . . . 0.0 109.879 -179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.618 HG23 ' CZ ' ' A' ' 40' ' ' PHE . 95.6 t -138.49 130.69 38.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.347 -0.846 . . . . 0.0 110.969 -178.823 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -111.37 94.71 5.11 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.528 ' CB ' ' HB1' ' A' ' 54' ' ' ALA . . . -100.45 147.9 25.35 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.226 -0.921 . . . . 0.0 111.146 -178.373 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.7 151.8 26.07 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.731 -0.605 . . . . 0.0 109.499 179.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.501 ' O ' HG23 ' A' ' 36' ' ' THR . . . 46.82 -156.55 0.61 Allowed Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.64 -1.784 . . . . 0.0 108.64 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . 0.47 ' HA ' HG23 ' A' ' 36' ' ' THR . 38.2 Cg_endo -88.05 39.33 0.52 Allowed 'Trans proline' 0 C--N 1.296 -2.191 0 C-N-CA 122.406 2.071 . . . . 0.0 110.438 178.374 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -145.38 146.65 31.65 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 119.93 -1.731 . . . . 0.0 112.156 -178.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.528 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -156.15 -178.81 7.59 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 178.558 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -141.62 152.49 44.04 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.735 -1.228 . . . . 0.0 109.477 179.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.637 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 5.4 m80 -108.16 138.82 43.78 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.473 -0.767 . . . . 0.0 110.618 -178.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -111.95 89.71 3.14 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.565 ' CZ ' HG12 ' A' ' 83' ' ' VAL . 34.5 m-85 -90.25 130.34 36.38 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.172 -0.955 . . . . 0.0 109.307 -179.172 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 9.4 p -116.58 -30.8 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.252 -0.905 . . . . 0.0 111.283 -178.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.413 ' CG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -100.91 146.7 32.58 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 120.703 -1.248 . . . . 0.0 109.453 -179.226 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.413 ' HD2' ' CG ' ' A' ' 60' ' ' LEU . 34.7 Cg_endo -76.91 121.46 5.86 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.255 1.97 . . . . 0.0 109.944 179.601 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 164.46 -157.05 29.28 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -112.47 120.76 42.73 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.022 -1.281 . . . . 0.0 109.986 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.477 ' CB ' ' CE1' ' A' ' 58' ' ' TYR . 86.4 m-85 -105.07 147.13 28.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.492 -0.755 . . . . 0.0 109.349 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -104.24 132.35 50.58 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.494 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 79.6 t -113.57 149.4 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.153 -0.967 . . . . 0.0 110.462 -179.128 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.5 p -148.15 153.91 39.46 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 178.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.728 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -150.94 163.03 39.67 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.946 -1.096 . . . . 0.0 110.883 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.429 ' HA ' ' O ' ' A' ' 77' ' ' ALA . 12.1 p -150.9 112.27 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.664 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -89.01 143.17 27.04 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 120.481 -1.387 . . . . 0.0 110.287 -178.205 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -122.63 117.74 26.51 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -105.88 -13.98 15.35 Favored 'General case' 0 C--N 1.29 -2.003 0 CA-C-O 121.587 0.708 . . . . 0.0 109.388 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 110.72 -51.42 0.7 Allowed Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 -179.09 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -110.77 -6.08 14.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.6 -0.941 . . . . 0.0 109.628 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.87 160.37 28.48 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 2.0 p -150.58 164.06 36.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.247 -1.149 . . . . 0.0 109.712 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.536 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -138.47 163.71 31.25 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.446 -0.783 . . . . 0.0 109.111 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 15.3 mt -122.9 150.35 43.03 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.173 -0.954 . . . . 0.0 109.939 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.728 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -132.43 160.43 36.44 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.436 -0.79 . . . . 0.0 109.885 -179.44 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.486 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -172.14 99.82 0.15 Allowed Glycine 0 N--CA 1.485 1.965 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.414 HG21 HD21 ' A' ' 10' ' ' LEU . 1.2 p -120.85 -172.42 2.38 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.137 -1.213 . . . . 0.0 110.167 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -151.01 145.31 25.46 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.565 HG12 ' CZ ' ' A' ' 58' ' ' TYR . 0.2 OUTLIER -132.64 144.23 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 120.749 -1.219 . . . . 0.0 109.906 -179.502 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -107.69 85.88 2.2 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.512 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 75.6 t -70.46 132.46 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.279 -0.888 . . . . 0.0 110.118 -179.254 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -114.14 -162.96 0.84 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.018 -1.051 . . . . 0.0 109.479 179.734 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.652 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.443 ' CG2' HG22 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.79 139.68 30.22 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.77 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.594 ' N ' ' CD1' ' A' ' 10' ' ' LEU . 5.6 mp -97.19 89.55 4.81 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.148 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.495 ' CB ' ' CE1' ' A' ' 26' ' ' HIS . 65.3 t -99.08 112.34 30.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.885 -1.134 . . . . 0.0 109.092 179.521 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.497 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -124.1 71.18 0.44 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.541 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.4 Cg_endo -73.64 150.4 45.22 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.803 2.336 . . . . 0.0 112.153 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.454 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.9 t-80 168.9 -38.87 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.681 0.753 . . . . 0.0 109.208 179.353 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.29 -138.05 14.56 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 -178.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.62 147.0 24.57 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 121.972 1.782 . . . . 0.0 109.166 178.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 2.7 mt -117.26 98.56 6.5 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.2 -0.937 . . . . 0.0 109.779 -179.301 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.09 165.66 14.98 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 t -60.85 114.74 3.22 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.243 -0.91 . . . . 0.0 109.272 -179.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.68 39.52 2.72 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.84 154.58 51.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.152 -1.205 . . . . 0.0 110.015 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.606 HD12 ' HB2' ' A' ' 55' ' ' SER . 0.1 OUTLIER -115.82 128.14 55.59 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.805 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.692 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -92.69 148.37 22.12 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.252 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.541 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -105.25 121.9 44.81 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.067 -1.645 . . . . 0.0 108.04 179.012 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.692 ' CE1' ' HB2' ' A' ' 23' ' ' ALA . 5.2 m-85 -105.39 170.53 7.83 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 121.914 0.864 . . . . 0.0 111.721 -177.009 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.567 ' CD2' ' C ' ' A' ' 26' ' ' HIS . 0.0 OUTLIER -166.72 140.14 3.84 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.793 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.679 ' CD1' ' CH2' ' A' ' 38' ' ' TRP . 4.6 mm -109.42 148.67 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.279 -0.888 . . . . 0.0 109.309 -178.345 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -133.33 122.6 24.07 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.989 -178.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.679 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 175.25 -61.86 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.078 -1.014 . . . . 0.0 109.552 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.679 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 35.3 Cg_endo -79.17 68.49 8.27 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.209 1.939 . . . . 0.0 109.699 179.551 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.621 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.0 OUTLIER -15.42 -64.03 0.03 OUTLIER Pre-proline 0 N--CA 1.506 2.327 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.83 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.621 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.4 Cg_endo -78.52 73.39 5.9 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 C-N-CA 121.774 1.65 . . . . 0.0 111.202 -179.513 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.49 HG21 ' HG2' ' A' ' 30' ' ' PRO . 2.8 t -96.41 136.64 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.894 -1.129 . . . . 0.0 109.656 179.338 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.5 t -115.89 -15.33 11.25 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.48 -0.763 . . . . 0.0 109.331 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.6 149.43 0.48 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.311 -0.868 . . . . 0.0 109.667 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.459 HG23 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -136.93 139.68 41.73 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.59 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.511 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 10.2 mtm-85 -93.33 109.04 20.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.138 -0.976 . . . . 0.0 109.136 179.657 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.679 ' CH2' ' CD1' ' A' ' 27' ' ' ILE . 18.7 m95 -93.85 179.81 5.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.918 -1.114 . . . . 0.0 109.621 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.482 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.76 106.61 3.41 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.328 -1.731 . . . . 0.0 106.328 177.369 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.616 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 3.7 m-30 -81.37 -66.44 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 118.451 -1.3 . . . . 0.0 111.37 -176.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.11 -4.91 59.03 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.1 p30 -90.41 23.71 2.86 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.335 -1.097 . . . . 0.0 109.164 179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 122.56 -38.11 2.64 Favored Glycine 0 C--N 1.298 -1.576 0 N-CA-C 106.129 -2.788 . . . . 0.0 106.129 -176.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.77 101.52 12.96 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 177.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.38 -98.28 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 0.0 109.958 -178.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.436 ' C ' HG21 ' A' ' 47' ' ' VAL . 1.6 mm-40 -56.92 150.1 17.33 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.286 0.565 . . . . 0.0 109.927 -179.588 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.668 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 70.8 t -138.9 132.97 40.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.47 -0.769 . . . . 0.0 110.591 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -112.89 89.8 3.18 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.283 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.529 ' HB1' ' CD1' ' A' ' 38' ' ' TRP . . . -92.84 152.53 19.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.373 -0.829 . . . . 0.0 111.423 -178.135 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.72 150.2 23.75 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.459 ' O ' HG23 ' A' ' 36' ' ' THR . . . 46.08 -156.4 0.49 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.24 -1.944 . . . . 0.0 108.24 -179.27 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -88.43 42.63 0.7 Allowed 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.122 1.881 . . . . 0.0 110.479 178.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.494 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -146.87 144.38 29.24 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.072 -1.642 . . . . 0.0 112.009 -179.089 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.463 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -149.54 -169.6 3.42 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.606 ' HB2' HD12 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -152.64 138.8 18.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.249 -0.907 . . . . 0.0 109.174 179.558 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.616 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 11.1 m80 -102.91 135.45 44.57 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.231 -0.918 . . . . 0.0 111.101 -178.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 2.0 ptp180 -100.44 95.06 6.49 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 177.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.592 ' CZ ' HG12 ' A' ' 83' ' ' VAL . 23.8 m-85 -95.5 120.24 35.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.225 -0.922 . . . . 0.0 109.232 -179.232 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.6 p -118.17 -29.71 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.241 -0.912 . . . . 0.0 111.165 -178.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -90.71 143.35 28.82 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 120.619 -1.3 . . . . 0.0 109.376 -179.678 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.405 ' HA ' HG13 ' A' ' 85' ' ' VAL . 34.0 Cg_endo -76.26 133.04 14.34 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.575 2.183 . . . . 0.0 110.281 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.59 -135.05 5.93 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 -179.616 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -127.27 164.51 21.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -1.193 . . . . 0.0 109.651 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.509 ' HB2' HG12 ' A' ' 83' ' ' VAL . 59.7 m-85 -142.98 152.84 42.39 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.466 -0.771 . . . . 0.0 109.205 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -112.99 130.37 56.16 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.514 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 59.2 t -116.0 150.58 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 110.821 -178.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.79 155.51 42.42 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.85 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.756 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -150.53 158.57 44.31 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.853 -1.155 . . . . 0.0 111.518 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -129.84 127.17 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.423 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.645 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.3 OUTLIER -89.07 141.87 28.12 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 120.656 -1.277 . . . . 0.0 109.015 -178.743 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.3 110.48 11.56 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.589 -1.245 . . . . 0.0 109.698 178.425 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.602 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 5.9 mp -105.49 -11.1 16.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.072 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.66 -49.62 0.83 Allowed Glycine 0 N--CA 1.486 2.011 0 N-CA-C 107.669 -2.173 . . . . 0.0 107.669 -178.128 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.44 -5.76 11.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.58 -0.953 . . . . 0.0 109.884 178.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -140.04 162.5 26.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.465 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.8 p -151.44 -179.23 7.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.306 -1.114 . . . . 0.0 109.579 -179.598 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.595 ' CB ' ' HG ' ' A' ' 70' ' ' LEU . . . -154.17 166.39 33.25 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.2 mt -119.93 132.75 55.62 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.068 -1.02 . . . . 0.0 110.227 -179.401 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.756 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -117.4 157.14 26.7 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.524 -0.735 . . . . 0.0 109.769 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.65 95.12 0.11 Allowed Glycine 0 N--CA 1.485 1.938 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.467 HG21 HD21 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -116.38 -173.33 2.35 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.232 -1.158 . . . . 0.0 109.937 179.932 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -150.74 153.7 36.0 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.435 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.592 HG12 ' CZ ' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.0 154.25 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.66 -1.275 . . . . 0.0 109.845 -179.519 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.45 ' N ' HG21 ' A' ' 83' ' ' VAL . 12.0 tt0 -123.07 99.81 6.56 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.464 -0.773 . . . . 0.0 108.985 179.073 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.405 HG13 ' HA ' ' A' ' 61' ' ' PRO . 41.6 t -86.15 137.71 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.24 -0.912 . . . . 0.0 109.846 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -113.15 154.41 26.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 -179.473 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.101 -0.999 . . . . 0.0 109.667 179.711 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.675 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.43 ' CG2' HG22 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -90.12 141.62 28.51 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.636 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.595 ' HG ' ' CD2' ' A' ' 79' ' ' LEU . 5.3 mp -98.01 97.96 9.36 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -178.188 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.481 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 47.2 t -109.69 115.92 50.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 120.875 -1.141 . . . . 0.0 109.189 179.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -125.67 68.68 0.51 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.634 ' O ' ' HB2' ' A' ' 14' ' ' HIS . 36.7 Cg_endo -75.16 151.05 38.34 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 123.082 2.521 . . . . 0.0 112.655 -179.252 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.634 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 21.6 t60 162.61 -36.36 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.881 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.472 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.85 -138.6 14.93 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -179.377 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.8 151.74 28.31 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.42 2.08 . . . . 0.0 109.878 179.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.456 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 65.8 mt -120.87 99.74 6.69 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.113 -0.992 . . . . 0.0 109.917 -179.717 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.402 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -91.78 170.94 9.49 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.7 t -53.15 120.06 5.47 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.914 . . . . 0.0 109.818 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.74 48.3 4.5 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . 0.456 ' HB3' ' CD2' ' A' ' 17' ' ' LEU . 1.6 mm-40 -115.78 143.81 44.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.432 -1.04 . . . . 0.0 110.449 -179.535 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.438 HD21 ' HA ' ' A' ' 57' ' ' ARG . 2.5 tm? -108.35 93.26 4.43 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.175 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.537 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -75.49 155.21 36.4 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.94 -1.1 . . . . 0.0 108.089 179.341 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.547 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.08 114.5 22.59 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.475 -1.39 . . . . 0.0 108.076 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.537 ' CE1' ' HB2' ' A' ' 23' ' ' ALA . 3.8 m-85 -100.15 174.65 6.05 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 122.135 0.969 . . . . 0.0 111.805 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.549 ' HA ' ' HA ' ' A' ' 53' ' ' ALA . 0.0 OUTLIER -168.53 139.09 2.52 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 177.997 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.7 ' CD1' ' CH2' ' A' ' 38' ' ' TRP . 4.7 mm -107.95 149.33 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.37 -0.831 . . . . 0.0 109.063 -178.37 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -133.35 125.09 28.41 Favored 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 118.598 -1.241 . . . . 0.0 112.274 -178.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.727 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . -179.8 -67.3 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 120.978 -1.076 . . . . 0.0 109.297 177.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.727 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.5 Cg_endo -79.89 69.58 7.88 Favored 'Trans proline' 0 C--N 1.314 -1.275 0 C-N-CA 121.944 1.763 . . . . 0.0 109.314 179.162 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.665 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -11.82 -66.21 0.02 OUTLIER Pre-proline 0 N--CA 1.51 2.546 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -178.707 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.665 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.6 Cg_endo -79.29 95.32 1.05 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 121.728 1.619 . . . . 0.0 110.424 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.448 ' CG2' ' O ' ' A' ' 30' ' ' PRO . 5.1 t -118.06 145.01 24.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 120.866 -1.146 . . . . 0.0 109.565 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.2 t -113.15 -18.64 12.09 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.495 -0.753 . . . . 0.0 110.209 179.736 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.22 152.3 0.86 Allowed 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.049 -1.032 . . . . 0.0 110.456 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.482 HG23 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -139.05 137.04 35.9 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.428 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.46 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 4.8 ttp180 -92.78 114.2 26.69 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.07 -1.019 . . . . 0.0 108.838 179.512 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.7 ' CH2' ' CD1' ' A' ' 27' ' ' ILE . 15.6 m95 -97.68 -178.61 4.17 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 -179.8 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.43 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -151.37 101.99 2.87 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 177.34 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.612 ' CD1' ' NE2' ' A' ' 56' ' ' HIS . 2.9 m-30 -80.19 -61.33 2.01 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 118.756 -1.178 . . . . 0.0 110.267 -177.52 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.62 14.63 52.59 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.068 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.06 -103.05 0.25 Allowed 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.662 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -86.63 -17.15 60.58 Favored Glycine 0 C--N 1.297 -1.59 0 N-CA-C 108.05 -2.02 . . . . 0.0 108.05 176.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 17.0 p -135.8 129.26 32.21 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.308 -1.113 . . . . 0.0 109.309 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.43 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.34 -87.66 0.08 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.024 -1.048 . . . . 0.0 109.96 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.465 ' C ' HG21 ' A' ' 47' ' ' VAL . 1.1 pt-20 -56.48 151.24 13.69 Favored 'General case' 0 N--CA 1.497 1.877 0 CA-C-O 121.358 0.599 . . . . 0.0 110.123 -179.716 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.669 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 61.5 t -140.14 134.44 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.287 -0.883 . . . . 0.0 111.019 -178.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -115.0 90.8 3.43 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 177.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.511 ' CB ' ' HB1' ' A' ' 54' ' ' ALA . . . -94.31 153.57 17.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.339 -0.85 . . . . 0.0 111.488 -177.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -89.33 150.52 22.54 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 179.283 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.482 ' O ' HG23 ' A' ' 36' ' ' THR . . . 47.84 -158.11 0.73 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 108.075 -2.01 . . . . 0.0 108.075 -179.188 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -87.69 41.0 0.65 Allowed 'Trans proline' 0 C--N 1.298 -2.101 0 C-N-CA 122.135 1.89 . . . . 0.0 110.013 178.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.549 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -145.25 147.55 32.52 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 120.232 -1.542 . . . . 0.0 111.891 -178.87 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.511 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -153.83 -169.56 3.31 Favored 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.863 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -151.87 145.24 24.77 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.135 -0.978 . . . . 0.0 109.184 179.433 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.612 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 10.6 m80 -104.33 137.67 41.89 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.259 -0.901 . . . . 0.0 111.228 -178.762 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.438 ' HA ' HD21 ' A' ' 22' ' ' LEU . 0.7 OUTLIER -108.46 88.67 2.78 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.589 ' CE2' ' CG1' ' A' ' 83' ' ' VAL . 34.2 m-85 -92.06 118.39 30.76 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.237 -0.915 . . . . 0.0 109.602 -179.296 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.2 t -106.96 -28.94 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.411 -0.806 . . . . 0.0 111.089 -178.678 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.413 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -97.21 146.92 32.17 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 120.628 -1.295 . . . . 0.0 109.617 -179.364 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.413 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.6 Cg_endo -78.28 123.81 6.26 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 C-N-CA 122.473 2.116 . . . . 0.0 109.837 179.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 158.6 -159.68 30.4 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.631 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.437 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 15.1 mtp-105 -111.34 125.97 54.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.073 -1.251 . . . . 0.0 110.152 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.573 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 82.9 m-85 -108.75 157.92 18.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.34 -0.85 . . . . 0.0 109.481 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 72.1 t60 -112.81 126.99 56.04 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.526 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.506 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 84.3 t -107.62 150.06 10.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.099 -1.001 . . . . 0.0 110.675 -179.054 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.404 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 1.2 p -147.75 155.64 41.91 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.258 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.749 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -152.5 165.96 33.47 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.822 -1.174 . . . . 0.0 110.751 -179.674 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 8.3 p -141.81 130.6 22.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 107.197 -1.409 . . . . 0.0 107.197 178.315 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.598 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.1 OUTLIER -88.16 140.7 29.22 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 120.947 -1.096 . . . . 0.0 108.821 -178.302 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.02 108.18 9.9 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 118.555 -1.258 . . . . 0.0 109.933 178.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -106.88 -9.66 16.26 Favored 'General case' 0 C--N 1.286 -2.188 0 CA-C-N 115.415 -0.811 . . . . 0.0 108.838 178.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 102.94 -48.39 1.04 Allowed Glycine 0 N--CA 1.487 2.057 0 N-CA-C 107.599 -2.2 . . . . 0.0 107.599 -178.19 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.04 -5.51 11.95 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.687 -0.89 . . . . 0.0 109.627 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -142.35 155.73 25.79 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.425 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 17.1 p -151.05 179.71 8.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.224 -1.162 . . . . 0.0 109.598 -179.533 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.586 ' CB ' ' HG ' ' A' ' 70' ' ' LEU . . . -156.02 170.41 22.23 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.458 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -124.31 136.39 54.08 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.107 -0.996 . . . . 0.0 109.906 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.749 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -119.5 158.44 26.27 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.566 -0.709 . . . . 0.0 109.711 -179.631 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.94 94.62 0.1 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.432 HG21 HD21 ' A' ' 10' ' ' LEU . 0.5 OUTLIER -115.03 -172.12 2.07 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.088 -1.242 . . . . 0.0 110.117 -179.878 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -150.64 148.37 28.53 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.589 ' CG1' ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -132.95 153.66 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 120.842 -1.161 . . . . 0.0 109.972 -179.725 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.413 ' N ' HG22 ' A' ' 83' ' ' VAL . 30.1 tt0 -122.57 89.29 3.09 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.309 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 92.9 t -79.63 143.56 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.253 -0.904 . . . . 0.0 109.82 -179.428 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -115.84 173.3 6.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.387 -0.821 . . . . 0.0 109.667 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.149 -0.969 . . . . 0.0 109.782 -179.944 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.654 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.474 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.544 HG22 HG21 ' A' ' 11' ' ' VAL . 1.1 t -70.79 148.89 47.42 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.224 -0.923 . . . . 0.0 109.299 -179.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.565 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.6 mp -88.16 109.84 20.22 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.325 -178.312 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.574 ' HB ' ' CE1' ' A' ' 26' ' ' HIS . 1.2 t -126.21 103.91 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.01 -1.056 . . . . 0.0 108.863 178.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.599 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.8 80.52 0.3 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 -179.33 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.585 ' O ' ' HB2' ' A' ' 14' ' ' HIS . 33.2 Cg_endo -73.07 146.65 41.67 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.612 2.208 . . . . 0.0 112.538 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.592 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 62.4 t60 164.62 171.09 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -93.31 -124.16 3.67 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 178.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.86 151.07 21.4 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.314 2.01 . . . . 0.0 109.938 179.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.596 ' HB3' HG21 ' A' ' 85' ' ' VAL . 22.1 mt -121.65 89.13 3.06 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.057 -1.027 . . . . 0.0 109.469 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -90.29 167.04 12.97 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 179.214 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.3 t -51.95 118.42 3.43 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.331 -0.855 . . . . 0.0 109.403 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.71 47.86 3.58 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.1 mm-40 -119.81 155.97 31.55 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.281 -1.129 . . . . 0.0 110.868 -179.396 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.432 HD12 ' O ' ' A' ' 23' ' ' ALA . 1.8 tm? -114.52 96.62 5.85 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.757 -0.589 . . . . 0.0 109.565 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.592 ' HA ' ' CG ' ' A' ' 14' ' ' HIS . . . -81.59 160.96 23.69 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 178.552 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.518 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -122.79 111.37 16.61 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.39 -1.444 . . . . 0.0 108.744 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.599 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 4.4 m-85 -100.7 166.38 10.91 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 122.172 0.987 . . . . 0.0 112.277 -177.176 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.574 ' CE1' ' HB ' ' A' ' 11' ' ' VAL . 7.5 p80 -163.45 151.77 13.65 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 176.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.754 HD11 ' HG ' ' A' ' 79' ' ' LEU . 0.3 OUTLIER -114.51 160.94 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.0 -1.062 . . . . 0.0 108.884 -178.33 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -138.05 120.17 15.63 Favored 'General case' 0 N--CA 1.499 2.008 0 C-N-CA 118.453 -1.299 . . . . 0.0 112.653 -178.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.746 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 176.44 -72.1 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.228 -0.92 . . . . 0.0 108.963 177.57 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.746 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 35.9 Cg_endo -77.57 77.93 3.7 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 C-N-CA 121.569 1.513 . . . . 0.0 108.745 178.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.559 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 2.6 mp -33.3 -56.34 0.61 Allowed Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 122.127 -0.358 . . . . 0.0 111.631 -178.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.559 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.9 Cg_endo -80.62 75.96 4.77 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.165 1.91 . . . . 0.0 111.328 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.629 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 36.8 t -103.46 148.53 8.34 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 120.984 -1.073 . . . . 0.0 109.098 179.102 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 15.4 t -113.59 -29.06 7.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.131 -0.981 . . . . 0.0 110.256 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -162.35 144.17 10.77 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.319 -0.863 . . . . 0.0 109.91 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.633 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 1.8 t -127.33 162.16 26.91 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 179.539 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.493 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 13.1 mtp85 -123.89 103.12 8.15 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.721 ' CH2' HD12 ' A' ' 27' ' ' ILE . 35.1 m95 -88.55 179.94 6.18 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.05 -1.031 . . . . 0.0 109.837 -179.462 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.465 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -148.71 100.7 3.13 Favored 'General case' 0 C--N 1.291 -1.939 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 177.44 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.602 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 4.1 m-30 -80.27 -50.69 9.85 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 118.869 -1.132 . . . . 0.0 109.829 -177.748 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 80.27 21.77 64.25 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.519 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 1.2 p30 -106.96 -104.87 0.34 Allowed 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 178.483 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.88 -15.41 72.87 Favored Glycine 0 N--CA 1.48 1.607 0 N-CA-C 107.715 -2.154 . . . . 0.0 107.715 176.508 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -140.26 130.62 25.27 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.396 -1.061 . . . . 0.0 109.035 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.465 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.17 -85.48 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.956 -1.09 . . . . 0.0 109.624 -179.796 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.457 ' C ' HG21 ' A' ' 47' ' ' VAL . 10.2 pt-20 -56.5 151.2 13.82 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-O 121.268 0.556 . . . . 0.0 109.878 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.689 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 61.6 t -139.28 125.02 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.428 -0.795 . . . . 0.0 110.737 -178.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -104.67 109.72 21.76 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.227 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.545 ' CB ' ' HB1' ' A' ' 54' ' ' ALA . . . -123.33 167.83 13.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.157 -0.964 . . . . 0.0 111.024 -178.487 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.64 153.34 17.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.68 -0.638 . . . . 0.0 109.641 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.558 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 46.33 -156.33 0.55 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -89.52 39.0 0.41 Allowed 'Trans proline' 0 C--N 1.297 -2.152 0 C-N-CA 122.484 2.123 . . . . 0.0 110.25 178.468 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -140.8 151.6 44.52 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 119.976 -1.703 . . . . 0.0 112.458 -178.368 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.552 ' HB2' ' CE2' ' A' ' 38' ' ' TRP . . . -172.2 153.24 3.0 Favored 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.029 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.43 ' HB2' ' CD1' ' A' ' 22' ' ' LEU . 0.0 OUTLIER -109.84 161.09 15.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.939 -1.1 . . . . 0.0 110.237 -179.82 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.602 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 2.9 m80 -109.24 134.04 52.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.457 -0.777 . . . . 0.0 110.298 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -110.8 92.13 3.93 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.617 ' CE1' ' CG ' ' A' ' 64' ' ' TYR . 22.0 m-85 -92.33 133.49 35.81 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.136 -0.978 . . . . 0.0 109.596 -179.39 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 53.6 t -117.86 -28.15 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.418 -0.801 . . . . 0.0 110.973 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.413 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -97.78 143.28 25.94 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 120.592 -1.317 . . . . 0.0 109.611 -179.545 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.44 ' HB3' ' CB ' ' A' ' 87' ' ' ALA . 36.0 Cg_endo -79.06 120.78 4.7 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.616 2.211 . . . . 0.0 110.152 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 159.08 -143.68 9.48 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 18.5 ttm-85 -112.39 154.26 26.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -1.171 . . . . 0.0 109.572 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.617 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 54.0 m-85 -139.1 167.52 21.88 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.526 -0.734 . . . . 0.0 109.06 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 65.6 t60 -125.84 144.59 50.59 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.501 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 39.1 t -126.97 148.63 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.09 -1.006 . . . . 0.0 110.751 -179.133 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.24 161.12 43.05 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.605 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.694 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -149.48 157.55 43.39 Favored 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 119.182 -1.007 . . . . 0.0 110.92 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.407 HG22 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -145.81 106.03 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 179.16 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.633 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -87.62 143.27 27.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.652 -1.28 . . . . 0.0 109.288 -179.254 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.64 115.12 17.55 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.211 -0.996 . . . . 0.0 109.639 179.077 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.1 mt -105.88 -12.62 15.78 Favored 'General case' 0 C--N 1.289 -2.058 0 CA-C-O 121.526 0.679 . . . . 0.0 109.215 179.437 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.42 -47.32 1.05 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -178.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.23 -5.82 11.85 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.581 -0.952 . . . . 0.0 109.801 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -146.19 154.67 26.1 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 18.4 p -150.62 174.23 13.23 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.177 -1.19 . . . . 0.0 109.675 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.609 ' HB1' HD13 ' A' ' 70' ' ' LEU . . . -151.81 134.59 15.59 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.182 -0.949 . . . . 0.0 109.397 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -99.69 143.01 30.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.252 -0.905 . . . . 0.0 110.311 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.754 ' HG ' HD11 ' A' ' 27' ' ' ILE . 0.0 OUTLIER -127.53 157.91 38.85 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 121.662 -0.649 . . . . 0.0 109.966 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.459 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.03 84.59 0.1 Allowed Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.442 HG21 HD21 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -103.2 178.01 4.68 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.204 -1.174 . . . . 0.0 110.055 -179.766 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -121.43 157.78 29.81 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.31 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.617 HG12 ' CE2' ' A' ' 58' ' ' TYR . 16.4 t -137.45 143.39 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 120.997 -1.064 . . . . 0.0 110.264 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.573 ' N ' HG11 ' A' ' 83' ' ' VAL . 3.5 tt0 -132.69 101.77 5.42 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.467 -0.77 . . . . 0.0 109.27 179.448 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.596 HG21 ' HB3' ' A' ' 17' ' ' LEU . 79.5 t -103.52 140.52 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.333 -0.855 . . . . 0.0 109.714 -179.473 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -104.9 -174.71 2.6 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.158 -0.964 . . . . 0.0 109.872 -179.479 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.44 ' CB ' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.158 -0.963 . . . . 0.0 109.848 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.693 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.487 1.389 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.447 ' CG2' HG22 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.15 141.72 28.34 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.693 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.587 ' HG ' ' CD2' ' A' ' 79' ' ' LEU . 5.8 mp -97.88 91.24 5.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 -178.121 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.509 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 57.0 t -101.14 117.76 46.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.953 -1.092 . . . . 0.0 108.653 179.171 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.467 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -125.08 72.6 0.43 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.588 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.508 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 32.7 Cg_endo -73.01 147.97 44.25 Favored 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.701 2.267 . . . . 0.0 111.758 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.494 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 23.6 t-80 157.52 -33.86 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.791 0 CA-C-N 115.442 -0.799 . . . . 0.0 108.965 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.95 -143.35 15.63 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.123 -1.991 . . . . 0.0 108.123 -179.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -77.16 147.79 26.64 Favored 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.049 1.833 . . . . 0.0 108.947 179.032 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.487 ' O ' ' HA ' ' A' ' 85' ' ' VAL . 5.6 mt -112.27 110.63 20.98 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.201 -0.937 . . . . 0.0 109.89 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -93.09 168.61 11.0 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 179.214 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.6 t -60.83 122.16 14.14 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.209 -0.932 . . . . 0.0 109.456 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.91 47.42 4.78 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.0 mm100 -125.62 157.89 36.05 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.252 -1.146 . . . . 0.0 110.934 -179.515 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.423 HD21 ' HA ' ' A' ' 22' ' ' LEU . 1.8 tm? -113.27 103.58 11.46 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.545 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -85.61 156.22 20.8 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.508 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.51 107.7 13.18 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.506 -1.371 . . . . 0.0 108.63 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.563 ' CE1' ' HB2' ' A' ' 56' ' ' HIS . 1.9 m-85 -95.36 168.78 10.51 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 121.976 0.893 . . . . 0.0 111.779 -177.53 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.541 ' CD2' ' C ' ' A' ' 26' ' ' HIS . 0.0 OUTLIER -163.72 141.21 7.28 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.502 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.693 HG23 ' CB ' ' A' ' 8' ' ' ALA . 4.9 mm -108.01 152.5 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.292 -0.88 . . . . 0.0 109.435 -178.216 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -135.28 121.7 20.5 Favored 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.781 -1.168 . . . . 0.0 112.133 -179.045 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.739 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . -177.72 -66.34 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.002 -1.061 . . . . 0.0 109.222 177.721 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.739 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.3 Cg_endo -81.72 61.7 8.02 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 C-N-CA 122.129 1.886 . . . . 0.0 109.15 178.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.664 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.1 mp -8.81 -67.09 0.01 OUTLIER Pre-proline 0 N--CA 1.508 2.45 0 N-CA-C 113.299 0.851 . . . . 0.0 113.299 -178.55 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.664 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.3 Cg_endo -77.72 68.42 7.67 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 121.892 1.728 . . . . 0.0 111.076 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.557 HG21 ' HG2' ' A' ' 30' ' ' PRO . 3.4 t -91.22 148.06 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 120.757 -1.214 . . . . 0.0 109.875 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.9 p -114.28 -18.11 11.67 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.603 -0.686 . . . . 0.0 110.045 179.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.95 152.53 0.75 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.26 -0.9 . . . . 0.0 110.284 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.48 HG23 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -140.7 140.66 34.94 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.318 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.487 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 18.3 mtm-85 -93.74 107.35 19.24 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.101 -0.999 . . . . 0.0 109.369 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.679 ' CH2' ' CD1' ' A' ' 27' ' ' ILE . 22.8 m95 -90.73 179.56 5.77 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.212 -0.93 . . . . 0.0 109.502 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.42 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.95 102.3 2.96 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 177.36 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.592 ' CD1' ' NE2' ' A' ' 56' ' ' HIS . 2.4 m-30 -80.37 -59.66 2.61 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 118.853 -1.139 . . . . 0.0 110.086 -177.722 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.03 20.06 40.63 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -107.15 -104.52 0.34 Allowed 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.619 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.91 -19.69 62.69 Favored Glycine 0 C--N 1.296 -1.67 0 N-CA-C 107.749 -2.141 . . . . 0.0 107.749 176.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 11.0 p -135.22 130.4 35.21 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.427 -1.043 . . . . 0.0 109.3 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.42 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.36 -86.65 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.115 -0.991 . . . . 0.0 109.936 -179.658 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.511 ' C ' HG21 ' A' ' 47' ' ' VAL . 4.3 pt-20 -57.62 152.84 14.32 Favored 'General case' 0 N--CA 1.497 1.89 0 CA-C-O 121.176 0.512 . . . . 0.0 110.112 -179.618 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.671 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 34.3 t -140.99 126.96 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.416 -0.803 . . . . 0.0 111.242 -178.745 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -105.44 91.78 3.92 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.345 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.526 ' CB ' ' HB1' ' A' ' 54' ' ' ALA . . . -96.03 154.97 16.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.244 -0.91 . . . . 0.0 111.677 -177.624 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.84 153.18 19.0 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.48 ' O ' HG23 ' A' ' 36' ' ' THR . . . 47.26 -158.23 0.55 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 108.248 -1.941 . . . . 0.0 108.248 -179.229 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -88.37 40.03 0.54 Allowed 'Trans proline' 0 C--N 1.297 -2.157 0 C-N-CA 122.029 1.819 . . . . 0.0 109.932 178.118 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.472 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -145.27 152.02 39.28 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 120.096 -1.628 . . . . 0.0 112.187 -178.651 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.564 ' HB1' ' NE1' ' A' ' 38' ' ' TRP . . . -165.12 155.91 14.15 Favored 'General case' 0 N--CA 1.498 1.941 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -114.41 160.71 18.84 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.932 -1.105 . . . . 0.0 110.192 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.592 ' NE2' ' CD1' ' A' ' 40' ' ' PHE . 5.8 m80 -114.54 139.34 49.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.538 -0.726 . . . . 0.0 110.489 -179.15 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -111.89 95.64 5.6 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 178.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.58 ' CE2' HG13 ' A' ' 83' ' ' VAL . 36.3 m-85 -99.02 129.86 45.32 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.161 -0.962 . . . . 0.0 109.432 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.7 t -117.91 -27.89 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.352 -0.842 . . . . 0.0 111.25 -178.433 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.459 HD22 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -99.51 146.39 31.71 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 120.511 -1.368 . . . . 0.0 109.596 -179.381 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.476 ' HA ' HG13 ' A' ' 85' ' ' VAL . 34.8 Cg_endo -77.73 124.42 6.89 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.404 2.069 . . . . 0.0 109.888 179.352 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 160.81 -151.78 22.31 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.609 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.17 120.11 33.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.113 -1.228 . . . . 0.0 109.82 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.558 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 81.6 m-85 -103.6 153.64 20.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.353 -0.842 . . . . 0.0 109.541 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.9 t60 -107.89 132.51 53.38 Favored 'General case' 0 N--CA 1.488 1.475 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.521 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 90.7 t -113.42 150.82 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 110.569 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 6.0 p -147.54 156.43 42.83 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 178.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.749 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -149.94 156.09 41.14 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.855 -1.153 . . . . 0.0 111.186 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -128.49 125.82 64.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 178.502 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.579 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.2 OUTLIER -87.76 144.58 26.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 120.535 -1.353 . . . . 0.0 109.007 -178.865 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.21 106.7 7.72 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 118.783 -1.167 . . . . 0.0 109.627 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -103.62 -10.62 18.28 Favored 'General case' 0 C--N 1.284 -2.28 0 CA-C-N 115.317 -0.856 . . . . 0.0 108.697 179.055 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.81 -47.27 1.07 Allowed Glycine 0 N--CA 1.488 2.125 0 N-CA-C 107.627 -2.189 . . . . 0.0 107.627 -178.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.31 -5.09 11.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.741 -0.858 . . . . 0.0 109.68 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.55 158.4 27.52 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.726 -1.349 . . . . 0.0 109.726 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.414 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 25.7 p -148.03 -177.71 5.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.364 -1.08 . . . . 0.0 109.405 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.578 ' CB ' ' HG ' ' A' ' 70' ' ' LEU . . . -156.55 162.69 39.9 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.8 mp -116.8 132.38 56.71 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.065 -1.022 . . . . 0.0 109.976 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.749 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -116.46 157.36 25.29 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.548 -0.72 . . . . 0.0 109.497 -179.752 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.521 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -168.24 96.3 0.12 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.407 HG21 HD21 ' A' ' 10' ' ' LEU . 0.7 OUTLIER -116.34 -171.74 2.05 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.044 -1.268 . . . . 0.0 109.732 179.791 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -151.55 147.63 27.03 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.408 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.58 HG13 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -131.77 138.44 52.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 120.68 -1.262 . . . . 0.0 110.018 -179.466 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 30.9 tt0 -105.22 90.47 3.44 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 178.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 17' ' ' LEU . 52.9 t -76.54 130.92 35.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.307 -0.871 . . . . 0.0 109.352 -179.575 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -114.46 144.16 43.77 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.467 -0.771 . . . . 0.0 109.768 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.241 -0.912 . . . . 0.0 109.301 179.676 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.733 ' CB ' HG23 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.469 HG22 ' CG2' ' A' ' 11' ' ' VAL . 1.1 t -94.26 147.23 23.39 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.65 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.3 mp -91.99 88.83 6.73 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.162 -178.215 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.534 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 22.1 t -97.76 100.15 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 120.702 -1.249 . . . . 0.0 108.561 178.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.53 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -117.96 78.73 0.3 Allowed Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.276 -179.304 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.532 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.1 Cg_endo -74.99 148.11 34.88 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.404 2.069 . . . . 0.0 111.635 179.412 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 3.3 p-80 174.35 162.01 0.19 Allowed 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.5 -130.0 1.36 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 179.354 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -78.87 147.3 21.36 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 C-N-CA 121.978 1.786 . . . . 0.0 109.145 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.472 ' HB3' HG21 ' A' ' 85' ' ' VAL . 0.4 OUTLIER -113.41 84.21 1.97 Allowed 'General case' 0 C--N 1.298 -1.671 0 O-C-N 121.194 -0.941 . . . . 0.0 109.046 -179.815 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -95.53 168.16 10.86 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.58 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 39.0 t -56.71 108.52 0.51 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.294 -0.879 . . . . 0.0 109.521 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.94 37.67 2.49 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -128.21 154.42 45.85 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.227 -1.161 . . . . 0.0 109.79 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.561 HD11 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -118.66 130.01 55.61 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.118 -0.988 . . . . 0.0 109.662 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.593 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -94.92 146.01 24.53 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.014 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.532 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -101.82 129.6 48.07 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 119.978 -1.701 . . . . 0.0 108.014 178.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.7 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 16.6 m-85 -112.22 166.39 11.31 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 121.959 0.885 . . . . 0.0 111.942 -176.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.571 ' CD2' ' C ' ' A' ' 26' ' ' HIS . 0.0 OUTLIER -164.5 134.41 3.92 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 178.22 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.745 HD13 ' HG ' ' A' ' 79' ' ' LEU . 0.4 OUTLIER -103.38 149.43 7.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.17 -0.956 . . . . 0.0 109.036 -178.437 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.429 ' CB ' HG21 ' A' ' 9' ' ' THR . . . -133.73 124.31 26.44 Favored 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.545 -1.262 . . . . 0.0 112.225 -178.856 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.724 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 179.15 -66.38 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 121.118 -0.989 . . . . 0.0 109.199 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.724 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 36.4 Cg_endo -80.51 68.64 8.25 Favored 'Trans proline' 0 C--N 1.314 -1.281 0 C-N-CA 121.983 1.788 . . . . 0.0 109.102 178.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.66 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -10.81 -66.52 0.01 OUTLIER Pre-proline 0 N--CA 1.507 2.42 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -178.664 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.66 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 37.0 Cg_endo -79.58 83.86 2.16 Favored 'Trans proline' 0 C--N 1.314 -1.257 0 C-N-CA 121.667 1.578 . . . . 0.0 111.001 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.495 HG21 ' HG2' ' A' ' 30' ' ' PRO . 6.3 t -106.12 143.22 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.836 -1.165 . . . . 0.0 109.384 179.365 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.5 t -118.62 -14.18 9.61 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.406 -0.809 . . . . 0.0 110.412 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -174.2 146.82 1.16 Allowed 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.898 -1.126 . . . . 0.0 110.532 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.521 HG23 ' O ' ' A' ' 51' ' ' GLY . 0.4 OUTLIER -142.96 136.94 29.02 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.69 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.519 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 7.5 mtm180 -94.28 112.36 24.15 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.19 -0.944 . . . . 0.0 108.872 179.448 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.73 ' CH2' HD12 ' A' ' 27' ' ' ILE . 18.6 m95 -94.32 -177.09 4.16 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.898 0.856 . . . . 0.0 109.079 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.436 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -151.39 103.77 3.02 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 106.282 -1.748 . . . . 0.0 106.282 177.424 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.655 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 4.1 m-30 -80.04 -63.65 1.36 Allowed 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.822 -1.151 . . . . 0.0 110.31 -177.586 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.26 9.32 55.68 Favored Glycine 0 N--CA 1.486 1.974 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -178.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -93.47 -101.72 0.13 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 178.471 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -89.02 -28.92 19.38 Favored Glycine 0 C--N 1.293 -1.826 0 N-CA-C 107.507 -2.237 . . . . 0.0 107.507 177.056 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.31 130.26 55.93 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.546 -0.973 . . . . 0.0 109.38 179.438 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.436 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.3 -85.02 0.1 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.202 -0.936 . . . . 0.0 109.541 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.489 ' C ' HG21 ' A' ' 47' ' ' VAL . 0.2 OUTLIER -59.77 155.26 16.39 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.265 0.555 . . . . 0.0 110.065 -179.775 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.667 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 60.6 t -142.01 136.16 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.469 -0.769 . . . . 0.0 111.076 -178.79 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -116.16 93.2 4.14 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 177.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.516 ' HB1' ' CD1' ' A' ' 38' ' ' TRP . . . -96.35 150.13 20.92 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.359 -0.838 . . . . 0.0 111.661 -177.841 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.69 146.71 27.3 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.521 ' O ' HG23 ' A' ' 36' ' ' THR . . . 47.73 -159.16 0.58 Allowed Glycine 0 N--CA 1.492 2.385 0 N-CA-C 107.91 -2.076 . . . . 0.0 107.91 -179.03 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -86.55 41.6 0.82 Allowed 'Trans proline' 0 C--N 1.299 -2.049 0 C-N-CA 121.909 1.739 . . . . 0.0 110.12 178.253 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.502 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -144.07 141.01 29.82 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.314 -1.491 . . . . 0.0 111.65 -178.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.484 ' HB1' ' CB ' ' A' ' 49' ' ' ALA . . . -146.26 -166.16 2.4 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.03 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.536 ' HB2' ' CD1' ' A' ' 22' ' ' LEU . 5.4 p -156.38 136.45 12.79 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.364 -0.835 . . . . 0.0 108.919 179.391 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.655 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 9.4 m80 -99.46 131.62 45.34 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.291 -0.881 . . . . 0.0 111.329 -178.26 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -97.08 96.06 8.2 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 178.23 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.592 ' CZ ' HG12 ' A' ' 83' ' ' VAL . 16.6 m-85 -100.1 105.16 16.76 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.905 -1.122 . . . . 0.0 109.547 -179.086 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.0 m -107.73 -9.32 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.488 -0.758 . . . . 0.0 111.292 -178.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.425 ' CD2' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -105.83 145.86 31.72 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 120.46 -1.4 . . . . 0.0 109.462 -179.818 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.47 ' HB3' ' CB ' ' A' ' 87' ' ' ALA . 35.5 Cg_endo -77.56 123.78 6.65 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.614 2.209 . . . . 0.0 110.133 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 150.37 -142.97 10.12 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 -179.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.26 158.54 37.87 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.204 -1.174 . . . . 0.0 109.475 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.562 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 92.5 m-85 -135.78 155.46 50.33 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.307 -0.87 . . . . 0.0 109.683 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 9.8 t60 -111.46 114.31 27.33 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.034 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.52 HG11 ' NE2' ' A' ' 56' ' ' HIS . 62.7 t -95.06 150.64 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.228 -0.92 . . . . 0.0 110.527 -178.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.408 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.8 OUTLIER -146.42 157.96 43.83 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.388 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.719 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -156.36 164.57 38.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.603 -1.311 . . . . 0.0 111.224 -179.457 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.421 ' CG1' ' HB2' ' A' ' 37' ' ' ARG . 9.8 p -142.16 127.29 17.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 178.427 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.586 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 0.1 OUTLIER -88.2 142.23 27.92 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.932 -1.105 . . . . 0.0 108.769 -178.471 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -131.41 106.23 8.11 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.551 -1.26 . . . . 0.0 109.949 178.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -104.6 -9.82 18.0 Favored 'General case' 0 C--N 1.284 -2.261 0 CA-C-N 115.218 -0.901 . . . . 0.0 108.701 178.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.11 -48.52 0.97 Allowed Glycine 0 N--CA 1.487 2.094 0 N-CA-C 107.776 -2.13 . . . . 0.0 107.776 -178.457 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.59 -5.52 11.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.633 -0.922 . . . . 0.0 109.61 179.089 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.94 156.66 26.07 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.0 p -150.38 -178.65 6.65 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.304 -1.115 . . . . 0.0 109.421 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.572 ' CB ' ' HG ' ' A' ' 70' ' ' LEU . . . -158.98 141.4 14.03 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.36 -0.837 . . . . 0.0 108.744 179.577 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -99.85 135.37 41.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.984 -1.073 . . . . 0.0 110.101 -179.211 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.745 ' HG ' HD13 ' A' ' 27' ' ' ILE . 0.0 OUTLIER -119.82 156.91 29.75 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.492 -0.755 . . . . 0.0 110.026 -179.569 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.511 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.46 89.73 0.1 Allowed Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.49 -172.7 2.12 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.991 -1.3 . . . . 0.0 110.267 -179.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -150.72 146.28 26.34 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.592 HG12 ' CZ ' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -131.2 157.59 43.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.856 -1.152 . . . . 0.0 109.93 -179.702 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . 0.45 ' N ' HG22 ' A' ' 83' ' ' VAL . 8.1 mt-30 -130.45 92.14 3.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.595 -0.691 . . . . 0.0 109.165 179.466 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.472 HG21 ' HB3' ' A' ' 17' ' ' LEU . 40.9 t -86.58 141.92 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.253 -0.904 . . . . 0.0 109.734 -179.663 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -108.34 175.69 5.38 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.29 -0.881 . . . . 0.0 110.309 -179.29 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.47 ' CB ' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.659 0 O-C-N 121.347 -0.846 . . . . 0.0 109.693 179.5 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.635 ' HA ' ' HB1' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.521 HG22 HG21 ' A' ' 11' ' ' VAL . 1.6 t -74.95 150.73 38.97 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.13 -0.982 . . . . 0.0 109.408 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.676 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 5.3 mp -87.15 105.6 17.31 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.977 -178.636 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.59 ' CG1' ' CE1' ' A' ' 26' ' ' HIS . 2.3 t -119.36 91.6 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.976 -1.078 . . . . 0.0 109.009 178.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.687 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -113.7 81.14 0.29 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.492 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.546 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.5 Cg_endo -73.34 149.04 44.45 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.662 2.242 . . . . 0.0 111.92 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.471 ' CD2' HD21 ' A' ' 17' ' ' LEU . 45.6 t60 166.96 -39.13 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.49 -138.86 14.76 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.057 -2.017 . . . . 0.0 108.057 -178.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -77.42 147.65 25.75 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 C-N-CA 122.096 1.864 . . . . 0.0 109.043 178.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.471 HD21 ' CD2' ' A' ' 14' ' ' HIS . 0.2 OUTLIER -106.31 109.84 21.9 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.098 -1.001 . . . . 0.0 109.721 -179.285 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -92.34 153.35 19.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 179.269 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.0 t -59.29 111.08 1.23 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -0.875 . . . . 0.0 109.37 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.47 35.44 3.09 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 13.6 mm100 -133.65 160.54 37.23 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.192 -1.181 . . . . 0.0 109.88 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.527 HD11 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -117.06 126.66 53.2 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.186 -0.946 . . . . 0.0 109.414 179.672 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.605 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . . . -90.06 145.42 25.08 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.084 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.546 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -99.89 129.78 46.01 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 119.918 -1.739 . . . . 0.0 108.165 179.111 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.75 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 16.8 m-85 -113.88 163.26 15.32 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 122.102 0.954 . . . . 0.0 111.977 -177.335 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . 0.59 ' CE1' ' CG1' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -165.9 139.77 4.43 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.079 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.707 HD13 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.31 154.69 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.868 -1.145 . . . . 0.0 108.777 -178.331 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -133.87 123.43 24.73 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 120.693 -1.255 . . . . 0.0 112.732 -178.08 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.724 ' CB ' ' HD3' ' A' ' 30' ' ' PRO . . . 171.45 -69.22 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.399 -0.813 . . . . 0.0 109.305 177.659 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.724 ' HD3' ' CB ' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -76.66 78.7 3.26 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 121.796 1.664 . . . . 0.0 109.486 179.198 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.712 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 6.0 mt -34.05 -53.82 0.86 Allowed Pre-proline 0 N--CA 1.504 2.251 0 O-C-N 121.944 -0.472 . . . . 0.0 111.703 -178.792 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' PRO . . . . . 0.712 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 36.8 Cg_endo -81.3 63.12 8.61 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 C-N-CA 122.077 1.851 . . . . 0.0 112.198 -179.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.608 ' CG2' ' HG2' ' A' ' 30' ' ' PRO . 74.4 t -87.59 148.02 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 120.595 -1.316 . . . . 0.0 109.696 179.118 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 70.7 p -119.53 -35.82 3.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.422 -0.798 . . . . 0.0 109.665 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -155.13 144.37 21.04 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.461 -0.774 . . . . 0.0 109.007 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.644 ' HA ' ' HA ' ' A' ' 70' ' ' LEU . 0.5 OUTLIER -129.29 156.44 44.0 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.976 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.542 ' HB2' HG22 ' A' ' 69' ' ' VAL . 49.1 mtp85 -119.51 101.06 7.67 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 109.044 179.82 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.75 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 30.3 m95 -89.24 178.77 6.27 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.123 -0.985 . . . . 0.0 109.476 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . 0.453 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.51 101.58 2.97 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 177.49 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.616 ' CD1' ' CE1' ' A' ' 56' ' ' HIS . 2.9 m-30 -79.75 -61.26 2.05 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.989 -177.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.77 15.86 47.68 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -178.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.27 -104.52 0.27 Allowed 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 178.607 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.31 -20.28 59.09 Favored Glycine 0 C--N 1.296 -1.649 0 N-CA-C 107.708 -2.157 . . . . 0.0 107.708 177.028 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 m -132.58 127.59 35.35 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.432 -1.04 . . . . 0.0 109.304 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.89 -85.96 0.09 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.17 -0.956 . . . . 0.0 109.72 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLU . . . . . 0.474 ' C ' HG21 ' A' ' 47' ' ' VAL . 0.9 OUTLIER -57.73 153.37 13.69 Favored 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 121.112 0.482 . . . . 0.0 109.71 -179.918 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.694 ' HB ' ' HB2' ' A' ' 38' ' ' TRP . 57.7 t -140.16 124.12 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.384 -0.823 . . . . 0.0 111.1 -178.445 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -104.61 99.47 9.14 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.074 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.424 ' HB2' ' CG2' ' A' ' 36' ' ' THR . . . -109.91 167.8 9.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.203 -0.936 . . . . 0.0 111.02 -178.596 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.97 151.94 21.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.715 -0.615 . . . . 0.0 109.352 179.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.467 ' HA2' HG13 ' A' ' 33' ' ' VAL . . . 45.92 -155.2 0.58 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -89.06 41.63 0.57 Allowed 'Trans proline' 0 C--N 1.295 -2.255 0 C-N-CA 122.272 1.981 . . . . 0.0 110.515 178.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.44 ' HA ' ' HA ' ' A' ' 26' ' ' HIS . . . -143.58 154.02 43.14 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.928 -1.733 . . . . 0.0 112.602 -178.716 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.406 ' HB1' ' NE1' ' A' ' 38' ' ' TRP . . . -166.56 -171.17 1.81 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.074 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.501 ' HB2' HD12 ' A' ' 22' ' ' LEU . 0.3 OUTLIER -150.45 143.25 24.65 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.116 -0.99 . . . . 0.0 109.263 179.449 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . 0.616 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 7.3 m80 -102.41 134.64 45.4 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.197 -0.94 . . . . 0.0 111.515 -178.686 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.15 95.47 6.57 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.331 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.6 ' CE1' ' CG ' ' A' ' 64' ' ' TYR . 18.6 m-85 -102.58 112.84 25.77 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.079 -1.013 . . . . 0.0 109.403 -179.285 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.6 p -110.85 -10.56 11.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.417 -0.802 . . . . 0.0 111.525 -178.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . 0.446 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -114.73 146.14 35.4 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 120.478 -1.389 . . . . 0.0 109.673 -179.743 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.446 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.1 Cg_endo -77.06 122.85 6.41 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.403 2.069 . . . . 0.0 109.935 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 161.77 -157.05 28.73 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.418 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -116.93 121.2 40.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.144 -1.21 . . . . 0.0 109.771 -179.824 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.6 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 90.3 m-85 -103.71 155.95 18.18 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.314 -0.867 . . . . 0.0 109.315 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 80.8 t60 -111.94 123.34 50.04 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.504 ' CG1' ' CE1' ' A' ' 56' ' ' HIS . 62.4 t -106.22 150.5 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.163 -0.961 . . . . 0.0 110.594 -178.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.53 159.56 44.2 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 178.664 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.718 ' HB2' ' HB2' ' A' ' 79' ' ' LEU . . . -151.09 154.52 37.13 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.939 -1.101 . . . . 0.0 110.921 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.542 HG22 ' HB2' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -144.75 104.3 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.102 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.644 ' HA ' ' HA ' ' A' ' 36' ' ' THR . 0.1 OUTLIER -88.74 150.73 22.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.757 -1.215 . . . . 0.0 110.204 -178.663 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.99 116.16 18.91 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.826 0.822 . . . . 0.0 108.937 178.453 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.477 ' CD2' ' HB2' ' A' ' 30' ' ' PRO . 5.6 mp -104.36 -12.96 16.29 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-O 121.508 0.671 . . . . 0.0 109.212 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.74 -53.75 0.62 Allowed Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.135 -1.986 . . . . 0.0 108.135 -178.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.71 -5.33 12.13 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.584 -0.95 . . . . 0.0 109.777 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.43 161.4 26.95 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.413 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 3.4 p -150.87 170.36 19.47 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.371 -1.076 . . . . 0.0 109.359 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.498 ' HB1' ' CD1' ' A' ' 70' ' ' LEU . . . -143.42 128.75 18.88 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.245 -0.91 . . . . 0.0 109.57 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.3 tp -95.11 140.79 29.55 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.471 -0.768 . . . . 0.0 110.029 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . 0.718 ' HB2' ' HB2' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -128.72 157.52 41.15 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.604 -0.685 . . . . 0.0 109.919 -179.464 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -164.88 86.48 0.1 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 179.589 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.401 HG21 HD11 ' A' ' 79' ' ' LEU . 0.0 OUTLIER -104.34 -176.32 3.05 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.122 -1.222 . . . . 0.0 109.762 -179.854 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -150.76 147.53 27.42 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.575 HG12 ' CZ ' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -131.83 149.78 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 O-C-N 120.768 -1.208 . . . . 0.0 109.618 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -119.22 87.46 2.74 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.441 HG13 ' HA ' ' A' ' 61' ' ' PRO . 84.5 t -75.01 134.84 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.312 -0.867 . . . . 0.0 109.815 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 -109.26 177.52 4.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.363 -0.835 . . . . 0.0 109.591 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.364 -0.835 . . . . 0.0 109.515 179.874 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.955 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.393 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.711 ' CG2' ' HB3' ' A' ' 28' ' ' ALA . 0.5 OUTLIER -81.49 144.66 31.19 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.214 -0.929 . . . . 0.0 108.95 -179.456 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.779 HD23 HG22 ' A' ' 81' ' ' THR . 5.8 mp -94.27 86.7 5.0 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.215 -178.164 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.691 HG12 ' HD3' ' A' ' 13' ' ' PRO . 32.9 t -94.88 102.39 13.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 120.873 -1.142 . . . . 0.0 108.386 178.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.505 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.95 76.72 0.28 Allowed Glycine 0 N--CA 1.488 2.113 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.038 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.691 ' HD3' HG12 ' A' ' 11' ' ' VAL . 31.4 Cg_endo -71.73 146.85 49.48 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.438 2.092 . . . . 0.0 111.401 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 174.51 164.17 0.22 Allowed 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 -179.664 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -89.29 -125.91 2.77 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 107.363 -2.295 . . . . 0.0 107.363 178.506 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -80.06 147.06 18.52 Favored 'Trans proline' 0 C--N 1.302 -1.875 0 C-N-CA 121.839 1.693 . . . . 0.0 108.293 177.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.73 HD12 HG22 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -114.15 80.13 1.35 Allowed 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.922 -1.111 . . . . 0.0 109.158 -179.633 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -91.61 172.29 8.6 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.2 t -59.39 117.85 5.31 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.2 -0.938 . . . . 0.0 109.325 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.81 46.71 3.09 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.643 ' HB3' HD13 ' A' ' 17' ' ' LEU . 0.0 OUTLIER -122.27 152.27 40.22 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.386 -1.067 . . . . 0.0 110.559 -179.627 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.661 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.0 tm? -109.99 94.58 5.09 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.739 -0.6 . . . . 0.0 109.65 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.713 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -75.66 158.9 31.76 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.729 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.502 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -124.71 117.81 25.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.463 -1.398 . . . . 0.0 108.573 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.804 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.8 m-85 -105.55 170.96 7.59 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 122.085 0.945 . . . . 0.0 111.828 -177.318 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.649 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.8 138.98 3.51 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 178.105 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.793 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.3 OUTLIER -105.32 152.52 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.085 -1.009 . . . . 0.0 109.47 -178.276 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.711 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -134.66 116.83 15.4 Favored 'General case' 0 N--CA 1.5 2.046 0 C-N-CA 118.823 -1.151 . . . . 0.0 111.644 -179.292 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.112 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 176.56 -62.26 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.915 0 O-C-N 121.076 -1.015 . . . . 0.0 109.952 178.173 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.112 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.4 Cg_endo -80.11 63.55 8.76 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.32 2.013 . . . . 0.0 109.711 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.64 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -13.13 -64.58 0.02 OUTLIER Pre-proline 0 N--CA 1.504 2.266 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 -178.902 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.64 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.2 Cg_endo -77.69 72.5 6.05 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 121.724 1.616 . . . . 0.0 111.282 -179.551 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.483 ' CG2' ' O ' ' A' ' 30' ' ' PRO . 2.7 t -98.77 127.26 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.996 -1.065 . . . . 0.0 109.341 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 p -111.21 -14.87 13.77 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.417 -0.802 . . . . 0.0 109.219 178.714 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -163.46 148.34 11.02 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.224 -0.922 . . . . 0.0 109.824 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.935 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.4 t -140.38 162.66 34.78 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.43 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.554 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -127.31 100.5 6.08 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.101 -0.999 . . . . 0.0 109.217 179.586 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.804 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 36.4 m95 -87.59 179.02 6.61 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.218 -0.926 . . . . 0.0 109.453 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.466 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.3 OUTLIER -146.84 103.14 3.6 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.862 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.981 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.5 m-30 -81.16 -59.1 2.77 Favored 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.314 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.28 8.48 68.44 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.518 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 10.4 p30 -98.49 35.7 1.76 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.372 -1.075 . . . . 0.0 108.111 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 108.33 -38.35 3.37 Favored Glycine 0 N--CA 1.483 1.785 0 N-CA-C 105.356 -3.098 . . . . 0.0 105.356 -175.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 74.6 m -101.86 95.06 6.14 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.466 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.2 -90.7 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -0.919 . . . . 0.0 110.151 -178.487 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -55.9 146.81 20.97 Favored 'General case' 0 N--CA 1.493 1.688 0 CA-C-O 121.251 0.548 . . . . 0.0 109.758 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.981 HG21 ' CE1' ' A' ' 40' ' ' PHE . 63.8 t -135.01 106.36 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.377 -0.827 . . . . 0.0 110.972 -178.36 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.8 94.12 9.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.988 -1.07 . . . . 0.0 108.211 178.168 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.935 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -101.65 166.6 10.6 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.258 -0.901 . . . . 0.0 110.801 -178.596 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.61 150.09 21.53 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.725 -0.61 . . . . 0.0 109.595 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.541 ' O ' HG22 ' A' ' 36' ' ' THR . . . 44.14 -153.26 0.41 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.461 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.8 Cg_endo -88.43 40.09 0.54 Allowed 'Trans proline' 0 C--N 1.301 -1.943 0 C-N-CA 122.372 2.048 . . . . 0.0 110.282 178.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.628 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.38 154.39 43.68 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.135 -1.603 . . . . 0.0 112.011 -178.882 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.447 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -165.88 -168.86 1.37 Allowed 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.362 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.661 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -157.32 146.59 20.08 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.133 -0.979 . . . . 0.0 109.131 179.236 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.742 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 2.4 m-70 -100.08 133.76 44.0 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.352 -0.843 . . . . 0.0 110.915 -178.532 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -107.5 88.63 2.78 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.418 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.131 ' CE2' HG11 ' A' ' 83' ' ' VAL . 13.8 m-85 -88.71 135.14 33.66 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.389 -0.819 . . . . 0.0 109.294 -178.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.9 p -127.96 -12.93 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.235 -0.916 . . . . 0.0 111.314 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.438 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -110.23 144.63 30.49 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 120.527 -1.358 . . . . 0.0 109.584 -179.767 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.755 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.0 Cg_endo -77.78 115.54 3.85 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.408 2.072 . . . . 0.0 109.868 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 163.97 -142.76 8.04 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.69 159.74 22.46 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.221 -1.164 . . . . 0.0 109.215 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.526 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 57.9 m-85 -140.68 160.85 39.14 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.413 -0.805 . . . . 0.0 109.297 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 49.2 t60 -122.0 142.09 50.68 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.702 HG22 ' CE1' ' A' ' 56' ' ' HIS . 21.7 t -125.17 149.6 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.862 -1.148 . . . . 0.0 110.991 -178.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.44 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -150.28 160.65 43.55 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 107.448 -1.315 . . . . 0.0 107.448 178.129 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.04 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -151.79 153.66 34.7 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.843 -1.16 . . . . 0.0 111.292 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.537 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.8 OUTLIER -126.0 121.99 60.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.58 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.9 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.6 OUTLIER -88.36 141.54 28.46 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 120.596 -1.315 . . . . 0.0 109.103 -178.406 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.66 109.12 10.4 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 118.679 -1.209 . . . . 0.0 109.694 178.573 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.841 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -104.07 -11.03 17.59 Favored 'General case' 0 C--N 1.288 -2.069 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.73 -49.46 0.84 Allowed Glycine 0 N--CA 1.487 2.074 0 N-CA-C 107.729 -2.148 . . . . 0.0 107.729 -178.442 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -118.41 -5.56 10.8 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.678 -0.895 . . . . 0.0 109.877 179.016 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.55 164.09 26.04 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.462 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 6.8 p -151.18 -177.23 5.92 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.344 -1.092 . . . . 0.0 109.684 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.9 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -153.17 154.81 35.5 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 179.646 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -112.94 124.79 53.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.141 -0.974 . . . . 0.0 109.938 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.04 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -114.53 155.24 26.81 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.416 -0.802 . . . . 0.0 110.032 -179.643 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -164.66 91.59 0.11 Allowed Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.271 -1.531 . . . . 0.0 109.271 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.779 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -106.88 175.84 5.37 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.127 -1.219 . . . . 0.0 109.895 -179.683 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -122.12 160.34 25.28 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.378 -0.826 . . . . 0.0 108.99 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.131 HG11 ' CE2' ' A' ' 58' ' ' TYR . 25.9 t -144.17 147.51 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.011 -1.055 . . . . 0.0 110.448 -179.022 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -137.14 98.98 3.87 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.385 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.73 HG22 HD12 ' A' ' 17' ' ' LEU . 29.1 t -96.93 139.83 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.111 -0.993 . . . . 0.0 110.658 -179.004 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 23.6 mm-40 -110.59 -159.41 0.68 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.512 -0.743 . . . . 0.0 109.62 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.755 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.123 -0.986 . . . . 0.0 109.243 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.706 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.926 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.3 t -70.62 149.44 47.05 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.196 -0.94 . . . . 0.0 109.336 -179.203 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.731 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 4.9 mp -84.62 108.18 17.22 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.088 -178.359 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.666 HG21 ' CE1' ' A' ' 26' ' ' HIS . 0.7 OUTLIER -123.53 104.28 14.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 120.777 -1.202 . . . . 0.0 108.912 178.708 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.85 76.52 0.3 Allowed Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.551 ' HD2' ' HA ' ' A' ' 25' ' ' PHE . 34.6 Cg_endo -73.26 150.43 47.28 Favored 'Trans proline' 0 C--N 1.308 -1.567 0 C-N-CA 122.728 2.285 . . . . 0.0 111.918 179.677 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.524 ' CD2' ' HA ' ' A' ' 23' ' ' ALA . 32.6 t-80 161.94 -36.82 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.796 0 CA-C-O 121.782 0.801 . . . . 0.0 108.944 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.97 -138.04 14.52 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 107.942 -2.063 . . . . 0.0 107.942 -178.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -77.74 147.83 25.03 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 122.027 1.818 . . . . 0.0 109.313 178.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.85 ' HB3' HG22 ' A' ' 85' ' ' VAL . 0.6 OUTLIER -110.59 115.73 30.12 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.251 -0.906 . . . . 0.0 109.486 -179.441 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -106.24 160.01 15.67 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 45.7 t -56.3 119.34 5.82 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.316 -0.865 . . . . 0.0 109.471 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.42 46.92 3.92 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 7.5 mm100 -127.4 153.52 46.15 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.145 -1.209 . . . . 0.0 110.543 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.838 HD11 ' HB2' ' A' ' 55' ' ' SER . 1.8 tm? -108.81 92.31 4.0 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.652 ' HB3' ' HB2' ' A' ' 56' ' ' HIS . . . -71.21 156.33 39.68 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 178.702 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.497 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -122.74 112.49 17.99 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.26 -1.525 . . . . 0.0 108.341 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.798 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.6 m-85 -100.64 173.84 6.35 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 122.512 1.148 . . . . 0.0 112.415 -177.19 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.666 ' CE1' HG21 ' A' ' 11' ' ' VAL . 5.9 p80 -172.47 147.61 1.91 Allowed 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.19 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.908 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.82 156.88 12.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.961 -1.087 . . . . 0.0 108.198 -178.484 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.926 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -132.66 122.34 24.52 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.442 -1.303 . . . . 0.0 112.702 -177.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.053 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.8 -70.06 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.797 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.79 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.053 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.1 Cg_endo -77.62 77.76 3.76 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 121.592 1.528 . . . . 0.0 108.718 178.68 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.567 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.3 OUTLIER -35.16 -55.57 1.01 Allowed Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.817 -0.552 . . . . 0.0 111.284 -178.795 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.613 ' O ' HD21 ' A' ' 72' ' ' LEU . 36.8 Cg_endo -80.62 81.29 2.78 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.141 1.894 . . . . 0.0 111.236 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 30' ' ' PRO . 40.1 t -111.89 150.3 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 120.908 -1.12 . . . . 0.0 109.0 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 18.5 p -116.91 -28.92 6.16 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.203 -0.936 . . . . 0.0 110.593 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.93 143.7 17.15 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.088 -1.008 . . . . 0.0 110.274 -179.569 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.905 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -130.79 157.37 43.05 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.517 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -125.05 104.25 8.45 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.305 -0.872 . . . . 0.0 108.669 179.102 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.798 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 32.7 m95 -88.85 -178.6 5.78 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 109.276 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.522 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -148.24 102.73 3.38 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 178.085 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.96 ' CE1' HG21 ' A' ' 47' ' ' VAL . 4.7 m-30 -81.61 -66.03 0.94 Allowed 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 119.182 -1.007 . . . . 0.0 110.561 -177.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.89 11.12 47.55 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.176 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.552 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 12.6 p30 -97.04 33.07 1.99 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.249 -1.148 . . . . 0.0 108.224 179.043 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.24 -34.84 5.08 Favored Glycine 0 N--CA 1.48 1.603 0 N-CA-C 105.449 -3.06 . . . . 0.0 105.449 -175.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 50.2 m -108.35 100.78 10.04 Favored 'General case' 0 N--CA 1.485 1.305 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.76 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.522 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -75.3 -86.96 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.166 -0.959 . . . . 0.0 109.773 -178.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -50.89 144.77 8.04 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.308 0.575 . . . . 0.0 109.806 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.96 HG21 ' CE1' ' A' ' 40' ' ' PHE . 91.9 t -133.84 105.91 8.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.36 -0.838 . . . . 0.0 110.764 -178.701 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -83.12 115.75 22.03 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.479 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.905 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -129.26 164.08 24.25 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.028 -1.045 . . . . 0.0 110.74 -178.764 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.18 151.02 19.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.659 -0.65 . . . . 0.0 109.574 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.589 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.65 -155.31 0.51 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -88.5 38.91 0.47 Allowed 'Trans proline' 0 C--N 1.298 -2.1 0 C-N-CA 122.269 1.979 . . . . 0.0 110.191 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.661 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -139.55 155.57 47.42 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 120.227 -1.546 . . . . 0.0 111.895 -178.705 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.504 ' HB2' ' NE1' ' A' ' 38' ' ' TRP . . . -165.18 -169.64 1.69 Allowed 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.838 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -154.0 144.09 22.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.018 -1.051 . . . . 0.0 109.816 179.407 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.652 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -94.48 129.89 41.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.705 -0.622 . . . . 0.0 111.031 -178.797 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -105.47 85.57 2.27 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.12 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.023 ' CE2' HG11 ' A' ' 83' ' ' VAL . 13.0 m-85 -92.29 134.2 35.12 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.986 -1.071 . . . . 0.0 110.073 -178.544 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.4 m -127.3 -3.12 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.605 -0.685 . . . . 0.0 111.046 -179.083 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.446 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.2 OUTLIER -117.61 140.5 27.6 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 120.651 -1.281 . . . . 0.0 109.36 -179.944 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.852 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.1 Cg_endo -77.65 109.47 2.76 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 122.479 2.119 . . . . 0.0 110.155 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 169.81 -144.23 8.41 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.89 162.25 15.0 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.166 -1.196 . . . . 0.0 109.826 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.512 ' HB2' ' HB ' ' A' ' 83' ' ' VAL . 61.5 m-85 -146.91 165.28 30.26 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -124.87 153.9 41.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.151 -0.968 . . . . 0.0 108.503 179.008 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.612 HG13 ' NE2' ' A' ' 56' ' ' HIS . 12.5 t -134.19 145.19 33.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 120.839 -1.163 . . . . 0.0 110.764 -179.057 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.452 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -150.63 159.03 44.79 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 178.129 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.993 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -152.03 157.26 41.43 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.868 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.587 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.3 p -150.14 108.19 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.851 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.16 151.11 22.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.931 -1.106 . . . . 0.0 109.154 -179.156 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.42 119.7 23.09 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.362 -0.935 . . . . 0.0 109.708 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.613 HD21 ' O ' ' A' ' 32' ' ' PRO . 7.4 mt -109.23 -12.97 14.73 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-O 121.518 0.675 . . . . 0.0 109.492 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.07 -47.41 1.05 Allowed Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -178.646 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -113.87 -6.24 13.22 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.574 -0.956 . . . . 0.0 109.696 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.65 158.84 27.83 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -150.8 168.34 24.73 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.199 -1.177 . . . . 0.0 109.395 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.851 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -141.74 132.62 25.87 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.199 -0.938 . . . . 0.0 109.358 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.2 mp -101.76 147.06 26.92 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.15 -0.969 . . . . 0.0 110.45 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.993 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -133.26 160.11 38.25 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.655 -0.653 . . . . 0.0 109.886 -179.292 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.491 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.42 88.91 0.09 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.509 HG22 HD13 ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.48 175.8 5.28 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.087 -1.243 . . . . 0.0 109.976 -179.755 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -117.87 155.37 30.27 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.243 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.023 HG11 ' CE2' ' A' ' 58' ' ' TYR . 25.1 t -134.82 143.42 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.172 -0.955 . . . . 0.0 110.049 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -131.83 104.0 6.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.37 -0.832 . . . . 0.0 109.038 179.407 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.85 HG22 ' HB3' ' A' ' 17' ' ' LEU . 86.0 t -102.43 132.19 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.345 -0.847 . . . . 0.0 109.964 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.45 -160.98 0.81 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.201 -0.937 . . . . 0.0 109.391 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.852 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.632 0 O-C-N 121.064 -1.022 . . . . 0.0 109.427 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.873 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.812 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.79 139.68 30.22 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.77 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.6 mp -97.19 89.55 4.81 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.148 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.941 HG12 ' HD3' ' A' ' 13' ' ' PRO . 65.3 t -99.08 112.34 30.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.885 -1.134 . . . . 0.0 109.092 179.521 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.504 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -124.1 71.18 0.44 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.941 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.4 Cg_endo -73.64 150.4 45.22 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.803 2.336 . . . . 0.0 112.153 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.468 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.9 t-80 168.9 -38.87 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.681 0.753 . . . . 0.0 109.208 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.29 -138.05 14.56 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 -178.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.62 147.0 24.57 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 121.972 1.782 . . . . 0.0 109.166 178.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.953 HD21 ' HB2' ' A' ' 23' ' ' ALA . 2.7 mt -117.26 98.56 6.5 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.2 -0.937 . . . . 0.0 109.779 -179.301 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.09 165.66 14.98 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.269 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 t -60.85 114.74 3.22 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.243 -0.91 . . . . 0.0 109.272 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.68 39.52 2.72 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.84 154.58 51.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.152 -1.205 . . . . 0.0 110.015 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.717 HD12 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -115.82 128.14 55.59 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.805 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.953 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -92.69 148.37 22.12 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.533 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -105.25 121.9 44.81 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.067 -1.645 . . . . 0.0 108.04 179.012 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.815 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 5.2 m-85 -105.39 170.53 7.83 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 121.914 0.864 . . . . 0.0 111.721 -177.009 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.587 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.72 140.14 3.84 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.793 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.999 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.6 mm -109.42 148.67 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.279 -0.888 . . . . 0.0 109.309 -178.345 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.644 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -133.33 122.6 24.07 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.989 -178.842 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.139 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 175.25 -61.86 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.078 -1.014 . . . . 0.0 109.552 178.134 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.139 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.3 Cg_endo -79.17 68.49 8.27 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.209 1.939 . . . . 0.0 109.699 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.634 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.0 OUTLIER -15.42 -64.03 0.03 OUTLIER Pre-proline 0 N--CA 1.506 2.327 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.83 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.634 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.4 Cg_endo -78.52 73.39 5.9 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 C-N-CA 121.774 1.65 . . . . 0.0 111.202 -179.513 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 30' ' ' PRO . 2.8 t -96.41 136.64 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.894 -1.129 . . . . 0.0 109.656 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.5 t -115.89 -15.33 11.25 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.48 -0.763 . . . . 0.0 109.331 179.01 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.6 149.43 0.48 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.311 -0.868 . . . . 0.0 109.667 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.624 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -136.93 139.68 41.73 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.59 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.61 ' O ' HG23 ' A' ' 69' ' ' VAL . 10.2 mtm-85 -93.33 109.04 20.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.138 -0.976 . . . . 0.0 109.136 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.977 ' CH2' HD11 ' A' ' 27' ' ' ILE . 18.7 m95 -93.85 179.81 5.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.918 -1.114 . . . . 0.0 109.621 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.489 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.76 106.61 3.41 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.328 -1.731 . . . . 0.0 106.328 177.369 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 1.014 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.7 m-30 -81.37 -66.44 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 118.451 -1.3 . . . . 0.0 111.37 -176.892 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.11 -4.91 59.03 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.1 p30 -90.41 23.71 2.86 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.335 -1.097 . . . . 0.0 109.164 179.34 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 122.56 -38.11 2.64 Favored Glycine 0 C--N 1.298 -1.576 0 N-CA-C 106.129 -2.788 . . . . 0.0 106.129 -176.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.77 101.52 12.96 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 177.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.489 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.38 -98.28 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 0.0 109.958 -178.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -56.92 150.1 17.33 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.286 0.565 . . . . 0.0 109.927 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 1.014 HG21 ' CE1' ' A' ' 40' ' ' PHE . 70.8 t -138.9 132.97 40.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.47 -0.769 . . . . 0.0 110.591 -178.627 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -112.89 89.8 3.18 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.283 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.686 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -92.84 152.53 19.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.373 -0.829 . . . . 0.0 111.423 -178.135 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.72 150.2 23.75 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.624 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.08 -156.4 0.49 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.24 -1.944 . . . . 0.0 108.24 -179.27 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.415 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.1 Cg_endo -88.43 42.63 0.7 Allowed 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.122 1.881 . . . . 0.0 110.479 178.436 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.686 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -146.87 144.38 29.24 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.072 -1.642 . . . . 0.0 112.009 -179.089 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 49' ' ' ALA . . . -149.54 -169.6 3.42 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.599 ' HB3' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -152.64 138.8 18.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.249 -0.907 . . . . 0.0 109.174 179.558 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.815 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 3.6 m-70 -102.91 135.45 44.57 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.231 -0.918 . . . . 0.0 111.101 -178.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.439 ' H ' ' HG2' ' A' ' 57' ' ' ARG . 2.0 ptp180 -100.44 95.06 6.49 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.022 ' CE2' HG11 ' A' ' 83' ' ' VAL . 23.8 m-85 -95.5 120.24 35.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.225 -0.922 . . . . 0.0 109.232 -179.232 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.6 p -118.17 -29.71 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.241 -0.912 . . . . 0.0 111.165 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.405 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -90.71 143.35 28.82 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 120.619 -1.3 . . . . 0.0 109.376 -179.678 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.405 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.0 Cg_endo -76.26 133.04 14.34 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.575 2.183 . . . . 0.0 110.281 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.59 -135.05 5.93 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 -179.616 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -127.27 164.51 21.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -1.193 . . . . 0.0 109.651 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.65 ' HB2' HG13 ' A' ' 83' ' ' VAL . 59.7 m-85 -142.98 152.84 42.39 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.466 -0.771 . . . . 0.0 109.205 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -112.99 130.37 56.16 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.774 HG13 ' CE1' ' A' ' 56' ' ' HIS . 59.2 t -116.0 150.58 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 110.821 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.79 155.51 42.42 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.85 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.064 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.53 158.57 44.31 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.853 -1.155 . . . . 0.0 111.518 -179.538 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -129.84 127.17 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.423 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 1.011 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.3 OUTLIER -89.07 141.87 28.12 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 120.656 -1.277 . . . . 0.0 109.015 -178.743 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.3 110.48 11.56 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.589 -1.245 . . . . 0.0 109.698 178.425 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.925 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.9 mp -105.49 -11.1 16.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.072 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.66 -49.62 0.83 Allowed Glycine 0 N--CA 1.486 2.011 0 N-CA-C 107.669 -2.173 . . . . 0.0 107.669 -178.128 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.44 -5.76 11.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.58 -0.953 . . . . 0.0 109.884 178.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -140.04 162.5 26.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.478 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.8 p -151.44 -179.23 7.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.306 -1.114 . . . . 0.0 109.579 -179.598 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 1.011 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -154.17 166.39 33.25 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.2 mt -119.93 132.75 55.62 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.068 -1.02 . . . . 0.0 110.227 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.064 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -117.4 157.14 26.7 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.524 -0.735 . . . . 0.0 109.769 -179.879 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.65 95.12 0.11 Allowed Glycine 0 N--CA 1.485 1.938 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.612 HG22 HD23 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -116.38 -173.33 2.35 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.232 -1.158 . . . . 0.0 109.937 179.932 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -150.74 153.7 36.0 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.435 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.022 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.0 154.25 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.66 -1.275 . . . . 0.0 109.845 -179.519 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLN . . . . . 0.425 ' N ' HG23 ' A' ' 83' ' ' VAL . 12.0 tt0 -123.07 99.81 6.56 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.464 -0.773 . . . . 0.0 108.985 179.073 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.778 HG21 ' HB3' ' A' ' 58' ' ' TYR . 41.6 t -86.15 137.71 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.24 -0.912 . . . . 0.0 109.846 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -113.15 154.41 26.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.101 -0.999 . . . . 0.0 109.667 179.711 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.736 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.886 HG22 ' HB3' ' A' ' 28' ' ' ALA . 0.8 OUTLIER -71.47 149.87 45.44 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.178 -0.951 . . . . 0.0 109.253 -179.427 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.756 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.0 mp -92.29 98.28 11.41 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.315 -178.555 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.64 HG21 ' CE1' ' A' ' 26' ' ' HIS . 11.1 t -108.81 101.3 12.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 120.873 -1.142 . . . . 0.0 108.273 178.371 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.555 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -115.64 75.49 0.26 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.459 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.512 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 32.8 Cg_endo -72.63 148.7 47.78 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.59 2.194 . . . . 0.0 111.694 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.507 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 54.3 t60 159.11 -35.63 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.659 0.742 . . . . 0.0 109.003 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.81 -141.52 15.25 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 108.437 -1.865 . . . . 0.0 108.437 -179.226 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -77.2 149.19 27.95 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 122.288 1.992 . . . . 0.0 109.434 179.106 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 1.013 HD21 ' HB2' ' A' ' 23' ' ' ALA . 1.4 mt -117.74 117.51 29.53 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.161 -0.962 . . . . 0.0 109.888 -179.39 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.429 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -94.06 168.77 10.73 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.137 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.572 ' H ' ' HB3' ' A' ' 87' ' ' ALA . 2.2 t -56.79 118.72 5.19 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.25 -0.906 . . . . 0.0 109.01 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.63 43.22 6.19 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.22 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.429 ' HB2' ' O ' ' A' ' 18' ' ' ALA . 7.9 tp-100 -111.6 150.77 29.6 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.42 -1.047 . . . . 0.0 110.869 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.783 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.1 tm? -111.52 102.68 11.0 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.573 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 1.013 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -86.68 156.34 20.02 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.512 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -118.97 108.78 15.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.367 -1.458 . . . . 0.0 108.474 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.684 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.2 m-85 -96.02 168.18 10.78 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 122.428 1.109 . . . . 0.0 112.394 -177.343 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.64 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.0 142.44 5.13 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.808 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.815 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -107.42 156.95 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 120.88 -1.138 . . . . 0.0 109.34 -178.467 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.886 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -134.76 120.6 19.62 Favored 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 118.738 -1.185 . . . . 0.0 112.472 -178.639 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.055 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.56 -71.85 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.211 -0.931 . . . . 0.0 109.263 177.663 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.055 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -76.27 78.24 3.3 Favored 'Trans proline' 0 C--N 1.313 -1.312 0 C-N-CA 121.766 1.644 . . . . 0.0 109.465 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.52 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -35.47 -54.0 1.25 Allowed Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.859 -0.526 . . . . 0.0 111.768 -179.145 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.582 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.1 Cg_endo -78.74 60.85 7.84 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.192 1.928 . . . . 0.0 111.819 -179.407 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.997 HG23 ' O ' ' A' ' 30' ' ' PRO . 55.6 t -89.51 145.28 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 120.798 -1.189 . . . . 0.0 109.358 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.7 t -116.63 -31.97 5.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.306 -0.871 . . . . 0.0 109.914 179.506 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.0 138.71 14.17 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.322 -0.861 . . . . 0.0 109.152 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.904 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.1 t -124.19 151.93 43.48 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.795 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.566 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -118.22 101.43 8.2 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.206 -0.934 . . . . 0.0 108.921 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.684 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 25.9 m95 -87.88 -179.59 6.27 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.124 -0.985 . . . . 0.0 109.162 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.405 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.8 OUTLIER -148.96 101.7 3.19 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 177.834 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.975 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.6 m-30 -80.35 -59.92 2.52 Favored 'General case' 0 C--N 1.301 -1.503 0 C-N-CA 119.028 -1.069 . . . . 0.0 110.111 -177.857 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.1 19.72 49.33 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -178.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -109.06 -104.71 0.36 Allowed 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 178.569 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -80.33 -21.03 65.59 Favored Glycine 0 N--CA 1.479 1.507 0 N-CA-C 107.852 -2.099 . . . . 0.0 107.852 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.16 130.17 30.69 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.347 -1.09 . . . . 0.0 109.557 179.549 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.405 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.2 -85.01 0.1 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.983 -1.073 . . . . 0.0 109.668 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -57.64 150.61 18.99 Favored 'General case' 0 N--CA 1.493 1.711 0 CA-C-O 121.132 0.492 . . . . 0.0 109.684 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.975 HG21 ' CE1' ' A' ' 40' ' ' PHE . 32.5 t -137.1 112.33 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 O-C-N 121.288 -0.882 . . . . 0.0 111.03 -178.797 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -96.09 95.75 8.39 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.42 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.904 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -107.63 171.37 7.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.455 -0.778 . . . . 0.0 111.06 -178.548 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.06 153.18 21.82 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.802 -0.561 . . . . 0.0 109.702 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.571 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.61 -156.42 0.59 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.776 -1.729 . . . . 0.0 108.776 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -88.45 41.75 0.63 Allowed 'Trans proline' 0 C--N 1.294 -2.298 0 C-N-CA 122.201 1.934 . . . . 0.0 110.277 178.746 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.599 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -142.8 152.88 42.7 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 119.933 -1.729 . . . . 0.0 112.508 -178.794 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.634 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -175.7 154.41 1.56 Allowed 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.469 ' CB ' HD11 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -113.34 161.83 16.79 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.742 -1.224 . . . . 0.0 110.327 -179.744 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.811 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 1.6 m-70 -113.11 141.2 47.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.506 -0.746 . . . . 0.0 110.578 -179.228 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.03 93.28 4.18 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.084 ' CE2' HG11 ' A' ' 83' ' ' VAL . 39.6 m-85 -95.91 133.56 39.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.024 -1.047 . . . . 0.0 109.553 -179.143 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 58.5 t -116.31 -41.65 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.319 -0.863 . . . . 0.0 111.029 -178.601 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.42 ' HA ' ' HD3' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -87.64 145.52 37.28 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.607 -1.308 . . . . 0.0 109.768 -179.117 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 60' ' ' LEU . 34.6 Cg_endo -78.39 129.66 9.56 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 122.551 2.167 . . . . 0.0 110.232 179.379 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.88 -136.91 5.28 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 3.5 mtp180 -131.51 126.3 34.6 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -1.173 . . . . 0.0 109.739 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.566 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 44.8 m-85 -110.62 158.81 18.17 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.217 -0.927 . . . . 0.0 109.393 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.465 ' CD2' HG22 ' A' ' 67' ' ' THR . 70.4 t60 -111.02 132.12 54.49 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.76 HG22 ' CE1' ' A' ' 56' ' ' HIS . 67.5 t -114.23 152.13 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.272 -0.892 . . . . 0.0 110.352 -179.092 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.465 HG22 ' CD2' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -147.88 158.84 44.24 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.707 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.109 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -154.71 120.44 5.15 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 120.871 -1.143 . . . . 0.0 111.679 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.539 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.5 p -112.68 110.91 33.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 177.609 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.842 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.9 146.75 24.74 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.755 -1.216 . . . . 0.0 109.441 -178.944 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -125.52 116.06 21.19 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.24 -0.912 . . . . 0.0 109.206 178.637 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.731 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -103.43 -13.75 16.51 Favored 'General case' 0 C--N 1.292 -1.906 0 CA-C-O 121.53 0.681 . . . . 0.0 109.33 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.56 -49.7 0.83 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.07 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -118.19 -5.76 10.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.674 -0.898 . . . . 0.0 109.857 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -143.03 161.49 27.56 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.431 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 3.2 p -151.45 168.82 23.68 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.291 -1.123 . . . . 0.0 109.362 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.842 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -140.69 136.1 32.29 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.13 -0.981 . . . . 0.0 109.066 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 13.6 mt -101.78 133.46 46.49 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.308 -0.87 . . . . 0.0 110.269 -179.182 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.109 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -122.13 156.16 34.23 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.593 -0.692 . . . . 0.0 109.952 -179.335 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.514 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -161.68 88.66 0.11 Allowed Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.564 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.696 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -105.82 -175.35 2.77 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.937 -1.331 . . . . 0.0 110.289 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -150.83 143.48 24.44 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.274 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.084 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -129.07 149.13 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 120.779 -1.201 . . . . 0.0 110.059 -179.43 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 72.2 mt-30 -114.7 98.7 7.01 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.462 -0.774 . . . . 0.0 108.97 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.794 HG21 ' HB3' ' A' ' 58' ' ' TYR . 96.4 t -83.74 144.65 9.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.087 -1.008 . . . . 0.0 109.945 -179.456 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -126.58 -154.87 0.65 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.489 -0.757 . . . . 0.0 109.343 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.572 ' HB3' ' H ' ' A' ' 19' ' ' SER . . . . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.454 -0.779 . . . . 0.0 110.579 179.35 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.691 ' HB3' ' CG2' ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.862 HG22 ' HB3' ' A' ' 28' ' ' ALA . 0.6 OUTLIER -70.06 149.48 47.61 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.219 -0.926 . . . . 0.0 109.346 -179.229 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 10' ' ' LEU . 4.2 mp -83.59 110.42 18.23 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.902 -178.446 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.668 HG21 ' CE1' ' A' ' 26' ' ' HIS . 0.5 OUTLIER -124.65 101.52 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 120.753 -1.217 . . . . 0.0 109.216 179.116 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.625 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.88 76.12 0.28 Allowed Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.588 ' O ' ' HB2' ' A' ' 14' ' ' HIS . 35.1 Cg_endo -72.9 149.7 47.9 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.774 2.316 . . . . 0.0 112.778 -179.464 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.588 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 152.25 175.28 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.908 0 CA-C-N 114.85 -1.068 . . . . 0.0 108.388 178.743 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.99 -141.6 2.11 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -76.91 150.06 29.8 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 122.123 1.882 . . . . 0.0 109.552 179.39 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 1.018 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.6 mm? -99.75 85.01 3.01 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.122 -0.986 . . . . 0.0 108.867 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -82.32 166.13 19.76 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.104 -0.997 . . . . 0.0 108.664 179.702 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.1 t -54.83 117.32 3.31 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.408 -0.808 . . . . 0.0 109.123 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.17 43.21 5.69 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 -179.356 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.613 ' HG2' HD13 ' A' ' 17' ' ' LEU . 19.6 tp60 -112.54 145.82 39.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.448 -1.031 . . . . 0.0 110.696 -179.116 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.648 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.3 tm? -106.51 93.95 4.87 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.254 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 1.018 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -76.88 159.05 30.34 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.077 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.541 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.53 118.2 28.69 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.132 -1.605 . . . . 0.0 108.004 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.754 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 8.3 m-85 -103.95 174.65 5.78 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 122.705 1.24 . . . . 0.0 112.592 -176.682 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.668 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.1 OUTLIER -174.93 149.52 1.14 Allowed 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 177.992 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.871 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -113.98 156.33 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.806 -1.184 . . . . 0.0 108.63 -178.258 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.862 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -129.95 121.16 26.05 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.704 -1.247 . . . . 0.0 112.559 -178.001 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.043 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 170.88 -72.36 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.406 -0.808 . . . . 0.0 108.955 177.685 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.043 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.7 Cg_endo -77.09 78.82 3.31 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 C-N-CA 121.616 1.544 . . . . 0.0 108.593 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.72 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 13.0 mt -40.51 -50.36 6.85 Favored Pre-proline 0 N--CA 1.497 1.891 0 O-C-N 121.782 -0.574 . . . . 0.0 111.653 -178.553 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.72 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 36.8 Cg_endo -80.99 60.05 7.71 Favored 'Trans proline' 0 C--N 1.315 -1.185 0 C-N-CA 122.024 1.816 . . . . 0.0 112.001 -179.282 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.904 HG23 ' O ' ' A' ' 30' ' ' PRO . 38.7 t -90.94 147.82 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 120.708 -1.245 . . . . 0.0 109.288 179.006 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.12 -30.57 6.62 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.334 -0.854 . . . . 0.0 110.171 179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.36 145.06 18.85 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.245 -0.909 . . . . 0.0 109.334 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.829 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.3 t -129.22 158.72 38.23 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.533 ' O ' HG23 ' A' ' 69' ' ' VAL . 2.9 mtm-85 -123.12 101.67 7.53 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.298 -0.877 . . . . 0.0 108.895 179.546 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.754 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 37.6 m95 -89.17 178.66 6.31 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.124 -0.985 . . . . 0.0 109.619 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.463 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.33 102.34 3.06 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 177.515 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.992 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.2 m-30 -79.66 -60.03 2.51 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 118.794 -1.162 . . . . 0.0 109.76 -177.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.13 18.32 47.06 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.42 -103.32 0.32 Allowed 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 178.655 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.64 -20.26 60.27 Favored Glycine 0 C--N 1.297 -1.618 0 N-CA-C 107.805 -2.118 . . . . 0.0 107.805 176.746 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 12.9 p -135.91 130.06 33.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.353 -1.086 . . . . 0.0 109.342 179.421 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.49 -85.37 0.1 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.047 -1.033 . . . . 0.0 109.877 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.1 pm0 -56.07 152.05 11.12 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.303 0.573 . . . . 0.0 110.306 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.992 HG21 ' CE1' ' A' ' 40' ' ' PHE . 26.1 t -140.8 121.87 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 111.047 -179.004 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 62.1 m-20 -104.58 107.81 18.94 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.829 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -120.99 170.87 9.09 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.055 -1.028 . . . . 0.0 111.092 -178.475 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.48 152.4 20.05 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.648 -0.657 . . . . 0.0 109.643 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.545 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.51 -156.08 0.61 Allowed Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.842 -1.703 . . . . 0.0 108.842 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -88.83 40.79 0.54 Allowed 'Trans proline' 0 C--N 1.297 -2.151 0 C-N-CA 122.244 1.963 . . . . 0.0 110.24 178.383 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.595 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -140.0 157.59 45.42 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 119.936 -1.727 . . . . 0.0 112.307 -178.681 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.48 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -171.59 -167.67 0.53 Allowed 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.506 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.504 ' O ' ' CZ ' ' A' ' 40' ' ' PHE . 0.0 OUTLIER -146.74 175.99 10.2 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.096 -1.003 . . . . 0.0 109.186 179.29 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.648 ' O ' HD22 ' A' ' 22' ' ' LEU . 4.6 m80 -133.92 132.95 40.85 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.927 -1.108 . . . . 0.0 110.408 -179.139 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.53 89.17 2.92 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.071 ' CE2' HG11 ' A' ' 83' ' ' VAL . 32.7 m-85 -92.41 126.85 37.67 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.206 -0.934 . . . . 0.0 109.122 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 9.8 p -114.44 -28.41 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.407 -0.808 . . . . 0.0 111.514 -178.356 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.416 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -98.63 145.86 30.63 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 120.512 -1.367 . . . . 0.0 109.429 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.563 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.1 Cg_endo -77.36 119.28 4.89 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 122.383 2.055 . . . . 0.0 109.814 179.638 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 161.49 -162.14 33.65 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.619 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -107.09 130.17 54.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.221 -1.164 . . . . 0.0 110.12 -179.756 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.563 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 73.1 m-85 -112.87 161.1 17.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.465 -0.772 . . . . 0.0 109.07 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 70.0 t60 -115.23 122.22 45.33 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.462 -0.774 . . . . 0.0 109.069 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.576 HG22 ' NE2' ' A' ' 56' ' ' HIS . 66.1 t -102.74 152.01 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.38 -0.825 . . . . 0.0 109.899 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.57 158.52 44.25 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 178.855 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.059 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.51 156.67 42.35 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.92 -1.113 . . . . 0.0 110.989 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.533 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -147.07 104.68 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.385 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 179.224 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.805 ' CD1' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.84 150.44 22.9 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.734 -1.229 . . . . 0.0 109.703 -179.181 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.45 117.04 20.66 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.588 -0.845 . . . . 0.0 109.309 178.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.538 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.2 mp -105.36 -13.13 15.75 Favored 'General case' 0 C--N 1.293 -1.881 0 CA-C-O 121.52 0.676 . . . . 0.0 109.239 179.69 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.33 -56.21 0.59 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -114.63 -7.25 12.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.576 -0.955 . . . . 0.0 109.759 179.145 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -137.47 161.13 25.29 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.422 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.0 p -151.2 170.06 20.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.411 -1.053 . . . . 0.0 109.409 -179.724 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.805 ' HB3' ' CD1' ' A' ' 70' ' ' LEU . . . -144.16 126.63 15.9 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.882 . . . . 0.0 109.198 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -95.25 152.14 18.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.224 -0.923 . . . . 0.0 110.639 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.059 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -135.7 158.53 44.17 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.747 -0.596 . . . . 0.0 109.472 179.878 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.544 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.96 88.54 0.1 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.542 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -110.83 -171.91 1.92 Allowed 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.05 -1.265 . . . . 0.0 109.965 -179.893 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -149.54 149.56 30.9 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.071 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -132.29 138.29 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.76 -1.213 . . . . 0.0 110.056 -179.654 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.46 83.33 2.43 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.408 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.84 HG21 ' HB3' ' A' ' 58' ' ' TYR . 53.4 t -72.62 134.3 30.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.148 -0.97 . . . . 0.0 109.627 -179.418 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -110.77 -179.1 3.65 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.386 -0.821 . . . . 0.0 109.643 -179.592 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.563 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.919 . . . . 0.0 109.185 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.731 ' HB3' ' CG2' ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.843 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.2 t -75.44 155.83 35.89 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.199 -0.938 . . . . 0.0 108.873 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.992 ' HB3' HD11 ' A' ' 79' ' ' LEU . 0.0 OUTLIER -96.8 90.96 5.45 Favored 'General case' 0 N--CA 1.49 1.553 0 C-N-CA 119.961 -0.696 . . . . 0.0 110.141 -178.854 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.637 HG21 ' CE1' ' A' ' 26' ' ' HIS . 25.3 t -93.96 96.23 5.88 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.618 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -114.74 75.69 0.25 Allowed Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.716 -1.231 . . . . 0.0 110.545 -178.692 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.584 ' HD3' HG12 ' A' ' 11' ' ' VAL . 32.7 Cg_endo -73.01 149.38 46.7 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.5 2.133 . . . . 0.0 111.494 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.582 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 69.6 t60 163.16 -37.5 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 CA-C-O 121.771 0.796 . . . . 0.0 109.06 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.77 -137.62 13.49 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.133 -1.987 . . . . 0.0 108.133 -178.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.25 147.08 25.68 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 C-N-CA 122.138 1.892 . . . . 0.0 109.351 178.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.955 HD21 ' HB2' ' A' ' 23' ' ' ALA . 12.1 mt -113.15 85.85 2.26 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.264 -0.897 . . . . 0.0 109.967 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.56 160.78 32.1 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.9 t -54.41 123.47 13.08 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.237 -0.914 . . . . 0.0 109.466 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.47 48.41 4.53 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.444 ' HB3' HD23 ' A' ' 17' ' ' LEU . 19.9 mm-40 -123.94 150.83 44.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.434 -1.039 . . . . 0.0 110.313 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.623 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.3 tm? -108.48 93.26 4.43 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.829 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.955 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -76.42 155.75 33.72 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.544 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.49 121.09 37.72 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.689 -1.257 . . . . 0.0 108.426 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.789 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.2 m-85 -108.33 171.07 7.62 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-O 122.204 1.002 . . . . 0.0 111.397 -177.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.637 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -168.64 135.79 1.96 Allowed 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 177.803 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.731 ' CG2' ' HB3' ' A' ' 8' ' ' ALA . 0.1 OUTLIER -101.48 149.64 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.882 -1.136 . . . . 0.0 108.692 -178.509 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.843 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -128.75 126.71 40.56 Favored 'General case' 0 N--CA 1.5 2.068 0 C-N-CA 118.775 -1.17 . . . . 0.0 112.501 -177.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.029 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 169.18 -69.6 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.532 -0.73 . . . . 0.0 109.081 177.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.029 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.8 Cg_endo -76.96 79.59 3.08 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 121.654 1.569 . . . . 0.0 109.144 179.061 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.515 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -34.89 -54.34 1.02 Allowed Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.989 -0.444 . . . . 0.0 112.004 -178.921 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.535 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.5 Cg_endo -79.48 69.4 7.95 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.23 1.954 . . . . 0.0 111.775 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.943 HG23 ' O ' ' A' ' 30' ' ' PRO . 47.8 t -98.34 148.24 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.834 -1.166 . . . . 0.0 109.327 179.018 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 24.3 p -119.14 -29.15 5.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.307 -0.871 . . . . 0.0 110.26 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -159.29 145.05 16.17 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.221 -0.924 . . . . 0.0 109.619 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.792 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -130.75 151.44 51.18 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.52 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.7 OUTLIER -120.56 104.73 10.18 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.202 -0.936 . . . . 0.0 108.713 179.173 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.789 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 37.5 m95 -89.6 -178.6 5.59 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-O 122.079 0.942 . . . . 0.0 109.432 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.69 ' CB ' HG23 ' A' ' 67' ' ' THR . 0.3 OUTLIER -150.45 101.03 2.93 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 106.329 -1.73 . . . . 0.0 106.329 177.45 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.964 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.3 m-30 -80.37 -56.08 4.44 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.121 -177.705 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.6 20.41 54.25 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.133 -1.587 . . . . 0.0 109.133 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.566 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 1.1 p30 -104.25 -104.48 0.3 Allowed 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 178.671 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.24 -15.91 68.15 Favored Glycine 0 C--N 1.296 -1.646 0 N-CA-C 107.754 -2.138 . . . . 0.0 107.754 176.571 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.7 p -138.29 130.97 29.39 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.489 -1.007 . . . . 0.0 108.892 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.408 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.74 -85.4 0.09 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.941 -1.099 . . . . 0.0 109.752 -179.602 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -57.16 154.09 10.68 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.332 0.587 . . . . 0.0 110.121 -179.694 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.964 HG21 ' CE1' ' A' ' 40' ' ' PHE . 52.6 t -140.01 121.63 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.431 -0.793 . . . . 0.0 110.689 -178.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -104.21 118.97 37.93 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 178.007 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.792 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -132.75 166.06 23.1 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.031 -1.043 . . . . 0.0 111.042 -178.513 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.31 153.47 18.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.672 -0.642 . . . . 0.0 109.796 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.57 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.35 -155.93 0.39 Allowed Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -88.96 38.99 0.44 Allowed 'Trans proline' 0 C--N 1.298 -2.118 0 C-N-CA 122.544 2.163 . . . . 0.0 110.149 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.627 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -138.16 152.63 48.87 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.115 -1.616 . . . . 0.0 112.054 -178.789 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.493 ' HB2' ' NE1' ' A' ' 38' ' ' TRP . . . -163.61 -166.79 1.26 Allowed 'General case' 0 N--CA 1.494 1.775 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.469 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.572 ' OG ' HD11 ' A' ' 22' ' ' LEU . 1.4 p -158.49 141.1 14.42 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.11 -0.994 . . . . 0.0 109.79 179.392 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.844 ' CE1' HG13 ' A' ' 66' ' ' VAL . 3.6 m-70 -94.02 136.7 34.03 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.476 -0.765 . . . . 0.0 111.081 -178.791 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -110.89 87.71 2.6 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 178.396 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.092 ' CE2' HG11 ' A' ' 83' ' ' VAL . 15.1 m-85 -87.73 138.55 31.37 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.202 -0.936 . . . . 0.0 109.704 -178.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 12.0 p -129.51 -26.83 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.362 -0.836 . . . . 0.0 111.257 -178.855 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.422 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -98.36 144.6 28.38 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 120.507 -1.371 . . . . 0.0 109.718 -179.421 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.53 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.5 Cg_endo -77.64 116.39 4.04 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.55 2.167 . . . . 0.0 109.929 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 160.54 -154.78 25.84 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.93 165.41 11.56 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.022 -1.281 . . . . 0.0 109.817 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.604 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 47.2 m-85 -149.17 166.43 28.86 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 20.0 t-80 -127.88 142.18 51.34 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.317 -0.864 . . . . 0.0 108.858 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.844 HG13 ' CE1' ' A' ' 56' ' ' HIS . 30.3 t -122.64 146.0 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 120.997 -1.064 . . . . 0.0 110.712 -179.236 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.69 HG23 ' CB ' ' A' ' 39' ' ' ASP . 0.5 OUTLIER -151.44 156.28 40.32 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.541 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.004 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.92 161.17 42.82 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 120.849 -1.157 . . . . 0.0 111.128 -179.76 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.602 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.5 p -150.78 105.58 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 178.865 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.86 ' CD1' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.4 144.85 25.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.754 -1.216 . . . . 0.0 109.811 -178.845 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.455 ' C ' HD12 ' A' ' 72' ' ' LEU . . . -118.74 119.97 36.0 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.38 -0.928 . . . . 0.0 109.247 178.673 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.774 HD21 ' HB2' ' A' ' 30' ' ' PRO . 6.4 mp -114.16 -9.33 12.91 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 121.479 0.657 . . . . 0.0 109.485 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.641 ' O ' ' HB3' ' A' ' 74' ' ' ALA . . . 102.19 101.43 2.57 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 107.495 -2.242 . . . . 0.0 107.495 -178.235 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.641 ' HB3' ' O ' ' A' ' 73' ' ' GLY . . . 71.53 -0.38 3.17 Favored 'General case' 0 N--CA 1.485 1.292 0 O-C-N 121.714 -0.874 . . . . 0.0 110.372 -178.634 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -145.71 142.41 10.63 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -150.28 163.95 37.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.098 -1.236 . . . . 0.0 109.973 -179.382 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.86 ' HB3' ' CD1' ' A' ' 70' ' ' LEU . . . -132.15 119.81 21.42 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -89.75 149.69 22.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.911 . . . . 0.0 110.407 -179.202 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.004 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.2 OUTLIER -131.75 160.29 35.95 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.451 0.643 . . . . 0.0 110.103 -179.583 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.64 ' H ' HD13 ' A' ' 79' ' ' LEU . . . -169.21 92.52 0.1 OUTLIER Glycine 0 N--CA 1.483 1.814 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.613 HG22 ' HB3' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -113.07 175.39 5.46 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.034 -1.274 . . . . 0.0 109.377 179.524 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -117.68 156.17 28.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.309 -0.869 . . . . 0.0 108.851 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.092 HG11 ' CE2' ' A' ' 58' ' ' TYR . 25.1 t -137.25 139.87 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 120.983 -1.073 . . . . 0.0 110.635 -178.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -123.5 93.81 4.06 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.168 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.694 HG21 ' HB3' ' A' ' 58' ' ' TYR . 40.8 t -87.16 135.36 25.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.237 -0.914 . . . . 0.0 110.058 -179.303 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -107.66 -157.32 0.61 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.447 -0.783 . . . . 0.0 109.424 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.53 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.005 -1.059 . . . . 0.0 109.107 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.665 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.95 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.1 t -69.2 150.44 47.48 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.19 -0.944 . . . . 0.0 109.584 -178.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.752 ' N ' HD12 ' A' ' 10' ' ' LEU . 4.6 mp -83.19 107.18 15.56 Favored 'General case' 0 N--CA 1.489 1.516 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.648 -178.56 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.637 HG22 HG23 ' A' ' 9' ' ' THR . 0.4 OUTLIER -120.79 96.26 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 120.823 -1.173 . . . . 0.0 108.977 179.088 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.632 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -115.95 80.03 0.29 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.021 -1.231 . . . . 0.0 110.021 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.545 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 32.2 Cg_endo -71.94 147.58 49.73 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.513 2.142 . . . . 0.0 112.018 179.598 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.519 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 32.7 t-80 158.87 -33.98 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.08 -141.32 15.23 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -77.07 148.4 27.52 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.082 1.855 . . . . 0.0 109.209 178.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 1.005 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.4 mm? -105.59 109.89 22.02 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.111 -0.993 . . . . 0.0 109.681 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -89.18 161.17 16.61 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.2 t -57.82 116.74 3.65 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.151 -0.968 . . . . 0.0 109.389 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 89.8 44.74 4.75 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -121.22 152.87 38.33 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.252 -1.146 . . . . 0.0 110.609 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.772 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.5 tm? -107.39 99.07 8.61 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.852 -0.795 . . . . 0.0 108.852 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 1.005 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -80.34 153.71 28.21 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.545 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -116.03 125.14 52.05 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.479 -1.388 . . . . 0.0 108.081 179.411 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.752 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.6 m-85 -112.57 172.44 6.92 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 122.526 1.155 . . . . 0.0 112.285 -177.188 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.627 ' CE1' HG21 ' A' ' 11' ' ' VAL . 4.1 p80 -173.95 148.51 1.41 Allowed 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 177.175 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.886 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.21 157.51 12.05 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 120.733 -1.229 . . . . 0.0 108.599 -178.166 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.95 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -132.41 121.63 23.74 Favored 'General case' 0 N--CA 1.5 2.058 0 C-N-CA 118.698 -1.201 . . . . 0.0 112.542 -177.791 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.036 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.31 -71.54 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.402 -0.811 . . . . 0.0 108.867 177.759 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.036 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.6 Cg_endo -77.39 76.86 4.05 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 C-N-CA 121.708 1.605 . . . . 0.0 108.725 178.522 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.561 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -35.45 -55.78 1.08 Allowed Pre-proline 0 N--CA 1.497 1.921 0 O-C-N 121.956 -0.465 . . . . 0.0 111.472 -178.746 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.561 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.7 Cg_endo -80.16 75.1 5.23 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.125 1.884 . . . . 0.0 111.332 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.898 HG23 ' O ' ' A' ' 30' ' ' PRO . 20.5 t -106.03 149.22 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.024 -1.048 . . . . 0.0 109.131 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.1 p -114.59 -28.85 7.01 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.285 -0.884 . . . . 0.0 110.626 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -158.72 143.08 15.72 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.073 -1.017 . . . . 0.0 110.164 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.871 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -129.99 155.55 45.91 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.481 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.521 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 2.6 ttm180 -122.72 104.06 9.06 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.248 -0.907 . . . . 0.0 108.713 179.059 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.752 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 32.1 m95 -88.78 179.89 6.13 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.306 -0.871 . . . . 0.0 109.324 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.501 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.21 103.1 3.14 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 106.811 -1.551 . . . . 0.0 106.811 177.889 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.997 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.5 m-30 -81.16 -67.0 0.82 Allowed 'General case' 0 N--CA 1.493 1.683 0 C-N-CA 119.001 -1.079 . . . . 0.0 110.738 -177.502 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.64 7.58 56.62 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -178.666 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.6 p30 -98.34 35.6 1.75 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.415 -1.05 . . . . 0.0 108.317 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.88 -39.19 2.96 Favored Glycine 0 C--N 1.295 -1.699 0 N-CA-C 105.773 -2.931 . . . . 0.0 105.773 -176.2 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 87.7 p -107.27 101.82 11.17 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 177.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.501 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -75.58 -89.99 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -0.944 . . . . 0.0 110.189 -178.602 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -52.21 145.74 10.25 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-O 121.296 0.57 . . . . 0.0 109.884 -179.416 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.997 HG21 ' CE1' ' A' ' 40' ' ' PHE . 47.7 t -135.9 110.79 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.299 -0.875 . . . . 0.0 110.851 -178.703 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.23 107.41 19.18 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.368 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.871 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -120.02 165.79 14.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.198 -0.939 . . . . 0.0 110.98 -178.432 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.07 152.59 18.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.598 -0.689 . . . . 0.0 109.446 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.6 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.53 -156.12 0.41 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -88.97 40.99 0.54 Allowed 'Trans proline' 0 C--N 1.295 -2.242 0 C-N-CA 122.209 1.94 . . . . 0.0 110.381 178.465 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.633 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -139.52 159.26 42.57 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 119.953 -1.717 . . . . 0.0 112.509 -178.659 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.476 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -171.55 -167.05 0.48 Allowed 'General case' 0 N--CA 1.495 1.823 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.648 ' HB2' HD11 ' A' ' 22' ' ' LEU . 24.3 p -156.52 144.32 19.38 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.011 -1.056 . . . . 0.0 109.536 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.836 ' CE1' HG22 ' A' ' 66' ' ' VAL . 3.0 m-70 -102.4 146.25 28.35 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.595 0.712 . . . . 0.0 111.327 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -118.26 90.47 3.34 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 178.626 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.076 ' CE2' HG11 ' A' ' 83' ' ' VAL . 30.2 m-85 -92.63 128.76 38.6 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.067 -1.02 . . . . 0.0 110.012 -178.752 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.0 p -117.62 -27.84 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.484 -0.76 . . . . 0.0 111.108 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.478 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -101.77 146.44 32.25 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 120.561 -1.337 . . . . 0.0 109.483 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.478 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.3 Cg_endo -77.6 121.74 5.69 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 C-N-CA 122.286 1.991 . . . . 0.0 109.849 179.481 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 162.45 -163.31 35.0 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.457 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.3 OUTLIER -105.92 121.26 43.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.107 -1.231 . . . . 0.0 110.052 -179.805 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.603 ' HB2' HG13 ' A' ' 83' ' ' VAL . 64.6 m-85 -104.2 151.29 23.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 0.0 109.091 179.49 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.1 t60 -108.37 125.33 51.61 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.352 -0.842 . . . . 0.0 109.154 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.836 HG22 ' CE1' ' A' ' 56' ' ' HIS . 64.8 t -108.3 151.59 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.921 . . . . 0.0 110.185 -179.401 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.81 158.4 44.13 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.092 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -151.23 155.28 38.5 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.011 -1.056 . . . . 0.0 110.768 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.603 ' O ' HG13 ' A' ' 69' ' ' VAL . 8.1 p -148.35 108.09 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.877 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.13 149.99 22.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.818 -1.176 . . . . 0.0 109.367 -179.112 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.19 119.97 20.57 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.372 -0.931 . . . . 0.0 109.93 179.255 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.501 HD21 ' HA ' ' A' ' 33' ' ' VAL . 11.6 mt -110.86 -12.21 14.28 Favored 'General case' 0 C--N 1.295 -1.776 0 CA-C-O 121.498 0.666 . . . . 0.0 109.406 179.35 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.43 -49.65 0.86 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 -178.716 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -112.17 -7.71 14.03 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.517 -0.99 . . . . 0.0 109.71 179.084 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -145.84 153.48 25.33 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.412 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 1.7 p -150.89 169.37 21.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.191 -1.182 . . . . 0.0 109.691 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.877 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -144.2 154.02 42.69 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.394 -0.816 . . . . 0.0 108.997 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 5.1 mp -122.65 150.51 42.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.143 -0.973 . . . . 0.0 109.89 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.092 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -136.06 158.92 43.25 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.552 -0.718 . . . . 0.0 110.013 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.532 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -167.2 87.54 0.1 OUTLIER Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.768 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.644 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -107.46 -174.51 2.55 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.126 -1.22 . . . . 0.0 110.353 -179.491 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -150.88 143.0 24.09 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.246 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.076 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -128.82 145.02 36.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 120.683 -1.261 . . . . 0.0 109.636 -179.539 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -109.6 84.33 1.91 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.45 -0.781 . . . . 0.0 109.246 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.821 HG21 ' HB3' ' A' ' 58' ' ' TYR . 48.1 t -69.51 133.47 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.01 -1.056 . . . . 0.0 109.394 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -114.9 162.71 16.56 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.456 -0.777 . . . . 0.0 109.845 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.441 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.324 -0.86 . . . . 0.0 109.388 179.533 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.758 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.415 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.874 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.2 t -70.44 148.53 48.22 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.222 -0.924 . . . . 0.0 109.272 -179.367 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.1 mp -85.59 103.86 14.81 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.083 -178.547 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.746 HG21 ' CE1' ' A' ' 26' ' ' HIS . 4.7 t -117.08 104.79 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 120.772 -1.205 . . . . 0.0 108.829 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.54 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -117.77 73.99 0.29 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.544 ' HD2' ' HA ' ' A' ' 25' ' ' PHE . 35.0 Cg_endo -73.17 151.96 49.95 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.874 2.383 . . . . 0.0 112.462 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.568 ' CE1' ' HG2' ' A' ' 21' ' ' GLN . 26.8 t-80 158.52 -39.78 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.27 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.14 -137.0 13.73 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.074 -2.01 . . . . 0.0 108.074 -179.072 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.413 ' C ' HD22 ' A' ' 17' ' ' LEU . 35.3 Cg_endo -78.15 148.44 24.38 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 C-N-CA 122.152 1.901 . . . . 0.0 109.521 178.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.774 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.0 mm? -112.16 102.42 10.61 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.097 -1.002 . . . . 0.0 109.465 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.414 ' HB3' ' OE1' ' A' ' 21' ' ' GLN . . . -88.51 165.05 15.14 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.164 -0.96 . . . . 0.0 108.848 179.567 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.7 t -56.41 122.16 11.26 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.321 -0.862 . . . . 0.0 109.363 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 83.26 47.62 5.68 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.716 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.568 ' HG2' ' CE1' ' A' ' 14' ' ' HIS . 1.6 tp60 -120.26 150.66 40.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.345 -1.091 . . . . 0.0 110.622 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.717 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.3 tm? -107.27 96.67 6.58 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.774 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -79.31 156.59 27.97 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 178.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.507 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.97 117.49 27.42 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.516 -1.365 . . . . 0.0 108.094 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.767 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.8 m-85 -101.95 176.55 5.17 Favored 'General case' 0 N--CA 1.488 1.459 0 CA-C-O 122.459 1.124 . . . . 0.0 112.223 -177.004 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.746 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -174.3 143.41 0.86 Allowed 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.502 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.862 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.72 153.55 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.911 -1.118 . . . . 0.0 108.388 -179.067 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.874 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -131.62 123.43 27.86 Favored 'General case' 0 N--CA 1.501 2.101 0 C-N-CA 118.429 -1.308 . . . . 0.0 112.781 -177.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.044 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 173.3 -68.56 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.948 0 O-C-N 121.296 -0.877 . . . . 0.0 109.525 177.799 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.044 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -76.17 78.44 3.21 Favored 'Trans proline' 0 C--N 1.312 -1.395 0 C-N-CA 121.787 1.658 . . . . 0.0 109.497 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.53 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -32.86 -55.06 0.59 Allowed Pre-proline 0 N--CA 1.499 2.014 0 O-C-N 121.966 -0.459 . . . . 0.0 112.103 -179.16 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.564 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.3 Cg_endo -79.27 61.13 8.07 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 C-N-CA 122.324 2.016 . . . . 0.0 112.084 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 30' ' ' PRO . 90.2 t -85.86 152.21 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 120.593 -1.317 . . . . 0.0 109.564 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.432 ' N ' HG12 ' A' ' 33' ' ' VAL . 1.6 t -126.07 -33.14 2.69 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.489 -0.757 . . . . 0.0 109.783 179.294 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.53 140.69 15.31 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.395 -0.816 . . . . 0.0 109.296 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.867 HG23 ' HB3' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -127.5 150.78 49.52 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.666 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.499 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -116.96 103.88 10.72 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.216 -0.928 . . . . 0.0 108.788 179.257 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.767 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 33.7 m95 -89.12 -179.74 5.96 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.24 -0.912 . . . . 0.0 109.383 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.442 ' CB ' HG23 ' A' ' 67' ' ' THR . 0.2 OUTLIER -150.48 101.84 2.99 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 177.686 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.95 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.6 m-30 -79.9 -62.55 1.65 Allowed 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 118.834 -1.146 . . . . 0.0 109.992 -177.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.57 16.94 43.9 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.35 -102.95 0.32 Allowed 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -85.5 -18.33 60.52 Favored Glycine 0 C--N 1.297 -1.585 0 N-CA-C 107.872 -2.091 . . . . 0.0 107.872 176.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.5 m -135.18 126.24 27.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.455 -1.027 . . . . 0.0 108.996 179.489 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.407 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.43 -85.91 0.09 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.02 -1.05 . . . . 0.0 109.692 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -57.95 152.94 15.23 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.239 0.542 . . . . 0.0 109.679 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.95 HG21 ' CE1' ' A' ' 40' ' ' PHE . 27.5 t -139.22 118.46 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.295 -0.878 . . . . 0.0 110.943 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -101.53 101.28 11.82 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.195 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.867 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -113.2 168.61 9.58 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.265 -0.897 . . . . 0.0 111.082 -178.42 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.65 155.01 18.37 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 121.422 0.63 . . . . 0.0 109.618 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.618 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.96 -156.26 0.48 Allowed Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -88.93 40.44 0.51 Allowed 'Trans proline' 0 C--N 1.296 -2.198 0 C-N-CA 122.194 1.929 . . . . 0.0 110.356 178.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.633 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -142.06 156.64 45.41 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 119.99 -1.694 . . . . 0.0 112.357 -178.821 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.453 ' HB2' ' NE1' ' A' ' 38' ' ' TRP . . . -167.41 -168.34 1.03 Allowed 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.416 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 11.5 p -156.24 141.61 17.57 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.023 -1.048 . . . . 0.0 109.678 179.494 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.818 ' CE1' HG22 ' A' ' 66' ' ' VAL . 4.0 m-70 -99.01 143.86 28.81 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-O 121.743 0.783 . . . . 0.0 111.614 -178.328 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.536 HH21 HD21 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -114.6 90.63 3.39 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.459 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.071 ' CE2' HG11 ' A' ' 83' ' ' VAL . 37.0 m-85 -93.59 136.95 33.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.955 -1.091 . . . . 0.0 109.762 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 8.4 p -123.62 -33.12 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.283 -0.886 . . . . 0.0 111.356 -178.564 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.443 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -95.03 147.36 32.91 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 120.526 -1.359 . . . . 0.0 109.478 -179.431 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.443 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.4 Cg_endo -78.75 116.59 3.8 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.545 2.163 . . . . 0.0 109.972 179.844 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 166.68 -155.17 26.16 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.479 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 8.2 mtm-85 -115.1 123.08 48.06 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.261 -1.14 . . . . 0.0 109.715 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.573 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 62.5 m-85 -106.45 157.63 17.5 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.441 -0.787 . . . . 0.0 109.367 179.782 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 67.2 t60 -109.85 129.39 55.65 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.818 HG22 ' CE1' ' A' ' 56' ' ' HIS . 83.0 t -110.36 151.49 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.385 -0.822 . . . . 0.0 109.969 -179.439 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.442 HG23 ' CB ' ' A' ' 39' ' ' ASP . 0.2 OUTLIER -150.46 157.12 42.66 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.133 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.111 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.43 156.41 41.41 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 120.889 -1.132 . . . . 0.0 110.979 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.594 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.4 p -147.32 107.66 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.799 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -90.19 153.19 20.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.896 -1.128 . . . . 0.0 110.445 -178.39 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -131.13 117.91 19.75 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.303 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.908 HD21 ' HB2' ' A' ' 30' ' ' PRO . 6.1 mp -106.05 -12.86 15.64 Favored 'General case' 0 C--N 1.293 -1.85 0 CA-C-O 121.495 0.664 . . . . 0.0 109.29 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.15 -45.76 1.26 Allowed Glycine 0 N--CA 1.488 2.116 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -178.665 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.13 -6.76 12.48 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.59 -0.947 . . . . 0.0 109.704 179.082 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -150.02 165.23 29.76 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.35 168.75 23.83 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.246 -1.149 . . . . 0.0 109.512 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.799 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -145.14 140.68 28.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.487 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.55 HD13 ' O ' ' A' ' 68' ' ' ALA . 1.7 mm? -107.16 150.88 26.11 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.067 -1.02 . . . . 0.0 110.3 -179.453 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.111 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -134.96 158.53 44.08 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.467 -0.771 . . . . 0.0 109.842 -179.751 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.529 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -167.72 91.47 0.1 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.6 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -114.26 -171.57 1.94 Allowed 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.08 -1.247 . . . . 0.0 110.165 -179.7 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -150.15 147.96 28.37 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 179.201 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.071 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -129.86 140.81 48.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 120.617 -1.302 . . . . 0.0 110.027 -179.271 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLN . . . . . 0.464 ' HG2' ' HG2' ' A' ' 63' ' ' ARG . 0.8 OUTLIER -104.07 85.55 2.41 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.381 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.746 HG22 ' HB3' ' A' ' 17' ' ' LEU . 98.4 t -77.74 136.99 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.151 -0.968 . . . . 0.0 109.644 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -124.05 142.55 51.09 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.278 -0.889 . . . . 0.0 109.579 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.168 -0.957 . . . . 0.0 109.648 179.809 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.748 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.891 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.0 OUTLIER -73.48 149.21 42.49 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.282 -0.886 . . . . 0.0 109.209 -179.442 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.741 HD23 HG22 ' A' ' 81' ' ' THR . 5.2 mp -91.38 103.81 16.4 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.322 -178.315 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.672 HG11 ' NE2' ' A' ' 26' ' ' HIS . 3.1 t -117.12 105.47 18.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 O-C-N 120.776 -1.203 . . . . 0.0 108.782 178.633 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.542 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.93 74.17 0.3 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.504 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 35.3 Cg_endo -73.14 152.54 50.9 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.752 2.301 . . . . 0.0 111.983 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.494 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.2 t-80 163.74 -37.99 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 CA-C-O 121.698 0.761 . . . . 0.0 108.961 179.58 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.5 -136.54 13.57 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.308 -1.917 . . . . 0.0 108.308 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -78.01 149.18 25.46 Favored 'Trans proline' 0 C--N 1.304 -1.797 0 C-N-CA 122.246 1.964 . . . . 0.0 109.352 179.112 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.821 HD21 ' HB2' ' A' ' 23' ' ' ALA . 22.7 mt -120.75 93.37 4.01 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.041 -1.037 . . . . 0.0 110.102 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 86' ' ' GLU . . . -87.42 164.03 16.42 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.082 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.437 ' CB ' ' HA ' ' A' ' 87' ' ' ALA . 40.6 t -49.96 121.27 5.17 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.564 -0.71 . . . . 0.0 110.085 -179.406 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.31 47.47 4.35 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.658 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.514 ' HB3' HD23 ' A' ' 17' ' ' LEU . 4.4 mm-40 -122.4 149.57 43.64 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.23 -1.159 . . . . 0.0 110.94 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.729 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.4 tm? -108.49 98.55 8.06 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.821 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -81.93 154.63 25.68 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.504 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -117.4 121.37 40.9 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.611 -1.306 . . . . 0.0 107.981 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.754 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 7.3 m-85 -108.15 173.5 6.29 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 122.425 1.107 . . . . 0.0 112.362 -176.813 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.672 ' NE2' HG11 ' A' ' 11' ' ' VAL . 3.4 p80 -171.27 144.51 2.03 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 177.286 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.832 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.54 158.33 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.095 -1.003 . . . . 0.0 108.571 -178.578 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.891 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -136.91 122.41 19.59 Favored 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 118.445 -1.302 . . . . 0.0 112.627 -178.462 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.048 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.01 -68.24 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 121.201 -0.937 . . . . 0.0 109.595 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.048 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -76.41 78.39 3.29 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 C-N-CA 121.758 1.639 . . . . 0.0 109.374 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.523 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 3.7 mp -32.5 -54.97 0.56 Allowed Pre-proline 0 N--CA 1.499 2.019 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.908 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.559 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.7 Cg_endo -79.85 60.77 7.96 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 C-N-CA 122.249 1.966 . . . . 0.0 111.994 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.904 HG23 ' O ' ' A' ' 30' ' ' PRO . 94.2 t -84.14 149.0 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.633 -1.292 . . . . 0.0 109.708 179.283 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 31.9 p -122.11 -36.62 2.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.41 -0.806 . . . . 0.0 109.611 179.242 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -154.04 136.36 14.92 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.515 -0.741 . . . . 0.0 109.257 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.882 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.2 t -123.59 140.05 53.38 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.506 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.515 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 1.2 ttp180 -107.68 106.05 16.19 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.816 179.285 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.754 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 36.1 m95 -89.08 179.55 6.12 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.998 0.904 . . . . 0.0 109.111 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.424 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.78 100.23 2.8 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 177.445 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.989 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.7 m-30 -80.01 -59.79 2.58 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.787 -1.165 . . . . 0.0 110.011 -177.496 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.54 17.27 53.06 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -104.35 -103.75 0.31 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 178.714 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.61 -21.63 59.63 Favored Glycine 0 C--N 1.297 -1.631 0 N-CA-C 107.717 -2.153 . . . . 0.0 107.717 176.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 11.6 p -134.58 129.8 35.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.427 -1.043 . . . . 0.0 109.148 179.38 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.424 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.25 -84.22 0.11 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.074 -1.016 . . . . 0.0 109.686 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -58.78 149.27 26.92 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.153 0.501 . . . . 0.0 109.848 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.989 HG21 ' CE1' ' A' ' 40' ' ' PHE . 42.3 t -137.72 121.05 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.385 -0.822 . . . . 0.0 110.755 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 61.8 m-20 -104.17 97.26 7.25 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.221 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.882 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -107.89 166.35 10.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.251 -0.905 . . . . 0.0 111.239 -178.292 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.58 154.58 18.15 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 121.275 0.56 . . . . 0.0 109.533 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.602 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.88 -155.65 0.53 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.788 -1.725 . . . . 0.0 108.788 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -89.53 40.74 0.48 Allowed 'Trans proline' 0 C--N 1.295 -2.252 0 C-N-CA 122.256 1.971 . . . . 0.0 110.486 178.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.656 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.43 156.42 44.65 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 119.882 -1.762 . . . . 0.0 112.581 -178.744 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.459 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -168.06 -167.69 0.86 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.3 p -155.52 141.38 18.12 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.959 -1.088 . . . . 0.0 109.738 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.793 ' CE1' HG22 ' A' ' 66' ' ' VAL . 4.5 m-70 -97.98 142.83 29.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.499 -0.75 . . . . 0.0 111.442 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.517 HH21 HD21 ' A' ' 22' ' ' LEU . 0.9 OUTLIER -114.52 90.52 3.36 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.697 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.089 ' CE2' HG11 ' A' ' 83' ' ' VAL . 31.2 m-85 -94.15 122.3 36.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.11 -0.994 . . . . 0.0 109.751 -178.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.0 m -115.83 -26.02 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.487 -0.758 . . . . 0.0 111.104 -178.804 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.452 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -98.04 146.31 31.28 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 120.647 -1.283 . . . . 0.0 109.227 -179.636 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.452 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.1 Cg_endo -77.19 123.8 6.87 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 122.41 2.073 . . . . 0.0 110.018 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 156.47 -169.8 33.92 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.419 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -103.84 121.74 43.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.285 -1.127 . . . . 0.0 109.884 -179.823 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.586 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 79.9 m-85 -100.2 160.76 14.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.391 -0.818 . . . . 0.0 109.645 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -115.18 121.88 44.34 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 178.78 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.793 HG22 ' CE1' ' A' ' 56' ' ' HIS . 64.5 t -102.86 151.57 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.265 -0.897 . . . . 0.0 110.648 -179.051 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.61 160.2 43.97 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 178.427 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.08 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -153.3 157.97 40.89 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.094 -1.004 . . . . 0.0 110.695 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.617 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.2 p -147.07 107.8 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.817 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.2 OUTLIER -88.94 147.86 24.11 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.849 -1.157 . . . . 0.0 110.147 -178.043 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.47 113.88 16.08 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 121.932 0.872 . . . . 0.0 108.808 178.267 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.893 HD21 ' HB2' ' A' ' 30' ' ' PRO . 6.0 mp -103.36 -12.57 17.13 Favored 'General case' 0 C--N 1.289 -2.027 0 CA-C-O 121.553 0.692 . . . . 0.0 109.194 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 112.3 -49.84 0.82 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 -178.838 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.1 -5.66 11.92 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.577 -0.955 . . . . 0.0 109.815 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.16 160.78 27.87 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.426 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.2 p -151.04 173.31 14.48 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.398 -1.06 . . . . 0.0 109.218 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.817 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -149.88 129.63 13.25 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.261 -0.899 . . . . 0.0 109.651 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.3 tt -94.33 140.0 30.35 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.424 -0.798 . . . . 0.0 110.007 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.08 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -126.23 155.25 42.13 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.449 -0.782 . . . . 0.0 110.275 -179.336 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.472 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -162.65 87.05 0.11 Allowed Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.413 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.741 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -105.31 -175.6 2.84 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.028 -1.278 . . . . 0.0 109.633 179.904 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ASP . . . . . 0.406 ' N ' ' OG1' ' A' ' 81' ' ' THR . 0.7 OUTLIER -150.96 146.49 26.28 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 179.258 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.089 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -131.69 141.49 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 120.602 -1.311 . . . . 0.0 110.239 -179.474 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 17.9 tt0 -104.37 89.37 3.21 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.744 HG21 ' HB3' ' A' ' 58' ' ' TYR . 43.4 t -82.07 133.79 28.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.204 -0.935 . . . . 0.0 110.115 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.597 ' HG3' ' HA ' ' A' ' 18' ' ' ALA . 11.2 pt-20 -103.56 -147.97 0.39 Allowed 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.437 ' HA ' ' CB ' ' A' ' 19' ' ' SER . . . . . . . . 0 N--CA 1.489 1.508 0 O-C-N 120.952 -1.092 . . . . 0.0 109.335 179.326 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.738 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.752 HG22 ' HB3' ' A' ' 28' ' ' ALA . 0.6 OUTLIER -68.93 147.39 51.73 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.277 -0.889 . . . . 0.0 109.278 -179.147 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.767 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.0 mp -92.63 109.16 20.57 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.261 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.624 HG21 ' CE1' ' A' ' 26' ' ' HIS . 2.5 t -123.88 106.11 16.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.9 -1.125 . . . . 0.0 108.738 178.594 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.556 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.91 76.24 0.3 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.881 -1.287 . . . . 0.0 109.881 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.509 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.0 Cg_endo -73.38 150.25 46.33 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.729 2.286 . . . . 0.0 112.064 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.54 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 80.6 t60 165.84 -38.77 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.701 0 CA-C-O 121.696 0.76 . . . . 0.0 109.114 179.623 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.01 -137.63 14.29 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 108.221 -1.952 . . . . 0.0 108.221 -179.106 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.83 148.86 25.71 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 C-N-CA 122.237 1.958 . . . . 0.0 109.371 179.053 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.829 HD21 ' HB2' ' A' ' 23' ' ' ALA . 34.5 mt -118.3 100.08 7.26 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.066 -1.021 . . . . 0.0 109.987 -179.539 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.466 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -86.5 171.3 11.19 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.149 -0.969 . . . . 0.0 108.432 179.144 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 37.4 t -54.59 126.26 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.189 -0.944 . . . . 0.0 109.851 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 77.45 51.61 5.97 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.48 ' HB3' HD23 ' A' ' 17' ' ' LEU . 0.4 OUTLIER -115.55 149.78 37.65 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.392 -1.064 . . . . 0.0 110.838 -179.426 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.739 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.1 tm? -109.46 96.67 6.43 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.829 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -81.21 155.97 25.88 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.949 -1.094 . . . . 0.0 108.123 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.509 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.61 116.6 26.35 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.523 -1.361 . . . . 0.0 108.11 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.67 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 4.4 m-85 -104.53 170.38 7.92 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-O 122.319 1.057 . . . . 0.0 112.229 -176.83 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.624 ' CE1' HG21 ' A' ' 11' ' ' VAL . 4.6 p80 -167.08 149.04 6.0 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.098 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.828 HD11 ' CH2' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -112.96 161.85 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.095 -1.003 . . . . 0.0 109.216 -178.294 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.752 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -138.97 118.96 13.33 Favored 'General case' 0 N--CA 1.501 2.086 0 C-N-CA 118.629 -1.228 . . . . 0.0 112.463 -178.636 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.031 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 173.43 -68.67 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.206 -0.934 . . . . 0.0 109.634 177.688 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.031 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 33.5 Cg_endo -76.64 78.19 3.41 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 121.716 1.611 . . . . 0.0 109.362 179.616 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.506 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -33.27 -54.43 0.68 Allowed Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.946 -0.471 . . . . 0.0 112.186 -179.008 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.611 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.3 Cg_endo -79.69 58.53 7.01 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.113 1.875 . . . . 0.0 112.055 -179.296 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.911 HG23 ' O ' ' A' ' 30' ' ' PRO . 93.9 t -81.78 147.44 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 120.724 -1.235 . . . . 0.0 109.42 179.05 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 74.0 p -122.27 -37.06 2.86 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.313 -0.867 . . . . 0.0 109.614 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -154.34 136.34 14.64 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.847 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.5 t -123.11 150.07 43.69 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.581 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.7 OUTLIER -115.54 103.44 10.74 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.351 -0.94 . . . . 0.0 108.847 179.155 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.828 ' CH2' HD11 ' A' ' 27' ' ' ILE . 31.7 m95 -87.66 179.13 6.57 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.158 -0.964 . . . . 0.0 109.113 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.509 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.5 OUTLIER -149.03 103.08 3.31 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 177.835 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 1.029 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.4 m-30 -81.13 -63.72 1.34 Allowed 'General case' 0 N--CA 1.491 1.597 0 C-N-CA 118.83 -1.148 . . . . 0.0 110.275 -177.782 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.59 7.05 62.0 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.152 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.501 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 13.6 p30 -98.79 31.15 3.04 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.324 -1.103 . . . . 0.0 108.647 179.367 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 117.94 -40.74 2.23 Favored Glycine 0 C--N 1.295 -1.742 0 N-CA-C 105.409 -3.077 . . . . 0.0 105.409 -176.18 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -106.57 100.29 9.82 Favored 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 177.5 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.513 ' O ' HG23 ' A' ' 47' ' ' VAL . . . -76.21 -89.84 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.029 -1.044 . . . . 0.0 109.943 -178.735 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -51.48 142.15 14.43 Favored 'General case' 0 N--CA 1.495 1.825 0 CA-C-O 121.287 0.565 . . . . 0.0 109.736 -179.773 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 1.029 HG21 ' CE1' ' A' ' 40' ' ' PHE . 95.8 t -134.92 113.77 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.345 -0.847 . . . . 0.0 110.813 -178.648 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -94.84 99.46 11.52 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.534 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.847 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -110.64 167.7 10.03 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.368 -0.832 . . . . 0.0 111.015 -178.656 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.33 153.65 19.14 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.695 -0.628 . . . . 0.0 109.564 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.549 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.28 -156.51 0.52 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -89.08 40.14 0.49 Allowed 'Trans proline' 0 C--N 1.294 -2.336 0 C-N-CA 122.279 1.986 . . . . 0.0 110.285 178.64 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.574 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -142.73 156.32 44.99 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.889 -1.757 . . . . 0.0 112.62 -178.525 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.509 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -170.64 -171.76 1.1 Allowed 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 179.229 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.504 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -148.98 150.2 32.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.94 -1.1 . . . . 0.0 109.637 179.494 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.82 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 2.8 m-70 -105.89 143.54 33.89 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.39 -0.819 . . . . 0.0 111.006 -178.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.431 ' NH2' HD21 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -118.16 89.4 3.12 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.709 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.111 ' CE2' HG11 ' A' ' 83' ' ' VAL . 43.0 m-85 -91.49 138.97 31.15 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.914 . . . . 0.0 109.898 -178.765 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.1 p -124.27 -35.85 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.336 -0.852 . . . . 0.0 111.355 -178.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.43 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -86.77 146.5 41.3 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 120.511 -1.368 . . . . 0.0 109.607 -179.446 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.473 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.5 Cg_endo -78.18 117.55 4.14 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 122.477 2.118 . . . . 0.0 110.013 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 162.11 -147.61 13.98 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.425 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -123.39 140.75 52.69 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.096 -1.237 . . . . 0.0 109.671 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.557 ' HB2' HG13 ' A' ' 83' ' ' VAL . 66.9 m-85 -119.98 164.37 16.19 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.322 -0.861 . . . . 0.0 109.906 -179.706 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 46.2 t-80 -115.77 127.42 55.08 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.53 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.787 HG22 ' CE1' ' A' ' 56' ' ' HIS . 66.7 t -110.06 152.48 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 110.488 -179.1 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -146.93 158.62 43.97 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.057 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -155.12 117.89 4.32 Favored 'General case' 0 N--CA 1.498 1.94 0 C-N-CA 118.885 -1.126 . . . . 0.0 111.689 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.581 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.2 p -108.49 110.43 31.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.596 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.815 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.04 154.51 20.14 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.762 -1.211 . . . . 0.0 110.038 -178.801 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.18 116.65 16.5 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.779 0.799 . . . . 0.0 108.883 178.333 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.933 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.8 mp -105.43 -12.88 15.83 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 121.539 0.685 . . . . 0.0 109.26 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.67 -44.59 1.44 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.906 -2.077 . . . . 0.0 107.906 -178.514 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -113.89 -5.82 13.21 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.557 -0.966 . . . . 0.0 109.847 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -153.63 166.06 31.69 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.43 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 1.4 p -150.9 170.79 18.46 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.272 -1.134 . . . . 0.0 109.404 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.815 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -145.72 135.02 22.97 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.271 -0.893 . . . . 0.0 109.541 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 4.1 mp -101.04 131.11 47.09 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.148 -0.97 . . . . 0.0 109.992 -179.572 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.057 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -118.11 155.17 30.86 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 121.451 -0.781 . . . . 0.0 110.208 -179.149 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -161.58 86.7 0.11 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.755 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -106.04 -172.78 2.15 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.015 -1.285 . . . . 0.0 109.888 -179.808 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -151.25 152.88 33.87 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 179.411 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.111 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.5 OUTLIER -132.77 155.48 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.781 -1.2 . . . . 0.0 109.88 -179.822 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLN . . . . . 0.437 ' N ' HG23 ' A' ' 83' ' ' VAL . 31.6 tt0 -122.17 88.27 2.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.494 -0.754 . . . . 0.0 109.231 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.672 HG22 ' HB3' ' A' ' 17' ' ' LEU . 80.0 t -81.8 139.87 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.216 -0.927 . . . . 0.0 109.613 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -117.29 170.65 8.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.291 -0.88 . . . . 0.0 109.666 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.473 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.553 0 O-C-N 121.12 -0.988 . . . . 0.0 109.352 179.638 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.996 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.686 ' CG2' ' HB3' ' A' ' 28' ' ' ALA . 0.4 OUTLIER -81.66 140.24 34.49 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 179.807 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.731 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.5 mp -100.26 100.33 11.13 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -178.246 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.774 HG12 ' HD3' ' A' ' 13' ' ' PRO . 21.8 t -113.81 116.35 52.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 120.654 -1.279 . . . . 0.0 109.177 178.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.521 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -120.87 72.58 0.35 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 108.901 -1.679 . . . . 0.0 108.901 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.774 ' HD3' HG12 ' A' ' 11' ' ' VAL . 32.5 Cg_endo -71.27 147.46 53.4 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.83 2.353 . . . . 0.0 113.069 -179.067 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.565 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 151.58 170.76 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 114.639 -1.164 . . . . 0.0 108.122 179.102 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.46 -141.34 1.15 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -76.74 151.91 32.35 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 C-N-CA 122.225 1.95 . . . . 0.0 109.464 179.255 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 1.142 HD21 ' HB2' ' A' ' 23' ' ' ALA . 51.3 mt -104.74 91.51 3.88 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.001 -1.062 . . . . 0.0 109.427 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.87 169.17 11.82 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.9 t -55.02 113.55 1.39 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.259 -0.9 . . . . 0.0 109.34 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.17 38.29 5.15 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.499 ' HG2' ' HA ' ' A' ' 17' ' ' LEU . 3.1 tp-100 -107.89 146.33 32.49 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.286 -1.126 . . . . 0.0 110.609 -179.447 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.701 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.8 tm? -108.65 94.43 5.05 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.531 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 1.142 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -77.68 158.62 29.62 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.027 -1.046 . . . . 0.0 108.266 179.238 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.534 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.92 119.3 31.14 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.566 -1.334 . . . . 0.0 107.869 179.293 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.697 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 3.1 m-85 -106.09 170.35 7.96 Favored 'General case' 0 N--CA 1.489 1.517 0 CA-C-O 121.96 0.886 . . . . 0.0 111.583 -177.006 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.625 ' CE1' HG21 ' A' ' 11' ' ' VAL . 2.3 p80 -164.66 143.65 7.03 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 107.813 -1.181 . . . . 0.0 107.813 176.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.951 HD12 ' HG ' ' A' ' 79' ' ' LEU . 6.0 mm -109.14 154.05 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.34 -0.85 . . . . 0.0 109.997 -177.805 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.686 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -136.69 113.38 10.24 Favored 'General case' 0 N--CA 1.498 1.962 0 C-N-CA 118.933 -1.107 . . . . 0.0 111.629 -179.443 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.081 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -178.39 -61.7 0.0 OUTLIER Pre-proline 0 N--CA 1.494 1.766 0 O-C-N 120.936 -1.102 . . . . 0.0 109.791 178.36 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.081 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.0 Cg_endo -80.19 63.06 8.71 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.14 1.893 . . . . 0.0 109.874 179.693 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.637 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -12.96 -64.32 0.02 OUTLIER Pre-proline 0 N--CA 1.506 2.37 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -179.101 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.637 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 35.5 Cg_endo -77.34 71.58 6.32 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 C-N-CA 121.788 1.659 . . . . 0.0 110.926 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.541 HG22 ' HG2' ' A' ' 30' ' ' PRO . 3.0 t -96.7 135.14 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 120.853 -1.155 . . . . 0.0 109.919 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.4 t -111.58 -16.72 13.2 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.414 -0.804 . . . . 0.0 109.375 178.64 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.83 150.54 0.5 Allowed 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.372 -0.83 . . . . 0.0 109.827 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.705 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -137.98 137.64 38.11 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.374 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.54 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.3 OUTLIER -89.61 104.26 16.84 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.192 -0.942 . . . . 0.0 108.7 179.555 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.915 ' CH2' HD11 ' A' ' 27' ' ' ILE . 26.1 m95 -87.65 178.73 6.68 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.906 -1.121 . . . . 0.0 109.45 -179.589 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.453 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.7 OUTLIER -149.8 102.27 3.13 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 178.359 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.986 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.1 m-30 -80.51 -58.58 3.05 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.696 -1.202 . . . . 0.0 109.966 -178.134 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.87 15.82 57.3 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.079 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -104.63 -105.72 0.3 Allowed 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 178.701 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.13 -17.41 67.17 Favored Glycine 0 C--N 1.296 -1.669 0 N-CA-C 107.982 -2.047 . . . . 0.0 107.982 177.042 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.4 m -135.88 125.42 25.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.413 -1.051 . . . . 0.0 109.042 179.6 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.24 -84.59 0.1 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.053 -1.029 . . . . 0.0 109.849 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -58.42 149.78 24.09 Favored 'General case' 0 N--CA 1.495 1.809 0 CA-C-O 121.272 0.558 . . . . 0.0 110.105 -179.685 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.986 HG21 ' CE1' ' A' ' 40' ' ' PHE . 21.1 t -139.68 128.98 28.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.26 -0.9 . . . . 0.0 111.263 -178.847 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -108.15 91.4 3.63 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 177.612 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.704 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -97.35 155.67 16.79 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.347 -0.845 . . . . 0.0 111.517 -177.796 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.56 151.01 20.38 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.778 -0.576 . . . . 0.0 109.477 179.494 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.705 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.84 -159.11 0.61 Allowed Glycine 0 N--CA 1.489 2.181 0 N-CA-C 107.997 -2.041 . . . . 0.0 107.997 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.507 ' HB3' HG21 ' A' ' 33' ' ' VAL . 37.8 Cg_endo -87.43 41.2 0.69 Allowed 'Trans proline' 0 C--N 1.297 -2.14 0 C-N-CA 122.017 1.811 . . . . 0.0 109.99 178.265 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.704 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.46 150.44 39.0 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.152 -1.592 . . . . 0.0 112.097 -178.654 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.565 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -160.02 -168.32 2.19 Favored 'General case' 0 N--CA 1.495 1.778 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 179.045 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.701 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.1 OUTLIER -152.67 154.31 35.06 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.219 -0.926 . . . . 0.0 109.09 179.491 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.794 ' CE1' HG22 ' A' ' 66' ' ' VAL . 4.6 m-70 -113.63 133.86 55.05 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.043 -1.036 . . . . 0.0 111.411 -178.63 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.75 87.17 2.61 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 178.723 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.113 ' CE2' HG11 ' A' ' 83' ' ' VAL . 31.7 m-85 -89.44 125.37 35.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.199 -0.938 . . . . 0.0 109.684 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 86.0 t -114.58 -34.52 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.428 -0.795 . . . . 0.0 110.928 -178.637 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.461 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.2 OUTLIER -90.78 145.94 33.02 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 120.542 -1.349 . . . . 0.0 109.487 -179.367 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.599 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 34.8 Cg_endo -77.66 125.52 7.58 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.44 2.093 . . . . 0.0 109.937 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.87 -154.57 25.63 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.468 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 3.9 mpt_? -114.68 133.85 55.55 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.101 -1.234 . . . . 0.0 109.65 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.609 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 82.2 m-85 -115.92 150.13 37.6 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.313 -0.867 . . . . 0.0 109.714 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.453 ' CD2' HG22 ' A' ' 67' ' ' THR . 58.9 t60 -103.95 129.63 51.52 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.482 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.794 HG22 ' CE1' ' A' ' 56' ' ' HIS . 92.0 t -111.03 155.18 12.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.255 -0.903 . . . . 0.0 110.236 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.453 HG22 ' CD2' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -149.84 158.6 44.32 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.658 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.054 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -154.04 123.47 6.58 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.752 -1.179 . . . . 0.0 111.709 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -95.89 126.59 48.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.732 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.949 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.6 OUTLIER -88.61 142.35 27.76 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 120.727 -1.233 . . . . 0.0 108.722 -178.738 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.75 110.39 11.3 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 120.739 -1.225 . . . . 0.0 109.832 178.715 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.837 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -105.39 -10.84 16.73 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.137 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.38 -45.51 1.3 Allowed Glycine 0 N--CA 1.486 2.029 0 N-CA-C 107.895 -2.082 . . . . 0.0 107.895 -178.295 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -119.84 -5.13 10.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.605 -0.938 . . . . 0.0 109.839 179.178 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.14 165.58 27.34 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 6.8 p -151.09 -176.88 5.72 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.391 -1.064 . . . . 0.0 109.741 -179.467 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.949 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -155.18 164.33 38.97 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.557 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.5 tp -120.82 119.85 33.89 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.147 -0.971 . . . . 0.0 110.067 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.054 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -105.53 156.12 18.53 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.603 -0.686 . . . . 0.0 109.392 -179.702 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.585 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.14 99.34 0.16 Allowed Glycine 0 N--CA 1.485 1.905 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.436 HG22 HD23 ' A' ' 10' ' ' LEU . 0.7 OUTLIER -115.65 -173.43 2.34 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 120.923 -1.34 . . . . 0.0 110.216 179.993 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -149.79 140.07 22.25 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.113 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -125.77 152.04 32.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.916 -1.115 . . . . 0.0 109.916 -179.455 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.74 86.44 2.52 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.864 HG21 ' HB3' ' A' ' 58' ' ' TYR . 78.8 t -77.85 140.79 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.04 -1.038 . . . . 0.0 110.355 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -114.99 -173.93 2.4 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.426 -0.797 . . . . 0.0 109.361 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.599 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.553 0 O-C-N 120.895 -1.128 . . . . 0.0 109.701 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.859 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.782 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -90.19 141.91 28.23 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.664 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.76 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.3 mp -97.05 95.33 7.71 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -178.283 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.931 HG12 ' HD3' ' A' ' 13' ' ' PRO . 47.5 t -105.65 118.12 52.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 120.894 -1.129 . . . . 0.0 109.186 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -123.75 71.42 0.43 Allowed Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.931 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.5 Cg_endo -72.81 150.81 50.42 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 123.136 2.557 . . . . 0.0 113.517 -178.915 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.588 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 145.74 179.04 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.091 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.283 178.717 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.81 -144.52 4.63 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.716 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -75.99 150.98 34.69 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.32 2.013 . . . . 0.0 109.51 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.895 HD21 ' HB2' ' A' ' 23' ' ' ALA . 17.2 mt -102.04 82.53 2.24 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.038 -1.039 . . . . 0.0 109.759 -179.578 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -75.3 165.5 25.08 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.037 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 18.1 t -58.49 114.12 2.31 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.043 -1.035 . . . . 0.0 109.187 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.54 44.28 2.98 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -120.69 155.38 33.99 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.337 -1.096 . . . . 0.0 110.879 -179.509 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.759 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.8 tm? -112.33 97.7 6.8 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.895 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -79.44 157.55 27.5 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.543 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.75 120.25 36.01 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.497 -1.377 . . . . 0.0 108.167 179.414 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.669 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 3.4 m-85 -105.16 173.55 6.26 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.987 0.899 . . . . 0.0 111.542 -177.162 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.643 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -168.26 138.7 2.61 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.06 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.96 HD12 ' HG ' ' A' ' 79' ' ' LEU . 5.0 mm -107.43 149.53 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.401 -0.812 . . . . 0.0 109.154 -178.282 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.653 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -134.42 124.56 25.88 Favored 'General case' 0 N--CA 1.502 2.156 0 C-N-CA 118.57 -1.252 . . . . 0.0 112.281 -178.755 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.025 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -178.8 -66.0 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.101 -0.999 . . . . 0.0 109.116 177.742 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.025 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.7 Cg_endo -81.01 66.71 8.81 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.056 1.838 . . . . 0.0 109.314 179.174 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.702 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -9.93 -66.56 0.01 OUTLIER Pre-proline 0 N--CA 1.513 2.688 0 N-CA-C 112.77 0.656 . . . . 0.0 112.77 -178.427 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.702 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 37.1 Cg_endo -79.35 90.52 1.26 Allowed 'Trans proline' 0 C--N 1.314 -1.261 0 C-N-CA 121.709 1.606 . . . . 0.0 110.577 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.541 HG22 ' HG2' ' A' ' 30' ' ' PRO . 8.7 t -112.59 145.62 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.948 -1.095 . . . . 0.0 109.637 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -113.7 -19.08 11.7 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.515 -0.741 . . . . 0.0 110.257 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.13 151.23 0.8 Allowed 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.094 -1.004 . . . . 0.0 110.431 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.69 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -139.1 137.96 36.64 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.382 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.525 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 7.0 ttm180 -92.61 112.67 24.7 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.145 -0.972 . . . . 0.0 108.836 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.942 ' CH2' HD11 ' A' ' 27' ' ' ILE . 17.8 m95 -95.77 -178.97 4.56 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -0.894 . . . . 0.0 109.454 -179.812 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.511 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.57 103.06 3.08 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 177.598 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 1.019 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.1 m-30 -80.84 -65.35 1.02 Allowed 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 118.896 -1.122 . . . . 0.0 110.697 -177.369 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.51 6.82 58.36 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.534 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 12.1 p30 -98.03 31.47 2.7 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.354 -1.086 . . . . 0.0 108.777 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 116.18 -39.95 2.56 Favored Glycine 0 C--N 1.295 -1.705 0 N-CA-C 105.626 -2.99 . . . . 0.0 105.626 -176.251 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 63.8 p -105.99 103.58 13.1 Favored 'General case' 0 N--CA 1.487 1.386 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 177.452 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.511 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -77.98 -88.97 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.115 -0.991 . . . . 0.0 110.429 -178.373 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -52.67 142.85 17.4 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.311 0.576 . . . . 0.0 109.992 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 1.019 HG21 ' CE1' ' A' ' 40' ' ' PHE . 90.4 t -135.67 132.61 51.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.346 -0.847 . . . . 0.0 110.953 -178.689 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -111.65 92.66 4.12 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.032 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.705 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -97.26 151.51 19.8 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.305 -0.872 . . . . 0.0 111.283 -177.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.17 150.48 23.92 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.69 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.25 -157.44 0.63 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 108.395 -1.882 . . . . 0.0 108.395 -179.168 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -87.92 39.75 0.56 Allowed 'Trans proline' 0 C--N 1.296 -2.193 0 C-N-CA 122.037 1.825 . . . . 0.0 110.128 178.564 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.705 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.13 149.38 34.91 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.124 -1.61 . . . . 0.0 112.029 -178.54 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.654 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -154.6 -167.18 2.53 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.866 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.667 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -153.89 145.47 23.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.246 -0.909 . . . . 0.0 109.016 179.448 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.83 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 3.6 m-70 -105.02 138.98 40.39 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.091 -1.006 . . . . 0.0 110.91 -178.804 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -110.07 90.16 3.23 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.889 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.123 ' CE2' HG11 ' A' ' 83' ' ' VAL . 30.9 m-85 -92.48 124.49 36.56 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 109.786 -178.792 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.4 m -119.1 -13.93 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.486 -0.759 . . . . 0.0 111.385 -178.776 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.439 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -102.7 148.41 35.49 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 120.663 -1.273 . . . . 0.0 109.618 -179.731 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.738 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 34.8 Cg_endo -78.21 116.45 3.91 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.453 2.102 . . . . 0.0 109.782 179.336 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.71 -156.92 27.38 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 2.3 ptt-85 -112.49 159.69 18.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.179 -1.189 . . . . 0.0 110.135 -179.779 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.704 ' HB2' HG13 ' A' ' 83' ' ' VAL . 87.4 m-85 -136.05 159.74 40.79 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.455 -0.778 . . . . 0.0 109.328 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -116.52 115.99 26.8 Favored 'General case' 0 N--CA 1.486 1.372 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.318 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.803 HG22 ' CE1' ' A' ' 56' ' ' HIS . 83.3 t -97.77 148.48 5.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.373 -0.83 . . . . 0.0 110.551 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.456 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 2.1 p -145.38 156.0 43.51 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 178.322 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.992 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -152.44 164.79 36.83 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.741 -1.224 . . . . 0.0 110.955 -179.494 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.442 HG12 ' HB3' ' A' ' 37' ' ' ARG . 9.5 p -139.69 129.26 29.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 N-CA-C 107.146 -1.428 . . . . 0.0 107.146 178.251 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.992 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.03 142.03 28.1 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.845 -1.159 . . . . 0.0 108.749 -178.358 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.61 107.4 9.16 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 118.585 -1.246 . . . . 0.0 109.935 178.568 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.543 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -105.39 -9.98 17.24 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.832 179.159 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.47 -49.5 0.87 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 107.734 -2.146 . . . . 0.0 107.734 -178.413 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.52 -5.91 11.19 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.626 -0.926 . . . . 0.0 109.692 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.65 154.73 23.84 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 29.7 p -149.53 -179.86 7.42 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.291 -1.123 . . . . 0.0 109.421 -179.483 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.992 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -154.79 162.9 40.94 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.622 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -116.67 131.41 56.96 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.098 -1.001 . . . . 0.0 110.128 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.992 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -115.48 157.68 23.66 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.555 -0.715 . . . . 0.0 109.717 -179.809 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.29 89.28 0.09 OUTLIER Glycine 0 N--CA 1.483 1.822 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.531 HG22 HD23 ' A' ' 10' ' ' LEU . 0.2 OUTLIER -109.14 -171.71 1.9 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.04 -1.27 . . . . 0.0 109.55 179.675 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -150.81 155.69 39.74 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 179.398 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.123 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.24 151.65 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.659 -1.276 . . . . 0.0 109.776 -179.868 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.05 85.93 2.42 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.031 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.887 HG21 ' HB3' ' A' ' 58' ' ' TYR . 47.3 t -77.52 136.71 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.791 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -123.25 141.08 52.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.425 -0.797 . . . . 0.0 109.959 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.738 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.911 . . . . 0.0 109.433 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.757 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.897 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.0 OUTLIER -73.51 148.95 42.61 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.182 -0.949 . . . . 0.0 109.157 -179.374 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.87 HD23 HG22 ' A' ' 81' ' ' THR . 5.3 mp -91.17 103.13 15.85 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.339 -178.413 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.622 HG11 ' NE2' ' A' ' 26' ' ' HIS . 2.6 t -115.38 104.54 16.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 120.928 -1.108 . . . . 0.0 108.682 178.497 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.557 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.37 76.51 0.29 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -179.348 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.527 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 31.1 Cg_endo -71.42 148.24 54.12 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.674 2.249 . . . . 0.0 111.973 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.468 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 41.4 t60 161.13 -37.19 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.3 -139.4 14.81 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 107.952 -2.059 . . . . 0.0 107.952 -179.148 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -76.66 145.78 26.29 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 122.02 1.813 . . . . 0.0 109.064 178.689 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.788 HD11 ' HB2' ' A' ' 23' ' ' ALA . 3.3 mm? -104.53 92.94 4.52 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.167 -0.958 . . . . 0.0 109.871 -179.074 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.495 ' HB3' ' HG3' ' A' ' 21' ' ' GLN . . . -74.9 160.2 30.92 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.165 -0.96 . . . . 0.0 108.515 179.104 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.622 ' H ' ' HB3' ' A' ' 87' ' ' ALA . 14.3 t -56.14 125.17 20.51 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.223 -0.923 . . . . 0.0 109.937 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 80.69 49.15 5.86 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.495 ' HG3' ' HB3' ' A' ' 18' ' ' ALA . 0.7 OUTLIER -123.4 151.82 42.21 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.35 -1.088 . . . . 0.0 110.744 -179.517 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.803 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.2 tm? -105.97 98.65 8.31 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.502 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.788 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -78.83 153.09 30.93 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.159 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.527 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -116.66 118.16 31.8 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.469 -1.395 . . . . 0.0 108.44 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.708 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 7.4 m-85 -107.79 168.35 9.33 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 122.417 1.103 . . . . 0.0 112.262 -177.183 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.622 ' NE2' HG11 ' A' ' 11' ' ' VAL . 4.1 p80 -167.92 145.52 4.36 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 176.782 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.85 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.2 161.25 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.868 -1.145 . . . . 0.0 108.906 -178.336 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.897 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -139.43 119.55 13.61 Favored 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.556 -1.258 . . . . 0.0 112.433 -178.714 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.04 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 174.24 -68.87 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 177.614 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.04 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -77.6 78.21 3.6 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 121.779 1.653 . . . . 0.0 109.34 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.49 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -33.52 -53.95 0.74 Allowed Pre-proline 0 N--CA 1.5 2.029 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -178.913 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.57 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.7 Cg_endo -79.81 58.57 7.04 Favored 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.183 1.922 . . . . 0.0 111.877 -179.283 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.94 HG23 ' O ' ' A' ' 30' ' ' PRO . 73.3 t -82.23 148.43 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 120.843 -1.16 . . . . 0.0 109.273 179.11 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.3 t -120.95 -36.79 3.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.318 -0.864 . . . . 0.0 109.661 179.007 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -152.06 139.19 19.22 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.453 -0.78 . . . . 0.0 109.156 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.89 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.2 t -127.52 134.92 49.75 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.545 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 2.8 tpp180 -104.07 104.06 13.95 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.042 -1.036 . . . . 0.0 109.174 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.708 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 29.4 m95 -87.82 -179.76 6.32 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.078 -1.014 . . . . 0.0 109.172 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -148.31 100.55 3.16 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 177.724 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.92 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.8 m-30 -80.01 -60.72 2.23 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 118.733 -1.187 . . . . 0.0 109.746 -178.122 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.98 15.93 55.27 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -178.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.25 -104.22 0.25 Allowed 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 178.485 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.08 -23.92 50.26 Favored Glycine 0 C--N 1.296 -1.649 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 176.85 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.8 m -128.62 127.69 42.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.501 -1.0 . . . . 0.0 109.04 179.426 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -81.11 -83.91 0.11 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.063 -1.023 . . . . 0.0 109.644 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -58.48 152.2 18.56 Favored 'General case' 0 N--CA 1.495 1.799 0 CA-C-O 121.222 0.534 . . . . 0.0 109.567 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.92 HG21 ' CE1' ' A' ' 40' ' ' PHE . 43.9 t -138.07 113.9 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.069 -1.019 . . . . 0.0 111.444 -178.444 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.19 105.18 17.09 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 177.873 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.89 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -118.74 168.34 10.82 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.143 -0.973 . . . . 0.0 111.042 -178.671 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.05 155.32 18.47 Favored 'General case' 0 N--CA 1.49 1.532 0 CA-C-O 121.503 0.668 . . . . 0.0 109.796 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.57 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.29 -155.42 0.64 Allowed Glycine 0 N--CA 1.488 2.159 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -89.77 40.48 0.45 Allowed 'Trans proline' 0 C--N 1.295 -2.284 0 C-N-CA 122.464 2.11 . . . . 0.0 110.484 178.66 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.58 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.75 154.09 43.1 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 119.899 -1.751 . . . . 0.0 112.658 -178.629 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.61 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -174.36 155.36 2.32 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.803 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -115.61 155.03 28.38 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.591 -1.318 . . . . 0.0 110.768 -179.766 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.789 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 2.1 m-70 -105.36 143.31 33.7 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.465 0.65 . . . . 0.0 110.791 -179.221 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -115.05 94.57 4.8 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.091 ' CE2' HG11 ' A' ' 83' ' ' VAL . 25.9 m-85 -99.1 126.98 44.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.148 -0.97 . . . . 0.0 109.747 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 8.2 m -119.46 -31.06 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.362 -0.836 . . . . 0.0 111.553 -178.497 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.519 ' HB3' ' OH ' ' A' ' 64' ' ' TYR . 0.6 OUTLIER -96.49 140.56 22.24 Favored Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 120.579 -1.325 . . . . 0.0 109.165 -179.49 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.479 ' N ' ' HG ' ' A' ' 60' ' ' LEU . 32.5 Cg_endo -73.1 135.78 23.55 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.293 1.995 . . . . 0.0 110.567 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 148.36 -140.01 8.04 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -179.538 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -129.54 137.64 50.88 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.211 -1.17 . . . . 0.0 109.61 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.578 ' HB2' HG13 ' A' ' 83' ' ' VAL . 79.0 m-85 -117.36 159.68 22.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.313 -0.867 . . . . 0.0 109.449 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 35.3 t-80 -114.13 126.27 54.9 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.838 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.753 HG22 ' CE1' ' A' ' 56' ' ' HIS . 60.1 t -108.94 151.41 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.295 -0.878 . . . . 0.0 110.559 -179.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.92 161.23 42.29 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.459 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.1 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -157.96 122.48 4.25 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.869 -1.144 . . . . 0.0 111.609 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.418 ' O ' HG13 ' A' ' 69' ' ' VAL . 2.1 p -112.96 109.15 27.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 177.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.805 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.89 147.27 24.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.787 -1.196 . . . . 0.0 109.791 -179.12 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -126.76 116.5 21.02 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.353 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.891 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.6 mp -103.53 -13.42 16.58 Favored 'General case' 0 C--N 1.292 -1.92 0 CA-C-O 121.495 0.664 . . . . 0.0 109.417 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 114.78 -51.55 0.71 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 107.9 -2.08 . . . . 0.0 107.9 -178.736 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.35 -5.73 12.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.576 -0.955 . . . . 0.0 109.894 179.148 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.3 162.98 27.88 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.778 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.7 p -151.24 169.48 21.82 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.393 -1.063 . . . . 0.0 109.59 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.805 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -142.85 136.15 28.43 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 109.463 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.5 tt -101.65 132.41 47.35 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.287 -0.883 . . . . 0.0 110.335 -179.426 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.1 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -121.06 155.01 35.34 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.561 -0.712 . . . . 0.0 110.21 -179.372 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.517 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -162.21 88.05 0.11 Allowed Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.437 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.87 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -104.98 -176.65 3.14 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.112 -1.228 . . . . 0.0 109.903 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -150.47 143.76 24.95 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.091 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -130.43 153.08 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 120.567 -1.333 . . . . 0.0 110.22 -179.331 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLN . . . . . 0.415 ' N ' HG23 ' A' ' 83' ' ' VAL . 32.4 tt0 -118.59 100.79 7.66 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.876 HG21 ' HB3' ' A' ' 58' ' ' TYR . 42.9 t -80.9 136.42 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.148 -0.97 . . . . 0.0 109.854 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -121.21 -156.61 0.69 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.619 -0.676 . . . . 0.0 109.54 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.622 ' HB3' ' H ' ' A' ' 19' ' ' SER . . . . . . . . 0 N--CA 1.487 1.406 0 O-C-N 121.484 -0.76 . . . . 0.0 110.325 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.718 ' CB ' HG22 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.432 0 CA-C-O 121.457 0.646 . . . . 0.0 109.412 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.813 HG23 HG23 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -87.3 141.04 28.94 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.857 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.754 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.4 mp -97.22 94.85 7.34 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.003 -177.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.825 HG12 ' HD3' ' A' ' 13' ' ' PRO . 41.1 t -107.1 115.99 49.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.89 -1.131 . . . . 0.0 108.568 178.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.455 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -121.98 71.78 0.39 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.363 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.825 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.4 Cg_endo -73.63 150.79 45.93 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.942 2.428 . . . . 0.0 112.036 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.537 ' CB ' ' O ' ' A' ' 13' ' ' PRO . 16.0 t-80 150.29 -39.52 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 CA-C-N 115.44 -0.8 . . . . 0.0 108.935 179.53 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 116.4 -142.97 17.88 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.49 -1.844 . . . . 0.0 108.49 -179.218 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.82 149.01 25.9 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 122.306 2.004 . . . . 0.0 109.779 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 1.02 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.4 mm? -105.2 106.74 17.37 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.181 -0.949 . . . . 0.0 109.207 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.426 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -93.44 168.72 10.87 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.01 -1.057 . . . . 0.0 108.905 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 28.1 t -56.42 120.81 8.29 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.364 -0.835 . . . . 0.0 109.045 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 80.3 44.14 9.0 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.379 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.454 ' HG2' HD13 ' A' ' 17' ' ' LEU . 23.0 tp60 -113.35 147.3 37.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.523 -0.986 . . . . 0.0 110.697 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.718 HD11 ' HB2' ' A' ' 55' ' ' SER . 1.8 tm? -108.35 96.32 6.27 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.565 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 1.02 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -78.86 156.59 28.6 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 178.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.499 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.63 108.85 14.05 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.415 -1.428 . . . . 0.0 108.224 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.734 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 2.6 m-85 -95.19 166.7 11.78 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 122.098 0.952 . . . . 0.0 111.57 -177.282 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.675 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -159.74 135.89 8.82 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 177.864 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.995 HD11 ' CH2' ' A' ' 38' ' ' TRP . 5.0 mm -108.97 152.01 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.368 -0.833 . . . . 0.0 109.526 -177.856 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.654 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -136.93 136.12 38.32 Favored 'General case' 0 N--CA 1.506 2.354 0 C-N-CA 118.439 -1.305 . . . . 0.0 113.045 -178.595 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.035 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 174.05 -71.4 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.951 0 O-C-N 121.002 -1.061 . . . . 0.0 108.963 177.352 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.035 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -79.44 72.89 6.28 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 C-N-CA 121.778 1.652 . . . . 0.0 109.13 178.486 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.623 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -13.81 -63.79 0.03 OUTLIER Pre-proline 0 N--CA 1.512 2.661 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -178.437 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.817 ' O ' HD21 ' A' ' 72' ' ' LEU . 36.4 Cg_endo -78.22 63.43 8.29 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 C-N-CA 121.889 1.726 . . . . 0.0 111.187 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.923 HG22 ' HG2' ' A' ' 30' ' ' PRO . 62.1 t -80.95 148.26 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.901 -1.124 . . . . 0.0 109.635 179.616 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 t -120.49 -18.33 7.88 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.345 -0.847 . . . . 0.0 110.648 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -176.48 139.27 0.33 Allowed 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.013 -1.055 . . . . 0.0 110.329 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.744 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -126.73 134.22 50.71 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.356 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.487 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 1.1 mtm180 -93.11 113.83 26.18 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.295 -0.878 . . . . 0.0 108.736 179.462 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.995 ' CH2' HD11 ' A' ' 27' ' ' ILE . 11.8 m95 -99.19 -179.25 4.18 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 121.976 0.893 . . . . 0.0 109.853 -179.403 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.514 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.62 103.3 3.1 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 177.245 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 1.037 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.7 m-30 -80.78 -65.14 1.05 Allowed 'General case' 0 N--CA 1.492 1.656 0 C-N-CA 118.784 -1.166 . . . . 0.0 110.809 -177.378 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.37 1.47 59.22 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -178.595 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.4 p30 -95.57 34.97 1.4 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.293 -1.122 . . . . 0.0 108.403 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.43 -36.46 4.25 Favored Glycine 0 C--N 1.296 -1.677 0 N-CA-C 105.845 -2.902 . . . . 0.0 105.845 -176.375 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.412 ' O ' ' HB2' ' A' ' 40' ' ' PHE . 18.1 m -104.05 94.05 5.18 Favored 'General case' 0 N--CA 1.487 1.375 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.057 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.49 -95.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.22 -0.925 . . . . 0.0 110.066 -178.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -52.22 146.67 8.78 Favored 'General case' 0 N--CA 1.496 1.87 0 CA-C-O 121.194 0.521 . . . . 0.0 109.879 -179.639 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 1.037 HG21 ' CE1' ' A' ' 40' ' ' PHE . 95.6 t -138.49 130.69 38.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.347 -0.846 . . . . 0.0 110.969 -178.823 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -111.37 94.71 5.11 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.799 ' CB ' ' HB2' ' A' ' 54' ' ' ALA . . . -100.45 147.9 25.35 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.226 -0.921 . . . . 0.0 111.146 -178.373 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.7 151.8 26.07 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.731 -0.605 . . . . 0.0 109.499 179.71 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.744 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.82 -156.55 0.61 Allowed Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.64 -1.784 . . . . 0.0 108.64 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -88.05 39.33 0.52 Allowed 'Trans proline' 0 C--N 1.296 -2.191 0 C-N-CA 122.406 2.071 . . . . 0.0 110.438 178.374 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.712 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.38 146.65 31.65 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 119.93 -1.731 . . . . 0.0 112.156 -178.707 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.799 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -156.15 -178.81 7.59 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 178.558 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.718 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -141.62 152.49 44.04 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.735 -1.228 . . . . 0.0 109.477 179.414 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.836 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 2.1 m-70 -108.16 138.82 43.78 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.473 -0.767 . . . . 0.0 110.618 -178.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.405 HH21 HD21 ' A' ' 22' ' ' LEU . 0.4 OUTLIER -111.95 89.71 3.14 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.972 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.056 ' CE2' HG11 ' A' ' 83' ' ' VAL . 34.5 m-85 -90.25 130.34 36.38 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.172 -0.955 . . . . 0.0 109.307 -179.172 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 9.4 p -116.58 -30.8 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.252 -0.905 . . . . 0.0 111.283 -178.451 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.438 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -100.91 146.7 32.58 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 120.703 -1.248 . . . . 0.0 109.453 -179.226 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.438 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 34.7 Cg_endo -76.91 121.46 5.86 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.255 1.97 . . . . 0.0 109.944 179.601 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 164.46 -157.05 29.28 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -112.47 120.76 42.73 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.022 -1.281 . . . . 0.0 109.986 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.506 ' HB2' HG13 ' A' ' 83' ' ' VAL . 86.4 m-85 -105.07 147.13 28.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.492 -0.755 . . . . 0.0 109.349 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -104.24 132.35 50.58 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.856 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.804 HG22 ' CE1' ' A' ' 56' ' ' HIS . 79.6 t -113.57 149.4 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.153 -0.967 . . . . 0.0 110.462 -179.128 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.5 p -148.15 153.91 39.46 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 178.875 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.109 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.94 163.03 39.67 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.946 -1.096 . . . . 0.0 110.883 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.612 ' O ' HG13 ' A' ' 69' ' ' VAL . 12.1 p -150.9 112.27 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.894 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.876 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.01 143.17 27.04 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 120.481 -1.387 . . . . 0.0 110.287 -178.205 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -122.63 117.74 26.51 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.401 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.817 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.9 OUTLIER -105.88 -13.98 15.35 Favored 'General case' 0 C--N 1.29 -2.003 0 CA-C-O 121.587 0.708 . . . . 0.0 109.388 179.866 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 110.72 -51.42 0.7 Allowed Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 -179.09 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -110.77 -6.08 14.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.6 -0.941 . . . . 0.0 109.628 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.87 160.37 28.48 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.415 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 2.0 p -150.58 164.06 36.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.247 -1.149 . . . . 0.0 109.712 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.876 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -138.47 163.71 31.25 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.446 -0.783 . . . . 0.0 109.111 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 15.3 mt -122.9 150.35 43.03 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.173 -0.954 . . . . 0.0 109.939 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.109 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -132.43 160.43 36.44 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.436 -0.79 . . . . 0.0 109.885 -179.44 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.497 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -172.14 99.82 0.15 Allowed Glycine 0 N--CA 1.485 1.965 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.603 HG22 HD23 ' A' ' 10' ' ' LEU . 1.2 p -120.85 -172.42 2.38 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.137 -1.213 . . . . 0.0 110.167 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -151.01 145.31 25.46 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.056 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.2 OUTLIER -132.64 144.23 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 120.749 -1.219 . . . . 0.0 109.906 -179.502 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -107.69 85.88 2.2 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.919 HG21 ' HB3' ' A' ' 58' ' ' TYR . 75.6 t -70.46 132.46 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.279 -0.888 . . . . 0.0 110.118 -179.254 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -114.14 -162.96 0.84 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.018 -1.051 . . . . 0.0 109.479 179.734 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.873 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.812 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.79 139.68 30.22 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.77 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.6 mp -97.19 89.55 4.81 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.148 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.941 HG12 ' HD3' ' A' ' 13' ' ' PRO . 65.3 t -99.08 112.34 30.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.885 -1.134 . . . . 0.0 109.092 179.521 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.504 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -124.1 71.18 0.44 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.941 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.4 Cg_endo -73.64 150.4 45.22 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.803 2.336 . . . . 0.0 112.153 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.468 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.9 t-80 168.9 -38.87 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.681 0.753 . . . . 0.0 109.208 179.353 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.29 -138.05 14.56 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 -178.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.62 147.0 24.57 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 121.972 1.782 . . . . 0.0 109.166 178.757 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.953 HD21 ' HB2' ' A' ' 23' ' ' ALA . 2.7 mt -117.26 98.56 6.5 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.2 -0.937 . . . . 0.0 109.779 -179.301 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.09 165.66 14.98 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 t -60.85 114.74 3.22 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.243 -0.91 . . . . 0.0 109.272 -179.839 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.68 39.52 2.72 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.84 154.58 51.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.152 -1.205 . . . . 0.0 110.015 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.717 HD12 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -115.82 128.14 55.59 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.805 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.953 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -92.69 148.37 22.12 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.252 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.533 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -105.25 121.9 44.81 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.067 -1.645 . . . . 0.0 108.04 179.012 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.815 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 5.2 m-85 -105.39 170.53 7.83 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 121.914 0.864 . . . . 0.0 111.721 -177.009 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.587 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.72 140.14 3.84 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.793 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.999 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.6 mm -109.42 148.67 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.279 -0.888 . . . . 0.0 109.309 -178.345 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.644 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -133.33 122.6 24.07 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.989 -178.842 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.139 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 175.25 -61.86 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.078 -1.014 . . . . 0.0 109.552 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.139 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.3 Cg_endo -79.17 68.49 8.27 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.209 1.939 . . . . 0.0 109.699 179.551 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.634 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.0 OUTLIER -15.42 -64.03 0.03 OUTLIER Pre-proline 0 N--CA 1.506 2.327 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.83 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.634 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.4 Cg_endo -78.52 73.39 5.9 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 C-N-CA 121.774 1.65 . . . . 0.0 111.202 -179.513 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 30' ' ' PRO . 2.8 t -96.41 136.64 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.894 -1.129 . . . . 0.0 109.656 179.338 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.5 t -115.89 -15.33 11.25 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.48 -0.763 . . . . 0.0 109.331 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.6 149.43 0.48 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.311 -0.868 . . . . 0.0 109.667 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.624 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -136.93 139.68 41.73 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.59 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.61 ' O ' HG23 ' A' ' 69' ' ' VAL . 10.2 mtm-85 -93.33 109.04 20.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.138 -0.976 . . . . 0.0 109.136 179.657 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.977 ' CH2' HD11 ' A' ' 27' ' ' ILE . 18.7 m95 -93.85 179.81 5.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.918 -1.114 . . . . 0.0 109.621 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.489 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.76 106.61 3.41 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.328 -1.731 . . . . 0.0 106.328 177.369 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 1.014 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.7 m-30 -81.37 -66.44 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 118.451 -1.3 . . . . 0.0 111.37 -176.892 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.11 -4.91 59.03 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.1 p30 -90.41 23.71 2.86 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.335 -1.097 . . . . 0.0 109.164 179.34 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 122.56 -38.11 2.64 Favored Glycine 0 C--N 1.298 -1.576 0 N-CA-C 106.129 -2.788 . . . . 0.0 106.129 -176.854 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.77 101.52 12.96 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 177.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.489 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.38 -98.28 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 0.0 109.958 -178.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -56.92 150.1 17.33 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.286 0.565 . . . . 0.0 109.927 -179.588 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 1.014 HG21 ' CE1' ' A' ' 40' ' ' PHE . 70.8 t -138.9 132.97 40.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.47 -0.769 . . . . 0.0 110.591 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -112.89 89.8 3.18 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.283 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.686 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -92.84 152.53 19.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.373 -0.829 . . . . 0.0 111.423 -178.135 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.72 150.2 23.75 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.305 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.624 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.08 -156.4 0.49 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.24 -1.944 . . . . 0.0 108.24 -179.27 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.415 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.1 Cg_endo -88.43 42.63 0.7 Allowed 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.122 1.881 . . . . 0.0 110.479 178.436 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.686 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -146.87 144.38 29.24 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.072 -1.642 . . . . 0.0 112.009 -179.089 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 49' ' ' ALA . . . -149.54 -169.6 3.42 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.89 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.599 ' HB3' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -152.64 138.8 18.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.249 -0.907 . . . . 0.0 109.174 179.558 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.815 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 3.6 m-70 -102.91 135.45 44.57 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.231 -0.918 . . . . 0.0 111.101 -178.903 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.439 ' H ' ' HG2' ' A' ' 57' ' ' ARG . 2.0 ptp180 -100.44 95.06 6.49 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 177.824 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.022 ' CE2' HG11 ' A' ' 83' ' ' VAL . 23.8 m-85 -95.5 120.24 35.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.225 -0.922 . . . . 0.0 109.232 -179.232 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.6 p -118.17 -29.71 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.241 -0.912 . . . . 0.0 111.165 -178.72 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.405 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -90.71 143.35 28.82 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 120.619 -1.3 . . . . 0.0 109.376 -179.678 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.405 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.0 Cg_endo -76.26 133.04 14.34 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.575 2.183 . . . . 0.0 110.281 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.59 -135.05 5.93 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 -179.616 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -127.27 164.51 21.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -1.193 . . . . 0.0 109.651 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.65 ' HB2' HG13 ' A' ' 83' ' ' VAL . 59.7 m-85 -142.98 152.84 42.39 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.466 -0.771 . . . . 0.0 109.205 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -112.99 130.37 56.16 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.686 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.774 HG13 ' CE1' ' A' ' 56' ' ' HIS . 59.2 t -116.0 150.58 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 110.821 -178.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.79 155.51 42.42 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.85 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.064 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.53 158.57 44.31 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.853 -1.155 . . . . 0.0 111.518 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -129.84 127.17 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.423 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 1.011 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.3 OUTLIER -89.07 141.87 28.12 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 120.656 -1.277 . . . . 0.0 109.015 -178.743 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.3 110.48 11.56 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.589 -1.245 . . . . 0.0 109.698 178.425 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.925 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.9 mp -105.49 -11.1 16.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.072 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.66 -49.62 0.83 Allowed Glycine 0 N--CA 1.486 2.011 0 N-CA-C 107.669 -2.173 . . . . 0.0 107.669 -178.128 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.44 -5.76 11.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.58 -0.953 . . . . 0.0 109.884 178.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -140.04 162.5 26.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.478 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.8 p -151.44 -179.23 7.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.306 -1.114 . . . . 0.0 109.579 -179.598 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 1.011 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -154.17 166.39 33.25 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.2 mt -119.93 132.75 55.62 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.068 -1.02 . . . . 0.0 110.227 -179.401 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.064 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -117.4 157.14 26.7 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.524 -0.735 . . . . 0.0 109.769 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.65 95.12 0.11 Allowed Glycine 0 N--CA 1.485 1.938 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.612 HG22 HD23 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -116.38 -173.33 2.35 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.232 -1.158 . . . . 0.0 109.937 179.932 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -150.74 153.7 36.0 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.435 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.022 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.0 154.25 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.66 -1.275 . . . . 0.0 109.845 -179.519 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLN . . . . . 0.425 ' N ' HG23 ' A' ' 83' ' ' VAL . 12.0 tt0 -123.07 99.81 6.56 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.464 -0.773 . . . . 0.0 108.985 179.073 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.778 HG21 ' HB3' ' A' ' 58' ' ' TYR . 41.6 t -86.15 137.71 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.24 -0.912 . . . . 0.0 109.846 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -113.15 154.41 26.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 -179.473 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.101 -0.999 . . . . 0.0 109.667 179.711 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.804 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.776 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -90.12 141.62 28.51 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.636 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.753 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.3 mp -98.01 97.96 9.36 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -178.188 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.968 HG12 ' HD3' ' A' ' 13' ' ' PRO . 47.2 t -109.69 115.92 50.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 120.875 -1.141 . . . . 0.0 109.189 179.355 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.524 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -125.67 68.68 0.51 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.968 ' HD3' HG12 ' A' ' 11' ' ' VAL . 36.7 Cg_endo -75.16 151.05 38.34 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 123.082 2.521 . . . . 0.0 112.655 -179.252 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.641 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 21.6 t60 162.61 -36.36 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.881 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.472 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.85 -138.6 14.93 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -179.377 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.8 151.74 28.31 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.42 2.08 . . . . 0.0 109.878 179.576 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.733 HD21 ' HB2' ' A' ' 23' ' ' ALA . 65.8 mt -120.87 99.74 6.69 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.113 -0.992 . . . . 0.0 109.917 -179.717 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.401 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -91.78 170.94 9.49 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.925 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.7 t -53.15 120.06 5.47 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.914 . . . . 0.0 109.818 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.74 48.3 4.5 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.472 ' HB3' ' CD2' ' A' ' 17' ' ' LEU . 1.6 mm-40 -115.78 143.81 44.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.432 -1.04 . . . . 0.0 110.449 -179.535 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.698 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.5 tm? -108.35 93.26 4.43 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.175 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.733 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -75.49 155.21 36.4 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.94 -1.1 . . . . 0.0 108.089 179.341 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.535 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.08 114.5 22.59 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.475 -1.39 . . . . 0.0 108.076 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.705 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 3.8 m-85 -100.15 174.65 6.05 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 122.135 0.969 . . . . 0.0 111.805 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.651 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -168.53 139.09 2.52 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 177.997 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 1.001 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.7 mm -107.95 149.33 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.37 -0.831 . . . . 0.0 109.063 -178.37 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.655 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -133.35 125.09 28.41 Favored 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 118.598 -1.241 . . . . 0.0 112.274 -178.572 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.089 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -179.8 -67.3 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 120.978 -1.076 . . . . 0.0 109.297 177.739 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.089 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.5 Cg_endo -79.89 69.58 7.88 Favored 'Trans proline' 0 C--N 1.314 -1.275 0 C-N-CA 121.944 1.763 . . . . 0.0 109.314 179.162 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.684 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -11.82 -66.21 0.02 OUTLIER Pre-proline 0 N--CA 1.51 2.546 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -178.707 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.684 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.6 Cg_endo -79.29 95.32 1.05 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 121.728 1.619 . . . . 0.0 110.424 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.497 HG22 ' HG2' ' A' ' 30' ' ' PRO . 5.1 t -118.06 145.01 24.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 120.866 -1.146 . . . . 0.0 109.565 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.2 t -113.15 -18.64 12.09 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.495 -0.753 . . . . 0.0 110.209 179.736 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.22 152.3 0.86 Allowed 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.049 -1.032 . . . . 0.0 110.456 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.689 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -139.05 137.04 35.9 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.428 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.472 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 4.8 ttp180 -92.78 114.2 26.69 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.07 -1.019 . . . . 0.0 108.838 179.512 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.992 ' CH2' HD11 ' A' ' 27' ' ' ILE . 15.6 m95 -97.68 -178.61 4.17 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 -179.8 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.425 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -151.37 101.99 2.87 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 177.34 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 1.013 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.9 m-30 -80.19 -61.33 2.01 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 118.756 -1.178 . . . . 0.0 110.267 -177.52 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.62 14.63 52.59 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.068 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.06 -103.05 0.25 Allowed 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.662 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -86.63 -17.15 60.58 Favored Glycine 0 C--N 1.297 -1.59 0 N-CA-C 108.05 -2.02 . . . . 0.0 108.05 176.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 17.0 p -135.8 129.26 32.21 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.308 -1.113 . . . . 0.0 109.309 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.425 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.34 -87.66 0.08 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.024 -1.048 . . . . 0.0 109.96 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -56.48 151.24 13.69 Favored 'General case' 0 N--CA 1.497 1.877 0 CA-C-O 121.358 0.599 . . . . 0.0 110.123 -179.716 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 1.013 HG21 ' CE1' ' A' ' 40' ' ' PHE . 61.5 t -140.14 134.44 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.287 -0.883 . . . . 0.0 111.019 -178.822 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -115.0 90.8 3.43 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 177.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.709 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -94.31 153.57 17.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.339 -0.85 . . . . 0.0 111.488 -177.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -89.33 150.52 22.54 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 179.283 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.689 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.84 -158.11 0.73 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 108.075 -2.01 . . . . 0.0 108.075 -179.188 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -87.69 41.0 0.65 Allowed 'Trans proline' 0 C--N 1.298 -2.101 0 C-N-CA 122.135 1.89 . . . . 0.0 110.013 178.117 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.709 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.25 147.55 32.52 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 120.232 -1.542 . . . . 0.0 111.891 -178.87 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.661 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -153.83 -169.56 3.31 Favored 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.863 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.698 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -151.87 145.24 24.77 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.135 -0.978 . . . . 0.0 109.184 179.433 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.815 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 3.6 m-70 -104.33 137.67 41.89 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.259 -0.901 . . . . 0.0 111.228 -178.762 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.415 HH21 HD21 ' A' ' 22' ' ' LEU . 0.7 OUTLIER -108.46 88.67 2.78 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.114 ' CE2' HG11 ' A' ' 83' ' ' VAL . 34.2 m-85 -92.06 118.39 30.76 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.237 -0.915 . . . . 0.0 109.602 -179.296 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.2 t -106.96 -28.94 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.411 -0.806 . . . . 0.0 111.089 -178.678 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.445 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -97.21 146.92 32.17 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 120.628 -1.295 . . . . 0.0 109.617 -179.364 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.639 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.6 Cg_endo -78.28 123.81 6.26 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 C-N-CA 122.473 2.116 . . . . 0.0 109.837 179.325 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 158.6 -159.68 30.4 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.631 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.445 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 15.1 mtp-105 -111.34 125.97 54.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.073 -1.251 . . . . 0.0 110.152 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.573 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 82.9 m-85 -108.75 157.92 18.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.34 -0.85 . . . . 0.0 109.481 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 72.1 t60 -112.81 126.99 56.04 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.526 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.789 HG22 ' CE1' ' A' ' 56' ' ' HIS . 84.3 t -107.62 150.06 10.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.099 -1.001 . . . . 0.0 110.675 -179.054 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.422 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 1.2 p -147.75 155.64 41.91 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.258 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.028 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -152.5 165.96 33.47 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.822 -1.174 . . . . 0.0 110.751 -179.674 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.462 HG12 ' HB3' ' A' ' 37' ' ' ARG . 8.3 p -141.81 130.6 22.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 107.197 -1.409 . . . . 0.0 107.197 178.315 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.995 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.16 140.7 29.22 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 120.947 -1.096 . . . . 0.0 108.821 -178.302 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.02 108.18 9.9 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 118.555 -1.258 . . . . 0.0 109.933 178.639 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.55 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -106.88 -9.66 16.26 Favored 'General case' 0 C--N 1.286 -2.188 0 CA-C-N 115.415 -0.811 . . . . 0.0 108.838 178.994 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 102.94 -48.39 1.04 Allowed Glycine 0 N--CA 1.487 2.057 0 N-CA-C 107.599 -2.2 . . . . 0.0 107.599 -178.19 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.04 -5.51 11.95 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.687 -0.89 . . . . 0.0 109.627 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -142.35 155.73 25.79 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 17.1 p -151.05 179.71 8.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.224 -1.162 . . . . 0.0 109.598 -179.533 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.995 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -156.02 170.41 22.23 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.458 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -124.31 136.39 54.08 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.107 -0.996 . . . . 0.0 109.906 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.028 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -119.5 158.44 26.27 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.566 -0.709 . . . . 0.0 109.711 -179.631 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.94 94.62 0.1 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.548 HG22 HD23 ' A' ' 10' ' ' LEU . 0.5 OUTLIER -115.03 -172.12 2.07 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.088 -1.242 . . . . 0.0 110.117 -179.878 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -150.64 148.37 28.53 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.114 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -132.95 153.66 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 120.842 -1.161 . . . . 0.0 109.972 -179.725 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 84' ' ' GLN . . . . . 0.427 ' N ' HG23 ' A' ' 83' ' ' VAL . 30.1 tt0 -122.57 89.29 3.09 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.309 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.822 HG21 ' HB3' ' A' ' 58' ' ' TYR . 92.9 t -79.63 143.56 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.253 -0.904 . . . . 0.0 109.82 -179.428 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -115.84 173.3 6.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.387 -0.821 . . . . 0.0 109.667 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.639 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.149 -0.969 . . . . 0.0 109.782 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.805 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.474 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.952 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.1 t -70.79 148.89 47.42 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.224 -0.923 . . . . 0.0 109.299 -179.14 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.758 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.6 mp -88.16 109.84 20.22 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.325 -178.312 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.585 ' HB ' ' CE1' ' A' ' 26' ' ' HIS . 1.2 t -126.21 103.91 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.01 -1.056 . . . . 0.0 108.863 178.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.583 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.8 80.52 0.3 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 -179.33 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.607 ' HD2' ' HA ' ' A' ' 25' ' ' PHE . 33.2 Cg_endo -73.07 146.65 41.67 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.612 2.208 . . . . 0.0 112.538 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.615 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 62.4 t60 164.62 171.09 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -93.31 -124.16 3.67 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 178.709 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.86 151.07 21.4 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.314 2.01 . . . . 0.0 109.938 179.162 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.826 ' HB3' HG22 ' A' ' 85' ' ' VAL . 22.1 mt -121.65 89.13 3.06 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.057 -1.027 . . . . 0.0 109.469 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -90.29 167.04 12.97 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 179.214 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.3 t -51.95 118.42 3.43 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.331 -0.855 . . . . 0.0 109.403 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.71 47.86 3.58 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.76 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.437 ' HB3' HD23 ' A' ' 17' ' ' LEU . 2.1 mm-40 -119.81 155.97 31.55 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.281 -1.129 . . . . 0.0 110.868 -179.396 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.786 HD11 ' HB2' ' A' ' 55' ' ' SER . 1.8 tm? -114.52 96.62 5.85 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.757 -0.589 . . . . 0.0 109.565 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.688 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -81.59 160.96 23.69 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 178.552 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.502 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -122.79 111.37 16.61 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.39 -1.444 . . . . 0.0 108.744 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.664 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 4.4 m-85 -100.7 166.38 10.91 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 122.172 0.987 . . . . 0.0 112.277 -177.176 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.585 ' CE1' ' HB ' ' A' ' 11' ' ' VAL . 7.5 p80 -163.45 151.77 13.65 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 176.846 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.906 HD11 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -114.51 160.94 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.0 -1.062 . . . . 0.0 108.884 -178.33 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.952 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -138.05 120.17 15.63 Favored 'General case' 0 N--CA 1.499 2.008 0 C-N-CA 118.453 -1.299 . . . . 0.0 112.653 -178.433 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.037 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 176.44 -72.1 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.228 -0.92 . . . . 0.0 108.963 177.57 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.037 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.9 Cg_endo -77.57 77.93 3.7 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 C-N-CA 121.569 1.513 . . . . 0.0 108.745 178.617 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.571 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 2.6 mp -33.3 -56.34 0.61 Allowed Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 122.127 -0.358 . . . . 0.0 111.631 -178.725 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.571 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.9 Cg_endo -80.62 75.96 4.77 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.165 1.91 . . . . 0.0 111.328 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.917 HG23 ' O ' ' A' ' 30' ' ' PRO . 36.8 t -103.46 148.53 8.34 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 120.984 -1.073 . . . . 0.0 109.098 179.102 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 15.4 t -113.59 -29.06 7.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.131 -0.981 . . . . 0.0 110.256 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -162.35 144.17 10.77 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.319 -0.863 . . . . 0.0 109.91 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.677 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -127.33 162.16 26.91 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 179.539 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.518 ' O ' HG23 ' A' ' 69' ' ' VAL . 13.1 mtp85 -123.89 103.12 8.15 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.906 ' CH2' HD11 ' A' ' 27' ' ' ILE . 35.1 m95 -88.55 179.94 6.18 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.05 -1.031 . . . . 0.0 109.837 -179.462 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.468 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -148.71 100.7 3.13 Favored 'General case' 0 C--N 1.291 -1.939 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 177.44 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.937 ' CE1' HG21 ' A' ' 47' ' ' VAL . 4.1 m-30 -80.27 -50.69 9.85 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 118.869 -1.132 . . . . 0.0 109.829 -177.748 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 80.27 21.77 64.25 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.535 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 1.2 p30 -106.96 -104.87 0.34 Allowed 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 178.483 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.88 -15.41 72.87 Favored Glycine 0 N--CA 1.48 1.607 0 N-CA-C 107.715 -2.154 . . . . 0.0 107.715 176.508 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -140.26 130.62 25.27 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.396 -1.061 . . . . 0.0 109.035 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.17 -85.48 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.956 -1.09 . . . . 0.0 109.624 -179.796 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -56.5 151.2 13.82 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-O 121.268 0.556 . . . . 0.0 109.878 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.937 HG21 ' CE1' ' A' ' 40' ' ' PHE . 61.6 t -139.28 125.02 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.428 -0.795 . . . . 0.0 110.737 -178.851 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -104.67 109.72 21.76 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.227 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.677 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -123.33 167.83 13.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.157 -0.964 . . . . 0.0 111.024 -178.487 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.64 153.34 17.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.68 -0.638 . . . . 0.0 109.641 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.576 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.33 -156.33 0.55 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -89.52 39.0 0.41 Allowed 'Trans proline' 0 C--N 1.297 -2.152 0 C-N-CA 122.484 2.123 . . . . 0.0 110.25 178.468 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.572 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -140.8 151.6 44.52 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 119.976 -1.703 . . . . 0.0 112.458 -178.368 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.657 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -172.2 153.24 3.0 Favored 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.029 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.786 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -109.84 161.09 15.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.939 -1.1 . . . . 0.0 110.237 -179.82 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.732 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 1.6 m-70 -109.24 134.04 52.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.457 -0.777 . . . . 0.0 110.298 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.688 ' NH2' HD21 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -110.8 92.13 3.93 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.924 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.126 ' CE2' HG11 ' A' ' 83' ' ' VAL . 22.0 m-85 -92.33 133.49 35.81 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.136 -0.978 . . . . 0.0 109.596 -179.39 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 53.6 t -117.86 -28.15 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.418 -0.801 . . . . 0.0 110.973 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.448 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -97.78 143.28 25.94 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 120.592 -1.317 . . . . 0.0 109.611 -179.545 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.905 ' CB ' ' HB2' ' A' ' 87' ' ' ALA . 36.0 Cg_endo -79.06 120.78 4.7 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.616 2.211 . . . . 0.0 110.152 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 159.08 -143.68 9.48 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 18.5 ttm-85 -112.39 154.26 26.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -1.171 . . . . 0.0 109.572 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.617 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 54.0 m-85 -139.1 167.52 21.88 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.526 -0.734 . . . . 0.0 109.06 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 65.6 t60 -125.84 144.59 50.59 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.702 HG22 ' CE1' ' A' ' 56' ' ' HIS . 39.1 t -126.97 148.63 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.09 -1.006 . . . . 0.0 110.751 -179.133 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.401 ' OG1' ' HB2' ' A' ' 39' ' ' ASP . 0.1 OUTLIER -150.24 161.12 43.05 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.605 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.04 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.48 157.55 43.39 Favored 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 119.182 -1.007 . . . . 0.0 110.92 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -145.81 106.03 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 179.16 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.843 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -87.62 143.27 27.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.652 -1.28 . . . . 0.0 109.288 -179.254 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.64 115.12 17.55 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.211 -0.996 . . . . 0.0 109.639 179.077 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.542 HD21 ' O ' ' A' ' 32' ' ' PRO . 9.1 mt -105.88 -12.62 15.78 Favored 'General case' 0 C--N 1.289 -2.058 0 CA-C-O 121.526 0.679 . . . . 0.0 109.215 179.437 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.42 -47.32 1.05 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -178.714 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.23 -5.82 11.85 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.581 -0.952 . . . . 0.0 109.801 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -146.19 154.67 26.1 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.405 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 18.4 p -150.62 174.23 13.23 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.177 -1.19 . . . . 0.0 109.675 -179.586 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.843 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -151.81 134.59 15.59 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.182 -0.949 . . . . 0.0 109.397 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -99.69 143.01 30.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.252 -0.905 . . . . 0.0 110.311 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.04 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -127.53 157.91 38.85 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 121.662 -0.649 . . . . 0.0 109.966 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.03 84.59 0.1 Allowed Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.537 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -103.2 178.01 4.68 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.204 -1.174 . . . . 0.0 110.055 -179.766 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -121.43 157.78 29.81 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.31 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.126 HG11 ' CE2' ' A' ' 58' ' ' TYR . 16.4 t -137.45 143.39 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 120.997 -1.064 . . . . 0.0 110.264 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -132.69 101.77 5.42 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.467 -0.77 . . . . 0.0 109.27 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.826 HG22 ' HB3' ' A' ' 17' ' ' LEU . 79.5 t -103.52 140.52 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.333 -0.855 . . . . 0.0 109.714 -179.473 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -104.9 -174.71 2.6 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.158 -0.964 . . . . 0.0 109.872 -179.479 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.905 ' HB2' ' CB ' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.158 -0.963 . . . . 0.0 109.848 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.793 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.389 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.755 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.15 141.72 28.34 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.693 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.728 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.8 mp -97.88 91.24 5.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 -178.121 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.929 HG12 ' HD3' ' A' ' 13' ' ' PRO . 57.0 t -101.14 117.76 46.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.953 -1.092 . . . . 0.0 108.653 179.171 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.461 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -125.08 72.6 0.43 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.588 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.929 ' HD3' HG12 ' A' ' 11' ' ' VAL . 32.7 Cg_endo -73.01 147.97 44.25 Favored 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.701 2.267 . . . . 0.0 111.758 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.514 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 23.6 t-80 157.52 -33.86 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.791 0 CA-C-N 115.442 -0.799 . . . . 0.0 108.965 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.95 -143.35 15.63 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.123 -1.991 . . . . 0.0 108.123 -179.037 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -77.16 147.79 26.64 Favored 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.049 1.833 . . . . 0.0 108.947 179.032 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 1.088 HD21 ' HB2' ' A' ' 23' ' ' ALA . 5.6 mt -112.27 110.63 20.98 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.201 -0.937 . . . . 0.0 109.89 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -93.09 168.61 11.0 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 179.214 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.6 t -60.83 122.16 14.14 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.209 -0.932 . . . . 0.0 109.456 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.91 47.42 4.78 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.0 mm100 -125.62 157.89 36.05 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.252 -1.146 . . . . 0.0 110.934 -179.515 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.742 HD22 ' O ' ' A' ' 56' ' ' HIS . 1.8 tm? -113.27 103.58 11.46 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 1.088 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -85.61 156.22 20.8 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.918 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.49 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.51 107.7 13.18 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.506 -1.371 . . . . 0.0 108.63 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.768 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 1.9 m-85 -95.36 168.78 10.51 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 121.976 0.893 . . . . 0.0 111.779 -177.53 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.595 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -163.72 141.21 7.28 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.502 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.995 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.9 mm -108.01 152.5 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.292 -0.88 . . . . 0.0 109.435 -178.216 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.637 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -135.28 121.7 20.5 Favored 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.781 -1.168 . . . . 0.0 112.133 -179.045 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.034 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -177.72 -66.34 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.002 -1.061 . . . . 0.0 109.222 177.721 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.034 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.3 Cg_endo -81.72 61.7 8.02 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 C-N-CA 122.129 1.886 . . . . 0.0 109.15 178.835 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.672 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.1 mp -8.81 -67.09 0.01 OUTLIER Pre-proline 0 N--CA 1.508 2.45 0 N-CA-C 113.299 0.851 . . . . 0.0 113.299 -178.55 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.672 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.3 Cg_endo -77.72 68.42 7.67 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 121.892 1.728 . . . . 0.0 111.076 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.684 HG22 ' HG2' ' A' ' 30' ' ' PRO . 3.4 t -91.22 148.06 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 120.757 -1.214 . . . . 0.0 109.875 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.9 p -114.28 -18.11 11.67 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.603 -0.686 . . . . 0.0 110.045 179.52 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.95 152.53 0.75 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.26 -0.9 . . . . 0.0 110.284 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.689 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -140.7 140.66 34.94 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.318 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.649 ' O ' HG23 ' A' ' 69' ' ' VAL . 18.3 mtm-85 -93.74 107.35 19.24 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.101 -0.999 . . . . 0.0 109.369 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.972 ' CH2' HD11 ' A' ' 27' ' ' ILE . 22.8 m95 -90.73 179.56 5.77 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.212 -0.93 . . . . 0.0 109.502 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.421 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.95 102.3 2.96 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 177.36 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.996 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.4 m-30 -80.37 -59.66 2.61 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 118.853 -1.139 . . . . 0.0 110.086 -177.722 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.03 20.06 40.63 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -107.15 -104.52 0.34 Allowed 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.619 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.91 -19.69 62.69 Favored Glycine 0 C--N 1.296 -1.67 0 N-CA-C 107.749 -2.141 . . . . 0.0 107.749 176.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 11.0 p -135.22 130.4 35.21 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.427 -1.043 . . . . 0.0 109.3 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.36 -86.65 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.115 -0.991 . . . . 0.0 109.936 -179.658 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -57.62 152.84 14.32 Favored 'General case' 0 N--CA 1.497 1.89 0 CA-C-O 121.176 0.512 . . . . 0.0 110.112 -179.618 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.996 HG21 ' CE1' ' A' ' 40' ' ' PHE . 34.3 t -140.99 126.96 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.416 -0.803 . . . . 0.0 111.242 -178.745 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -105.44 91.78 3.92 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.345 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.8 ' CB ' ' HB2' ' A' ' 54' ' ' ALA . . . -96.03 154.97 16.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.244 -0.91 . . . . 0.0 111.677 -177.624 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.84 153.18 19.0 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.689 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.26 -158.23 0.55 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 108.248 -1.941 . . . . 0.0 108.248 -179.229 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.402 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.2 Cg_endo -88.37 40.03 0.54 Allowed 'Trans proline' 0 C--N 1.297 -2.157 0 C-N-CA 122.029 1.819 . . . . 0.0 109.932 178.118 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.657 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.27 152.02 39.28 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 120.096 -1.628 . . . . 0.0 112.187 -178.651 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.8 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -165.12 155.91 14.15 Favored 'General case' 0 N--CA 1.498 1.941 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.841 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.654 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -114.41 160.71 18.84 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.932 -1.105 . . . . 0.0 110.192 -179.883 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.787 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 2.1 m-70 -114.54 139.34 49.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.538 -0.726 . . . . 0.0 110.489 -179.15 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.484 HH21 HD21 ' A' ' 22' ' ' LEU . 0.7 OUTLIER -111.89 95.64 5.6 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 178.999 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.086 ' CE2' HG11 ' A' ' 83' ' ' VAL . 36.3 m-85 -99.02 129.86 45.32 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.161 -0.962 . . . . 0.0 109.432 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.7 t -117.91 -27.89 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.352 -0.842 . . . . 0.0 111.25 -178.433 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.486 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -99.51 146.39 31.71 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 120.511 -1.368 . . . . 0.0 109.596 -179.381 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.486 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 34.8 Cg_endo -77.73 124.42 6.89 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.404 2.069 . . . . 0.0 109.888 179.352 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 160.81 -151.78 22.31 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.609 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.409 ' HG2' ' HA ' ' A' ' 84' ' ' GLN . 0.0 OUTLIER -122.17 120.11 33.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.113 -1.228 . . . . 0.0 109.82 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.558 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 81.6 m-85 -103.6 153.64 20.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.353 -0.842 . . . . 0.0 109.541 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.9 t60 -107.89 132.51 53.38 Favored 'General case' 0 N--CA 1.488 1.475 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.168 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.679 HG13 ' CE1' ' A' ' 56' ' ' HIS . 90.7 t -113.42 150.82 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 110.569 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.406 ' OG1' ' HB2' ' A' ' 39' ' ' ASP . 6.0 p -147.54 156.43 42.83 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.096 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.94 156.09 41.14 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.855 -1.153 . . . . 0.0 111.186 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.649 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -128.49 125.82 64.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 178.502 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.999 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.2 OUTLIER -87.76 144.58 26.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 120.535 -1.353 . . . . 0.0 109.007 -178.865 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.21 106.7 7.72 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 118.783 -1.167 . . . . 0.0 109.627 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.562 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -103.62 -10.62 18.28 Favored 'General case' 0 C--N 1.284 -2.28 0 CA-C-N 115.317 -0.856 . . . . 0.0 108.697 179.055 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.81 -47.27 1.07 Allowed Glycine 0 N--CA 1.488 2.125 0 N-CA-C 107.627 -2.189 . . . . 0.0 107.627 -178.416 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.31 -5.09 11.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.741 -0.858 . . . . 0.0 109.68 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.55 158.4 27.52 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.726 -1.349 . . . . 0.0 109.726 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.435 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 25.7 p -148.03 -177.71 5.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.364 -1.08 . . . . 0.0 109.405 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.999 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -156.55 162.69 39.9 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.8 mp -116.8 132.38 56.71 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.065 -1.022 . . . . 0.0 109.976 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.096 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -116.46 157.36 25.29 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.548 -0.72 . . . . 0.0 109.497 -179.752 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.529 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -168.24 96.3 0.12 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.553 HG22 HD23 ' A' ' 10' ' ' LEU . 0.7 OUTLIER -116.34 -171.74 2.05 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.044 -1.268 . . . . 0.0 109.732 179.791 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -151.55 147.63 27.03 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.408 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.086 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -131.77 138.44 52.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 120.68 -1.262 . . . . 0.0 110.018 -179.466 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 84' ' ' GLN . . . . . 0.409 ' HA ' ' HG2' ' A' ' 63' ' ' ARG . 30.9 tt0 -105.22 90.47 3.44 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 178.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.781 HG21 ' HB3' ' A' ' 58' ' ' TYR . 52.9 t -76.54 130.92 35.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.307 -0.871 . . . . 0.0 109.352 -179.575 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -114.46 144.16 43.77 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.467 -0.771 . . . . 0.0 109.768 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.241 -0.912 . . . . 0.0 109.301 179.676 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.919 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.974 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.1 t -94.26 147.23 23.39 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.3 mp -91.99 88.83 6.73 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.162 -178.215 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.726 HG23 HG23 ' A' ' 9' ' ' THR . 22.1 t -97.76 100.15 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 120.702 -1.249 . . . . 0.0 108.561 178.901 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -117.96 78.73 0.3 Allowed Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.276 -179.304 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.551 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.1 Cg_endo -74.99 148.11 34.88 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.404 2.069 . . . . 0.0 111.635 179.412 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.524 ' ND1' ' HB1' ' A' ' 23' ' ' ALA . 3.3 p-80 174.35 162.01 0.19 Allowed 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.5 -130.0 1.36 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 179.354 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -78.87 147.3 21.36 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 C-N-CA 121.978 1.786 . . . . 0.0 109.145 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.767 HD13 ' HB3' ' A' ' 21' ' ' GLN . 0.4 OUTLIER -113.41 84.21 1.97 Allowed 'General case' 0 C--N 1.298 -1.671 0 O-C-N 121.194 -0.941 . . . . 0.0 109.046 -179.815 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.462 ' HB3' ' OE1' ' A' ' 21' ' ' GLN . . . -95.53 168.16 10.86 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 39.0 t -56.71 108.52 0.51 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.294 -0.879 . . . . 0.0 109.521 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.94 37.67 2.49 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.767 ' HB3' HD13 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -128.21 154.42 45.85 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.227 -1.161 . . . . 0.0 109.79 -179.972 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.835 HD11 ' HB2' ' A' ' 55' ' ' SER . 0.1 OUTLIER -118.66 130.01 55.61 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.118 -0.988 . . . . 0.0 109.662 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.801 ' HB3' ' HE1' ' A' ' 25' ' ' PHE . . . -94.92 146.01 24.53 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.014 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.519 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -101.82 129.6 48.07 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 119.978 -1.701 . . . . 0.0 108.014 178.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.801 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 16.6 m-85 -112.22 166.39 11.31 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 121.959 0.885 . . . . 0.0 111.942 -176.777 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.624 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -164.5 134.41 3.92 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 178.22 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.885 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.4 OUTLIER -103.38 149.43 7.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.17 -0.956 . . . . 0.0 109.036 -178.437 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.974 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -133.73 124.31 26.44 Favored 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.545 -1.262 . . . . 0.0 112.225 -178.856 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.046 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 179.15 -66.38 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 121.118 -0.989 . . . . 0.0 109.199 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.046 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.4 Cg_endo -80.51 68.64 8.25 Favored 'Trans proline' 0 C--N 1.314 -1.281 0 C-N-CA 121.983 1.788 . . . . 0.0 109.102 178.952 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.679 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -10.81 -66.52 0.01 OUTLIER Pre-proline 0 N--CA 1.507 2.42 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -178.664 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.679 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 37.0 Cg_endo -79.58 83.86 2.16 Favored 'Trans proline' 0 C--N 1.314 -1.257 0 C-N-CA 121.667 1.578 . . . . 0.0 111.001 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.625 HG22 ' HG2' ' A' ' 30' ' ' PRO . 6.3 t -106.12 143.22 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.836 -1.165 . . . . 0.0 109.384 179.365 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.5 t -118.62 -14.18 9.61 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.406 -0.809 . . . . 0.0 110.412 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -174.2 146.82 1.16 Allowed 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.898 -1.126 . . . . 0.0 110.532 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.671 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.4 OUTLIER -142.96 136.94 29.02 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.69 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.573 ' HB2' HG12 ' A' ' 69' ' ' VAL . 7.5 mtm180 -94.28 112.36 24.15 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.19 -0.944 . . . . 0.0 108.872 179.448 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.727 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 18.6 m95 -94.32 -177.09 4.16 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.898 0.856 . . . . 0.0 109.079 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.442 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -151.39 103.77 3.02 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 106.282 -1.748 . . . . 0.0 106.282 177.424 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 1.003 ' CE1' HG21 ' A' ' 47' ' ' VAL . 4.1 m-30 -80.04 -63.65 1.36 Allowed 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.822 -1.151 . . . . 0.0 110.31 -177.586 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.26 9.32 55.68 Favored Glycine 0 N--CA 1.486 1.974 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -178.59 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -93.47 -101.72 0.13 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 178.471 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -89.02 -28.92 19.38 Favored Glycine 0 C--N 1.293 -1.826 0 N-CA-C 107.507 -2.237 . . . . 0.0 107.507 177.056 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.31 130.26 55.93 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.546 -0.973 . . . . 0.0 109.38 179.438 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.442 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.3 -85.02 0.1 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.202 -0.936 . . . . 0.0 109.541 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -59.77 155.26 16.39 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.265 0.555 . . . . 0.0 110.065 -179.775 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 1.003 HG21 ' CE1' ' A' ' 40' ' ' PHE . 60.6 t -142.01 136.16 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.469 -0.769 . . . . 0.0 111.076 -178.79 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -116.16 93.2 4.14 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 177.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.672 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -96.35 150.13 20.92 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.359 -0.838 . . . . 0.0 111.661 -177.841 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.69 146.71 27.3 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.671 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.73 -159.16 0.58 Allowed Glycine 0 N--CA 1.492 2.385 0 N-CA-C 107.91 -2.076 . . . . 0.0 107.91 -179.03 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -86.55 41.6 0.82 Allowed 'Trans proline' 0 C--N 1.299 -2.049 0 C-N-CA 121.909 1.739 . . . . 0.0 110.12 178.253 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.672 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -144.07 141.01 29.82 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.314 -1.491 . . . . 0.0 111.65 -178.909 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.632 ' HB2' ' HB2' ' A' ' 49' ' ' ALA . . . -146.26 -166.16 2.4 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.03 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.835 ' HB2' HD11 ' A' ' 22' ' ' LEU . 5.4 p -156.38 136.45 12.79 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.364 -0.835 . . . . 0.0 108.919 179.391 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.848 ' CE1' HG13 ' A' ' 66' ' ' VAL . 3.0 m-70 -99.46 131.62 45.34 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.291 -0.881 . . . . 0.0 111.329 -178.26 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.404 ' H ' ' HG2' ' A' ' 57' ' ' ARG . 6.7 ptp180 -97.08 96.06 8.2 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 178.23 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.107 ' CE2' HG11 ' A' ' 83' ' ' VAL . 16.6 m-85 -100.1 105.16 16.76 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.905 -1.122 . . . . 0.0 109.547 -179.086 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.0 m -107.73 -9.32 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.488 -0.758 . . . . 0.0 111.292 -178.78 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.48 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -105.83 145.86 31.72 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 120.46 -1.4 . . . . 0.0 109.462 -179.818 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 1.036 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.5 Cg_endo -77.56 123.78 6.65 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.614 2.209 . . . . 0.0 110.133 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 150.37 -142.97 10.12 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 -179.747 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.26 158.54 37.87 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.204 -1.174 . . . . 0.0 109.475 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.655 ' HB2' HG13 ' A' ' 83' ' ' VAL . 92.5 m-85 -135.78 155.46 50.33 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.307 -0.87 . . . . 0.0 109.683 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 38.5 t-80 -111.46 114.31 27.33 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.034 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.848 HG13 ' CE1' ' A' ' 56' ' ' HIS . 62.7 t -95.06 150.64 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.228 -0.92 . . . . 0.0 110.527 -178.84 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.43 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.8 OUTLIER -146.42 157.96 43.83 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.388 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.018 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -156.36 164.57 38.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.603 -1.311 . . . . 0.0 111.224 -179.457 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.573 HG12 ' HB2' ' A' ' 37' ' ' ARG . 9.8 p -142.16 127.29 17.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 178.427 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 1.054 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.2 142.23 27.92 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.932 -1.105 . . . . 0.0 108.769 -178.471 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -131.41 106.23 8.11 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.551 -1.26 . . . . 0.0 109.949 178.597 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.638 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -104.6 -9.82 18.0 Favored 'General case' 0 C--N 1.284 -2.261 0 CA-C-N 115.218 -0.901 . . . . 0.0 108.701 178.937 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.11 -48.52 0.97 Allowed Glycine 0 N--CA 1.487 2.094 0 N-CA-C 107.776 -2.13 . . . . 0.0 107.776 -178.457 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.59 -5.52 11.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.633 -0.922 . . . . 0.0 109.61 179.089 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.94 156.66 26.07 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.406 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 22.0 p -150.38 -178.65 6.65 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.304 -1.115 . . . . 0.0 109.421 -179.542 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 1.054 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -158.98 141.4 14.03 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.36 -0.837 . . . . 0.0 108.744 179.577 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -99.85 135.37 41.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.984 -1.073 . . . . 0.0 110.101 -179.211 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.018 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -119.82 156.91 29.75 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.492 -0.755 . . . . 0.0 110.026 -179.569 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.52 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.46 89.73 0.1 Allowed Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.743 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -107.49 -172.7 2.12 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.991 -1.3 . . . . 0.0 110.267 -179.571 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -150.72 146.28 26.34 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.107 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -131.2 157.59 43.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.856 -1.152 . . . . 0.0 109.93 -179.702 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 84' ' ' GLN . . . . . 0.491 ' N ' HG23 ' A' ' 83' ' ' VAL . 8.1 mt-30 -130.45 92.14 3.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.595 -0.691 . . . . 0.0 109.165 179.466 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.758 HG22 ' HB3' ' A' ' 17' ' ' LEU . 40.9 t -86.58 141.92 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.253 -0.904 . . . . 0.0 109.734 -179.663 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -108.34 175.69 5.38 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.29 -0.881 . . . . 0.0 110.309 -179.29 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 1.036 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.659 0 O-C-N 121.347 -0.846 . . . . 0.0 109.693 179.5 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.714 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.943 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.6 t -74.95 150.73 38.97 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.13 -0.982 . . . . 0.0 109.408 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.753 HD23 HG22 ' A' ' 81' ' ' THR . 5.3 mp -87.15 105.6 17.31 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.977 -178.636 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.617 HG21 ' CE1' ' A' ' 26' ' ' HIS . 2.3 t -119.36 91.6 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.976 -1.078 . . . . 0.0 109.009 178.894 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.715 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -113.7 81.14 0.29 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.492 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.54 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.5 Cg_endo -73.34 149.04 44.45 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.662 2.242 . . . . 0.0 111.92 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.599 ' CD2' HD22 ' A' ' 17' ' ' LEU . 45.6 t60 166.96 -39.13 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.49 -138.86 14.76 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.057 -2.017 . . . . 0.0 108.057 -178.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -77.42 147.65 25.75 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 C-N-CA 122.096 1.864 . . . . 0.0 109.043 178.809 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.839 HD21 ' HB2' ' A' ' 23' ' ' ALA . 0.2 OUTLIER -106.31 109.84 21.9 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.098 -1.001 . . . . 0.0 109.721 -179.285 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.602 ' HB3' ' HG3' ' A' ' 21' ' ' GLN . . . -92.34 153.35 19.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 179.269 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.0 t -59.29 111.08 1.23 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -0.875 . . . . 0.0 109.37 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.47 35.44 3.09 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLN . . . . . 0.602 ' HG3' ' HB3' ' A' ' 18' ' ' ALA . 13.6 mm100 -133.65 160.54 37.23 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.192 -1.181 . . . . 0.0 109.88 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.708 HD12 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -117.06 126.66 53.2 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.186 -0.946 . . . . 0.0 109.414 179.672 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.839 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -90.06 145.42 25.08 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.084 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.54 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -99.89 129.78 46.01 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 119.918 -1.739 . . . . 0.0 108.165 179.111 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.816 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 16.8 m-85 -113.88 163.26 15.32 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 122.102 0.954 . . . . 0.0 111.977 -177.335 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' HIS . . . . . 0.617 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -165.9 139.77 4.43 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.079 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.828 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.31 154.69 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.868 -1.145 . . . . 0.0 108.777 -178.331 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.943 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -133.87 123.43 24.73 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 120.693 -1.255 . . . . 0.0 112.732 -178.08 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 1.041 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 171.45 -69.22 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.399 -0.813 . . . . 0.0 109.305 177.659 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 1.041 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -76.66 78.7 3.26 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 121.796 1.664 . . . . 0.0 109.486 179.198 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.709 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 6.0 mt -34.05 -53.82 0.86 Allowed Pre-proline 0 N--CA 1.504 2.251 0 O-C-N 121.944 -0.472 . . . . 0.0 111.703 -178.792 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' PRO . . . . . 0.709 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 36.8 Cg_endo -81.3 63.12 8.61 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 C-N-CA 122.077 1.851 . . . . 0.0 112.198 -179.055 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.918 HG23 ' O ' ' A' ' 30' ' ' PRO . 74.4 t -87.59 148.02 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 120.595 -1.316 . . . . 0.0 109.696 179.118 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 70.7 p -119.53 -35.82 3.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.422 -0.798 . . . . 0.0 109.665 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -155.13 144.37 21.04 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.461 -0.774 . . . . 0.0 109.007 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.929 HG23 ' HB3' ' A' ' 49' ' ' ALA . 0.5 OUTLIER -129.29 156.44 44.0 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.976 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.49 ' O ' HG23 ' A' ' 69' ' ' VAL . 49.1 mtp85 -119.51 101.06 7.67 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 109.044 179.82 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.783 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 30.3 m95 -89.24 178.77 6.27 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.123 -0.985 . . . . 0.0 109.476 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ASP . . . . . 0.457 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.51 101.58 2.97 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 177.49 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 1.004 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.9 m-30 -79.75 -61.26 2.05 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.989 -177.847 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.77 15.86 47.68 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -178.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.27 -104.52 0.27 Allowed 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 178.607 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.31 -20.28 59.09 Favored Glycine 0 C--N 1.296 -1.649 0 N-CA-C 107.708 -2.157 . . . . 0.0 107.708 177.028 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 m -132.58 127.59 35.35 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.432 -1.04 . . . . 0.0 109.304 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.457 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.89 -85.96 0.09 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.17 -0.956 . . . . 0.0 109.72 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -57.73 153.37 13.69 Favored 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 121.112 0.482 . . . . 0.0 109.71 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 1.004 HG21 ' CE1' ' A' ' 40' ' ' PHE . 57.7 t -140.16 124.12 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.384 -0.823 . . . . 0.0 111.1 -178.445 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -104.61 99.47 9.14 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.074 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.929 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -109.91 167.8 9.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.203 -0.936 . . . . 0.0 111.02 -178.596 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.97 151.94 21.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.715 -0.615 . . . . 0.0 109.352 179.736 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.555 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.92 -155.2 0.58 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -89.06 41.63 0.57 Allowed 'Trans proline' 0 C--N 1.295 -2.255 0 C-N-CA 122.272 1.981 . . . . 0.0 110.515 178.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.652 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.58 154.02 43.14 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.928 -1.733 . . . . 0.0 112.602 -178.716 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.434 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -166.56 -171.17 1.81 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.074 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.646 ' HB3' HD11 ' A' ' 22' ' ' LEU . 0.3 OUTLIER -150.45 143.25 24.65 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.116 -0.99 . . . . 0.0 109.263 179.449 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 56' ' ' HIS . . . . . 0.829 ' CE1' HG22 ' A' ' 66' ' ' VAL . 2.3 m-70 -102.41 134.64 45.4 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.197 -0.94 . . . . 0.0 111.515 -178.686 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.15 95.47 6.57 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.331 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 1.119 ' CE2' HG11 ' A' ' 83' ' ' VAL . 18.6 m-85 -102.58 112.84 25.77 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.079 -1.013 . . . . 0.0 109.403 -179.285 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.6 p -110.85 -10.56 11.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.417 -0.802 . . . . 0.0 111.525 -178.515 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.479 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -114.73 146.14 35.4 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 120.478 -1.389 . . . . 0.0 109.673 -179.743 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.479 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.1 Cg_endo -77.06 122.85 6.41 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.403 2.069 . . . . 0.0 109.935 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 161.77 -157.05 28.73 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.607 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.425 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -116.93 121.2 40.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.144 -1.21 . . . . 0.0 109.771 -179.824 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.6 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 90.3 m-85 -103.71 155.95 18.18 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.314 -0.867 . . . . 0.0 109.315 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 80.8 t60 -111.94 123.34 50.04 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.045 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.829 HG22 ' CE1' ' A' ' 56' ' ' HIS . 62.4 t -106.22 150.5 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.163 -0.961 . . . . 0.0 110.594 -178.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.53 159.56 44.2 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 178.664 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 1.06 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -151.09 154.52 37.13 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.939 -1.101 . . . . 0.0 110.921 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -144.75 104.3 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.102 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.821 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.74 150.73 22.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.757 -1.215 . . . . 0.0 110.204 -178.663 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.99 116.16 18.91 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.826 0.822 . . . . 0.0 108.937 178.453 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.916 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.6 mp -104.36 -12.96 16.29 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-O 121.508 0.671 . . . . 0.0 109.212 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.74 -53.75 0.62 Allowed Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.135 -1.986 . . . . 0.0 108.135 -178.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.71 -5.33 12.13 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.584 -0.95 . . . . 0.0 109.777 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.43 161.4 26.95 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.419 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 3.4 p -150.87 170.36 19.47 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.371 -1.076 . . . . 0.0 109.359 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.821 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -143.42 128.75 18.88 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.245 -0.91 . . . . 0.0 109.57 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.3 tp -95.11 140.79 29.55 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.471 -0.768 . . . . 0.0 110.029 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 1.06 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -128.72 157.52 41.15 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.604 -0.685 . . . . 0.0 109.919 -179.464 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -164.88 86.48 0.1 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 179.589 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.753 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -104.34 -176.32 3.05 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.122 -1.222 . . . . 0.0 109.762 -179.854 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -150.76 147.53 27.42 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.119 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -131.83 149.78 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 O-C-N 120.768 -1.208 . . . . 0.0 109.618 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -119.22 87.46 2.74 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.681 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.773 HG21 ' HB3' ' A' ' 58' ' ' TYR . 84.5 t -75.01 134.84 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.312 -0.867 . . . . 0.0 109.815 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 -109.26 177.52 4.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.363 -0.835 . . . . 0.0 109.591 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.364 -0.835 . . . . 0.0 109.515 179.874 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.955 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.393 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.711 ' CG2' ' HB3' ' A' ' 28' ' ' ALA . 0.5 OUTLIER -81.49 144.66 31.19 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.214 -0.929 . . . . 0.0 108.95 -179.456 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.779 HD23 HG22 ' A' ' 81' ' ' THR . 5.8 mp -94.27 86.7 5.0 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.215 -178.164 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.691 HG12 ' HD3' ' A' ' 13' ' ' PRO . 32.9 t -94.88 102.39 13.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 120.873 -1.142 . . . . 0.0 108.386 178.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.505 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.95 76.72 0.28 Allowed Glycine 0 N--CA 1.488 2.113 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.038 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.691 ' HD3' HG12 ' A' ' 11' ' ' VAL . 31.4 Cg_endo -71.73 146.85 49.48 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.438 2.092 . . . . 0.0 111.401 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 174.51 164.17 0.22 Allowed 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 -179.664 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -89.29 -125.91 2.77 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 107.363 -2.295 . . . . 0.0 107.363 178.506 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -80.06 147.06 18.52 Favored 'Trans proline' 0 C--N 1.302 -1.875 0 C-N-CA 121.839 1.693 . . . . 0.0 108.293 177.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.73 HD12 HG22 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -114.15 80.13 1.35 Allowed 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.922 -1.111 . . . . 0.0 109.158 -179.633 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -91.61 172.29 8.6 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.2 t -59.39 117.85 5.31 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.2 -0.938 . . . . 0.0 109.325 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.81 46.71 3.09 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.643 ' HB3' HD13 ' A' ' 17' ' ' LEU . 0.0 OUTLIER -122.27 152.27 40.22 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.386 -1.067 . . . . 0.0 110.559 -179.627 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.661 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.0 tm? -109.99 94.58 5.09 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.739 -0.6 . . . . 0.0 109.65 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.713 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -75.66 158.9 31.76 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.729 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.502 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -124.71 117.81 25.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.463 -1.398 . . . . 0.0 108.573 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.804 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.8 m-85 -105.55 170.96 7.59 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 122.085 0.945 . . . . 0.0 111.828 -177.318 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.649 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.8 138.98 3.51 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 178.105 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.793 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.3 OUTLIER -105.32 152.52 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.085 -1.009 . . . . 0.0 109.47 -178.276 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.711 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -134.66 116.83 15.4 Favored 'General case' 0 N--CA 1.5 2.046 0 C-N-CA 118.823 -1.151 . . . . 0.0 111.644 -179.292 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.112 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 176.56 -62.26 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.915 0 O-C-N 121.076 -1.015 . . . . 0.0 109.952 178.173 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.112 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.4 Cg_endo -80.11 63.55 8.76 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.32 2.013 . . . . 0.0 109.711 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.64 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -13.13 -64.58 0.02 OUTLIER Pre-proline 0 N--CA 1.504 2.266 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 -178.902 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.64 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.2 Cg_endo -77.69 72.5 6.05 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 121.724 1.616 . . . . 0.0 111.282 -179.551 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.483 ' CG2' ' O ' ' A' ' 30' ' ' PRO . 2.7 t -98.77 127.26 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.996 -1.065 . . . . 0.0 109.341 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 p -111.21 -14.87 13.77 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.417 -0.802 . . . . 0.0 109.219 178.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -163.46 148.34 11.02 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.224 -0.922 . . . . 0.0 109.824 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.935 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.4 t -140.38 162.66 34.78 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.43 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.554 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -127.31 100.5 6.08 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.101 -0.999 . . . . 0.0 109.217 179.586 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.804 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 36.4 m95 -87.59 179.02 6.61 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.218 -0.926 . . . . 0.0 109.453 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.466 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.3 OUTLIER -146.84 103.14 3.6 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.862 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.981 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.5 m-30 -81.16 -59.1 2.77 Favored 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.314 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.28 8.48 68.44 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.518 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 10.4 p30 -98.49 35.7 1.76 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.372 -1.075 . . . . 0.0 108.111 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 108.33 -38.35 3.37 Favored Glycine 0 N--CA 1.483 1.785 0 N-CA-C 105.356 -3.098 . . . . 0.0 105.356 -175.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 74.6 m -101.86 95.06 6.14 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.466 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.2 -90.7 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -0.919 . . . . 0.0 110.151 -178.487 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -55.9 146.81 20.97 Favored 'General case' 0 N--CA 1.493 1.688 0 CA-C-O 121.251 0.548 . . . . 0.0 109.758 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.981 HG21 ' CE1' ' A' ' 40' ' ' PHE . 63.8 t -135.01 106.36 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.377 -0.827 . . . . 0.0 110.972 -178.36 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.8 94.12 9.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.988 -1.07 . . . . 0.0 108.211 178.168 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.935 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -101.65 166.6 10.6 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.258 -0.901 . . . . 0.0 110.801 -178.596 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.61 150.09 21.53 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.725 -0.61 . . . . 0.0 109.595 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.541 ' O ' HG22 ' A' ' 36' ' ' THR . . . 44.14 -153.26 0.41 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.461 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.8 Cg_endo -88.43 40.09 0.54 Allowed 'Trans proline' 0 C--N 1.301 -1.943 0 C-N-CA 122.372 2.048 . . . . 0.0 110.282 178.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.628 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.38 154.39 43.68 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.135 -1.603 . . . . 0.0 112.011 -178.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.447 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -165.88 -168.86 1.37 Allowed 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.362 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.661 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -157.32 146.59 20.08 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.133 -0.979 . . . . 0.0 109.131 179.236 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.742 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 2.4 m-70 -100.08 133.76 44.0 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.352 -0.843 . . . . 0.0 110.915 -178.532 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -107.5 88.63 2.78 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.418 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.131 ' CE2' HG11 ' A' ' 83' ' ' VAL . 13.8 m-85 -88.71 135.14 33.66 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.389 -0.819 . . . . 0.0 109.294 -178.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.9 p -127.96 -12.93 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.235 -0.916 . . . . 0.0 111.314 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.438 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -110.23 144.63 30.49 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 120.527 -1.358 . . . . 0.0 109.584 -179.767 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.755 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.0 Cg_endo -77.78 115.54 3.85 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.408 2.072 . . . . 0.0 109.868 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 163.97 -142.76 8.04 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.69 159.74 22.46 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.221 -1.164 . . . . 0.0 109.215 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.526 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 57.9 m-85 -140.68 160.85 39.14 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.413 -0.805 . . . . 0.0 109.297 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 49.2 t60 -122.0 142.09 50.68 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.702 HG22 ' CE1' ' A' ' 56' ' ' HIS . 21.7 t -125.17 149.6 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.862 -1.148 . . . . 0.0 110.991 -178.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.44 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -150.28 160.65 43.55 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 107.448 -1.315 . . . . 0.0 107.448 178.129 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.04 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -151.79 153.66 34.7 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.843 -1.16 . . . . 0.0 111.292 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.537 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.8 OUTLIER -126.0 121.99 60.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.58 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.9 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.6 OUTLIER -88.36 141.54 28.46 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 120.596 -1.315 . . . . 0.0 109.103 -178.406 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.66 109.12 10.4 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 118.679 -1.209 . . . . 0.0 109.694 178.573 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.841 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -104.07 -11.03 17.59 Favored 'General case' 0 C--N 1.288 -2.069 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.73 -49.46 0.84 Allowed Glycine 0 N--CA 1.487 2.074 0 N-CA-C 107.729 -2.148 . . . . 0.0 107.729 -178.442 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -118.41 -5.56 10.8 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.678 -0.895 . . . . 0.0 109.877 179.016 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.55 164.09 26.04 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.462 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 6.8 p -151.18 -177.23 5.92 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.344 -1.092 . . . . 0.0 109.684 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.9 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -153.17 154.81 35.5 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 179.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -112.94 124.79 53.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.141 -0.974 . . . . 0.0 109.938 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.04 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -114.53 155.24 26.81 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.416 -0.802 . . . . 0.0 110.032 -179.643 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -164.66 91.59 0.11 Allowed Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.271 -1.531 . . . . 0.0 109.271 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.779 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -106.88 175.84 5.37 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.127 -1.219 . . . . 0.0 109.895 -179.683 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -122.12 160.34 25.28 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.378 -0.826 . . . . 0.0 108.99 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.131 HG11 ' CE2' ' A' ' 58' ' ' TYR . 25.9 t -144.17 147.51 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.011 -1.055 . . . . 0.0 110.448 -179.022 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -137.14 98.98 3.87 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.385 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.73 HG22 HD12 ' A' ' 17' ' ' LEU . 29.1 t -96.93 139.83 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.111 -0.993 . . . . 0.0 110.658 -179.004 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 23.6 mm-40 -110.59 -159.41 0.68 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.512 -0.743 . . . . 0.0 109.62 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.755 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.123 -0.986 . . . . 0.0 109.243 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.706 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.926 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.3 t -70.62 149.44 47.05 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.196 -0.94 . . . . 0.0 109.336 -179.203 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.731 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 4.9 mp -84.62 108.18 17.22 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.088 -178.359 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.666 HG21 ' CE1' ' A' ' 26' ' ' HIS . 0.7 OUTLIER -123.53 104.28 14.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 120.777 -1.202 . . . . 0.0 108.912 178.708 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.85 76.52 0.3 Allowed Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.551 ' HD2' ' HA ' ' A' ' 25' ' ' PHE . 34.6 Cg_endo -73.26 150.43 47.28 Favored 'Trans proline' 0 C--N 1.308 -1.567 0 C-N-CA 122.728 2.285 . . . . 0.0 111.918 179.677 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.524 ' CD2' ' HA ' ' A' ' 23' ' ' ALA . 32.6 t-80 161.94 -36.82 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.796 0 CA-C-O 121.782 0.801 . . . . 0.0 108.944 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.97 -138.04 14.52 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 107.942 -2.063 . . . . 0.0 107.942 -178.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -77.74 147.83 25.03 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 122.027 1.818 . . . . 0.0 109.313 178.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.85 ' HB3' HG22 ' A' ' 85' ' ' VAL . 0.6 OUTLIER -110.59 115.73 30.12 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.251 -0.906 . . . . 0.0 109.486 -179.441 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -106.24 160.01 15.67 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 45.7 t -56.3 119.34 5.82 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.316 -0.865 . . . . 0.0 109.471 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.42 46.92 3.92 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 7.5 mm100 -127.4 153.52 46.15 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.145 -1.209 . . . . 0.0 110.543 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.838 HD11 ' HB2' ' A' ' 55' ' ' SER . 1.8 tm? -108.81 92.31 4.0 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.652 ' HB3' ' HB2' ' A' ' 56' ' ' HIS . . . -71.21 156.33 39.68 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 178.702 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.497 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -122.74 112.49 17.99 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.26 -1.525 . . . . 0.0 108.341 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.798 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.6 m-85 -100.64 173.84 6.35 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 122.512 1.148 . . . . 0.0 112.415 -177.19 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.666 ' CE1' HG21 ' A' ' 11' ' ' VAL . 5.9 p80 -172.47 147.61 1.91 Allowed 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.19 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.908 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.82 156.88 12.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.961 -1.087 . . . . 0.0 108.198 -178.484 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.926 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -132.66 122.34 24.52 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.442 -1.303 . . . . 0.0 112.702 -177.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.053 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.8 -70.06 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.797 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.79 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.053 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.1 Cg_endo -77.62 77.76 3.76 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 121.592 1.528 . . . . 0.0 108.718 178.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.567 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.3 OUTLIER -35.16 -55.57 1.01 Allowed Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.817 -0.552 . . . . 0.0 111.284 -178.795 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.613 ' O ' HD21 ' A' ' 72' ' ' LEU . 36.8 Cg_endo -80.62 81.29 2.78 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.141 1.894 . . . . 0.0 111.236 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 30' ' ' PRO . 40.1 t -111.89 150.3 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 120.908 -1.12 . . . . 0.0 109.0 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 18.5 p -116.91 -28.92 6.16 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.203 -0.936 . . . . 0.0 110.593 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.93 143.7 17.15 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.088 -1.008 . . . . 0.0 110.274 -179.569 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.905 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -130.79 157.37 43.05 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.517 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -125.05 104.25 8.45 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.305 -0.872 . . . . 0.0 108.669 179.102 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.798 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 32.7 m95 -88.85 -178.6 5.78 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 109.276 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.522 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -148.24 102.73 3.38 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 178.085 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.96 ' CE1' HG21 ' A' ' 47' ' ' VAL . 4.7 m-30 -81.61 -66.03 0.94 Allowed 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 119.182 -1.007 . . . . 0.0 110.561 -177.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.89 11.12 47.55 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.176 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.552 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 12.6 p30 -97.04 33.07 1.99 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.249 -1.148 . . . . 0.0 108.224 179.043 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.24 -34.84 5.08 Favored Glycine 0 N--CA 1.48 1.603 0 N-CA-C 105.449 -3.06 . . . . 0.0 105.449 -175.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 50.2 m -108.35 100.78 10.04 Favored 'General case' 0 N--CA 1.485 1.305 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.76 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.522 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -75.3 -86.96 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.166 -0.959 . . . . 0.0 109.773 -178.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -50.89 144.77 8.04 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.308 0.575 . . . . 0.0 109.806 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.96 HG21 ' CE1' ' A' ' 40' ' ' PHE . 91.9 t -133.84 105.91 8.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.36 -0.838 . . . . 0.0 110.764 -178.701 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -83.12 115.75 22.03 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.479 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.905 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -129.26 164.08 24.25 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.028 -1.045 . . . . 0.0 110.74 -178.764 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.18 151.02 19.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.659 -0.65 . . . . 0.0 109.574 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.589 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.65 -155.31 0.51 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -88.5 38.91 0.47 Allowed 'Trans proline' 0 C--N 1.298 -2.1 0 C-N-CA 122.269 1.979 . . . . 0.0 110.191 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.661 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -139.55 155.57 47.42 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 120.227 -1.546 . . . . 0.0 111.895 -178.705 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.504 ' HB2' ' NE1' ' A' ' 38' ' ' TRP . . . -165.18 -169.64 1.69 Allowed 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.838 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -154.0 144.09 22.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.018 -1.051 . . . . 0.0 109.816 179.407 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.652 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -94.48 129.89 41.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.705 -0.622 . . . . 0.0 111.031 -178.797 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -105.47 85.57 2.27 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.12 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.023 ' CE2' HG11 ' A' ' 83' ' ' VAL . 13.0 m-85 -92.29 134.2 35.12 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.986 -1.071 . . . . 0.0 110.073 -178.544 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.4 m -127.3 -3.12 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.605 -0.685 . . . . 0.0 111.046 -179.083 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.446 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.2 OUTLIER -117.61 140.5 27.6 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 120.651 -1.281 . . . . 0.0 109.36 -179.944 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.852 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.1 Cg_endo -77.65 109.47 2.76 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 122.479 2.119 . . . . 0.0 110.155 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 169.81 -144.23 8.41 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.89 162.25 15.0 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.166 -1.196 . . . . 0.0 109.826 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.512 ' HB2' ' HB ' ' A' ' 83' ' ' VAL . 61.5 m-85 -146.91 165.28 30.26 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -124.87 153.9 41.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.151 -0.968 . . . . 0.0 108.503 179.008 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.612 HG13 ' NE2' ' A' ' 56' ' ' HIS . 12.5 t -134.19 145.19 33.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 120.839 -1.163 . . . . 0.0 110.764 -179.057 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.452 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -150.63 159.03 44.79 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 178.129 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.993 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -152.03 157.26 41.43 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.868 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.587 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.3 p -150.14 108.19 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.851 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.16 151.11 22.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.931 -1.106 . . . . 0.0 109.154 -179.156 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.42 119.7 23.09 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.362 -0.935 . . . . 0.0 109.708 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.613 HD21 ' O ' ' A' ' 32' ' ' PRO . 7.4 mt -109.23 -12.97 14.73 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-O 121.518 0.675 . . . . 0.0 109.492 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.07 -47.41 1.05 Allowed Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -178.646 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -113.87 -6.24 13.22 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.574 -0.956 . . . . 0.0 109.696 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.65 158.84 27.83 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -150.8 168.34 24.73 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.199 -1.177 . . . . 0.0 109.395 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.851 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -141.74 132.62 25.87 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.199 -0.938 . . . . 0.0 109.358 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.2 mp -101.76 147.06 26.92 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.15 -0.969 . . . . 0.0 110.45 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.993 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -133.26 160.11 38.25 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.655 -0.653 . . . . 0.0 109.886 -179.292 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.491 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.42 88.91 0.09 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.509 HG22 HD13 ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.48 175.8 5.28 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.087 -1.243 . . . . 0.0 109.976 -179.755 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -117.87 155.37 30.27 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.243 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.023 HG11 ' CE2' ' A' ' 58' ' ' TYR . 25.1 t -134.82 143.42 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.172 -0.955 . . . . 0.0 110.049 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -131.83 104.0 6.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.37 -0.832 . . . . 0.0 109.038 179.407 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.85 HG22 ' HB3' ' A' ' 17' ' ' LEU . 86.0 t -102.43 132.19 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.345 -0.847 . . . . 0.0 109.964 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.45 -160.98 0.81 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.201 -0.937 . . . . 0.0 109.391 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.852 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.632 0 O-C-N 121.064 -1.022 . . . . 0.0 109.427 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.873 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.812 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.79 139.68 30.22 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.77 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.6 mp -97.19 89.55 4.81 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.148 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.941 HG12 ' HD3' ' A' ' 13' ' ' PRO . 65.3 t -99.08 112.34 30.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.885 -1.134 . . . . 0.0 109.092 179.521 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.504 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -124.1 71.18 0.44 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.941 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.4 Cg_endo -73.64 150.4 45.22 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.803 2.336 . . . . 0.0 112.153 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.468 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.9 t-80 168.9 -38.87 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.681 0.753 . . . . 0.0 109.208 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.29 -138.05 14.56 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 -178.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.62 147.0 24.57 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 121.972 1.782 . . . . 0.0 109.166 178.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.953 HD21 ' HB2' ' A' ' 23' ' ' ALA . 2.7 mt -117.26 98.56 6.5 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.2 -0.937 . . . . 0.0 109.779 -179.301 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.09 165.66 14.98 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.269 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 t -60.85 114.74 3.22 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.243 -0.91 . . . . 0.0 109.272 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.68 39.52 2.72 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.84 154.58 51.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.152 -1.205 . . . . 0.0 110.015 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.717 HD12 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -115.82 128.14 55.59 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.805 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.953 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -92.69 148.37 22.12 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.533 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -105.25 121.9 44.81 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.067 -1.645 . . . . 0.0 108.04 179.012 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.815 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 5.2 m-85 -105.39 170.53 7.83 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 121.914 0.864 . . . . 0.0 111.721 -177.009 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.587 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.72 140.14 3.84 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.793 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.999 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.6 mm -109.42 148.67 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.279 -0.888 . . . . 0.0 109.309 -178.345 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.644 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -133.33 122.6 24.07 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.989 -178.842 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.139 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 175.25 -61.86 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.078 -1.014 . . . . 0.0 109.552 178.134 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.139 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.3 Cg_endo -79.17 68.49 8.27 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.209 1.939 . . . . 0.0 109.699 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.634 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.0 OUTLIER -15.42 -64.03 0.03 OUTLIER Pre-proline 0 N--CA 1.506 2.327 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.83 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.634 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.4 Cg_endo -78.52 73.39 5.9 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 C-N-CA 121.774 1.65 . . . . 0.0 111.202 -179.513 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 30' ' ' PRO . 2.8 t -96.41 136.64 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.894 -1.129 . . . . 0.0 109.656 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.5 t -115.89 -15.33 11.25 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.48 -0.763 . . . . 0.0 109.331 179.01 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.6 149.43 0.48 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.311 -0.868 . . . . 0.0 109.667 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.624 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -136.93 139.68 41.73 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.59 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.61 ' O ' HG23 ' A' ' 69' ' ' VAL . 10.2 mtm-85 -93.33 109.04 20.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.138 -0.976 . . . . 0.0 109.136 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.977 ' CH2' HD11 ' A' ' 27' ' ' ILE . 18.7 m95 -93.85 179.81 5.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.918 -1.114 . . . . 0.0 109.621 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.489 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.76 106.61 3.41 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.328 -1.731 . . . . 0.0 106.328 177.369 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 1.014 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.7 m-30 -81.37 -66.44 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 118.451 -1.3 . . . . 0.0 111.37 -176.892 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.11 -4.91 59.03 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.1 p30 -90.41 23.71 2.86 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.335 -1.097 . . . . 0.0 109.164 179.34 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 122.56 -38.11 2.64 Favored Glycine 0 C--N 1.298 -1.576 0 N-CA-C 106.129 -2.788 . . . . 0.0 106.129 -176.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.77 101.52 12.96 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 177.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.489 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.38 -98.28 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 0.0 109.958 -178.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -56.92 150.1 17.33 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.286 0.565 . . . . 0.0 109.927 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 1.014 HG21 ' CE1' ' A' ' 40' ' ' PHE . 70.8 t -138.9 132.97 40.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.47 -0.769 . . . . 0.0 110.591 -178.627 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -112.89 89.8 3.18 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.283 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.686 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -92.84 152.53 19.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.373 -0.829 . . . . 0.0 111.423 -178.135 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.72 150.2 23.75 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.624 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.08 -156.4 0.49 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.24 -1.944 . . . . 0.0 108.24 -179.27 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.415 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.1 Cg_endo -88.43 42.63 0.7 Allowed 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.122 1.881 . . . . 0.0 110.479 178.436 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.686 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -146.87 144.38 29.24 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.072 -1.642 . . . . 0.0 112.009 -179.089 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 49' ' ' ALA . . . -149.54 -169.6 3.42 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.599 ' HB3' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -152.64 138.8 18.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.249 -0.907 . . . . 0.0 109.174 179.558 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.815 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 3.6 m-70 -102.91 135.45 44.57 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.231 -0.918 . . . . 0.0 111.101 -178.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.439 ' H ' ' HG2' ' A' ' 57' ' ' ARG . 2.0 ptp180 -100.44 95.06 6.49 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.022 ' CE2' HG11 ' A' ' 83' ' ' VAL . 23.8 m-85 -95.5 120.24 35.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.225 -0.922 . . . . 0.0 109.232 -179.232 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.6 p -118.17 -29.71 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.241 -0.912 . . . . 0.0 111.165 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.405 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -90.71 143.35 28.82 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 120.619 -1.3 . . . . 0.0 109.376 -179.678 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.405 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.0 Cg_endo -76.26 133.04 14.34 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.575 2.183 . . . . 0.0 110.281 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.59 -135.05 5.93 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 -179.616 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -127.27 164.51 21.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -1.193 . . . . 0.0 109.651 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.65 ' HB2' HG13 ' A' ' 83' ' ' VAL . 59.7 m-85 -142.98 152.84 42.39 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.466 -0.771 . . . . 0.0 109.205 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -112.99 130.37 56.16 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.774 HG13 ' CE1' ' A' ' 56' ' ' HIS . 59.2 t -116.0 150.58 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 110.821 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.79 155.51 42.42 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.85 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.064 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.53 158.57 44.31 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.853 -1.155 . . . . 0.0 111.518 -179.538 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -129.84 127.17 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.423 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 1.011 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.3 OUTLIER -89.07 141.87 28.12 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 120.656 -1.277 . . . . 0.0 109.015 -178.743 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.3 110.48 11.56 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.589 -1.245 . . . . 0.0 109.698 178.425 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.925 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.9 mp -105.49 -11.1 16.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.072 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.66 -49.62 0.83 Allowed Glycine 0 N--CA 1.486 2.011 0 N-CA-C 107.669 -2.173 . . . . 0.0 107.669 -178.128 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.44 -5.76 11.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.58 -0.953 . . . . 0.0 109.884 178.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -140.04 162.5 26.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.478 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.8 p -151.44 -179.23 7.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.306 -1.114 . . . . 0.0 109.579 -179.598 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 1.011 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -154.17 166.39 33.25 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.2 mt -119.93 132.75 55.62 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.068 -1.02 . . . . 0.0 110.227 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.064 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -117.4 157.14 26.7 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.524 -0.735 . . . . 0.0 109.769 -179.879 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.65 95.12 0.11 Allowed Glycine 0 N--CA 1.485 1.938 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.612 HG22 HD23 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -116.38 -173.33 2.35 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.232 -1.158 . . . . 0.0 109.937 179.932 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -150.74 153.7 36.0 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.435 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.022 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.0 154.25 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.66 -1.275 . . . . 0.0 109.845 -179.519 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLN . . . . . 0.425 ' N ' HG23 ' A' ' 83' ' ' VAL . 12.0 tt0 -123.07 99.81 6.56 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.464 -0.773 . . . . 0.0 108.985 179.073 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.778 HG21 ' HB3' ' A' ' 58' ' ' TYR . 41.6 t -86.15 137.71 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.24 -0.912 . . . . 0.0 109.846 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -113.15 154.41 26.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.101 -0.999 . . . . 0.0 109.667 179.711 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.736 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.886 HG22 ' HB3' ' A' ' 28' ' ' ALA . 0.8 OUTLIER -71.47 149.87 45.44 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.178 -0.951 . . . . 0.0 109.253 -179.427 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.756 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.0 mp -92.29 98.28 11.41 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.315 -178.555 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.64 HG21 ' CE1' ' A' ' 26' ' ' HIS . 11.1 t -108.81 101.3 12.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 120.873 -1.142 . . . . 0.0 108.273 178.371 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.555 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -115.64 75.49 0.26 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.459 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.512 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 32.8 Cg_endo -72.63 148.7 47.78 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.59 2.194 . . . . 0.0 111.694 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.507 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 54.3 t60 159.11 -35.63 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.659 0.742 . . . . 0.0 109.003 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.81 -141.52 15.25 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 108.437 -1.865 . . . . 0.0 108.437 -179.226 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -77.2 149.19 27.95 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 122.288 1.992 . . . . 0.0 109.434 179.106 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 1.013 HD21 ' HB2' ' A' ' 23' ' ' ALA . 1.4 mt -117.74 117.51 29.53 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.161 -0.962 . . . . 0.0 109.888 -179.39 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.429 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -94.06 168.77 10.73 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.137 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.572 ' H ' ' HB3' ' A' ' 87' ' ' ALA . 2.2 t -56.79 118.72 5.19 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.25 -0.906 . . . . 0.0 109.01 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.63 43.22 6.19 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.22 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.429 ' HB2' ' O ' ' A' ' 18' ' ' ALA . 7.9 tp-100 -111.6 150.77 29.6 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.42 -1.047 . . . . 0.0 110.869 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.783 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.1 tm? -111.52 102.68 11.0 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.573 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 1.013 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -86.68 156.34 20.02 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.512 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -118.97 108.78 15.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.367 -1.458 . . . . 0.0 108.474 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.684 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.2 m-85 -96.02 168.18 10.78 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 122.428 1.109 . . . . 0.0 112.394 -177.343 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.64 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.0 142.44 5.13 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.808 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.815 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -107.42 156.95 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 120.88 -1.138 . . . . 0.0 109.34 -178.467 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.886 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -134.76 120.6 19.62 Favored 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 118.738 -1.185 . . . . 0.0 112.472 -178.639 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.055 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.56 -71.85 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.211 -0.931 . . . . 0.0 109.263 177.663 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.055 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -76.27 78.24 3.3 Favored 'Trans proline' 0 C--N 1.313 -1.312 0 C-N-CA 121.766 1.644 . . . . 0.0 109.465 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.52 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -35.47 -54.0 1.25 Allowed Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.859 -0.526 . . . . 0.0 111.768 -179.145 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.582 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.1 Cg_endo -78.74 60.85 7.84 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.192 1.928 . . . . 0.0 111.819 -179.407 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.997 HG23 ' O ' ' A' ' 30' ' ' PRO . 55.6 t -89.51 145.28 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 120.798 -1.189 . . . . 0.0 109.358 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.7 t -116.63 -31.97 5.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.306 -0.871 . . . . 0.0 109.914 179.506 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.0 138.71 14.17 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.322 -0.861 . . . . 0.0 109.152 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.904 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.1 t -124.19 151.93 43.48 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.795 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.566 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -118.22 101.43 8.2 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.206 -0.934 . . . . 0.0 108.921 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.684 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 25.9 m95 -87.88 -179.59 6.27 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.124 -0.985 . . . . 0.0 109.162 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.405 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.8 OUTLIER -148.96 101.7 3.19 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 177.834 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.975 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.6 m-30 -80.35 -59.92 2.52 Favored 'General case' 0 C--N 1.301 -1.503 0 C-N-CA 119.028 -1.069 . . . . 0.0 110.111 -177.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.1 19.72 49.33 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -178.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -109.06 -104.71 0.36 Allowed 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 178.569 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -80.33 -21.03 65.59 Favored Glycine 0 N--CA 1.479 1.507 0 N-CA-C 107.852 -2.099 . . . . 0.0 107.852 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.16 130.17 30.69 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.347 -1.09 . . . . 0.0 109.557 179.549 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.405 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.2 -85.01 0.1 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.983 -1.073 . . . . 0.0 109.668 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -57.64 150.61 18.99 Favored 'General case' 0 N--CA 1.493 1.711 0 CA-C-O 121.132 0.492 . . . . 0.0 109.684 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.975 HG21 ' CE1' ' A' ' 40' ' ' PHE . 32.5 t -137.1 112.33 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 O-C-N 121.288 -0.882 . . . . 0.0 111.03 -178.797 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -96.09 95.75 8.39 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.42 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.904 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -107.63 171.37 7.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.455 -0.778 . . . . 0.0 111.06 -178.548 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.06 153.18 21.82 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.802 -0.561 . . . . 0.0 109.702 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.571 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.61 -156.42 0.59 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.776 -1.729 . . . . 0.0 108.776 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -88.45 41.75 0.63 Allowed 'Trans proline' 0 C--N 1.294 -2.298 0 C-N-CA 122.201 1.934 . . . . 0.0 110.277 178.746 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.599 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -142.8 152.88 42.7 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 119.933 -1.729 . . . . 0.0 112.508 -178.794 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.634 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -175.7 154.41 1.56 Allowed 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.469 ' CB ' HD11 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -113.34 161.83 16.79 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.742 -1.224 . . . . 0.0 110.327 -179.744 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.811 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 1.6 m-70 -113.11 141.2 47.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.506 -0.746 . . . . 0.0 110.578 -179.228 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.03 93.28 4.18 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.084 ' CE2' HG11 ' A' ' 83' ' ' VAL . 39.6 m-85 -95.91 133.56 39.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.024 -1.047 . . . . 0.0 109.553 -179.143 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 58.5 t -116.31 -41.65 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.319 -0.863 . . . . 0.0 111.029 -178.601 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.42 ' HA ' ' HD3' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -87.64 145.52 37.28 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.607 -1.308 . . . . 0.0 109.768 -179.117 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 60' ' ' LEU . 34.6 Cg_endo -78.39 129.66 9.56 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 122.551 2.167 . . . . 0.0 110.232 179.379 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.88 -136.91 5.28 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 3.5 mtp180 -131.51 126.3 34.6 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -1.173 . . . . 0.0 109.739 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.566 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 44.8 m-85 -110.62 158.81 18.17 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.217 -0.927 . . . . 0.0 109.393 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.465 ' CD2' HG22 ' A' ' 67' ' ' THR . 70.4 t60 -111.02 132.12 54.49 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.76 HG22 ' CE1' ' A' ' 56' ' ' HIS . 67.5 t -114.23 152.13 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.272 -0.892 . . . . 0.0 110.352 -179.092 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.465 HG22 ' CD2' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -147.88 158.84 44.24 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.707 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.109 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -154.71 120.44 5.15 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 120.871 -1.143 . . . . 0.0 111.679 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.539 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.5 p -112.68 110.91 33.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 177.609 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.842 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.9 146.75 24.74 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.755 -1.216 . . . . 0.0 109.441 -178.944 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -125.52 116.06 21.19 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.24 -0.912 . . . . 0.0 109.206 178.637 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.731 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -103.43 -13.75 16.51 Favored 'General case' 0 C--N 1.292 -1.906 0 CA-C-O 121.53 0.681 . . . . 0.0 109.33 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.56 -49.7 0.83 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.07 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -118.19 -5.76 10.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.674 -0.898 . . . . 0.0 109.857 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -143.03 161.49 27.56 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.431 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 3.2 p -151.45 168.82 23.68 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.291 -1.123 . . . . 0.0 109.362 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.842 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -140.69 136.1 32.29 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.13 -0.981 . . . . 0.0 109.066 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 13.6 mt -101.78 133.46 46.49 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.308 -0.87 . . . . 0.0 110.269 -179.182 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.109 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -122.13 156.16 34.23 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.593 -0.692 . . . . 0.0 109.952 -179.335 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.514 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -161.68 88.66 0.11 Allowed Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.564 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.696 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -105.82 -175.35 2.77 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.937 -1.331 . . . . 0.0 110.289 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -150.83 143.48 24.44 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.274 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.084 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -129.07 149.13 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 120.779 -1.201 . . . . 0.0 110.059 -179.43 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 72.2 mt-30 -114.7 98.7 7.01 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.462 -0.774 . . . . 0.0 108.97 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.794 HG21 ' HB3' ' A' ' 58' ' ' TYR . 96.4 t -83.74 144.65 9.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.087 -1.008 . . . . 0.0 109.945 -179.456 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -126.58 -154.87 0.65 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.489 -0.757 . . . . 0.0 109.343 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.572 ' HB3' ' H ' ' A' ' 19' ' ' SER . . . . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.454 -0.779 . . . . 0.0 110.579 179.35 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.691 ' HB3' ' CG2' ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.862 HG22 ' HB3' ' A' ' 28' ' ' ALA . 0.6 OUTLIER -70.06 149.48 47.61 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.219 -0.926 . . . . 0.0 109.346 -179.229 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 10' ' ' LEU . 4.2 mp -83.59 110.42 18.23 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.902 -178.446 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.668 HG21 ' CE1' ' A' ' 26' ' ' HIS . 0.5 OUTLIER -124.65 101.52 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 120.753 -1.217 . . . . 0.0 109.216 179.116 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.625 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.88 76.12 0.28 Allowed Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.588 ' O ' ' HB2' ' A' ' 14' ' ' HIS . 35.1 Cg_endo -72.9 149.7 47.9 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.774 2.316 . . . . 0.0 112.778 -179.464 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.588 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 152.25 175.28 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.908 0 CA-C-N 114.85 -1.068 . . . . 0.0 108.388 178.743 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.99 -141.6 2.11 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -76.91 150.06 29.8 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 122.123 1.882 . . . . 0.0 109.552 179.39 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 1.018 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.6 mm? -99.75 85.01 3.01 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.122 -0.986 . . . . 0.0 108.867 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -82.32 166.13 19.76 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.104 -0.997 . . . . 0.0 108.664 179.702 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.1 t -54.83 117.32 3.31 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.408 -0.808 . . . . 0.0 109.123 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.17 43.21 5.69 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 -179.356 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.613 ' HG2' HD13 ' A' ' 17' ' ' LEU . 19.6 tp60 -112.54 145.82 39.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.448 -1.031 . . . . 0.0 110.696 -179.116 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.648 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.3 tm? -106.51 93.95 4.87 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.254 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 1.018 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -76.88 159.05 30.34 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.077 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.541 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.53 118.2 28.69 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.132 -1.605 . . . . 0.0 108.004 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.754 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 8.3 m-85 -103.95 174.65 5.78 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 122.705 1.24 . . . . 0.0 112.592 -176.682 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.668 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.1 OUTLIER -174.93 149.52 1.14 Allowed 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 177.992 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.871 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -113.98 156.33 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.806 -1.184 . . . . 0.0 108.63 -178.258 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.862 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -129.95 121.16 26.05 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.704 -1.247 . . . . 0.0 112.559 -178.001 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.043 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 170.88 -72.36 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.406 -0.808 . . . . 0.0 108.955 177.685 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.043 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.7 Cg_endo -77.09 78.82 3.31 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 C-N-CA 121.616 1.544 . . . . 0.0 108.593 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.72 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 13.0 mt -40.51 -50.36 6.85 Favored Pre-proline 0 N--CA 1.497 1.891 0 O-C-N 121.782 -0.574 . . . . 0.0 111.653 -178.553 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.72 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 36.8 Cg_endo -80.99 60.05 7.71 Favored 'Trans proline' 0 C--N 1.315 -1.185 0 C-N-CA 122.024 1.816 . . . . 0.0 112.001 -179.282 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.904 HG23 ' O ' ' A' ' 30' ' ' PRO . 38.7 t -90.94 147.82 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 120.708 -1.245 . . . . 0.0 109.288 179.006 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.12 -30.57 6.62 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.334 -0.854 . . . . 0.0 110.171 179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.36 145.06 18.85 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.245 -0.909 . . . . 0.0 109.334 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.829 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.3 t -129.22 158.72 38.23 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.533 ' O ' HG23 ' A' ' 69' ' ' VAL . 2.9 mtm-85 -123.12 101.67 7.53 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.298 -0.877 . . . . 0.0 108.895 179.546 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.754 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 37.6 m95 -89.17 178.66 6.31 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.124 -0.985 . . . . 0.0 109.619 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.463 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.33 102.34 3.06 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 177.515 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.992 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.2 m-30 -79.66 -60.03 2.51 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 118.794 -1.162 . . . . 0.0 109.76 -177.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.13 18.32 47.06 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.42 -103.32 0.32 Allowed 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 178.655 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.64 -20.26 60.27 Favored Glycine 0 C--N 1.297 -1.618 0 N-CA-C 107.805 -2.118 . . . . 0.0 107.805 176.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 12.9 p -135.91 130.06 33.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.353 -1.086 . . . . 0.0 109.342 179.421 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.49 -85.37 0.1 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.047 -1.033 . . . . 0.0 109.877 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.1 pm0 -56.07 152.05 11.12 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.303 0.573 . . . . 0.0 110.306 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.992 HG21 ' CE1' ' A' ' 40' ' ' PHE . 26.1 t -140.8 121.87 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 111.047 -179.004 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 62.1 m-20 -104.58 107.81 18.94 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.829 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -120.99 170.87 9.09 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.055 -1.028 . . . . 0.0 111.092 -178.475 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.48 152.4 20.05 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.648 -0.657 . . . . 0.0 109.643 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.545 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.51 -156.08 0.61 Allowed Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.842 -1.703 . . . . 0.0 108.842 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -88.83 40.79 0.54 Allowed 'Trans proline' 0 C--N 1.297 -2.151 0 C-N-CA 122.244 1.963 . . . . 0.0 110.24 178.383 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.595 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -140.0 157.59 45.42 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 119.936 -1.727 . . . . 0.0 112.307 -178.681 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.48 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -171.59 -167.67 0.53 Allowed 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.506 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.504 ' O ' ' CZ ' ' A' ' 40' ' ' PHE . 0.0 OUTLIER -146.74 175.99 10.2 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.096 -1.003 . . . . 0.0 109.186 179.29 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.648 ' O ' HD22 ' A' ' 22' ' ' LEU . 4.6 m80 -133.92 132.95 40.85 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.927 -1.108 . . . . 0.0 110.408 -179.139 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.53 89.17 2.92 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.071 ' CE2' HG11 ' A' ' 83' ' ' VAL . 32.7 m-85 -92.41 126.85 37.67 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.206 -0.934 . . . . 0.0 109.122 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 9.8 p -114.44 -28.41 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.407 -0.808 . . . . 0.0 111.514 -178.356 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.416 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -98.63 145.86 30.63 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 120.512 -1.367 . . . . 0.0 109.429 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.563 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.1 Cg_endo -77.36 119.28 4.89 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 122.383 2.055 . . . . 0.0 109.814 179.638 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 161.49 -162.14 33.65 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.619 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -107.09 130.17 54.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.221 -1.164 . . . . 0.0 110.12 -179.756 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.563 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 73.1 m-85 -112.87 161.1 17.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.465 -0.772 . . . . 0.0 109.07 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 70.0 t60 -115.23 122.22 45.33 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.462 -0.774 . . . . 0.0 109.069 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.576 HG22 ' NE2' ' A' ' 56' ' ' HIS . 66.1 t -102.74 152.01 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.38 -0.825 . . . . 0.0 109.899 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.57 158.52 44.25 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 178.855 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.059 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.51 156.67 42.35 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.92 -1.113 . . . . 0.0 110.989 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.533 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -147.07 104.68 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.385 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 179.224 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.805 ' CD1' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.84 150.44 22.9 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.734 -1.229 . . . . 0.0 109.703 -179.181 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.45 117.04 20.66 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.588 -0.845 . . . . 0.0 109.309 178.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.538 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.2 mp -105.36 -13.13 15.75 Favored 'General case' 0 C--N 1.293 -1.881 0 CA-C-O 121.52 0.676 . . . . 0.0 109.239 179.69 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.33 -56.21 0.59 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -114.63 -7.25 12.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.576 -0.955 . . . . 0.0 109.759 179.145 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -137.47 161.13 25.29 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.422 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.0 p -151.2 170.06 20.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.411 -1.053 . . . . 0.0 109.409 -179.724 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.805 ' HB3' ' CD1' ' A' ' 70' ' ' LEU . . . -144.16 126.63 15.9 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.882 . . . . 0.0 109.198 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -95.25 152.14 18.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.224 -0.923 . . . . 0.0 110.639 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.059 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -135.7 158.53 44.17 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.747 -0.596 . . . . 0.0 109.472 179.878 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.544 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.96 88.54 0.1 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.542 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -110.83 -171.91 1.92 Allowed 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.05 -1.265 . . . . 0.0 109.965 -179.893 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -149.54 149.56 30.9 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.071 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -132.29 138.29 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.76 -1.213 . . . . 0.0 110.056 -179.654 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.46 83.33 2.43 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.408 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.84 HG21 ' HB3' ' A' ' 58' ' ' TYR . 53.4 t -72.62 134.3 30.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.148 -0.97 . . . . 0.0 109.627 -179.418 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -110.77 -179.1 3.65 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.386 -0.821 . . . . 0.0 109.643 -179.592 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.563 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.919 . . . . 0.0 109.185 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.731 ' HB3' ' CG2' ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.843 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.2 t -75.44 155.83 35.89 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.199 -0.938 . . . . 0.0 108.873 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.992 ' HB3' HD11 ' A' ' 79' ' ' LEU . 0.0 OUTLIER -96.8 90.96 5.45 Favored 'General case' 0 N--CA 1.49 1.553 0 C-N-CA 119.961 -0.696 . . . . 0.0 110.141 -178.854 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.637 HG21 ' CE1' ' A' ' 26' ' ' HIS . 25.3 t -93.96 96.23 5.88 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.618 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -114.74 75.69 0.25 Allowed Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.716 -1.231 . . . . 0.0 110.545 -178.692 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.584 ' HD3' HG12 ' A' ' 11' ' ' VAL . 32.7 Cg_endo -73.01 149.38 46.7 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.5 2.133 . . . . 0.0 111.494 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.582 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 69.6 t60 163.16 -37.5 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 CA-C-O 121.771 0.796 . . . . 0.0 109.06 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.77 -137.62 13.49 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.133 -1.987 . . . . 0.0 108.133 -178.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.25 147.08 25.68 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 C-N-CA 122.138 1.892 . . . . 0.0 109.351 178.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.955 HD21 ' HB2' ' A' ' 23' ' ' ALA . 12.1 mt -113.15 85.85 2.26 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.264 -0.897 . . . . 0.0 109.967 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.56 160.78 32.1 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.9 t -54.41 123.47 13.08 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.237 -0.914 . . . . 0.0 109.466 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.47 48.41 4.53 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.444 ' HB3' HD23 ' A' ' 17' ' ' LEU . 19.9 mm-40 -123.94 150.83 44.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.434 -1.039 . . . . 0.0 110.313 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.623 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.3 tm? -108.48 93.26 4.43 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.829 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.955 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -76.42 155.75 33.72 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.544 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.49 121.09 37.72 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.689 -1.257 . . . . 0.0 108.426 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.789 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.2 m-85 -108.33 171.07 7.62 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-O 122.204 1.002 . . . . 0.0 111.397 -177.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.637 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -168.64 135.79 1.96 Allowed 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 177.803 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.731 ' CG2' ' HB3' ' A' ' 8' ' ' ALA . 0.1 OUTLIER -101.48 149.64 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.882 -1.136 . . . . 0.0 108.692 -178.509 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.843 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -128.75 126.71 40.56 Favored 'General case' 0 N--CA 1.5 2.068 0 C-N-CA 118.775 -1.17 . . . . 0.0 112.501 -177.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.029 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 169.18 -69.6 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.532 -0.73 . . . . 0.0 109.081 177.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.029 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.8 Cg_endo -76.96 79.59 3.08 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 121.654 1.569 . . . . 0.0 109.144 179.061 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.515 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -34.89 -54.34 1.02 Allowed Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.989 -0.444 . . . . 0.0 112.004 -178.921 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.535 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.5 Cg_endo -79.48 69.4 7.95 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.23 1.954 . . . . 0.0 111.775 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.943 HG23 ' O ' ' A' ' 30' ' ' PRO . 47.8 t -98.34 148.24 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.834 -1.166 . . . . 0.0 109.327 179.018 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 24.3 p -119.14 -29.15 5.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.307 -0.871 . . . . 0.0 110.26 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -159.29 145.05 16.17 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.221 -0.924 . . . . 0.0 109.619 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.792 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -130.75 151.44 51.18 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.52 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.7 OUTLIER -120.56 104.73 10.18 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.202 -0.936 . . . . 0.0 108.713 179.173 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.789 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 37.5 m95 -89.6 -178.6 5.59 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-O 122.079 0.942 . . . . 0.0 109.432 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.69 ' CB ' HG23 ' A' ' 67' ' ' THR . 0.3 OUTLIER -150.45 101.03 2.93 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 106.329 -1.73 . . . . 0.0 106.329 177.45 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.964 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.3 m-30 -80.37 -56.08 4.44 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.121 -177.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.6 20.41 54.25 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.133 -1.587 . . . . 0.0 109.133 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.566 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 1.1 p30 -104.25 -104.48 0.3 Allowed 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 178.671 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.24 -15.91 68.15 Favored Glycine 0 C--N 1.296 -1.646 0 N-CA-C 107.754 -2.138 . . . . 0.0 107.754 176.571 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.7 p -138.29 130.97 29.39 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.489 -1.007 . . . . 0.0 108.892 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.408 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.74 -85.4 0.09 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.941 -1.099 . . . . 0.0 109.752 -179.602 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -57.16 154.09 10.68 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.332 0.587 . . . . 0.0 110.121 -179.694 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.964 HG21 ' CE1' ' A' ' 40' ' ' PHE . 52.6 t -140.01 121.63 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.431 -0.793 . . . . 0.0 110.689 -178.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -104.21 118.97 37.93 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 178.007 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.792 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -132.75 166.06 23.1 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.031 -1.043 . . . . 0.0 111.042 -178.513 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.31 153.47 18.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.672 -0.642 . . . . 0.0 109.796 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.57 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.35 -155.93 0.39 Allowed Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -88.96 38.99 0.44 Allowed 'Trans proline' 0 C--N 1.298 -2.118 0 C-N-CA 122.544 2.163 . . . . 0.0 110.149 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.627 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -138.16 152.63 48.87 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.115 -1.616 . . . . 0.0 112.054 -178.789 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.493 ' HB2' ' NE1' ' A' ' 38' ' ' TRP . . . -163.61 -166.79 1.26 Allowed 'General case' 0 N--CA 1.494 1.775 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.469 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.572 ' OG ' HD11 ' A' ' 22' ' ' LEU . 1.4 p -158.49 141.1 14.42 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.11 -0.994 . . . . 0.0 109.79 179.392 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.844 ' CE1' HG13 ' A' ' 66' ' ' VAL . 3.6 m-70 -94.02 136.7 34.03 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.476 -0.765 . . . . 0.0 111.081 -178.791 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -110.89 87.71 2.6 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 178.396 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.092 ' CE2' HG11 ' A' ' 83' ' ' VAL . 15.1 m-85 -87.73 138.55 31.37 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.202 -0.936 . . . . 0.0 109.704 -178.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 12.0 p -129.51 -26.83 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.362 -0.836 . . . . 0.0 111.257 -178.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.422 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -98.36 144.6 28.38 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 120.507 -1.371 . . . . 0.0 109.718 -179.421 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.53 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.5 Cg_endo -77.64 116.39 4.04 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.55 2.167 . . . . 0.0 109.929 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 160.54 -154.78 25.84 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.93 165.41 11.56 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.022 -1.281 . . . . 0.0 109.817 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.604 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 47.2 m-85 -149.17 166.43 28.86 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 20.0 t-80 -127.88 142.18 51.34 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.317 -0.864 . . . . 0.0 108.858 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.844 HG13 ' CE1' ' A' ' 56' ' ' HIS . 30.3 t -122.64 146.0 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 120.997 -1.064 . . . . 0.0 110.712 -179.236 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.69 HG23 ' CB ' ' A' ' 39' ' ' ASP . 0.5 OUTLIER -151.44 156.28 40.32 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.541 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.004 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.92 161.17 42.82 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 120.849 -1.157 . . . . 0.0 111.128 -179.76 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.602 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.5 p -150.78 105.58 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 178.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.86 ' CD1' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.4 144.85 25.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.754 -1.216 . . . . 0.0 109.811 -178.845 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.455 ' C ' HD12 ' A' ' 72' ' ' LEU . . . -118.74 119.97 36.0 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.38 -0.928 . . . . 0.0 109.247 178.673 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.774 HD21 ' HB2' ' A' ' 30' ' ' PRO . 6.4 mp -114.16 -9.33 12.91 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 121.479 0.657 . . . . 0.0 109.485 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.641 ' O ' ' HB3' ' A' ' 74' ' ' ALA . . . 102.19 101.43 2.57 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 107.495 -2.242 . . . . 0.0 107.495 -178.235 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.641 ' HB3' ' O ' ' A' ' 73' ' ' GLY . . . 71.53 -0.38 3.17 Favored 'General case' 0 N--CA 1.485 1.292 0 O-C-N 121.714 -0.874 . . . . 0.0 110.372 -178.634 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -145.71 142.41 10.63 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -150.28 163.95 37.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.098 -1.236 . . . . 0.0 109.973 -179.382 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.86 ' HB3' ' CD1' ' A' ' 70' ' ' LEU . . . -132.15 119.81 21.42 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -89.75 149.69 22.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.911 . . . . 0.0 110.407 -179.202 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.004 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.2 OUTLIER -131.75 160.29 35.95 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.451 0.643 . . . . 0.0 110.103 -179.583 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.64 ' H ' HD13 ' A' ' 79' ' ' LEU . . . -169.21 92.52 0.1 OUTLIER Glycine 0 N--CA 1.483 1.814 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.613 HG22 ' HB3' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -113.07 175.39 5.46 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.034 -1.274 . . . . 0.0 109.377 179.524 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -117.68 156.17 28.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.309 -0.869 . . . . 0.0 108.851 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.092 HG11 ' CE2' ' A' ' 58' ' ' TYR . 25.1 t -137.25 139.87 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 120.983 -1.073 . . . . 0.0 110.635 -178.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -123.5 93.81 4.06 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.168 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.694 HG21 ' HB3' ' A' ' 58' ' ' TYR . 40.8 t -87.16 135.36 25.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.237 -0.914 . . . . 0.0 110.058 -179.303 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -107.66 -157.32 0.61 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.447 -0.783 . . . . 0.0 109.424 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.53 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.005 -1.059 . . . . 0.0 109.107 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.665 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.95 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.1 t -69.2 150.44 47.48 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.19 -0.944 . . . . 0.0 109.584 -178.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.752 ' N ' HD12 ' A' ' 10' ' ' LEU . 4.6 mp -83.19 107.18 15.56 Favored 'General case' 0 N--CA 1.489 1.516 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.648 -178.56 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.637 HG22 HG23 ' A' ' 9' ' ' THR . 0.4 OUTLIER -120.79 96.26 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 120.823 -1.173 . . . . 0.0 108.977 179.088 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.632 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -115.95 80.03 0.29 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.021 -1.231 . . . . 0.0 110.021 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.545 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 32.2 Cg_endo -71.94 147.58 49.73 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.513 2.142 . . . . 0.0 112.018 179.598 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.519 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 32.7 t-80 158.87 -33.98 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.08 -141.32 15.23 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -77.07 148.4 27.52 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.082 1.855 . . . . 0.0 109.209 178.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 1.005 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.4 mm? -105.59 109.89 22.02 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.111 -0.993 . . . . 0.0 109.681 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -89.18 161.17 16.61 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.2 t -57.82 116.74 3.65 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.151 -0.968 . . . . 0.0 109.389 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 89.8 44.74 4.75 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -121.22 152.87 38.33 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.252 -1.146 . . . . 0.0 110.609 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.772 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.5 tm? -107.39 99.07 8.61 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.852 -0.795 . . . . 0.0 108.852 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 1.005 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -80.34 153.71 28.21 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.545 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -116.03 125.14 52.05 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.479 -1.388 . . . . 0.0 108.081 179.411 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.752 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.6 m-85 -112.57 172.44 6.92 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 122.526 1.155 . . . . 0.0 112.285 -177.188 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.627 ' CE1' HG21 ' A' ' 11' ' ' VAL . 4.1 p80 -173.95 148.51 1.41 Allowed 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 177.175 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.886 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.21 157.51 12.05 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 120.733 -1.229 . . . . 0.0 108.599 -178.166 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.95 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -132.41 121.63 23.74 Favored 'General case' 0 N--CA 1.5 2.058 0 C-N-CA 118.698 -1.201 . . . . 0.0 112.542 -177.791 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.036 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.31 -71.54 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.402 -0.811 . . . . 0.0 108.867 177.759 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.036 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.6 Cg_endo -77.39 76.86 4.05 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 C-N-CA 121.708 1.605 . . . . 0.0 108.725 178.522 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.561 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -35.45 -55.78 1.08 Allowed Pre-proline 0 N--CA 1.497 1.921 0 O-C-N 121.956 -0.465 . . . . 0.0 111.472 -178.746 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.561 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.7 Cg_endo -80.16 75.1 5.23 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.125 1.884 . . . . 0.0 111.332 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.898 HG23 ' O ' ' A' ' 30' ' ' PRO . 20.5 t -106.03 149.22 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.024 -1.048 . . . . 0.0 109.131 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.1 p -114.59 -28.85 7.01 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.285 -0.884 . . . . 0.0 110.626 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -158.72 143.08 15.72 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.073 -1.017 . . . . 0.0 110.164 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.871 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -129.99 155.55 45.91 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.481 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.521 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 2.6 ttm180 -122.72 104.06 9.06 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.248 -0.907 . . . . 0.0 108.713 179.059 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.752 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 32.1 m95 -88.78 179.89 6.13 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.306 -0.871 . . . . 0.0 109.324 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.501 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.21 103.1 3.14 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 106.811 -1.551 . . . . 0.0 106.811 177.889 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.997 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.5 m-30 -81.16 -67.0 0.82 Allowed 'General case' 0 N--CA 1.493 1.683 0 C-N-CA 119.001 -1.079 . . . . 0.0 110.738 -177.502 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.64 7.58 56.62 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -178.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.6 p30 -98.34 35.6 1.75 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.415 -1.05 . . . . 0.0 108.317 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.88 -39.19 2.96 Favored Glycine 0 C--N 1.295 -1.699 0 N-CA-C 105.773 -2.931 . . . . 0.0 105.773 -176.2 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 87.7 p -107.27 101.82 11.17 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 177.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.501 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -75.58 -89.99 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -0.944 . . . . 0.0 110.189 -178.602 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -52.21 145.74 10.25 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-O 121.296 0.57 . . . . 0.0 109.884 -179.416 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.997 HG21 ' CE1' ' A' ' 40' ' ' PHE . 47.7 t -135.9 110.79 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.299 -0.875 . . . . 0.0 110.851 -178.703 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.23 107.41 19.18 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.368 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.871 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -120.02 165.79 14.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.198 -0.939 . . . . 0.0 110.98 -178.432 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.07 152.59 18.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.598 -0.689 . . . . 0.0 109.446 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.6 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.53 -156.12 0.41 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -88.97 40.99 0.54 Allowed 'Trans proline' 0 C--N 1.295 -2.242 0 C-N-CA 122.209 1.94 . . . . 0.0 110.381 178.465 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.633 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -139.52 159.26 42.57 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 119.953 -1.717 . . . . 0.0 112.509 -178.659 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.476 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -171.55 -167.05 0.48 Allowed 'General case' 0 N--CA 1.495 1.823 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.648 ' HB2' HD11 ' A' ' 22' ' ' LEU . 24.3 p -156.52 144.32 19.38 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.011 -1.056 . . . . 0.0 109.536 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.836 ' CE1' HG22 ' A' ' 66' ' ' VAL . 3.0 m-70 -102.4 146.25 28.35 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.595 0.712 . . . . 0.0 111.327 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -118.26 90.47 3.34 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 178.626 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.076 ' CE2' HG11 ' A' ' 83' ' ' VAL . 30.2 m-85 -92.63 128.76 38.6 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.067 -1.02 . . . . 0.0 110.012 -178.752 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.0 p -117.62 -27.84 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.484 -0.76 . . . . 0.0 111.108 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.478 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -101.77 146.44 32.25 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 120.561 -1.337 . . . . 0.0 109.483 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.478 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.3 Cg_endo -77.6 121.74 5.69 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 C-N-CA 122.286 1.991 . . . . 0.0 109.849 179.481 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 162.45 -163.31 35.0 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.457 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.3 OUTLIER -105.92 121.26 43.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.107 -1.231 . . . . 0.0 110.052 -179.805 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.603 ' HB2' HG13 ' A' ' 83' ' ' VAL . 64.6 m-85 -104.2 151.29 23.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 0.0 109.091 179.49 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.1 t60 -108.37 125.33 51.61 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.352 -0.842 . . . . 0.0 109.154 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.836 HG22 ' CE1' ' A' ' 56' ' ' HIS . 64.8 t -108.3 151.59 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.921 . . . . 0.0 110.185 -179.401 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.81 158.4 44.13 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.092 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -151.23 155.28 38.5 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.011 -1.056 . . . . 0.0 110.768 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.603 ' O ' HG13 ' A' ' 69' ' ' VAL . 8.1 p -148.35 108.09 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.877 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.13 149.99 22.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.818 -1.176 . . . . 0.0 109.367 -179.112 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.19 119.97 20.57 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.372 -0.931 . . . . 0.0 109.93 179.255 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.501 HD21 ' HA ' ' A' ' 33' ' ' VAL . 11.6 mt -110.86 -12.21 14.28 Favored 'General case' 0 C--N 1.295 -1.776 0 CA-C-O 121.498 0.666 . . . . 0.0 109.406 179.35 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.43 -49.65 0.86 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 -178.716 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -112.17 -7.71 14.03 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.517 -0.99 . . . . 0.0 109.71 179.084 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -145.84 153.48 25.33 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.412 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 1.7 p -150.89 169.37 21.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.191 -1.182 . . . . 0.0 109.691 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.877 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -144.2 154.02 42.69 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.394 -0.816 . . . . 0.0 108.997 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 5.1 mp -122.65 150.51 42.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.143 -0.973 . . . . 0.0 109.89 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.092 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -136.06 158.92 43.25 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.552 -0.718 . . . . 0.0 110.013 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.532 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -167.2 87.54 0.1 OUTLIER Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.768 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.644 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -107.46 -174.51 2.55 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.126 -1.22 . . . . 0.0 110.353 -179.491 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -150.88 143.0 24.09 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.246 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.076 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -128.82 145.02 36.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 120.683 -1.261 . . . . 0.0 109.636 -179.539 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -109.6 84.33 1.91 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.45 -0.781 . . . . 0.0 109.246 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.821 HG21 ' HB3' ' A' ' 58' ' ' TYR . 48.1 t -69.51 133.47 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.01 -1.056 . . . . 0.0 109.394 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -114.9 162.71 16.56 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.456 -0.777 . . . . 0.0 109.845 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.441 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.324 -0.86 . . . . 0.0 109.388 179.533 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.758 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.415 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.874 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.2 t -70.44 148.53 48.22 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.222 -0.924 . . . . 0.0 109.272 -179.367 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.1 mp -85.59 103.86 14.81 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.083 -178.547 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.746 HG21 ' CE1' ' A' ' 26' ' ' HIS . 4.7 t -117.08 104.79 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 120.772 -1.205 . . . . 0.0 108.829 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.54 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -117.77 73.99 0.29 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.544 ' HD2' ' HA ' ' A' ' 25' ' ' PHE . 35.0 Cg_endo -73.17 151.96 49.95 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.874 2.383 . . . . 0.0 112.462 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.568 ' CE1' ' HG2' ' A' ' 21' ' ' GLN . 26.8 t-80 158.52 -39.78 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.27 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.14 -137.0 13.73 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.074 -2.01 . . . . 0.0 108.074 -179.072 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.413 ' C ' HD22 ' A' ' 17' ' ' LEU . 35.3 Cg_endo -78.15 148.44 24.38 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 C-N-CA 122.152 1.901 . . . . 0.0 109.521 178.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.774 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.0 mm? -112.16 102.42 10.61 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.097 -1.002 . . . . 0.0 109.465 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.414 ' HB3' ' OE1' ' A' ' 21' ' ' GLN . . . -88.51 165.05 15.14 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.164 -0.96 . . . . 0.0 108.848 179.567 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.7 t -56.41 122.16 11.26 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.321 -0.862 . . . . 0.0 109.363 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 83.26 47.62 5.68 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.716 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.568 ' HG2' ' CE1' ' A' ' 14' ' ' HIS . 1.6 tp60 -120.26 150.66 40.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.345 -1.091 . . . . 0.0 110.622 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.717 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.3 tm? -107.27 96.67 6.58 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.774 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -79.31 156.59 27.97 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 178.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.507 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.97 117.49 27.42 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.516 -1.365 . . . . 0.0 108.094 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.767 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.8 m-85 -101.95 176.55 5.17 Favored 'General case' 0 N--CA 1.488 1.459 0 CA-C-O 122.459 1.124 . . . . 0.0 112.223 -177.004 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.746 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -174.3 143.41 0.86 Allowed 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.502 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.862 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.72 153.55 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.911 -1.118 . . . . 0.0 108.388 -179.067 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.874 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -131.62 123.43 27.86 Favored 'General case' 0 N--CA 1.501 2.101 0 C-N-CA 118.429 -1.308 . . . . 0.0 112.781 -177.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.044 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 173.3 -68.56 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.948 0 O-C-N 121.296 -0.877 . . . . 0.0 109.525 177.799 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.044 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -76.17 78.44 3.21 Favored 'Trans proline' 0 C--N 1.312 -1.395 0 C-N-CA 121.787 1.658 . . . . 0.0 109.497 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.53 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -32.86 -55.06 0.59 Allowed Pre-proline 0 N--CA 1.499 2.014 0 O-C-N 121.966 -0.459 . . . . 0.0 112.103 -179.16 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.564 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.3 Cg_endo -79.27 61.13 8.07 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 C-N-CA 122.324 2.016 . . . . 0.0 112.084 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 30' ' ' PRO . 90.2 t -85.86 152.21 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 120.593 -1.317 . . . . 0.0 109.564 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.432 ' N ' HG12 ' A' ' 33' ' ' VAL . 1.6 t -126.07 -33.14 2.69 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.489 -0.757 . . . . 0.0 109.783 179.294 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.53 140.69 15.31 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.395 -0.816 . . . . 0.0 109.296 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.867 HG23 ' HB3' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -127.5 150.78 49.52 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.666 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.499 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -116.96 103.88 10.72 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.216 -0.928 . . . . 0.0 108.788 179.257 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.767 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 33.7 m95 -89.12 -179.74 5.96 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.24 -0.912 . . . . 0.0 109.383 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.442 ' CB ' HG23 ' A' ' 67' ' ' THR . 0.2 OUTLIER -150.48 101.84 2.99 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 177.686 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.95 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.6 m-30 -79.9 -62.55 1.65 Allowed 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 118.834 -1.146 . . . . 0.0 109.992 -177.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.57 16.94 43.9 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.35 -102.95 0.32 Allowed 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -85.5 -18.33 60.52 Favored Glycine 0 C--N 1.297 -1.585 0 N-CA-C 107.872 -2.091 . . . . 0.0 107.872 176.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.5 m -135.18 126.24 27.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.455 -1.027 . . . . 0.0 108.996 179.489 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.407 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.43 -85.91 0.09 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.02 -1.05 . . . . 0.0 109.692 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -57.95 152.94 15.23 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.239 0.542 . . . . 0.0 109.679 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.95 HG21 ' CE1' ' A' ' 40' ' ' PHE . 27.5 t -139.22 118.46 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.295 -0.878 . . . . 0.0 110.943 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -101.53 101.28 11.82 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.195 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.867 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -113.2 168.61 9.58 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.265 -0.897 . . . . 0.0 111.082 -178.42 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.65 155.01 18.37 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 121.422 0.63 . . . . 0.0 109.618 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.618 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.96 -156.26 0.48 Allowed Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -88.93 40.44 0.51 Allowed 'Trans proline' 0 C--N 1.296 -2.198 0 C-N-CA 122.194 1.929 . . . . 0.0 110.356 178.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.633 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -142.06 156.64 45.41 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 119.99 -1.694 . . . . 0.0 112.357 -178.821 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.453 ' HB2' ' NE1' ' A' ' 38' ' ' TRP . . . -167.41 -168.34 1.03 Allowed 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.416 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 11.5 p -156.24 141.61 17.57 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.023 -1.048 . . . . 0.0 109.678 179.494 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.818 ' CE1' HG22 ' A' ' 66' ' ' VAL . 4.0 m-70 -99.01 143.86 28.81 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-O 121.743 0.783 . . . . 0.0 111.614 -178.328 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.536 HH21 HD21 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -114.6 90.63 3.39 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.459 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.071 ' CE2' HG11 ' A' ' 83' ' ' VAL . 37.0 m-85 -93.59 136.95 33.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.955 -1.091 . . . . 0.0 109.762 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 8.4 p -123.62 -33.12 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.283 -0.886 . . . . 0.0 111.356 -178.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.443 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -95.03 147.36 32.91 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 120.526 -1.359 . . . . 0.0 109.478 -179.431 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.443 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.4 Cg_endo -78.75 116.59 3.8 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.545 2.163 . . . . 0.0 109.972 179.844 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 166.68 -155.17 26.16 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.479 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 8.2 mtm-85 -115.1 123.08 48.06 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.261 -1.14 . . . . 0.0 109.715 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.573 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 62.5 m-85 -106.45 157.63 17.5 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.441 -0.787 . . . . 0.0 109.367 179.782 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 67.2 t60 -109.85 129.39 55.65 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.818 HG22 ' CE1' ' A' ' 56' ' ' HIS . 83.0 t -110.36 151.49 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.385 -0.822 . . . . 0.0 109.969 -179.439 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.442 HG23 ' CB ' ' A' ' 39' ' ' ASP . 0.2 OUTLIER -150.46 157.12 42.66 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.133 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.111 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.43 156.41 41.41 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 120.889 -1.132 . . . . 0.0 110.979 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.594 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.4 p -147.32 107.66 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.799 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -90.19 153.19 20.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.896 -1.128 . . . . 0.0 110.445 -178.39 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -131.13 117.91 19.75 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.303 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.908 HD21 ' HB2' ' A' ' 30' ' ' PRO . 6.1 mp -106.05 -12.86 15.64 Favored 'General case' 0 C--N 1.293 -1.85 0 CA-C-O 121.495 0.664 . . . . 0.0 109.29 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.15 -45.76 1.26 Allowed Glycine 0 N--CA 1.488 2.116 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -178.665 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.13 -6.76 12.48 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.59 -0.947 . . . . 0.0 109.704 179.082 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -150.02 165.23 29.76 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.35 168.75 23.83 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.246 -1.149 . . . . 0.0 109.512 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.799 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -145.14 140.68 28.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.487 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.55 HD13 ' O ' ' A' ' 68' ' ' ALA . 1.7 mm? -107.16 150.88 26.11 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.067 -1.02 . . . . 0.0 110.3 -179.453 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.111 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -134.96 158.53 44.08 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.467 -0.771 . . . . 0.0 109.842 -179.751 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.529 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -167.72 91.47 0.1 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.6 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -114.26 -171.57 1.94 Allowed 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.08 -1.247 . . . . 0.0 110.165 -179.7 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -150.15 147.96 28.37 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 179.201 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.071 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -129.86 140.81 48.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 120.617 -1.302 . . . . 0.0 110.027 -179.271 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLN . . . . . 0.464 ' HG2' ' HG2' ' A' ' 63' ' ' ARG . 0.8 OUTLIER -104.07 85.55 2.41 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.381 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.746 HG22 ' HB3' ' A' ' 17' ' ' LEU . 98.4 t -77.74 136.99 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.151 -0.968 . . . . 0.0 109.644 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -124.05 142.55 51.09 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.278 -0.889 . . . . 0.0 109.579 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.168 -0.957 . . . . 0.0 109.648 179.809 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.748 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.891 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.0 OUTLIER -73.48 149.21 42.49 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.282 -0.886 . . . . 0.0 109.209 -179.442 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.741 HD23 HG22 ' A' ' 81' ' ' THR . 5.2 mp -91.38 103.81 16.4 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.322 -178.315 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.672 HG11 ' NE2' ' A' ' 26' ' ' HIS . 3.1 t -117.12 105.47 18.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 O-C-N 120.776 -1.203 . . . . 0.0 108.782 178.633 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.542 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.93 74.17 0.3 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.504 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 35.3 Cg_endo -73.14 152.54 50.9 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.752 2.301 . . . . 0.0 111.983 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.494 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.2 t-80 163.74 -37.99 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 CA-C-O 121.698 0.761 . . . . 0.0 108.961 179.58 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.5 -136.54 13.57 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.308 -1.917 . . . . 0.0 108.308 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -78.01 149.18 25.46 Favored 'Trans proline' 0 C--N 1.304 -1.797 0 C-N-CA 122.246 1.964 . . . . 0.0 109.352 179.112 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.821 HD21 ' HB2' ' A' ' 23' ' ' ALA . 22.7 mt -120.75 93.37 4.01 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.041 -1.037 . . . . 0.0 110.102 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 86' ' ' GLU . . . -87.42 164.03 16.42 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.082 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.437 ' CB ' ' HA ' ' A' ' 87' ' ' ALA . 40.6 t -49.96 121.27 5.17 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.564 -0.71 . . . . 0.0 110.085 -179.406 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.31 47.47 4.35 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.658 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.514 ' HB3' HD23 ' A' ' 17' ' ' LEU . 4.4 mm-40 -122.4 149.57 43.64 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.23 -1.159 . . . . 0.0 110.94 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.729 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.4 tm? -108.49 98.55 8.06 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.821 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -81.93 154.63 25.68 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.504 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -117.4 121.37 40.9 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.611 -1.306 . . . . 0.0 107.981 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.754 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 7.3 m-85 -108.15 173.5 6.29 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 122.425 1.107 . . . . 0.0 112.362 -176.813 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.672 ' NE2' HG11 ' A' ' 11' ' ' VAL . 3.4 p80 -171.27 144.51 2.03 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 177.286 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.832 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.54 158.33 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.095 -1.003 . . . . 0.0 108.571 -178.578 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.891 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -136.91 122.41 19.59 Favored 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 118.445 -1.302 . . . . 0.0 112.627 -178.462 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.048 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.01 -68.24 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 121.201 -0.937 . . . . 0.0 109.595 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.048 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -76.41 78.39 3.29 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 C-N-CA 121.758 1.639 . . . . 0.0 109.374 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.523 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 3.7 mp -32.5 -54.97 0.56 Allowed Pre-proline 0 N--CA 1.499 2.019 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.559 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.7 Cg_endo -79.85 60.77 7.96 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 C-N-CA 122.249 1.966 . . . . 0.0 111.994 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.904 HG23 ' O ' ' A' ' 30' ' ' PRO . 94.2 t -84.14 149.0 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.633 -1.292 . . . . 0.0 109.708 179.283 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 31.9 p -122.11 -36.62 2.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.41 -0.806 . . . . 0.0 109.611 179.242 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -154.04 136.36 14.92 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.515 -0.741 . . . . 0.0 109.257 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.882 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.2 t -123.59 140.05 53.38 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.506 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.515 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 1.2 ttp180 -107.68 106.05 16.19 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.816 179.285 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.754 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 36.1 m95 -89.08 179.55 6.12 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.998 0.904 . . . . 0.0 109.111 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.424 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.78 100.23 2.8 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 177.445 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.989 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.7 m-30 -80.01 -59.79 2.58 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.787 -1.165 . . . . 0.0 110.011 -177.496 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.54 17.27 53.06 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -104.35 -103.75 0.31 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 178.714 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.61 -21.63 59.63 Favored Glycine 0 C--N 1.297 -1.631 0 N-CA-C 107.717 -2.153 . . . . 0.0 107.717 176.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 11.6 p -134.58 129.8 35.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.427 -1.043 . . . . 0.0 109.148 179.38 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.424 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.25 -84.22 0.11 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.074 -1.016 . . . . 0.0 109.686 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -58.78 149.27 26.92 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.153 0.501 . . . . 0.0 109.848 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.989 HG21 ' CE1' ' A' ' 40' ' ' PHE . 42.3 t -137.72 121.05 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.385 -0.822 . . . . 0.0 110.755 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 61.8 m-20 -104.17 97.26 7.25 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.221 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.882 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -107.89 166.35 10.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.251 -0.905 . . . . 0.0 111.239 -178.292 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.58 154.58 18.15 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 121.275 0.56 . . . . 0.0 109.533 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.602 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.88 -155.65 0.53 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.788 -1.725 . . . . 0.0 108.788 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -89.53 40.74 0.48 Allowed 'Trans proline' 0 C--N 1.295 -2.252 0 C-N-CA 122.256 1.971 . . . . 0.0 110.486 178.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.656 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.43 156.42 44.65 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 119.882 -1.762 . . . . 0.0 112.581 -178.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.459 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -168.06 -167.69 0.86 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.3 p -155.52 141.38 18.12 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.959 -1.088 . . . . 0.0 109.738 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.793 ' CE1' HG22 ' A' ' 66' ' ' VAL . 4.5 m-70 -97.98 142.83 29.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.499 -0.75 . . . . 0.0 111.442 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.517 HH21 HD21 ' A' ' 22' ' ' LEU . 0.9 OUTLIER -114.52 90.52 3.36 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.697 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.089 ' CE2' HG11 ' A' ' 83' ' ' VAL . 31.2 m-85 -94.15 122.3 36.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.11 -0.994 . . . . 0.0 109.751 -178.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.0 m -115.83 -26.02 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.487 -0.758 . . . . 0.0 111.104 -178.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.452 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -98.04 146.31 31.28 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 120.647 -1.283 . . . . 0.0 109.227 -179.636 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.452 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.1 Cg_endo -77.19 123.8 6.87 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 122.41 2.073 . . . . 0.0 110.018 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 156.47 -169.8 33.92 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.419 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -103.84 121.74 43.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.285 -1.127 . . . . 0.0 109.884 -179.823 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.586 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 79.9 m-85 -100.2 160.76 14.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.391 -0.818 . . . . 0.0 109.645 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -115.18 121.88 44.34 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 178.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.793 HG22 ' CE1' ' A' ' 56' ' ' HIS . 64.5 t -102.86 151.57 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.265 -0.897 . . . . 0.0 110.648 -179.051 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.61 160.2 43.97 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 178.427 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.08 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -153.3 157.97 40.89 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.094 -1.004 . . . . 0.0 110.695 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.617 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.2 p -147.07 107.8 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.817 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.2 OUTLIER -88.94 147.86 24.11 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.849 -1.157 . . . . 0.0 110.147 -178.043 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.47 113.88 16.08 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 121.932 0.872 . . . . 0.0 108.808 178.267 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.893 HD21 ' HB2' ' A' ' 30' ' ' PRO . 6.0 mp -103.36 -12.57 17.13 Favored 'General case' 0 C--N 1.289 -2.027 0 CA-C-O 121.553 0.692 . . . . 0.0 109.194 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 112.3 -49.84 0.82 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 -178.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.1 -5.66 11.92 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.577 -0.955 . . . . 0.0 109.815 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.16 160.78 27.87 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.426 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.2 p -151.04 173.31 14.48 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.398 -1.06 . . . . 0.0 109.218 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.817 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -149.88 129.63 13.25 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.261 -0.899 . . . . 0.0 109.651 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.3 tt -94.33 140.0 30.35 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.424 -0.798 . . . . 0.0 110.007 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.08 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -126.23 155.25 42.13 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.449 -0.782 . . . . 0.0 110.275 -179.336 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.472 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -162.65 87.05 0.11 Allowed Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.413 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.741 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -105.31 -175.6 2.84 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.028 -1.278 . . . . 0.0 109.633 179.904 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ASP . . . . . 0.406 ' N ' ' OG1' ' A' ' 81' ' ' THR . 0.7 OUTLIER -150.96 146.49 26.28 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 179.258 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.089 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -131.69 141.49 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 120.602 -1.311 . . . . 0.0 110.239 -179.474 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 17.9 tt0 -104.37 89.37 3.21 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.744 HG21 ' HB3' ' A' ' 58' ' ' TYR . 43.4 t -82.07 133.79 28.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.204 -0.935 . . . . 0.0 110.115 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.597 ' HG3' ' HA ' ' A' ' 18' ' ' ALA . 11.2 pt-20 -103.56 -147.97 0.39 Allowed 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.437 ' HA ' ' CB ' ' A' ' 19' ' ' SER . . . . . . . . 0 N--CA 1.489 1.508 0 O-C-N 120.952 -1.092 . . . . 0.0 109.335 179.326 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.738 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.752 HG22 ' HB3' ' A' ' 28' ' ' ALA . 0.6 OUTLIER -68.93 147.39 51.73 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.277 -0.889 . . . . 0.0 109.278 -179.147 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.767 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.0 mp -92.63 109.16 20.57 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.261 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.624 HG21 ' CE1' ' A' ' 26' ' ' HIS . 2.5 t -123.88 106.11 16.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.9 -1.125 . . . . 0.0 108.738 178.594 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.556 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.91 76.24 0.3 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.881 -1.287 . . . . 0.0 109.881 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.509 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.0 Cg_endo -73.38 150.25 46.33 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.729 2.286 . . . . 0.0 112.064 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.54 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 80.6 t60 165.84 -38.77 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.701 0 CA-C-O 121.696 0.76 . . . . 0.0 109.114 179.623 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.01 -137.63 14.29 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 108.221 -1.952 . . . . 0.0 108.221 -179.106 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.83 148.86 25.71 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 C-N-CA 122.237 1.958 . . . . 0.0 109.371 179.053 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.829 HD21 ' HB2' ' A' ' 23' ' ' ALA . 34.5 mt -118.3 100.08 7.26 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.066 -1.021 . . . . 0.0 109.987 -179.539 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.466 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -86.5 171.3 11.19 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.149 -0.969 . . . . 0.0 108.432 179.144 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 37.4 t -54.59 126.26 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.189 -0.944 . . . . 0.0 109.851 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 77.45 51.61 5.97 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.48 ' HB3' HD23 ' A' ' 17' ' ' LEU . 0.4 OUTLIER -115.55 149.78 37.65 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.392 -1.064 . . . . 0.0 110.838 -179.426 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.739 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.1 tm? -109.46 96.67 6.43 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.829 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -81.21 155.97 25.88 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.949 -1.094 . . . . 0.0 108.123 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.509 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.61 116.6 26.35 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.523 -1.361 . . . . 0.0 108.11 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.67 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 4.4 m-85 -104.53 170.38 7.92 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-O 122.319 1.057 . . . . 0.0 112.229 -176.83 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.624 ' CE1' HG21 ' A' ' 11' ' ' VAL . 4.6 p80 -167.08 149.04 6.0 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.098 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.828 HD11 ' CH2' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -112.96 161.85 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.095 -1.003 . . . . 0.0 109.216 -178.294 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.752 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -138.97 118.96 13.33 Favored 'General case' 0 N--CA 1.501 2.086 0 C-N-CA 118.629 -1.228 . . . . 0.0 112.463 -178.636 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.031 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 173.43 -68.67 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.206 -0.934 . . . . 0.0 109.634 177.688 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.031 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 33.5 Cg_endo -76.64 78.19 3.41 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 121.716 1.611 . . . . 0.0 109.362 179.616 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.506 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -33.27 -54.43 0.68 Allowed Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.946 -0.471 . . . . 0.0 112.186 -179.008 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.611 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.3 Cg_endo -79.69 58.53 7.01 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.113 1.875 . . . . 0.0 112.055 -179.296 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.911 HG23 ' O ' ' A' ' 30' ' ' PRO . 93.9 t -81.78 147.44 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 120.724 -1.235 . . . . 0.0 109.42 179.05 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 74.0 p -122.27 -37.06 2.86 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.313 -0.867 . . . . 0.0 109.614 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -154.34 136.34 14.64 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.847 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.5 t -123.11 150.07 43.69 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.581 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.7 OUTLIER -115.54 103.44 10.74 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.351 -0.94 . . . . 0.0 108.847 179.155 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.828 ' CH2' HD11 ' A' ' 27' ' ' ILE . 31.7 m95 -87.66 179.13 6.57 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.158 -0.964 . . . . 0.0 109.113 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.509 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.5 OUTLIER -149.03 103.08 3.31 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 177.835 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 1.029 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.4 m-30 -81.13 -63.72 1.34 Allowed 'General case' 0 N--CA 1.491 1.597 0 C-N-CA 118.83 -1.148 . . . . 0.0 110.275 -177.782 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.59 7.05 62.0 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.152 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.501 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 13.6 p30 -98.79 31.15 3.04 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.324 -1.103 . . . . 0.0 108.647 179.367 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 117.94 -40.74 2.23 Favored Glycine 0 C--N 1.295 -1.742 0 N-CA-C 105.409 -3.077 . . . . 0.0 105.409 -176.18 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -106.57 100.29 9.82 Favored 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 177.5 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.513 ' O ' HG23 ' A' ' 47' ' ' VAL . . . -76.21 -89.84 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.029 -1.044 . . . . 0.0 109.943 -178.735 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -51.48 142.15 14.43 Favored 'General case' 0 N--CA 1.495 1.825 0 CA-C-O 121.287 0.565 . . . . 0.0 109.736 -179.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 1.029 HG21 ' CE1' ' A' ' 40' ' ' PHE . 95.8 t -134.92 113.77 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.345 -0.847 . . . . 0.0 110.813 -178.648 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -94.84 99.46 11.52 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.534 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.847 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -110.64 167.7 10.03 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.368 -0.832 . . . . 0.0 111.015 -178.656 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.33 153.65 19.14 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.695 -0.628 . . . . 0.0 109.564 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.549 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.28 -156.51 0.52 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -89.08 40.14 0.49 Allowed 'Trans proline' 0 C--N 1.294 -2.336 0 C-N-CA 122.279 1.986 . . . . 0.0 110.285 178.64 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.574 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -142.73 156.32 44.99 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.889 -1.757 . . . . 0.0 112.62 -178.525 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.509 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -170.64 -171.76 1.1 Allowed 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 179.229 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.504 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -148.98 150.2 32.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.94 -1.1 . . . . 0.0 109.637 179.494 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.82 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 2.8 m-70 -105.89 143.54 33.89 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.39 -0.819 . . . . 0.0 111.006 -178.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.431 ' NH2' HD21 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -118.16 89.4 3.12 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.709 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.111 ' CE2' HG11 ' A' ' 83' ' ' VAL . 43.0 m-85 -91.49 138.97 31.15 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.914 . . . . 0.0 109.898 -178.765 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.1 p -124.27 -35.85 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.336 -0.852 . . . . 0.0 111.355 -178.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.43 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -86.77 146.5 41.3 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 120.511 -1.368 . . . . 0.0 109.607 -179.446 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.473 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.5 Cg_endo -78.18 117.55 4.14 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 122.477 2.118 . . . . 0.0 110.013 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 162.11 -147.61 13.98 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.425 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -123.39 140.75 52.69 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.096 -1.237 . . . . 0.0 109.671 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.557 ' HB2' HG13 ' A' ' 83' ' ' VAL . 66.9 m-85 -119.98 164.37 16.19 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.322 -0.861 . . . . 0.0 109.906 -179.706 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 46.2 t-80 -115.77 127.42 55.08 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.787 HG22 ' CE1' ' A' ' 56' ' ' HIS . 66.7 t -110.06 152.48 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 110.488 -179.1 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -146.93 158.62 43.97 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.057 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -155.12 117.89 4.32 Favored 'General case' 0 N--CA 1.498 1.94 0 C-N-CA 118.885 -1.126 . . . . 0.0 111.689 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.581 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.2 p -108.49 110.43 31.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.596 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.815 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.04 154.51 20.14 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.762 -1.211 . . . . 0.0 110.038 -178.801 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.18 116.65 16.5 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.779 0.799 . . . . 0.0 108.883 178.333 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.933 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.8 mp -105.43 -12.88 15.83 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 121.539 0.685 . . . . 0.0 109.26 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.67 -44.59 1.44 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.906 -2.077 . . . . 0.0 107.906 -178.514 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -113.89 -5.82 13.21 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.557 -0.966 . . . . 0.0 109.847 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -153.63 166.06 31.69 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.43 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 1.4 p -150.9 170.79 18.46 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.272 -1.134 . . . . 0.0 109.404 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.815 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -145.72 135.02 22.97 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.271 -0.893 . . . . 0.0 109.541 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 4.1 mp -101.04 131.11 47.09 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.148 -0.97 . . . . 0.0 109.992 -179.572 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.057 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -118.11 155.17 30.86 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 121.451 -0.781 . . . . 0.0 110.208 -179.149 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -161.58 86.7 0.11 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.755 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -106.04 -172.78 2.15 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.015 -1.285 . . . . 0.0 109.888 -179.808 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -151.25 152.88 33.87 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 179.411 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.111 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.5 OUTLIER -132.77 155.48 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.781 -1.2 . . . . 0.0 109.88 -179.822 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLN . . . . . 0.437 ' N ' HG23 ' A' ' 83' ' ' VAL . 31.6 tt0 -122.17 88.27 2.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.494 -0.754 . . . . 0.0 109.231 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.672 HG22 ' HB3' ' A' ' 17' ' ' LEU . 80.0 t -81.8 139.87 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.216 -0.927 . . . . 0.0 109.613 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -117.29 170.65 8.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.291 -0.88 . . . . 0.0 109.666 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.473 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.553 0 O-C-N 121.12 -0.988 . . . . 0.0 109.352 179.638 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.996 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.686 ' CG2' ' HB3' ' A' ' 28' ' ' ALA . 0.4 OUTLIER -81.66 140.24 34.49 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 179.807 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.731 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.5 mp -100.26 100.33 11.13 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -178.246 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.774 HG12 ' HD3' ' A' ' 13' ' ' PRO . 21.8 t -113.81 116.35 52.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 120.654 -1.279 . . . . 0.0 109.177 178.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.521 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -120.87 72.58 0.35 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 108.901 -1.679 . . . . 0.0 108.901 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.774 ' HD3' HG12 ' A' ' 11' ' ' VAL . 32.5 Cg_endo -71.27 147.46 53.4 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.83 2.353 . . . . 0.0 113.069 -179.067 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.565 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 151.58 170.76 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 114.639 -1.164 . . . . 0.0 108.122 179.102 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.46 -141.34 1.15 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -76.74 151.91 32.35 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 C-N-CA 122.225 1.95 . . . . 0.0 109.464 179.255 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 1.142 HD21 ' HB2' ' A' ' 23' ' ' ALA . 51.3 mt -104.74 91.51 3.88 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.001 -1.062 . . . . 0.0 109.427 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.87 169.17 11.82 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.9 t -55.02 113.55 1.39 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.259 -0.9 . . . . 0.0 109.34 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.17 38.29 5.15 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.499 ' HG2' ' HA ' ' A' ' 17' ' ' LEU . 3.1 tp-100 -107.89 146.33 32.49 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.286 -1.126 . . . . 0.0 110.609 -179.447 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.701 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.8 tm? -108.65 94.43 5.05 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.531 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 1.142 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -77.68 158.62 29.62 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.027 -1.046 . . . . 0.0 108.266 179.238 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.534 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.92 119.3 31.14 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.566 -1.334 . . . . 0.0 107.869 179.293 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.697 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 3.1 m-85 -106.09 170.35 7.96 Favored 'General case' 0 N--CA 1.489 1.517 0 CA-C-O 121.96 0.886 . . . . 0.0 111.583 -177.006 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.625 ' CE1' HG21 ' A' ' 11' ' ' VAL . 2.3 p80 -164.66 143.65 7.03 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 107.813 -1.181 . . . . 0.0 107.813 176.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.951 HD12 ' HG ' ' A' ' 79' ' ' LEU . 6.0 mm -109.14 154.05 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.34 -0.85 . . . . 0.0 109.997 -177.805 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.686 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -136.69 113.38 10.24 Favored 'General case' 0 N--CA 1.498 1.962 0 C-N-CA 118.933 -1.107 . . . . 0.0 111.629 -179.443 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.081 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -178.39 -61.7 0.0 OUTLIER Pre-proline 0 N--CA 1.494 1.766 0 O-C-N 120.936 -1.102 . . . . 0.0 109.791 178.36 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.081 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.0 Cg_endo -80.19 63.06 8.71 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.14 1.893 . . . . 0.0 109.874 179.693 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.637 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -12.96 -64.32 0.02 OUTLIER Pre-proline 0 N--CA 1.506 2.37 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -179.101 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.637 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 35.5 Cg_endo -77.34 71.58 6.32 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 C-N-CA 121.788 1.659 . . . . 0.0 110.926 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.541 HG22 ' HG2' ' A' ' 30' ' ' PRO . 3.0 t -96.7 135.14 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 120.853 -1.155 . . . . 0.0 109.919 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.4 t -111.58 -16.72 13.2 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.414 -0.804 . . . . 0.0 109.375 178.64 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.83 150.54 0.5 Allowed 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.372 -0.83 . . . . 0.0 109.827 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.705 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -137.98 137.64 38.11 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.374 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.54 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.3 OUTLIER -89.61 104.26 16.84 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.192 -0.942 . . . . 0.0 108.7 179.555 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.915 ' CH2' HD11 ' A' ' 27' ' ' ILE . 26.1 m95 -87.65 178.73 6.68 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.906 -1.121 . . . . 0.0 109.45 -179.589 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.453 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.7 OUTLIER -149.8 102.27 3.13 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 178.359 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.986 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.1 m-30 -80.51 -58.58 3.05 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.696 -1.202 . . . . 0.0 109.966 -178.134 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.87 15.82 57.3 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.079 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -104.63 -105.72 0.3 Allowed 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 178.701 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.13 -17.41 67.17 Favored Glycine 0 C--N 1.296 -1.669 0 N-CA-C 107.982 -2.047 . . . . 0.0 107.982 177.042 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.4 m -135.88 125.42 25.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.413 -1.051 . . . . 0.0 109.042 179.6 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.24 -84.59 0.1 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.053 -1.029 . . . . 0.0 109.849 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -58.42 149.78 24.09 Favored 'General case' 0 N--CA 1.495 1.809 0 CA-C-O 121.272 0.558 . . . . 0.0 110.105 -179.685 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.986 HG21 ' CE1' ' A' ' 40' ' ' PHE . 21.1 t -139.68 128.98 28.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.26 -0.9 . . . . 0.0 111.263 -178.847 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -108.15 91.4 3.63 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 177.612 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.704 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -97.35 155.67 16.79 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.347 -0.845 . . . . 0.0 111.517 -177.796 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.56 151.01 20.38 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.778 -0.576 . . . . 0.0 109.477 179.494 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.705 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.84 -159.11 0.61 Allowed Glycine 0 N--CA 1.489 2.181 0 N-CA-C 107.997 -2.041 . . . . 0.0 107.997 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.507 ' HB3' HG21 ' A' ' 33' ' ' VAL . 37.8 Cg_endo -87.43 41.2 0.69 Allowed 'Trans proline' 0 C--N 1.297 -2.14 0 C-N-CA 122.017 1.811 . . . . 0.0 109.99 178.265 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.704 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.46 150.44 39.0 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.152 -1.592 . . . . 0.0 112.097 -178.654 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.565 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -160.02 -168.32 2.19 Favored 'General case' 0 N--CA 1.495 1.778 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 179.045 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.701 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.1 OUTLIER -152.67 154.31 35.06 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.219 -0.926 . . . . 0.0 109.09 179.491 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.794 ' CE1' HG22 ' A' ' 66' ' ' VAL . 4.6 m-70 -113.63 133.86 55.05 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.043 -1.036 . . . . 0.0 111.411 -178.63 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.75 87.17 2.61 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 178.723 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.113 ' CE2' HG11 ' A' ' 83' ' ' VAL . 31.7 m-85 -89.44 125.37 35.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.199 -0.938 . . . . 0.0 109.684 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 86.0 t -114.58 -34.52 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.428 -0.795 . . . . 0.0 110.928 -178.637 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.461 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.2 OUTLIER -90.78 145.94 33.02 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 120.542 -1.349 . . . . 0.0 109.487 -179.367 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.599 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 34.8 Cg_endo -77.66 125.52 7.58 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.44 2.093 . . . . 0.0 109.937 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.87 -154.57 25.63 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.468 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 3.9 mpt_? -114.68 133.85 55.55 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.101 -1.234 . . . . 0.0 109.65 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.609 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 82.2 m-85 -115.92 150.13 37.6 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.313 -0.867 . . . . 0.0 109.714 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.453 ' CD2' HG22 ' A' ' 67' ' ' THR . 58.9 t60 -103.95 129.63 51.52 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.482 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.794 HG22 ' CE1' ' A' ' 56' ' ' HIS . 92.0 t -111.03 155.18 12.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.255 -0.903 . . . . 0.0 110.236 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.453 HG22 ' CD2' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -149.84 158.6 44.32 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.658 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.054 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -154.04 123.47 6.58 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.752 -1.179 . . . . 0.0 111.709 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -95.89 126.59 48.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.732 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.949 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.6 OUTLIER -88.61 142.35 27.76 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 120.727 -1.233 . . . . 0.0 108.722 -178.738 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.75 110.39 11.3 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 120.739 -1.225 . . . . 0.0 109.832 178.715 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.837 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -105.39 -10.84 16.73 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.137 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.38 -45.51 1.3 Allowed Glycine 0 N--CA 1.486 2.029 0 N-CA-C 107.895 -2.082 . . . . 0.0 107.895 -178.295 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -119.84 -5.13 10.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.605 -0.938 . . . . 0.0 109.839 179.178 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.14 165.58 27.34 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 6.8 p -151.09 -176.88 5.72 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.391 -1.064 . . . . 0.0 109.741 -179.467 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.949 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -155.18 164.33 38.97 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.557 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.5 tp -120.82 119.85 33.89 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.147 -0.971 . . . . 0.0 110.067 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.054 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -105.53 156.12 18.53 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.603 -0.686 . . . . 0.0 109.392 -179.702 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.585 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.14 99.34 0.16 Allowed Glycine 0 N--CA 1.485 1.905 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.436 HG22 HD23 ' A' ' 10' ' ' LEU . 0.7 OUTLIER -115.65 -173.43 2.34 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 120.923 -1.34 . . . . 0.0 110.216 179.993 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -149.79 140.07 22.25 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.113 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -125.77 152.04 32.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.916 -1.115 . . . . 0.0 109.916 -179.455 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.74 86.44 2.52 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.864 HG21 ' HB3' ' A' ' 58' ' ' TYR . 78.8 t -77.85 140.79 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.04 -1.038 . . . . 0.0 110.355 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -114.99 -173.93 2.4 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.426 -0.797 . . . . 0.0 109.361 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.599 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.553 0 O-C-N 120.895 -1.128 . . . . 0.0 109.701 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.859 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.782 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -90.19 141.91 28.23 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.664 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.76 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.3 mp -97.05 95.33 7.71 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -178.283 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.931 HG12 ' HD3' ' A' ' 13' ' ' PRO . 47.5 t -105.65 118.12 52.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 120.894 -1.129 . . . . 0.0 109.186 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -123.75 71.42 0.43 Allowed Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.931 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.5 Cg_endo -72.81 150.81 50.42 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 123.136 2.557 . . . . 0.0 113.517 -178.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.588 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 145.74 179.04 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.091 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.283 178.717 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.81 -144.52 4.63 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.716 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -75.99 150.98 34.69 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.32 2.013 . . . . 0.0 109.51 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.895 HD21 ' HB2' ' A' ' 23' ' ' ALA . 17.2 mt -102.04 82.53 2.24 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.038 -1.039 . . . . 0.0 109.759 -179.578 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -75.3 165.5 25.08 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.037 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 18.1 t -58.49 114.12 2.31 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.043 -1.035 . . . . 0.0 109.187 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.54 44.28 2.98 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -120.69 155.38 33.99 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.337 -1.096 . . . . 0.0 110.879 -179.509 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.759 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.8 tm? -112.33 97.7 6.8 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.895 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -79.44 157.55 27.5 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.543 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.75 120.25 36.01 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.497 -1.377 . . . . 0.0 108.167 179.414 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.669 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 3.4 m-85 -105.16 173.55 6.26 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.987 0.899 . . . . 0.0 111.542 -177.162 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.643 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -168.26 138.7 2.61 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.06 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.96 HD12 ' HG ' ' A' ' 79' ' ' LEU . 5.0 mm -107.43 149.53 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.401 -0.812 . . . . 0.0 109.154 -178.282 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.653 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -134.42 124.56 25.88 Favored 'General case' 0 N--CA 1.502 2.156 0 C-N-CA 118.57 -1.252 . . . . 0.0 112.281 -178.755 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.025 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -178.8 -66.0 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.101 -0.999 . . . . 0.0 109.116 177.742 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.025 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.7 Cg_endo -81.01 66.71 8.81 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.056 1.838 . . . . 0.0 109.314 179.174 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.702 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -9.93 -66.56 0.01 OUTLIER Pre-proline 0 N--CA 1.513 2.688 0 N-CA-C 112.77 0.656 . . . . 0.0 112.77 -178.427 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.702 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 37.1 Cg_endo -79.35 90.52 1.26 Allowed 'Trans proline' 0 C--N 1.314 -1.261 0 C-N-CA 121.709 1.606 . . . . 0.0 110.577 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.541 HG22 ' HG2' ' A' ' 30' ' ' PRO . 8.7 t -112.59 145.62 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.948 -1.095 . . . . 0.0 109.637 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -113.7 -19.08 11.7 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.515 -0.741 . . . . 0.0 110.257 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.13 151.23 0.8 Allowed 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.094 -1.004 . . . . 0.0 110.431 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.69 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -139.1 137.96 36.64 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.382 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.525 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 7.0 ttm180 -92.61 112.67 24.7 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.145 -0.972 . . . . 0.0 108.836 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.942 ' CH2' HD11 ' A' ' 27' ' ' ILE . 17.8 m95 -95.77 -178.97 4.56 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -0.894 . . . . 0.0 109.454 -179.812 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.511 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.57 103.06 3.08 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 177.598 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 1.019 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.1 m-30 -80.84 -65.35 1.02 Allowed 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 118.896 -1.122 . . . . 0.0 110.697 -177.369 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.51 6.82 58.36 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.534 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 12.1 p30 -98.03 31.47 2.7 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.354 -1.086 . . . . 0.0 108.777 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 116.18 -39.95 2.56 Favored Glycine 0 C--N 1.295 -1.705 0 N-CA-C 105.626 -2.99 . . . . 0.0 105.626 -176.251 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 63.8 p -105.99 103.58 13.1 Favored 'General case' 0 N--CA 1.487 1.386 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 177.452 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.511 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -77.98 -88.97 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.115 -0.991 . . . . 0.0 110.429 -178.373 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -52.67 142.85 17.4 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.311 0.576 . . . . 0.0 109.992 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 1.019 HG21 ' CE1' ' A' ' 40' ' ' PHE . 90.4 t -135.67 132.61 51.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.346 -0.847 . . . . 0.0 110.953 -178.689 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -111.65 92.66 4.12 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.032 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.705 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -97.26 151.51 19.8 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.305 -0.872 . . . . 0.0 111.283 -177.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.17 150.48 23.92 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.69 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.25 -157.44 0.63 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 108.395 -1.882 . . . . 0.0 108.395 -179.168 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -87.92 39.75 0.56 Allowed 'Trans proline' 0 C--N 1.296 -2.193 0 C-N-CA 122.037 1.825 . . . . 0.0 110.128 178.564 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.705 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.13 149.38 34.91 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.124 -1.61 . . . . 0.0 112.029 -178.54 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.654 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -154.6 -167.18 2.53 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.866 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.667 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -153.89 145.47 23.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.246 -0.909 . . . . 0.0 109.016 179.448 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.83 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 3.6 m-70 -105.02 138.98 40.39 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.091 -1.006 . . . . 0.0 110.91 -178.804 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -110.07 90.16 3.23 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.889 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.123 ' CE2' HG11 ' A' ' 83' ' ' VAL . 30.9 m-85 -92.48 124.49 36.56 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 109.786 -178.792 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.4 m -119.1 -13.93 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.486 -0.759 . . . . 0.0 111.385 -178.776 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.439 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -102.7 148.41 35.49 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 120.663 -1.273 . . . . 0.0 109.618 -179.731 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.738 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 34.8 Cg_endo -78.21 116.45 3.91 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.453 2.102 . . . . 0.0 109.782 179.336 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.71 -156.92 27.38 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 2.3 ptt-85 -112.49 159.69 18.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.179 -1.189 . . . . 0.0 110.135 -179.779 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.704 ' HB2' HG13 ' A' ' 83' ' ' VAL . 87.4 m-85 -136.05 159.74 40.79 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.455 -0.778 . . . . 0.0 109.328 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -116.52 115.99 26.8 Favored 'General case' 0 N--CA 1.486 1.372 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.318 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.803 HG22 ' CE1' ' A' ' 56' ' ' HIS . 83.3 t -97.77 148.48 5.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.373 -0.83 . . . . 0.0 110.551 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.456 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 2.1 p -145.38 156.0 43.51 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 178.322 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.992 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -152.44 164.79 36.83 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.741 -1.224 . . . . 0.0 110.955 -179.494 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.442 HG12 ' HB3' ' A' ' 37' ' ' ARG . 9.5 p -139.69 129.26 29.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 N-CA-C 107.146 -1.428 . . . . 0.0 107.146 178.251 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.992 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.03 142.03 28.1 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.845 -1.159 . . . . 0.0 108.749 -178.358 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.61 107.4 9.16 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 118.585 -1.246 . . . . 0.0 109.935 178.568 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.543 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -105.39 -9.98 17.24 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.832 179.159 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.47 -49.5 0.87 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 107.734 -2.146 . . . . 0.0 107.734 -178.413 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.52 -5.91 11.19 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.626 -0.926 . . . . 0.0 109.692 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.65 154.73 23.84 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 29.7 p -149.53 -179.86 7.42 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.291 -1.123 . . . . 0.0 109.421 -179.483 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.992 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -154.79 162.9 40.94 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.622 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -116.67 131.41 56.96 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.098 -1.001 . . . . 0.0 110.128 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.992 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -115.48 157.68 23.66 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.555 -0.715 . . . . 0.0 109.717 -179.809 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.29 89.28 0.09 OUTLIER Glycine 0 N--CA 1.483 1.822 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.531 HG22 HD23 ' A' ' 10' ' ' LEU . 0.2 OUTLIER -109.14 -171.71 1.9 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.04 -1.27 . . . . 0.0 109.55 179.675 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -150.81 155.69 39.74 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 179.398 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.123 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.24 151.65 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.659 -1.276 . . . . 0.0 109.776 -179.868 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.05 85.93 2.42 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.031 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.887 HG21 ' HB3' ' A' ' 58' ' ' TYR . 47.3 t -77.52 136.71 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.791 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -123.25 141.08 52.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.425 -0.797 . . . . 0.0 109.959 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.738 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.911 . . . . 0.0 109.433 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.757 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.897 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.0 OUTLIER -73.51 148.95 42.61 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.182 -0.949 . . . . 0.0 109.157 -179.374 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.87 HD23 HG22 ' A' ' 81' ' ' THR . 5.3 mp -91.17 103.13 15.85 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.339 -178.413 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.622 HG11 ' NE2' ' A' ' 26' ' ' HIS . 2.6 t -115.38 104.54 16.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 120.928 -1.108 . . . . 0.0 108.682 178.497 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.557 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.37 76.51 0.29 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -179.348 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.527 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 31.1 Cg_endo -71.42 148.24 54.12 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.674 2.249 . . . . 0.0 111.973 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.468 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 41.4 t60 161.13 -37.19 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.3 -139.4 14.81 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 107.952 -2.059 . . . . 0.0 107.952 -179.148 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -76.66 145.78 26.29 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 122.02 1.813 . . . . 0.0 109.064 178.689 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.788 HD11 ' HB2' ' A' ' 23' ' ' ALA . 3.3 mm? -104.53 92.94 4.52 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.167 -0.958 . . . . 0.0 109.871 -179.074 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.495 ' HB3' ' HG3' ' A' ' 21' ' ' GLN . . . -74.9 160.2 30.92 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.165 -0.96 . . . . 0.0 108.515 179.104 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.622 ' H ' ' HB3' ' A' ' 87' ' ' ALA . 14.3 t -56.14 125.17 20.51 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.223 -0.923 . . . . 0.0 109.937 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 80.69 49.15 5.86 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.495 ' HG3' ' HB3' ' A' ' 18' ' ' ALA . 0.7 OUTLIER -123.4 151.82 42.21 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.35 -1.088 . . . . 0.0 110.744 -179.517 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.803 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.2 tm? -105.97 98.65 8.31 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.502 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.788 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -78.83 153.09 30.93 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.159 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.527 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -116.66 118.16 31.8 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.469 -1.395 . . . . 0.0 108.44 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.708 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 7.4 m-85 -107.79 168.35 9.33 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 122.417 1.103 . . . . 0.0 112.262 -177.183 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.622 ' NE2' HG11 ' A' ' 11' ' ' VAL . 4.1 p80 -167.92 145.52 4.36 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 176.782 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.85 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.2 161.25 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.868 -1.145 . . . . 0.0 108.906 -178.336 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.897 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -139.43 119.55 13.61 Favored 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.556 -1.258 . . . . 0.0 112.433 -178.714 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.04 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 174.24 -68.87 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 177.614 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.04 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -77.6 78.21 3.6 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 121.779 1.653 . . . . 0.0 109.34 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.49 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -33.52 -53.95 0.74 Allowed Pre-proline 0 N--CA 1.5 2.029 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -178.913 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.57 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.7 Cg_endo -79.81 58.57 7.04 Favored 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.183 1.922 . . . . 0.0 111.877 -179.283 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.94 HG23 ' O ' ' A' ' 30' ' ' PRO . 73.3 t -82.23 148.43 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 120.843 -1.16 . . . . 0.0 109.273 179.11 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.3 t -120.95 -36.79 3.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.318 -0.864 . . . . 0.0 109.661 179.007 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -152.06 139.19 19.22 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.453 -0.78 . . . . 0.0 109.156 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.89 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.2 t -127.52 134.92 49.75 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.545 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 2.8 tpp180 -104.07 104.06 13.95 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.042 -1.036 . . . . 0.0 109.174 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.708 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 29.4 m95 -87.82 -179.76 6.32 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.078 -1.014 . . . . 0.0 109.172 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -148.31 100.55 3.16 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 177.724 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.92 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.8 m-30 -80.01 -60.72 2.23 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 118.733 -1.187 . . . . 0.0 109.746 -178.122 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.98 15.93 55.27 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -178.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.25 -104.22 0.25 Allowed 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 178.485 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.08 -23.92 50.26 Favored Glycine 0 C--N 1.296 -1.649 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 176.85 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.8 m -128.62 127.69 42.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.501 -1.0 . . . . 0.0 109.04 179.426 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -81.11 -83.91 0.11 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.063 -1.023 . . . . 0.0 109.644 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -58.48 152.2 18.56 Favored 'General case' 0 N--CA 1.495 1.799 0 CA-C-O 121.222 0.534 . . . . 0.0 109.567 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.92 HG21 ' CE1' ' A' ' 40' ' ' PHE . 43.9 t -138.07 113.9 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.069 -1.019 . . . . 0.0 111.444 -178.444 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.19 105.18 17.09 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 177.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.89 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -118.74 168.34 10.82 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.143 -0.973 . . . . 0.0 111.042 -178.671 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.05 155.32 18.47 Favored 'General case' 0 N--CA 1.49 1.532 0 CA-C-O 121.503 0.668 . . . . 0.0 109.796 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.57 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.29 -155.42 0.64 Allowed Glycine 0 N--CA 1.488 2.159 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -89.77 40.48 0.45 Allowed 'Trans proline' 0 C--N 1.295 -2.284 0 C-N-CA 122.464 2.11 . . . . 0.0 110.484 178.66 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.58 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.75 154.09 43.1 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 119.899 -1.751 . . . . 0.0 112.658 -178.629 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.61 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -174.36 155.36 2.32 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.803 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -115.61 155.03 28.38 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.591 -1.318 . . . . 0.0 110.768 -179.766 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.789 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 2.1 m-70 -105.36 143.31 33.7 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.465 0.65 . . . . 0.0 110.791 -179.221 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -115.05 94.57 4.8 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.091 ' CE2' HG11 ' A' ' 83' ' ' VAL . 25.9 m-85 -99.1 126.98 44.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.148 -0.97 . . . . 0.0 109.747 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 8.2 m -119.46 -31.06 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.362 -0.836 . . . . 0.0 111.553 -178.497 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.519 ' HB3' ' OH ' ' A' ' 64' ' ' TYR . 0.6 OUTLIER -96.49 140.56 22.24 Favored Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 120.579 -1.325 . . . . 0.0 109.165 -179.49 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.479 ' N ' ' HG ' ' A' ' 60' ' ' LEU . 32.5 Cg_endo -73.1 135.78 23.55 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.293 1.995 . . . . 0.0 110.567 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 148.36 -140.01 8.04 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -179.538 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -129.54 137.64 50.88 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.211 -1.17 . . . . 0.0 109.61 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.578 ' HB2' HG13 ' A' ' 83' ' ' VAL . 79.0 m-85 -117.36 159.68 22.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.313 -0.867 . . . . 0.0 109.449 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 35.3 t-80 -114.13 126.27 54.9 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.753 HG22 ' CE1' ' A' ' 56' ' ' HIS . 60.1 t -108.94 151.41 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.295 -0.878 . . . . 0.0 110.559 -179.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.92 161.23 42.29 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.459 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.1 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -157.96 122.48 4.25 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.869 -1.144 . . . . 0.0 111.609 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.418 ' O ' HG13 ' A' ' 69' ' ' VAL . 2.1 p -112.96 109.15 27.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 177.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.805 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.89 147.27 24.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.787 -1.196 . . . . 0.0 109.791 -179.12 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -126.76 116.5 21.02 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.353 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.891 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.6 mp -103.53 -13.42 16.58 Favored 'General case' 0 C--N 1.292 -1.92 0 CA-C-O 121.495 0.664 . . . . 0.0 109.417 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 114.78 -51.55 0.71 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 107.9 -2.08 . . . . 0.0 107.9 -178.736 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.35 -5.73 12.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.576 -0.955 . . . . 0.0 109.894 179.148 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.3 162.98 27.88 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.778 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.7 p -151.24 169.48 21.82 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.393 -1.063 . . . . 0.0 109.59 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.805 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -142.85 136.15 28.43 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 109.463 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.5 tt -101.65 132.41 47.35 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.287 -0.883 . . . . 0.0 110.335 -179.426 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.1 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -121.06 155.01 35.34 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.561 -0.712 . . . . 0.0 110.21 -179.372 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.517 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -162.21 88.05 0.11 Allowed Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.437 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.87 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -104.98 -176.65 3.14 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.112 -1.228 . . . . 0.0 109.903 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -150.47 143.76 24.95 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.091 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -130.43 153.08 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 120.567 -1.333 . . . . 0.0 110.22 -179.331 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLN . . . . . 0.415 ' N ' HG23 ' A' ' 83' ' ' VAL . 32.4 tt0 -118.59 100.79 7.66 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.876 HG21 ' HB3' ' A' ' 58' ' ' TYR . 42.9 t -80.9 136.42 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.148 -0.97 . . . . 0.0 109.854 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -121.21 -156.61 0.69 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.619 -0.676 . . . . 0.0 109.54 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.622 ' HB3' ' H ' ' A' ' 19' ' ' SER . . . . . . . . 0 N--CA 1.487 1.406 0 O-C-N 121.484 -0.76 . . . . 0.0 110.325 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.718 ' CB ' HG22 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.432 0 CA-C-O 121.457 0.646 . . . . 0.0 109.412 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.813 HG23 HG23 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -87.3 141.04 28.94 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.857 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.754 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.4 mp -97.22 94.85 7.34 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.003 -177.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.825 HG12 ' HD3' ' A' ' 13' ' ' PRO . 41.1 t -107.1 115.99 49.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.89 -1.131 . . . . 0.0 108.568 178.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.455 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -121.98 71.78 0.39 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.363 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.825 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.4 Cg_endo -73.63 150.79 45.93 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.942 2.428 . . . . 0.0 112.036 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.537 ' CB ' ' O ' ' A' ' 13' ' ' PRO . 16.0 t-80 150.29 -39.52 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 CA-C-N 115.44 -0.8 . . . . 0.0 108.935 179.53 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 116.4 -142.97 17.88 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.49 -1.844 . . . . 0.0 108.49 -179.218 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.82 149.01 25.9 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 122.306 2.004 . . . . 0.0 109.779 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 1.02 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.4 mm? -105.2 106.74 17.37 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.181 -0.949 . . . . 0.0 109.207 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.426 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -93.44 168.72 10.87 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.01 -1.057 . . . . 0.0 108.905 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 28.1 t -56.42 120.81 8.29 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.364 -0.835 . . . . 0.0 109.045 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 80.3 44.14 9.0 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.379 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.454 ' HG2' HD13 ' A' ' 17' ' ' LEU . 23.0 tp60 -113.35 147.3 37.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.523 -0.986 . . . . 0.0 110.697 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.718 HD11 ' HB2' ' A' ' 55' ' ' SER . 1.8 tm? -108.35 96.32 6.27 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.565 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 1.02 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -78.86 156.59 28.6 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 178.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.499 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.63 108.85 14.05 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.415 -1.428 . . . . 0.0 108.224 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.734 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 2.6 m-85 -95.19 166.7 11.78 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 122.098 0.952 . . . . 0.0 111.57 -177.282 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.675 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -159.74 135.89 8.82 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 177.864 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.995 HD11 ' CH2' ' A' ' 38' ' ' TRP . 5.0 mm -108.97 152.01 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.368 -0.833 . . . . 0.0 109.526 -177.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.654 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -136.93 136.12 38.32 Favored 'General case' 0 N--CA 1.506 2.354 0 C-N-CA 118.439 -1.305 . . . . 0.0 113.045 -178.595 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.035 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 174.05 -71.4 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.951 0 O-C-N 121.002 -1.061 . . . . 0.0 108.963 177.352 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.035 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -79.44 72.89 6.28 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 C-N-CA 121.778 1.652 . . . . 0.0 109.13 178.486 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.623 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -13.81 -63.79 0.03 OUTLIER Pre-proline 0 N--CA 1.512 2.661 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -178.437 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.817 ' O ' HD21 ' A' ' 72' ' ' LEU . 36.4 Cg_endo -78.22 63.43 8.29 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 C-N-CA 121.889 1.726 . . . . 0.0 111.187 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.923 HG22 ' HG2' ' A' ' 30' ' ' PRO . 62.1 t -80.95 148.26 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.901 -1.124 . . . . 0.0 109.635 179.616 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 t -120.49 -18.33 7.88 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.345 -0.847 . . . . 0.0 110.648 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -176.48 139.27 0.33 Allowed 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.013 -1.055 . . . . 0.0 110.329 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.744 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -126.73 134.22 50.71 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.356 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.487 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 1.1 mtm180 -93.11 113.83 26.18 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.295 -0.878 . . . . 0.0 108.736 179.462 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.995 ' CH2' HD11 ' A' ' 27' ' ' ILE . 11.8 m95 -99.19 -179.25 4.18 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 121.976 0.893 . . . . 0.0 109.853 -179.403 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.514 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.62 103.3 3.1 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 177.245 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 1.037 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.7 m-30 -80.78 -65.14 1.05 Allowed 'General case' 0 N--CA 1.492 1.656 0 C-N-CA 118.784 -1.166 . . . . 0.0 110.809 -177.378 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.37 1.47 59.22 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -178.595 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.4 p30 -95.57 34.97 1.4 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.293 -1.122 . . . . 0.0 108.403 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.43 -36.46 4.25 Favored Glycine 0 C--N 1.296 -1.677 0 N-CA-C 105.845 -2.902 . . . . 0.0 105.845 -176.375 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.412 ' O ' ' HB2' ' A' ' 40' ' ' PHE . 18.1 m -104.05 94.05 5.18 Favored 'General case' 0 N--CA 1.487 1.375 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.057 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.49 -95.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.22 -0.925 . . . . 0.0 110.066 -178.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -52.22 146.67 8.78 Favored 'General case' 0 N--CA 1.496 1.87 0 CA-C-O 121.194 0.521 . . . . 0.0 109.879 -179.639 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 1.037 HG21 ' CE1' ' A' ' 40' ' ' PHE . 95.6 t -138.49 130.69 38.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.347 -0.846 . . . . 0.0 110.969 -178.823 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -111.37 94.71 5.11 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.799 ' CB ' ' HB2' ' A' ' 54' ' ' ALA . . . -100.45 147.9 25.35 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.226 -0.921 . . . . 0.0 111.146 -178.373 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.7 151.8 26.07 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.731 -0.605 . . . . 0.0 109.499 179.71 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.744 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.82 -156.55 0.61 Allowed Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.64 -1.784 . . . . 0.0 108.64 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -88.05 39.33 0.52 Allowed 'Trans proline' 0 C--N 1.296 -2.191 0 C-N-CA 122.406 2.071 . . . . 0.0 110.438 178.374 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.712 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.38 146.65 31.65 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 119.93 -1.731 . . . . 0.0 112.156 -178.707 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.799 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -156.15 -178.81 7.59 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 178.558 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.718 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -141.62 152.49 44.04 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.735 -1.228 . . . . 0.0 109.477 179.414 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.836 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 2.1 m-70 -108.16 138.82 43.78 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.473 -0.767 . . . . 0.0 110.618 -178.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.405 HH21 HD21 ' A' ' 22' ' ' LEU . 0.4 OUTLIER -111.95 89.71 3.14 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.972 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.056 ' CE2' HG11 ' A' ' 83' ' ' VAL . 34.5 m-85 -90.25 130.34 36.38 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.172 -0.955 . . . . 0.0 109.307 -179.172 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 9.4 p -116.58 -30.8 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.252 -0.905 . . . . 0.0 111.283 -178.451 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.438 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -100.91 146.7 32.58 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 120.703 -1.248 . . . . 0.0 109.453 -179.226 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.438 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 34.7 Cg_endo -76.91 121.46 5.86 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.255 1.97 . . . . 0.0 109.944 179.601 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 164.46 -157.05 29.28 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -112.47 120.76 42.73 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.022 -1.281 . . . . 0.0 109.986 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.506 ' HB2' HG13 ' A' ' 83' ' ' VAL . 86.4 m-85 -105.07 147.13 28.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.492 -0.755 . . . . 0.0 109.349 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -104.24 132.35 50.58 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.856 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.804 HG22 ' CE1' ' A' ' 56' ' ' HIS . 79.6 t -113.57 149.4 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.153 -0.967 . . . . 0.0 110.462 -179.128 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.5 p -148.15 153.91 39.46 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 178.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.109 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.94 163.03 39.67 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.946 -1.096 . . . . 0.0 110.883 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.612 ' O ' HG13 ' A' ' 69' ' ' VAL . 12.1 p -150.9 112.27 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.894 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.876 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.01 143.17 27.04 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 120.481 -1.387 . . . . 0.0 110.287 -178.205 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -122.63 117.74 26.51 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.401 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.817 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.9 OUTLIER -105.88 -13.98 15.35 Favored 'General case' 0 C--N 1.29 -2.003 0 CA-C-O 121.587 0.708 . . . . 0.0 109.388 179.866 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 110.72 -51.42 0.7 Allowed Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 -179.09 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -110.77 -6.08 14.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.6 -0.941 . . . . 0.0 109.628 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.87 160.37 28.48 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.415 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 2.0 p -150.58 164.06 36.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.247 -1.149 . . . . 0.0 109.712 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.876 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -138.47 163.71 31.25 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.446 -0.783 . . . . 0.0 109.111 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 15.3 mt -122.9 150.35 43.03 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.173 -0.954 . . . . 0.0 109.939 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.109 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -132.43 160.43 36.44 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.436 -0.79 . . . . 0.0 109.885 -179.44 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.497 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -172.14 99.82 0.15 Allowed Glycine 0 N--CA 1.485 1.965 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.603 HG22 HD23 ' A' ' 10' ' ' LEU . 1.2 p -120.85 -172.42 2.38 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.137 -1.213 . . . . 0.0 110.167 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -151.01 145.31 25.46 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.056 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.2 OUTLIER -132.64 144.23 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 120.749 -1.219 . . . . 0.0 109.906 -179.502 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -107.69 85.88 2.2 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.919 HG21 ' HB3' ' A' ' 58' ' ' TYR . 75.6 t -70.46 132.46 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.279 -0.888 . . . . 0.0 110.118 -179.254 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -114.14 -162.96 0.84 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.018 -1.051 . . . . 0.0 109.479 179.734 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.873 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.812 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.79 139.68 30.22 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.77 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.6 mp -97.19 89.55 4.81 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.148 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.941 HG12 ' HD3' ' A' ' 13' ' ' PRO . 65.3 t -99.08 112.34 30.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.885 -1.134 . . . . 0.0 109.092 179.521 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.504 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -124.1 71.18 0.44 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.941 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.4 Cg_endo -73.64 150.4 45.22 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.803 2.336 . . . . 0.0 112.153 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.468 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.9 t-80 168.9 -38.87 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.681 0.753 . . . . 0.0 109.208 179.353 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.29 -138.05 14.56 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 -178.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.62 147.0 24.57 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 121.972 1.782 . . . . 0.0 109.166 178.757 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.953 HD21 ' HB2' ' A' ' 23' ' ' ALA . 2.7 mt -117.26 98.56 6.5 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.2 -0.937 . . . . 0.0 109.779 -179.301 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.09 165.66 14.98 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 t -60.85 114.74 3.22 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.243 -0.91 . . . . 0.0 109.272 -179.839 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.68 39.52 2.72 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.84 154.58 51.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.152 -1.205 . . . . 0.0 110.015 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.717 HD12 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -115.82 128.14 55.59 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.805 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.953 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -92.69 148.37 22.12 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.252 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.533 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -105.25 121.9 44.81 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.067 -1.645 . . . . 0.0 108.04 179.012 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.815 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 5.2 m-85 -105.39 170.53 7.83 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 121.914 0.864 . . . . 0.0 111.721 -177.009 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.587 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.72 140.14 3.84 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.793 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.999 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.6 mm -109.42 148.67 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.279 -0.888 . . . . 0.0 109.309 -178.345 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.644 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -133.33 122.6 24.07 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.989 -178.842 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.139 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 175.25 -61.86 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.078 -1.014 . . . . 0.0 109.552 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.139 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.3 Cg_endo -79.17 68.49 8.27 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.209 1.939 . . . . 0.0 109.699 179.551 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.634 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.0 OUTLIER -15.42 -64.03 0.03 OUTLIER Pre-proline 0 N--CA 1.506 2.327 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.83 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.634 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.4 Cg_endo -78.52 73.39 5.9 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 C-N-CA 121.774 1.65 . . . . 0.0 111.202 -179.513 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 30' ' ' PRO . 2.8 t -96.41 136.64 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.894 -1.129 . . . . 0.0 109.656 179.338 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.5 t -115.89 -15.33 11.25 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.48 -0.763 . . . . 0.0 109.331 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.6 149.43 0.48 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.311 -0.868 . . . . 0.0 109.667 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.624 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -136.93 139.68 41.73 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.59 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.61 ' O ' HG23 ' A' ' 69' ' ' VAL . 10.2 mtm-85 -93.33 109.04 20.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.138 -0.976 . . . . 0.0 109.136 179.657 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.977 ' CH2' HD11 ' A' ' 27' ' ' ILE . 18.7 m95 -93.85 179.81 5.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.918 -1.114 . . . . 0.0 109.621 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.489 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.76 106.61 3.41 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.328 -1.731 . . . . 0.0 106.328 177.369 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 1.014 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.7 m-30 -81.37 -66.44 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 118.451 -1.3 . . . . 0.0 111.37 -176.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.11 -4.91 59.03 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.1 p30 -90.41 23.71 2.86 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.335 -1.097 . . . . 0.0 109.164 179.34 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 122.56 -38.11 2.64 Favored Glycine 0 C--N 1.298 -1.576 0 N-CA-C 106.129 -2.788 . . . . 0.0 106.129 -176.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.77 101.52 12.96 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 177.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.489 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.38 -98.28 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 0.0 109.958 -178.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -56.92 150.1 17.33 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.286 0.565 . . . . 0.0 109.927 -179.588 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 1.014 HG21 ' CE1' ' A' ' 40' ' ' PHE . 70.8 t -138.9 132.97 40.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.47 -0.769 . . . . 0.0 110.591 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -112.89 89.8 3.18 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.283 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.686 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -92.84 152.53 19.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.373 -0.829 . . . . 0.0 111.423 -178.135 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.72 150.2 23.75 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.305 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.624 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.08 -156.4 0.49 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.24 -1.944 . . . . 0.0 108.24 -179.27 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.415 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.1 Cg_endo -88.43 42.63 0.7 Allowed 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.122 1.881 . . . . 0.0 110.479 178.436 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.686 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -146.87 144.38 29.24 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.072 -1.642 . . . . 0.0 112.009 -179.089 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 49' ' ' ALA . . . -149.54 -169.6 3.42 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.599 ' HB3' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -152.64 138.8 18.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.249 -0.907 . . . . 0.0 109.174 179.558 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.815 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 3.6 m-70 -102.91 135.45 44.57 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.231 -0.918 . . . . 0.0 111.101 -178.903 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.439 ' H ' ' HG2' ' A' ' 57' ' ' ARG . 2.0 ptp180 -100.44 95.06 6.49 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 177.824 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.022 ' CE2' HG11 ' A' ' 83' ' ' VAL . 23.8 m-85 -95.5 120.24 35.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.225 -0.922 . . . . 0.0 109.232 -179.232 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.6 p -118.17 -29.71 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.241 -0.912 . . . . 0.0 111.165 -178.72 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.405 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -90.71 143.35 28.82 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 120.619 -1.3 . . . . 0.0 109.376 -179.678 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.405 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.0 Cg_endo -76.26 133.04 14.34 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.575 2.183 . . . . 0.0 110.281 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.59 -135.05 5.93 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 -179.616 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -127.27 164.51 21.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -1.193 . . . . 0.0 109.651 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.65 ' HB2' HG13 ' A' ' 83' ' ' VAL . 59.7 m-85 -142.98 152.84 42.39 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.466 -0.771 . . . . 0.0 109.205 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -112.99 130.37 56.16 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.686 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.774 HG13 ' CE1' ' A' ' 56' ' ' HIS . 59.2 t -116.0 150.58 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 110.821 -178.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.79 155.51 42.42 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.85 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.064 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.53 158.57 44.31 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.853 -1.155 . . . . 0.0 111.518 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -129.84 127.17 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.423 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 1.011 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.3 OUTLIER -89.07 141.87 28.12 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 120.656 -1.277 . . . . 0.0 109.015 -178.743 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.3 110.48 11.56 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.589 -1.245 . . . . 0.0 109.698 178.425 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.925 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.9 mp -105.49 -11.1 16.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.072 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.66 -49.62 0.83 Allowed Glycine 0 N--CA 1.486 2.011 0 N-CA-C 107.669 -2.173 . . . . 0.0 107.669 -178.128 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.44 -5.76 11.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.58 -0.953 . . . . 0.0 109.884 178.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -140.04 162.5 26.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.478 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.8 p -151.44 -179.23 7.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.306 -1.114 . . . . 0.0 109.579 -179.598 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 1.011 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -154.17 166.39 33.25 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.2 mt -119.93 132.75 55.62 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.068 -1.02 . . . . 0.0 110.227 -179.401 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.064 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -117.4 157.14 26.7 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.524 -0.735 . . . . 0.0 109.769 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.65 95.12 0.11 Allowed Glycine 0 N--CA 1.485 1.938 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.612 HG22 HD23 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -116.38 -173.33 2.35 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.232 -1.158 . . . . 0.0 109.937 179.932 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -150.74 153.7 36.0 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.435 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.022 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.0 154.25 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.66 -1.275 . . . . 0.0 109.845 -179.519 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLN . . . . . 0.425 ' N ' HG23 ' A' ' 83' ' ' VAL . 12.0 tt0 -123.07 99.81 6.56 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.464 -0.773 . . . . 0.0 108.985 179.073 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.778 HG21 ' HB3' ' A' ' 58' ' ' TYR . 41.6 t -86.15 137.71 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.24 -0.912 . . . . 0.0 109.846 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -113.15 154.41 26.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 -179.473 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.101 -0.999 . . . . 0.0 109.667 179.711 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.804 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.776 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -90.12 141.62 28.51 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.636 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.753 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.3 mp -98.01 97.96 9.36 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -178.188 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.968 HG12 ' HD3' ' A' ' 13' ' ' PRO . 47.2 t -109.69 115.92 50.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 120.875 -1.141 . . . . 0.0 109.189 179.355 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.524 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -125.67 68.68 0.51 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.968 ' HD3' HG12 ' A' ' 11' ' ' VAL . 36.7 Cg_endo -75.16 151.05 38.34 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 123.082 2.521 . . . . 0.0 112.655 -179.252 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.641 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 21.6 t60 162.61 -36.36 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.881 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.472 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.85 -138.6 14.93 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -179.377 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.8 151.74 28.31 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.42 2.08 . . . . 0.0 109.878 179.576 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.733 HD21 ' HB2' ' A' ' 23' ' ' ALA . 65.8 mt -120.87 99.74 6.69 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.113 -0.992 . . . . 0.0 109.917 -179.717 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.401 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -91.78 170.94 9.49 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.7 t -53.15 120.06 5.47 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.914 . . . . 0.0 109.818 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.74 48.3 4.5 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.472 ' HB3' ' CD2' ' A' ' 17' ' ' LEU . 1.6 mm-40 -115.78 143.81 44.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.432 -1.04 . . . . 0.0 110.449 -179.535 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.698 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.5 tm? -108.35 93.26 4.43 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.175 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.733 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -75.49 155.21 36.4 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.94 -1.1 . . . . 0.0 108.089 179.341 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.535 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.08 114.5 22.59 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.475 -1.39 . . . . 0.0 108.076 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.705 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 3.8 m-85 -100.15 174.65 6.05 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 122.135 0.969 . . . . 0.0 111.805 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.651 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -168.53 139.09 2.52 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 177.997 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 1.001 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.7 mm -107.95 149.33 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.37 -0.831 . . . . 0.0 109.063 -178.37 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.655 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -133.35 125.09 28.41 Favored 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 118.598 -1.241 . . . . 0.0 112.274 -178.572 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.089 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -179.8 -67.3 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 120.978 -1.076 . . . . 0.0 109.297 177.739 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.089 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.5 Cg_endo -79.89 69.58 7.88 Favored 'Trans proline' 0 C--N 1.314 -1.275 0 C-N-CA 121.944 1.763 . . . . 0.0 109.314 179.162 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.684 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -11.82 -66.21 0.02 OUTLIER Pre-proline 0 N--CA 1.51 2.546 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -178.707 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.684 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.6 Cg_endo -79.29 95.32 1.05 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 121.728 1.619 . . . . 0.0 110.424 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.497 HG22 ' HG2' ' A' ' 30' ' ' PRO . 5.1 t -118.06 145.01 24.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 120.866 -1.146 . . . . 0.0 109.565 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.2 t -113.15 -18.64 12.09 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.495 -0.753 . . . . 0.0 110.209 179.736 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.22 152.3 0.86 Allowed 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.049 -1.032 . . . . 0.0 110.456 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.689 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -139.05 137.04 35.9 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.428 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.472 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 4.8 ttp180 -92.78 114.2 26.69 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.07 -1.019 . . . . 0.0 108.838 179.512 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.992 ' CH2' HD11 ' A' ' 27' ' ' ILE . 15.6 m95 -97.68 -178.61 4.17 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 -179.8 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.425 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -151.37 101.99 2.87 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 177.34 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 1.013 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.9 m-30 -80.19 -61.33 2.01 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 118.756 -1.178 . . . . 0.0 110.267 -177.52 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.62 14.63 52.59 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.068 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.06 -103.05 0.25 Allowed 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.662 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -86.63 -17.15 60.58 Favored Glycine 0 C--N 1.297 -1.59 0 N-CA-C 108.05 -2.02 . . . . 0.0 108.05 176.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 17.0 p -135.8 129.26 32.21 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.308 -1.113 . . . . 0.0 109.309 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.425 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.34 -87.66 0.08 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.024 -1.048 . . . . 0.0 109.96 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -56.48 151.24 13.69 Favored 'General case' 0 N--CA 1.497 1.877 0 CA-C-O 121.358 0.599 . . . . 0.0 110.123 -179.716 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 1.013 HG21 ' CE1' ' A' ' 40' ' ' PHE . 61.5 t -140.14 134.44 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.287 -0.883 . . . . 0.0 111.019 -178.822 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -115.0 90.8 3.43 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 177.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.709 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -94.31 153.57 17.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.339 -0.85 . . . . 0.0 111.488 -177.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -89.33 150.52 22.54 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 179.283 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.689 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.84 -158.11 0.73 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 108.075 -2.01 . . . . 0.0 108.075 -179.188 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -87.69 41.0 0.65 Allowed 'Trans proline' 0 C--N 1.298 -2.101 0 C-N-CA 122.135 1.89 . . . . 0.0 110.013 178.117 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.709 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.25 147.55 32.52 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 120.232 -1.542 . . . . 0.0 111.891 -178.87 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.661 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -153.83 -169.56 3.31 Favored 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.863 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.698 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -151.87 145.24 24.77 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.135 -0.978 . . . . 0.0 109.184 179.433 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.815 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 3.6 m-70 -104.33 137.67 41.89 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.259 -0.901 . . . . 0.0 111.228 -178.762 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.415 HH21 HD21 ' A' ' 22' ' ' LEU . 0.7 OUTLIER -108.46 88.67 2.78 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.114 ' CE2' HG11 ' A' ' 83' ' ' VAL . 34.2 m-85 -92.06 118.39 30.76 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.237 -0.915 . . . . 0.0 109.602 -179.296 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.2 t -106.96 -28.94 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.411 -0.806 . . . . 0.0 111.089 -178.678 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.445 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -97.21 146.92 32.17 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 120.628 -1.295 . . . . 0.0 109.617 -179.364 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.639 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.6 Cg_endo -78.28 123.81 6.26 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 C-N-CA 122.473 2.116 . . . . 0.0 109.837 179.325 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 158.6 -159.68 30.4 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.631 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.445 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 15.1 mtp-105 -111.34 125.97 54.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.073 -1.251 . . . . 0.0 110.152 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.573 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 82.9 m-85 -108.75 157.92 18.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.34 -0.85 . . . . 0.0 109.481 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 72.1 t60 -112.81 126.99 56.04 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.526 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.789 HG22 ' CE1' ' A' ' 56' ' ' HIS . 84.3 t -107.62 150.06 10.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.099 -1.001 . . . . 0.0 110.675 -179.054 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.422 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 1.2 p -147.75 155.64 41.91 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.258 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.028 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -152.5 165.96 33.47 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.822 -1.174 . . . . 0.0 110.751 -179.674 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.462 HG12 ' HB3' ' A' ' 37' ' ' ARG . 8.3 p -141.81 130.6 22.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 107.197 -1.409 . . . . 0.0 107.197 178.315 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.995 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.16 140.7 29.22 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 120.947 -1.096 . . . . 0.0 108.821 -178.302 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.02 108.18 9.9 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 118.555 -1.258 . . . . 0.0 109.933 178.639 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.55 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -106.88 -9.66 16.26 Favored 'General case' 0 C--N 1.286 -2.188 0 CA-C-N 115.415 -0.811 . . . . 0.0 108.838 178.994 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 102.94 -48.39 1.04 Allowed Glycine 0 N--CA 1.487 2.057 0 N-CA-C 107.599 -2.2 . . . . 0.0 107.599 -178.19 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.04 -5.51 11.95 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.687 -0.89 . . . . 0.0 109.627 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -142.35 155.73 25.79 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 17.1 p -151.05 179.71 8.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.224 -1.162 . . . . 0.0 109.598 -179.533 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.995 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -156.02 170.41 22.23 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.458 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -124.31 136.39 54.08 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.107 -0.996 . . . . 0.0 109.906 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.028 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -119.5 158.44 26.27 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.566 -0.709 . . . . 0.0 109.711 -179.631 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.94 94.62 0.1 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.548 HG22 HD23 ' A' ' 10' ' ' LEU . 0.5 OUTLIER -115.03 -172.12 2.07 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.088 -1.242 . . . . 0.0 110.117 -179.878 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -150.64 148.37 28.53 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.114 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -132.95 153.66 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 120.842 -1.161 . . . . 0.0 109.972 -179.725 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLN . . . . . 0.427 ' N ' HG23 ' A' ' 83' ' ' VAL . 30.1 tt0 -122.57 89.29 3.09 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.309 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.822 HG21 ' HB3' ' A' ' 58' ' ' TYR . 92.9 t -79.63 143.56 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.253 -0.904 . . . . 0.0 109.82 -179.428 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -115.84 173.3 6.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.387 -0.821 . . . . 0.0 109.667 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.639 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.149 -0.969 . . . . 0.0 109.782 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.805 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.474 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.952 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.1 t -70.79 148.89 47.42 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.224 -0.923 . . . . 0.0 109.299 -179.14 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.758 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.6 mp -88.16 109.84 20.22 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.325 -178.312 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.585 ' HB ' ' CE1' ' A' ' 26' ' ' HIS . 1.2 t -126.21 103.91 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.01 -1.056 . . . . 0.0 108.863 178.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.583 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.8 80.52 0.3 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 -179.33 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.607 ' HD2' ' HA ' ' A' ' 25' ' ' PHE . 33.2 Cg_endo -73.07 146.65 41.67 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.612 2.208 . . . . 0.0 112.538 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.615 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 62.4 t60 164.62 171.09 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -93.31 -124.16 3.67 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 178.709 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.86 151.07 21.4 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.314 2.01 . . . . 0.0 109.938 179.162 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.826 ' HB3' HG22 ' A' ' 85' ' ' VAL . 22.1 mt -121.65 89.13 3.06 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.057 -1.027 . . . . 0.0 109.469 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -90.29 167.04 12.97 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 179.214 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.3 t -51.95 118.42 3.43 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.331 -0.855 . . . . 0.0 109.403 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.71 47.86 3.58 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.76 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.437 ' HB3' HD23 ' A' ' 17' ' ' LEU . 2.1 mm-40 -119.81 155.97 31.55 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.281 -1.129 . . . . 0.0 110.868 -179.396 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.786 HD11 ' HB2' ' A' ' 55' ' ' SER . 1.8 tm? -114.52 96.62 5.85 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.757 -0.589 . . . . 0.0 109.565 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.688 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -81.59 160.96 23.69 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 178.552 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.502 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -122.79 111.37 16.61 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.39 -1.444 . . . . 0.0 108.744 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.664 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 4.4 m-85 -100.7 166.38 10.91 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 122.172 0.987 . . . . 0.0 112.277 -177.176 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.585 ' CE1' ' HB ' ' A' ' 11' ' ' VAL . 7.5 p80 -163.45 151.77 13.65 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 176.846 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.906 HD11 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -114.51 160.94 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.0 -1.062 . . . . 0.0 108.884 -178.33 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.952 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -138.05 120.17 15.63 Favored 'General case' 0 N--CA 1.499 2.008 0 C-N-CA 118.453 -1.299 . . . . 0.0 112.653 -178.433 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.037 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 176.44 -72.1 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.228 -0.92 . . . . 0.0 108.963 177.57 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.037 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.9 Cg_endo -77.57 77.93 3.7 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 C-N-CA 121.569 1.513 . . . . 0.0 108.745 178.617 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.571 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 2.6 mp -33.3 -56.34 0.61 Allowed Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 122.127 -0.358 . . . . 0.0 111.631 -178.725 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.571 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.9 Cg_endo -80.62 75.96 4.77 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.165 1.91 . . . . 0.0 111.328 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.917 HG23 ' O ' ' A' ' 30' ' ' PRO . 36.8 t -103.46 148.53 8.34 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 120.984 -1.073 . . . . 0.0 109.098 179.102 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 15.4 t -113.59 -29.06 7.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.131 -0.981 . . . . 0.0 110.256 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -162.35 144.17 10.77 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.319 -0.863 . . . . 0.0 109.91 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.677 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -127.33 162.16 26.91 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 179.539 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.518 ' O ' HG23 ' A' ' 69' ' ' VAL . 13.1 mtp85 -123.89 103.12 8.15 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.906 ' CH2' HD11 ' A' ' 27' ' ' ILE . 35.1 m95 -88.55 179.94 6.18 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.05 -1.031 . . . . 0.0 109.837 -179.462 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.468 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -148.71 100.7 3.13 Favored 'General case' 0 C--N 1.291 -1.939 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 177.44 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.937 ' CE1' HG21 ' A' ' 47' ' ' VAL . 4.1 m-30 -80.27 -50.69 9.85 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 118.869 -1.132 . . . . 0.0 109.829 -177.748 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 80.27 21.77 64.25 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.535 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 1.2 p30 -106.96 -104.87 0.34 Allowed 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 178.483 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.88 -15.41 72.87 Favored Glycine 0 N--CA 1.48 1.607 0 N-CA-C 107.715 -2.154 . . . . 0.0 107.715 176.508 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -140.26 130.62 25.27 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.396 -1.061 . . . . 0.0 109.035 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.17 -85.48 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.956 -1.09 . . . . 0.0 109.624 -179.796 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -56.5 151.2 13.82 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-O 121.268 0.556 . . . . 0.0 109.878 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.937 HG21 ' CE1' ' A' ' 40' ' ' PHE . 61.6 t -139.28 125.02 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.428 -0.795 . . . . 0.0 110.737 -178.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -104.67 109.72 21.76 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.227 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.677 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -123.33 167.83 13.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.157 -0.964 . . . . 0.0 111.024 -178.487 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.64 153.34 17.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.68 -0.638 . . . . 0.0 109.641 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.576 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.33 -156.33 0.55 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -89.52 39.0 0.41 Allowed 'Trans proline' 0 C--N 1.297 -2.152 0 C-N-CA 122.484 2.123 . . . . 0.0 110.25 178.468 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.572 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -140.8 151.6 44.52 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 119.976 -1.703 . . . . 0.0 112.458 -178.368 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.657 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -172.2 153.24 3.0 Favored 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.029 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.786 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -109.84 161.09 15.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.939 -1.1 . . . . 0.0 110.237 -179.82 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.732 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 1.6 m-70 -109.24 134.04 52.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.457 -0.777 . . . . 0.0 110.298 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.688 ' NH2' HD21 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -110.8 92.13 3.93 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.924 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.126 ' CE2' HG11 ' A' ' 83' ' ' VAL . 22.0 m-85 -92.33 133.49 35.81 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.136 -0.978 . . . . 0.0 109.596 -179.39 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 53.6 t -117.86 -28.15 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.418 -0.801 . . . . 0.0 110.973 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.448 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -97.78 143.28 25.94 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 120.592 -1.317 . . . . 0.0 109.611 -179.545 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.905 ' CB ' ' HB2' ' A' ' 87' ' ' ALA . 36.0 Cg_endo -79.06 120.78 4.7 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.616 2.211 . . . . 0.0 110.152 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 159.08 -143.68 9.48 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 18.5 ttm-85 -112.39 154.26 26.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -1.171 . . . . 0.0 109.572 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.617 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 54.0 m-85 -139.1 167.52 21.88 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.526 -0.734 . . . . 0.0 109.06 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 65.6 t60 -125.84 144.59 50.59 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.702 HG22 ' CE1' ' A' ' 56' ' ' HIS . 39.1 t -126.97 148.63 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.09 -1.006 . . . . 0.0 110.751 -179.133 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.401 ' OG1' ' HB2' ' A' ' 39' ' ' ASP . 0.1 OUTLIER -150.24 161.12 43.05 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.605 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.04 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.48 157.55 43.39 Favored 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 119.182 -1.007 . . . . 0.0 110.92 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -145.81 106.03 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 179.16 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.843 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -87.62 143.27 27.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.652 -1.28 . . . . 0.0 109.288 -179.254 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.64 115.12 17.55 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.211 -0.996 . . . . 0.0 109.639 179.077 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.542 HD21 ' O ' ' A' ' 32' ' ' PRO . 9.1 mt -105.88 -12.62 15.78 Favored 'General case' 0 C--N 1.289 -2.058 0 CA-C-O 121.526 0.679 . . . . 0.0 109.215 179.437 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.42 -47.32 1.05 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -178.714 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.23 -5.82 11.85 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.581 -0.952 . . . . 0.0 109.801 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -146.19 154.67 26.1 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.405 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 18.4 p -150.62 174.23 13.23 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.177 -1.19 . . . . 0.0 109.675 -179.586 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.843 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -151.81 134.59 15.59 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.182 -0.949 . . . . 0.0 109.397 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -99.69 143.01 30.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.252 -0.905 . . . . 0.0 110.311 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.04 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -127.53 157.91 38.85 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 121.662 -0.649 . . . . 0.0 109.966 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.03 84.59 0.1 Allowed Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.537 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -103.2 178.01 4.68 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.204 -1.174 . . . . 0.0 110.055 -179.766 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -121.43 157.78 29.81 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.31 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.126 HG11 ' CE2' ' A' ' 58' ' ' TYR . 16.4 t -137.45 143.39 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 120.997 -1.064 . . . . 0.0 110.264 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -132.69 101.77 5.42 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.467 -0.77 . . . . 0.0 109.27 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.826 HG22 ' HB3' ' A' ' 17' ' ' LEU . 79.5 t -103.52 140.52 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.333 -0.855 . . . . 0.0 109.714 -179.473 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -104.9 -174.71 2.6 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.158 -0.964 . . . . 0.0 109.872 -179.479 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.905 ' HB2' ' CB ' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.158 -0.963 . . . . 0.0 109.848 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.793 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.389 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.755 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.15 141.72 28.34 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.693 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.728 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.8 mp -97.88 91.24 5.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 -178.121 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.929 HG12 ' HD3' ' A' ' 13' ' ' PRO . 57.0 t -101.14 117.76 46.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.953 -1.092 . . . . 0.0 108.653 179.171 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.461 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -125.08 72.6 0.43 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.588 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.929 ' HD3' HG12 ' A' ' 11' ' ' VAL . 32.7 Cg_endo -73.01 147.97 44.25 Favored 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.701 2.267 . . . . 0.0 111.758 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.514 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 23.6 t-80 157.52 -33.86 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.791 0 CA-C-N 115.442 -0.799 . . . . 0.0 108.965 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.95 -143.35 15.63 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.123 -1.991 . . . . 0.0 108.123 -179.037 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -77.16 147.79 26.64 Favored 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.049 1.833 . . . . 0.0 108.947 179.032 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 1.088 HD21 ' HB2' ' A' ' 23' ' ' ALA . 5.6 mt -112.27 110.63 20.98 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.201 -0.937 . . . . 0.0 109.89 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -93.09 168.61 11.0 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 179.214 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.6 t -60.83 122.16 14.14 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.209 -0.932 . . . . 0.0 109.456 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.91 47.42 4.78 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.0 mm100 -125.62 157.89 36.05 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.252 -1.146 . . . . 0.0 110.934 -179.515 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.742 HD22 ' O ' ' A' ' 56' ' ' HIS . 1.8 tm? -113.27 103.58 11.46 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 1.088 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -85.61 156.22 20.8 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.918 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.49 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.51 107.7 13.18 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.506 -1.371 . . . . 0.0 108.63 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.768 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 1.9 m-85 -95.36 168.78 10.51 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 121.976 0.893 . . . . 0.0 111.779 -177.53 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.595 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -163.72 141.21 7.28 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.502 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.995 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.9 mm -108.01 152.5 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.292 -0.88 . . . . 0.0 109.435 -178.216 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.637 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -135.28 121.7 20.5 Favored 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.781 -1.168 . . . . 0.0 112.133 -179.045 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.034 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -177.72 -66.34 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.002 -1.061 . . . . 0.0 109.222 177.721 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.034 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.3 Cg_endo -81.72 61.7 8.02 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 C-N-CA 122.129 1.886 . . . . 0.0 109.15 178.835 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.672 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.1 mp -8.81 -67.09 0.01 OUTLIER Pre-proline 0 N--CA 1.508 2.45 0 N-CA-C 113.299 0.851 . . . . 0.0 113.299 -178.55 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.672 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.3 Cg_endo -77.72 68.42 7.67 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 121.892 1.728 . . . . 0.0 111.076 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.684 HG22 ' HG2' ' A' ' 30' ' ' PRO . 3.4 t -91.22 148.06 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 120.757 -1.214 . . . . 0.0 109.875 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.9 p -114.28 -18.11 11.67 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.603 -0.686 . . . . 0.0 110.045 179.52 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.95 152.53 0.75 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.26 -0.9 . . . . 0.0 110.284 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.689 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -140.7 140.66 34.94 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.318 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.649 ' O ' HG23 ' A' ' 69' ' ' VAL . 18.3 mtm-85 -93.74 107.35 19.24 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.101 -0.999 . . . . 0.0 109.369 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.972 ' CH2' HD11 ' A' ' 27' ' ' ILE . 22.8 m95 -90.73 179.56 5.77 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.212 -0.93 . . . . 0.0 109.502 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.421 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.95 102.3 2.96 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 177.36 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.996 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.4 m-30 -80.37 -59.66 2.61 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 118.853 -1.139 . . . . 0.0 110.086 -177.722 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.03 20.06 40.63 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -107.15 -104.52 0.34 Allowed 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.619 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.91 -19.69 62.69 Favored Glycine 0 C--N 1.296 -1.67 0 N-CA-C 107.749 -2.141 . . . . 0.0 107.749 176.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 11.0 p -135.22 130.4 35.21 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.427 -1.043 . . . . 0.0 109.3 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.36 -86.65 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.115 -0.991 . . . . 0.0 109.936 -179.658 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -57.62 152.84 14.32 Favored 'General case' 0 N--CA 1.497 1.89 0 CA-C-O 121.176 0.512 . . . . 0.0 110.112 -179.618 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.996 HG21 ' CE1' ' A' ' 40' ' ' PHE . 34.3 t -140.99 126.96 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.416 -0.803 . . . . 0.0 111.242 -178.745 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -105.44 91.78 3.92 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.345 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.8 ' CB ' ' HB2' ' A' ' 54' ' ' ALA . . . -96.03 154.97 16.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.244 -0.91 . . . . 0.0 111.677 -177.624 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.84 153.18 19.0 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.689 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.26 -158.23 0.55 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 108.248 -1.941 . . . . 0.0 108.248 -179.229 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.402 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.2 Cg_endo -88.37 40.03 0.54 Allowed 'Trans proline' 0 C--N 1.297 -2.157 0 C-N-CA 122.029 1.819 . . . . 0.0 109.932 178.118 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.657 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.27 152.02 39.28 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 120.096 -1.628 . . . . 0.0 112.187 -178.651 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.8 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -165.12 155.91 14.15 Favored 'General case' 0 N--CA 1.498 1.941 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.841 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.654 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -114.41 160.71 18.84 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.932 -1.105 . . . . 0.0 110.192 -179.883 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.787 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 2.1 m-70 -114.54 139.34 49.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.538 -0.726 . . . . 0.0 110.489 -179.15 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.484 HH21 HD21 ' A' ' 22' ' ' LEU . 0.7 OUTLIER -111.89 95.64 5.6 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 178.999 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.086 ' CE2' HG11 ' A' ' 83' ' ' VAL . 36.3 m-85 -99.02 129.86 45.32 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.161 -0.962 . . . . 0.0 109.432 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.7 t -117.91 -27.89 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.352 -0.842 . . . . 0.0 111.25 -178.433 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.486 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -99.51 146.39 31.71 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 120.511 -1.368 . . . . 0.0 109.596 -179.381 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.486 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 34.8 Cg_endo -77.73 124.42 6.89 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.404 2.069 . . . . 0.0 109.888 179.352 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 160.81 -151.78 22.31 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.609 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.409 ' HG2' ' HA ' ' A' ' 84' ' ' GLN . 0.0 OUTLIER -122.17 120.11 33.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.113 -1.228 . . . . 0.0 109.82 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.558 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 81.6 m-85 -103.6 153.64 20.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.353 -0.842 . . . . 0.0 109.541 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.9 t60 -107.89 132.51 53.38 Favored 'General case' 0 N--CA 1.488 1.475 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.168 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.679 HG13 ' CE1' ' A' ' 56' ' ' HIS . 90.7 t -113.42 150.82 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 110.569 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.406 ' OG1' ' HB2' ' A' ' 39' ' ' ASP . 6.0 p -147.54 156.43 42.83 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.096 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.94 156.09 41.14 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.855 -1.153 . . . . 0.0 111.186 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.649 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -128.49 125.82 64.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 178.502 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.999 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.2 OUTLIER -87.76 144.58 26.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 120.535 -1.353 . . . . 0.0 109.007 -178.865 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.21 106.7 7.72 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 118.783 -1.167 . . . . 0.0 109.627 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.562 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -103.62 -10.62 18.28 Favored 'General case' 0 C--N 1.284 -2.28 0 CA-C-N 115.317 -0.856 . . . . 0.0 108.697 179.055 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.81 -47.27 1.07 Allowed Glycine 0 N--CA 1.488 2.125 0 N-CA-C 107.627 -2.189 . . . . 0.0 107.627 -178.416 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.31 -5.09 11.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.741 -0.858 . . . . 0.0 109.68 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.55 158.4 27.52 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.726 -1.349 . . . . 0.0 109.726 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.435 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 25.7 p -148.03 -177.71 5.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.364 -1.08 . . . . 0.0 109.405 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.999 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -156.55 162.69 39.9 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.8 mp -116.8 132.38 56.71 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.065 -1.022 . . . . 0.0 109.976 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.096 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -116.46 157.36 25.29 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.548 -0.72 . . . . 0.0 109.497 -179.752 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.529 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -168.24 96.3 0.12 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.553 HG22 HD23 ' A' ' 10' ' ' LEU . 0.7 OUTLIER -116.34 -171.74 2.05 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.044 -1.268 . . . . 0.0 109.732 179.791 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -151.55 147.63 27.03 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.408 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.086 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -131.77 138.44 52.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 120.68 -1.262 . . . . 0.0 110.018 -179.466 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLN . . . . . 0.409 ' HA ' ' HG2' ' A' ' 63' ' ' ARG . 30.9 tt0 -105.22 90.47 3.44 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 178.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.781 HG21 ' HB3' ' A' ' 58' ' ' TYR . 52.9 t -76.54 130.92 35.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.307 -0.871 . . . . 0.0 109.352 -179.575 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -114.46 144.16 43.77 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.467 -0.771 . . . . 0.0 109.768 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.241 -0.912 . . . . 0.0 109.301 179.676 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.919 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.974 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.1 t -94.26 147.23 23.39 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.3 mp -91.99 88.83 6.73 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.162 -178.215 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.726 HG23 HG23 ' A' ' 9' ' ' THR . 22.1 t -97.76 100.15 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 120.702 -1.249 . . . . 0.0 108.561 178.901 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -117.96 78.73 0.3 Allowed Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.276 -179.304 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.551 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.1 Cg_endo -74.99 148.11 34.88 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.404 2.069 . . . . 0.0 111.635 179.412 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.524 ' ND1' ' HB1' ' A' ' 23' ' ' ALA . 3.3 p-80 174.35 162.01 0.19 Allowed 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.5 -130.0 1.36 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 179.354 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -78.87 147.3 21.36 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 C-N-CA 121.978 1.786 . . . . 0.0 109.145 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.767 HD13 ' HB3' ' A' ' 21' ' ' GLN . 0.4 OUTLIER -113.41 84.21 1.97 Allowed 'General case' 0 C--N 1.298 -1.671 0 O-C-N 121.194 -0.941 . . . . 0.0 109.046 -179.815 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.462 ' HB3' ' OE1' ' A' ' 21' ' ' GLN . . . -95.53 168.16 10.86 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 39.0 t -56.71 108.52 0.51 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.294 -0.879 . . . . 0.0 109.521 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.94 37.67 2.49 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.767 ' HB3' HD13 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -128.21 154.42 45.85 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.227 -1.161 . . . . 0.0 109.79 -179.972 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.835 HD11 ' HB2' ' A' ' 55' ' ' SER . 0.1 OUTLIER -118.66 130.01 55.61 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.118 -0.988 . . . . 0.0 109.662 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.801 ' HB3' ' HE1' ' A' ' 25' ' ' PHE . . . -94.92 146.01 24.53 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.014 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.519 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -101.82 129.6 48.07 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 119.978 -1.701 . . . . 0.0 108.014 178.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.801 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 16.6 m-85 -112.22 166.39 11.31 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 121.959 0.885 . . . . 0.0 111.942 -176.777 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.624 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -164.5 134.41 3.92 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 178.22 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.885 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.4 OUTLIER -103.38 149.43 7.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.17 -0.956 . . . . 0.0 109.036 -178.437 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.974 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -133.73 124.31 26.44 Favored 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.545 -1.262 . . . . 0.0 112.225 -178.856 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.046 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 179.15 -66.38 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 121.118 -0.989 . . . . 0.0 109.199 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.046 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.4 Cg_endo -80.51 68.64 8.25 Favored 'Trans proline' 0 C--N 1.314 -1.281 0 C-N-CA 121.983 1.788 . . . . 0.0 109.102 178.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.679 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -10.81 -66.52 0.01 OUTLIER Pre-proline 0 N--CA 1.507 2.42 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -178.664 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.679 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 37.0 Cg_endo -79.58 83.86 2.16 Favored 'Trans proline' 0 C--N 1.314 -1.257 0 C-N-CA 121.667 1.578 . . . . 0.0 111.001 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.625 HG22 ' HG2' ' A' ' 30' ' ' PRO . 6.3 t -106.12 143.22 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.836 -1.165 . . . . 0.0 109.384 179.365 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.5 t -118.62 -14.18 9.61 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.406 -0.809 . . . . 0.0 110.412 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -174.2 146.82 1.16 Allowed 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.898 -1.126 . . . . 0.0 110.532 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.671 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.4 OUTLIER -142.96 136.94 29.02 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.69 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.573 ' HB2' HG12 ' A' ' 69' ' ' VAL . 7.5 mtm180 -94.28 112.36 24.15 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.19 -0.944 . . . . 0.0 108.872 179.448 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.727 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 18.6 m95 -94.32 -177.09 4.16 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.898 0.856 . . . . 0.0 109.079 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.442 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -151.39 103.77 3.02 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 106.282 -1.748 . . . . 0.0 106.282 177.424 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 1.003 ' CE1' HG21 ' A' ' 47' ' ' VAL . 4.1 m-30 -80.04 -63.65 1.36 Allowed 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.822 -1.151 . . . . 0.0 110.31 -177.586 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.26 9.32 55.68 Favored Glycine 0 N--CA 1.486 1.974 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -178.59 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -93.47 -101.72 0.13 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 178.471 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -89.02 -28.92 19.38 Favored Glycine 0 C--N 1.293 -1.826 0 N-CA-C 107.507 -2.237 . . . . 0.0 107.507 177.056 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.31 130.26 55.93 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.546 -0.973 . . . . 0.0 109.38 179.438 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.442 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.3 -85.02 0.1 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.202 -0.936 . . . . 0.0 109.541 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -59.77 155.26 16.39 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.265 0.555 . . . . 0.0 110.065 -179.775 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 1.003 HG21 ' CE1' ' A' ' 40' ' ' PHE . 60.6 t -142.01 136.16 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.469 -0.769 . . . . 0.0 111.076 -178.79 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -116.16 93.2 4.14 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 177.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.672 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -96.35 150.13 20.92 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.359 -0.838 . . . . 0.0 111.661 -177.841 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.69 146.71 27.3 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.671 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.73 -159.16 0.58 Allowed Glycine 0 N--CA 1.492 2.385 0 N-CA-C 107.91 -2.076 . . . . 0.0 107.91 -179.03 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -86.55 41.6 0.82 Allowed 'Trans proline' 0 C--N 1.299 -2.049 0 C-N-CA 121.909 1.739 . . . . 0.0 110.12 178.253 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.672 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -144.07 141.01 29.82 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.314 -1.491 . . . . 0.0 111.65 -178.909 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.632 ' HB2' ' HB2' ' A' ' 49' ' ' ALA . . . -146.26 -166.16 2.4 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.03 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.835 ' HB2' HD11 ' A' ' 22' ' ' LEU . 5.4 p -156.38 136.45 12.79 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.364 -0.835 . . . . 0.0 108.919 179.391 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.848 ' CE1' HG13 ' A' ' 66' ' ' VAL . 3.0 m-70 -99.46 131.62 45.34 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.291 -0.881 . . . . 0.0 111.329 -178.26 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.404 ' H ' ' HG2' ' A' ' 57' ' ' ARG . 6.7 ptp180 -97.08 96.06 8.2 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 178.23 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.107 ' CE2' HG11 ' A' ' 83' ' ' VAL . 16.6 m-85 -100.1 105.16 16.76 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.905 -1.122 . . . . 0.0 109.547 -179.086 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.0 m -107.73 -9.32 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.488 -0.758 . . . . 0.0 111.292 -178.78 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.48 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -105.83 145.86 31.72 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 120.46 -1.4 . . . . 0.0 109.462 -179.818 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 1.036 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.5 Cg_endo -77.56 123.78 6.65 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.614 2.209 . . . . 0.0 110.133 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 150.37 -142.97 10.12 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 -179.747 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.26 158.54 37.87 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.204 -1.174 . . . . 0.0 109.475 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.655 ' HB2' HG13 ' A' ' 83' ' ' VAL . 92.5 m-85 -135.78 155.46 50.33 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.307 -0.87 . . . . 0.0 109.683 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 38.5 t-80 -111.46 114.31 27.33 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.034 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.848 HG13 ' CE1' ' A' ' 56' ' ' HIS . 62.7 t -95.06 150.64 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.228 -0.92 . . . . 0.0 110.527 -178.84 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.43 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.8 OUTLIER -146.42 157.96 43.83 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.388 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.018 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -156.36 164.57 38.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.603 -1.311 . . . . 0.0 111.224 -179.457 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.573 HG12 ' HB2' ' A' ' 37' ' ' ARG . 9.8 p -142.16 127.29 17.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 178.427 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 1.054 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.2 142.23 27.92 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.932 -1.105 . . . . 0.0 108.769 -178.471 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -131.41 106.23 8.11 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.551 -1.26 . . . . 0.0 109.949 178.597 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.638 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -104.6 -9.82 18.0 Favored 'General case' 0 C--N 1.284 -2.261 0 CA-C-N 115.218 -0.901 . . . . 0.0 108.701 178.937 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.11 -48.52 0.97 Allowed Glycine 0 N--CA 1.487 2.094 0 N-CA-C 107.776 -2.13 . . . . 0.0 107.776 -178.457 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.59 -5.52 11.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.633 -0.922 . . . . 0.0 109.61 179.089 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.94 156.66 26.07 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.406 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 22.0 p -150.38 -178.65 6.65 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.304 -1.115 . . . . 0.0 109.421 -179.542 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 1.054 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -158.98 141.4 14.03 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.36 -0.837 . . . . 0.0 108.744 179.577 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -99.85 135.37 41.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.984 -1.073 . . . . 0.0 110.101 -179.211 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.018 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -119.82 156.91 29.75 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.492 -0.755 . . . . 0.0 110.026 -179.569 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.52 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.46 89.73 0.1 Allowed Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.743 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -107.49 -172.7 2.12 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.991 -1.3 . . . . 0.0 110.267 -179.571 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -150.72 146.28 26.34 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.107 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -131.2 157.59 43.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.856 -1.152 . . . . 0.0 109.93 -179.702 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLN . . . . . 0.491 ' N ' HG23 ' A' ' 83' ' ' VAL . 8.1 mt-30 -130.45 92.14 3.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.595 -0.691 . . . . 0.0 109.165 179.466 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.758 HG22 ' HB3' ' A' ' 17' ' ' LEU . 40.9 t -86.58 141.92 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.253 -0.904 . . . . 0.0 109.734 -179.663 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -108.34 175.69 5.38 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.29 -0.881 . . . . 0.0 110.309 -179.29 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 1.036 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.659 0 O-C-N 121.347 -0.846 . . . . 0.0 109.693 179.5 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.714 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.943 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.6 t -74.95 150.73 38.97 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.13 -0.982 . . . . 0.0 109.408 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.753 HD23 HG22 ' A' ' 81' ' ' THR . 5.3 mp -87.15 105.6 17.31 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.977 -178.636 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.617 HG21 ' CE1' ' A' ' 26' ' ' HIS . 2.3 t -119.36 91.6 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.976 -1.078 . . . . 0.0 109.009 178.894 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.715 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -113.7 81.14 0.29 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.492 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.54 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.5 Cg_endo -73.34 149.04 44.45 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.662 2.242 . . . . 0.0 111.92 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.599 ' CD2' HD22 ' A' ' 17' ' ' LEU . 45.6 t60 166.96 -39.13 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.49 -138.86 14.76 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.057 -2.017 . . . . 0.0 108.057 -178.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -77.42 147.65 25.75 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 C-N-CA 122.096 1.864 . . . . 0.0 109.043 178.809 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.839 HD21 ' HB2' ' A' ' 23' ' ' ALA . 0.2 OUTLIER -106.31 109.84 21.9 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.098 -1.001 . . . . 0.0 109.721 -179.285 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.602 ' HB3' ' HG3' ' A' ' 21' ' ' GLN . . . -92.34 153.35 19.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 179.269 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.0 t -59.29 111.08 1.23 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -0.875 . . . . 0.0 109.37 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.47 35.44 3.09 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLN . . . . . 0.602 ' HG3' ' HB3' ' A' ' 18' ' ' ALA . 13.6 mm100 -133.65 160.54 37.23 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.192 -1.181 . . . . 0.0 109.88 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.708 HD12 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -117.06 126.66 53.2 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.186 -0.946 . . . . 0.0 109.414 179.672 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.839 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -90.06 145.42 25.08 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.084 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.54 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -99.89 129.78 46.01 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 119.918 -1.739 . . . . 0.0 108.165 179.111 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.816 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 16.8 m-85 -113.88 163.26 15.32 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 122.102 0.954 . . . . 0.0 111.977 -177.335 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' HIS . . . . . 0.617 ' CE1' HG21 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -165.9 139.77 4.43 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.079 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.828 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.31 154.69 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.868 -1.145 . . . . 0.0 108.777 -178.331 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.943 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -133.87 123.43 24.73 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 120.693 -1.255 . . . . 0.0 112.732 -178.08 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 1.041 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 171.45 -69.22 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.399 -0.813 . . . . 0.0 109.305 177.659 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 1.041 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -76.66 78.7 3.26 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 121.796 1.664 . . . . 0.0 109.486 179.198 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.709 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 6.0 mt -34.05 -53.82 0.86 Allowed Pre-proline 0 N--CA 1.504 2.251 0 O-C-N 121.944 -0.472 . . . . 0.0 111.703 -178.792 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' PRO . . . . . 0.709 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 36.8 Cg_endo -81.3 63.12 8.61 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 C-N-CA 122.077 1.851 . . . . 0.0 112.198 -179.055 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.918 HG23 ' O ' ' A' ' 30' ' ' PRO . 74.4 t -87.59 148.02 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 120.595 -1.316 . . . . 0.0 109.696 179.118 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 70.7 p -119.53 -35.82 3.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.422 -0.798 . . . . 0.0 109.665 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -155.13 144.37 21.04 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.461 -0.774 . . . . 0.0 109.007 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.929 HG23 ' HB3' ' A' ' 49' ' ' ALA . 0.5 OUTLIER -129.29 156.44 44.0 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.976 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.49 ' O ' HG23 ' A' ' 69' ' ' VAL . 49.1 mtp85 -119.51 101.06 7.67 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 109.044 179.82 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.783 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 30.3 m95 -89.24 178.77 6.27 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.123 -0.985 . . . . 0.0 109.476 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ASP . . . . . 0.457 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.51 101.58 2.97 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 177.49 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 1.004 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.9 m-30 -79.75 -61.26 2.05 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.989 -177.847 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.77 15.86 47.68 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -178.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.27 -104.52 0.27 Allowed 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 178.607 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.31 -20.28 59.09 Favored Glycine 0 C--N 1.296 -1.649 0 N-CA-C 107.708 -2.157 . . . . 0.0 107.708 177.028 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 m -132.58 127.59 35.35 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.432 -1.04 . . . . 0.0 109.304 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.457 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.89 -85.96 0.09 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.17 -0.956 . . . . 0.0 109.72 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -57.73 153.37 13.69 Favored 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 121.112 0.482 . . . . 0.0 109.71 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 1.004 HG21 ' CE1' ' A' ' 40' ' ' PHE . 57.7 t -140.16 124.12 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.384 -0.823 . . . . 0.0 111.1 -178.445 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -104.61 99.47 9.14 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.074 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.929 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -109.91 167.8 9.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.203 -0.936 . . . . 0.0 111.02 -178.596 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.97 151.94 21.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.715 -0.615 . . . . 0.0 109.352 179.736 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.555 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.92 -155.2 0.58 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -89.06 41.63 0.57 Allowed 'Trans proline' 0 C--N 1.295 -2.255 0 C-N-CA 122.272 1.981 . . . . 0.0 110.515 178.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.652 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.58 154.02 43.14 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.928 -1.733 . . . . 0.0 112.602 -178.716 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.434 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -166.56 -171.17 1.81 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.074 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.646 ' HB3' HD11 ' A' ' 22' ' ' LEU . 0.3 OUTLIER -150.45 143.25 24.65 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.116 -0.99 . . . . 0.0 109.263 179.449 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 56' ' ' HIS . . . . . 0.829 ' CE1' HG22 ' A' ' 66' ' ' VAL . 2.3 m-70 -102.41 134.64 45.4 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.197 -0.94 . . . . 0.0 111.515 -178.686 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.15 95.47 6.57 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.331 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 1.119 ' CE2' HG11 ' A' ' 83' ' ' VAL . 18.6 m-85 -102.58 112.84 25.77 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.079 -1.013 . . . . 0.0 109.403 -179.285 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.6 p -110.85 -10.56 11.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.417 -0.802 . . . . 0.0 111.525 -178.515 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.479 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -114.73 146.14 35.4 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 120.478 -1.389 . . . . 0.0 109.673 -179.743 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.479 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.1 Cg_endo -77.06 122.85 6.41 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.403 2.069 . . . . 0.0 109.935 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 161.77 -157.05 28.73 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.607 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.425 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -116.93 121.2 40.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.144 -1.21 . . . . 0.0 109.771 -179.824 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.6 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 90.3 m-85 -103.71 155.95 18.18 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.314 -0.867 . . . . 0.0 109.315 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 80.8 t60 -111.94 123.34 50.04 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.045 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.829 HG22 ' CE1' ' A' ' 56' ' ' HIS . 62.4 t -106.22 150.5 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.163 -0.961 . . . . 0.0 110.594 -178.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.53 159.56 44.2 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 178.664 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 1.06 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -151.09 154.52 37.13 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.939 -1.101 . . . . 0.0 110.921 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -144.75 104.3 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.102 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.821 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.74 150.73 22.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.757 -1.215 . . . . 0.0 110.204 -178.663 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.99 116.16 18.91 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.826 0.822 . . . . 0.0 108.937 178.453 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.916 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.6 mp -104.36 -12.96 16.29 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-O 121.508 0.671 . . . . 0.0 109.212 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.74 -53.75 0.62 Allowed Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.135 -1.986 . . . . 0.0 108.135 -178.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.71 -5.33 12.13 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.584 -0.95 . . . . 0.0 109.777 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.43 161.4 26.95 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.419 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 3.4 p -150.87 170.36 19.47 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.371 -1.076 . . . . 0.0 109.359 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.821 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -143.42 128.75 18.88 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.245 -0.91 . . . . 0.0 109.57 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.3 tp -95.11 140.79 29.55 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.471 -0.768 . . . . 0.0 110.029 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 1.06 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -128.72 157.52 41.15 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.604 -0.685 . . . . 0.0 109.919 -179.464 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -164.88 86.48 0.1 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 179.589 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.753 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -104.34 -176.32 3.05 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.122 -1.222 . . . . 0.0 109.762 -179.854 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -150.76 147.53 27.42 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.119 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -131.83 149.78 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 O-C-N 120.768 -1.208 . . . . 0.0 109.618 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -119.22 87.46 2.74 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.681 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.773 HG21 ' HB3' ' A' ' 58' ' ' TYR . 84.5 t -75.01 134.84 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.312 -0.867 . . . . 0.0 109.815 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 -109.26 177.52 4.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.363 -0.835 . . . . 0.0 109.591 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.364 -0.835 . . . . 0.0 109.515 179.874 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.955 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.393 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.711 ' CG2' ' HB3' ' A' ' 28' ' ' ALA . 0.5 OUTLIER -81.49 144.66 31.19 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.214 -0.929 . . . . 0.0 108.95 -179.456 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.779 HD23 HG22 ' A' ' 81' ' ' THR . 5.8 mp -94.27 86.7 5.0 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.215 -178.164 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.842 HG11 ' CE1' ' A' ' 26' ' ' HIS . 32.9 t -94.88 102.39 13.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 120.873 -1.142 . . . . 0.0 108.386 178.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.505 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.95 76.72 0.28 Allowed Glycine 0 N--CA 1.488 2.113 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.038 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.691 ' HD3' HG12 ' A' ' 11' ' ' VAL . 31.4 Cg_endo -71.73 146.85 49.48 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.438 2.092 . . . . 0.0 111.401 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 174.51 164.17 0.22 Allowed 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 -179.664 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -89.29 -125.91 2.77 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 107.363 -2.295 . . . . 0.0 107.363 178.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -80.06 147.06 18.52 Favored 'Trans proline' 0 C--N 1.302 -1.875 0 C-N-CA 121.839 1.693 . . . . 0.0 108.293 177.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.73 HD12 HG22 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -114.15 80.13 1.35 Allowed 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.922 -1.111 . . . . 0.0 109.158 -179.633 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -91.61 172.29 8.6 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.2 t -59.39 117.85 5.31 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.2 -0.938 . . . . 0.0 109.325 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.81 46.71 3.09 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.643 ' HB3' HD13 ' A' ' 17' ' ' LEU . 0.0 OUTLIER -122.27 152.27 40.22 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.386 -1.067 . . . . 0.0 110.559 -179.627 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.661 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.0 tm? -109.99 94.58 5.09 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.739 -0.6 . . . . 0.0 109.65 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.713 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -75.66 158.9 31.76 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.502 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -124.71 117.81 25.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.463 -1.398 . . . . 0.0 108.573 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.804 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.8 m-85 -105.55 170.96 7.59 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 122.085 0.945 . . . . 0.0 111.828 -177.318 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.842 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.8 138.98 3.51 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 178.105 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.793 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.3 OUTLIER -105.32 152.52 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.085 -1.009 . . . . 0.0 109.47 -178.276 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.711 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -134.66 116.83 15.4 Favored 'General case' 0 N--CA 1.5 2.046 0 C-N-CA 118.823 -1.151 . . . . 0.0 111.644 -179.292 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.112 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 176.56 -62.26 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.915 0 O-C-N 121.076 -1.015 . . . . 0.0 109.952 178.173 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.112 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.4 Cg_endo -80.11 63.55 8.76 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.32 2.013 . . . . 0.0 109.711 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.64 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -13.13 -64.58 0.02 OUTLIER Pre-proline 0 N--CA 1.504 2.266 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 -178.902 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.64 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.2 Cg_endo -77.69 72.5 6.05 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 121.724 1.616 . . . . 0.0 111.282 -179.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.483 ' CG2' ' O ' ' A' ' 30' ' ' PRO . 2.7 t -98.77 127.26 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.996 -1.065 . . . . 0.0 109.341 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 p -111.21 -14.87 13.77 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.417 -0.802 . . . . 0.0 109.219 178.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -163.46 148.34 11.02 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.224 -0.922 . . . . 0.0 109.824 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.935 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.4 t -140.38 162.66 34.78 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.554 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -127.31 100.5 6.08 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.101 -0.999 . . . . 0.0 109.217 179.586 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.804 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 36.4 m95 -87.59 179.02 6.61 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.218 -0.926 . . . . 0.0 109.453 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.466 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.3 OUTLIER -146.84 103.14 3.6 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.862 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.981 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.5 m-30 -81.16 -59.1 2.77 Favored 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.314 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.28 8.48 68.44 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.518 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 10.4 p30 -98.49 35.7 1.76 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.372 -1.075 . . . . 0.0 108.111 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 108.33 -38.35 3.37 Favored Glycine 0 N--CA 1.483 1.785 0 N-CA-C 105.356 -3.098 . . . . 0.0 105.356 -175.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 74.6 m -101.86 95.06 6.14 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.466 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.2 -90.7 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -0.919 . . . . 0.0 110.151 -178.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -55.9 146.81 20.97 Favored 'General case' 0 N--CA 1.493 1.688 0 CA-C-O 121.251 0.548 . . . . 0.0 109.758 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.981 HG21 ' CE1' ' A' ' 40' ' ' PHE . 63.8 t -135.01 106.36 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.377 -0.827 . . . . 0.0 110.972 -178.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.8 94.12 9.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.988 -1.07 . . . . 0.0 108.211 178.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.935 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -101.65 166.6 10.6 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.258 -0.901 . . . . 0.0 110.801 -178.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.61 150.09 21.53 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.725 -0.61 . . . . 0.0 109.595 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.541 ' O ' HG22 ' A' ' 36' ' ' THR . . . 44.14 -153.26 0.41 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.461 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.8 Cg_endo -88.43 40.09 0.54 Allowed 'Trans proline' 0 C--N 1.301 -1.943 0 C-N-CA 122.372 2.048 . . . . 0.0 110.282 178.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.628 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.38 154.39 43.68 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.135 -1.603 . . . . 0.0 112.011 -178.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.447 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -165.88 -168.86 1.37 Allowed 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.362 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.661 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -157.32 146.59 20.08 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.133 -0.979 . . . . 0.0 109.131 179.236 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.63 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 7.5 m80 -100.08 133.76 44.0 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.352 -0.843 . . . . 0.0 110.915 -178.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -107.5 88.63 2.78 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.418 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.131 ' CE2' HG11 ' A' ' 83' ' ' VAL . 13.8 m-85 -88.71 135.14 33.66 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.389 -0.819 . . . . 0.0 109.294 -178.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.9 p -127.96 -12.93 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.235 -0.916 . . . . 0.0 111.314 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.438 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -110.23 144.63 30.49 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 120.527 -1.358 . . . . 0.0 109.584 -179.767 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.755 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.0 Cg_endo -77.78 115.54 3.85 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.408 2.072 . . . . 0.0 109.868 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 163.97 -142.76 8.04 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.69 159.74 22.46 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.221 -1.164 . . . . 0.0 109.215 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.526 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 57.9 m-85 -140.68 160.85 39.14 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.413 -0.805 . . . . 0.0 109.297 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 49.2 t60 -122.0 142.09 50.68 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.624 HG13 ' CE1' ' A' ' 56' ' ' HIS . 21.7 t -125.17 149.6 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.862 -1.148 . . . . 0.0 110.991 -178.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.44 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -150.28 160.65 43.55 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 107.448 -1.315 . . . . 0.0 107.448 178.129 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.04 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -151.79 153.66 34.7 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.843 -1.16 . . . . 0.0 111.292 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.537 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.8 OUTLIER -126.0 121.99 60.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.58 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.9 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.6 OUTLIER -88.36 141.54 28.46 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 120.596 -1.315 . . . . 0.0 109.103 -178.406 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.66 109.12 10.4 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 118.679 -1.209 . . . . 0.0 109.694 178.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.841 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -104.07 -11.03 17.59 Favored 'General case' 0 C--N 1.288 -2.069 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.73 -49.46 0.84 Allowed Glycine 0 N--CA 1.487 2.074 0 N-CA-C 107.729 -2.148 . . . . 0.0 107.729 -178.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -118.41 -5.56 10.8 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.678 -0.895 . . . . 0.0 109.877 179.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.55 164.09 26.04 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.462 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 6.8 p -151.18 -177.23 5.92 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.344 -1.092 . . . . 0.0 109.684 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.9 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -153.17 154.81 35.5 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 179.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -112.94 124.79 53.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.141 -0.974 . . . . 0.0 109.938 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.04 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -114.53 155.24 26.81 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.416 -0.802 . . . . 0.0 110.032 -179.643 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -164.66 91.59 0.11 Allowed Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.271 -1.531 . . . . 0.0 109.271 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.779 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -106.88 175.84 5.37 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.127 -1.219 . . . . 0.0 109.895 -179.683 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -122.12 160.34 25.28 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.378 -0.826 . . . . 0.0 108.99 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.131 HG11 ' CE2' ' A' ' 58' ' ' TYR . 25.9 t -144.17 147.51 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.011 -1.055 . . . . 0.0 110.448 -179.022 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -137.14 98.98 3.87 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.385 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.73 HG22 HD12 ' A' ' 17' ' ' LEU . 29.1 t -96.93 139.83 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.111 -0.993 . . . . 0.0 110.658 -179.004 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 23.6 mm-40 -110.59 -159.41 0.68 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.512 -0.743 . . . . 0.0 109.62 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.755 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.123 -0.986 . . . . 0.0 109.243 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.706 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.926 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.3 t -70.62 149.44 47.05 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.196 -0.94 . . . . 0.0 109.336 -179.203 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.731 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 4.9 mp -84.62 108.18 17.22 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.088 -178.359 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.666 HG21 ' CE1' ' A' ' 26' ' ' HIS . 0.7 OUTLIER -123.53 104.28 14.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 120.777 -1.202 . . . . 0.0 108.912 178.708 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.85 76.52 0.3 Allowed Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.551 ' HD2' ' HA ' ' A' ' 25' ' ' PHE . 34.6 Cg_endo -73.26 150.43 47.28 Favored 'Trans proline' 0 C--N 1.308 -1.567 0 C-N-CA 122.728 2.285 . . . . 0.0 111.918 179.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.524 ' CD2' ' HA ' ' A' ' 23' ' ' ALA . 32.6 t-80 161.94 -36.82 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.796 0 CA-C-O 121.782 0.801 . . . . 0.0 108.944 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.97 -138.04 14.52 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 107.942 -2.063 . . . . 0.0 107.942 -178.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -77.74 147.83 25.03 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 122.027 1.818 . . . . 0.0 109.313 178.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.85 ' HB3' HG22 ' A' ' 85' ' ' VAL . 0.6 OUTLIER -110.59 115.73 30.12 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.251 -0.906 . . . . 0.0 109.486 -179.441 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -106.24 160.01 15.67 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 45.7 t -56.3 119.34 5.82 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.316 -0.865 . . . . 0.0 109.471 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.42 46.92 3.92 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 7.5 mm100 -127.4 153.52 46.15 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.145 -1.209 . . . . 0.0 110.543 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.838 HD11 ' HB2' ' A' ' 55' ' ' SER . 1.8 tm? -108.81 92.31 4.0 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.652 ' HB3' ' HB2' ' A' ' 56' ' ' HIS . . . -71.21 156.33 39.68 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 178.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.497 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -122.74 112.49 17.99 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.26 -1.525 . . . . 0.0 108.341 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.798 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.6 m-85 -100.64 173.84 6.35 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 122.512 1.148 . . . . 0.0 112.415 -177.19 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.666 ' CE1' HG21 ' A' ' 11' ' ' VAL . 5.9 p80 -172.47 147.61 1.91 Allowed 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.19 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.908 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.82 156.88 12.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.961 -1.087 . . . . 0.0 108.198 -178.484 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.926 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -132.66 122.34 24.52 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.442 -1.303 . . . . 0.0 112.702 -177.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.053 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.8 -70.06 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.797 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.053 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.1 Cg_endo -77.62 77.76 3.76 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 121.592 1.528 . . . . 0.0 108.718 178.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.567 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.3 OUTLIER -35.16 -55.57 1.01 Allowed Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.817 -0.552 . . . . 0.0 111.284 -178.795 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.613 ' O ' HD21 ' A' ' 72' ' ' LEU . 36.8 Cg_endo -80.62 81.29 2.78 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.141 1.894 . . . . 0.0 111.236 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 30' ' ' PRO . 40.1 t -111.89 150.3 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 120.908 -1.12 . . . . 0.0 109.0 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 18.5 p -116.91 -28.92 6.16 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.203 -0.936 . . . . 0.0 110.593 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.93 143.7 17.15 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.088 -1.008 . . . . 0.0 110.274 -179.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.905 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -130.79 157.37 43.05 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.517 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -125.05 104.25 8.45 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.305 -0.872 . . . . 0.0 108.669 179.102 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.798 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 32.7 m95 -88.85 -178.6 5.78 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 109.276 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.522 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -148.24 102.73 3.38 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 178.085 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.96 ' CE1' HG21 ' A' ' 47' ' ' VAL . 4.7 m-30 -81.61 -66.03 0.94 Allowed 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 119.182 -1.007 . . . . 0.0 110.561 -177.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.89 11.12 47.55 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.552 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 12.6 p30 -97.04 33.07 1.99 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.249 -1.148 . . . . 0.0 108.224 179.043 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.24 -34.84 5.08 Favored Glycine 0 N--CA 1.48 1.603 0 N-CA-C 105.449 -3.06 . . . . 0.0 105.449 -175.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 50.2 m -108.35 100.78 10.04 Favored 'General case' 0 N--CA 1.485 1.305 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.522 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -75.3 -86.96 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.166 -0.959 . . . . 0.0 109.773 -178.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -50.89 144.77 8.04 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.308 0.575 . . . . 0.0 109.806 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.96 HG21 ' CE1' ' A' ' 40' ' ' PHE . 91.9 t -133.84 105.91 8.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.36 -0.838 . . . . 0.0 110.764 -178.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -83.12 115.75 22.03 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.479 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.905 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -129.26 164.08 24.25 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.028 -1.045 . . . . 0.0 110.74 -178.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.18 151.02 19.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.659 -0.65 . . . . 0.0 109.574 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.589 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.65 -155.31 0.51 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -88.5 38.91 0.47 Allowed 'Trans proline' 0 C--N 1.298 -2.1 0 C-N-CA 122.269 1.979 . . . . 0.0 110.191 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.661 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -139.55 155.57 47.42 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 120.227 -1.546 . . . . 0.0 111.895 -178.705 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.504 ' HB2' ' NE1' ' A' ' 38' ' ' TRP . . . -165.18 -169.64 1.69 Allowed 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.838 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -154.0 144.09 22.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.018 -1.051 . . . . 0.0 109.816 179.407 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.652 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -94.48 129.89 41.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.705 -0.622 . . . . 0.0 111.031 -178.797 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -105.47 85.57 2.27 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.023 ' CE2' HG11 ' A' ' 83' ' ' VAL . 13.0 m-85 -92.29 134.2 35.12 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.986 -1.071 . . . . 0.0 110.073 -178.544 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.4 m -127.3 -3.12 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.605 -0.685 . . . . 0.0 111.046 -179.083 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.446 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.2 OUTLIER -117.61 140.5 27.6 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 120.651 -1.281 . . . . 0.0 109.36 -179.944 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.852 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.1 Cg_endo -77.65 109.47 2.76 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 122.479 2.119 . . . . 0.0 110.155 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 169.81 -144.23 8.41 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.89 162.25 15.0 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.166 -1.196 . . . . 0.0 109.826 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.512 ' HB2' ' HB ' ' A' ' 83' ' ' VAL . 61.5 m-85 -146.91 165.28 30.26 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -124.87 153.9 41.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.151 -0.968 . . . . 0.0 108.503 179.008 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.612 HG13 ' NE2' ' A' ' 56' ' ' HIS . 12.5 t -134.19 145.19 33.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 120.839 -1.163 . . . . 0.0 110.764 -179.057 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.452 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -150.63 159.03 44.79 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 178.129 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.993 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -152.03 157.26 41.43 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.868 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.587 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.3 p -150.14 108.19 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.851 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.16 151.11 22.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.931 -1.106 . . . . 0.0 109.154 -179.156 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.42 119.7 23.09 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.362 -0.935 . . . . 0.0 109.708 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.613 HD21 ' O ' ' A' ' 32' ' ' PRO . 7.4 mt -109.23 -12.97 14.73 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-O 121.518 0.675 . . . . 0.0 109.492 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.07 -47.41 1.05 Allowed Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -178.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -113.87 -6.24 13.22 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.574 -0.956 . . . . 0.0 109.696 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.65 158.84 27.83 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -150.8 168.34 24.73 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.199 -1.177 . . . . 0.0 109.395 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.851 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -141.74 132.62 25.87 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.199 -0.938 . . . . 0.0 109.358 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.2 mp -101.76 147.06 26.92 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.15 -0.969 . . . . 0.0 110.45 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.993 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -133.26 160.11 38.25 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.655 -0.653 . . . . 0.0 109.886 -179.292 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.491 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.42 88.91 0.09 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.509 HG22 HD13 ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.48 175.8 5.28 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.087 -1.243 . . . . 0.0 109.976 -179.755 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -117.87 155.37 30.27 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.243 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.023 HG11 ' CE2' ' A' ' 58' ' ' TYR . 25.1 t -134.82 143.42 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.172 -0.955 . . . . 0.0 110.049 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -131.83 104.0 6.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.37 -0.832 . . . . 0.0 109.038 179.407 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.85 HG22 ' HB3' ' A' ' 17' ' ' LEU . 86.0 t -102.43 132.19 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.345 -0.847 . . . . 0.0 109.964 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.45 -160.98 0.81 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.201 -0.937 . . . . 0.0 109.391 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.852 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.632 0 O-C-N 121.064 -1.022 . . . . 0.0 109.427 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.873 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.812 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.79 139.68 30.22 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.77 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.6 mp -97.19 89.55 4.81 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.148 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.941 HG12 ' HD3' ' A' ' 13' ' ' PRO . 65.3 t -99.08 112.34 30.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.885 -1.134 . . . . 0.0 109.092 179.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.504 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -124.1 71.18 0.44 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.941 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.4 Cg_endo -73.64 150.4 45.22 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.803 2.336 . . . . 0.0 112.153 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.468 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.9 t-80 168.9 -38.87 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.681 0.753 . . . . 0.0 109.208 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.29 -138.05 14.56 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 -178.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.62 147.0 24.57 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 121.972 1.782 . . . . 0.0 109.166 178.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.953 HD21 ' HB2' ' A' ' 23' ' ' ALA . 2.7 mt -117.26 98.56 6.5 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.2 -0.937 . . . . 0.0 109.779 -179.301 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.09 165.66 14.98 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 t -60.85 114.74 3.22 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.243 -0.91 . . . . 0.0 109.272 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.68 39.52 2.72 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.84 154.58 51.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.152 -1.205 . . . . 0.0 110.015 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.717 HD12 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -115.82 128.14 55.59 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.805 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.953 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -92.69 148.37 22.12 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.533 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -105.25 121.9 44.81 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.067 -1.645 . . . . 0.0 108.04 179.012 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.815 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 5.2 m-85 -105.39 170.53 7.83 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 121.914 0.864 . . . . 0.0 111.721 -177.009 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.709 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.72 140.14 3.84 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.793 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.999 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.6 mm -109.42 148.67 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.279 -0.888 . . . . 0.0 109.309 -178.345 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.644 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -133.33 122.6 24.07 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.989 -178.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.139 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 175.25 -61.86 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.078 -1.014 . . . . 0.0 109.552 178.134 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.139 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.3 Cg_endo -79.17 68.49 8.27 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.209 1.939 . . . . 0.0 109.699 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.634 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.0 OUTLIER -15.42 -64.03 0.03 OUTLIER Pre-proline 0 N--CA 1.506 2.327 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.83 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.634 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.4 Cg_endo -78.52 73.39 5.9 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 C-N-CA 121.774 1.65 . . . . 0.0 111.202 -179.513 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 30' ' ' PRO . 2.8 t -96.41 136.64 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.894 -1.129 . . . . 0.0 109.656 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.5 t -115.89 -15.33 11.25 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.48 -0.763 . . . . 0.0 109.331 179.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.6 149.43 0.48 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.311 -0.868 . . . . 0.0 109.667 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.624 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -136.93 139.68 41.73 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.59 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.61 ' O ' HG23 ' A' ' 69' ' ' VAL . 10.2 mtm-85 -93.33 109.04 20.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.138 -0.976 . . . . 0.0 109.136 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.977 ' CH2' HD11 ' A' ' 27' ' ' ILE . 18.7 m95 -93.85 179.81 5.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.918 -1.114 . . . . 0.0 109.621 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.489 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.76 106.61 3.41 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.328 -1.731 . . . . 0.0 106.328 177.369 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 1.014 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.7 m-30 -81.37 -66.44 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 118.451 -1.3 . . . . 0.0 111.37 -176.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.11 -4.91 59.03 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.1 p30 -90.41 23.71 2.86 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.335 -1.097 . . . . 0.0 109.164 179.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 122.56 -38.11 2.64 Favored Glycine 0 C--N 1.298 -1.576 0 N-CA-C 106.129 -2.788 . . . . 0.0 106.129 -176.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.77 101.52 12.96 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 177.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.489 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.38 -98.28 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 0.0 109.958 -178.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -56.92 150.1 17.33 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.286 0.565 . . . . 0.0 109.927 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 1.014 HG21 ' CE1' ' A' ' 40' ' ' PHE . 70.8 t -138.9 132.97 40.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.47 -0.769 . . . . 0.0 110.591 -178.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -112.89 89.8 3.18 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.686 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -92.84 152.53 19.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.373 -0.829 . . . . 0.0 111.423 -178.135 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.72 150.2 23.75 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.624 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.08 -156.4 0.49 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.24 -1.944 . . . . 0.0 108.24 -179.27 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.415 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.1 Cg_endo -88.43 42.63 0.7 Allowed 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.122 1.881 . . . . 0.0 110.479 178.436 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.686 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -146.87 144.38 29.24 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.072 -1.642 . . . . 0.0 112.009 -179.089 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 49' ' ' ALA . . . -149.54 -169.6 3.42 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.599 ' HB3' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -152.64 138.8 18.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.249 -0.907 . . . . 0.0 109.174 179.558 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.616 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 11.1 m80 -102.91 135.45 44.57 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.231 -0.918 . . . . 0.0 111.101 -178.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.439 ' H ' ' HG2' ' A' ' 57' ' ' ARG . 2.0 ptp180 -100.44 95.06 6.49 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.022 ' CE2' HG11 ' A' ' 83' ' ' VAL . 23.8 m-85 -95.5 120.24 35.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.225 -0.922 . . . . 0.0 109.232 -179.232 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.6 p -118.17 -29.71 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.241 -0.912 . . . . 0.0 111.165 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.405 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -90.71 143.35 28.82 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 120.619 -1.3 . . . . 0.0 109.376 -179.678 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.405 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.0 Cg_endo -76.26 133.04 14.34 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.575 2.183 . . . . 0.0 110.281 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.59 -135.05 5.93 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 -179.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -127.27 164.51 21.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -1.193 . . . . 0.0 109.651 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.65 ' HB2' HG13 ' A' ' 83' ' ' VAL . 59.7 m-85 -142.98 152.84 42.39 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.466 -0.771 . . . . 0.0 109.205 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -112.99 130.37 56.16 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.575 HG13 ' CE1' ' A' ' 56' ' ' HIS . 59.2 t -116.0 150.58 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 110.821 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.79 155.51 42.42 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.064 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.53 158.57 44.31 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.853 -1.155 . . . . 0.0 111.518 -179.538 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -129.84 127.17 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.423 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 1.011 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.3 OUTLIER -89.07 141.87 28.12 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 120.656 -1.277 . . . . 0.0 109.015 -178.743 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.3 110.48 11.56 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.589 -1.245 . . . . 0.0 109.698 178.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.925 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.9 mp -105.49 -11.1 16.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.072 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.66 -49.62 0.83 Allowed Glycine 0 N--CA 1.486 2.011 0 N-CA-C 107.669 -2.173 . . . . 0.0 107.669 -178.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.44 -5.76 11.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.58 -0.953 . . . . 0.0 109.884 178.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -140.04 162.5 26.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.478 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.8 p -151.44 -179.23 7.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.306 -1.114 . . . . 0.0 109.579 -179.598 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 1.011 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -154.17 166.39 33.25 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.2 mt -119.93 132.75 55.62 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.068 -1.02 . . . . 0.0 110.227 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.064 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -117.4 157.14 26.7 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.524 -0.735 . . . . 0.0 109.769 -179.879 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.65 95.12 0.11 Allowed Glycine 0 N--CA 1.485 1.938 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.612 HG22 HD23 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -116.38 -173.33 2.35 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.232 -1.158 . . . . 0.0 109.937 179.932 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -150.74 153.7 36.0 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.435 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.022 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.0 154.25 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.66 -1.275 . . . . 0.0 109.845 -179.519 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . 0.425 ' N ' HG23 ' A' ' 83' ' ' VAL . 12.0 tt0 -123.07 99.81 6.56 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.464 -0.773 . . . . 0.0 108.985 179.073 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.778 HG21 ' HB3' ' A' ' 58' ' ' TYR . 41.6 t -86.15 137.71 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.24 -0.912 . . . . 0.0 109.846 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -113.15 154.41 26.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.101 -0.999 . . . . 0.0 109.667 179.711 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.736 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.886 HG22 ' HB3' ' A' ' 28' ' ' ALA . 0.8 OUTLIER -71.47 149.87 45.44 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.178 -0.951 . . . . 0.0 109.253 -179.427 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.756 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.0 mp -92.29 98.28 11.41 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.315 -178.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.822 HG11 ' CE1' ' A' ' 26' ' ' HIS . 11.1 t -108.81 101.3 12.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 120.873 -1.142 . . . . 0.0 108.273 178.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.555 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -115.64 75.49 0.26 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.459 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.512 ' HD3' HG12 ' A' ' 11' ' ' VAL . 32.8 Cg_endo -72.63 148.7 47.78 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.59 2.194 . . . . 0.0 111.694 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.507 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 54.3 t60 159.11 -35.63 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.659 0.742 . . . . 0.0 109.003 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.81 -141.52 15.25 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 108.437 -1.865 . . . . 0.0 108.437 -179.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -77.2 149.19 27.95 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 122.288 1.992 . . . . 0.0 109.434 179.106 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 1.013 HD21 ' HB2' ' A' ' 23' ' ' ALA . 1.4 mt -117.74 117.51 29.53 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.161 -0.962 . . . . 0.0 109.888 -179.39 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.429 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -94.06 168.77 10.73 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.137 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.572 ' H ' ' HB3' ' A' ' 87' ' ' ALA . 2.2 t -56.79 118.72 5.19 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.25 -0.906 . . . . 0.0 109.01 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.63 43.22 6.19 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.22 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.429 ' HB2' ' O ' ' A' ' 18' ' ' ALA . 7.9 tp-100 -111.6 150.77 29.6 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.42 -1.047 . . . . 0.0 110.869 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.783 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.1 tm? -111.52 102.68 11.0 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.573 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 1.013 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -86.68 156.34 20.02 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.512 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -118.97 108.78 15.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.367 -1.458 . . . . 0.0 108.474 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.684 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.2 m-85 -96.02 168.18 10.78 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 122.428 1.109 . . . . 0.0 112.394 -177.343 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.822 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.0 142.44 5.13 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.808 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.815 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -107.42 156.95 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 120.88 -1.138 . . . . 0.0 109.34 -178.467 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.886 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -134.76 120.6 19.62 Favored 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 118.738 -1.185 . . . . 0.0 112.472 -178.639 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.055 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.56 -71.85 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.211 -0.931 . . . . 0.0 109.263 177.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.055 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -76.27 78.24 3.3 Favored 'Trans proline' 0 C--N 1.313 -1.312 0 C-N-CA 121.766 1.644 . . . . 0.0 109.465 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.52 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -35.47 -54.0 1.25 Allowed Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.859 -0.526 . . . . 0.0 111.768 -179.145 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.582 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.1 Cg_endo -78.74 60.85 7.84 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.192 1.928 . . . . 0.0 111.819 -179.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.997 HG23 ' O ' ' A' ' 30' ' ' PRO . 55.6 t -89.51 145.28 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 120.798 -1.189 . . . . 0.0 109.358 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.7 t -116.63 -31.97 5.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.306 -0.871 . . . . 0.0 109.914 179.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.0 138.71 14.17 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.322 -0.861 . . . . 0.0 109.152 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.904 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.1 t -124.19 151.93 43.48 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.566 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -118.22 101.43 8.2 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.206 -0.934 . . . . 0.0 108.921 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.684 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 25.9 m95 -87.88 -179.59 6.27 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.124 -0.985 . . . . 0.0 109.162 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.405 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.8 OUTLIER -148.96 101.7 3.19 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 177.834 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.975 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.6 m-30 -80.35 -59.92 2.52 Favored 'General case' 0 C--N 1.301 -1.503 0 C-N-CA 119.028 -1.069 . . . . 0.0 110.111 -177.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.1 19.72 49.33 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -178.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -109.06 -104.71 0.36 Allowed 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 178.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -80.33 -21.03 65.59 Favored Glycine 0 N--CA 1.479 1.507 0 N-CA-C 107.852 -2.099 . . . . 0.0 107.852 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.16 130.17 30.69 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.347 -1.09 . . . . 0.0 109.557 179.549 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.405 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.2 -85.01 0.1 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.983 -1.073 . . . . 0.0 109.668 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -57.64 150.61 18.99 Favored 'General case' 0 N--CA 1.493 1.711 0 CA-C-O 121.132 0.492 . . . . 0.0 109.684 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.975 HG21 ' CE1' ' A' ' 40' ' ' PHE . 32.5 t -137.1 112.33 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 O-C-N 121.288 -0.882 . . . . 0.0 111.03 -178.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -96.09 95.75 8.39 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.904 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -107.63 171.37 7.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.455 -0.778 . . . . 0.0 111.06 -178.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.06 153.18 21.82 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.802 -0.561 . . . . 0.0 109.702 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.571 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.61 -156.42 0.59 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.776 -1.729 . . . . 0.0 108.776 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -88.45 41.75 0.63 Allowed 'Trans proline' 0 C--N 1.294 -2.298 0 C-N-CA 122.201 1.934 . . . . 0.0 110.277 178.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.599 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -142.8 152.88 42.7 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 119.933 -1.729 . . . . 0.0 112.508 -178.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.634 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -175.7 154.41 1.56 Allowed 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.469 ' CB ' HD11 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -113.34 161.83 16.79 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.742 -1.224 . . . . 0.0 110.327 -179.744 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.783 ' O ' HD22 ' A' ' 22' ' ' LEU . 2.3 m80 -113.11 141.2 47.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.506 -0.746 . . . . 0.0 110.578 -179.228 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.03 93.28 4.18 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.084 ' CE2' HG11 ' A' ' 83' ' ' VAL . 39.6 m-85 -95.91 133.56 39.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.024 -1.047 . . . . 0.0 109.553 -179.143 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 58.5 t -116.31 -41.65 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.319 -0.863 . . . . 0.0 111.029 -178.601 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.42 ' HA ' ' HD3' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -87.64 145.52 37.28 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.607 -1.308 . . . . 0.0 109.768 -179.117 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 60' ' ' LEU . 34.6 Cg_endo -78.39 129.66 9.56 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 122.551 2.167 . . . . 0.0 110.232 179.379 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.88 -136.91 5.28 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 3.5 mtp180 -131.51 126.3 34.6 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -1.173 . . . . 0.0 109.739 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.566 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 44.8 m-85 -110.62 158.81 18.17 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.217 -0.927 . . . . 0.0 109.393 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.465 ' CD2' HG22 ' A' ' 67' ' ' THR . 70.4 t60 -111.02 132.12 54.49 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.57 HG22 ' NE2' ' A' ' 56' ' ' HIS . 67.5 t -114.23 152.13 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.272 -0.892 . . . . 0.0 110.352 -179.092 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.465 HG22 ' CD2' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -147.88 158.84 44.24 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.707 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.109 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -154.71 120.44 5.15 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 120.871 -1.143 . . . . 0.0 111.679 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.539 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.5 p -112.68 110.91 33.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 177.609 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.842 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.9 146.75 24.74 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.755 -1.216 . . . . 0.0 109.441 -178.944 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -125.52 116.06 21.19 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.24 -0.912 . . . . 0.0 109.206 178.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.731 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -103.43 -13.75 16.51 Favored 'General case' 0 C--N 1.292 -1.906 0 CA-C-O 121.53 0.681 . . . . 0.0 109.33 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.56 -49.7 0.83 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.07 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -118.19 -5.76 10.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.674 -0.898 . . . . 0.0 109.857 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -143.03 161.49 27.56 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.431 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 3.2 p -151.45 168.82 23.68 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.291 -1.123 . . . . 0.0 109.362 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.842 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -140.69 136.1 32.29 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.13 -0.981 . . . . 0.0 109.066 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 13.6 mt -101.78 133.46 46.49 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.308 -0.87 . . . . 0.0 110.269 -179.182 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.109 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -122.13 156.16 34.23 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.593 -0.692 . . . . 0.0 109.952 -179.335 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.514 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -161.68 88.66 0.11 Allowed Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.564 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.696 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -105.82 -175.35 2.77 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.937 -1.331 . . . . 0.0 110.289 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -150.83 143.48 24.44 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.274 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.084 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -129.07 149.13 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 120.779 -1.201 . . . . 0.0 110.059 -179.43 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 72.2 mt-30 -114.7 98.7 7.01 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.462 -0.774 . . . . 0.0 108.97 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.794 HG21 ' HB3' ' A' ' 58' ' ' TYR . 96.4 t -83.74 144.65 9.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.087 -1.008 . . . . 0.0 109.945 -179.456 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -126.58 -154.87 0.65 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.489 -0.757 . . . . 0.0 109.343 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.572 ' HB3' ' H ' ' A' ' 19' ' ' SER . . . . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.454 -0.779 . . . . 0.0 110.579 179.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.691 ' HB3' ' CG2' ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.862 HG22 ' HB3' ' A' ' 28' ' ' ALA . 0.6 OUTLIER -70.06 149.48 47.61 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.219 -0.926 . . . . 0.0 109.346 -179.229 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 10' ' ' LEU . 4.2 mp -83.59 110.42 18.23 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.902 -178.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.716 HG11 ' CE1' ' A' ' 26' ' ' HIS . 0.5 OUTLIER -124.65 101.52 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 120.753 -1.217 . . . . 0.0 109.216 179.116 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.625 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.88 76.12 0.28 Allowed Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.588 ' O ' ' HB2' ' A' ' 14' ' ' HIS . 35.1 Cg_endo -72.9 149.7 47.9 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.774 2.316 . . . . 0.0 112.778 -179.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.588 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 152.25 175.28 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.908 0 CA-C-N 114.85 -1.068 . . . . 0.0 108.388 178.743 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.99 -141.6 2.11 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -76.91 150.06 29.8 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 122.123 1.882 . . . . 0.0 109.552 179.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 1.018 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.6 mm? -99.75 85.01 3.01 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.122 -0.986 . . . . 0.0 108.867 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -82.32 166.13 19.76 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.104 -0.997 . . . . 0.0 108.664 179.702 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.1 t -54.83 117.32 3.31 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.408 -0.808 . . . . 0.0 109.123 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.17 43.21 5.69 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 -179.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.613 ' HG2' HD13 ' A' ' 17' ' ' LEU . 19.6 tp60 -112.54 145.82 39.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.448 -1.031 . . . . 0.0 110.696 -179.116 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.648 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.3 tm? -106.51 93.95 4.87 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.254 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 1.018 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -76.88 159.05 30.34 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.077 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.541 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.53 118.2 28.69 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.132 -1.605 . . . . 0.0 108.004 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.754 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 8.3 m-85 -103.95 174.65 5.78 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 122.705 1.24 . . . . 0.0 112.592 -176.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.716 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.3 OUTLIER -174.93 149.52 1.14 Allowed 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 177.992 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.871 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -113.98 156.33 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.806 -1.184 . . . . 0.0 108.63 -178.258 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.862 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -129.95 121.16 26.05 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.704 -1.247 . . . . 0.0 112.559 -178.001 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.043 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 170.88 -72.36 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.406 -0.808 . . . . 0.0 108.955 177.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.043 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.7 Cg_endo -77.09 78.82 3.31 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 C-N-CA 121.616 1.544 . . . . 0.0 108.593 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.72 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 13.0 mt -40.51 -50.36 6.85 Favored Pre-proline 0 N--CA 1.497 1.891 0 O-C-N 121.782 -0.574 . . . . 0.0 111.653 -178.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.72 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 36.8 Cg_endo -80.99 60.05 7.71 Favored 'Trans proline' 0 C--N 1.315 -1.185 0 C-N-CA 122.024 1.816 . . . . 0.0 112.001 -179.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.904 HG23 ' O ' ' A' ' 30' ' ' PRO . 38.7 t -90.94 147.82 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 120.708 -1.245 . . . . 0.0 109.288 179.006 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.12 -30.57 6.62 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.334 -0.854 . . . . 0.0 110.171 179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.36 145.06 18.85 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.245 -0.909 . . . . 0.0 109.334 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.829 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.3 t -129.22 158.72 38.23 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.533 ' O ' HG23 ' A' ' 69' ' ' VAL . 2.9 mtm-85 -123.12 101.67 7.53 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.298 -0.877 . . . . 0.0 108.895 179.546 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.754 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 37.6 m95 -89.17 178.66 6.31 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.124 -0.985 . . . . 0.0 109.619 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.463 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.33 102.34 3.06 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 177.515 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.992 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.2 m-30 -79.66 -60.03 2.51 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 118.794 -1.162 . . . . 0.0 109.76 -177.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.13 18.32 47.06 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.42 -103.32 0.32 Allowed 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 178.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.64 -20.26 60.27 Favored Glycine 0 C--N 1.297 -1.618 0 N-CA-C 107.805 -2.118 . . . . 0.0 107.805 176.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 12.9 p -135.91 130.06 33.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.353 -1.086 . . . . 0.0 109.342 179.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.49 -85.37 0.1 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.047 -1.033 . . . . 0.0 109.877 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.1 pm0 -56.07 152.05 11.12 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.303 0.573 . . . . 0.0 110.306 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.992 HG21 ' CE1' ' A' ' 40' ' ' PHE . 26.1 t -140.8 121.87 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 111.047 -179.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 62.1 m-20 -104.58 107.81 18.94 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.829 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -120.99 170.87 9.09 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.055 -1.028 . . . . 0.0 111.092 -178.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.48 152.4 20.05 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.648 -0.657 . . . . 0.0 109.643 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.545 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.51 -156.08 0.61 Allowed Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.842 -1.703 . . . . 0.0 108.842 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -88.83 40.79 0.54 Allowed 'Trans proline' 0 C--N 1.297 -2.151 0 C-N-CA 122.244 1.963 . . . . 0.0 110.24 178.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.595 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -140.0 157.59 45.42 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 119.936 -1.727 . . . . 0.0 112.307 -178.681 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.48 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -171.59 -167.67 0.53 Allowed 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.506 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.504 ' O ' ' CZ ' ' A' ' 40' ' ' PHE . 0.0 OUTLIER -146.74 175.99 10.2 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.096 -1.003 . . . . 0.0 109.186 179.29 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.648 ' O ' HD22 ' A' ' 22' ' ' LEU . 4.6 m80 -133.92 132.95 40.85 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.927 -1.108 . . . . 0.0 110.408 -179.139 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.53 89.17 2.92 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.071 ' CE2' HG11 ' A' ' 83' ' ' VAL . 32.7 m-85 -92.41 126.85 37.67 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.206 -0.934 . . . . 0.0 109.122 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 9.8 p -114.44 -28.41 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.407 -0.808 . . . . 0.0 111.514 -178.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.416 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -98.63 145.86 30.63 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 120.512 -1.367 . . . . 0.0 109.429 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.563 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.1 Cg_endo -77.36 119.28 4.89 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 122.383 2.055 . . . . 0.0 109.814 179.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 161.49 -162.14 33.65 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -107.09 130.17 54.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.221 -1.164 . . . . 0.0 110.12 -179.756 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.563 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 73.1 m-85 -112.87 161.1 17.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.465 -0.772 . . . . 0.0 109.07 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 70.0 t60 -115.23 122.22 45.33 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.462 -0.774 . . . . 0.0 109.069 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.576 HG22 ' NE2' ' A' ' 56' ' ' HIS . 66.1 t -102.74 152.01 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.38 -0.825 . . . . 0.0 109.899 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.57 158.52 44.25 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 178.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.059 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.51 156.67 42.35 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.92 -1.113 . . . . 0.0 110.989 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.533 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -147.07 104.68 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.385 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 179.224 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.805 ' CD1' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.84 150.44 22.9 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.734 -1.229 . . . . 0.0 109.703 -179.181 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.45 117.04 20.66 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.588 -0.845 . . . . 0.0 109.309 178.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.538 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.2 mp -105.36 -13.13 15.75 Favored 'General case' 0 C--N 1.293 -1.881 0 CA-C-O 121.52 0.676 . . . . 0.0 109.239 179.69 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.33 -56.21 0.59 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -114.63 -7.25 12.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.576 -0.955 . . . . 0.0 109.759 179.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -137.47 161.13 25.29 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.422 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.0 p -151.2 170.06 20.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.411 -1.053 . . . . 0.0 109.409 -179.724 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.805 ' HB3' ' CD1' ' A' ' 70' ' ' LEU . . . -144.16 126.63 15.9 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.882 . . . . 0.0 109.198 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -95.25 152.14 18.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.224 -0.923 . . . . 0.0 110.639 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.059 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -135.7 158.53 44.17 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.747 -0.596 . . . . 0.0 109.472 179.878 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.544 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.96 88.54 0.1 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.542 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -110.83 -171.91 1.92 Allowed 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.05 -1.265 . . . . 0.0 109.965 -179.893 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -149.54 149.56 30.9 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.071 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -132.29 138.29 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.76 -1.213 . . . . 0.0 110.056 -179.654 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.46 83.33 2.43 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.408 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.84 HG21 ' HB3' ' A' ' 58' ' ' TYR . 53.4 t -72.62 134.3 30.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.148 -0.97 . . . . 0.0 109.627 -179.418 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -110.77 -179.1 3.65 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.386 -0.821 . . . . 0.0 109.643 -179.592 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.563 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.919 . . . . 0.0 109.185 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.731 ' HB3' ' CG2' ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.843 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.2 t -75.44 155.83 35.89 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.199 -0.938 . . . . 0.0 108.873 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.992 ' HB3' HD11 ' A' ' 79' ' ' LEU . 0.0 OUTLIER -96.8 90.96 5.45 Favored 'General case' 0 N--CA 1.49 1.553 0 C-N-CA 119.961 -0.696 . . . . 0.0 110.141 -178.854 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.835 HG11 ' CE1' ' A' ' 26' ' ' HIS . 25.3 t -93.96 96.23 5.88 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.618 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -114.74 75.69 0.25 Allowed Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.716 -1.231 . . . . 0.0 110.545 -178.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.584 ' HD3' HG12 ' A' ' 11' ' ' VAL . 32.7 Cg_endo -73.01 149.38 46.7 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.5 2.133 . . . . 0.0 111.494 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.582 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 69.6 t60 163.16 -37.5 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 CA-C-O 121.771 0.796 . . . . 0.0 109.06 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.77 -137.62 13.49 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.133 -1.987 . . . . 0.0 108.133 -178.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.25 147.08 25.68 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 C-N-CA 122.138 1.892 . . . . 0.0 109.351 178.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.955 HD21 ' HB2' ' A' ' 23' ' ' ALA . 12.1 mt -113.15 85.85 2.26 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.264 -0.897 . . . . 0.0 109.967 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.56 160.78 32.1 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.9 t -54.41 123.47 13.08 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.237 -0.914 . . . . 0.0 109.466 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.47 48.41 4.53 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.444 ' HB3' HD23 ' A' ' 17' ' ' LEU . 19.9 mm-40 -123.94 150.83 44.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.434 -1.039 . . . . 0.0 110.313 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.623 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.3 tm? -108.48 93.26 4.43 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.829 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.955 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -76.42 155.75 33.72 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.544 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.49 121.09 37.72 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.689 -1.257 . . . . 0.0 108.426 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.789 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.2 m-85 -108.33 171.07 7.62 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-O 122.204 1.002 . . . . 0.0 111.397 -177.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.835 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -168.64 135.79 1.96 Allowed 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 177.803 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.731 ' CG2' ' HB3' ' A' ' 8' ' ' ALA . 0.1 OUTLIER -101.48 149.64 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.882 -1.136 . . . . 0.0 108.692 -178.509 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.843 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -128.75 126.71 40.56 Favored 'General case' 0 N--CA 1.5 2.068 0 C-N-CA 118.775 -1.17 . . . . 0.0 112.501 -177.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.029 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 169.18 -69.6 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.532 -0.73 . . . . 0.0 109.081 177.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.029 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.8 Cg_endo -76.96 79.59 3.08 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 121.654 1.569 . . . . 0.0 109.144 179.061 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.515 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -34.89 -54.34 1.02 Allowed Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.989 -0.444 . . . . 0.0 112.004 -178.921 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.535 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.5 Cg_endo -79.48 69.4 7.95 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.23 1.954 . . . . 0.0 111.775 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.943 HG23 ' O ' ' A' ' 30' ' ' PRO . 47.8 t -98.34 148.24 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.834 -1.166 . . . . 0.0 109.327 179.018 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 24.3 p -119.14 -29.15 5.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.307 -0.871 . . . . 0.0 110.26 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -159.29 145.05 16.17 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.221 -0.924 . . . . 0.0 109.619 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.792 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -130.75 151.44 51.18 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.52 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.7 OUTLIER -120.56 104.73 10.18 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.202 -0.936 . . . . 0.0 108.713 179.173 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.789 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 37.5 m95 -89.6 -178.6 5.59 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-O 122.079 0.942 . . . . 0.0 109.432 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.69 ' CB ' HG23 ' A' ' 67' ' ' THR . 0.3 OUTLIER -150.45 101.03 2.93 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 106.329 -1.73 . . . . 0.0 106.329 177.45 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.964 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.3 m-30 -80.37 -56.08 4.44 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.121 -177.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.6 20.41 54.25 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.133 -1.587 . . . . 0.0 109.133 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.566 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 1.1 p30 -104.25 -104.48 0.3 Allowed 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 178.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.24 -15.91 68.15 Favored Glycine 0 C--N 1.296 -1.646 0 N-CA-C 107.754 -2.138 . . . . 0.0 107.754 176.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.7 p -138.29 130.97 29.39 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.489 -1.007 . . . . 0.0 108.892 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.408 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.74 -85.4 0.09 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.941 -1.099 . . . . 0.0 109.752 -179.602 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -57.16 154.09 10.68 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.332 0.587 . . . . 0.0 110.121 -179.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.964 HG21 ' CE1' ' A' ' 40' ' ' PHE . 52.6 t -140.01 121.63 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.431 -0.793 . . . . 0.0 110.689 -178.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -104.21 118.97 37.93 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 178.007 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.792 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -132.75 166.06 23.1 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.031 -1.043 . . . . 0.0 111.042 -178.513 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.31 153.47 18.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.672 -0.642 . . . . 0.0 109.796 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.57 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.35 -155.93 0.39 Allowed Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -88.96 38.99 0.44 Allowed 'Trans proline' 0 C--N 1.298 -2.118 0 C-N-CA 122.544 2.163 . . . . 0.0 110.149 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.627 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -138.16 152.63 48.87 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.115 -1.616 . . . . 0.0 112.054 -178.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.493 ' HB2' ' NE1' ' A' ' 38' ' ' TRP . . . -163.61 -166.79 1.26 Allowed 'General case' 0 N--CA 1.494 1.775 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.469 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.572 ' OG ' HD11 ' A' ' 22' ' ' LEU . 1.4 p -158.49 141.1 14.42 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.11 -0.994 . . . . 0.0 109.79 179.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.767 ' CE1' HG13 ' A' ' 66' ' ' VAL . 9.7 m80 -94.02 136.7 34.03 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.476 -0.765 . . . . 0.0 111.081 -178.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -110.89 87.71 2.6 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 178.396 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.092 ' CE2' HG11 ' A' ' 83' ' ' VAL . 15.1 m-85 -87.73 138.55 31.37 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.202 -0.936 . . . . 0.0 109.704 -178.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 12.0 p -129.51 -26.83 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.362 -0.836 . . . . 0.0 111.257 -178.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.422 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -98.36 144.6 28.38 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 120.507 -1.371 . . . . 0.0 109.718 -179.421 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.53 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.5 Cg_endo -77.64 116.39 4.04 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.55 2.167 . . . . 0.0 109.929 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 160.54 -154.78 25.84 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.93 165.41 11.56 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.022 -1.281 . . . . 0.0 109.817 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.604 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 47.2 m-85 -149.17 166.43 28.86 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 28.0 t60 -127.88 142.18 51.34 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.317 -0.864 . . . . 0.0 108.858 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.767 HG13 ' CE1' ' A' ' 56' ' ' HIS . 30.3 t -122.64 146.0 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 120.997 -1.064 . . . . 0.0 110.712 -179.236 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.69 HG23 ' CB ' ' A' ' 39' ' ' ASP . 0.5 OUTLIER -151.44 156.28 40.32 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.541 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.004 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.92 161.17 42.82 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 120.849 -1.157 . . . . 0.0 111.128 -179.76 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.602 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.5 p -150.78 105.58 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 178.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.86 ' CD1' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.4 144.85 25.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.754 -1.216 . . . . 0.0 109.811 -178.845 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.455 ' C ' HD12 ' A' ' 72' ' ' LEU . . . -118.74 119.97 36.0 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.38 -0.928 . . . . 0.0 109.247 178.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.774 HD21 ' HB2' ' A' ' 30' ' ' PRO . 6.4 mp -114.16 -9.33 12.91 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 121.479 0.657 . . . . 0.0 109.485 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.641 ' O ' ' HB3' ' A' ' 74' ' ' ALA . . . 102.19 101.43 2.57 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 107.495 -2.242 . . . . 0.0 107.495 -178.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.641 ' HB3' ' O ' ' A' ' 73' ' ' GLY . . . 71.53 -0.38 3.17 Favored 'General case' 0 N--CA 1.485 1.292 0 O-C-N 121.714 -0.874 . . . . 0.0 110.372 -178.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -145.71 142.41 10.63 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -150.28 163.95 37.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.098 -1.236 . . . . 0.0 109.973 -179.382 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.86 ' HB3' ' CD1' ' A' ' 70' ' ' LEU . . . -132.15 119.81 21.42 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -89.75 149.69 22.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.911 . . . . 0.0 110.407 -179.202 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.004 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.2 OUTLIER -131.75 160.29 35.95 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.451 0.643 . . . . 0.0 110.103 -179.583 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.64 ' H ' HD13 ' A' ' 79' ' ' LEU . . . -169.21 92.52 0.1 OUTLIER Glycine 0 N--CA 1.483 1.814 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.613 HG22 ' HB3' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -113.07 175.39 5.46 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.034 -1.274 . . . . 0.0 109.377 179.524 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -117.68 156.17 28.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.309 -0.869 . . . . 0.0 108.851 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.092 HG11 ' CE2' ' A' ' 58' ' ' TYR . 25.1 t -137.25 139.87 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 120.983 -1.073 . . . . 0.0 110.635 -178.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -123.5 93.81 4.06 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.168 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.694 HG21 ' HB3' ' A' ' 58' ' ' TYR . 40.8 t -87.16 135.36 25.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.237 -0.914 . . . . 0.0 110.058 -179.303 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -107.66 -157.32 0.61 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.447 -0.783 . . . . 0.0 109.424 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.53 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.005 -1.059 . . . . 0.0 109.107 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.665 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.95 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.1 t -69.2 150.44 47.48 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.19 -0.944 . . . . 0.0 109.584 -178.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.752 ' N ' HD12 ' A' ' 10' ' ' LEU . 4.6 mp -83.19 107.18 15.56 Favored 'General case' 0 N--CA 1.489 1.516 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.648 -178.56 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.637 HG22 HG23 ' A' ' 9' ' ' THR . 0.4 OUTLIER -120.79 96.26 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 120.823 -1.173 . . . . 0.0 108.977 179.088 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.632 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -115.95 80.03 0.29 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.021 -1.231 . . . . 0.0 110.021 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.545 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 32.2 Cg_endo -71.94 147.58 49.73 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.513 2.142 . . . . 0.0 112.018 179.598 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.519 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 32.7 t-80 158.87 -33.98 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.08 -141.32 15.23 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -77.07 148.4 27.52 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.082 1.855 . . . . 0.0 109.209 178.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 1.005 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.4 mm? -105.59 109.89 22.02 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.111 -0.993 . . . . 0.0 109.681 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -89.18 161.17 16.61 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.2 t -57.82 116.74 3.65 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.151 -0.968 . . . . 0.0 109.389 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 89.8 44.74 4.75 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -121.22 152.87 38.33 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.252 -1.146 . . . . 0.0 110.609 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.772 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.5 tm? -107.39 99.07 8.61 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.852 -0.795 . . . . 0.0 108.852 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 1.005 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -80.34 153.71 28.21 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.545 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -116.03 125.14 52.05 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.479 -1.388 . . . . 0.0 108.081 179.411 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.752 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.6 m-85 -112.57 172.44 6.92 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 122.526 1.155 . . . . 0.0 112.285 -177.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.627 ' CE1' HG21 ' A' ' 11' ' ' VAL . 4.1 p80 -173.95 148.51 1.41 Allowed 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 177.175 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.886 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.21 157.51 12.05 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 120.733 -1.229 . . . . 0.0 108.599 -178.166 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.95 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -132.41 121.63 23.74 Favored 'General case' 0 N--CA 1.5 2.058 0 C-N-CA 118.698 -1.201 . . . . 0.0 112.542 -177.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.036 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.31 -71.54 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.402 -0.811 . . . . 0.0 108.867 177.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.036 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.6 Cg_endo -77.39 76.86 4.05 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 C-N-CA 121.708 1.605 . . . . 0.0 108.725 178.522 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.561 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -35.45 -55.78 1.08 Allowed Pre-proline 0 N--CA 1.497 1.921 0 O-C-N 121.956 -0.465 . . . . 0.0 111.472 -178.746 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.561 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.7 Cg_endo -80.16 75.1 5.23 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.125 1.884 . . . . 0.0 111.332 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.898 HG23 ' O ' ' A' ' 30' ' ' PRO . 20.5 t -106.03 149.22 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.024 -1.048 . . . . 0.0 109.131 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.1 p -114.59 -28.85 7.01 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.285 -0.884 . . . . 0.0 110.626 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -158.72 143.08 15.72 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.073 -1.017 . . . . 0.0 110.164 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.871 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -129.99 155.55 45.91 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.481 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.521 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 2.6 ttm180 -122.72 104.06 9.06 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.248 -0.907 . . . . 0.0 108.713 179.059 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.752 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 32.1 m95 -88.78 179.89 6.13 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.306 -0.871 . . . . 0.0 109.324 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.501 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.21 103.1 3.14 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 106.811 -1.551 . . . . 0.0 106.811 177.889 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.997 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.5 m-30 -81.16 -67.0 0.82 Allowed 'General case' 0 N--CA 1.493 1.683 0 C-N-CA 119.001 -1.079 . . . . 0.0 110.738 -177.502 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.64 7.58 56.62 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -178.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.6 p30 -98.34 35.6 1.75 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.415 -1.05 . . . . 0.0 108.317 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.88 -39.19 2.96 Favored Glycine 0 C--N 1.295 -1.699 0 N-CA-C 105.773 -2.931 . . . . 0.0 105.773 -176.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 87.7 p -107.27 101.82 11.17 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 177.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.501 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -75.58 -89.99 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -0.944 . . . . 0.0 110.189 -178.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -52.21 145.74 10.25 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-O 121.296 0.57 . . . . 0.0 109.884 -179.416 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.997 HG21 ' CE1' ' A' ' 40' ' ' PHE . 47.7 t -135.9 110.79 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.299 -0.875 . . . . 0.0 110.851 -178.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.23 107.41 19.18 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.368 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.871 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -120.02 165.79 14.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.198 -0.939 . . . . 0.0 110.98 -178.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.07 152.59 18.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.598 -0.689 . . . . 0.0 109.446 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.6 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.53 -156.12 0.41 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -88.97 40.99 0.54 Allowed 'Trans proline' 0 C--N 1.295 -2.242 0 C-N-CA 122.209 1.94 . . . . 0.0 110.381 178.465 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.633 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -139.52 159.26 42.57 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 119.953 -1.717 . . . . 0.0 112.509 -178.659 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.476 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -171.55 -167.05 0.48 Allowed 'General case' 0 N--CA 1.495 1.823 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.648 ' HB2' HD11 ' A' ' 22' ' ' LEU . 24.3 p -156.52 144.32 19.38 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.011 -1.056 . . . . 0.0 109.536 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.772 ' O ' HD22 ' A' ' 22' ' ' LEU . 9.1 m80 -102.4 146.25 28.35 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.595 0.712 . . . . 0.0 111.327 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -118.26 90.47 3.34 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 178.626 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.076 ' CE2' HG11 ' A' ' 83' ' ' VAL . 30.2 m-85 -92.63 128.76 38.6 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.067 -1.02 . . . . 0.0 110.012 -178.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.0 p -117.62 -27.84 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.484 -0.76 . . . . 0.0 111.108 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.478 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -101.77 146.44 32.25 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 120.561 -1.337 . . . . 0.0 109.483 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.478 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.3 Cg_endo -77.6 121.74 5.69 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 C-N-CA 122.286 1.991 . . . . 0.0 109.849 179.481 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 162.45 -163.31 35.0 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.457 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.3 OUTLIER -105.92 121.26 43.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.107 -1.231 . . . . 0.0 110.052 -179.805 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.603 ' HB2' HG13 ' A' ' 83' ' ' VAL . 64.6 m-85 -104.2 151.29 23.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 0.0 109.091 179.49 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.1 t60 -108.37 125.33 51.61 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.352 -0.842 . . . . 0.0 109.154 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.636 HG22 ' NE2' ' A' ' 56' ' ' HIS . 64.8 t -108.3 151.59 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.921 . . . . 0.0 110.185 -179.401 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.81 158.4 44.13 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.092 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -151.23 155.28 38.5 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.011 -1.056 . . . . 0.0 110.768 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.603 ' O ' HG13 ' A' ' 69' ' ' VAL . 8.1 p -148.35 108.09 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.877 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.13 149.99 22.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.818 -1.176 . . . . 0.0 109.367 -179.112 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.19 119.97 20.57 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.372 -0.931 . . . . 0.0 109.93 179.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.501 HD21 ' HA ' ' A' ' 33' ' ' VAL . 11.6 mt -110.86 -12.21 14.28 Favored 'General case' 0 C--N 1.295 -1.776 0 CA-C-O 121.498 0.666 . . . . 0.0 109.406 179.35 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.43 -49.65 0.86 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 -178.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -112.17 -7.71 14.03 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.517 -0.99 . . . . 0.0 109.71 179.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -145.84 153.48 25.33 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.412 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 1.7 p -150.89 169.37 21.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.191 -1.182 . . . . 0.0 109.691 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.877 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -144.2 154.02 42.69 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.394 -0.816 . . . . 0.0 108.997 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 5.1 mp -122.65 150.51 42.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.143 -0.973 . . . . 0.0 109.89 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.092 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -136.06 158.92 43.25 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.552 -0.718 . . . . 0.0 110.013 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.532 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -167.2 87.54 0.1 OUTLIER Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.644 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -107.46 -174.51 2.55 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.126 -1.22 . . . . 0.0 110.353 -179.491 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -150.88 143.0 24.09 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.246 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.076 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -128.82 145.02 36.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 120.683 -1.261 . . . . 0.0 109.636 -179.539 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -109.6 84.33 1.91 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.45 -0.781 . . . . 0.0 109.246 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.821 HG21 ' HB3' ' A' ' 58' ' ' TYR . 48.1 t -69.51 133.47 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.01 -1.056 . . . . 0.0 109.394 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -114.9 162.71 16.56 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.456 -0.777 . . . . 0.0 109.845 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.441 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.324 -0.86 . . . . 0.0 109.388 179.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.758 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.415 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.874 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.2 t -70.44 148.53 48.22 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.222 -0.924 . . . . 0.0 109.272 -179.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.1 mp -85.59 103.86 14.81 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.083 -178.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.879 HG11 ' CE1' ' A' ' 26' ' ' HIS . 4.7 t -117.08 104.79 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 120.772 -1.205 . . . . 0.0 108.829 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.54 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -117.77 73.99 0.29 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.544 ' HD2' ' HA ' ' A' ' 25' ' ' PHE . 35.0 Cg_endo -73.17 151.96 49.95 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.874 2.383 . . . . 0.0 112.462 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.568 ' CE1' ' HG2' ' A' ' 21' ' ' GLN . 26.8 t-80 158.52 -39.78 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.27 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.14 -137.0 13.73 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.074 -2.01 . . . . 0.0 108.074 -179.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.413 ' C ' HD22 ' A' ' 17' ' ' LEU . 35.3 Cg_endo -78.15 148.44 24.38 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 C-N-CA 122.152 1.901 . . . . 0.0 109.521 178.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.774 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.0 mm? -112.16 102.42 10.61 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.097 -1.002 . . . . 0.0 109.465 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.414 ' HB3' ' OE1' ' A' ' 21' ' ' GLN . . . -88.51 165.05 15.14 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.164 -0.96 . . . . 0.0 108.848 179.567 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.7 t -56.41 122.16 11.26 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.321 -0.862 . . . . 0.0 109.363 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 83.26 47.62 5.68 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.568 ' HG2' ' CE1' ' A' ' 14' ' ' HIS . 1.6 tp60 -120.26 150.66 40.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.345 -1.091 . . . . 0.0 110.622 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.717 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.3 tm? -107.27 96.67 6.58 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.774 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -79.31 156.59 27.97 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 178.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.507 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.97 117.49 27.42 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.516 -1.365 . . . . 0.0 108.094 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.767 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.8 m-85 -101.95 176.55 5.17 Favored 'General case' 0 N--CA 1.488 1.459 0 CA-C-O 122.459 1.124 . . . . 0.0 112.223 -177.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.879 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -174.3 143.41 0.86 Allowed 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.502 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.862 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.72 153.55 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.911 -1.118 . . . . 0.0 108.388 -179.067 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.874 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -131.62 123.43 27.86 Favored 'General case' 0 N--CA 1.501 2.101 0 C-N-CA 118.429 -1.308 . . . . 0.0 112.781 -177.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.044 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 173.3 -68.56 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.948 0 O-C-N 121.296 -0.877 . . . . 0.0 109.525 177.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.044 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -76.17 78.44 3.21 Favored 'Trans proline' 0 C--N 1.312 -1.395 0 C-N-CA 121.787 1.658 . . . . 0.0 109.497 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.53 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -32.86 -55.06 0.59 Allowed Pre-proline 0 N--CA 1.499 2.014 0 O-C-N 121.966 -0.459 . . . . 0.0 112.103 -179.16 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.564 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.3 Cg_endo -79.27 61.13 8.07 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 C-N-CA 122.324 2.016 . . . . 0.0 112.084 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 30' ' ' PRO . 90.2 t -85.86 152.21 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 120.593 -1.317 . . . . 0.0 109.564 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.432 ' N ' HG12 ' A' ' 33' ' ' VAL . 1.6 t -126.07 -33.14 2.69 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.489 -0.757 . . . . 0.0 109.783 179.294 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.53 140.69 15.31 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.395 -0.816 . . . . 0.0 109.296 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.867 HG23 ' HB3' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -127.5 150.78 49.52 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.666 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.499 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -116.96 103.88 10.72 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.216 -0.928 . . . . 0.0 108.788 179.257 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.767 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 33.7 m95 -89.12 -179.74 5.96 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.24 -0.912 . . . . 0.0 109.383 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.442 ' CB ' HG23 ' A' ' 67' ' ' THR . 0.2 OUTLIER -150.48 101.84 2.99 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 177.686 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.95 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.6 m-30 -79.9 -62.55 1.65 Allowed 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 118.834 -1.146 . . . . 0.0 109.992 -177.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.57 16.94 43.9 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.35 -102.95 0.32 Allowed 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -85.5 -18.33 60.52 Favored Glycine 0 C--N 1.297 -1.585 0 N-CA-C 107.872 -2.091 . . . . 0.0 107.872 176.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.5 m -135.18 126.24 27.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.455 -1.027 . . . . 0.0 108.996 179.489 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.407 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.43 -85.91 0.09 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.02 -1.05 . . . . 0.0 109.692 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -57.95 152.94 15.23 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.239 0.542 . . . . 0.0 109.679 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.95 HG21 ' CE1' ' A' ' 40' ' ' PHE . 27.5 t -139.22 118.46 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.295 -0.878 . . . . 0.0 110.943 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -101.53 101.28 11.82 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.867 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -113.2 168.61 9.58 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.265 -0.897 . . . . 0.0 111.082 -178.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.65 155.01 18.37 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 121.422 0.63 . . . . 0.0 109.618 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.618 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.96 -156.26 0.48 Allowed Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -88.93 40.44 0.51 Allowed 'Trans proline' 0 C--N 1.296 -2.198 0 C-N-CA 122.194 1.929 . . . . 0.0 110.356 178.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.633 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -142.06 156.64 45.41 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 119.99 -1.694 . . . . 0.0 112.357 -178.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.453 ' HB2' ' NE1' ' A' ' 38' ' ' TRP . . . -167.41 -168.34 1.03 Allowed 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.416 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 11.5 p -156.24 141.61 17.57 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.023 -1.048 . . . . 0.0 109.678 179.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.717 ' O ' HD22 ' A' ' 22' ' ' LEU . 12.0 m80 -99.01 143.86 28.81 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-O 121.743 0.783 . . . . 0.0 111.614 -178.328 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.536 HH21 HD21 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -114.6 90.63 3.39 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.459 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.071 ' CE2' HG11 ' A' ' 83' ' ' VAL . 37.0 m-85 -93.59 136.95 33.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.955 -1.091 . . . . 0.0 109.762 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 8.4 p -123.62 -33.12 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.283 -0.886 . . . . 0.0 111.356 -178.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.443 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -95.03 147.36 32.91 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 120.526 -1.359 . . . . 0.0 109.478 -179.431 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.443 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.4 Cg_endo -78.75 116.59 3.8 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.545 2.163 . . . . 0.0 109.972 179.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 166.68 -155.17 26.16 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.479 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 8.2 mtm-85 -115.1 123.08 48.06 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.261 -1.14 . . . . 0.0 109.715 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.573 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 62.5 m-85 -106.45 157.63 17.5 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.441 -0.787 . . . . 0.0 109.367 179.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 67.2 t60 -109.85 129.39 55.65 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.618 HG22 ' NE2' ' A' ' 56' ' ' HIS . 83.0 t -110.36 151.49 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.385 -0.822 . . . . 0.0 109.969 -179.439 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.442 HG23 ' CB ' ' A' ' 39' ' ' ASP . 0.2 OUTLIER -150.46 157.12 42.66 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.133 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.111 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.43 156.41 41.41 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 120.889 -1.132 . . . . 0.0 110.979 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.594 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.4 p -147.32 107.66 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.799 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -90.19 153.19 20.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.896 -1.128 . . . . 0.0 110.445 -178.39 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -131.13 117.91 19.75 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.303 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.908 HD21 ' HB2' ' A' ' 30' ' ' PRO . 6.1 mp -106.05 -12.86 15.64 Favored 'General case' 0 C--N 1.293 -1.85 0 CA-C-O 121.495 0.664 . . . . 0.0 109.29 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.15 -45.76 1.26 Allowed Glycine 0 N--CA 1.488 2.116 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -178.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.13 -6.76 12.48 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.59 -0.947 . . . . 0.0 109.704 179.082 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -150.02 165.23 29.76 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.35 168.75 23.83 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.246 -1.149 . . . . 0.0 109.512 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.799 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -145.14 140.68 28.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.487 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.55 HD13 ' O ' ' A' ' 68' ' ' ALA . 1.7 mm? -107.16 150.88 26.11 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.067 -1.02 . . . . 0.0 110.3 -179.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.111 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -134.96 158.53 44.08 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.467 -0.771 . . . . 0.0 109.842 -179.751 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.529 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -167.72 91.47 0.1 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.6 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -114.26 -171.57 1.94 Allowed 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.08 -1.247 . . . . 0.0 110.165 -179.7 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -150.15 147.96 28.37 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 179.201 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.071 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -129.86 140.81 48.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 120.617 -1.302 . . . . 0.0 110.027 -179.271 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . 0.464 ' HG2' ' HG2' ' A' ' 63' ' ' ARG . 0.8 OUTLIER -104.07 85.55 2.41 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.381 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.746 HG22 ' HB3' ' A' ' 17' ' ' LEU . 98.4 t -77.74 136.99 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.151 -0.968 . . . . 0.0 109.644 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -124.05 142.55 51.09 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.278 -0.889 . . . . 0.0 109.579 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.168 -0.957 . . . . 0.0 109.648 179.809 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.748 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.891 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.0 OUTLIER -73.48 149.21 42.49 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.282 -0.886 . . . . 0.0 109.209 -179.442 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.741 HD23 HG22 ' A' ' 81' ' ' THR . 5.2 mp -91.38 103.81 16.4 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.322 -178.315 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.672 HG11 ' NE2' ' A' ' 26' ' ' HIS . 3.1 t -117.12 105.47 18.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 O-C-N 120.776 -1.203 . . . . 0.0 108.782 178.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.542 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.93 74.17 0.3 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.504 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 35.3 Cg_endo -73.14 152.54 50.9 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.752 2.301 . . . . 0.0 111.983 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.494 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.2 t-80 163.74 -37.99 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 CA-C-O 121.698 0.761 . . . . 0.0 108.961 179.58 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.5 -136.54 13.57 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.308 -1.917 . . . . 0.0 108.308 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -78.01 149.18 25.46 Favored 'Trans proline' 0 C--N 1.304 -1.797 0 C-N-CA 122.246 1.964 . . . . 0.0 109.352 179.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.821 HD21 ' HB2' ' A' ' 23' ' ' ALA . 22.7 mt -120.75 93.37 4.01 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.041 -1.037 . . . . 0.0 110.102 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 86' ' ' GLU . . . -87.42 164.03 16.42 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.082 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.437 ' CB ' ' HA ' ' A' ' 87' ' ' ALA . 40.6 t -49.96 121.27 5.17 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.564 -0.71 . . . . 0.0 110.085 -179.406 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.31 47.47 4.35 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.514 ' HB3' HD23 ' A' ' 17' ' ' LEU . 4.4 mm-40 -122.4 149.57 43.64 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.23 -1.159 . . . . 0.0 110.94 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.729 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.4 tm? -108.49 98.55 8.06 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.821 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -81.93 154.63 25.68 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.504 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -117.4 121.37 40.9 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.611 -1.306 . . . . 0.0 107.981 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.754 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 7.3 m-85 -108.15 173.5 6.29 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 122.425 1.107 . . . . 0.0 112.362 -176.813 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.672 ' NE2' HG11 ' A' ' 11' ' ' VAL . 3.4 p80 -171.27 144.51 2.03 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 177.286 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.832 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.54 158.33 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.095 -1.003 . . . . 0.0 108.571 -178.578 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.891 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -136.91 122.41 19.59 Favored 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 118.445 -1.302 . . . . 0.0 112.627 -178.462 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.048 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.01 -68.24 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 121.201 -0.937 . . . . 0.0 109.595 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.048 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -76.41 78.39 3.29 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 C-N-CA 121.758 1.639 . . . . 0.0 109.374 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.523 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 3.7 mp -32.5 -54.97 0.56 Allowed Pre-proline 0 N--CA 1.499 2.019 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.559 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.7 Cg_endo -79.85 60.77 7.96 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 C-N-CA 122.249 1.966 . . . . 0.0 111.994 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.904 HG23 ' O ' ' A' ' 30' ' ' PRO . 94.2 t -84.14 149.0 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.633 -1.292 . . . . 0.0 109.708 179.283 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 31.9 p -122.11 -36.62 2.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.41 -0.806 . . . . 0.0 109.611 179.242 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -154.04 136.36 14.92 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.515 -0.741 . . . . 0.0 109.257 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.882 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.2 t -123.59 140.05 53.38 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.506 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.515 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 1.2 ttp180 -107.68 106.05 16.19 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.816 179.285 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.754 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 36.1 m95 -89.08 179.55 6.12 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.998 0.904 . . . . 0.0 109.111 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.424 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.78 100.23 2.8 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 177.445 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.989 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.7 m-30 -80.01 -59.79 2.58 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.787 -1.165 . . . . 0.0 110.011 -177.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.54 17.27 53.06 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -104.35 -103.75 0.31 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 178.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.61 -21.63 59.63 Favored Glycine 0 C--N 1.297 -1.631 0 N-CA-C 107.717 -2.153 . . . . 0.0 107.717 176.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 11.6 p -134.58 129.8 35.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.427 -1.043 . . . . 0.0 109.148 179.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.424 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.25 -84.22 0.11 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.074 -1.016 . . . . 0.0 109.686 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -58.78 149.27 26.92 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.153 0.501 . . . . 0.0 109.848 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.989 HG21 ' CE1' ' A' ' 40' ' ' PHE . 42.3 t -137.72 121.05 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.385 -0.822 . . . . 0.0 110.755 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 61.8 m-20 -104.17 97.26 7.25 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.882 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -107.89 166.35 10.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.251 -0.905 . . . . 0.0 111.239 -178.292 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.58 154.58 18.15 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 121.275 0.56 . . . . 0.0 109.533 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.602 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.88 -155.65 0.53 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.788 -1.725 . . . . 0.0 108.788 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -89.53 40.74 0.48 Allowed 'Trans proline' 0 C--N 1.295 -2.252 0 C-N-CA 122.256 1.971 . . . . 0.0 110.486 178.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.656 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.43 156.42 44.65 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 119.882 -1.762 . . . . 0.0 112.581 -178.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.459 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -168.06 -167.69 0.86 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.3 p -155.52 141.38 18.12 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.959 -1.088 . . . . 0.0 109.738 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.729 ' O ' HD22 ' A' ' 22' ' ' LEU . 12.9 m80 -97.98 142.83 29.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.499 -0.75 . . . . 0.0 111.442 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.517 HH21 HD21 ' A' ' 22' ' ' LEU . 0.9 OUTLIER -114.52 90.52 3.36 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.697 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.089 ' CE2' HG11 ' A' ' 83' ' ' VAL . 31.2 m-85 -94.15 122.3 36.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.11 -0.994 . . . . 0.0 109.751 -178.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.0 m -115.83 -26.02 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.487 -0.758 . . . . 0.0 111.104 -178.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.452 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -98.04 146.31 31.28 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 120.647 -1.283 . . . . 0.0 109.227 -179.636 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.452 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.1 Cg_endo -77.19 123.8 6.87 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 122.41 2.073 . . . . 0.0 110.018 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 156.47 -169.8 33.92 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.419 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -103.84 121.74 43.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.285 -1.127 . . . . 0.0 109.884 -179.823 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.586 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 79.9 m-85 -100.2 160.76 14.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.391 -0.818 . . . . 0.0 109.645 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.478 ' CD2' HG22 ' A' ' 67' ' ' THR . 35.8 t60 -115.18 121.88 44.34 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 178.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.593 HG22 ' NE2' ' A' ' 56' ' ' HIS . 64.5 t -102.86 151.57 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.265 -0.897 . . . . 0.0 110.648 -179.051 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.478 HG22 ' CD2' ' A' ' 65' ' ' HIS . 0.1 OUTLIER -150.61 160.2 43.97 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 178.427 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.08 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -153.3 157.97 40.89 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.094 -1.004 . . . . 0.0 110.695 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.617 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.2 p -147.07 107.8 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.817 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.2 OUTLIER -88.94 147.86 24.11 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.849 -1.157 . . . . 0.0 110.147 -178.043 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.47 113.88 16.08 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 121.932 0.872 . . . . 0.0 108.808 178.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.893 HD21 ' HB2' ' A' ' 30' ' ' PRO . 6.0 mp -103.36 -12.57 17.13 Favored 'General case' 0 C--N 1.289 -2.027 0 CA-C-O 121.553 0.692 . . . . 0.0 109.194 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 112.3 -49.84 0.82 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 -178.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.1 -5.66 11.92 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.577 -0.955 . . . . 0.0 109.815 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.16 160.78 27.87 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.426 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.2 p -151.04 173.31 14.48 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.398 -1.06 . . . . 0.0 109.218 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.817 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -149.88 129.63 13.25 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.261 -0.899 . . . . 0.0 109.651 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.3 tt -94.33 140.0 30.35 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.424 -0.798 . . . . 0.0 110.007 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.08 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -126.23 155.25 42.13 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.449 -0.782 . . . . 0.0 110.275 -179.336 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.472 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -162.65 87.05 0.11 Allowed Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.413 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.741 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -105.31 -175.6 2.84 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.028 -1.278 . . . . 0.0 109.633 179.904 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . 0.406 ' N ' ' OG1' ' A' ' 81' ' ' THR . 0.7 OUTLIER -150.96 146.49 26.28 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 179.258 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.089 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -131.69 141.49 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 120.602 -1.311 . . . . 0.0 110.239 -179.474 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 17.9 tt0 -104.37 89.37 3.21 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.744 HG21 ' HB3' ' A' ' 58' ' ' TYR . 43.4 t -82.07 133.79 28.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.204 -0.935 . . . . 0.0 110.115 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.597 ' HG3' ' HA ' ' A' ' 18' ' ' ALA . 11.2 pt-20 -103.56 -147.97 0.39 Allowed 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.437 ' HA ' ' CB ' ' A' ' 19' ' ' SER . . . . . . . . 0 N--CA 1.489 1.508 0 O-C-N 120.952 -1.092 . . . . 0.0 109.335 179.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.738 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.752 HG22 ' HB3' ' A' ' 28' ' ' ALA . 0.6 OUTLIER -68.93 147.39 51.73 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.277 -0.889 . . . . 0.0 109.278 -179.147 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.767 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.0 mp -92.63 109.16 20.57 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.261 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.624 HG21 ' CE1' ' A' ' 26' ' ' HIS . 2.5 t -123.88 106.11 16.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.9 -1.125 . . . . 0.0 108.738 178.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.556 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.91 76.24 0.3 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.881 -1.287 . . . . 0.0 109.881 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.509 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.0 Cg_endo -73.38 150.25 46.33 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.729 2.286 . . . . 0.0 112.064 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.54 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 40.0 t-80 165.84 -38.77 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.701 0 CA-C-O 121.696 0.76 . . . . 0.0 109.114 179.623 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.01 -137.63 14.29 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 108.221 -1.952 . . . . 0.0 108.221 -179.106 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.83 148.86 25.71 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 C-N-CA 122.237 1.958 . . . . 0.0 109.371 179.053 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.829 HD21 ' HB2' ' A' ' 23' ' ' ALA . 34.5 mt -118.3 100.08 7.26 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.066 -1.021 . . . . 0.0 109.987 -179.539 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.466 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -86.5 171.3 11.19 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.149 -0.969 . . . . 0.0 108.432 179.144 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 37.4 t -54.59 126.26 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.189 -0.944 . . . . 0.0 109.851 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 77.45 51.61 5.97 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.48 ' HB3' HD23 ' A' ' 17' ' ' LEU . 0.4 OUTLIER -115.55 149.78 37.65 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.392 -1.064 . . . . 0.0 110.838 -179.426 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.739 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.1 tm? -109.46 96.67 6.43 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.829 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -81.21 155.97 25.88 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.949 -1.094 . . . . 0.0 108.123 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.509 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.61 116.6 26.35 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.523 -1.361 . . . . 0.0 108.11 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.67 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 4.4 m-85 -104.53 170.38 7.92 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-O 122.319 1.057 . . . . 0.0 112.229 -176.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.624 ' CE1' HG21 ' A' ' 11' ' ' VAL . 4.6 p80 -167.08 149.04 6.0 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.828 HD11 ' CH2' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -112.96 161.85 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.095 -1.003 . . . . 0.0 109.216 -178.294 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.752 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -138.97 118.96 13.33 Favored 'General case' 0 N--CA 1.501 2.086 0 C-N-CA 118.629 -1.228 . . . . 0.0 112.463 -178.636 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.031 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 173.43 -68.67 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.206 -0.934 . . . . 0.0 109.634 177.688 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.031 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 33.5 Cg_endo -76.64 78.19 3.41 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 121.716 1.611 . . . . 0.0 109.362 179.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.506 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -33.27 -54.43 0.68 Allowed Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.946 -0.471 . . . . 0.0 112.186 -179.008 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.611 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.3 Cg_endo -79.69 58.53 7.01 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.113 1.875 . . . . 0.0 112.055 -179.296 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.911 HG23 ' O ' ' A' ' 30' ' ' PRO . 93.9 t -81.78 147.44 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 120.724 -1.235 . . . . 0.0 109.42 179.05 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 74.0 p -122.27 -37.06 2.86 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.313 -0.867 . . . . 0.0 109.614 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -154.34 136.34 14.64 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.847 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.5 t -123.11 150.07 43.69 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.581 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.7 OUTLIER -115.54 103.44 10.74 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.351 -0.94 . . . . 0.0 108.847 179.155 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.828 ' CH2' HD11 ' A' ' 27' ' ' ILE . 31.7 m95 -87.66 179.13 6.57 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.158 -0.964 . . . . 0.0 109.113 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.509 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.5 OUTLIER -149.03 103.08 3.31 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 177.835 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 1.029 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.4 m-30 -81.13 -63.72 1.34 Allowed 'General case' 0 N--CA 1.491 1.597 0 C-N-CA 118.83 -1.148 . . . . 0.0 110.275 -177.782 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.59 7.05 62.0 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.501 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 13.6 p30 -98.79 31.15 3.04 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.324 -1.103 . . . . 0.0 108.647 179.367 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 117.94 -40.74 2.23 Favored Glycine 0 C--N 1.295 -1.742 0 N-CA-C 105.409 -3.077 . . . . 0.0 105.409 -176.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -106.57 100.29 9.82 Favored 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 177.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.513 ' O ' HG23 ' A' ' 47' ' ' VAL . . . -76.21 -89.84 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.029 -1.044 . . . . 0.0 109.943 -178.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -51.48 142.15 14.43 Favored 'General case' 0 N--CA 1.495 1.825 0 CA-C-O 121.287 0.565 . . . . 0.0 109.736 -179.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 1.029 HG21 ' CE1' ' A' ' 40' ' ' PHE . 95.8 t -134.92 113.77 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.345 -0.847 . . . . 0.0 110.813 -178.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -94.84 99.46 11.52 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.534 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.847 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -110.64 167.7 10.03 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.368 -0.832 . . . . 0.0 111.015 -178.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.33 153.65 19.14 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.695 -0.628 . . . . 0.0 109.564 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.549 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.28 -156.51 0.52 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -89.08 40.14 0.49 Allowed 'Trans proline' 0 C--N 1.294 -2.336 0 C-N-CA 122.279 1.986 . . . . 0.0 110.285 178.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.574 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -142.73 156.32 44.99 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.889 -1.757 . . . . 0.0 112.62 -178.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.509 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -170.64 -171.76 1.1 Allowed 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 179.229 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.504 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -148.98 150.2 32.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.94 -1.1 . . . . 0.0 109.637 179.494 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.739 ' O ' HD22 ' A' ' 22' ' ' LEU . 8.5 m80 -105.89 143.54 33.89 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.39 -0.819 . . . . 0.0 111.006 -178.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.431 ' NH2' HD21 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -118.16 89.4 3.12 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.709 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.111 ' CE2' HG11 ' A' ' 83' ' ' VAL . 43.0 m-85 -91.49 138.97 31.15 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.914 . . . . 0.0 109.898 -178.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.1 p -124.27 -35.85 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.336 -0.852 . . . . 0.0 111.355 -178.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.43 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -86.77 146.5 41.3 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 120.511 -1.368 . . . . 0.0 109.607 -179.446 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.473 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.5 Cg_endo -78.18 117.55 4.14 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 122.477 2.118 . . . . 0.0 110.013 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 162.11 -147.61 13.98 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.425 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -123.39 140.75 52.69 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.096 -1.237 . . . . 0.0 109.671 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.557 ' HB2' HG13 ' A' ' 83' ' ' VAL . 66.9 m-85 -119.98 164.37 16.19 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.322 -0.861 . . . . 0.0 109.906 -179.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 64.1 t60 -115.77 127.42 55.08 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.589 HG22 ' NE2' ' A' ' 56' ' ' HIS . 66.7 t -110.06 152.48 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 110.488 -179.1 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -146.93 158.62 43.97 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.057 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -155.12 117.89 4.32 Favored 'General case' 0 N--CA 1.498 1.94 0 C-N-CA 118.885 -1.126 . . . . 0.0 111.689 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.581 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.2 p -108.49 110.43 31.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.815 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.04 154.51 20.14 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.762 -1.211 . . . . 0.0 110.038 -178.801 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.18 116.65 16.5 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.779 0.799 . . . . 0.0 108.883 178.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.933 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.8 mp -105.43 -12.88 15.83 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 121.539 0.685 . . . . 0.0 109.26 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.67 -44.59 1.44 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.906 -2.077 . . . . 0.0 107.906 -178.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -113.89 -5.82 13.21 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.557 -0.966 . . . . 0.0 109.847 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -153.63 166.06 31.69 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.43 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 1.4 p -150.9 170.79 18.46 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.272 -1.134 . . . . 0.0 109.404 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.815 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -145.72 135.02 22.97 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.271 -0.893 . . . . 0.0 109.541 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 4.1 mp -101.04 131.11 47.09 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.148 -0.97 . . . . 0.0 109.992 -179.572 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.057 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -118.11 155.17 30.86 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 121.451 -0.781 . . . . 0.0 110.208 -179.149 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -161.58 86.7 0.11 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.755 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -106.04 -172.78 2.15 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.015 -1.285 . . . . 0.0 109.888 -179.808 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -151.25 152.88 33.87 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 179.411 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.111 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.5 OUTLIER -132.77 155.48 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.781 -1.2 . . . . 0.0 109.88 -179.822 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . 0.437 ' N ' HG23 ' A' ' 83' ' ' VAL . 31.6 tt0 -122.17 88.27 2.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.494 -0.754 . . . . 0.0 109.231 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.672 HG22 ' HB3' ' A' ' 17' ' ' LEU . 80.0 t -81.8 139.87 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.216 -0.927 . . . . 0.0 109.613 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -117.29 170.65 8.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.291 -0.88 . . . . 0.0 109.666 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.473 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.553 0 O-C-N 121.12 -0.988 . . . . 0.0 109.352 179.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.996 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.686 ' CG2' ' HB3' ' A' ' 28' ' ' ALA . 0.4 OUTLIER -81.66 140.24 34.49 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 179.807 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.731 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.5 mp -100.26 100.33 11.13 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -178.246 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.774 HG12 ' HD3' ' A' ' 13' ' ' PRO . 21.8 t -113.81 116.35 52.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 120.654 -1.279 . . . . 0.0 109.177 178.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.521 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -120.87 72.58 0.35 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 108.901 -1.679 . . . . 0.0 108.901 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.774 ' HD3' HG12 ' A' ' 11' ' ' VAL . 32.5 Cg_endo -71.27 147.46 53.4 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.83 2.353 . . . . 0.0 113.069 -179.067 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.565 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 151.58 170.76 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 114.639 -1.164 . . . . 0.0 108.122 179.102 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.46 -141.34 1.15 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -76.74 151.91 32.35 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 C-N-CA 122.225 1.95 . . . . 0.0 109.464 179.255 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 1.142 HD21 ' HB2' ' A' ' 23' ' ' ALA . 51.3 mt -104.74 91.51 3.88 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.001 -1.062 . . . . 0.0 109.427 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.87 169.17 11.82 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.9 t -55.02 113.55 1.39 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.259 -0.9 . . . . 0.0 109.34 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.17 38.29 5.15 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.499 ' HG2' ' HA ' ' A' ' 17' ' ' LEU . 3.1 tp-100 -107.89 146.33 32.49 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.286 -1.126 . . . . 0.0 110.609 -179.447 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.701 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.8 tm? -108.65 94.43 5.05 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.531 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 1.142 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -77.68 158.62 29.62 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.027 -1.046 . . . . 0.0 108.266 179.238 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.534 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.92 119.3 31.14 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.566 -1.334 . . . . 0.0 107.869 179.293 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.697 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 3.1 m-85 -106.09 170.35 7.96 Favored 'General case' 0 N--CA 1.489 1.517 0 CA-C-O 121.96 0.886 . . . . 0.0 111.583 -177.006 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.625 ' CE1' HG21 ' A' ' 11' ' ' VAL . 2.3 p80 -164.66 143.65 7.03 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 107.813 -1.181 . . . . 0.0 107.813 176.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.951 HD12 ' HG ' ' A' ' 79' ' ' LEU . 6.0 mm -109.14 154.05 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.34 -0.85 . . . . 0.0 109.997 -177.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.686 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -136.69 113.38 10.24 Favored 'General case' 0 N--CA 1.498 1.962 0 C-N-CA 118.933 -1.107 . . . . 0.0 111.629 -179.443 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.081 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -178.39 -61.7 0.0 OUTLIER Pre-proline 0 N--CA 1.494 1.766 0 O-C-N 120.936 -1.102 . . . . 0.0 109.791 178.36 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.081 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.0 Cg_endo -80.19 63.06 8.71 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.14 1.893 . . . . 0.0 109.874 179.693 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.637 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -12.96 -64.32 0.02 OUTLIER Pre-proline 0 N--CA 1.506 2.37 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -179.101 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.637 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 35.5 Cg_endo -77.34 71.58 6.32 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 C-N-CA 121.788 1.659 . . . . 0.0 110.926 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.541 HG22 ' HG2' ' A' ' 30' ' ' PRO . 3.0 t -96.7 135.14 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 120.853 -1.155 . . . . 0.0 109.919 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.4 t -111.58 -16.72 13.2 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.414 -0.804 . . . . 0.0 109.375 178.64 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.83 150.54 0.5 Allowed 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.372 -0.83 . . . . 0.0 109.827 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.705 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -137.98 137.64 38.11 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.374 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.54 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.3 OUTLIER -89.61 104.26 16.84 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.192 -0.942 . . . . 0.0 108.7 179.555 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.915 ' CH2' HD11 ' A' ' 27' ' ' ILE . 26.1 m95 -87.65 178.73 6.68 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.906 -1.121 . . . . 0.0 109.45 -179.589 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.453 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.7 OUTLIER -149.8 102.27 3.13 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 178.359 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.986 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.1 m-30 -80.51 -58.58 3.05 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.696 -1.202 . . . . 0.0 109.966 -178.134 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.87 15.82 57.3 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.079 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -104.63 -105.72 0.3 Allowed 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 178.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.13 -17.41 67.17 Favored Glycine 0 C--N 1.296 -1.669 0 N-CA-C 107.982 -2.047 . . . . 0.0 107.982 177.042 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.4 m -135.88 125.42 25.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.413 -1.051 . . . . 0.0 109.042 179.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.24 -84.59 0.1 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.053 -1.029 . . . . 0.0 109.849 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -58.42 149.78 24.09 Favored 'General case' 0 N--CA 1.495 1.809 0 CA-C-O 121.272 0.558 . . . . 0.0 110.105 -179.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.986 HG21 ' CE1' ' A' ' 40' ' ' PHE . 21.1 t -139.68 128.98 28.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.26 -0.9 . . . . 0.0 111.263 -178.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -108.15 91.4 3.63 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 177.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.704 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -97.35 155.67 16.79 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.347 -0.845 . . . . 0.0 111.517 -177.796 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.56 151.01 20.38 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.778 -0.576 . . . . 0.0 109.477 179.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.705 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.84 -159.11 0.61 Allowed Glycine 0 N--CA 1.489 2.181 0 N-CA-C 107.997 -2.041 . . . . 0.0 107.997 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.507 ' HB3' HG21 ' A' ' 33' ' ' VAL . 37.8 Cg_endo -87.43 41.2 0.69 Allowed 'Trans proline' 0 C--N 1.297 -2.14 0 C-N-CA 122.017 1.811 . . . . 0.0 109.99 178.265 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.704 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.46 150.44 39.0 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.152 -1.592 . . . . 0.0 112.097 -178.654 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.565 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -160.02 -168.32 2.19 Favored 'General case' 0 N--CA 1.495 1.778 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 179.045 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.701 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.1 OUTLIER -152.67 154.31 35.06 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.219 -0.926 . . . . 0.0 109.09 179.491 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.685 ' O ' HD22 ' A' ' 22' ' ' LEU . 13.3 m80 -113.63 133.86 55.05 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.043 -1.036 . . . . 0.0 111.411 -178.63 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.75 87.17 2.61 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 178.723 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.113 ' CE2' HG11 ' A' ' 83' ' ' VAL . 31.7 m-85 -89.44 125.37 35.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.199 -0.938 . . . . 0.0 109.684 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 86.0 t -114.58 -34.52 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.428 -0.795 . . . . 0.0 110.928 -178.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.461 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.2 OUTLIER -90.78 145.94 33.02 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 120.542 -1.349 . . . . 0.0 109.487 -179.367 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.599 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 34.8 Cg_endo -77.66 125.52 7.58 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.44 2.093 . . . . 0.0 109.937 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.87 -154.57 25.63 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.468 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 3.9 mpt_? -114.68 133.85 55.55 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.101 -1.234 . . . . 0.0 109.65 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.609 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 82.2 m-85 -115.92 150.13 37.6 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.313 -0.867 . . . . 0.0 109.714 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.453 ' CD2' HG22 ' A' ' 67' ' ' THR . 58.9 t60 -103.95 129.63 51.52 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.482 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.585 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 92.0 t -111.03 155.18 12.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.255 -0.903 . . . . 0.0 110.236 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.453 HG22 ' CD2' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -149.84 158.6 44.32 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.658 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.054 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -154.04 123.47 6.58 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.752 -1.179 . . . . 0.0 111.709 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -95.89 126.59 48.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.732 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.949 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.6 OUTLIER -88.61 142.35 27.76 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 120.727 -1.233 . . . . 0.0 108.722 -178.738 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.75 110.39 11.3 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 120.739 -1.225 . . . . 0.0 109.832 178.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.837 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -105.39 -10.84 16.73 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.137 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.38 -45.51 1.3 Allowed Glycine 0 N--CA 1.486 2.029 0 N-CA-C 107.895 -2.082 . . . . 0.0 107.895 -178.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -119.84 -5.13 10.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.605 -0.938 . . . . 0.0 109.839 179.178 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.14 165.58 27.34 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 6.8 p -151.09 -176.88 5.72 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.391 -1.064 . . . . 0.0 109.741 -179.467 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.949 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -155.18 164.33 38.97 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.5 tp -120.82 119.85 33.89 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.147 -0.971 . . . . 0.0 110.067 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.054 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -105.53 156.12 18.53 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.603 -0.686 . . . . 0.0 109.392 -179.702 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.585 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.14 99.34 0.16 Allowed Glycine 0 N--CA 1.485 1.905 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.436 HG22 HD23 ' A' ' 10' ' ' LEU . 0.7 OUTLIER -115.65 -173.43 2.34 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 120.923 -1.34 . . . . 0.0 110.216 179.993 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -149.79 140.07 22.25 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.113 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -125.77 152.04 32.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.916 -1.115 . . . . 0.0 109.916 -179.455 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.74 86.44 2.52 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.864 HG21 ' HB3' ' A' ' 58' ' ' TYR . 78.8 t -77.85 140.79 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.04 -1.038 . . . . 0.0 110.355 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -114.99 -173.93 2.4 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.426 -0.797 . . . . 0.0 109.361 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.599 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.553 0 O-C-N 120.895 -1.128 . . . . 0.0 109.701 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.859 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.782 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -90.19 141.91 28.23 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.664 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.76 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.3 mp -97.05 95.33 7.71 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -178.283 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.931 HG12 ' HD3' ' A' ' 13' ' ' PRO . 47.5 t -105.65 118.12 52.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 120.894 -1.129 . . . . 0.0 109.186 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -123.75 71.42 0.43 Allowed Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.931 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.5 Cg_endo -72.81 150.81 50.42 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 123.136 2.557 . . . . 0.0 113.517 -178.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.588 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 145.74 179.04 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.091 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.283 178.717 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.81 -144.52 4.63 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -75.99 150.98 34.69 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.32 2.013 . . . . 0.0 109.51 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.895 HD21 ' HB2' ' A' ' 23' ' ' ALA . 17.2 mt -102.04 82.53 2.24 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.038 -1.039 . . . . 0.0 109.759 -179.578 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -75.3 165.5 25.08 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.037 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 18.1 t -58.49 114.12 2.31 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.043 -1.035 . . . . 0.0 109.187 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.54 44.28 2.98 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -120.69 155.38 33.99 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.337 -1.096 . . . . 0.0 110.879 -179.509 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.759 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.8 tm? -112.33 97.7 6.8 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.895 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -79.44 157.55 27.5 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.543 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.75 120.25 36.01 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.497 -1.377 . . . . 0.0 108.167 179.414 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.669 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 3.4 m-85 -105.16 173.55 6.26 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.987 0.899 . . . . 0.0 111.542 -177.162 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.734 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -168.26 138.7 2.61 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.06 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.96 HD12 ' HG ' ' A' ' 79' ' ' LEU . 5.0 mm -107.43 149.53 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.401 -0.812 . . . . 0.0 109.154 -178.282 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.653 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -134.42 124.56 25.88 Favored 'General case' 0 N--CA 1.502 2.156 0 C-N-CA 118.57 -1.252 . . . . 0.0 112.281 -178.755 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.025 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -178.8 -66.0 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.101 -0.999 . . . . 0.0 109.116 177.742 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.025 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.7 Cg_endo -81.01 66.71 8.81 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.056 1.838 . . . . 0.0 109.314 179.174 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.702 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -9.93 -66.56 0.01 OUTLIER Pre-proline 0 N--CA 1.513 2.688 0 N-CA-C 112.77 0.656 . . . . 0.0 112.77 -178.427 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.702 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 37.1 Cg_endo -79.35 90.52 1.26 Allowed 'Trans proline' 0 C--N 1.314 -1.261 0 C-N-CA 121.709 1.606 . . . . 0.0 110.577 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.541 HG22 ' HG2' ' A' ' 30' ' ' PRO . 8.7 t -112.59 145.62 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.948 -1.095 . . . . 0.0 109.637 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -113.7 -19.08 11.7 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.515 -0.741 . . . . 0.0 110.257 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.13 151.23 0.8 Allowed 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.094 -1.004 . . . . 0.0 110.431 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.69 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -139.1 137.96 36.64 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.382 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.525 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 7.0 ttm180 -92.61 112.67 24.7 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.145 -0.972 . . . . 0.0 108.836 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.942 ' CH2' HD11 ' A' ' 27' ' ' ILE . 17.8 m95 -95.77 -178.97 4.56 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -0.894 . . . . 0.0 109.454 -179.812 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.511 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.57 103.06 3.08 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 177.598 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 1.019 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.1 m-30 -80.84 -65.35 1.02 Allowed 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 118.896 -1.122 . . . . 0.0 110.697 -177.369 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.51 6.82 58.36 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.534 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 12.1 p30 -98.03 31.47 2.7 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.354 -1.086 . . . . 0.0 108.777 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 116.18 -39.95 2.56 Favored Glycine 0 C--N 1.295 -1.705 0 N-CA-C 105.626 -2.99 . . . . 0.0 105.626 -176.251 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 63.8 p -105.99 103.58 13.1 Favored 'General case' 0 N--CA 1.487 1.386 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 177.452 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.511 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -77.98 -88.97 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.115 -0.991 . . . . 0.0 110.429 -178.373 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -52.67 142.85 17.4 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.311 0.576 . . . . 0.0 109.992 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 1.019 HG21 ' CE1' ' A' ' 40' ' ' PHE . 90.4 t -135.67 132.61 51.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.346 -0.847 . . . . 0.0 110.953 -178.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -111.65 92.66 4.12 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.032 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.705 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -97.26 151.51 19.8 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.305 -0.872 . . . . 0.0 111.283 -177.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.17 150.48 23.92 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.69 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.25 -157.44 0.63 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 108.395 -1.882 . . . . 0.0 108.395 -179.168 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -87.92 39.75 0.56 Allowed 'Trans proline' 0 C--N 1.296 -2.193 0 C-N-CA 122.037 1.825 . . . . 0.0 110.128 178.564 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.705 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.13 149.38 34.91 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.124 -1.61 . . . . 0.0 112.029 -178.54 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.654 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -154.6 -167.18 2.53 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.667 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -153.89 145.47 23.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.246 -0.909 . . . . 0.0 109.016 179.448 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.759 ' O ' HD22 ' A' ' 22' ' ' LEU . 10.8 m80 -105.02 138.98 40.39 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.091 -1.006 . . . . 0.0 110.91 -178.804 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -110.07 90.16 3.23 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.123 ' CE2' HG11 ' A' ' 83' ' ' VAL . 30.9 m-85 -92.48 124.49 36.56 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 109.786 -178.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.4 m -119.1 -13.93 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.486 -0.759 . . . . 0.0 111.385 -178.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.439 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -102.7 148.41 35.49 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 120.663 -1.273 . . . . 0.0 109.618 -179.731 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.738 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 34.8 Cg_endo -78.21 116.45 3.91 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.453 2.102 . . . . 0.0 109.782 179.336 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.71 -156.92 27.38 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 2.3 ptt-85 -112.49 159.69 18.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.179 -1.189 . . . . 0.0 110.135 -179.779 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.704 ' HB2' HG13 ' A' ' 83' ' ' VAL . 87.4 m-85 -136.05 159.74 40.79 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.455 -0.778 . . . . 0.0 109.328 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -116.52 115.99 26.8 Favored 'General case' 0 N--CA 1.486 1.372 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.603 HG22 ' NE2' ' A' ' 56' ' ' HIS . 83.3 t -97.77 148.48 5.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.373 -0.83 . . . . 0.0 110.551 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.456 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 2.1 p -145.38 156.0 43.51 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 178.322 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.992 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -152.44 164.79 36.83 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.741 -1.224 . . . . 0.0 110.955 -179.494 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.442 HG12 ' HB3' ' A' ' 37' ' ' ARG . 9.5 p -139.69 129.26 29.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 N-CA-C 107.146 -1.428 . . . . 0.0 107.146 178.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.992 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.03 142.03 28.1 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.845 -1.159 . . . . 0.0 108.749 -178.358 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.61 107.4 9.16 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 118.585 -1.246 . . . . 0.0 109.935 178.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.543 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -105.39 -9.98 17.24 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.832 179.159 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.47 -49.5 0.87 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 107.734 -2.146 . . . . 0.0 107.734 -178.413 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.52 -5.91 11.19 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.626 -0.926 . . . . 0.0 109.692 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.65 154.73 23.84 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 29.7 p -149.53 -179.86 7.42 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.291 -1.123 . . . . 0.0 109.421 -179.483 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.992 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -154.79 162.9 40.94 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.622 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -116.67 131.41 56.96 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.098 -1.001 . . . . 0.0 110.128 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.992 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -115.48 157.68 23.66 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.555 -0.715 . . . . 0.0 109.717 -179.809 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.29 89.28 0.09 OUTLIER Glycine 0 N--CA 1.483 1.822 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.531 HG22 HD23 ' A' ' 10' ' ' LEU . 0.2 OUTLIER -109.14 -171.71 1.9 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.04 -1.27 . . . . 0.0 109.55 179.675 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -150.81 155.69 39.74 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 179.398 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.123 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.24 151.65 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.659 -1.276 . . . . 0.0 109.776 -179.868 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.05 85.93 2.42 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.031 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.887 HG21 ' HB3' ' A' ' 58' ' ' TYR . 47.3 t -77.52 136.71 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.791 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -123.25 141.08 52.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.425 -0.797 . . . . 0.0 109.959 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.738 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.911 . . . . 0.0 109.433 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.757 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.897 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.0 OUTLIER -73.51 148.95 42.61 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.182 -0.949 . . . . 0.0 109.157 -179.374 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.87 HD23 HG22 ' A' ' 81' ' ' THR . 5.3 mp -91.17 103.13 15.85 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.339 -178.413 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.622 HG11 ' NE2' ' A' ' 26' ' ' HIS . 2.6 t -115.38 104.54 16.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 120.928 -1.108 . . . . 0.0 108.682 178.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.557 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.37 76.51 0.29 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -179.348 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.527 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 31.1 Cg_endo -71.42 148.24 54.12 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.674 2.249 . . . . 0.0 111.973 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.468 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 41.4 t60 161.13 -37.19 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.3 -139.4 14.81 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 107.952 -2.059 . . . . 0.0 107.952 -179.148 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -76.66 145.78 26.29 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 122.02 1.813 . . . . 0.0 109.064 178.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.788 HD11 ' HB2' ' A' ' 23' ' ' ALA . 3.3 mm? -104.53 92.94 4.52 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.167 -0.958 . . . . 0.0 109.871 -179.074 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.495 ' HB3' ' HG3' ' A' ' 21' ' ' GLN . . . -74.9 160.2 30.92 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.165 -0.96 . . . . 0.0 108.515 179.104 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.622 ' H ' ' HB3' ' A' ' 87' ' ' ALA . 14.3 t -56.14 125.17 20.51 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.223 -0.923 . . . . 0.0 109.937 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 80.69 49.15 5.86 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.495 ' HG3' ' HB3' ' A' ' 18' ' ' ALA . 0.7 OUTLIER -123.4 151.82 42.21 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.35 -1.088 . . . . 0.0 110.744 -179.517 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.803 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.2 tm? -105.97 98.65 8.31 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.502 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.788 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -78.83 153.09 30.93 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.159 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.527 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -116.66 118.16 31.8 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.469 -1.395 . . . . 0.0 108.44 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.708 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 7.4 m-85 -107.79 168.35 9.33 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 122.417 1.103 . . . . 0.0 112.262 -177.183 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.622 ' NE2' HG11 ' A' ' 11' ' ' VAL . 4.1 p80 -167.92 145.52 4.36 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 176.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.85 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.2 161.25 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.868 -1.145 . . . . 0.0 108.906 -178.336 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.897 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -139.43 119.55 13.61 Favored 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.556 -1.258 . . . . 0.0 112.433 -178.714 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.04 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 174.24 -68.87 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 177.614 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.04 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -77.6 78.21 3.6 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 121.779 1.653 . . . . 0.0 109.34 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.49 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -33.52 -53.95 0.74 Allowed Pre-proline 0 N--CA 1.5 2.029 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -178.913 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.57 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.7 Cg_endo -79.81 58.57 7.04 Favored 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.183 1.922 . . . . 0.0 111.877 -179.283 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.94 HG23 ' O ' ' A' ' 30' ' ' PRO . 73.3 t -82.23 148.43 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 120.843 -1.16 . . . . 0.0 109.273 179.11 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.3 t -120.95 -36.79 3.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.318 -0.864 . . . . 0.0 109.661 179.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -152.06 139.19 19.22 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.453 -0.78 . . . . 0.0 109.156 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.89 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.2 t -127.52 134.92 49.75 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.545 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 2.8 tpp180 -104.07 104.06 13.95 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.042 -1.036 . . . . 0.0 109.174 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.708 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 29.4 m95 -87.82 -179.76 6.32 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.078 -1.014 . . . . 0.0 109.172 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -148.31 100.55 3.16 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 177.724 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.92 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.8 m-30 -80.01 -60.72 2.23 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 118.733 -1.187 . . . . 0.0 109.746 -178.122 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.98 15.93 55.27 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -178.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.25 -104.22 0.25 Allowed 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 178.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.08 -23.92 50.26 Favored Glycine 0 C--N 1.296 -1.649 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 176.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.8 m -128.62 127.69 42.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.501 -1.0 . . . . 0.0 109.04 179.426 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -81.11 -83.91 0.11 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.063 -1.023 . . . . 0.0 109.644 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -58.48 152.2 18.56 Favored 'General case' 0 N--CA 1.495 1.799 0 CA-C-O 121.222 0.534 . . . . 0.0 109.567 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.92 HG21 ' CE1' ' A' ' 40' ' ' PHE . 43.9 t -138.07 113.9 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.069 -1.019 . . . . 0.0 111.444 -178.444 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.19 105.18 17.09 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 177.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.89 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -118.74 168.34 10.82 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.143 -0.973 . . . . 0.0 111.042 -178.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.05 155.32 18.47 Favored 'General case' 0 N--CA 1.49 1.532 0 CA-C-O 121.503 0.668 . . . . 0.0 109.796 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.57 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.29 -155.42 0.64 Allowed Glycine 0 N--CA 1.488 2.159 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -89.77 40.48 0.45 Allowed 'Trans proline' 0 C--N 1.295 -2.284 0 C-N-CA 122.464 2.11 . . . . 0.0 110.484 178.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.58 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.75 154.09 43.1 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 119.899 -1.751 . . . . 0.0 112.658 -178.629 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.61 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -174.36 155.36 2.32 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.803 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -115.61 155.03 28.38 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.591 -1.318 . . . . 0.0 110.768 -179.766 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.734 ' O ' HD22 ' A' ' 22' ' ' LEU . 5.3 m80 -105.36 143.31 33.7 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.465 0.65 . . . . 0.0 110.791 -179.221 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -115.05 94.57 4.8 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.091 ' CE2' HG11 ' A' ' 83' ' ' VAL . 25.9 m-85 -99.1 126.98 44.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.148 -0.97 . . . . 0.0 109.747 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 8.2 m -119.46 -31.06 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.362 -0.836 . . . . 0.0 111.553 -178.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.519 ' HB3' ' OH ' ' A' ' 64' ' ' TYR . 0.6 OUTLIER -96.49 140.56 22.24 Favored Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 120.579 -1.325 . . . . 0.0 109.165 -179.49 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.479 ' N ' ' HG ' ' A' ' 60' ' ' LEU . 32.5 Cg_endo -73.1 135.78 23.55 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.293 1.995 . . . . 0.0 110.567 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 148.36 -140.01 8.04 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -179.538 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -129.54 137.64 50.88 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.211 -1.17 . . . . 0.0 109.61 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.578 ' HB2' HG13 ' A' ' 83' ' ' VAL . 79.0 m-85 -117.36 159.68 22.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.313 -0.867 . . . . 0.0 109.449 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.425 ' CD2' HG22 ' A' ' 67' ' ' THR . 11.2 t60 -114.13 126.27 54.9 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.838 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.595 HG13 ' CE1' ' A' ' 56' ' ' HIS . 60.1 t -108.94 151.41 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.295 -0.878 . . . . 0.0 110.559 -179.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.425 HG22 ' CD2' ' A' ' 65' ' ' HIS . 0.1 OUTLIER -148.92 161.23 42.29 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.459 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.1 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -157.96 122.48 4.25 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.869 -1.144 . . . . 0.0 111.609 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.418 ' O ' HG13 ' A' ' 69' ' ' VAL . 2.1 p -112.96 109.15 27.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 177.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.805 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.89 147.27 24.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.787 -1.196 . . . . 0.0 109.791 -179.12 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -126.76 116.5 21.02 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.353 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.891 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.6 mp -103.53 -13.42 16.58 Favored 'General case' 0 C--N 1.292 -1.92 0 CA-C-O 121.495 0.664 . . . . 0.0 109.417 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 114.78 -51.55 0.71 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 107.9 -2.08 . . . . 0.0 107.9 -178.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.35 -5.73 12.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.576 -0.955 . . . . 0.0 109.894 179.148 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.3 162.98 27.88 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.7 p -151.24 169.48 21.82 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.393 -1.063 . . . . 0.0 109.59 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.805 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -142.85 136.15 28.43 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 109.463 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.5 tt -101.65 132.41 47.35 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.287 -0.883 . . . . 0.0 110.335 -179.426 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.1 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -121.06 155.01 35.34 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.561 -0.712 . . . . 0.0 110.21 -179.372 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.517 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -162.21 88.05 0.11 Allowed Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.437 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.87 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -104.98 -176.65 3.14 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.112 -1.228 . . . . 0.0 109.903 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -150.47 143.76 24.95 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.091 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -130.43 153.08 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 120.567 -1.333 . . . . 0.0 110.22 -179.331 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . 0.415 ' N ' HG23 ' A' ' 83' ' ' VAL . 32.4 tt0 -118.59 100.79 7.66 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.876 HG21 ' HB3' ' A' ' 58' ' ' TYR . 42.9 t -80.9 136.42 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.148 -0.97 . . . . 0.0 109.854 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -121.21 -156.61 0.69 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.619 -0.676 . . . . 0.0 109.54 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.622 ' HB3' ' H ' ' A' ' 19' ' ' SER . . . . . . . . 0 N--CA 1.487 1.406 0 O-C-N 121.484 -0.76 . . . . 0.0 110.325 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.718 ' CB ' HG22 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.432 0 CA-C-O 121.457 0.646 . . . . 0.0 109.412 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.813 HG23 HG23 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -87.3 141.04 28.94 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.857 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.754 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.4 mp -97.22 94.85 7.34 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.003 -177.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.825 HG12 ' HD3' ' A' ' 13' ' ' PRO . 41.1 t -107.1 115.99 49.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.89 -1.131 . . . . 0.0 108.568 178.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.455 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -121.98 71.78 0.39 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.363 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.825 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.4 Cg_endo -73.63 150.79 45.93 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.942 2.428 . . . . 0.0 112.036 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.537 ' CB ' ' O ' ' A' ' 13' ' ' PRO . 16.0 t-80 150.29 -39.52 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 CA-C-N 115.44 -0.8 . . . . 0.0 108.935 179.53 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 116.4 -142.97 17.88 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.49 -1.844 . . . . 0.0 108.49 -179.218 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.82 149.01 25.9 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 122.306 2.004 . . . . 0.0 109.779 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 1.02 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.4 mm? -105.2 106.74 17.37 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.181 -0.949 . . . . 0.0 109.207 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.426 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -93.44 168.72 10.87 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.01 -1.057 . . . . 0.0 108.905 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 28.1 t -56.42 120.81 8.29 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.364 -0.835 . . . . 0.0 109.045 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 80.3 44.14 9.0 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.454 ' HG2' HD13 ' A' ' 17' ' ' LEU . 23.0 tp60 -113.35 147.3 37.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.523 -0.986 . . . . 0.0 110.697 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.718 HD11 ' HB2' ' A' ' 55' ' ' SER . 1.8 tm? -108.35 96.32 6.27 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.565 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 1.02 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -78.86 156.59 28.6 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 178.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.499 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.63 108.85 14.05 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.415 -1.428 . . . . 0.0 108.224 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.734 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 2.6 m-85 -95.19 166.7 11.78 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 122.098 0.952 . . . . 0.0 111.57 -177.282 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.729 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -159.74 135.89 8.82 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 177.864 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.995 HD11 ' CH2' ' A' ' 38' ' ' TRP . 5.0 mm -108.97 152.01 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.368 -0.833 . . . . 0.0 109.526 -177.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.654 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -136.93 136.12 38.32 Favored 'General case' 0 N--CA 1.506 2.354 0 C-N-CA 118.439 -1.305 . . . . 0.0 113.045 -178.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.035 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 174.05 -71.4 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.951 0 O-C-N 121.002 -1.061 . . . . 0.0 108.963 177.352 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.035 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -79.44 72.89 6.28 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 C-N-CA 121.778 1.652 . . . . 0.0 109.13 178.486 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.623 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -13.81 -63.79 0.03 OUTLIER Pre-proline 0 N--CA 1.512 2.661 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -178.437 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.817 ' O ' HD21 ' A' ' 72' ' ' LEU . 36.4 Cg_endo -78.22 63.43 8.29 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 C-N-CA 121.889 1.726 . . . . 0.0 111.187 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.923 HG22 ' HG2' ' A' ' 30' ' ' PRO . 62.1 t -80.95 148.26 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.901 -1.124 . . . . 0.0 109.635 179.616 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 t -120.49 -18.33 7.88 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.345 -0.847 . . . . 0.0 110.648 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -176.48 139.27 0.33 Allowed 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.013 -1.055 . . . . 0.0 110.329 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.744 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -126.73 134.22 50.71 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.356 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.487 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 1.1 mtm180 -93.11 113.83 26.18 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.295 -0.878 . . . . 0.0 108.736 179.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.995 ' CH2' HD11 ' A' ' 27' ' ' ILE . 11.8 m95 -99.19 -179.25 4.18 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 121.976 0.893 . . . . 0.0 109.853 -179.403 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.514 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.62 103.3 3.1 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 177.245 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 1.037 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.7 m-30 -80.78 -65.14 1.05 Allowed 'General case' 0 N--CA 1.492 1.656 0 C-N-CA 118.784 -1.166 . . . . 0.0 110.809 -177.378 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.37 1.47 59.22 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -178.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.4 p30 -95.57 34.97 1.4 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.293 -1.122 . . . . 0.0 108.403 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.43 -36.46 4.25 Favored Glycine 0 C--N 1.296 -1.677 0 N-CA-C 105.845 -2.902 . . . . 0.0 105.845 -176.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.412 ' O ' ' HB2' ' A' ' 40' ' ' PHE . 18.1 m -104.05 94.05 5.18 Favored 'General case' 0 N--CA 1.487 1.375 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.057 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.49 -95.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.22 -0.925 . . . . 0.0 110.066 -178.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -52.22 146.67 8.78 Favored 'General case' 0 N--CA 1.496 1.87 0 CA-C-O 121.194 0.521 . . . . 0.0 109.879 -179.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 1.037 HG21 ' CE1' ' A' ' 40' ' ' PHE . 95.6 t -138.49 130.69 38.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.347 -0.846 . . . . 0.0 110.969 -178.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -111.37 94.71 5.11 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.799 ' CB ' ' HB2' ' A' ' 54' ' ' ALA . . . -100.45 147.9 25.35 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.226 -0.921 . . . . 0.0 111.146 -178.373 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.7 151.8 26.07 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.731 -0.605 . . . . 0.0 109.499 179.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.744 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.82 -156.55 0.61 Allowed Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.64 -1.784 . . . . 0.0 108.64 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -88.05 39.33 0.52 Allowed 'Trans proline' 0 C--N 1.296 -2.191 0 C-N-CA 122.406 2.071 . . . . 0.0 110.438 178.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.712 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.38 146.65 31.65 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 119.93 -1.731 . . . . 0.0 112.156 -178.707 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.799 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -156.15 -178.81 7.59 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 178.558 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.718 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -141.62 152.49 44.04 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.735 -1.228 . . . . 0.0 109.477 179.414 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.667 ' O ' HD22 ' A' ' 22' ' ' LEU . 5.4 m80 -108.16 138.82 43.78 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.473 -0.767 . . . . 0.0 110.618 -178.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.405 HH21 HD21 ' A' ' 22' ' ' LEU . 0.4 OUTLIER -111.95 89.71 3.14 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.972 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.056 ' CE2' HG11 ' A' ' 83' ' ' VAL . 34.5 m-85 -90.25 130.34 36.38 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.172 -0.955 . . . . 0.0 109.307 -179.172 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 9.4 p -116.58 -30.8 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.252 -0.905 . . . . 0.0 111.283 -178.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.438 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -100.91 146.7 32.58 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 120.703 -1.248 . . . . 0.0 109.453 -179.226 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.438 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 34.7 Cg_endo -76.91 121.46 5.86 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.255 1.97 . . . . 0.0 109.944 179.601 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 164.46 -157.05 29.28 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -112.47 120.76 42.73 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.022 -1.281 . . . . 0.0 109.986 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.506 ' HB2' HG13 ' A' ' 83' ' ' VAL . 86.4 m-85 -105.07 147.13 28.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.492 -0.755 . . . . 0.0 109.349 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -104.24 132.35 50.58 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.602 HG22 ' NE2' ' A' ' 56' ' ' HIS . 79.6 t -113.57 149.4 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.153 -0.967 . . . . 0.0 110.462 -179.128 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.5 p -148.15 153.91 39.46 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 178.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.109 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.94 163.03 39.67 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.946 -1.096 . . . . 0.0 110.883 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.612 ' O ' HG13 ' A' ' 69' ' ' VAL . 12.1 p -150.9 112.27 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.876 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.01 143.17 27.04 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 120.481 -1.387 . . . . 0.0 110.287 -178.205 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -122.63 117.74 26.51 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.817 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.9 OUTLIER -105.88 -13.98 15.35 Favored 'General case' 0 C--N 1.29 -2.003 0 CA-C-O 121.587 0.708 . . . . 0.0 109.388 179.866 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 110.72 -51.42 0.7 Allowed Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 -179.09 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -110.77 -6.08 14.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.6 -0.941 . . . . 0.0 109.628 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.87 160.37 28.48 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.415 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 2.0 p -150.58 164.06 36.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.247 -1.149 . . . . 0.0 109.712 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.876 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -138.47 163.71 31.25 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.446 -0.783 . . . . 0.0 109.111 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 15.3 mt -122.9 150.35 43.03 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.173 -0.954 . . . . 0.0 109.939 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.109 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -132.43 160.43 36.44 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.436 -0.79 . . . . 0.0 109.885 -179.44 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.497 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -172.14 99.82 0.15 Allowed Glycine 0 N--CA 1.485 1.965 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.603 HG22 HD23 ' A' ' 10' ' ' LEU . 1.2 p -120.85 -172.42 2.38 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.137 -1.213 . . . . 0.0 110.167 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -151.01 145.31 25.46 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.056 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.2 OUTLIER -132.64 144.23 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 120.749 -1.219 . . . . 0.0 109.906 -179.502 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -107.69 85.88 2.2 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.919 HG21 ' HB3' ' A' ' 58' ' ' TYR . 75.6 t -70.46 132.46 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.279 -0.888 . . . . 0.0 110.118 -179.254 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -114.14 -162.96 0.84 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.018 -1.051 . . . . 0.0 109.479 179.734 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.873 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.812 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.79 139.68 30.22 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.77 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.6 mp -97.19 89.55 4.81 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.148 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.941 HG12 ' HD3' ' A' ' 13' ' ' PRO . 65.3 t -99.08 112.34 30.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.885 -1.134 . . . . 0.0 109.092 179.521 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.504 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -124.1 71.18 0.44 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.941 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.4 Cg_endo -73.64 150.4 45.22 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.803 2.336 . . . . 0.0 112.153 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.468 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.9 t-80 168.9 -38.87 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.681 0.753 . . . . 0.0 109.208 179.353 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.29 -138.05 14.56 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 -178.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.62 147.0 24.57 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 121.972 1.782 . . . . 0.0 109.166 178.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.953 HD21 ' HB2' ' A' ' 23' ' ' ALA . 2.7 mt -117.26 98.56 6.5 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.2 -0.937 . . . . 0.0 109.779 -179.301 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.09 165.66 14.98 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 t -60.85 114.74 3.22 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.243 -0.91 . . . . 0.0 109.272 -179.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.68 39.52 2.72 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.84 154.58 51.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.152 -1.205 . . . . 0.0 110.015 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.717 HD12 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -115.82 128.14 55.59 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.805 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.953 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -92.69 148.37 22.12 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.252 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.533 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -105.25 121.9 44.81 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.067 -1.645 . . . . 0.0 108.04 179.012 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.815 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 5.2 m-85 -105.39 170.53 7.83 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 121.914 0.864 . . . . 0.0 111.721 -177.009 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.709 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.72 140.14 3.84 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.793 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.999 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.6 mm -109.42 148.67 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.279 -0.888 . . . . 0.0 109.309 -178.345 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.644 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -133.33 122.6 24.07 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.989 -178.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.139 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 175.25 -61.86 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.078 -1.014 . . . . 0.0 109.552 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.139 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.3 Cg_endo -79.17 68.49 8.27 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.209 1.939 . . . . 0.0 109.699 179.551 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.634 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.0 OUTLIER -15.42 -64.03 0.03 OUTLIER Pre-proline 0 N--CA 1.506 2.327 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.83 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.634 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.4 Cg_endo -78.52 73.39 5.9 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 C-N-CA 121.774 1.65 . . . . 0.0 111.202 -179.513 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 30' ' ' PRO . 2.8 t -96.41 136.64 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.894 -1.129 . . . . 0.0 109.656 179.338 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.5 t -115.89 -15.33 11.25 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.48 -0.763 . . . . 0.0 109.331 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.6 149.43 0.48 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.311 -0.868 . . . . 0.0 109.667 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.624 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -136.93 139.68 41.73 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.59 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.61 ' O ' HG23 ' A' ' 69' ' ' VAL . 10.2 mtm-85 -93.33 109.04 20.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.138 -0.976 . . . . 0.0 109.136 179.657 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.977 ' CH2' HD11 ' A' ' 27' ' ' ILE . 18.7 m95 -93.85 179.81 5.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.918 -1.114 . . . . 0.0 109.621 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.489 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.76 106.61 3.41 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.328 -1.731 . . . . 0.0 106.328 177.369 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 1.014 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.7 m-30 -81.37 -66.44 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 118.451 -1.3 . . . . 0.0 111.37 -176.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.11 -4.91 59.03 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.1 p30 -90.41 23.71 2.86 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.335 -1.097 . . . . 0.0 109.164 179.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 122.56 -38.11 2.64 Favored Glycine 0 C--N 1.298 -1.576 0 N-CA-C 106.129 -2.788 . . . . 0.0 106.129 -176.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.77 101.52 12.96 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 177.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.489 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.38 -98.28 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 0.0 109.958 -178.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -56.92 150.1 17.33 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.286 0.565 . . . . 0.0 109.927 -179.588 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 1.014 HG21 ' CE1' ' A' ' 40' ' ' PHE . 70.8 t -138.9 132.97 40.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.47 -0.769 . . . . 0.0 110.591 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -112.89 89.8 3.18 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.283 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.686 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -92.84 152.53 19.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.373 -0.829 . . . . 0.0 111.423 -178.135 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.72 150.2 23.75 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.624 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.08 -156.4 0.49 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.24 -1.944 . . . . 0.0 108.24 -179.27 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.415 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.1 Cg_endo -88.43 42.63 0.7 Allowed 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.122 1.881 . . . . 0.0 110.479 178.436 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.686 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -146.87 144.38 29.24 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.072 -1.642 . . . . 0.0 112.009 -179.089 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 49' ' ' ALA . . . -149.54 -169.6 3.42 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.599 ' HB3' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -152.64 138.8 18.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.249 -0.907 . . . . 0.0 109.174 179.558 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.616 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 11.1 m80 -102.91 135.45 44.57 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.231 -0.918 . . . . 0.0 111.101 -178.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.439 ' H ' ' HG2' ' A' ' 57' ' ' ARG . 2.0 ptp180 -100.44 95.06 6.49 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 177.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.022 ' CE2' HG11 ' A' ' 83' ' ' VAL . 23.8 m-85 -95.5 120.24 35.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.225 -0.922 . . . . 0.0 109.232 -179.232 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.6 p -118.17 -29.71 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.241 -0.912 . . . . 0.0 111.165 -178.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.405 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -90.71 143.35 28.82 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 120.619 -1.3 . . . . 0.0 109.376 -179.678 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.405 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.0 Cg_endo -76.26 133.04 14.34 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.575 2.183 . . . . 0.0 110.281 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.59 -135.05 5.93 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 -179.616 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -127.27 164.51 21.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -1.193 . . . . 0.0 109.651 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.65 ' HB2' HG13 ' A' ' 83' ' ' VAL . 59.7 m-85 -142.98 152.84 42.39 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.466 -0.771 . . . . 0.0 109.205 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -112.99 130.37 56.16 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.575 HG13 ' CE1' ' A' ' 56' ' ' HIS . 59.2 t -116.0 150.58 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 110.821 -178.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.79 155.51 42.42 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.064 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.53 158.57 44.31 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.853 -1.155 . . . . 0.0 111.518 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -129.84 127.17 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.423 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 1.011 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.3 OUTLIER -89.07 141.87 28.12 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 120.656 -1.277 . . . . 0.0 109.015 -178.743 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.3 110.48 11.56 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.589 -1.245 . . . . 0.0 109.698 178.425 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.925 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.9 mp -105.49 -11.1 16.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.072 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.66 -49.62 0.83 Allowed Glycine 0 N--CA 1.486 2.011 0 N-CA-C 107.669 -2.173 . . . . 0.0 107.669 -178.128 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.44 -5.76 11.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.58 -0.953 . . . . 0.0 109.884 178.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -140.04 162.5 26.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.478 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.8 p -151.44 -179.23 7.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.306 -1.114 . . . . 0.0 109.579 -179.598 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 1.011 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -154.17 166.39 33.25 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.2 mt -119.93 132.75 55.62 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.068 -1.02 . . . . 0.0 110.227 -179.401 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.064 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -117.4 157.14 26.7 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.524 -0.735 . . . . 0.0 109.769 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.65 95.12 0.11 Allowed Glycine 0 N--CA 1.485 1.938 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.612 HG22 HD23 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -116.38 -173.33 2.35 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.232 -1.158 . . . . 0.0 109.937 179.932 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -150.74 153.7 36.0 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.435 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.022 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.0 154.25 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.66 -1.275 . . . . 0.0 109.845 -179.519 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . 0.425 ' N ' HG23 ' A' ' 83' ' ' VAL . 12.0 tt0 -123.07 99.81 6.56 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.464 -0.773 . . . . 0.0 108.985 179.073 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.778 HG21 ' HB3' ' A' ' 58' ' ' TYR . 41.6 t -86.15 137.71 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.24 -0.912 . . . . 0.0 109.846 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -113.15 154.41 26.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 -179.473 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.101 -0.999 . . . . 0.0 109.667 179.711 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.804 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.776 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -90.12 141.62 28.51 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.636 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.753 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.3 mp -98.01 97.96 9.36 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -178.188 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.968 HG12 ' HD3' ' A' ' 13' ' ' PRO . 47.2 t -109.69 115.92 50.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 120.875 -1.141 . . . . 0.0 109.189 179.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.524 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -125.67 68.68 0.51 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.968 ' HD3' HG12 ' A' ' 11' ' ' VAL . 36.7 Cg_endo -75.16 151.05 38.34 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 123.082 2.521 . . . . 0.0 112.655 -179.252 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.641 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 21.6 t60 162.61 -36.36 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.881 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.472 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.85 -138.6 14.93 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -179.377 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.8 151.74 28.31 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.42 2.08 . . . . 0.0 109.878 179.576 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.733 HD21 ' HB2' ' A' ' 23' ' ' ALA . 65.8 mt -120.87 99.74 6.69 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.113 -0.992 . . . . 0.0 109.917 -179.717 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.401 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -91.78 170.94 9.49 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.7 t -53.15 120.06 5.47 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.914 . . . . 0.0 109.818 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.74 48.3 4.5 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.472 ' HB3' ' CD2' ' A' ' 17' ' ' LEU . 1.6 mm-40 -115.78 143.81 44.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.432 -1.04 . . . . 0.0 110.449 -179.535 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.698 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.5 tm? -108.35 93.26 4.43 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.175 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.733 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -75.49 155.21 36.4 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.94 -1.1 . . . . 0.0 108.089 179.341 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.535 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.08 114.5 22.59 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.475 -1.39 . . . . 0.0 108.076 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.705 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 3.8 m-85 -100.15 174.65 6.05 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 122.135 0.969 . . . . 0.0 111.805 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.728 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -168.53 139.09 2.52 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 177.997 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 1.001 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.7 mm -107.95 149.33 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.37 -0.831 . . . . 0.0 109.063 -178.37 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.655 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -133.35 125.09 28.41 Favored 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 118.598 -1.241 . . . . 0.0 112.274 -178.572 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.089 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -179.8 -67.3 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 120.978 -1.076 . . . . 0.0 109.297 177.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.089 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.5 Cg_endo -79.89 69.58 7.88 Favored 'Trans proline' 0 C--N 1.314 -1.275 0 C-N-CA 121.944 1.763 . . . . 0.0 109.314 179.162 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.684 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -11.82 -66.21 0.02 OUTLIER Pre-proline 0 N--CA 1.51 2.546 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -178.707 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.684 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.6 Cg_endo -79.29 95.32 1.05 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 121.728 1.619 . . . . 0.0 110.424 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.497 HG22 ' HG2' ' A' ' 30' ' ' PRO . 5.1 t -118.06 145.01 24.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 120.866 -1.146 . . . . 0.0 109.565 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.2 t -113.15 -18.64 12.09 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.495 -0.753 . . . . 0.0 110.209 179.736 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.22 152.3 0.86 Allowed 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.049 -1.032 . . . . 0.0 110.456 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.689 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -139.05 137.04 35.9 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.428 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.472 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 4.8 ttp180 -92.78 114.2 26.69 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.07 -1.019 . . . . 0.0 108.838 179.512 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.992 ' CH2' HD11 ' A' ' 27' ' ' ILE . 15.6 m95 -97.68 -178.61 4.17 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 -179.8 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.425 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -151.37 101.99 2.87 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 177.34 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 1.013 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.9 m-30 -80.19 -61.33 2.01 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 118.756 -1.178 . . . . 0.0 110.267 -177.52 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.62 14.63 52.59 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.068 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.06 -103.05 0.25 Allowed 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -86.63 -17.15 60.58 Favored Glycine 0 C--N 1.297 -1.59 0 N-CA-C 108.05 -2.02 . . . . 0.0 108.05 176.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 17.0 p -135.8 129.26 32.21 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.308 -1.113 . . . . 0.0 109.309 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.425 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.34 -87.66 0.08 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.024 -1.048 . . . . 0.0 109.96 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -56.48 151.24 13.69 Favored 'General case' 0 N--CA 1.497 1.877 0 CA-C-O 121.358 0.599 . . . . 0.0 110.123 -179.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 1.013 HG21 ' CE1' ' A' ' 40' ' ' PHE . 61.5 t -140.14 134.44 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.287 -0.883 . . . . 0.0 111.019 -178.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -115.0 90.8 3.43 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 177.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.709 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -94.31 153.57 17.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.339 -0.85 . . . . 0.0 111.488 -177.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -89.33 150.52 22.54 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 179.283 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.689 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.84 -158.11 0.73 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 108.075 -2.01 . . . . 0.0 108.075 -179.188 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -87.69 41.0 0.65 Allowed 'Trans proline' 0 C--N 1.298 -2.101 0 C-N-CA 122.135 1.89 . . . . 0.0 110.013 178.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.709 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.25 147.55 32.52 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 120.232 -1.542 . . . . 0.0 111.891 -178.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.661 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -153.83 -169.56 3.31 Favored 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.698 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -151.87 145.24 24.77 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.135 -0.978 . . . . 0.0 109.184 179.433 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.696 ' O ' HD22 ' A' ' 22' ' ' LEU . 10.6 m80 -104.33 137.67 41.89 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.259 -0.901 . . . . 0.0 111.228 -178.762 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.415 HH21 HD21 ' A' ' 22' ' ' LEU . 0.7 OUTLIER -108.46 88.67 2.78 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.114 ' CE2' HG11 ' A' ' 83' ' ' VAL . 34.2 m-85 -92.06 118.39 30.76 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.237 -0.915 . . . . 0.0 109.602 -179.296 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.2 t -106.96 -28.94 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.411 -0.806 . . . . 0.0 111.089 -178.678 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.445 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -97.21 146.92 32.17 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 120.628 -1.295 . . . . 0.0 109.617 -179.364 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.639 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.6 Cg_endo -78.28 123.81 6.26 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 C-N-CA 122.473 2.116 . . . . 0.0 109.837 179.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 158.6 -159.68 30.4 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.631 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.445 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 15.1 mtp-105 -111.34 125.97 54.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.073 -1.251 . . . . 0.0 110.152 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.573 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 82.9 m-85 -108.75 157.92 18.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.34 -0.85 . . . . 0.0 109.481 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 72.1 t60 -112.81 126.99 56.04 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.526 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.589 HG22 ' NE2' ' A' ' 56' ' ' HIS . 84.3 t -107.62 150.06 10.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.099 -1.001 . . . . 0.0 110.675 -179.054 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.422 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 1.2 p -147.75 155.64 41.91 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.258 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.028 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -152.5 165.96 33.47 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.822 -1.174 . . . . 0.0 110.751 -179.674 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.462 HG12 ' HB3' ' A' ' 37' ' ' ARG . 8.3 p -141.81 130.6 22.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 107.197 -1.409 . . . . 0.0 107.197 178.315 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.995 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.16 140.7 29.22 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 120.947 -1.096 . . . . 0.0 108.821 -178.302 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.02 108.18 9.9 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 118.555 -1.258 . . . . 0.0 109.933 178.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.55 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -106.88 -9.66 16.26 Favored 'General case' 0 C--N 1.286 -2.188 0 CA-C-N 115.415 -0.811 . . . . 0.0 108.838 178.994 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 102.94 -48.39 1.04 Allowed Glycine 0 N--CA 1.487 2.057 0 N-CA-C 107.599 -2.2 . . . . 0.0 107.599 -178.19 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.04 -5.51 11.95 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.687 -0.89 . . . . 0.0 109.627 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -142.35 155.73 25.79 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 17.1 p -151.05 179.71 8.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.224 -1.162 . . . . 0.0 109.598 -179.533 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.995 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -156.02 170.41 22.23 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.458 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -124.31 136.39 54.08 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.107 -0.996 . . . . 0.0 109.906 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.028 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -119.5 158.44 26.27 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.566 -0.709 . . . . 0.0 109.711 -179.631 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.94 94.62 0.1 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.548 HG22 HD23 ' A' ' 10' ' ' LEU . 0.5 OUTLIER -115.03 -172.12 2.07 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.088 -1.242 . . . . 0.0 110.117 -179.878 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -150.64 148.37 28.53 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.114 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -132.95 153.66 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 120.842 -1.161 . . . . 0.0 109.972 -179.725 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . 0.427 ' N ' HG23 ' A' ' 83' ' ' VAL . 30.1 tt0 -122.57 89.29 3.09 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.309 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.822 HG21 ' HB3' ' A' ' 58' ' ' TYR . 92.9 t -79.63 143.56 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.253 -0.904 . . . . 0.0 109.82 -179.428 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -115.84 173.3 6.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.387 -0.821 . . . . 0.0 109.667 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.639 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.149 -0.969 . . . . 0.0 109.782 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.805 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.474 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.952 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.1 t -70.79 148.89 47.42 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.224 -0.923 . . . . 0.0 109.299 -179.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.758 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.6 mp -88.16 109.84 20.22 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.325 -178.312 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.585 ' HB ' ' CE1' ' A' ' 26' ' ' HIS . 1.2 t -126.21 103.91 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.01 -1.056 . . . . 0.0 108.863 178.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.583 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.8 80.52 0.3 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 -179.33 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.607 ' HD2' ' HA ' ' A' ' 25' ' ' PHE . 33.2 Cg_endo -73.07 146.65 41.67 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.612 2.208 . . . . 0.0 112.538 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.615 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 62.4 t60 164.62 171.09 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -93.31 -124.16 3.67 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 178.709 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.86 151.07 21.4 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.314 2.01 . . . . 0.0 109.938 179.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.826 ' HB3' HG22 ' A' ' 85' ' ' VAL . 22.1 mt -121.65 89.13 3.06 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.057 -1.027 . . . . 0.0 109.469 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -90.29 167.04 12.97 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 179.214 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.3 t -51.95 118.42 3.43 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.331 -0.855 . . . . 0.0 109.403 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.71 47.86 3.58 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.437 ' HB3' HD23 ' A' ' 17' ' ' LEU . 2.1 mm-40 -119.81 155.97 31.55 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.281 -1.129 . . . . 0.0 110.868 -179.396 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.786 HD11 ' HB2' ' A' ' 55' ' ' SER . 1.8 tm? -114.52 96.62 5.85 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.757 -0.589 . . . . 0.0 109.565 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.688 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -81.59 160.96 23.69 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 178.552 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.502 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -122.79 111.37 16.61 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.39 -1.444 . . . . 0.0 108.744 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.664 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 4.4 m-85 -100.7 166.38 10.91 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 122.172 0.987 . . . . 0.0 112.277 -177.176 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.585 ' CE1' ' HB ' ' A' ' 11' ' ' VAL . 7.5 p80 -163.45 151.77 13.65 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 176.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.906 HD11 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -114.51 160.94 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.0 -1.062 . . . . 0.0 108.884 -178.33 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.952 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -138.05 120.17 15.63 Favored 'General case' 0 N--CA 1.499 2.008 0 C-N-CA 118.453 -1.299 . . . . 0.0 112.653 -178.433 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.037 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 176.44 -72.1 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.228 -0.92 . . . . 0.0 108.963 177.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.037 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.9 Cg_endo -77.57 77.93 3.7 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 C-N-CA 121.569 1.513 . . . . 0.0 108.745 178.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.571 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 2.6 mp -33.3 -56.34 0.61 Allowed Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 122.127 -0.358 . . . . 0.0 111.631 -178.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.571 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.9 Cg_endo -80.62 75.96 4.77 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.165 1.91 . . . . 0.0 111.328 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.917 HG23 ' O ' ' A' ' 30' ' ' PRO . 36.8 t -103.46 148.53 8.34 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 120.984 -1.073 . . . . 0.0 109.098 179.102 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 15.4 t -113.59 -29.06 7.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.131 -0.981 . . . . 0.0 110.256 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -162.35 144.17 10.77 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.319 -0.863 . . . . 0.0 109.91 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.677 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -127.33 162.16 26.91 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 179.539 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.518 ' O ' HG23 ' A' ' 69' ' ' VAL . 13.1 mtp85 -123.89 103.12 8.15 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.906 ' CH2' HD11 ' A' ' 27' ' ' ILE . 35.1 m95 -88.55 179.94 6.18 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.05 -1.031 . . . . 0.0 109.837 -179.462 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.468 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -148.71 100.7 3.13 Favored 'General case' 0 C--N 1.291 -1.939 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 177.44 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.937 ' CE1' HG21 ' A' ' 47' ' ' VAL . 4.1 m-30 -80.27 -50.69 9.85 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 118.869 -1.132 . . . . 0.0 109.829 -177.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 80.27 21.77 64.25 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.535 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 1.2 p30 -106.96 -104.87 0.34 Allowed 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 178.483 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.88 -15.41 72.87 Favored Glycine 0 N--CA 1.48 1.607 0 N-CA-C 107.715 -2.154 . . . . 0.0 107.715 176.508 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -140.26 130.62 25.27 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.396 -1.061 . . . . 0.0 109.035 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.17 -85.48 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.956 -1.09 . . . . 0.0 109.624 -179.796 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -56.5 151.2 13.82 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-O 121.268 0.556 . . . . 0.0 109.878 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.937 HG21 ' CE1' ' A' ' 40' ' ' PHE . 61.6 t -139.28 125.02 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.428 -0.795 . . . . 0.0 110.737 -178.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -104.67 109.72 21.76 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.227 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.677 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -123.33 167.83 13.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.157 -0.964 . . . . 0.0 111.024 -178.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.64 153.34 17.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.68 -0.638 . . . . 0.0 109.641 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.576 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.33 -156.33 0.55 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -89.52 39.0 0.41 Allowed 'Trans proline' 0 C--N 1.297 -2.152 0 C-N-CA 122.484 2.123 . . . . 0.0 110.25 178.468 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.572 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -140.8 151.6 44.52 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 119.976 -1.703 . . . . 0.0 112.458 -178.368 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.657 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -172.2 153.24 3.0 Favored 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.029 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.786 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -109.84 161.09 15.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.939 -1.1 . . . . 0.0 110.237 -179.82 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.623 ' O ' HD22 ' A' ' 22' ' ' LEU . 2.9 m80 -109.24 134.04 52.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.457 -0.777 . . . . 0.0 110.298 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.688 ' NH2' HD21 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -110.8 92.13 3.93 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.924 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.126 ' CE2' HG11 ' A' ' 83' ' ' VAL . 22.0 m-85 -92.33 133.49 35.81 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.136 -0.978 . . . . 0.0 109.596 -179.39 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 53.6 t -117.86 -28.15 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.418 -0.801 . . . . 0.0 110.973 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.448 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -97.78 143.28 25.94 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 120.592 -1.317 . . . . 0.0 109.611 -179.545 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.905 ' CB ' ' HB2' ' A' ' 87' ' ' ALA . 36.0 Cg_endo -79.06 120.78 4.7 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.616 2.211 . . . . 0.0 110.152 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 159.08 -143.68 9.48 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 18.5 ttm-85 -112.39 154.26 26.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -1.171 . . . . 0.0 109.572 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.617 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 54.0 m-85 -139.1 167.52 21.88 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.526 -0.734 . . . . 0.0 109.06 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 65.6 t60 -125.84 144.59 50.59 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.615 HG13 ' CE1' ' A' ' 56' ' ' HIS . 39.1 t -126.97 148.63 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.09 -1.006 . . . . 0.0 110.751 -179.133 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.401 ' OG1' ' HB2' ' A' ' 39' ' ' ASP . 0.1 OUTLIER -150.24 161.12 43.05 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.605 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.04 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.48 157.55 43.39 Favored 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 119.182 -1.007 . . . . 0.0 110.92 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -145.81 106.03 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 179.16 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.843 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -87.62 143.27 27.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.652 -1.28 . . . . 0.0 109.288 -179.254 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.64 115.12 17.55 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.211 -0.996 . . . . 0.0 109.639 179.077 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.542 HD21 ' O ' ' A' ' 32' ' ' PRO . 9.1 mt -105.88 -12.62 15.78 Favored 'General case' 0 C--N 1.289 -2.058 0 CA-C-O 121.526 0.679 . . . . 0.0 109.215 179.437 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.42 -47.32 1.05 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -178.714 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.23 -5.82 11.85 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.581 -0.952 . . . . 0.0 109.801 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -146.19 154.67 26.1 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.405 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 18.4 p -150.62 174.23 13.23 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.177 -1.19 . . . . 0.0 109.675 -179.586 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.843 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -151.81 134.59 15.59 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.182 -0.949 . . . . 0.0 109.397 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -99.69 143.01 30.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.252 -0.905 . . . . 0.0 110.311 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.04 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -127.53 157.91 38.85 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 121.662 -0.649 . . . . 0.0 109.966 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.03 84.59 0.1 Allowed Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.537 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -103.2 178.01 4.68 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.204 -1.174 . . . . 0.0 110.055 -179.766 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -121.43 157.78 29.81 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.31 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.126 HG11 ' CE2' ' A' ' 58' ' ' TYR . 16.4 t -137.45 143.39 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 120.997 -1.064 . . . . 0.0 110.264 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -132.69 101.77 5.42 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.467 -0.77 . . . . 0.0 109.27 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.826 HG22 ' HB3' ' A' ' 17' ' ' LEU . 79.5 t -103.52 140.52 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.333 -0.855 . . . . 0.0 109.714 -179.473 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -104.9 -174.71 2.6 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.158 -0.964 . . . . 0.0 109.872 -179.479 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.905 ' HB2' ' CB ' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.158 -0.963 . . . . 0.0 109.848 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.793 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.389 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.755 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.15 141.72 28.34 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.693 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.728 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.8 mp -97.88 91.24 5.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 -178.121 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.929 HG12 ' HD3' ' A' ' 13' ' ' PRO . 57.0 t -101.14 117.76 46.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.953 -1.092 . . . . 0.0 108.653 179.171 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.461 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -125.08 72.6 0.43 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.588 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.929 ' HD3' HG12 ' A' ' 11' ' ' VAL . 32.7 Cg_endo -73.01 147.97 44.25 Favored 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.701 2.267 . . . . 0.0 111.758 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.514 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 23.6 t-80 157.52 -33.86 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.791 0 CA-C-N 115.442 -0.799 . . . . 0.0 108.965 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.95 -143.35 15.63 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.123 -1.991 . . . . 0.0 108.123 -179.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -77.16 147.79 26.64 Favored 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.049 1.833 . . . . 0.0 108.947 179.032 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 1.088 HD21 ' HB2' ' A' ' 23' ' ' ALA . 5.6 mt -112.27 110.63 20.98 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.201 -0.937 . . . . 0.0 109.89 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -93.09 168.61 11.0 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 179.214 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.6 t -60.83 122.16 14.14 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.209 -0.932 . . . . 0.0 109.456 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.91 47.42 4.78 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.0 mm100 -125.62 157.89 36.05 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.252 -1.146 . . . . 0.0 110.934 -179.515 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.742 HD22 ' O ' ' A' ' 56' ' ' HIS . 1.8 tm? -113.27 103.58 11.46 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 1.088 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -85.61 156.22 20.8 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.49 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.51 107.7 13.18 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.506 -1.371 . . . . 0.0 108.63 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.768 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 1.9 m-85 -95.36 168.78 10.51 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 121.976 0.893 . . . . 0.0 111.779 -177.53 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.737 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -163.72 141.21 7.28 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.502 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.995 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.9 mm -108.01 152.5 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.292 -0.88 . . . . 0.0 109.435 -178.216 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.637 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -135.28 121.7 20.5 Favored 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.781 -1.168 . . . . 0.0 112.133 -179.045 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.034 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -177.72 -66.34 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.002 -1.061 . . . . 0.0 109.222 177.721 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.034 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.3 Cg_endo -81.72 61.7 8.02 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 C-N-CA 122.129 1.886 . . . . 0.0 109.15 178.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.672 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.1 mp -8.81 -67.09 0.01 OUTLIER Pre-proline 0 N--CA 1.508 2.45 0 N-CA-C 113.299 0.851 . . . . 0.0 113.299 -178.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.672 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.3 Cg_endo -77.72 68.42 7.67 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 121.892 1.728 . . . . 0.0 111.076 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.684 HG22 ' HG2' ' A' ' 30' ' ' PRO . 3.4 t -91.22 148.06 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 120.757 -1.214 . . . . 0.0 109.875 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.9 p -114.28 -18.11 11.67 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.603 -0.686 . . . . 0.0 110.045 179.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.95 152.53 0.75 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.26 -0.9 . . . . 0.0 110.284 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.689 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -140.7 140.66 34.94 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.318 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.649 ' O ' HG23 ' A' ' 69' ' ' VAL . 18.3 mtm-85 -93.74 107.35 19.24 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.101 -0.999 . . . . 0.0 109.369 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.972 ' CH2' HD11 ' A' ' 27' ' ' ILE . 22.8 m95 -90.73 179.56 5.77 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.212 -0.93 . . . . 0.0 109.502 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.421 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.95 102.3 2.96 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 177.36 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.996 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.4 m-30 -80.37 -59.66 2.61 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 118.853 -1.139 . . . . 0.0 110.086 -177.722 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.03 20.06 40.63 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -107.15 -104.52 0.34 Allowed 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.619 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.91 -19.69 62.69 Favored Glycine 0 C--N 1.296 -1.67 0 N-CA-C 107.749 -2.141 . . . . 0.0 107.749 176.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 11.0 p -135.22 130.4 35.21 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.427 -1.043 . . . . 0.0 109.3 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.36 -86.65 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.115 -0.991 . . . . 0.0 109.936 -179.658 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -57.62 152.84 14.32 Favored 'General case' 0 N--CA 1.497 1.89 0 CA-C-O 121.176 0.512 . . . . 0.0 110.112 -179.618 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.996 HG21 ' CE1' ' A' ' 40' ' ' PHE . 34.3 t -140.99 126.96 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.416 -0.803 . . . . 0.0 111.242 -178.745 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -105.44 91.78 3.92 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.345 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.8 ' CB ' ' HB2' ' A' ' 54' ' ' ALA . . . -96.03 154.97 16.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.244 -0.91 . . . . 0.0 111.677 -177.624 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.84 153.18 19.0 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.689 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.26 -158.23 0.55 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 108.248 -1.941 . . . . 0.0 108.248 -179.229 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.402 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.2 Cg_endo -88.37 40.03 0.54 Allowed 'Trans proline' 0 C--N 1.297 -2.157 0 C-N-CA 122.029 1.819 . . . . 0.0 109.932 178.118 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.657 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.27 152.02 39.28 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 120.096 -1.628 . . . . 0.0 112.187 -178.651 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.8 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -165.12 155.91 14.15 Favored 'General case' 0 N--CA 1.498 1.941 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.654 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -114.41 160.71 18.84 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.932 -1.105 . . . . 0.0 110.192 -179.883 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.742 ' O ' HD22 ' A' ' 22' ' ' LEU . 5.8 m80 -114.54 139.34 49.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.538 -0.726 . . . . 0.0 110.489 -179.15 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.484 HH21 HD21 ' A' ' 22' ' ' LEU . 0.7 OUTLIER -111.89 95.64 5.6 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 178.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.086 ' CE2' HG11 ' A' ' 83' ' ' VAL . 36.3 m-85 -99.02 129.86 45.32 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.161 -0.962 . . . . 0.0 109.432 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.7 t -117.91 -27.89 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.352 -0.842 . . . . 0.0 111.25 -178.433 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.486 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -99.51 146.39 31.71 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 120.511 -1.368 . . . . 0.0 109.596 -179.381 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.486 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 34.8 Cg_endo -77.73 124.42 6.89 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.404 2.069 . . . . 0.0 109.888 179.352 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 160.81 -151.78 22.31 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.609 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.409 ' HG2' ' HA ' ' A' ' 84' ' ' GLN . 0.0 OUTLIER -122.17 120.11 33.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.113 -1.228 . . . . 0.0 109.82 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.558 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 81.6 m-85 -103.6 153.64 20.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.353 -0.842 . . . . 0.0 109.541 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.9 t60 -107.89 132.51 53.38 Favored 'General case' 0 N--CA 1.488 1.475 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.529 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 90.7 t -113.42 150.82 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 110.569 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.406 ' OG1' ' HB2' ' A' ' 39' ' ' ASP . 6.0 p -147.54 156.43 42.83 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.096 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.94 156.09 41.14 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.855 -1.153 . . . . 0.0 111.186 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.649 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -128.49 125.82 64.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 178.502 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.999 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.2 OUTLIER -87.76 144.58 26.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 120.535 -1.353 . . . . 0.0 109.007 -178.865 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.21 106.7 7.72 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 118.783 -1.167 . . . . 0.0 109.627 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.562 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -103.62 -10.62 18.28 Favored 'General case' 0 C--N 1.284 -2.28 0 CA-C-N 115.317 -0.856 . . . . 0.0 108.697 179.055 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.81 -47.27 1.07 Allowed Glycine 0 N--CA 1.488 2.125 0 N-CA-C 107.627 -2.189 . . . . 0.0 107.627 -178.416 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.31 -5.09 11.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.741 -0.858 . . . . 0.0 109.68 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.55 158.4 27.52 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.726 -1.349 . . . . 0.0 109.726 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.435 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 25.7 p -148.03 -177.71 5.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.364 -1.08 . . . . 0.0 109.405 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.999 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -156.55 162.69 39.9 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.8 mp -116.8 132.38 56.71 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.065 -1.022 . . . . 0.0 109.976 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.096 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -116.46 157.36 25.29 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.548 -0.72 . . . . 0.0 109.497 -179.752 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.529 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -168.24 96.3 0.12 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.553 HG22 HD23 ' A' ' 10' ' ' LEU . 0.7 OUTLIER -116.34 -171.74 2.05 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.044 -1.268 . . . . 0.0 109.732 179.791 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -151.55 147.63 27.03 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.408 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.086 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -131.77 138.44 52.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 120.68 -1.262 . . . . 0.0 110.018 -179.466 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . 0.409 ' HA ' ' HG2' ' A' ' 63' ' ' ARG . 30.9 tt0 -105.22 90.47 3.44 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 178.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.781 HG21 ' HB3' ' A' ' 58' ' ' TYR . 52.9 t -76.54 130.92 35.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.307 -0.871 . . . . 0.0 109.352 -179.575 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -114.46 144.16 43.77 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.467 -0.771 . . . . 0.0 109.768 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.241 -0.912 . . . . 0.0 109.301 179.676 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.919 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.974 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.1 t -94.26 147.23 23.39 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.3 mp -91.99 88.83 6.73 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.162 -178.215 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.801 HG11 ' CE1' ' A' ' 26' ' ' HIS . 22.1 t -97.76 100.15 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 120.702 -1.249 . . . . 0.0 108.561 178.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -117.96 78.73 0.3 Allowed Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.276 -179.304 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.551 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.1 Cg_endo -74.99 148.11 34.88 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.404 2.069 . . . . 0.0 111.635 179.412 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.524 ' ND1' ' HB1' ' A' ' 23' ' ' ALA . 3.3 p-80 174.35 162.01 0.19 Allowed 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.5 -130.0 1.36 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 179.354 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -78.87 147.3 21.36 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 C-N-CA 121.978 1.786 . . . . 0.0 109.145 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.767 HD13 ' HB3' ' A' ' 21' ' ' GLN . 0.4 OUTLIER -113.41 84.21 1.97 Allowed 'General case' 0 C--N 1.298 -1.671 0 O-C-N 121.194 -0.941 . . . . 0.0 109.046 -179.815 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.462 ' HB3' ' OE1' ' A' ' 21' ' ' GLN . . . -95.53 168.16 10.86 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 39.0 t -56.71 108.52 0.51 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.294 -0.879 . . . . 0.0 109.521 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.94 37.67 2.49 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.767 ' HB3' HD13 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -128.21 154.42 45.85 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.227 -1.161 . . . . 0.0 109.79 -179.972 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.835 HD11 ' HB2' ' A' ' 55' ' ' SER . 0.1 OUTLIER -118.66 130.01 55.61 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.118 -0.988 . . . . 0.0 109.662 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.801 ' HB3' ' HE1' ' A' ' 25' ' ' PHE . . . -94.92 146.01 24.53 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.014 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.519 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -101.82 129.6 48.07 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 119.978 -1.701 . . . . 0.0 108.014 178.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.801 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 16.6 m-85 -112.22 166.39 11.31 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 121.959 0.885 . . . . 0.0 111.942 -176.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.801 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -164.5 134.41 3.92 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 178.22 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.885 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.4 OUTLIER -103.38 149.43 7.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.17 -0.956 . . . . 0.0 109.036 -178.437 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.974 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -133.73 124.31 26.44 Favored 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.545 -1.262 . . . . 0.0 112.225 -178.856 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.046 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 179.15 -66.38 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 121.118 -0.989 . . . . 0.0 109.199 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.046 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.4 Cg_endo -80.51 68.64 8.25 Favored 'Trans proline' 0 C--N 1.314 -1.281 0 C-N-CA 121.983 1.788 . . . . 0.0 109.102 178.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.679 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -10.81 -66.52 0.01 OUTLIER Pre-proline 0 N--CA 1.507 2.42 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -178.664 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.679 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 37.0 Cg_endo -79.58 83.86 2.16 Favored 'Trans proline' 0 C--N 1.314 -1.257 0 C-N-CA 121.667 1.578 . . . . 0.0 111.001 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.625 HG22 ' HG2' ' A' ' 30' ' ' PRO . 6.3 t -106.12 143.22 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.836 -1.165 . . . . 0.0 109.384 179.365 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.5 t -118.62 -14.18 9.61 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.406 -0.809 . . . . 0.0 110.412 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -174.2 146.82 1.16 Allowed 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.898 -1.126 . . . . 0.0 110.532 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.671 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.4 OUTLIER -142.96 136.94 29.02 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.69 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.573 ' HB2' HG12 ' A' ' 69' ' ' VAL . 7.5 mtm180 -94.28 112.36 24.15 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.19 -0.944 . . . . 0.0 108.872 179.448 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.727 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 18.6 m95 -94.32 -177.09 4.16 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.898 0.856 . . . . 0.0 109.079 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.442 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -151.39 103.77 3.02 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 106.282 -1.748 . . . . 0.0 106.282 177.424 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 1.003 ' CE1' HG21 ' A' ' 47' ' ' VAL . 4.1 m-30 -80.04 -63.65 1.36 Allowed 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.822 -1.151 . . . . 0.0 110.31 -177.586 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.26 9.32 55.68 Favored Glycine 0 N--CA 1.486 1.974 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -178.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -93.47 -101.72 0.13 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 178.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -89.02 -28.92 19.38 Favored Glycine 0 C--N 1.293 -1.826 0 N-CA-C 107.507 -2.237 . . . . 0.0 107.507 177.056 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.31 130.26 55.93 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.546 -0.973 . . . . 0.0 109.38 179.438 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.442 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.3 -85.02 0.1 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.202 -0.936 . . . . 0.0 109.541 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -59.77 155.26 16.39 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.265 0.555 . . . . 0.0 110.065 -179.775 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 1.003 HG21 ' CE1' ' A' ' 40' ' ' PHE . 60.6 t -142.01 136.16 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.469 -0.769 . . . . 0.0 111.076 -178.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -116.16 93.2 4.14 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 177.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.672 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -96.35 150.13 20.92 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.359 -0.838 . . . . 0.0 111.661 -177.841 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.69 146.71 27.3 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.671 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.73 -159.16 0.58 Allowed Glycine 0 N--CA 1.492 2.385 0 N-CA-C 107.91 -2.076 . . . . 0.0 107.91 -179.03 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -86.55 41.6 0.82 Allowed 'Trans proline' 0 C--N 1.299 -2.049 0 C-N-CA 121.909 1.739 . . . . 0.0 110.12 178.253 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.672 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -144.07 141.01 29.82 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.314 -1.491 . . . . 0.0 111.65 -178.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.632 ' HB2' ' HB2' ' A' ' 49' ' ' ALA . . . -146.26 -166.16 2.4 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.03 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.835 ' HB2' HD11 ' A' ' 22' ' ' LEU . 5.4 p -156.38 136.45 12.79 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.364 -0.835 . . . . 0.0 108.919 179.391 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.655 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 9.4 m80 -99.46 131.62 45.34 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.291 -0.881 . . . . 0.0 111.329 -178.26 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.404 ' H ' ' HG2' ' A' ' 57' ' ' ARG . 6.7 ptp180 -97.08 96.06 8.2 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 178.23 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.107 ' CE2' HG11 ' A' ' 83' ' ' VAL . 16.6 m-85 -100.1 105.16 16.76 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.905 -1.122 . . . . 0.0 109.547 -179.086 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.0 m -107.73 -9.32 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.488 -0.758 . . . . 0.0 111.292 -178.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.48 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -105.83 145.86 31.72 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 120.46 -1.4 . . . . 0.0 109.462 -179.818 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 1.036 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.5 Cg_endo -77.56 123.78 6.65 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.614 2.209 . . . . 0.0 110.133 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 150.37 -142.97 10.12 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 -179.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.26 158.54 37.87 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.204 -1.174 . . . . 0.0 109.475 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.655 ' HB2' HG13 ' A' ' 83' ' ' VAL . 92.5 m-85 -135.78 155.46 50.33 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.307 -0.87 . . . . 0.0 109.683 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.403 ' CD2' HG22 ' A' ' 67' ' ' THR . 9.8 t60 -111.46 114.31 27.33 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.034 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.648 HG13 ' NE2' ' A' ' 56' ' ' HIS . 62.7 t -95.06 150.64 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.228 -0.92 . . . . 0.0 110.527 -178.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.43 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.8 OUTLIER -146.42 157.96 43.83 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.388 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.018 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -156.36 164.57 38.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.603 -1.311 . . . . 0.0 111.224 -179.457 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.573 HG12 ' HB2' ' A' ' 37' ' ' ARG . 9.8 p -142.16 127.29 17.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 178.427 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 1.054 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.2 142.23 27.92 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.932 -1.105 . . . . 0.0 108.769 -178.471 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -131.41 106.23 8.11 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.551 -1.26 . . . . 0.0 109.949 178.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.638 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -104.6 -9.82 18.0 Favored 'General case' 0 C--N 1.284 -2.261 0 CA-C-N 115.218 -0.901 . . . . 0.0 108.701 178.937 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.11 -48.52 0.97 Allowed Glycine 0 N--CA 1.487 2.094 0 N-CA-C 107.776 -2.13 . . . . 0.0 107.776 -178.457 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.59 -5.52 11.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.633 -0.922 . . . . 0.0 109.61 179.089 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.94 156.66 26.07 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.406 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 22.0 p -150.38 -178.65 6.65 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.304 -1.115 . . . . 0.0 109.421 -179.542 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 1.054 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -158.98 141.4 14.03 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.36 -0.837 . . . . 0.0 108.744 179.577 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -99.85 135.37 41.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.984 -1.073 . . . . 0.0 110.101 -179.211 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.018 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -119.82 156.91 29.75 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.492 -0.755 . . . . 0.0 110.026 -179.569 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.52 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.46 89.73 0.1 Allowed Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.743 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -107.49 -172.7 2.12 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.991 -1.3 . . . . 0.0 110.267 -179.571 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -150.72 146.28 26.34 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.107 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -131.2 157.59 43.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.856 -1.152 . . . . 0.0 109.93 -179.702 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . 0.491 ' N ' HG23 ' A' ' 83' ' ' VAL . 8.1 mt-30 -130.45 92.14 3.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.595 -0.691 . . . . 0.0 109.165 179.466 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.758 HG22 ' HB3' ' A' ' 17' ' ' LEU . 40.9 t -86.58 141.92 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.253 -0.904 . . . . 0.0 109.734 -179.663 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -108.34 175.69 5.38 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.29 -0.881 . . . . 0.0 110.309 -179.29 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 1.036 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.659 0 O-C-N 121.347 -0.846 . . . . 0.0 109.693 179.5 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.714 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.943 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.6 t -74.95 150.73 38.97 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.13 -0.982 . . . . 0.0 109.408 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.753 HD23 HG22 ' A' ' 81' ' ' THR . 5.3 mp -87.15 105.6 17.31 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.977 -178.636 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.821 HG11 ' CE1' ' A' ' 26' ' ' HIS . 2.3 t -119.36 91.6 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.976 -1.078 . . . . 0.0 109.009 178.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.715 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -113.7 81.14 0.29 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.492 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.54 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.5 Cg_endo -73.34 149.04 44.45 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.662 2.242 . . . . 0.0 111.92 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.599 ' CD2' HD22 ' A' ' 17' ' ' LEU . 45.6 t60 166.96 -39.13 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.49 -138.86 14.76 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.057 -2.017 . . . . 0.0 108.057 -178.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -77.42 147.65 25.75 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 C-N-CA 122.096 1.864 . . . . 0.0 109.043 178.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.839 HD21 ' HB2' ' A' ' 23' ' ' ALA . 0.2 OUTLIER -106.31 109.84 21.9 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.098 -1.001 . . . . 0.0 109.721 -179.285 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.602 ' HB3' ' HG3' ' A' ' 21' ' ' GLN . . . -92.34 153.35 19.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 179.269 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.0 t -59.29 111.08 1.23 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -0.875 . . . . 0.0 109.37 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.47 35.44 3.09 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLN . . . . . 0.602 ' HG3' ' HB3' ' A' ' 18' ' ' ALA . 13.6 mm100 -133.65 160.54 37.23 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.192 -1.181 . . . . 0.0 109.88 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.708 HD12 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -117.06 126.66 53.2 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.186 -0.946 . . . . 0.0 109.414 179.672 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.839 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -90.06 145.42 25.08 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.084 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.54 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -99.89 129.78 46.01 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 119.918 -1.739 . . . . 0.0 108.165 179.111 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.816 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 16.8 m-85 -113.88 163.26 15.32 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 122.102 0.954 . . . . 0.0 111.977 -177.335 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . 0.821 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -165.9 139.77 4.43 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.079 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.828 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.31 154.69 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.868 -1.145 . . . . 0.0 108.777 -178.331 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.943 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -133.87 123.43 24.73 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 120.693 -1.255 . . . . 0.0 112.732 -178.08 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 1.041 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 171.45 -69.22 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.399 -0.813 . . . . 0.0 109.305 177.659 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 1.041 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -76.66 78.7 3.26 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 121.796 1.664 . . . . 0.0 109.486 179.198 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.709 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 6.0 mt -34.05 -53.82 0.86 Allowed Pre-proline 0 N--CA 1.504 2.251 0 O-C-N 121.944 -0.472 . . . . 0.0 111.703 -178.792 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' PRO . . . . . 0.709 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 36.8 Cg_endo -81.3 63.12 8.61 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 C-N-CA 122.077 1.851 . . . . 0.0 112.198 -179.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.918 HG23 ' O ' ' A' ' 30' ' ' PRO . 74.4 t -87.59 148.02 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 120.595 -1.316 . . . . 0.0 109.696 179.118 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 70.7 p -119.53 -35.82 3.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.422 -0.798 . . . . 0.0 109.665 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -155.13 144.37 21.04 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.461 -0.774 . . . . 0.0 109.007 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.929 HG23 ' HB3' ' A' ' 49' ' ' ALA . 0.5 OUTLIER -129.29 156.44 44.0 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.976 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.49 ' O ' HG23 ' A' ' 69' ' ' VAL . 49.1 mtp85 -119.51 101.06 7.67 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 109.044 179.82 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.783 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 30.3 m95 -89.24 178.77 6.27 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.123 -0.985 . . . . 0.0 109.476 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . 0.457 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.51 101.58 2.97 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 177.49 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 1.004 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.9 m-30 -79.75 -61.26 2.05 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.989 -177.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.77 15.86 47.68 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -178.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.27 -104.52 0.27 Allowed 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 178.607 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.31 -20.28 59.09 Favored Glycine 0 C--N 1.296 -1.649 0 N-CA-C 107.708 -2.157 . . . . 0.0 107.708 177.028 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 m -132.58 127.59 35.35 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.432 -1.04 . . . . 0.0 109.304 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.457 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.89 -85.96 0.09 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.17 -0.956 . . . . 0.0 109.72 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -57.73 153.37 13.69 Favored 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 121.112 0.482 . . . . 0.0 109.71 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 1.004 HG21 ' CE1' ' A' ' 40' ' ' PHE . 57.7 t -140.16 124.12 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.384 -0.823 . . . . 0.0 111.1 -178.445 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -104.61 99.47 9.14 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.074 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.929 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -109.91 167.8 9.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.203 -0.936 . . . . 0.0 111.02 -178.596 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.97 151.94 21.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.715 -0.615 . . . . 0.0 109.352 179.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.555 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.92 -155.2 0.58 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -89.06 41.63 0.57 Allowed 'Trans proline' 0 C--N 1.295 -2.255 0 C-N-CA 122.272 1.981 . . . . 0.0 110.515 178.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.652 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.58 154.02 43.14 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.928 -1.733 . . . . 0.0 112.602 -178.716 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.434 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -166.56 -171.17 1.81 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.074 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.646 ' HB3' HD11 ' A' ' 22' ' ' LEU . 0.3 OUTLIER -150.45 143.25 24.65 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.116 -0.99 . . . . 0.0 109.263 179.449 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' HIS . . . . . 0.629 ' NE2' HG22 ' A' ' 66' ' ' VAL . 7.3 m80 -102.41 134.64 45.4 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.197 -0.94 . . . . 0.0 111.515 -178.686 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.15 95.47 6.57 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.331 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 1.119 ' CE2' HG11 ' A' ' 83' ' ' VAL . 18.6 m-85 -102.58 112.84 25.77 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.079 -1.013 . . . . 0.0 109.403 -179.285 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.6 p -110.85 -10.56 11.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.417 -0.802 . . . . 0.0 111.525 -178.515 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.479 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -114.73 146.14 35.4 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 120.478 -1.389 . . . . 0.0 109.673 -179.743 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.479 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.1 Cg_endo -77.06 122.85 6.41 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.403 2.069 . . . . 0.0 109.935 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 161.77 -157.05 28.73 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.607 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.425 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -116.93 121.2 40.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.144 -1.21 . . . . 0.0 109.771 -179.824 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.6 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 90.3 m-85 -103.71 155.95 18.18 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.314 -0.867 . . . . 0.0 109.315 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 80.8 t60 -111.94 123.34 50.04 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.045 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.629 HG22 ' NE2' ' A' ' 56' ' ' HIS . 62.4 t -106.22 150.5 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.163 -0.961 . . . . 0.0 110.594 -178.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.53 159.56 44.2 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 178.664 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 1.06 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -151.09 154.52 37.13 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.939 -1.101 . . . . 0.0 110.921 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -144.75 104.3 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.102 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.821 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.74 150.73 22.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.757 -1.215 . . . . 0.0 110.204 -178.663 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.99 116.16 18.91 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.826 0.822 . . . . 0.0 108.937 178.453 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.916 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.6 mp -104.36 -12.96 16.29 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-O 121.508 0.671 . . . . 0.0 109.212 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.74 -53.75 0.62 Allowed Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.135 -1.986 . . . . 0.0 108.135 -178.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.71 -5.33 12.13 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.584 -0.95 . . . . 0.0 109.777 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.43 161.4 26.95 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.419 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 3.4 p -150.87 170.36 19.47 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.371 -1.076 . . . . 0.0 109.359 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.821 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -143.42 128.75 18.88 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.245 -0.91 . . . . 0.0 109.57 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.3 tp -95.11 140.79 29.55 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.471 -0.768 . . . . 0.0 110.029 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 1.06 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -128.72 157.52 41.15 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.604 -0.685 . . . . 0.0 109.919 -179.464 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -164.88 86.48 0.1 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 179.589 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.753 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -104.34 -176.32 3.05 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.122 -1.222 . . . . 0.0 109.762 -179.854 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -150.76 147.53 27.42 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.119 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -131.83 149.78 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 O-C-N 120.768 -1.208 . . . . 0.0 109.618 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -119.22 87.46 2.74 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.681 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.773 HG21 ' HB3' ' A' ' 58' ' ' TYR . 84.5 t -75.01 134.84 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.312 -0.867 . . . . 0.0 109.815 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 -109.26 177.52 4.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.363 -0.835 . . . . 0.0 109.591 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.364 -0.835 . . . . 0.0 109.515 179.874 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.955 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.393 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.711 ' CG2' ' HB3' ' A' ' 28' ' ' ALA . 0.5 OUTLIER -81.49 144.66 31.19 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.214 -0.929 . . . . 0.0 108.95 -179.456 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.779 HD23 HG22 ' A' ' 81' ' ' THR . 5.8 mp -94.27 86.7 5.0 Favored 'General case' 0 C--N 1.301 -1.503 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.215 -178.164 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.842 HG11 ' CE1' ' A' ' 26' ' ' HIS . 32.9 t -94.88 102.39 13.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 O-C-N 120.873 -1.142 . . . . 0.0 108.386 178.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.505 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.95 76.72 0.28 Allowed Glycine 0 N--CA 1.488 2.113 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.038 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.691 ' HD3' HG12 ' A' ' 11' ' ' VAL . 31.4 Cg_endo -71.73 146.85 49.48 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.438 2.092 . . . . 0.0 111.401 179.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 174.51 164.17 0.22 Allowed 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 -179.664 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -89.29 -125.91 2.77 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 107.363 -2.295 . . . . 0.0 107.363 178.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -80.06 147.06 18.52 Favored 'Trans proline' 0 C--N 1.302 -1.875 0 C-N-CA 121.839 1.693 . . . . 0.0 108.293 177.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.73 HD12 HG22 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -114.15 80.13 1.35 Allowed 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.922 -1.111 . . . . 0.0 109.158 -179.633 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -91.61 172.29 8.6 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.2 t -59.39 117.85 5.31 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.2 -0.938 . . . . 0.0 109.325 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 93.81 46.71 3.09 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.643 ' HB3' HD13 ' A' ' 17' ' ' LEU . 0.0 OUTLIER -122.27 152.27 40.22 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.386 -1.067 . . . . 0.0 110.559 -179.627 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.661 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.0 tm? -109.99 94.58 5.09 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.739 -0.6 . . . . 0.0 109.65 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.713 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -75.66 158.9 31.76 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.502 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -124.71 117.81 25.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.463 -1.398 . . . . 0.0 108.573 179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.804 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.8 m-85 -105.55 170.96 7.59 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 122.085 0.945 . . . . 0.0 111.828 -177.318 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.842 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.8 138.98 3.51 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 178.105 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.793 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.3 OUTLIER -105.32 152.52 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.085 -1.009 . . . . 0.0 109.47 -178.276 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.711 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -134.66 116.83 15.4 Favored 'General case' 0 N--CA 1.5 2.046 0 C-N-CA 118.823 -1.151 . . . . 0.0 111.644 -179.292 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.112 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 176.56 -62.26 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.915 0 O-C-N 121.076 -1.015 . . . . 0.0 109.952 178.173 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.112 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.4 Cg_endo -80.11 63.55 8.76 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 122.32 2.013 . . . . 0.0 109.711 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.64 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -13.13 -64.58 0.02 OUTLIER Pre-proline 0 N--CA 1.504 2.266 0 N-CA-C 113.296 0.85 . . . . 0.0 113.296 -178.902 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.64 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.2 Cg_endo -77.69 72.5 6.05 Favored 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 121.724 1.616 . . . . 0.0 111.282 -179.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.483 ' CG2' ' O ' ' A' ' 30' ' ' PRO . 2.7 t -98.77 127.26 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.996 -1.065 . . . . 0.0 109.341 179.122 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 p -111.21 -14.87 13.77 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.417 -0.802 . . . . 0.0 109.219 178.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -163.46 148.34 11.02 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.224 -0.922 . . . . 0.0 109.824 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.935 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.4 t -140.38 162.66 34.78 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.554 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -127.31 100.5 6.08 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.101 -0.999 . . . . 0.0 109.217 179.586 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.804 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 36.4 m95 -87.59 179.02 6.61 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.218 -0.926 . . . . 0.0 109.453 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.466 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.3 OUTLIER -146.84 103.14 3.6 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.862 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.981 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.5 m-30 -81.16 -59.1 2.77 Favored 'General case' 0 N--CA 1.489 1.52 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.314 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.28 8.48 68.44 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.518 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 10.4 p30 -98.49 35.7 1.76 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.372 -1.075 . . . . 0.0 108.111 179.295 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 108.33 -38.35 3.37 Favored Glycine 0 N--CA 1.483 1.785 0 N-CA-C 105.356 -3.098 . . . . 0.0 105.356 -175.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 74.6 m -101.86 95.06 6.14 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 177.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.466 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.2 -90.7 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -0.919 . . . . 0.0 110.151 -178.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -55.9 146.81 20.97 Favored 'General case' 0 N--CA 1.493 1.688 0 CA-C-O 121.251 0.548 . . . . 0.0 109.758 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.981 HG21 ' CE1' ' A' ' 40' ' ' PHE . 63.8 t -135.01 106.36 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.377 -0.827 . . . . 0.0 110.972 -178.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.8 94.12 9.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.988 -1.07 . . . . 0.0 108.211 178.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.935 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -101.65 166.6 10.6 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.258 -0.901 . . . . 0.0 110.801 -178.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.61 150.09 21.53 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.725 -0.61 . . . . 0.0 109.595 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.541 ' O ' HG22 ' A' ' 36' ' ' THR . . . 44.14 -153.26 0.41 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.461 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.8 Cg_endo -88.43 40.09 0.54 Allowed 'Trans proline' 0 C--N 1.301 -1.943 0 C-N-CA 122.372 2.048 . . . . 0.0 110.282 178.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.628 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.38 154.39 43.68 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.135 -1.603 . . . . 0.0 112.011 -178.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.447 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -165.88 -168.86 1.37 Allowed 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.362 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.661 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -157.32 146.59 20.08 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.133 -0.979 . . . . 0.0 109.131 179.236 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.63 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 7.5 m80 -100.08 133.76 44.0 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.352 -0.843 . . . . 0.0 110.915 -178.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -107.5 88.63 2.78 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.418 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.131 ' CE2' HG11 ' A' ' 83' ' ' VAL . 13.8 m-85 -88.71 135.14 33.66 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.389 -0.819 . . . . 0.0 109.294 -178.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 13.9 p -127.96 -12.93 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.235 -0.916 . . . . 0.0 111.314 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.438 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -110.23 144.63 30.49 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 120.527 -1.358 . . . . 0.0 109.584 -179.767 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.755 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.0 Cg_endo -77.78 115.54 3.85 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.408 2.072 . . . . 0.0 109.868 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 163.97 -142.76 8.04 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.69 159.74 22.46 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.221 -1.164 . . . . 0.0 109.215 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.526 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 57.9 m-85 -140.68 160.85 39.14 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.413 -0.805 . . . . 0.0 109.297 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 49.2 t60 -122.0 142.09 50.68 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.624 HG13 ' CE1' ' A' ' 56' ' ' HIS . 21.7 t -125.17 149.6 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 120.862 -1.148 . . . . 0.0 110.991 -178.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.44 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -150.28 160.65 43.55 Favored 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 107.448 -1.315 . . . . 0.0 107.448 178.129 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.04 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -151.79 153.66 34.7 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.843 -1.16 . . . . 0.0 111.292 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.537 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.8 OUTLIER -126.0 121.99 60.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.58 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.9 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.6 OUTLIER -88.36 141.54 28.46 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 120.596 -1.315 . . . . 0.0 109.103 -178.406 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.66 109.12 10.4 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 118.679 -1.209 . . . . 0.0 109.694 178.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.841 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -104.07 -11.03 17.59 Favored 'General case' 0 C--N 1.288 -2.069 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 111.73 -49.46 0.84 Allowed Glycine 0 N--CA 1.487 2.074 0 N-CA-C 107.729 -2.148 . . . . 0.0 107.729 -178.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -118.41 -5.56 10.8 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.678 -0.895 . . . . 0.0 109.877 179.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.55 164.09 26.04 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.462 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 6.8 p -151.18 -177.23 5.92 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.344 -1.092 . . . . 0.0 109.684 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.9 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -153.17 154.81 35.5 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 179.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -112.94 124.79 53.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.141 -0.974 . . . . 0.0 109.938 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.04 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -114.53 155.24 26.81 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.416 -0.802 . . . . 0.0 110.032 -179.643 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -164.66 91.59 0.11 Allowed Glycine 0 N--CA 1.485 1.925 0 N-CA-C 109.271 -1.531 . . . . 0.0 109.271 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.779 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -106.88 175.84 5.37 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.127 -1.219 . . . . 0.0 109.895 -179.683 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -122.12 160.34 25.28 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.378 -0.826 . . . . 0.0 108.99 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.131 HG11 ' CE2' ' A' ' 58' ' ' TYR . 25.9 t -144.17 147.51 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.011 -1.055 . . . . 0.0 110.448 -179.022 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -137.14 98.98 3.87 Favored 'General case' 0 N--CA 1.492 1.641 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.385 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.73 HG22 HD12 ' A' ' 17' ' ' LEU . 29.1 t -96.93 139.83 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.111 -0.993 . . . . 0.0 110.658 -179.004 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 23.6 mm-40 -110.59 -159.41 0.68 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.512 -0.743 . . . . 0.0 109.62 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.755 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.123 -0.986 . . . . 0.0 109.243 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.706 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.926 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.3 t -70.62 149.44 47.05 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.196 -0.94 . . . . 0.0 109.336 -179.203 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.731 ' HG ' ' CD1' ' A' ' 79' ' ' LEU . 4.9 mp -84.62 108.18 17.22 Favored 'General case' 0 N--CA 1.49 1.529 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.088 -178.359 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.666 HG21 ' CE1' ' A' ' 26' ' ' HIS . 0.7 OUTLIER -123.53 104.28 14.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 O-C-N 120.777 -1.202 . . . . 0.0 108.912 178.708 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.85 76.52 0.3 Allowed Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -179.37 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.551 ' HD2' ' HA ' ' A' ' 25' ' ' PHE . 34.6 Cg_endo -73.26 150.43 47.28 Favored 'Trans proline' 0 C--N 1.308 -1.567 0 C-N-CA 122.728 2.285 . . . . 0.0 111.918 179.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.524 ' CD2' ' HA ' ' A' ' 23' ' ' ALA . 32.6 t-80 161.94 -36.82 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.796 0 CA-C-O 121.782 0.801 . . . . 0.0 108.944 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.97 -138.04 14.52 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 107.942 -2.063 . . . . 0.0 107.942 -178.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -77.74 147.83 25.03 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 C-N-CA 122.027 1.818 . . . . 0.0 109.313 178.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.85 ' HB3' HG22 ' A' ' 85' ' ' VAL . 0.6 OUTLIER -110.59 115.73 30.12 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.251 -0.906 . . . . 0.0 109.486 -179.441 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -106.24 160.01 15.67 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 45.7 t -56.3 119.34 5.82 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.316 -0.865 . . . . 0.0 109.471 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.42 46.92 3.92 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 -179.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 7.5 mm100 -127.4 153.52 46.15 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.145 -1.209 . . . . 0.0 110.543 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.838 HD11 ' HB2' ' A' ' 55' ' ' SER . 1.8 tm? -108.81 92.31 4.0 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.652 ' HB3' ' HB2' ' A' ' 56' ' ' HIS . . . -71.21 156.33 39.68 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 178.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.497 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -122.74 112.49 17.99 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.26 -1.525 . . . . 0.0 108.341 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.798 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.6 m-85 -100.64 173.84 6.35 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 122.512 1.148 . . . . 0.0 112.415 -177.19 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.666 ' CE1' HG21 ' A' ' 11' ' ' VAL . 5.9 p80 -172.47 147.61 1.91 Allowed 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.19 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.908 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.82 156.88 12.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 120.961 -1.087 . . . . 0.0 108.198 -178.484 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.926 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -132.66 122.34 24.52 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.442 -1.303 . . . . 0.0 112.702 -177.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.053 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.8 -70.06 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.797 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.053 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.1 Cg_endo -77.62 77.76 3.76 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 121.592 1.528 . . . . 0.0 108.718 178.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.567 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.3 OUTLIER -35.16 -55.57 1.01 Allowed Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 121.817 -0.552 . . . . 0.0 111.284 -178.795 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.613 ' O ' HD21 ' A' ' 72' ' ' LEU . 36.8 Cg_endo -80.62 81.29 2.78 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.141 1.894 . . . . 0.0 111.236 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 30' ' ' PRO . 40.1 t -111.89 150.3 14.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 120.908 -1.12 . . . . 0.0 109.0 179.107 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 18.5 p -116.91 -28.92 6.16 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.203 -0.936 . . . . 0.0 110.593 -179.82 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.93 143.7 17.15 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.088 -1.008 . . . . 0.0 110.274 -179.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.905 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -130.79 157.37 43.05 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 179.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.517 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -125.05 104.25 8.45 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.305 -0.872 . . . . 0.0 108.669 179.102 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.798 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 32.7 m95 -88.85 -178.6 5.78 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 109.276 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.522 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -148.24 102.73 3.38 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 178.085 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.96 ' CE1' HG21 ' A' ' 47' ' ' VAL . 4.7 m-30 -81.61 -66.03 0.94 Allowed 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 119.182 -1.007 . . . . 0.0 110.561 -177.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 98.89 11.12 47.55 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.552 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 12.6 p30 -97.04 33.07 1.99 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.249 -1.148 . . . . 0.0 108.224 179.043 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.24 -34.84 5.08 Favored Glycine 0 N--CA 1.48 1.603 0 N-CA-C 105.449 -3.06 . . . . 0.0 105.449 -175.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 50.2 m -108.35 100.78 10.04 Favored 'General case' 0 N--CA 1.485 1.305 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.522 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -75.3 -86.96 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.166 -0.959 . . . . 0.0 109.773 -178.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -50.89 144.77 8.04 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-O 121.308 0.575 . . . . 0.0 109.806 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.96 HG21 ' CE1' ' A' ' 40' ' ' PHE . 91.9 t -133.84 105.91 8.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.36 -0.838 . . . . 0.0 110.764 -178.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -83.12 115.75 22.03 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.479 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.905 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -129.26 164.08 24.25 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.028 -1.045 . . . . 0.0 110.74 -178.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.18 151.02 19.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.659 -0.65 . . . . 0.0 109.574 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.589 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.65 -155.31 0.51 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -88.5 38.91 0.47 Allowed 'Trans proline' 0 C--N 1.298 -2.1 0 C-N-CA 122.269 1.979 . . . . 0.0 110.191 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.661 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -139.55 155.57 47.42 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 120.227 -1.546 . . . . 0.0 111.895 -178.705 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.504 ' HB2' ' NE1' ' A' ' 38' ' ' TRP . . . -165.18 -169.64 1.69 Allowed 'General case' 0 N--CA 1.494 1.725 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.838 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -154.0 144.09 22.03 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.018 -1.051 . . . . 0.0 109.816 179.407 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.652 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -94.48 129.89 41.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.705 -0.622 . . . . 0.0 111.031 -178.797 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -105.47 85.57 2.27 Favored 'General case' 0 N--CA 1.49 1.525 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.023 ' CE2' HG11 ' A' ' 83' ' ' VAL . 13.0 m-85 -92.29 134.2 35.12 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.986 -1.071 . . . . 0.0 110.073 -178.544 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.4 m -127.3 -3.12 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.605 -0.685 . . . . 0.0 111.046 -179.083 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.446 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.2 OUTLIER -117.61 140.5 27.6 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 120.651 -1.281 . . . . 0.0 109.36 -179.944 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.852 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.1 Cg_endo -77.65 109.47 2.76 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 122.479 2.119 . . . . 0.0 110.155 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 169.81 -144.23 8.41 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.89 162.25 15.0 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.166 -1.196 . . . . 0.0 109.826 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.512 ' HB2' ' HB ' ' A' ' 83' ' ' VAL . 61.5 m-85 -146.91 165.28 30.26 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -124.87 153.9 41.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.151 -0.968 . . . . 0.0 108.503 179.008 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.612 HG13 ' NE2' ' A' ' 56' ' ' HIS . 12.5 t -134.19 145.19 33.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 120.839 -1.163 . . . . 0.0 110.764 -179.057 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.452 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.1 OUTLIER -150.63 159.03 44.79 Favored 'General case' 0 N--CA 1.489 1.525 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 178.129 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.993 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -152.03 157.26 41.43 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.868 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.587 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.3 p -150.14 108.19 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.851 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.16 151.11 22.37 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.931 -1.106 . . . . 0.0 109.154 -179.156 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.42 119.7 23.09 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.362 -0.935 . . . . 0.0 109.708 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.613 HD21 ' O ' ' A' ' 32' ' ' PRO . 7.4 mt -109.23 -12.97 14.73 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-O 121.518 0.675 . . . . 0.0 109.492 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.07 -47.41 1.05 Allowed Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -178.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -113.87 -6.24 13.22 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.574 -0.956 . . . . 0.0 109.696 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.65 158.84 27.83 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -150.8 168.34 24.73 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.199 -1.177 . . . . 0.0 109.395 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.851 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -141.74 132.62 25.87 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.199 -0.938 . . . . 0.0 109.358 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.2 mp -101.76 147.06 26.92 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.15 -0.969 . . . . 0.0 110.45 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.993 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -133.26 160.11 38.25 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.655 -0.653 . . . . 0.0 109.886 -179.292 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.491 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.42 88.91 0.09 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.509 HG22 HD13 ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.48 175.8 5.28 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.087 -1.243 . . . . 0.0 109.976 -179.755 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -117.87 155.37 30.27 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.243 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.023 HG11 ' CE2' ' A' ' 58' ' ' TYR . 25.1 t -134.82 143.42 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.172 -0.955 . . . . 0.0 110.049 -179.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -131.83 104.0 6.64 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.37 -0.832 . . . . 0.0 109.038 179.407 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.85 HG22 ' HB3' ' A' ' 17' ' ' LEU . 86.0 t -102.43 132.19 49.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.345 -0.847 . . . . 0.0 109.964 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -102.45 -160.98 0.81 Allowed 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.201 -0.937 . . . . 0.0 109.391 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.852 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.632 0 O-C-N 121.064 -1.022 . . . . 0.0 109.427 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.873 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.812 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.79 139.68 30.22 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.77 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.6 mp -97.19 89.55 4.81 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.148 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.941 HG12 ' HD3' ' A' ' 13' ' ' PRO . 65.3 t -99.08 112.34 30.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.885 -1.134 . . . . 0.0 109.092 179.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.504 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -124.1 71.18 0.44 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.941 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.4 Cg_endo -73.64 150.4 45.22 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.803 2.336 . . . . 0.0 112.153 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.468 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.9 t-80 168.9 -38.87 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.681 0.753 . . . . 0.0 109.208 179.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.29 -138.05 14.56 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 -178.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.62 147.0 24.57 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 121.972 1.782 . . . . 0.0 109.166 178.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.953 HD21 ' HB2' ' A' ' 23' ' ' ALA . 2.7 mt -117.26 98.56 6.5 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.2 -0.937 . . . . 0.0 109.779 -179.301 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.09 165.66 14.98 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 t -60.85 114.74 3.22 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.243 -0.91 . . . . 0.0 109.272 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.68 39.52 2.72 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.84 154.58 51.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.152 -1.205 . . . . 0.0 110.015 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.717 HD12 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -115.82 128.14 55.59 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.805 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.953 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -92.69 148.37 22.12 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.533 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -105.25 121.9 44.81 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.067 -1.645 . . . . 0.0 108.04 179.012 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.815 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 5.2 m-85 -105.39 170.53 7.83 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 121.914 0.864 . . . . 0.0 111.721 -177.009 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.709 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.72 140.14 3.84 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.793 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.999 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.6 mm -109.42 148.67 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.279 -0.888 . . . . 0.0 109.309 -178.345 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.644 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -133.33 122.6 24.07 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.989 -178.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.139 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 175.25 -61.86 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.078 -1.014 . . . . 0.0 109.552 178.134 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.139 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.3 Cg_endo -79.17 68.49 8.27 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.209 1.939 . . . . 0.0 109.699 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.634 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.0 OUTLIER -15.42 -64.03 0.03 OUTLIER Pre-proline 0 N--CA 1.506 2.327 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.83 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.634 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.4 Cg_endo -78.52 73.39 5.9 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 C-N-CA 121.774 1.65 . . . . 0.0 111.202 -179.513 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 30' ' ' PRO . 2.8 t -96.41 136.64 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.894 -1.129 . . . . 0.0 109.656 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.5 t -115.89 -15.33 11.25 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.48 -0.763 . . . . 0.0 109.331 179.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.6 149.43 0.48 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.311 -0.868 . . . . 0.0 109.667 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.624 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -136.93 139.68 41.73 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.59 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.61 ' O ' HG23 ' A' ' 69' ' ' VAL . 10.2 mtm-85 -93.33 109.04 20.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.138 -0.976 . . . . 0.0 109.136 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.977 ' CH2' HD11 ' A' ' 27' ' ' ILE . 18.7 m95 -93.85 179.81 5.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.918 -1.114 . . . . 0.0 109.621 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.489 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.76 106.61 3.41 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.328 -1.731 . . . . 0.0 106.328 177.369 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 1.014 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.7 m-30 -81.37 -66.44 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 118.451 -1.3 . . . . 0.0 111.37 -176.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.11 -4.91 59.03 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.1 p30 -90.41 23.71 2.86 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.335 -1.097 . . . . 0.0 109.164 179.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 122.56 -38.11 2.64 Favored Glycine 0 C--N 1.298 -1.576 0 N-CA-C 106.129 -2.788 . . . . 0.0 106.129 -176.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.77 101.52 12.96 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 177.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.489 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.38 -98.28 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 0.0 109.958 -178.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -56.92 150.1 17.33 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.286 0.565 . . . . 0.0 109.927 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 1.014 HG21 ' CE1' ' A' ' 40' ' ' PHE . 70.8 t -138.9 132.97 40.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.47 -0.769 . . . . 0.0 110.591 -178.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -112.89 89.8 3.18 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.686 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -92.84 152.53 19.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.373 -0.829 . . . . 0.0 111.423 -178.135 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.72 150.2 23.75 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.624 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.08 -156.4 0.49 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.24 -1.944 . . . . 0.0 108.24 -179.27 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.415 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.1 Cg_endo -88.43 42.63 0.7 Allowed 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.122 1.881 . . . . 0.0 110.479 178.436 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.686 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -146.87 144.38 29.24 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.072 -1.642 . . . . 0.0 112.009 -179.089 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 49' ' ' ALA . . . -149.54 -169.6 3.42 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.599 ' HB3' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -152.64 138.8 18.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.249 -0.907 . . . . 0.0 109.174 179.558 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.616 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 11.1 m80 -102.91 135.45 44.57 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.231 -0.918 . . . . 0.0 111.101 -178.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.439 ' H ' ' HG2' ' A' ' 57' ' ' ARG . 2.0 ptp180 -100.44 95.06 6.49 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.022 ' CE2' HG11 ' A' ' 83' ' ' VAL . 23.8 m-85 -95.5 120.24 35.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.225 -0.922 . . . . 0.0 109.232 -179.232 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.6 p -118.17 -29.71 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.241 -0.912 . . . . 0.0 111.165 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.405 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -90.71 143.35 28.82 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 120.619 -1.3 . . . . 0.0 109.376 -179.678 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.405 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.0 Cg_endo -76.26 133.04 14.34 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.575 2.183 . . . . 0.0 110.281 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.59 -135.05 5.93 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 -179.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -127.27 164.51 21.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -1.193 . . . . 0.0 109.651 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.65 ' HB2' HG13 ' A' ' 83' ' ' VAL . 59.7 m-85 -142.98 152.84 42.39 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.466 -0.771 . . . . 0.0 109.205 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -112.99 130.37 56.16 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.575 HG13 ' CE1' ' A' ' 56' ' ' HIS . 59.2 t -116.0 150.58 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 110.821 -178.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.79 155.51 42.42 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.064 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.53 158.57 44.31 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.853 -1.155 . . . . 0.0 111.518 -179.538 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -129.84 127.17 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.423 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 1.011 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.3 OUTLIER -89.07 141.87 28.12 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 120.656 -1.277 . . . . 0.0 109.015 -178.743 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.3 110.48 11.56 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.589 -1.245 . . . . 0.0 109.698 178.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.925 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.9 mp -105.49 -11.1 16.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.072 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.66 -49.62 0.83 Allowed Glycine 0 N--CA 1.486 2.011 0 N-CA-C 107.669 -2.173 . . . . 0.0 107.669 -178.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.44 -5.76 11.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.58 -0.953 . . . . 0.0 109.884 178.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -140.04 162.5 26.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.478 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.8 p -151.44 -179.23 7.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.306 -1.114 . . . . 0.0 109.579 -179.598 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 1.011 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -154.17 166.39 33.25 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.2 mt -119.93 132.75 55.62 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.068 -1.02 . . . . 0.0 110.227 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.064 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -117.4 157.14 26.7 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.524 -0.735 . . . . 0.0 109.769 -179.879 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.65 95.12 0.11 Allowed Glycine 0 N--CA 1.485 1.938 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.612 HG22 HD23 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -116.38 -173.33 2.35 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.232 -1.158 . . . . 0.0 109.937 179.932 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -150.74 153.7 36.0 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.435 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.022 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.0 154.25 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.66 -1.275 . . . . 0.0 109.845 -179.519 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . 0.425 ' N ' HG23 ' A' ' 83' ' ' VAL . 12.0 tt0 -123.07 99.81 6.56 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.464 -0.773 . . . . 0.0 108.985 179.073 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.778 HG21 ' HB3' ' A' ' 58' ' ' TYR . 41.6 t -86.15 137.71 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.24 -0.912 . . . . 0.0 109.846 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -113.15 154.41 26.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 -179.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.101 -0.999 . . . . 0.0 109.667 179.711 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.736 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.886 HG22 ' HB3' ' A' ' 28' ' ' ALA . 0.8 OUTLIER -71.47 149.87 45.44 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.178 -0.951 . . . . 0.0 109.253 -179.427 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.756 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.0 mp -92.29 98.28 11.41 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.315 -178.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.822 HG11 ' CE1' ' A' ' 26' ' ' HIS . 11.1 t -108.81 101.3 12.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 120.873 -1.142 . . . . 0.0 108.273 178.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.555 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -115.64 75.49 0.26 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.459 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.512 ' HD3' HG12 ' A' ' 11' ' ' VAL . 32.8 Cg_endo -72.63 148.7 47.78 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.59 2.194 . . . . 0.0 111.694 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.507 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 54.3 t60 159.11 -35.63 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.659 0.742 . . . . 0.0 109.003 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.81 -141.52 15.25 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 108.437 -1.865 . . . . 0.0 108.437 -179.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -77.2 149.19 27.95 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 122.288 1.992 . . . . 0.0 109.434 179.106 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 1.013 HD21 ' HB2' ' A' ' 23' ' ' ALA . 1.4 mt -117.74 117.51 29.53 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.161 -0.962 . . . . 0.0 109.888 -179.39 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.429 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -94.06 168.77 10.73 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.137 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.572 ' H ' ' HB3' ' A' ' 87' ' ' ALA . 2.2 t -56.79 118.72 5.19 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.25 -0.906 . . . . 0.0 109.01 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.63 43.22 6.19 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.22 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.429 ' HB2' ' O ' ' A' ' 18' ' ' ALA . 7.9 tp-100 -111.6 150.77 29.6 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.42 -1.047 . . . . 0.0 110.869 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.783 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.1 tm? -111.52 102.68 11.0 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.573 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 1.013 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -86.68 156.34 20.02 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.512 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -118.97 108.78 15.18 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.367 -1.458 . . . . 0.0 108.474 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.684 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.2 m-85 -96.02 168.18 10.78 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 122.428 1.109 . . . . 0.0 112.394 -177.343 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.822 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.0 142.44 5.13 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.808 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.815 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -107.42 156.95 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 120.88 -1.138 . . . . 0.0 109.34 -178.467 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.886 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -134.76 120.6 19.62 Favored 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 118.738 -1.185 . . . . 0.0 112.472 -178.639 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.055 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.56 -71.85 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.887 0 O-C-N 121.211 -0.931 . . . . 0.0 109.263 177.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.055 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -76.27 78.24 3.3 Favored 'Trans proline' 0 C--N 1.313 -1.312 0 C-N-CA 121.766 1.644 . . . . 0.0 109.465 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.52 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -35.47 -54.0 1.25 Allowed Pre-proline 0 N--CA 1.497 1.922 0 O-C-N 121.859 -0.526 . . . . 0.0 111.768 -179.145 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.582 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.1 Cg_endo -78.74 60.85 7.84 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.192 1.928 . . . . 0.0 111.819 -179.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.997 HG23 ' O ' ' A' ' 30' ' ' PRO . 55.6 t -89.51 145.28 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.001 0 O-C-N 120.798 -1.189 . . . . 0.0 109.358 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.7 t -116.63 -31.97 5.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.306 -0.871 . . . . 0.0 109.914 179.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.0 138.71 14.17 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.322 -0.861 . . . . 0.0 109.152 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.904 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.1 t -124.19 151.93 43.48 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.566 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.9 OUTLIER -118.22 101.43 8.2 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.206 -0.934 . . . . 0.0 108.921 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.684 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 25.9 m95 -87.88 -179.59 6.27 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.124 -0.985 . . . . 0.0 109.162 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.405 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.8 OUTLIER -148.96 101.7 3.19 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 177.834 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.975 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.6 m-30 -80.35 -59.92 2.52 Favored 'General case' 0 C--N 1.301 -1.503 0 C-N-CA 119.028 -1.069 . . . . 0.0 110.111 -177.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.1 19.72 49.33 Favored Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.175 -1.57 . . . . 0.0 109.175 -178.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -109.06 -104.71 0.36 Allowed 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 178.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -80.33 -21.03 65.59 Favored Glycine 0 N--CA 1.479 1.507 0 N-CA-C 107.852 -2.099 . . . . 0.0 107.852 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.16 130.17 30.69 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.347 -1.09 . . . . 0.0 109.557 179.549 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.405 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.2 -85.01 0.1 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.983 -1.073 . . . . 0.0 109.668 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -57.64 150.61 18.99 Favored 'General case' 0 N--CA 1.493 1.711 0 CA-C-O 121.132 0.492 . . . . 0.0 109.684 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.975 HG21 ' CE1' ' A' ' 40' ' ' PHE . 32.5 t -137.1 112.33 10.86 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 O-C-N 121.288 -0.882 . . . . 0.0 111.03 -178.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -96.09 95.75 8.39 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.904 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -107.63 171.37 7.43 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.455 -0.778 . . . . 0.0 111.06 -178.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -105.06 153.18 21.82 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.802 -0.561 . . . . 0.0 109.702 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.571 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.61 -156.42 0.59 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.776 -1.729 . . . . 0.0 108.776 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -88.45 41.75 0.63 Allowed 'Trans proline' 0 C--N 1.294 -2.298 0 C-N-CA 122.201 1.934 . . . . 0.0 110.277 178.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.599 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -142.8 152.88 42.7 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 119.933 -1.729 . . . . 0.0 112.508 -178.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.634 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -175.7 154.41 1.56 Allowed 'General case' 0 N--CA 1.498 1.936 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.469 ' CB ' HD11 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -113.34 161.83 16.79 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.742 -1.224 . . . . 0.0 110.327 -179.744 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.783 ' O ' HD22 ' A' ' 22' ' ' LEU . 2.3 m80 -113.11 141.2 47.18 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.506 -0.746 . . . . 0.0 110.578 -179.228 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.03 93.28 4.18 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.084 ' CE2' HG11 ' A' ' 83' ' ' VAL . 39.6 m-85 -95.91 133.56 39.94 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.024 -1.047 . . . . 0.0 109.553 -179.143 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 58.5 t -116.31 -41.65 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.319 -0.863 . . . . 0.0 111.029 -178.601 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.42 ' HA ' ' HD3' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -87.64 145.52 37.28 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.607 -1.308 . . . . 0.0 109.768 -179.117 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 60' ' ' LEU . 34.6 Cg_endo -78.39 129.66 9.56 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 C-N-CA 122.551 2.167 . . . . 0.0 110.232 179.379 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.88 -136.91 5.28 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 3.5 mtp180 -131.51 126.3 34.6 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -1.173 . . . . 0.0 109.739 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.566 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 44.8 m-85 -110.62 158.81 18.17 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.217 -0.927 . . . . 0.0 109.393 179.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.465 ' CD2' HG22 ' A' ' 67' ' ' THR . 70.4 t60 -111.02 132.12 54.49 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.57 HG22 ' NE2' ' A' ' 56' ' ' HIS . 67.5 t -114.23 152.13 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.272 -0.892 . . . . 0.0 110.352 -179.092 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.465 HG22 ' CD2' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -147.88 158.84 44.24 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.707 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.109 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -154.71 120.44 5.15 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 120.871 -1.143 . . . . 0.0 111.679 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.539 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.5 p -112.68 110.91 33.93 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 177.609 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.842 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.9 146.75 24.74 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.755 -1.216 . . . . 0.0 109.441 -178.944 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -125.52 116.06 21.19 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.24 -0.912 . . . . 0.0 109.206 178.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.731 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -103.43 -13.75 16.51 Favored 'General case' 0 C--N 1.292 -1.906 0 CA-C-O 121.53 0.681 . . . . 0.0 109.33 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.56 -49.7 0.83 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.07 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -118.19 -5.76 10.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.674 -0.898 . . . . 0.0 109.857 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -143.03 161.49 27.56 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.431 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 3.2 p -151.45 168.82 23.68 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.291 -1.123 . . . . 0.0 109.362 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.842 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -140.69 136.1 32.29 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.13 -0.981 . . . . 0.0 109.066 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 13.6 mt -101.78 133.46 46.49 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.308 -0.87 . . . . 0.0 110.269 -179.182 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.109 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -122.13 156.16 34.23 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.593 -0.692 . . . . 0.0 109.952 -179.335 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.514 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -161.68 88.66 0.11 Allowed Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.273 -1.531 . . . . 0.0 109.273 179.564 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.696 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -105.82 -175.35 2.77 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.937 -1.331 . . . . 0.0 110.289 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -150.83 143.48 24.44 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.274 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.084 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -129.07 149.13 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 120.779 -1.201 . . . . 0.0 110.059 -179.43 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 72.2 mt-30 -114.7 98.7 7.01 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.462 -0.774 . . . . 0.0 108.97 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.794 HG21 ' HB3' ' A' ' 58' ' ' TYR . 96.4 t -83.74 144.65 9.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.087 -1.008 . . . . 0.0 109.945 -179.456 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -126.58 -154.87 0.65 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.489 -0.757 . . . . 0.0 109.343 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.572 ' HB3' ' H ' ' A' ' 19' ' ' SER . . . . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.454 -0.779 . . . . 0.0 110.579 179.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.691 ' HB3' ' CG2' ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.862 HG22 ' HB3' ' A' ' 28' ' ' ALA . 0.6 OUTLIER -70.06 149.48 47.61 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.219 -0.926 . . . . 0.0 109.346 -179.229 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 10' ' ' LEU . 4.2 mp -83.59 110.42 18.23 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.902 -178.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.716 HG11 ' CE1' ' A' ' 26' ' ' HIS . 0.5 OUTLIER -124.65 101.52 9.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 O-C-N 120.753 -1.217 . . . . 0.0 109.216 179.116 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.625 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.88 76.12 0.28 Allowed Glycine 0 N--CA 1.495 2.578 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.588 ' O ' ' HB2' ' A' ' 14' ' ' HIS . 35.1 Cg_endo -72.9 149.7 47.9 Favored 'Trans proline' 0 C--N 1.309 -1.53 0 C-N-CA 122.774 2.316 . . . . 0.0 112.778 -179.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.588 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 152.25 175.28 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.908 0 CA-C-N 114.85 -1.068 . . . . 0.0 108.388 178.743 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.99 -141.6 2.11 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -76.91 150.06 29.8 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 122.123 1.882 . . . . 0.0 109.552 179.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 1.018 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.6 mm? -99.75 85.01 3.01 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.122 -0.986 . . . . 0.0 108.867 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -82.32 166.13 19.76 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.104 -0.997 . . . . 0.0 108.664 179.702 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.1 t -54.83 117.32 3.31 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.408 -0.808 . . . . 0.0 109.123 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.17 43.21 5.69 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 -179.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.613 ' HG2' HD13 ' A' ' 17' ' ' LEU . 19.6 tp60 -112.54 145.82 39.61 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.448 -1.031 . . . . 0.0 110.696 -179.116 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.648 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.3 tm? -106.51 93.95 4.87 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.254 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 1.018 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -76.88 159.05 30.34 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.077 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.541 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.53 118.2 28.69 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.132 -1.605 . . . . 0.0 108.004 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.754 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 8.3 m-85 -103.95 174.65 5.78 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 122.705 1.24 . . . . 0.0 112.592 -176.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.716 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.3 OUTLIER -174.93 149.52 1.14 Allowed 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 177.992 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.871 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -113.98 156.33 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.806 -1.184 . . . . 0.0 108.63 -178.258 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.862 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -129.95 121.16 26.05 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.704 -1.247 . . . . 0.0 112.559 -178.001 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.043 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 170.88 -72.36 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.83 0 O-C-N 121.406 -0.808 . . . . 0.0 108.955 177.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.043 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.7 Cg_endo -77.09 78.82 3.31 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 C-N-CA 121.616 1.544 . . . . 0.0 108.593 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.72 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 13.0 mt -40.51 -50.36 6.85 Favored Pre-proline 0 N--CA 1.497 1.891 0 O-C-N 121.782 -0.574 . . . . 0.0 111.653 -178.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.72 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 36.8 Cg_endo -80.99 60.05 7.71 Favored 'Trans proline' 0 C--N 1.315 -1.185 0 C-N-CA 122.024 1.816 . . . . 0.0 112.001 -179.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.904 HG23 ' O ' ' A' ' 30' ' ' PRO . 38.7 t -90.94 147.82 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 120.708 -1.245 . . . . 0.0 109.288 179.006 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.12 -30.57 6.62 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.334 -0.854 . . . . 0.0 110.171 179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.36 145.06 18.85 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.245 -0.909 . . . . 0.0 109.334 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.829 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.3 t -129.22 158.72 38.23 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.533 ' O ' HG23 ' A' ' 69' ' ' VAL . 2.9 mtm-85 -123.12 101.67 7.53 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.298 -0.877 . . . . 0.0 108.895 179.546 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.754 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 37.6 m95 -89.17 178.66 6.31 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.124 -0.985 . . . . 0.0 109.619 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.463 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.33 102.34 3.06 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 106.535 -1.654 . . . . 0.0 106.535 177.515 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.992 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.2 m-30 -79.66 -60.03 2.51 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 118.794 -1.162 . . . . 0.0 109.76 -177.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.13 18.32 47.06 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -105.42 -103.32 0.32 Allowed 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 178.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.64 -20.26 60.27 Favored Glycine 0 C--N 1.297 -1.618 0 N-CA-C 107.805 -2.118 . . . . 0.0 107.805 176.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 12.9 p -135.91 130.06 33.2 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.353 -1.086 . . . . 0.0 109.342 179.421 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.49 -85.37 0.1 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.047 -1.033 . . . . 0.0 109.877 -179.689 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 3.1 pm0 -56.07 152.05 11.12 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.303 0.573 . . . . 0.0 110.306 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.992 HG21 ' CE1' ' A' ' 40' ' ' PHE . 26.1 t -140.8 121.87 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 111.047 -179.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 62.1 m-20 -104.58 107.81 18.94 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 177.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.829 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -120.99 170.87 9.09 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.055 -1.028 . . . . 0.0 111.092 -178.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.48 152.4 20.05 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.648 -0.657 . . . . 0.0 109.643 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.545 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.51 -156.08 0.61 Allowed Glycine 0 N--CA 1.489 2.179 0 N-CA-C 108.842 -1.703 . . . . 0.0 108.842 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -88.83 40.79 0.54 Allowed 'Trans proline' 0 C--N 1.297 -2.151 0 C-N-CA 122.244 1.963 . . . . 0.0 110.24 178.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.595 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -140.0 157.59 45.42 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 119.936 -1.727 . . . . 0.0 112.307 -178.681 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.48 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -171.59 -167.67 0.53 Allowed 'General case' 0 N--CA 1.495 1.815 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.506 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.504 ' O ' ' CZ ' ' A' ' 40' ' ' PHE . 0.0 OUTLIER -146.74 175.99 10.2 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.096 -1.003 . . . . 0.0 109.186 179.29 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.648 ' O ' HD22 ' A' ' 22' ' ' LEU . 4.6 m80 -133.92 132.95 40.85 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.927 -1.108 . . . . 0.0 110.408 -179.139 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.53 89.17 2.92 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 179.454 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.071 ' CE2' HG11 ' A' ' 83' ' ' VAL . 32.7 m-85 -92.41 126.85 37.67 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.206 -0.934 . . . . 0.0 109.122 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 9.8 p -114.44 -28.41 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.407 -0.808 . . . . 0.0 111.514 -178.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.416 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -98.63 145.86 30.63 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 120.512 -1.367 . . . . 0.0 109.429 -179.36 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.563 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.1 Cg_endo -77.36 119.28 4.89 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 122.383 2.055 . . . . 0.0 109.814 179.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 161.49 -162.14 33.65 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -107.09 130.17 54.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.221 -1.164 . . . . 0.0 110.12 -179.756 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.563 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 73.1 m-85 -112.87 161.1 17.35 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.465 -0.772 . . . . 0.0 109.07 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 70.0 t60 -115.23 122.22 45.33 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.462 -0.774 . . . . 0.0 109.069 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.576 HG22 ' NE2' ' A' ' 56' ' ' HIS . 66.1 t -102.74 152.01 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.38 -0.825 . . . . 0.0 109.899 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.57 158.52 44.25 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 178.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.059 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.51 156.67 42.35 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.92 -1.113 . . . . 0.0 110.989 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.533 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -147.07 104.68 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.385 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 179.224 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.805 ' CD1' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.84 150.44 22.9 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.734 -1.229 . . . . 0.0 109.703 -179.181 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.45 117.04 20.66 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.588 -0.845 . . . . 0.0 109.309 178.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.538 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.2 mp -105.36 -13.13 15.75 Favored 'General case' 0 C--N 1.293 -1.881 0 CA-C-O 121.52 0.676 . . . . 0.0 109.239 179.69 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 119.33 -56.21 0.59 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -114.63 -7.25 12.76 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.576 -0.955 . . . . 0.0 109.759 179.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -137.47 161.13 25.29 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.422 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.0 p -151.2 170.06 20.38 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.411 -1.053 . . . . 0.0 109.409 -179.724 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.805 ' HB3' ' CD1' ' A' ' 70' ' ' LEU . . . -144.16 126.63 15.9 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.29 -0.882 . . . . 0.0 109.198 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -95.25 152.14 18.63 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.224 -0.923 . . . . 0.0 110.639 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.059 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -135.7 158.53 44.17 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.747 -0.596 . . . . 0.0 109.472 179.878 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.544 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.96 88.54 0.1 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.542 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -110.83 -171.91 1.92 Allowed 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.05 -1.265 . . . . 0.0 109.965 -179.893 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -149.54 149.56 30.9 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.071 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -132.29 138.29 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.76 -1.213 . . . . 0.0 110.056 -179.654 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -101.46 83.33 2.43 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.408 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.84 HG21 ' HB3' ' A' ' 58' ' ' TYR . 53.4 t -72.62 134.3 30.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.148 -0.97 . . . . 0.0 109.627 -179.418 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -110.77 -179.1 3.65 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.386 -0.821 . . . . 0.0 109.643 -179.592 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.563 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.919 . . . . 0.0 109.185 179.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.731 ' HB3' ' CG2' ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.843 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.2 t -75.44 155.83 35.89 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.199 -0.938 . . . . 0.0 108.873 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.992 ' HB3' HD11 ' A' ' 79' ' ' LEU . 0.0 OUTLIER -96.8 90.96 5.45 Favored 'General case' 0 N--CA 1.49 1.553 0 C-N-CA 119.961 -0.696 . . . . 0.0 110.141 -178.854 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.835 HG11 ' CE1' ' A' ' 26' ' ' HIS . 25.3 t -93.96 96.23 5.88 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.618 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -114.74 75.69 0.25 Allowed Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.716 -1.231 . . . . 0.0 110.545 -178.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.584 ' HD3' HG12 ' A' ' 11' ' ' VAL . 32.7 Cg_endo -73.01 149.38 46.7 Favored 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.5 2.133 . . . . 0.0 111.494 179.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.582 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 69.6 t60 163.16 -37.5 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 CA-C-O 121.771 0.796 . . . . 0.0 109.06 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.77 -137.62 13.49 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.133 -1.987 . . . . 0.0 108.133 -178.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -77.25 147.08 25.68 Favored 'Trans proline' 0 C--N 1.305 -1.727 0 C-N-CA 122.138 1.892 . . . . 0.0 109.351 178.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.955 HD21 ' HB2' ' A' ' 23' ' ' ALA . 12.1 mt -113.15 85.85 2.26 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.264 -0.897 . . . . 0.0 109.967 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.56 160.78 32.1 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 179.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.9 t -54.41 123.47 13.08 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.237 -0.914 . . . . 0.0 109.466 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.47 48.41 4.53 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.087 -1.605 . . . . 0.0 109.087 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.444 ' HB3' HD23 ' A' ' 17' ' ' LEU . 19.9 mm-40 -123.94 150.83 44.29 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.434 -1.039 . . . . 0.0 110.313 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.623 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.3 tm? -108.48 93.26 4.43 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.829 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.955 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -76.42 155.75 33.72 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.544 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.49 121.09 37.72 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.689 -1.257 . . . . 0.0 108.426 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.789 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.2 m-85 -108.33 171.07 7.62 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-O 122.204 1.002 . . . . 0.0 111.397 -177.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.835 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -168.64 135.79 1.96 Allowed 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 177.803 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.731 ' CG2' ' HB3' ' A' ' 8' ' ' ALA . 0.1 OUTLIER -101.48 149.64 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.882 -1.136 . . . . 0.0 108.692 -178.509 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.843 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -128.75 126.71 40.56 Favored 'General case' 0 N--CA 1.5 2.068 0 C-N-CA 118.775 -1.17 . . . . 0.0 112.501 -177.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.029 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 169.18 -69.6 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.532 -0.73 . . . . 0.0 109.081 177.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.029 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.8 Cg_endo -76.96 79.59 3.08 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 121.654 1.569 . . . . 0.0 109.144 179.061 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.515 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -34.89 -54.34 1.02 Allowed Pre-proline 0 N--CA 1.497 1.913 0 O-C-N 121.989 -0.444 . . . . 0.0 112.004 -178.921 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.535 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.5 Cg_endo -79.48 69.4 7.95 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.23 1.954 . . . . 0.0 111.775 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.943 HG23 ' O ' ' A' ' 30' ' ' PRO . 47.8 t -98.34 148.24 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.834 -1.166 . . . . 0.0 109.327 179.018 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 24.3 p -119.14 -29.15 5.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.307 -0.871 . . . . 0.0 110.26 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -159.29 145.05 16.17 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.221 -0.924 . . . . 0.0 109.619 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.792 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -130.75 151.44 51.18 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.52 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.7 OUTLIER -120.56 104.73 10.18 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.202 -0.936 . . . . 0.0 108.713 179.173 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.789 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 37.5 m95 -89.6 -178.6 5.59 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-O 122.079 0.942 . . . . 0.0 109.432 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.69 ' CB ' HG23 ' A' ' 67' ' ' THR . 0.3 OUTLIER -150.45 101.03 2.93 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 106.329 -1.73 . . . . 0.0 106.329 177.45 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.964 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.3 m-30 -80.37 -56.08 4.44 Favored 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.121 -177.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.6 20.41 54.25 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 109.133 -1.587 . . . . 0.0 109.133 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.566 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 1.1 p30 -104.25 -104.48 0.3 Allowed 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 178.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.24 -15.91 68.15 Favored Glycine 0 C--N 1.296 -1.646 0 N-CA-C 107.754 -2.138 . . . . 0.0 107.754 176.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.7 p -138.29 130.97 29.39 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.489 -1.007 . . . . 0.0 108.892 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.408 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.74 -85.4 0.09 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.941 -1.099 . . . . 0.0 109.752 -179.602 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -57.16 154.09 10.68 Favored 'General case' 0 N--CA 1.492 1.651 0 CA-C-O 121.332 0.587 . . . . 0.0 110.121 -179.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.964 HG21 ' CE1' ' A' ' 40' ' ' PHE . 52.6 t -140.01 121.63 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.431 -0.793 . . . . 0.0 110.689 -178.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -104.21 118.97 37.93 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 178.007 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.792 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -132.75 166.06 23.1 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.031 -1.043 . . . . 0.0 111.042 -178.513 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -93.31 153.47 18.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.672 -0.642 . . . . 0.0 109.796 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.57 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.35 -155.93 0.39 Allowed Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.091 -1.604 . . . . 0.0 109.091 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -88.96 38.99 0.44 Allowed 'Trans proline' 0 C--N 1.298 -2.118 0 C-N-CA 122.544 2.163 . . . . 0.0 110.149 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.627 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -138.16 152.63 48.87 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.115 -1.616 . . . . 0.0 112.054 -178.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.493 ' HB2' ' NE1' ' A' ' 38' ' ' TRP . . . -163.61 -166.79 1.26 Allowed 'General case' 0 N--CA 1.494 1.775 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.469 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.572 ' OG ' HD11 ' A' ' 22' ' ' LEU . 1.4 p -158.49 141.1 14.42 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.11 -0.994 . . . . 0.0 109.79 179.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.767 ' CE1' HG13 ' A' ' 66' ' ' VAL . 9.7 m80 -94.02 136.7 34.03 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.476 -0.765 . . . . 0.0 111.081 -178.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -110.89 87.71 2.6 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 178.396 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.092 ' CE2' HG11 ' A' ' 83' ' ' VAL . 15.1 m-85 -87.73 138.55 31.37 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.202 -0.936 . . . . 0.0 109.704 -178.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 12.0 p -129.51 -26.83 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.362 -0.836 . . . . 0.0 111.257 -178.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.422 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -98.36 144.6 28.38 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 120.507 -1.371 . . . . 0.0 109.718 -179.421 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.53 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.5 Cg_endo -77.64 116.39 4.04 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 C-N-CA 122.55 2.167 . . . . 0.0 109.929 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 160.54 -154.78 25.84 Favored Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.93 165.41 11.56 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.022 -1.281 . . . . 0.0 109.817 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.604 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 47.2 m-85 -149.17 166.43 28.86 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 28.0 t60 -127.88 142.18 51.34 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.317 -0.864 . . . . 0.0 108.858 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.767 HG13 ' CE1' ' A' ' 56' ' ' HIS . 30.3 t -122.64 146.0 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 120.997 -1.064 . . . . 0.0 110.712 -179.236 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.69 HG23 ' CB ' ' A' ' 39' ' ' ASP . 0.5 OUTLIER -151.44 156.28 40.32 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.541 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.004 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.92 161.17 42.82 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 120.849 -1.157 . . . . 0.0 111.128 -179.76 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.602 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.5 p -150.78 105.58 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 178.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.86 ' CD1' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.4 144.85 25.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.754 -1.216 . . . . 0.0 109.811 -178.845 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.455 ' C ' HD12 ' A' ' 72' ' ' LEU . . . -118.74 119.97 36.0 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.38 -0.928 . . . . 0.0 109.247 178.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.774 HD21 ' HB2' ' A' ' 30' ' ' PRO . 6.4 mp -114.16 -9.33 12.91 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-O 121.479 0.657 . . . . 0.0 109.485 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.641 ' O ' ' HB3' ' A' ' 74' ' ' ALA . . . 102.19 101.43 2.57 Favored Glycine 0 N--CA 1.488 2.1 0 N-CA-C 107.495 -2.242 . . . . 0.0 107.495 -178.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.641 ' HB3' ' O ' ' A' ' 73' ' ' GLY . . . 71.53 -0.38 3.17 Favored 'General case' 0 N--CA 1.485 1.292 0 O-C-N 121.714 -0.874 . . . . 0.0 110.372 -178.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -145.71 142.41 10.63 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 108.526 -1.83 . . . . 0.0 108.526 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -150.28 163.95 37.0 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.098 -1.236 . . . . 0.0 109.973 -179.382 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.86 ' HB3' ' CD1' ' A' ' 70' ' ' LEU . . . -132.15 119.81 21.42 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -89.75 149.69 22.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.911 . . . . 0.0 110.407 -179.202 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.004 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.2 OUTLIER -131.75 160.29 35.95 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.451 0.643 . . . . 0.0 110.103 -179.583 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.64 ' H ' HD13 ' A' ' 79' ' ' LEU . . . -169.21 92.52 0.1 OUTLIER Glycine 0 N--CA 1.483 1.814 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.613 HG22 ' HB3' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -113.07 175.39 5.46 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.034 -1.274 . . . . 0.0 109.377 179.524 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -117.68 156.17 28.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.309 -0.869 . . . . 0.0 108.851 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.092 HG11 ' CE2' ' A' ' 58' ' ' TYR . 25.1 t -137.25 139.87 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 120.983 -1.073 . . . . 0.0 110.635 -178.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -123.5 93.81 4.06 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 179.168 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.694 HG21 ' HB3' ' A' ' 58' ' ' TYR . 40.8 t -87.16 135.36 25.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.237 -0.914 . . . . 0.0 110.058 -179.303 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -107.66 -157.32 0.61 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.447 -0.783 . . . . 0.0 109.424 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.53 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.005 -1.059 . . . . 0.0 109.107 179.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.665 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.95 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.1 t -69.2 150.44 47.48 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.19 -0.944 . . . . 0.0 109.584 -178.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.752 ' N ' HD12 ' A' ' 10' ' ' LEU . 4.6 mp -83.19 107.18 15.56 Favored 'General case' 0 N--CA 1.489 1.516 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.648 -178.56 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.637 HG22 HG23 ' A' ' 9' ' ' THR . 0.4 OUTLIER -120.79 96.26 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 120.823 -1.173 . . . . 0.0 108.977 179.088 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.632 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -115.95 80.03 0.29 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.021 -1.231 . . . . 0.0 110.021 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.545 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 32.2 Cg_endo -71.94 147.58 49.73 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.513 2.142 . . . . 0.0 112.018 179.598 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.519 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 32.7 t-80 158.87 -33.98 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.08 -141.32 15.23 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 -179.033 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -77.07 148.4 27.52 Favored 'Trans proline' 0 C--N 1.304 -1.773 0 C-N-CA 122.082 1.855 . . . . 0.0 109.209 178.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 1.005 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.4 mm? -105.59 109.89 22.02 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.111 -0.993 . . . . 0.0 109.681 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -89.18 161.17 16.61 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.2 t -57.82 116.74 3.65 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.151 -0.968 . . . . 0.0 109.389 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 89.8 44.74 4.75 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -121.22 152.87 38.33 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.252 -1.146 . . . . 0.0 110.609 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.772 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.5 tm? -107.39 99.07 8.61 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.852 -0.795 . . . . 0.0 108.852 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 1.005 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -80.34 153.71 28.21 Favored 'General case' 0 N--CA 1.489 1.506 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 178.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.545 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -116.03 125.14 52.05 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.479 -1.388 . . . . 0.0 108.081 179.411 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.752 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 6.6 m-85 -112.57 172.44 6.92 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-O 122.526 1.155 . . . . 0.0 112.285 -177.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.627 ' CE1' HG21 ' A' ' 11' ' ' VAL . 4.1 p80 -173.95 148.51 1.41 Allowed 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 106.799 -1.556 . . . . 0.0 106.799 177.175 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.886 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.21 157.51 12.05 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 120.733 -1.229 . . . . 0.0 108.599 -178.166 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.95 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -132.41 121.63 23.74 Favored 'General case' 0 N--CA 1.5 2.058 0 C-N-CA 118.698 -1.201 . . . . 0.0 112.542 -177.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.036 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.31 -71.54 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.783 0 O-C-N 121.402 -0.811 . . . . 0.0 108.867 177.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.036 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.6 Cg_endo -77.39 76.86 4.05 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 C-N-CA 121.708 1.605 . . . . 0.0 108.725 178.522 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.561 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -35.45 -55.78 1.08 Allowed Pre-proline 0 N--CA 1.497 1.921 0 O-C-N 121.956 -0.465 . . . . 0.0 111.472 -178.746 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.561 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.7 Cg_endo -80.16 75.1 5.23 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.125 1.884 . . . . 0.0 111.332 -179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.898 HG23 ' O ' ' A' ' 30' ' ' PRO . 20.5 t -106.03 149.22 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.024 -1.048 . . . . 0.0 109.131 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 17.1 p -114.59 -28.85 7.01 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.285 -0.884 . . . . 0.0 110.626 -179.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -158.72 143.08 15.72 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.073 -1.017 . . . . 0.0 110.164 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.871 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -129.99 155.55 45.91 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.481 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.521 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 2.6 ttm180 -122.72 104.06 9.06 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.248 -0.907 . . . . 0.0 108.713 179.059 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.752 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 32.1 m95 -88.78 179.89 6.13 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.306 -0.871 . . . . 0.0 109.324 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.501 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.21 103.1 3.14 Favored 'General case' 0 C--N 1.295 -1.78 0 N-CA-C 106.811 -1.551 . . . . 0.0 106.811 177.889 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.997 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.5 m-30 -81.16 -67.0 0.82 Allowed 'General case' 0 N--CA 1.493 1.683 0 C-N-CA 119.001 -1.079 . . . . 0.0 110.738 -177.502 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.64 7.58 56.62 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.341 -1.504 . . . . 0.0 109.341 -178.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.6 p30 -98.34 35.6 1.75 Allowed 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.415 -1.05 . . . . 0.0 108.317 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.88 -39.19 2.96 Favored Glycine 0 C--N 1.295 -1.699 0 N-CA-C 105.773 -2.931 . . . . 0.0 105.773 -176.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 87.7 p -107.27 101.82 11.17 Favored 'General case' 0 N--CA 1.49 1.55 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 177.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.501 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -75.58 -89.99 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -0.944 . . . . 0.0 110.189 -178.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -52.21 145.74 10.25 Favored 'General case' 0 N--CA 1.497 1.915 0 CA-C-O 121.296 0.57 . . . . 0.0 109.884 -179.416 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.997 HG21 ' CE1' ' A' ' 40' ' ' PHE . 47.7 t -135.9 110.79 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.299 -0.875 . . . . 0.0 110.851 -178.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.23 107.41 19.18 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.368 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.871 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -120.02 165.79 14.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.198 -0.939 . . . . 0.0 110.98 -178.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -97.07 152.59 18.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.598 -0.689 . . . . 0.0 109.446 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.6 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.53 -156.12 0.41 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -88.97 40.99 0.54 Allowed 'Trans proline' 0 C--N 1.295 -2.242 0 C-N-CA 122.209 1.94 . . . . 0.0 110.381 178.465 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.633 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -139.52 159.26 42.57 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 119.953 -1.717 . . . . 0.0 112.509 -178.659 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.476 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -171.55 -167.05 0.48 Allowed 'General case' 0 N--CA 1.495 1.823 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.648 ' HB2' HD11 ' A' ' 22' ' ' LEU . 24.3 p -156.52 144.32 19.38 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.011 -1.056 . . . . 0.0 109.536 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.772 ' O ' HD22 ' A' ' 22' ' ' LEU . 9.1 m80 -102.4 146.25 28.35 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.595 0.712 . . . . 0.0 111.327 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -118.26 90.47 3.34 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 178.626 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.076 ' CE2' HG11 ' A' ' 83' ' ' VAL . 30.2 m-85 -92.63 128.76 38.6 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.067 -1.02 . . . . 0.0 110.012 -178.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.0 p -117.62 -27.84 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.484 -0.76 . . . . 0.0 111.108 -178.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.478 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -101.77 146.44 32.25 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 120.561 -1.337 . . . . 0.0 109.483 -179.493 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.478 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.3 Cg_endo -77.6 121.74 5.69 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 C-N-CA 122.286 1.991 . . . . 0.0 109.849 179.481 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 162.45 -163.31 35.0 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.457 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.3 OUTLIER -105.92 121.26 43.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.107 -1.231 . . . . 0.0 110.052 -179.805 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.603 ' HB2' HG13 ' A' ' 83' ' ' VAL . 64.6 m-85 -104.2 151.29 23.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.351 -0.843 . . . . 0.0 109.091 179.49 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.1 t60 -108.37 125.33 51.61 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.352 -0.842 . . . . 0.0 109.154 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.636 HG22 ' NE2' ' A' ' 56' ' ' HIS . 64.8 t -108.3 151.59 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.921 . . . . 0.0 110.185 -179.401 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.81 158.4 44.13 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.092 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -151.23 155.28 38.5 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.011 -1.056 . . . . 0.0 110.768 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.603 ' O ' HG13 ' A' ' 69' ' ' VAL . 8.1 p -148.35 108.09 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.877 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.13 149.99 22.92 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.818 -1.176 . . . . 0.0 109.367 -179.112 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.19 119.97 20.57 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.372 -0.931 . . . . 0.0 109.93 179.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.501 HD21 ' HA ' ' A' ' 33' ' ' VAL . 11.6 mt -110.86 -12.21 14.28 Favored 'General case' 0 C--N 1.295 -1.776 0 CA-C-O 121.498 0.666 . . . . 0.0 109.406 179.35 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.43 -49.65 0.86 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 -178.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -112.17 -7.71 14.03 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.517 -0.99 . . . . 0.0 109.71 179.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -145.84 153.48 25.33 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.412 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 1.7 p -150.89 169.37 21.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.191 -1.182 . . . . 0.0 109.691 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.877 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -144.2 154.02 42.69 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.394 -0.816 . . . . 0.0 108.997 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 5.1 mp -122.65 150.51 42.59 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.143 -0.973 . . . . 0.0 109.89 -179.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.092 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -136.06 158.92 43.25 Favored 'General case' 0 C--N 1.306 -1.326 0 O-C-N 121.552 -0.718 . . . . 0.0 110.013 -179.297 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.532 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -167.2 87.54 0.1 OUTLIER Glycine 0 N--CA 1.488 2.11 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.644 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -107.46 -174.51 2.55 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.126 -1.22 . . . . 0.0 110.353 -179.491 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -150.88 143.0 24.09 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.246 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.076 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -128.82 145.02 36.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 120.683 -1.261 . . . . 0.0 109.636 -179.539 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -109.6 84.33 1.91 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.45 -0.781 . . . . 0.0 109.246 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.821 HG21 ' HB3' ' A' ' 58' ' ' TYR . 48.1 t -69.51 133.47 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.01 -1.056 . . . . 0.0 109.394 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -114.9 162.71 16.56 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.456 -0.777 . . . . 0.0 109.845 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.441 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.324 -0.86 . . . . 0.0 109.388 179.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.758 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.415 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.874 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.2 t -70.44 148.53 48.22 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.222 -0.924 . . . . 0.0 109.272 -179.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.1 mp -85.59 103.86 14.81 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.083 -178.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.879 HG11 ' CE1' ' A' ' 26' ' ' HIS . 4.7 t -117.08 104.79 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 120.772 -1.205 . . . . 0.0 108.829 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.54 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -117.77 73.99 0.29 Allowed Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.651 -1.379 . . . . 0.0 109.651 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.544 ' HD2' ' HA ' ' A' ' 25' ' ' PHE . 35.0 Cg_endo -73.17 151.96 49.95 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.874 2.383 . . . . 0.0 112.462 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.568 ' CE1' ' HG2' ' A' ' 21' ' ' GLN . 26.8 t-80 158.52 -39.78 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.27 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.14 -137.0 13.73 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 108.074 -2.01 . . . . 0.0 108.074 -179.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.413 ' C ' HD22 ' A' ' 17' ' ' LEU . 35.3 Cg_endo -78.15 148.44 24.38 Favored 'Trans proline' 0 C--N 1.304 -1.787 0 C-N-CA 122.152 1.901 . . . . 0.0 109.521 178.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.774 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.0 mm? -112.16 102.42 10.61 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.097 -1.002 . . . . 0.0 109.465 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.414 ' HB3' ' OE1' ' A' ' 21' ' ' GLN . . . -88.51 165.05 15.14 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.164 -0.96 . . . . 0.0 108.848 179.567 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.7 t -56.41 122.16 11.26 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.321 -0.862 . . . . 0.0 109.363 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 83.26 47.62 5.68 Favored Glycine 0 N--CA 1.488 2.158 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.568 ' HG2' ' CE1' ' A' ' 14' ' ' HIS . 1.6 tp60 -120.26 150.66 40.35 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.345 -1.091 . . . . 0.0 110.622 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.717 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.3 tm? -107.27 96.67 6.58 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.774 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -79.31 156.59 27.97 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 107.95 -1.129 . . . . 0.0 107.95 178.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.507 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.97 117.49 27.42 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.516 -1.365 . . . . 0.0 108.094 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.767 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 5.8 m-85 -101.95 176.55 5.17 Favored 'General case' 0 N--CA 1.488 1.459 0 CA-C-O 122.459 1.124 . . . . 0.0 112.223 -177.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.879 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -174.3 143.41 0.86 Allowed 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.502 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.862 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -111.72 153.55 13.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.911 -1.118 . . . . 0.0 108.388 -179.067 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.874 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -131.62 123.43 27.86 Favored 'General case' 0 N--CA 1.501 2.101 0 C-N-CA 118.429 -1.308 . . . . 0.0 112.781 -177.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.044 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 173.3 -68.56 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.948 0 O-C-N 121.296 -0.877 . . . . 0.0 109.525 177.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.044 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -76.17 78.44 3.21 Favored 'Trans proline' 0 C--N 1.312 -1.395 0 C-N-CA 121.787 1.658 . . . . 0.0 109.497 179.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.53 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -32.86 -55.06 0.59 Allowed Pre-proline 0 N--CA 1.499 2.014 0 O-C-N 121.966 -0.459 . . . . 0.0 112.103 -179.16 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.564 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.3 Cg_endo -79.27 61.13 8.07 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 C-N-CA 122.324 2.016 . . . . 0.0 112.084 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 30' ' ' PRO . 90.2 t -85.86 152.21 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.964 0 O-C-N 120.593 -1.317 . . . . 0.0 109.564 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.432 ' N ' HG12 ' A' ' 33' ' ' VAL . 1.6 t -126.07 -33.14 2.69 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.489 -0.757 . . . . 0.0 109.783 179.294 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -157.53 140.69 15.31 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.395 -0.816 . . . . 0.0 109.296 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.867 HG23 ' HB3' ' A' ' 49' ' ' ALA . 0.8 OUTLIER -127.5 150.78 49.52 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.666 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.499 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.0 OUTLIER -116.96 103.88 10.72 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.216 -0.928 . . . . 0.0 108.788 179.257 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.767 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 33.7 m95 -89.12 -179.74 5.96 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.24 -0.912 . . . . 0.0 109.383 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.442 ' CB ' HG23 ' A' ' 67' ' ' THR . 0.2 OUTLIER -150.48 101.84 2.99 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 177.686 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.95 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.6 m-30 -79.9 -62.55 1.65 Allowed 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 118.834 -1.146 . . . . 0.0 109.992 -177.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.57 16.94 43.9 Favored Glycine 0 N--CA 1.488 2.107 0 N-CA-C 109.166 -1.573 . . . . 0.0 109.166 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -105.35 -102.95 0.32 Allowed 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -85.5 -18.33 60.52 Favored Glycine 0 C--N 1.297 -1.585 0 N-CA-C 107.872 -2.091 . . . . 0.0 107.872 176.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.5 m -135.18 126.24 27.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.455 -1.027 . . . . 0.0 108.996 179.489 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.407 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.43 -85.91 0.09 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.02 -1.05 . . . . 0.0 109.692 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -57.95 152.94 15.23 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.239 0.542 . . . . 0.0 109.679 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.95 HG21 ' CE1' ' A' ' 40' ' ' PHE . 27.5 t -139.22 118.46 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.295 -0.878 . . . . 0.0 110.943 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -101.53 101.28 11.82 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.867 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -113.2 168.61 9.58 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.265 -0.897 . . . . 0.0 111.082 -178.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -101.65 155.01 18.37 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 121.422 0.63 . . . . 0.0 109.618 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.618 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.96 -156.26 0.48 Allowed Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -88.93 40.44 0.51 Allowed 'Trans proline' 0 C--N 1.296 -2.198 0 C-N-CA 122.194 1.929 . . . . 0.0 110.356 178.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.633 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -142.06 156.64 45.41 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 119.99 -1.694 . . . . 0.0 112.357 -178.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.453 ' HB2' ' NE1' ' A' ' 38' ' ' TRP . . . -167.41 -168.34 1.03 Allowed 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.25 -1.019 . . . . 0.0 108.25 179.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.416 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 11.5 p -156.24 141.61 17.57 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.023 -1.048 . . . . 0.0 109.678 179.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.717 ' O ' HD22 ' A' ' 22' ' ' LEU . 12.0 m80 -99.01 143.86 28.81 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-O 121.743 0.783 . . . . 0.0 111.614 -178.328 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.536 HH21 HD21 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -114.6 90.63 3.39 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.459 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.071 ' CE2' HG11 ' A' ' 83' ' ' VAL . 37.0 m-85 -93.59 136.95 33.35 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.955 -1.091 . . . . 0.0 109.762 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 8.4 p -123.62 -33.12 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.283 -0.886 . . . . 0.0 111.356 -178.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.443 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -95.03 147.36 32.91 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 120.526 -1.359 . . . . 0.0 109.478 -179.431 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.443 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.4 Cg_endo -78.75 116.59 3.8 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.545 2.163 . . . . 0.0 109.972 179.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 166.68 -155.17 26.16 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.479 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 8.2 mtm-85 -115.1 123.08 48.06 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.261 -1.14 . . . . 0.0 109.715 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.573 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 62.5 m-85 -106.45 157.63 17.5 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.441 -0.787 . . . . 0.0 109.367 179.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 67.2 t60 -109.85 129.39 55.65 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.618 HG22 ' NE2' ' A' ' 56' ' ' HIS . 83.0 t -110.36 151.49 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.385 -0.822 . . . . 0.0 109.969 -179.439 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.442 HG23 ' CB ' ' A' ' 39' ' ' ASP . 0.2 OUTLIER -150.46 157.12 42.66 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.133 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.111 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.43 156.41 41.41 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 120.889 -1.132 . . . . 0.0 110.979 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.594 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.4 p -147.32 107.66 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.799 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -90.19 153.19 20.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.896 -1.128 . . . . 0.0 110.445 -178.39 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -131.13 117.91 19.75 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.303 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.908 HD21 ' HB2' ' A' ' 30' ' ' PRO . 6.1 mp -106.05 -12.86 15.64 Favored 'General case' 0 C--N 1.293 -1.85 0 CA-C-O 121.495 0.664 . . . . 0.0 109.29 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 107.15 -45.76 1.26 Allowed Glycine 0 N--CA 1.488 2.116 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -178.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.13 -6.76 12.48 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.59 -0.947 . . . . 0.0 109.704 179.082 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -150.02 165.23 29.76 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.641 -1.383 . . . . 0.0 109.641 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.35 168.75 23.83 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.246 -1.149 . . . . 0.0 109.512 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.799 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -145.14 140.68 28.16 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.197 -0.939 . . . . 0.0 109.487 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.55 HD13 ' O ' ' A' ' 68' ' ' ALA . 1.7 mm? -107.16 150.88 26.11 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.067 -1.02 . . . . 0.0 110.3 -179.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.111 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -134.96 158.53 44.08 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.467 -0.771 . . . . 0.0 109.842 -179.751 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.529 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -167.72 91.47 0.1 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.6 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -114.26 -171.57 1.94 Allowed 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.08 -1.247 . . . . 0.0 110.165 -179.7 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -150.15 147.96 28.37 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 179.201 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.071 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -129.86 140.81 48.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 120.617 -1.302 . . . . 0.0 110.027 -179.271 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . 0.464 ' HG2' ' HG2' ' A' ' 63' ' ' ARG . 0.8 OUTLIER -104.07 85.55 2.41 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 179.381 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.746 HG22 ' HB3' ' A' ' 17' ' ' LEU . 98.4 t -77.74 136.99 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.151 -0.968 . . . . 0.0 109.644 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -124.05 142.55 51.09 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.278 -0.889 . . . . 0.0 109.579 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.168 -0.957 . . . . 0.0 109.648 179.809 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.748 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.891 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.0 OUTLIER -73.48 149.21 42.49 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.282 -0.886 . . . . 0.0 109.209 -179.442 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.741 HD23 HG22 ' A' ' 81' ' ' THR . 5.2 mp -91.38 103.81 16.4 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.322 -178.315 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.672 HG11 ' NE2' ' A' ' 26' ' ' HIS . 3.1 t -117.12 105.47 18.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 O-C-N 120.776 -1.203 . . . . 0.0 108.782 178.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.542 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.93 74.17 0.3 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.504 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 35.3 Cg_endo -73.14 152.54 50.9 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.752 2.301 . . . . 0.0 111.983 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.494 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.2 t-80 163.74 -37.99 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 CA-C-O 121.698 0.761 . . . . 0.0 108.961 179.58 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 112.5 -136.54 13.57 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 108.308 -1.917 . . . . 0.0 108.308 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -78.01 149.18 25.46 Favored 'Trans proline' 0 C--N 1.304 -1.797 0 C-N-CA 122.246 1.964 . . . . 0.0 109.352 179.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.821 HD21 ' HB2' ' A' ' 23' ' ' ALA . 22.7 mt -120.75 93.37 4.01 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.041 -1.037 . . . . 0.0 110.102 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 86' ' ' GLU . . . -87.42 164.03 16.42 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.082 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.437 ' CB ' ' HA ' ' A' ' 87' ' ' ALA . 40.6 t -49.96 121.27 5.17 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.564 -0.71 . . . . 0.0 110.085 -179.406 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 88.31 47.47 4.35 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 179.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.514 ' HB3' HD23 ' A' ' 17' ' ' LEU . 4.4 mm-40 -122.4 149.57 43.64 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.23 -1.159 . . . . 0.0 110.94 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.729 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.4 tm? -108.49 98.55 8.06 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.821 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -81.93 154.63 25.68 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.504 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -117.4 121.37 40.9 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.611 -1.306 . . . . 0.0 107.981 179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.754 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 7.3 m-85 -108.15 173.5 6.29 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 122.425 1.107 . . . . 0.0 112.362 -176.813 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.672 ' NE2' HG11 ' A' ' 11' ' ' VAL . 3.4 p80 -171.27 144.51 2.03 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 177.286 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.832 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.54 158.33 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.095 -1.003 . . . . 0.0 108.571 -178.578 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.891 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -136.91 122.41 19.59 Favored 'General case' 0 N--CA 1.501 2.121 0 C-N-CA 118.445 -1.302 . . . . 0.0 112.627 -178.462 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.048 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 172.01 -68.24 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.916 0 O-C-N 121.201 -0.937 . . . . 0.0 109.595 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.048 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -76.41 78.39 3.29 Favored 'Trans proline' 0 C--N 1.313 -1.332 0 C-N-CA 121.758 1.639 . . . . 0.0 109.374 179.387 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.523 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 3.7 mp -32.5 -54.97 0.56 Allowed Pre-proline 0 N--CA 1.499 2.019 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -178.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.559 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.7 Cg_endo -79.85 60.77 7.96 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 C-N-CA 122.249 1.966 . . . . 0.0 111.994 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.904 HG23 ' O ' ' A' ' 30' ' ' PRO . 94.2 t -84.14 149.0 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.633 -1.292 . . . . 0.0 109.708 179.283 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 31.9 p -122.11 -36.62 2.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.41 -0.806 . . . . 0.0 109.611 179.242 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -154.04 136.36 14.92 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.515 -0.741 . . . . 0.0 109.257 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.882 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.2 t -123.59 140.05 53.38 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.506 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.515 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 1.2 ttp180 -107.68 106.05 16.19 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.816 179.285 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.754 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 36.1 m95 -89.08 179.55 6.12 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.998 0.904 . . . . 0.0 109.111 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.424 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.78 100.23 2.8 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 177.445 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.989 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.7 m-30 -80.01 -59.79 2.58 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.787 -1.165 . . . . 0.0 110.011 -177.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.54 17.27 53.06 Favored Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -104.35 -103.75 0.31 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 178.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.61 -21.63 59.63 Favored Glycine 0 C--N 1.297 -1.631 0 N-CA-C 107.717 -2.153 . . . . 0.0 107.717 176.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 11.6 p -134.58 129.8 35.55 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.427 -1.043 . . . . 0.0 109.148 179.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.424 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.25 -84.22 0.11 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.074 -1.016 . . . . 0.0 109.686 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -58.78 149.27 26.92 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.153 0.501 . . . . 0.0 109.848 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.989 HG21 ' CE1' ' A' ' 40' ' ' PHE . 42.3 t -137.72 121.05 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.385 -0.822 . . . . 0.0 110.755 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 61.8 m-20 -104.17 97.26 7.25 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.882 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -107.89 166.35 10.77 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.251 -0.905 . . . . 0.0 111.239 -178.292 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.58 154.58 18.15 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-O 121.275 0.56 . . . . 0.0 109.533 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.602 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.88 -155.65 0.53 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.788 -1.725 . . . . 0.0 108.788 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -89.53 40.74 0.48 Allowed 'Trans proline' 0 C--N 1.295 -2.252 0 C-N-CA 122.256 1.971 . . . . 0.0 110.486 178.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.656 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.43 156.42 44.65 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 119.882 -1.762 . . . . 0.0 112.581 -178.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.459 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -168.06 -167.69 0.86 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 7.3 p -155.52 141.38 18.12 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.959 -1.088 . . . . 0.0 109.738 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.729 ' O ' HD22 ' A' ' 22' ' ' LEU . 12.9 m80 -97.98 142.83 29.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.499 -0.75 . . . . 0.0 111.442 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.517 HH21 HD21 ' A' ' 22' ' ' LEU . 0.9 OUTLIER -114.52 90.52 3.36 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.697 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.089 ' CE2' HG11 ' A' ' 83' ' ' VAL . 31.2 m-85 -94.15 122.3 36.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.11 -0.994 . . . . 0.0 109.751 -178.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.0 m -115.83 -26.02 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.487 -0.758 . . . . 0.0 111.104 -178.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.452 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -98.04 146.31 31.28 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 120.647 -1.283 . . . . 0.0 109.227 -179.636 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.452 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.1 Cg_endo -77.19 123.8 6.87 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 122.41 2.073 . . . . 0.0 110.018 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 156.47 -169.8 33.92 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.419 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -103.84 121.74 43.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.285 -1.127 . . . . 0.0 109.884 -179.823 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.586 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 79.9 m-85 -100.2 160.76 14.08 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.391 -0.818 . . . . 0.0 109.645 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.478 ' CD2' HG22 ' A' ' 67' ' ' THR . 35.8 t60 -115.18 121.88 44.34 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 178.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.593 HG22 ' NE2' ' A' ' 56' ' ' HIS . 64.5 t -102.86 151.57 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.265 -0.897 . . . . 0.0 110.648 -179.051 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.478 HG22 ' CD2' ' A' ' 65' ' ' HIS . 0.1 OUTLIER -150.61 160.2 43.97 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 178.427 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.08 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -153.3 157.97 40.89 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.094 -1.004 . . . . 0.0 110.695 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.617 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.2 p -147.07 107.8 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.817 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.2 OUTLIER -88.94 147.86 24.11 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 120.849 -1.157 . . . . 0.0 110.147 -178.043 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.47 113.88 16.08 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 121.932 0.872 . . . . 0.0 108.808 178.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.893 HD21 ' HB2' ' A' ' 30' ' ' PRO . 6.0 mp -103.36 -12.57 17.13 Favored 'General case' 0 C--N 1.289 -2.027 0 CA-C-O 121.553 0.692 . . . . 0.0 109.194 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 112.3 -49.84 0.82 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 -178.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.1 -5.66 11.92 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.577 -0.955 . . . . 0.0 109.815 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.16 160.78 27.87 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.426 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.2 p -151.04 173.31 14.48 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.398 -1.06 . . . . 0.0 109.218 -179.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.817 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -149.88 129.63 13.25 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.261 -0.899 . . . . 0.0 109.651 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.3 tt -94.33 140.0 30.35 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.424 -0.798 . . . . 0.0 110.007 -179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.08 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -126.23 155.25 42.13 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.449 -0.782 . . . . 0.0 110.275 -179.336 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.472 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -162.65 87.05 0.11 Allowed Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.413 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.741 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -105.31 -175.6 2.84 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.028 -1.278 . . . . 0.0 109.633 179.904 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . 0.406 ' N ' ' OG1' ' A' ' 81' ' ' THR . 0.7 OUTLIER -150.96 146.49 26.28 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 179.258 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.089 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -131.69 141.49 45.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 120.602 -1.311 . . . . 0.0 110.239 -179.474 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 17.9 tt0 -104.37 89.37 3.21 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.744 HG21 ' HB3' ' A' ' 58' ' ' TYR . 43.4 t -82.07 133.79 28.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.204 -0.935 . . . . 0.0 110.115 -179.08 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.597 ' HG3' ' HA ' ' A' ' 18' ' ' ALA . 11.2 pt-20 -103.56 -147.97 0.39 Allowed 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.437 ' HA ' ' CB ' ' A' ' 19' ' ' SER . . . . . . . . 0 N--CA 1.489 1.508 0 O-C-N 120.952 -1.092 . . . . 0.0 109.335 179.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.738 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.752 HG22 ' HB3' ' A' ' 28' ' ' ALA . 0.6 OUTLIER -68.93 147.39 51.73 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.277 -0.889 . . . . 0.0 109.278 -179.147 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.767 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.0 mp -92.63 109.16 20.57 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.261 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.624 HG21 ' CE1' ' A' ' 26' ' ' HIS . 2.5 t -123.88 106.11 16.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.9 -1.125 . . . . 0.0 108.738 178.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.556 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.91 76.24 0.3 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.881 -1.287 . . . . 0.0 109.881 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.509 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.0 Cg_endo -73.38 150.25 46.33 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.729 2.286 . . . . 0.0 112.064 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.54 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 40.0 t-80 165.84 -38.77 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.701 0 CA-C-O 121.696 0.76 . . . . 0.0 109.114 179.623 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.01 -137.63 14.29 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 108.221 -1.952 . . . . 0.0 108.221 -179.106 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -77.83 148.86 25.71 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 C-N-CA 122.237 1.958 . . . . 0.0 109.371 179.053 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.829 HD21 ' HB2' ' A' ' 23' ' ' ALA . 34.5 mt -118.3 100.08 7.26 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.066 -1.021 . . . . 0.0 109.987 -179.539 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.466 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -86.5 171.3 11.19 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.149 -0.969 . . . . 0.0 108.432 179.144 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 37.4 t -54.59 126.26 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.189 -0.944 . . . . 0.0 109.851 -179.51 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 77.45 51.61 5.97 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.48 ' HB3' HD23 ' A' ' 17' ' ' LEU . 0.4 OUTLIER -115.55 149.78 37.65 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.392 -1.064 . . . . 0.0 110.838 -179.426 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.739 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.1 tm? -109.46 96.67 6.43 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.829 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -81.21 155.97 25.88 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.949 -1.094 . . . . 0.0 108.123 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.509 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.61 116.6 26.35 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.523 -1.361 . . . . 0.0 108.11 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.67 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 4.4 m-85 -104.53 170.38 7.92 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-O 122.319 1.057 . . . . 0.0 112.229 -176.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.624 ' CE1' HG21 ' A' ' 11' ' ' VAL . 4.6 p80 -167.08 149.04 6.0 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.828 HD11 ' CH2' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -112.96 161.85 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.095 -1.003 . . . . 0.0 109.216 -178.294 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.752 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -138.97 118.96 13.33 Favored 'General case' 0 N--CA 1.501 2.086 0 C-N-CA 118.629 -1.228 . . . . 0.0 112.463 -178.636 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.031 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 173.43 -68.67 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.914 0 O-C-N 121.206 -0.934 . . . . 0.0 109.634 177.688 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.031 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 33.5 Cg_endo -76.64 78.19 3.41 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 121.716 1.611 . . . . 0.0 109.362 179.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.506 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -33.27 -54.43 0.68 Allowed Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.946 -0.471 . . . . 0.0 112.186 -179.008 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.611 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.3 Cg_endo -79.69 58.53 7.01 Favored 'Trans proline' 0 C--N 1.314 -1.273 0 C-N-CA 122.113 1.875 . . . . 0.0 112.055 -179.296 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.911 HG23 ' O ' ' A' ' 30' ' ' PRO . 93.9 t -81.78 147.44 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 120.724 -1.235 . . . . 0.0 109.42 179.05 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 74.0 p -122.27 -37.06 2.86 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.313 -0.867 . . . . 0.0 109.614 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -154.34 136.34 14.64 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.847 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.5 t -123.11 150.07 43.69 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.581 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.7 OUTLIER -115.54 103.44 10.74 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.351 -0.94 . . . . 0.0 108.847 179.155 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.828 ' CH2' HD11 ' A' ' 27' ' ' ILE . 31.7 m95 -87.66 179.13 6.57 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.158 -0.964 . . . . 0.0 109.113 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.509 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.5 OUTLIER -149.03 103.08 3.31 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 177.835 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 1.029 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.4 m-30 -81.13 -63.72 1.34 Allowed 'General case' 0 N--CA 1.491 1.597 0 C-N-CA 118.83 -1.148 . . . . 0.0 110.275 -177.782 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.59 7.05 62.0 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.501 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 13.6 p30 -98.79 31.15 3.04 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.324 -1.103 . . . . 0.0 108.647 179.367 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 117.94 -40.74 2.23 Favored Glycine 0 C--N 1.295 -1.742 0 N-CA-C 105.409 -3.077 . . . . 0.0 105.409 -176.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -106.57 100.29 9.82 Favored 'General case' 0 N--CA 1.485 1.311 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 177.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.513 ' O ' HG23 ' A' ' 47' ' ' VAL . . . -76.21 -89.84 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.029 -1.044 . . . . 0.0 109.943 -178.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -51.48 142.15 14.43 Favored 'General case' 0 N--CA 1.495 1.825 0 CA-C-O 121.287 0.565 . . . . 0.0 109.736 -179.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 1.029 HG21 ' CE1' ' A' ' 40' ' ' PHE . 95.8 t -134.92 113.77 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.345 -0.847 . . . . 0.0 110.813 -178.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -94.84 99.46 11.52 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.534 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.847 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -110.64 167.7 10.03 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.368 -0.832 . . . . 0.0 111.015 -178.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.33 153.65 19.14 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.695 -0.628 . . . . 0.0 109.564 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.549 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.28 -156.51 0.52 Allowed Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 -179.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -89.08 40.14 0.49 Allowed 'Trans proline' 0 C--N 1.294 -2.336 0 C-N-CA 122.279 1.986 . . . . 0.0 110.285 178.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.574 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -142.73 156.32 44.99 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.889 -1.757 . . . . 0.0 112.62 -178.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.509 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -170.64 -171.76 1.1 Allowed 'General case' 0 N--CA 1.495 1.782 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 179.229 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.504 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -148.98 150.2 32.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.94 -1.1 . . . . 0.0 109.637 179.494 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.739 ' O ' HD22 ' A' ' 22' ' ' LEU . 8.5 m80 -105.89 143.54 33.89 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.39 -0.819 . . . . 0.0 111.006 -178.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.431 ' NH2' HD21 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -118.16 89.4 3.12 Favored 'General case' 0 N--CA 1.489 1.476 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.709 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.111 ' CE2' HG11 ' A' ' 83' ' ' VAL . 43.0 m-85 -91.49 138.97 31.15 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.914 . . . . 0.0 109.898 -178.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.1 p -124.27 -35.85 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.336 -0.852 . . . . 0.0 111.355 -178.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.43 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -86.77 146.5 41.3 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 120.511 -1.368 . . . . 0.0 109.607 -179.446 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.473 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.5 Cg_endo -78.18 117.55 4.14 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 122.477 2.118 . . . . 0.0 110.013 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 162.11 -147.61 13.98 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.425 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -123.39 140.75 52.69 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.096 -1.237 . . . . 0.0 109.671 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.557 ' HB2' HG13 ' A' ' 83' ' ' VAL . 66.9 m-85 -119.98 164.37 16.19 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.322 -0.861 . . . . 0.0 109.906 -179.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 64.1 t60 -115.77 127.42 55.08 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 178.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.589 HG22 ' NE2' ' A' ' 56' ' ' HIS . 66.7 t -110.06 152.48 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 110.488 -179.1 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -146.93 158.62 43.97 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.057 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -155.12 117.89 4.32 Favored 'General case' 0 N--CA 1.498 1.94 0 C-N-CA 118.885 -1.126 . . . . 0.0 111.689 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.581 ' O ' HG13 ' A' ' 69' ' ' VAL . 7.2 p -108.49 110.43 31.98 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 177.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.815 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.04 154.51 20.14 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.762 -1.211 . . . . 0.0 110.038 -178.801 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.18 116.65 16.5 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.779 0.799 . . . . 0.0 108.883 178.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.933 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.8 mp -105.43 -12.88 15.83 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 121.539 0.685 . . . . 0.0 109.26 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.67 -44.59 1.44 Allowed Glycine 0 N--CA 1.488 2.149 0 N-CA-C 107.906 -2.077 . . . . 0.0 107.906 -178.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -113.89 -5.82 13.21 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.557 -0.966 . . . . 0.0 109.847 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -153.63 166.06 31.69 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.43 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 1.4 p -150.9 170.79 18.46 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.272 -1.134 . . . . 0.0 109.404 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.815 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -145.72 135.02 22.97 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.271 -0.893 . . . . 0.0 109.541 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 4.1 mp -101.04 131.11 47.09 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.148 -0.97 . . . . 0.0 109.992 -179.572 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.057 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -118.11 155.17 30.86 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 121.451 -0.781 . . . . 0.0 110.208 -179.149 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -161.58 86.7 0.11 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.755 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -106.04 -172.78 2.15 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.015 -1.285 . . . . 0.0 109.888 -179.808 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -151.25 152.88 33.87 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 179.411 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.111 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.5 OUTLIER -132.77 155.48 41.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.781 -1.2 . . . . 0.0 109.88 -179.822 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . 0.437 ' N ' HG23 ' A' ' 83' ' ' VAL . 31.6 tt0 -122.17 88.27 2.9 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.494 -0.754 . . . . 0.0 109.231 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.672 HG22 ' HB3' ' A' ' 17' ' ' LEU . 80.0 t -81.8 139.87 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.216 -0.927 . . . . 0.0 109.613 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -117.29 170.65 8.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.291 -0.88 . . . . 0.0 109.666 -179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.473 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.553 0 O-C-N 121.12 -0.988 . . . . 0.0 109.352 179.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.996 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.686 ' CG2' ' HB3' ' A' ' 28' ' ' ALA . 0.4 OUTLIER -81.66 140.24 34.49 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 179.807 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.731 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.5 mp -100.26 100.33 11.13 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -178.246 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.774 HG12 ' HD3' ' A' ' 13' ' ' PRO . 21.8 t -113.81 116.35 52.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 120.654 -1.279 . . . . 0.0 109.177 178.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.521 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -120.87 72.58 0.35 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 108.901 -1.679 . . . . 0.0 108.901 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.774 ' HD3' HG12 ' A' ' 11' ' ' VAL . 32.5 Cg_endo -71.27 147.46 53.4 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.83 2.353 . . . . 0.0 113.069 -179.067 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.565 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 151.58 170.76 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 114.639 -1.164 . . . . 0.0 108.122 179.102 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.46 -141.34 1.15 Allowed Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -76.74 151.91 32.35 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 C-N-CA 122.225 1.95 . . . . 0.0 109.464 179.255 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 1.142 HD21 ' HB2' ' A' ' 23' ' ' ALA . 51.3 mt -104.74 91.51 3.88 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.001 -1.062 . . . . 0.0 109.427 -179.614 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.87 169.17 11.82 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.9 t -55.02 113.55 1.39 Allowed 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.259 -0.9 . . . . 0.0 109.34 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 94.17 38.29 5.15 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.237 -1.545 . . . . 0.0 109.237 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.499 ' HG2' ' HA ' ' A' ' 17' ' ' LEU . 3.1 tp-100 -107.89 146.33 32.49 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.286 -1.126 . . . . 0.0 110.609 -179.447 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.701 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.8 tm? -108.65 94.43 5.05 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.531 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 1.142 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -77.68 158.62 29.62 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.027 -1.046 . . . . 0.0 108.266 179.238 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.534 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.92 119.3 31.14 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.566 -1.334 . . . . 0.0 107.869 179.293 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.697 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 3.1 m-85 -106.09 170.35 7.96 Favored 'General case' 0 N--CA 1.489 1.517 0 CA-C-O 121.96 0.886 . . . . 0.0 111.583 -177.006 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.625 ' CE1' HG21 ' A' ' 11' ' ' VAL . 2.3 p80 -164.66 143.65 7.03 Favored 'General case' 0 N--CA 1.488 1.429 0 N-CA-C 107.813 -1.181 . . . . 0.0 107.813 176.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.951 HD12 ' HG ' ' A' ' 79' ' ' LEU . 6.0 mm -109.14 154.05 10.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.34 -0.85 . . . . 0.0 109.997 -177.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.686 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -136.69 113.38 10.24 Favored 'General case' 0 N--CA 1.498 1.962 0 C-N-CA 118.933 -1.107 . . . . 0.0 111.629 -179.443 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.081 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -178.39 -61.7 0.0 OUTLIER Pre-proline 0 N--CA 1.494 1.766 0 O-C-N 120.936 -1.102 . . . . 0.0 109.791 178.36 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.081 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.0 Cg_endo -80.19 63.06 8.71 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.14 1.893 . . . . 0.0 109.874 179.693 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.637 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.1 OUTLIER -12.96 -64.32 0.02 OUTLIER Pre-proline 0 N--CA 1.506 2.37 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -179.101 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.637 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 35.5 Cg_endo -77.34 71.58 6.32 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 C-N-CA 121.788 1.659 . . . . 0.0 110.926 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.541 HG22 ' HG2' ' A' ' 30' ' ' PRO . 3.0 t -96.7 135.14 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 120.853 -1.155 . . . . 0.0 109.919 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 6.4 t -111.58 -16.72 13.2 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.414 -0.804 . . . . 0.0 109.375 178.64 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.83 150.54 0.5 Allowed 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.372 -0.83 . . . . 0.0 109.827 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.705 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -137.98 137.64 38.11 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.374 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.54 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 0.3 OUTLIER -89.61 104.26 16.84 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.192 -0.942 . . . . 0.0 108.7 179.555 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.915 ' CH2' HD11 ' A' ' 27' ' ' ILE . 26.1 m95 -87.65 178.73 6.68 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.906 -1.121 . . . . 0.0 109.45 -179.589 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.453 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.7 OUTLIER -149.8 102.27 3.13 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 178.359 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.986 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.1 m-30 -80.51 -58.58 3.05 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.696 -1.202 . . . . 0.0 109.966 -178.134 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.87 15.82 57.3 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.079 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -104.63 -105.72 0.3 Allowed 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 178.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.13 -17.41 67.17 Favored Glycine 0 C--N 1.296 -1.669 0 N-CA-C 107.982 -2.047 . . . . 0.0 107.982 177.042 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.4 m -135.88 125.42 25.18 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.413 -1.051 . . . . 0.0 109.042 179.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.24 -84.59 0.1 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.053 -1.029 . . . . 0.0 109.849 -179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -58.42 149.78 24.09 Favored 'General case' 0 N--CA 1.495 1.809 0 CA-C-O 121.272 0.558 . . . . 0.0 110.105 -179.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.986 HG21 ' CE1' ' A' ' 40' ' ' PHE . 21.1 t -139.68 128.98 28.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 O-C-N 121.26 -0.9 . . . . 0.0 111.263 -178.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -108.15 91.4 3.63 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 177.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.704 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -97.35 155.67 16.79 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.347 -0.845 . . . . 0.0 111.517 -177.796 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.56 151.01 20.38 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.778 -0.576 . . . . 0.0 109.477 179.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.705 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.84 -159.11 0.61 Allowed Glycine 0 N--CA 1.489 2.181 0 N-CA-C 107.997 -2.041 . . . . 0.0 107.997 -179.152 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.507 ' HB3' HG21 ' A' ' 33' ' ' VAL . 37.8 Cg_endo -87.43 41.2 0.69 Allowed 'Trans proline' 0 C--N 1.297 -2.14 0 C-N-CA 122.017 1.811 . . . . 0.0 109.99 178.265 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.704 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.46 150.44 39.0 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 120.152 -1.592 . . . . 0.0 112.097 -178.654 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.565 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -160.02 -168.32 2.19 Favored 'General case' 0 N--CA 1.495 1.778 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 179.045 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.701 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.1 OUTLIER -152.67 154.31 35.06 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.219 -0.926 . . . . 0.0 109.09 179.491 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.685 ' O ' HD22 ' A' ' 22' ' ' LEU . 13.3 m80 -113.63 133.86 55.05 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.043 -1.036 . . . . 0.0 111.411 -178.63 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.75 87.17 2.61 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 178.723 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.113 ' CE2' HG11 ' A' ' 83' ' ' VAL . 31.7 m-85 -89.44 125.37 35.14 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.199 -0.938 . . . . 0.0 109.684 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 86.0 t -114.58 -34.52 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.428 -0.795 . . . . 0.0 110.928 -178.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.461 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.2 OUTLIER -90.78 145.94 33.02 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 120.542 -1.349 . . . . 0.0 109.487 -179.367 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.599 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 34.8 Cg_endo -77.66 125.52 7.58 Favored 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.44 2.093 . . . . 0.0 109.937 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.87 -154.57 25.63 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.468 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 3.9 mpt_? -114.68 133.85 55.55 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.101 -1.234 . . . . 0.0 109.65 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.609 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 82.2 m-85 -115.92 150.13 37.6 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.313 -0.867 . . . . 0.0 109.714 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.453 ' CD2' HG22 ' A' ' 67' ' ' THR . 58.9 t60 -103.95 129.63 51.52 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.482 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.585 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 92.0 t -111.03 155.18 12.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.255 -0.903 . . . . 0.0 110.236 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.453 HG22 ' CD2' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -149.84 158.6 44.32 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.658 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.054 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -154.04 123.47 6.58 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.752 -1.179 . . . . 0.0 111.709 -179.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -95.89 126.59 48.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.732 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.949 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.6 OUTLIER -88.61 142.35 27.76 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 120.727 -1.233 . . . . 0.0 108.722 -178.738 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.75 110.39 11.3 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 120.739 -1.225 . . . . 0.0 109.832 178.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.837 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.7 mp -105.39 -10.84 16.73 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.137 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 108.38 -45.51 1.3 Allowed Glycine 0 N--CA 1.486 2.029 0 N-CA-C 107.895 -2.082 . . . . 0.0 107.895 -178.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -119.84 -5.13 10.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.605 -0.938 . . . . 0.0 109.839 179.178 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.14 165.58 27.34 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 6.8 p -151.09 -176.88 5.72 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.391 -1.064 . . . . 0.0 109.741 -179.467 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.949 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -155.18 164.33 38.97 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.5 tp -120.82 119.85 33.89 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.147 -0.971 . . . . 0.0 110.067 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.054 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -105.53 156.12 18.53 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.603 -0.686 . . . . 0.0 109.392 -179.702 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.585 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.14 99.34 0.16 Allowed Glycine 0 N--CA 1.485 1.905 0 N-CA-C 109.991 -1.244 . . . . 0.0 109.991 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.436 HG22 HD23 ' A' ' 10' ' ' LEU . 0.7 OUTLIER -115.65 -173.43 2.34 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 120.923 -1.34 . . . . 0.0 110.216 179.993 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -149.79 140.07 22.25 Favored 'General case' 0 N--CA 1.491 1.579 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.113 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -125.77 152.04 32.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 120.916 -1.115 . . . . 0.0 109.916 -179.455 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.74 86.44 2.52 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.455 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.864 HG21 ' HB3' ' A' ' 58' ' ' TYR . 78.8 t -77.85 140.79 16.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.04 -1.038 . . . . 0.0 110.355 -179.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -114.99 -173.93 2.4 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.426 -0.797 . . . . 0.0 109.361 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.599 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.553 0 O-C-N 120.895 -1.128 . . . . 0.0 109.701 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.859 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.782 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -90.19 141.91 28.23 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.096 -1.076 . . . . 0.0 108.096 179.664 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.76 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.3 mp -97.05 95.33 7.71 Favored 'General case' 0 C--N 1.303 -1.417 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -178.283 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.931 HG12 ' HD3' ' A' ' 13' ' ' PRO . 47.5 t -105.65 118.12 52.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 120.894 -1.129 . . . . 0.0 109.186 179.475 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -123.75 71.42 0.43 Allowed Glycine 0 N--CA 1.494 2.505 0 N-CA-C 109.063 -1.615 . . . . 0.0 109.063 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.931 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.5 Cg_endo -72.81 150.81 50.42 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 123.136 2.557 . . . . 0.0 113.517 -178.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.588 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 0.1 OUTLIER 145.74 179.04 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.091 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.283 178.717 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.81 -144.52 4.63 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -75.99 150.98 34.69 Favored 'Trans proline' 0 C--N 1.307 -1.648 0 C-N-CA 122.32 2.013 . . . . 0.0 109.51 179.662 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.895 HD21 ' HB2' ' A' ' 23' ' ' ALA . 17.2 mt -102.04 82.53 2.24 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.038 -1.039 . . . . 0.0 109.759 -179.578 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -75.3 165.5 25.08 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.037 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 18.1 t -58.49 114.12 2.31 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.043 -1.035 . . . . 0.0 109.187 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 96.54 44.28 2.98 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -120.69 155.38 33.99 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.337 -1.096 . . . . 0.0 110.879 -179.509 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.759 HD22 ' O ' ' A' ' 56' ' ' HIS . 2.8 tm? -112.33 97.7 6.8 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.895 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -79.44 157.55 27.5 Favored 'General case' 0 N--CA 1.495 1.775 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.543 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.75 120.25 36.01 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.497 -1.377 . . . . 0.0 108.167 179.414 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.669 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 3.4 m-85 -105.16 173.55 6.26 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 121.987 0.899 . . . . 0.0 111.542 -177.162 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.734 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -168.26 138.7 2.61 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.06 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.96 HD12 ' HG ' ' A' ' 79' ' ' LEU . 5.0 mm -107.43 149.53 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.401 -0.812 . . . . 0.0 109.154 -178.282 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.653 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -134.42 124.56 25.88 Favored 'General case' 0 N--CA 1.502 2.156 0 C-N-CA 118.57 -1.252 . . . . 0.0 112.281 -178.755 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.025 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -178.8 -66.0 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.831 0 O-C-N 121.101 -0.999 . . . . 0.0 109.116 177.742 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.025 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.7 Cg_endo -81.01 66.71 8.81 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.056 1.838 . . . . 0.0 109.314 179.174 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.702 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -9.93 -66.56 0.01 OUTLIER Pre-proline 0 N--CA 1.513 2.688 0 N-CA-C 112.77 0.656 . . . . 0.0 112.77 -178.427 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.702 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 37.1 Cg_endo -79.35 90.52 1.26 Allowed 'Trans proline' 0 C--N 1.314 -1.261 0 C-N-CA 121.709 1.606 . . . . 0.0 110.577 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.541 HG22 ' HG2' ' A' ' 30' ' ' PRO . 8.7 t -112.59 145.62 18.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.948 -1.095 . . . . 0.0 109.637 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -113.7 -19.08 11.7 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.515 -0.741 . . . . 0.0 110.257 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.13 151.23 0.8 Allowed 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.094 -1.004 . . . . 0.0 110.431 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.69 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -139.1 137.96 36.64 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 178.382 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.525 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 7.0 ttm180 -92.61 112.67 24.7 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.145 -0.972 . . . . 0.0 108.836 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.942 ' CH2' HD11 ' A' ' 27' ' ' ILE . 17.8 m95 -95.77 -178.97 4.56 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -0.894 . . . . 0.0 109.454 -179.812 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.511 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.57 103.06 3.08 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 177.598 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 1.019 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.1 m-30 -80.84 -65.35 1.02 Allowed 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 118.896 -1.122 . . . . 0.0 110.697 -177.369 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 96.51 6.82 58.36 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.534 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 12.1 p30 -98.03 31.47 2.7 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.354 -1.086 . . . . 0.0 108.777 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 116.18 -39.95 2.56 Favored Glycine 0 C--N 1.295 -1.705 0 N-CA-C 105.626 -2.99 . . . . 0.0 105.626 -176.251 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 63.8 p -105.99 103.58 13.1 Favored 'General case' 0 N--CA 1.487 1.386 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 177.452 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.511 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -77.98 -88.97 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.115 -0.991 . . . . 0.0 110.429 -178.373 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -52.67 142.85 17.4 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.311 0.576 . . . . 0.0 109.992 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 1.019 HG21 ' CE1' ' A' ' 40' ' ' PHE . 90.4 t -135.67 132.61 51.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.346 -0.847 . . . . 0.0 110.953 -178.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -111.65 92.66 4.12 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.032 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.705 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -97.26 151.51 19.8 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.305 -0.872 . . . . 0.0 111.283 -177.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.17 150.48 23.92 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.69 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.25 -157.44 0.63 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 108.395 -1.882 . . . . 0.0 108.395 -179.168 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -87.92 39.75 0.56 Allowed 'Trans proline' 0 C--N 1.296 -2.193 0 C-N-CA 122.037 1.825 . . . . 0.0 110.128 178.564 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.705 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.13 149.38 34.91 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.124 -1.61 . . . . 0.0 112.029 -178.54 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.654 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -154.6 -167.18 2.53 Favored 'General case' 0 N--CA 1.496 1.864 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.667 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -153.89 145.47 23.24 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.246 -0.909 . . . . 0.0 109.016 179.448 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.759 ' O ' HD22 ' A' ' 22' ' ' LEU . 10.8 m80 -105.02 138.98 40.39 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.091 -1.006 . . . . 0.0 110.91 -178.804 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -110.07 90.16 3.23 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.123 ' CE2' HG11 ' A' ' 83' ' ' VAL . 30.9 m-85 -92.48 124.49 36.56 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 109.786 -178.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 11.4 m -119.1 -13.93 9.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.486 -0.759 . . . . 0.0 111.385 -178.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.439 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -102.7 148.41 35.49 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 120.663 -1.273 . . . . 0.0 109.618 -179.731 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.738 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 34.8 Cg_endo -78.21 116.45 3.91 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.453 2.102 . . . . 0.0 109.782 179.336 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 155.71 -156.92 27.38 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 2.3 ptt-85 -112.49 159.69 18.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.179 -1.189 . . . . 0.0 110.135 -179.779 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.704 ' HB2' HG13 ' A' ' 83' ' ' VAL . 87.4 m-85 -136.05 159.74 40.79 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.455 -0.778 . . . . 0.0 109.328 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -116.52 115.99 26.8 Favored 'General case' 0 N--CA 1.486 1.372 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.603 HG22 ' NE2' ' A' ' 56' ' ' HIS . 83.3 t -97.77 148.48 5.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.373 -0.83 . . . . 0.0 110.551 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.456 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 2.1 p -145.38 156.0 43.51 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 178.322 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.992 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -152.44 164.79 36.83 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.741 -1.224 . . . . 0.0 110.955 -179.494 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.442 HG12 ' HB3' ' A' ' 37' ' ' ARG . 9.5 p -139.69 129.26 29.28 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 N-CA-C 107.146 -1.428 . . . . 0.0 107.146 178.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.992 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.03 142.03 28.1 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.845 -1.159 . . . . 0.0 108.749 -178.358 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.61 107.4 9.16 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 118.585 -1.246 . . . . 0.0 109.935 178.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.543 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -105.39 -9.98 17.24 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.832 179.159 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.47 -49.5 0.87 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 107.734 -2.146 . . . . 0.0 107.734 -178.413 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.52 -5.91 11.19 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.626 -0.926 . . . . 0.0 109.692 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.65 154.73 23.84 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 29.7 p -149.53 -179.86 7.42 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.291 -1.123 . . . . 0.0 109.421 -179.483 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.992 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -154.79 162.9 40.94 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.622 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -116.67 131.41 56.96 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.098 -1.001 . . . . 0.0 110.128 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.992 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -115.48 157.68 23.66 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.555 -0.715 . . . . 0.0 109.717 -179.809 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.29 89.28 0.09 OUTLIER Glycine 0 N--CA 1.483 1.822 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.531 HG22 HD23 ' A' ' 10' ' ' LEU . 0.2 OUTLIER -109.14 -171.71 1.9 Allowed 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.04 -1.27 . . . . 0.0 109.55 179.675 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -150.81 155.69 39.74 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 179.398 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.123 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.24 151.65 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 120.659 -1.276 . . . . 0.0 109.776 -179.868 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -117.05 85.93 2.42 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.031 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.887 HG21 ' HB3' ' A' ' 58' ' ' TYR . 47.3 t -77.52 136.71 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.351 -0.843 . . . . 0.0 109.791 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -123.25 141.08 52.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.425 -0.797 . . . . 0.0 109.959 -179.638 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.738 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.242 -0.911 . . . . 0.0 109.433 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.757 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.897 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.0 OUTLIER -73.51 148.95 42.61 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.182 -0.949 . . . . 0.0 109.157 -179.374 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.87 HD23 HG22 ' A' ' 81' ' ' THR . 5.3 mp -91.17 103.13 15.85 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.339 -178.413 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.622 HG11 ' NE2' ' A' ' 26' ' ' HIS . 2.6 t -115.38 104.54 16.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 120.928 -1.108 . . . . 0.0 108.682 178.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.557 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -118.37 76.51 0.29 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -179.348 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.527 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 31.1 Cg_endo -71.42 148.24 54.12 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.674 2.249 . . . . 0.0 111.973 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.468 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 41.4 t60 161.13 -37.19 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.3 -139.4 14.81 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 107.952 -2.059 . . . . 0.0 107.952 -179.148 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -76.66 145.78 26.29 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 C-N-CA 122.02 1.813 . . . . 0.0 109.064 178.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.788 HD11 ' HB2' ' A' ' 23' ' ' ALA . 3.3 mm? -104.53 92.94 4.52 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.167 -0.958 . . . . 0.0 109.871 -179.074 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.495 ' HB3' ' HG3' ' A' ' 21' ' ' GLN . . . -74.9 160.2 30.92 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.165 -0.96 . . . . 0.0 108.515 179.104 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.622 ' H ' ' HB3' ' A' ' 87' ' ' ALA . 14.3 t -56.14 125.17 20.51 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.223 -0.923 . . . . 0.0 109.937 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 80.69 49.15 5.86 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.495 ' HG3' ' HB3' ' A' ' 18' ' ' ALA . 0.7 OUTLIER -123.4 151.82 42.21 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.35 -1.088 . . . . 0.0 110.744 -179.517 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.803 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.2 tm? -105.97 98.65 8.31 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.502 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.788 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -78.83 153.09 30.93 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.159 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.527 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -116.66 118.16 31.8 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.469 -1.395 . . . . 0.0 108.44 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.708 ' HB3' ' CH2' ' A' ' 38' ' ' TRP . 7.4 m-85 -107.79 168.35 9.33 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 122.417 1.103 . . . . 0.0 112.262 -177.183 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.622 ' NE2' HG11 ' A' ' 11' ' ' VAL . 4.1 p80 -167.92 145.52 4.36 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 176.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.85 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.2 161.25 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.868 -1.145 . . . . 0.0 108.906 -178.336 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.897 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -139.43 119.55 13.61 Favored 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.556 -1.258 . . . . 0.0 112.433 -178.714 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.04 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 174.24 -68.87 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.958 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 177.614 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.04 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.1 Cg_endo -77.6 78.21 3.6 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 121.779 1.653 . . . . 0.0 109.34 179.399 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.49 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -33.52 -53.95 0.74 Allowed Pre-proline 0 N--CA 1.5 2.029 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -178.913 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.57 ' O ' HD23 ' A' ' 72' ' ' LEU . 36.7 Cg_endo -79.81 58.57 7.04 Favored 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.183 1.922 . . . . 0.0 111.877 -179.283 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.94 HG23 ' O ' ' A' ' 30' ' ' PRO . 73.3 t -82.23 148.43 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 120.843 -1.16 . . . . 0.0 109.273 179.11 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.3 t -120.95 -36.79 3.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.318 -0.864 . . . . 0.0 109.661 179.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -152.06 139.19 19.22 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.453 -0.78 . . . . 0.0 109.156 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.89 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.2 t -127.52 134.92 49.75 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.545 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 2.8 tpp180 -104.07 104.06 13.95 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.042 -1.036 . . . . 0.0 109.174 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.708 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 29.4 m95 -87.82 -179.76 6.32 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.078 -1.014 . . . . 0.0 109.172 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -148.31 100.55 3.16 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 177.724 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.92 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.8 m-30 -80.01 -60.72 2.23 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 118.733 -1.187 . . . . 0.0 109.746 -178.122 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.98 15.93 55.27 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -178.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.25 -104.22 0.25 Allowed 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 178.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.08 -23.92 50.26 Favored Glycine 0 C--N 1.296 -1.649 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 176.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.8 m -128.62 127.69 42.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.501 -1.0 . . . . 0.0 109.04 179.426 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -81.11 -83.91 0.11 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.063 -1.023 . . . . 0.0 109.644 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -58.48 152.2 18.56 Favored 'General case' 0 N--CA 1.495 1.799 0 CA-C-O 121.222 0.534 . . . . 0.0 109.567 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.92 HG21 ' CE1' ' A' ' 40' ' ' PHE . 43.9 t -138.07 113.9 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.069 -1.019 . . . . 0.0 111.444 -178.444 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.19 105.18 17.09 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 177.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.89 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -118.74 168.34 10.82 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.143 -0.973 . . . . 0.0 111.042 -178.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.05 155.32 18.47 Favored 'General case' 0 N--CA 1.49 1.532 0 CA-C-O 121.503 0.668 . . . . 0.0 109.796 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.57 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.29 -155.42 0.64 Allowed Glycine 0 N--CA 1.488 2.159 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -89.77 40.48 0.45 Allowed 'Trans proline' 0 C--N 1.295 -2.284 0 C-N-CA 122.464 2.11 . . . . 0.0 110.484 178.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.58 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.75 154.09 43.1 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 119.899 -1.751 . . . . 0.0 112.658 -178.629 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.61 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -174.36 155.36 2.32 Favored 'General case' 0 N--CA 1.497 1.889 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.803 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -115.61 155.03 28.38 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 120.591 -1.318 . . . . 0.0 110.768 -179.766 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.734 ' O ' HD22 ' A' ' 22' ' ' LEU . 5.3 m80 -105.36 143.31 33.7 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.465 0.65 . . . . 0.0 110.791 -179.221 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -115.05 94.57 4.8 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.091 ' CE2' HG11 ' A' ' 83' ' ' VAL . 25.9 m-85 -99.1 126.98 44.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.148 -0.97 . . . . 0.0 109.747 -178.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 8.2 m -119.46 -31.06 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.362 -0.836 . . . . 0.0 111.553 -178.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.519 ' HB3' ' OH ' ' A' ' 64' ' ' TYR . 0.6 OUTLIER -96.49 140.56 22.24 Favored Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 120.579 -1.325 . . . . 0.0 109.165 -179.49 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.479 ' N ' ' HG ' ' A' ' 60' ' ' LEU . 32.5 Cg_endo -73.1 135.78 23.55 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.293 1.995 . . . . 0.0 110.567 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 148.36 -140.01 8.04 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -179.538 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -129.54 137.64 50.88 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.211 -1.17 . . . . 0.0 109.61 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.578 ' HB2' HG13 ' A' ' 83' ' ' VAL . 79.0 m-85 -117.36 159.68 22.36 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.313 -0.867 . . . . 0.0 109.449 179.637 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.425 ' CD2' HG22 ' A' ' 67' ' ' THR . 11.2 t60 -114.13 126.27 54.9 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 178.838 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.595 HG13 ' CE1' ' A' ' 56' ' ' HIS . 60.1 t -108.94 151.41 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.295 -0.878 . . . . 0.0 110.559 -179.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.425 HG22 ' CD2' ' A' ' 65' ' ' HIS . 0.1 OUTLIER -148.92 161.23 42.29 Favored 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.459 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.1 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -157.96 122.48 4.25 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.869 -1.144 . . . . 0.0 111.609 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.418 ' O ' HG13 ' A' ' 69' ' ' VAL . 2.1 p -112.96 109.15 27.53 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 177.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.805 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.89 147.27 24.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.787 -1.196 . . . . 0.0 109.791 -179.12 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -126.76 116.5 21.02 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.353 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.891 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.6 mp -103.53 -13.42 16.58 Favored 'General case' 0 C--N 1.292 -1.92 0 CA-C-O 121.495 0.664 . . . . 0.0 109.417 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 114.78 -51.55 0.71 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 107.9 -2.08 . . . . 0.0 107.9 -178.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.35 -5.73 12.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.576 -0.955 . . . . 0.0 109.894 179.148 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.3 162.98 27.88 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.7 p -151.24 169.48 21.82 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.393 -1.063 . . . . 0.0 109.59 -179.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.805 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -142.85 136.15 28.43 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 109.463 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.5 tt -101.65 132.41 47.35 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.287 -0.883 . . . . 0.0 110.335 -179.426 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.1 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -121.06 155.01 35.34 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 121.561 -0.712 . . . . 0.0 110.21 -179.372 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.517 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -162.21 88.05 0.11 Allowed Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.437 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.87 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -104.98 -176.65 3.14 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.112 -1.228 . . . . 0.0 109.903 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -150.47 143.76 24.95 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.091 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -130.43 153.08 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 120.567 -1.333 . . . . 0.0 110.22 -179.331 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . 0.415 ' N ' HG23 ' A' ' 83' ' ' VAL . 32.4 tt0 -118.59 100.79 7.66 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 178.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.876 HG21 ' HB3' ' A' ' 58' ' ' TYR . 42.9 t -80.9 136.42 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.148 -0.97 . . . . 0.0 109.854 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 37.5 mt-10 -121.21 -156.61 0.69 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.619 -0.676 . . . . 0.0 109.54 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.622 ' HB3' ' H ' ' A' ' 19' ' ' SER . . . . . . . . 0 N--CA 1.487 1.406 0 O-C-N 121.484 -0.76 . . . . 0.0 110.325 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.718 ' CB ' HG22 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.432 0 CA-C-O 121.457 0.646 . . . . 0.0 109.412 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.813 HG23 HG23 ' A' ' 11' ' ' VAL . 0.6 OUTLIER -87.3 141.04 28.94 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 179.857 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.754 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.4 mp -97.22 94.85 7.34 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.003 -177.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.825 HG12 ' HD3' ' A' ' 13' ' ' PRO . 41.1 t -107.1 115.99 49.77 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.89 -1.131 . . . . 0.0 108.568 178.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.455 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -121.98 71.78 0.39 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.363 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.825 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.4 Cg_endo -73.63 150.79 45.93 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.942 2.428 . . . . 0.0 112.036 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.537 ' CB ' ' O ' ' A' ' 13' ' ' PRO . 16.0 t-80 150.29 -39.52 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.867 0 CA-C-N 115.44 -0.8 . . . . 0.0 108.935 179.53 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 116.4 -142.97 17.88 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.49 -1.844 . . . . 0.0 108.49 -179.218 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.82 149.01 25.9 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 122.306 2.004 . . . . 0.0 109.779 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 1.02 HD11 ' HB2' ' A' ' 23' ' ' ALA . 4.4 mm? -105.2 106.74 17.37 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.181 -0.949 . . . . 0.0 109.207 -179.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.426 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -93.44 168.72 10.87 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.01 -1.057 . . . . 0.0 108.905 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 28.1 t -56.42 120.81 8.29 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.364 -0.835 . . . . 0.0 109.045 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 80.3 44.14 9.0 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.454 ' HG2' HD13 ' A' ' 17' ' ' LEU . 23.0 tp60 -113.35 147.3 37.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.523 -0.986 . . . . 0.0 110.697 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.718 HD11 ' HB2' ' A' ' 55' ' ' SER . 1.8 tm? -108.35 96.32 6.27 Favored 'General case' 0 N--CA 1.488 1.437 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 179.565 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 1.02 ' HB2' HD11 ' A' ' 17' ' ' LEU . . . -78.86 156.59 28.6 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 107.772 -1.195 . . . . 0.0 107.772 178.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.499 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -121.63 108.85 14.05 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.415 -1.428 . . . . 0.0 108.224 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.734 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 2.6 m-85 -95.19 166.7 11.78 Favored 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 122.098 0.952 . . . . 0.0 111.57 -177.282 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.729 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -159.74 135.89 8.82 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 177.864 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.995 HD11 ' CH2' ' A' ' 38' ' ' TRP . 5.0 mm -108.97 152.01 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.933 0 O-C-N 121.368 -0.833 . . . . 0.0 109.526 -177.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.654 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -136.93 136.12 38.32 Favored 'General case' 0 N--CA 1.506 2.354 0 C-N-CA 118.439 -1.305 . . . . 0.0 113.045 -178.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.035 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 174.05 -71.4 0.0 OUTLIER Pre-proline 0 N--CA 1.498 1.951 0 O-C-N 121.002 -1.061 . . . . 0.0 108.963 177.352 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.035 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -79.44 72.89 6.28 Favored 'Trans proline' 0 C--N 1.315 -1.213 0 C-N-CA 121.778 1.652 . . . . 0.0 109.13 178.486 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.623 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 0.0 OUTLIER -13.81 -63.79 0.03 OUTLIER Pre-proline 0 N--CA 1.512 2.661 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -178.437 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.817 ' O ' HD21 ' A' ' 72' ' ' LEU . 36.4 Cg_endo -78.22 63.43 8.29 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 C-N-CA 121.889 1.726 . . . . 0.0 111.187 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.923 HG22 ' HG2' ' A' ' 30' ' ' PRO . 62.1 t -80.95 148.26 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.901 -1.124 . . . . 0.0 109.635 179.616 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 t -120.49 -18.33 7.88 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.345 -0.847 . . . . 0.0 110.648 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -176.48 139.27 0.33 Allowed 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.013 -1.055 . . . . 0.0 110.329 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.744 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -126.73 134.22 50.71 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.356 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.487 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 1.1 mtm180 -93.11 113.83 26.18 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.295 -0.878 . . . . 0.0 108.736 179.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.995 ' CH2' HD11 ' A' ' 27' ' ' ILE . 11.8 m95 -99.19 -179.25 4.18 Favored 'General case' 0 N--CA 1.491 1.608 0 CA-C-O 121.976 0.893 . . . . 0.0 109.853 -179.403 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.514 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.1 OUTLIER -150.62 103.3 3.1 Favored 'General case' 0 C--N 1.295 -1.775 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 177.245 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 1.037 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.7 m-30 -80.78 -65.14 1.05 Allowed 'General case' 0 N--CA 1.492 1.656 0 C-N-CA 118.784 -1.166 . . . . 0.0 110.809 -177.378 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.37 1.47 59.22 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -178.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 13.4 p30 -95.57 34.97 1.4 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.293 -1.122 . . . . 0.0 108.403 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 110.43 -36.46 4.25 Favored Glycine 0 C--N 1.296 -1.677 0 N-CA-C 105.845 -2.902 . . . . 0.0 105.845 -176.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.412 ' O ' ' HB2' ' A' ' 40' ' ' PHE . 18.1 m -104.05 94.05 5.18 Favored 'General case' 0 N--CA 1.487 1.375 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.057 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.49 -95.6 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.22 -0.925 . . . . 0.0 110.066 -178.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -52.22 146.67 8.78 Favored 'General case' 0 N--CA 1.496 1.87 0 CA-C-O 121.194 0.521 . . . . 0.0 109.879 -179.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 1.037 HG21 ' CE1' ' A' ' 40' ' ' PHE . 95.6 t -138.49 130.69 38.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.347 -0.846 . . . . 0.0 110.969 -178.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -111.37 94.71 5.11 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.799 ' CB ' ' HB2' ' A' ' 54' ' ' ALA . . . -100.45 147.9 25.35 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.226 -0.921 . . . . 0.0 111.146 -178.373 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -82.7 151.8 26.07 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.731 -0.605 . . . . 0.0 109.499 179.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.744 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.82 -156.55 0.61 Allowed Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.64 -1.784 . . . . 0.0 108.64 -179.518 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -88.05 39.33 0.52 Allowed 'Trans proline' 0 C--N 1.296 -2.191 0 C-N-CA 122.406 2.071 . . . . 0.0 110.438 178.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.712 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.38 146.65 31.65 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 119.93 -1.731 . . . . 0.0 112.156 -178.707 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.799 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -156.15 -178.81 7.59 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 178.558 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.718 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -141.62 152.49 44.04 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.735 -1.228 . . . . 0.0 109.477 179.414 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.667 ' O ' HD22 ' A' ' 22' ' ' LEU . 5.4 m80 -108.16 138.82 43.78 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.473 -0.767 . . . . 0.0 110.618 -178.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.405 HH21 HD21 ' A' ' 22' ' ' LEU . 0.4 OUTLIER -111.95 89.71 3.14 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 178.972 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.056 ' CE2' HG11 ' A' ' 83' ' ' VAL . 34.5 m-85 -90.25 130.34 36.38 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.172 -0.955 . . . . 0.0 109.307 -179.172 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 9.4 p -116.58 -30.8 1.92 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.252 -0.905 . . . . 0.0 111.283 -178.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.438 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -100.91 146.7 32.58 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 120.703 -1.248 . . . . 0.0 109.453 -179.226 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.438 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 34.7 Cg_endo -76.91 121.46 5.86 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.255 1.97 . . . . 0.0 109.944 179.601 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 164.46 -157.05 29.28 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -112.47 120.76 42.73 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.022 -1.281 . . . . 0.0 109.986 -179.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.506 ' HB2' HG13 ' A' ' 83' ' ' VAL . 86.4 m-85 -105.07 147.13 28.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.492 -0.755 . . . . 0.0 109.349 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -104.24 132.35 50.58 Favored 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.602 HG22 ' NE2' ' A' ' 56' ' ' HIS . 79.6 t -113.57 149.4 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.153 -0.967 . . . . 0.0 110.462 -179.128 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.5 p -148.15 153.91 39.46 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 178.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.109 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.94 163.03 39.67 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.946 -1.096 . . . . 0.0 110.883 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.612 ' O ' HG13 ' A' ' 69' ' ' VAL . 12.1 p -150.9 112.27 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 178.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.876 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -89.01 143.17 27.04 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 120.481 -1.387 . . . . 0.0 110.287 -178.205 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -122.63 117.74 26.51 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 178.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.817 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.9 OUTLIER -105.88 -13.98 15.35 Favored 'General case' 0 C--N 1.29 -2.003 0 CA-C-O 121.587 0.708 . . . . 0.0 109.388 179.866 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 110.72 -51.42 0.7 Allowed Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.363 -1.895 . . . . 0.0 108.363 -179.09 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -110.77 -6.08 14.84 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.6 -0.941 . . . . 0.0 109.628 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -149.87 160.37 28.48 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.415 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 2.0 p -150.58 164.06 36.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.247 -1.149 . . . . 0.0 109.712 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.876 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -138.47 163.71 31.25 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.446 -0.783 . . . . 0.0 109.111 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 15.3 mt -122.9 150.35 43.03 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.173 -0.954 . . . . 0.0 109.939 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.109 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -132.43 160.43 36.44 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.436 -0.79 . . . . 0.0 109.885 -179.44 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.497 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -172.14 99.82 0.15 Allowed Glycine 0 N--CA 1.485 1.965 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.603 HG22 HD23 ' A' ' 10' ' ' LEU . 1.2 p -120.85 -172.42 2.38 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.137 -1.213 . . . . 0.0 110.167 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -151.01 145.31 25.46 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 179.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.056 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.2 OUTLIER -132.64 144.23 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 120.749 -1.219 . . . . 0.0 109.906 -179.502 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -107.69 85.88 2.2 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.238 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.919 HG21 ' HB3' ' A' ' 58' ' ' TYR . 75.6 t -70.46 132.46 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.279 -0.888 . . . . 0.0 110.118 -179.254 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -114.14 -162.96 0.84 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.018 -1.051 . . . . 0.0 109.479 179.734 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.873 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.812 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.79 139.68 30.22 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.77 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.736 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.6 mp -97.19 89.55 4.81 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -178.148 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.941 HG12 ' HD3' ' A' ' 13' ' ' PRO . 65.3 t -99.08 112.34 30.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.885 -1.134 . . . . 0.0 109.092 179.521 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.504 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -124.1 71.18 0.44 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.941 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.4 Cg_endo -73.64 150.4 45.22 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 122.803 2.336 . . . . 0.0 112.153 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.468 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 28.9 t-80 168.9 -38.87 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.681 0.753 . . . . 0.0 109.208 179.353 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.29 -138.05 14.56 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 -178.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -77.62 147.0 24.57 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 121.972 1.782 . . . . 0.0 109.166 178.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.953 HD21 ' HB2' ' A' ' 23' ' ' ALA . 2.7 mt -117.26 98.56 6.5 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.2 -0.937 . . . . 0.0 109.779 -179.301 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -88.09 165.66 14.98 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 t -60.85 114.74 3.22 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.243 -0.91 . . . . 0.0 109.272 -179.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 102.68 39.52 2.72 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.84 154.58 51.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.152 -1.205 . . . . 0.0 110.015 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.717 HD12 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -115.82 128.14 55.59 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.323 -0.861 . . . . 0.0 109.449 179.805 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.953 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -92.69 148.37 22.12 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 179.252 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.533 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -105.25 121.9 44.81 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 120.067 -1.645 . . . . 0.0 108.04 179.012 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.815 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 5.2 m-85 -105.39 170.53 7.83 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 121.914 0.864 . . . . 0.0 111.721 -177.009 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.709 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -166.72 140.14 3.84 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.793 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.999 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.6 mm -109.42 148.67 13.0 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.279 -0.888 . . . . 0.0 109.309 -178.345 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.644 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -133.33 122.6 24.07 Favored 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.989 -178.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.139 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 175.25 -61.86 0.0 OUTLIER Pre-proline 0 N--CA 1.497 1.886 0 O-C-N 121.078 -1.014 . . . . 0.0 109.552 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.139 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.3 Cg_endo -79.17 68.49 8.27 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.209 1.939 . . . . 0.0 109.699 179.551 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.634 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.0 OUTLIER -15.42 -64.03 0.03 OUTLIER Pre-proline 0 N--CA 1.506 2.327 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -178.83 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.634 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.4 Cg_endo -78.52 73.39 5.9 Favored 'Trans proline' 0 C--N 1.314 -1.25 0 C-N-CA 121.774 1.65 . . . . 0.0 111.202 -179.513 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.522 HG22 ' HG2' ' A' ' 30' ' ' PRO . 2.8 t -96.41 136.64 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.894 -1.129 . . . . 0.0 109.656 179.338 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 1.5 t -115.89 -15.33 11.25 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.48 -0.763 . . . . 0.0 109.331 179.01 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -178.6 149.43 0.48 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.311 -0.868 . . . . 0.0 109.667 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.624 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -136.93 139.68 41.73 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 178.59 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.61 ' O ' HG23 ' A' ' 69' ' ' VAL . 10.2 mtm-85 -93.33 109.04 20.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.138 -0.976 . . . . 0.0 109.136 179.657 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.977 ' CH2' HD11 ' A' ' 27' ' ' ILE . 18.7 m95 -93.85 179.81 5.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.918 -1.114 . . . . 0.0 109.621 -179.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.489 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.76 106.61 3.41 Favored 'General case' 0 C--N 1.292 -1.905 0 N-CA-C 106.328 -1.731 . . . . 0.0 106.328 177.369 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 1.014 ' CE1' HG21 ' A' ' 47' ' ' VAL . 3.7 m-30 -81.37 -66.44 0.89 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 118.451 -1.3 . . . . 0.0 111.37 -176.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 99.11 -4.91 59.03 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.1 p30 -90.41 23.71 2.86 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.335 -1.097 . . . . 0.0 109.164 179.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 122.56 -38.11 2.64 Favored Glycine 0 C--N 1.298 -1.576 0 N-CA-C 106.129 -2.788 . . . . 0.0 106.129 -176.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -98.77 101.52 12.96 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 177.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.489 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -71.38 -98.28 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.187 -0.946 . . . . 0.0 109.958 -178.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -56.92 150.1 17.33 Favored 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.286 0.565 . . . . 0.0 109.927 -179.588 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 1.014 HG21 ' CE1' ' A' ' 40' ' ' PHE . 70.8 t -138.9 132.97 40.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 O-C-N 121.47 -0.769 . . . . 0.0 110.591 -178.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -112.89 89.8 3.18 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 178.283 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.686 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -92.84 152.53 19.37 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.373 -0.829 . . . . 0.0 111.423 -178.135 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.72 150.2 23.75 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.624 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.08 -156.4 0.49 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.24 -1.944 . . . . 0.0 108.24 -179.27 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.415 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.1 Cg_endo -88.43 42.63 0.7 Allowed 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.122 1.881 . . . . 0.0 110.479 178.436 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.686 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -146.87 144.38 29.24 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 120.072 -1.642 . . . . 0.0 112.009 -179.089 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.593 ' HB2' ' HB2' ' A' ' 49' ' ' ALA . . . -149.54 -169.6 3.42 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.599 ' HB3' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -152.64 138.8 18.3 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.249 -0.907 . . . . 0.0 109.174 179.558 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.616 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 11.1 m80 -102.91 135.45 44.57 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.231 -0.918 . . . . 0.0 111.101 -178.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.439 ' H ' ' HG2' ' A' ' 57' ' ' ARG . 2.0 ptp180 -100.44 95.06 6.49 Favored 'General case' 0 N--CA 1.489 1.512 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 177.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.022 ' CE2' HG11 ' A' ' 83' ' ' VAL . 23.8 m-85 -95.5 120.24 35.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.225 -0.922 . . . . 0.0 109.232 -179.232 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 4.6 p -118.17 -29.71 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.241 -0.912 . . . . 0.0 111.165 -178.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.405 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -90.71 143.35 28.82 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 120.619 -1.3 . . . . 0.0 109.376 -179.678 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.405 ' HD2' HD23 ' A' ' 60' ' ' LEU . 34.0 Cg_endo -76.26 133.04 14.34 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 122.575 2.183 . . . . 0.0 110.281 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.59 -135.05 5.93 Favored Glycine 0 N--CA 1.488 2.161 0 N-CA-C 108.938 -1.665 . . . . 0.0 108.938 -179.616 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -127.27 164.51 21.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -1.193 . . . . 0.0 109.651 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.65 ' HB2' HG13 ' A' ' 83' ' ' VAL . 59.7 m-85 -142.98 152.84 42.39 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.466 -0.771 . . . . 0.0 109.205 -179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -112.99 130.37 56.16 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.575 HG13 ' CE1' ' A' ' 56' ' ' HIS . 59.2 t -116.0 150.58 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 110.821 -178.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -146.79 155.51 42.42 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.064 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -150.53 158.57 44.31 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 120.853 -1.155 . . . . 0.0 111.518 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.61 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -129.84 127.17 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.423 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 1.011 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.3 OUTLIER -89.07 141.87 28.12 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 120.656 -1.277 . . . . 0.0 109.015 -178.743 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.3 110.48 11.56 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.589 -1.245 . . . . 0.0 109.698 178.425 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.925 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.9 mp -105.49 -11.1 16.54 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.072 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.66 -49.62 0.83 Allowed Glycine 0 N--CA 1.486 2.011 0 N-CA-C 107.669 -2.173 . . . . 0.0 107.669 -178.128 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.44 -5.76 11.23 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.58 -0.953 . . . . 0.0 109.884 178.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -140.04 162.5 26.36 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.478 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 4.8 p -151.44 -179.23 7.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.306 -1.114 . . . . 0.0 109.579 -179.598 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 1.011 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -154.17 166.39 33.25 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.2 mt -119.93 132.75 55.62 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.068 -1.02 . . . . 0.0 110.227 -179.401 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.064 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -117.4 157.14 26.7 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.524 -0.735 . . . . 0.0 109.769 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.65 95.12 0.11 Allowed Glycine 0 N--CA 1.485 1.938 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.612 HG22 HD23 ' A' ' 10' ' ' LEU . 0.4 OUTLIER -116.38 -173.33 2.35 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.232 -1.158 . . . . 0.0 109.937 179.932 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -150.74 153.7 36.0 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.435 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.022 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -138.0 154.25 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 120.66 -1.275 . . . . 0.0 109.845 -179.519 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . 0.425 ' N ' HG23 ' A' ' 83' ' ' VAL . 12.0 tt0 -123.07 99.81 6.56 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.464 -0.773 . . . . 0.0 108.985 179.073 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.778 HG21 ' HB3' ' A' ' 58' ' ' TYR . 41.6 t -86.15 137.71 20.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.24 -0.912 . . . . 0.0 109.846 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -113.15 154.41 26.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 109.508 -179.473 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.101 -0.999 . . . . 0.0 109.667 179.711 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.804 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.776 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -90.12 141.62 28.51 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 179.636 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.753 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.3 mp -98.01 97.96 9.36 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 -178.188 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.968 HG12 ' HD3' ' A' ' 13' ' ' PRO . 47.2 t -109.69 115.92 50.86 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 120.875 -1.141 . . . . 0.0 109.189 179.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.524 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -125.67 68.68 0.51 Allowed Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.968 ' HD3' HG12 ' A' ' 11' ' ' VAL . 36.7 Cg_endo -75.16 151.05 38.34 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 123.082 2.521 . . . . 0.0 112.655 -179.252 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.641 ' HB2' ' O ' ' A' ' 13' ' ' PRO . 21.6 t60 162.61 -36.36 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.881 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.472 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.85 -138.6 14.93 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -179.377 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.8 151.74 28.31 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 122.42 2.08 . . . . 0.0 109.878 179.576 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.733 HD21 ' HB2' ' A' ' 23' ' ' ALA . 65.8 mt -120.87 99.74 6.69 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.113 -0.992 . . . . 0.0 109.917 -179.717 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.401 ' O ' ' HB2' ' A' ' 21' ' ' GLN . . . -91.78 170.94 9.49 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 178.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.7 t -53.15 120.06 5.47 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.914 . . . . 0.0 109.818 -179.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.74 48.3 4.5 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.472 ' HB3' ' CD2' ' A' ' 17' ' ' LEU . 1.6 mm-40 -115.78 143.81 44.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.432 -1.04 . . . . 0.0 110.449 -179.535 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.698 HD11 ' HB2' ' A' ' 55' ' ' SER . 2.5 tm? -108.35 93.26 4.43 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.175 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.733 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -75.49 155.21 36.4 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.94 -1.1 . . . . 0.0 108.089 179.341 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.535 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -119.08 114.5 22.59 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.475 -1.39 . . . . 0.0 108.076 179.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.705 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 3.8 m-85 -100.15 174.65 6.05 Favored 'General case' 0 N--CA 1.488 1.45 0 CA-C-O 122.135 0.969 . . . . 0.0 111.805 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.728 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -168.53 139.09 2.52 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 177.997 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 1.001 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.7 mm -107.95 149.33 11.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.37 -0.831 . . . . 0.0 109.063 -178.37 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.655 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -133.35 125.09 28.41 Favored 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 118.598 -1.241 . . . . 0.0 112.274 -178.572 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.089 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -179.8 -67.3 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 120.978 -1.076 . . . . 0.0 109.297 177.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.089 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.5 Cg_endo -79.89 69.58 7.88 Favored 'Trans proline' 0 C--N 1.314 -1.275 0 C-N-CA 121.944 1.763 . . . . 0.0 109.314 179.162 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.684 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.7 OUTLIER -11.82 -66.21 0.02 OUTLIER Pre-proline 0 N--CA 1.51 2.546 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -178.707 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.684 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.6 Cg_endo -79.29 95.32 1.05 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 121.728 1.619 . . . . 0.0 110.424 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.497 HG22 ' HG2' ' A' ' 30' ' ' PRO . 5.1 t -118.06 145.01 24.58 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 120.866 -1.146 . . . . 0.0 109.565 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.2 t -113.15 -18.64 12.09 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.495 -0.753 . . . . 0.0 110.209 179.736 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.22 152.3 0.86 Allowed 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.049 -1.032 . . . . 0.0 110.456 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.689 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.6 OUTLIER -139.05 137.04 35.9 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 178.428 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.472 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 4.8 ttp180 -92.78 114.2 26.69 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.07 -1.019 . . . . 0.0 108.838 179.512 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.992 ' CH2' HD11 ' A' ' 27' ' ' ILE . 15.6 m95 -97.68 -178.61 4.17 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 -179.8 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.425 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -151.37 101.99 2.87 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 177.34 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 1.013 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.9 m-30 -80.19 -61.33 2.01 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 118.756 -1.178 . . . . 0.0 110.267 -177.52 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.62 14.63 52.59 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.068 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.06 -103.05 0.25 Allowed 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -86.63 -17.15 60.58 Favored Glycine 0 C--N 1.297 -1.59 0 N-CA-C 108.05 -2.02 . . . . 0.0 108.05 176.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 17.0 p -135.8 129.26 32.21 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.308 -1.113 . . . . 0.0 109.309 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.425 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.34 -87.66 0.08 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.024 -1.048 . . . . 0.0 109.96 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 1.1 pt-20 -56.48 151.24 13.69 Favored 'General case' 0 N--CA 1.497 1.877 0 CA-C-O 121.358 0.599 . . . . 0.0 110.123 -179.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 1.013 HG21 ' CE1' ' A' ' 40' ' ' PHE . 61.5 t -140.14 134.44 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.287 -0.883 . . . . 0.0 111.019 -178.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -115.0 90.8 3.43 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 177.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.709 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -94.31 153.57 17.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.339 -0.85 . . . . 0.0 111.488 -177.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -89.33 150.52 22.54 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 179.283 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.689 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.84 -158.11 0.73 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 108.075 -2.01 . . . . 0.0 108.075 -179.188 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -87.69 41.0 0.65 Allowed 'Trans proline' 0 C--N 1.298 -2.101 0 C-N-CA 122.135 1.89 . . . . 0.0 110.013 178.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.709 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.25 147.55 32.52 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 120.232 -1.542 . . . . 0.0 111.891 -178.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.661 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -153.83 -169.56 3.31 Favored 'General case' 0 N--CA 1.496 1.847 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 178.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.698 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -151.87 145.24 24.77 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.135 -0.978 . . . . 0.0 109.184 179.433 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.696 ' O ' HD22 ' A' ' 22' ' ' LEU . 10.6 m80 -104.33 137.67 41.89 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.259 -0.901 . . . . 0.0 111.228 -178.762 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.415 HH21 HD21 ' A' ' 22' ' ' LEU . 0.7 OUTLIER -108.46 88.67 2.78 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.114 ' CE2' HG11 ' A' ' 83' ' ' VAL . 34.2 m-85 -92.06 118.39 30.76 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.237 -0.915 . . . . 0.0 109.602 -179.296 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 95.2 t -106.96 -28.94 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.411 -0.806 . . . . 0.0 111.089 -178.678 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.445 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -97.21 146.92 32.17 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 120.628 -1.295 . . . . 0.0 109.617 -179.364 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.639 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.6 Cg_endo -78.28 123.81 6.26 Favored 'Trans proline' 0 C--N 1.306 -1.691 0 C-N-CA 122.473 2.116 . . . . 0.0 109.837 179.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 158.6 -159.68 30.4 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.631 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.445 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 15.1 mtp-105 -111.34 125.97 54.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.073 -1.251 . . . . 0.0 110.152 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.573 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 82.9 m-85 -108.75 157.92 18.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.34 -0.85 . . . . 0.0 109.481 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 72.1 t60 -112.81 126.99 56.04 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.526 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.589 HG22 ' NE2' ' A' ' 56' ' ' HIS . 84.3 t -107.62 150.06 10.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.099 -1.001 . . . . 0.0 110.675 -179.054 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.422 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 1.2 p -147.75 155.64 41.91 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.258 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.028 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -152.5 165.96 33.47 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.822 -1.174 . . . . 0.0 110.751 -179.674 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.462 HG12 ' HB3' ' A' ' 37' ' ' ARG . 8.3 p -141.81 130.6 22.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 N-CA-C 107.197 -1.409 . . . . 0.0 107.197 178.315 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.995 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.16 140.7 29.22 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 120.947 -1.096 . . . . 0.0 108.821 -178.302 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -130.02 108.18 9.9 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 118.555 -1.258 . . . . 0.0 109.933 178.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.55 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -106.88 -9.66 16.26 Favored 'General case' 0 C--N 1.286 -2.188 0 CA-C-N 115.415 -0.811 . . . . 0.0 108.838 178.994 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 102.94 -48.39 1.04 Allowed Glycine 0 N--CA 1.487 2.057 0 N-CA-C 107.599 -2.2 . . . . 0.0 107.599 -178.19 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.04 -5.51 11.95 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.687 -0.89 . . . . 0.0 109.627 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -142.35 155.73 25.79 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 17.1 p -151.05 179.71 8.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.224 -1.162 . . . . 0.0 109.598 -179.533 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.995 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -156.02 170.41 22.23 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.458 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -124.31 136.39 54.08 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.107 -0.996 . . . . 0.0 109.906 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.028 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -119.5 158.44 26.27 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.566 -0.709 . . . . 0.0 109.711 -179.631 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -169.94 94.62 0.1 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.548 HG22 HD23 ' A' ' 10' ' ' LEU . 0.5 OUTLIER -115.03 -172.12 2.07 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.088 -1.242 . . . . 0.0 110.117 -179.878 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -150.64 148.37 28.53 Favored 'General case' 0 N--CA 1.494 1.757 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.114 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -132.95 153.66 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 120.842 -1.161 . . . . 0.0 109.972 -179.725 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . 0.427 ' N ' HG23 ' A' ' 83' ' ' VAL . 30.1 tt0 -122.57 89.29 3.09 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.309 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.822 HG21 ' HB3' ' A' ' 58' ' ' TYR . 92.9 t -79.63 143.56 12.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.253 -0.904 . . . . 0.0 109.82 -179.428 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -115.84 173.3 6.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.387 -0.821 . . . . 0.0 109.667 -179.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.639 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.149 -0.969 . . . . 0.0 109.782 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.805 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.474 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.952 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.1 t -70.79 148.89 47.42 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.224 -0.923 . . . . 0.0 109.299 -179.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.758 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.6 mp -88.16 109.84 20.22 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.325 -178.312 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.585 ' HB ' ' CE1' ' A' ' 26' ' ' HIS . 1.2 t -126.21 103.91 12.21 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 O-C-N 121.01 -1.056 . . . . 0.0 108.863 178.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.583 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -116.8 80.52 0.3 Allowed Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 -179.33 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.607 ' HD2' ' HA ' ' A' ' 25' ' ' PHE . 33.2 Cg_endo -73.07 146.65 41.67 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.612 2.208 . . . . 0.0 112.538 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.615 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 62.4 t60 164.62 171.09 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -93.31 -124.16 3.67 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 178.709 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -79.86 151.07 21.4 Favored 'Trans proline' 0 C--N 1.306 -1.702 0 C-N-CA 122.314 2.01 . . . . 0.0 109.938 179.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.826 ' HB3' HG22 ' A' ' 85' ' ' VAL . 22.1 mt -121.65 89.13 3.06 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.057 -1.027 . . . . 0.0 109.469 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -90.29 167.04 12.97 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 179.214 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.3 t -51.95 118.42 3.43 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.331 -0.855 . . . . 0.0 109.403 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 90.71 47.86 3.58 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.205 -1.558 . . . . 0.0 109.205 -179.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.437 ' HB3' HD23 ' A' ' 17' ' ' LEU . 2.1 mm-40 -119.81 155.97 31.55 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.281 -1.129 . . . . 0.0 110.868 -179.396 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.786 HD11 ' HB2' ' A' ' 55' ' ' SER . 1.8 tm? -114.52 96.62 5.85 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.757 -0.589 . . . . 0.0 109.565 179.769 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.688 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -81.59 160.96 23.69 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 178.552 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.502 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -122.79 111.37 16.61 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.39 -1.444 . . . . 0.0 108.744 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.664 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 4.4 m-85 -100.7 166.38 10.91 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 122.172 0.987 . . . . 0.0 112.277 -177.176 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.585 ' CE1' ' HB ' ' A' ' 11' ' ' VAL . 7.5 p80 -163.45 151.77 13.65 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 176.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.906 HD11 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -114.51 160.94 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.0 -1.062 . . . . 0.0 108.884 -178.33 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.952 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -138.05 120.17 15.63 Favored 'General case' 0 N--CA 1.499 2.008 0 C-N-CA 118.453 -1.299 . . . . 0.0 112.653 -178.433 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.037 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 176.44 -72.1 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.228 -0.92 . . . . 0.0 108.963 177.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.037 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 35.9 Cg_endo -77.57 77.93 3.7 Favored 'Trans proline' 0 C--N 1.314 -1.26 0 C-N-CA 121.569 1.513 . . . . 0.0 108.745 178.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.571 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 2.6 mp -33.3 -56.34 0.61 Allowed Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 122.127 -0.358 . . . . 0.0 111.631 -178.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.571 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.9 Cg_endo -80.62 75.96 4.77 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.165 1.91 . . . . 0.0 111.328 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.917 HG23 ' O ' ' A' ' 30' ' ' PRO . 36.8 t -103.46 148.53 8.34 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 120.984 -1.073 . . . . 0.0 109.098 179.102 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 15.4 t -113.59 -29.06 7.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.131 -0.981 . . . . 0.0 110.256 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -162.35 144.17 10.77 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.319 -0.863 . . . . 0.0 109.91 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.677 HG23 ' HB3' ' A' ' 49' ' ' ALA . 1.8 t -127.33 162.16 26.91 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 179.539 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.518 ' O ' HG23 ' A' ' 69' ' ' VAL . 13.1 mtp85 -123.89 103.12 8.15 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.171 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.906 ' CH2' HD11 ' A' ' 27' ' ' ILE . 35.1 m95 -88.55 179.94 6.18 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.05 -1.031 . . . . 0.0 109.837 -179.462 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.468 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -148.71 100.7 3.13 Favored 'General case' 0 C--N 1.291 -1.939 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 177.44 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.937 ' CE1' HG21 ' A' ' 47' ' ' VAL . 4.1 m-30 -80.27 -50.69 9.85 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 118.869 -1.132 . . . . 0.0 109.829 -177.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 80.27 21.77 64.25 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.535 ' HB3' ' CD1' ' A' ' 58' ' ' TYR . 1.2 p30 -106.96 -104.87 0.34 Allowed 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 178.483 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.88 -15.41 72.87 Favored Glycine 0 N--CA 1.48 1.607 0 N-CA-C 107.715 -2.154 . . . . 0.0 107.715 176.508 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -140.26 130.62 25.27 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.396 -1.061 . . . . 0.0 109.035 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.468 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.17 -85.48 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.956 -1.09 . . . . 0.0 109.624 -179.796 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -56.5 151.2 13.82 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-O 121.268 0.556 . . . . 0.0 109.878 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.937 HG21 ' CE1' ' A' ' 40' ' ' PHE . 61.6 t -139.28 125.02 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.428 -0.795 . . . . 0.0 110.737 -178.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -104.67 109.72 21.76 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.227 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.677 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -123.33 167.83 13.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.157 -0.964 . . . . 0.0 111.024 -178.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -95.64 153.34 17.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.68 -0.638 . . . . 0.0 109.641 179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.576 ' O ' HG22 ' A' ' 36' ' ' THR . . . 46.33 -156.33 0.55 Allowed Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 -179.656 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -89.52 39.0 0.41 Allowed 'Trans proline' 0 C--N 1.297 -2.152 0 C-N-CA 122.484 2.123 . . . . 0.0 110.25 178.468 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.572 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -140.8 151.6 44.52 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 119.976 -1.703 . . . . 0.0 112.458 -178.368 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.657 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -172.2 153.24 3.0 Favored 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.029 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.786 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.0 OUTLIER -109.84 161.09 15.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.939 -1.1 . . . . 0.0 110.237 -179.82 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.623 ' O ' HD22 ' A' ' 22' ' ' LEU . 2.9 m80 -109.24 134.04 52.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.457 -0.777 . . . . 0.0 110.298 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.688 ' NH2' HD21 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -110.8 92.13 3.93 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.924 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.126 ' CE2' HG11 ' A' ' 83' ' ' VAL . 22.0 m-85 -92.33 133.49 35.81 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.136 -0.978 . . . . 0.0 109.596 -179.39 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 53.6 t -117.86 -28.15 2.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.418 -0.801 . . . . 0.0 110.973 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.448 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -97.78 143.28 25.94 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 120.592 -1.317 . . . . 0.0 109.611 -179.545 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.905 ' CB ' ' HB2' ' A' ' 87' ' ' ALA . 36.0 Cg_endo -79.06 120.78 4.7 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.616 2.211 . . . . 0.0 110.152 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 159.08 -143.68 9.48 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 18.5 ttm-85 -112.39 154.26 26.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.209 -1.171 . . . . 0.0 109.572 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.617 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 54.0 m-85 -139.1 167.52 21.88 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.526 -0.734 . . . . 0.0 109.06 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 65.6 t60 -125.84 144.59 50.59 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.615 HG13 ' CE1' ' A' ' 56' ' ' HIS . 39.1 t -126.97 148.63 31.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.09 -1.006 . . . . 0.0 110.751 -179.133 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.401 ' OG1' ' HB2' ' A' ' 39' ' ' ASP . 0.1 OUTLIER -150.24 161.12 43.05 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 178.605 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.04 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.48 157.55 43.39 Favored 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 119.182 -1.007 . . . . 0.0 110.92 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -145.81 106.03 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 179.16 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.843 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -87.62 143.27 27.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.652 -1.28 . . . . 0.0 109.288 -179.254 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.64 115.12 17.55 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.211 -0.996 . . . . 0.0 109.639 179.077 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.542 HD21 ' O ' ' A' ' 32' ' ' PRO . 9.1 mt -105.88 -12.62 15.78 Favored 'General case' 0 C--N 1.289 -2.058 0 CA-C-O 121.526 0.679 . . . . 0.0 109.215 179.437 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 109.42 -47.32 1.05 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -178.714 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.23 -5.82 11.85 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.581 -0.952 . . . . 0.0 109.801 179.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -146.19 154.67 26.1 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.405 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 18.4 p -150.62 174.23 13.23 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.177 -1.19 . . . . 0.0 109.675 -179.586 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.843 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -151.81 134.59 15.59 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.182 -0.949 . . . . 0.0 109.397 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -99.69 143.01 30.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.252 -0.905 . . . . 0.0 110.311 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.04 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -127.53 157.91 38.85 Favored 'General case' 0 C--N 1.306 -1.294 0 O-C-N 121.662 -0.649 . . . . 0.0 109.966 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.03 84.59 0.1 Allowed Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.537 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -103.2 178.01 4.68 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.204 -1.174 . . . . 0.0 110.055 -179.766 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -121.43 157.78 29.81 Favored 'General case' 0 N--CA 1.492 1.669 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.31 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.126 HG11 ' CE2' ' A' ' 58' ' ' TYR . 16.4 t -137.45 143.39 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 120.997 -1.064 . . . . 0.0 110.264 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -132.69 101.77 5.42 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.467 -0.77 . . . . 0.0 109.27 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.826 HG22 ' HB3' ' A' ' 17' ' ' LEU . 79.5 t -103.52 140.52 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.333 -0.855 . . . . 0.0 109.714 -179.473 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -104.9 -174.71 2.6 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.158 -0.964 . . . . 0.0 109.872 -179.479 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.905 ' HB2' ' CB ' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.158 -0.963 . . . . 0.0 109.848 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.793 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.389 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.755 HG23 HG23 ' A' ' 11' ' ' VAL . 0.5 OUTLIER -88.15 141.72 28.34 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.693 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.728 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.8 mp -97.88 91.24 5.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 -178.121 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.929 HG12 ' HD3' ' A' ' 13' ' ' PRO . 57.0 t -101.14 117.76 46.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.953 -1.092 . . . . 0.0 108.653 179.171 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.461 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -125.08 72.6 0.43 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.588 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.929 ' HD3' HG12 ' A' ' 11' ' ' VAL . 32.7 Cg_endo -73.01 147.97 44.25 Favored 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 122.701 2.267 . . . . 0.0 111.758 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.514 ' CG ' ' HA ' ' A' ' 23' ' ' ALA . 23.6 t-80 157.52 -33.86 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.791 0 CA-C-N 115.442 -0.799 . . . . 0.0 108.965 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.95 -143.35 15.63 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.123 -1.991 . . . . 0.0 108.123 -179.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -77.16 147.79 26.64 Favored 'Trans proline' 0 C--N 1.304 -1.807 0 C-N-CA 122.049 1.833 . . . . 0.0 108.947 179.032 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 1.088 HD21 ' HB2' ' A' ' 23' ' ' ALA . 5.6 mt -112.27 110.63 20.98 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.201 -0.937 . . . . 0.0 109.89 -179.308 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -93.09 168.61 11.0 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 179.214 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.6 t -60.83 122.16 14.14 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.209 -0.932 . . . . 0.0 109.456 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 86.91 47.42 4.78 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . . . . . . . . . 2.0 mm100 -125.62 157.89 36.05 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.252 -1.146 . . . . 0.0 110.934 -179.515 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.742 HD22 ' O ' ' A' ' 56' ' ' HIS . 1.8 tm? -113.27 103.58 11.46 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 1.088 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -85.61 156.22 20.8 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 178.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.49 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -120.51 107.7 13.18 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.506 -1.371 . . . . 0.0 108.63 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.768 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 1.9 m-85 -95.36 168.78 10.51 Favored 'General case' 0 N--CA 1.492 1.656 0 CA-C-O 121.976 0.893 . . . . 0.0 111.779 -177.53 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.737 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -163.72 141.21 7.28 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.502 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.995 HD12 ' HG ' ' A' ' 79' ' ' LEU . 4.9 mm -108.01 152.5 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.292 -0.88 . . . . 0.0 109.435 -178.216 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.637 ' HB3' ' CG2' ' A' ' 9' ' ' THR . . . -135.28 121.7 20.5 Favored 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.781 -1.168 . . . . 0.0 112.133 -179.045 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.034 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . -177.72 -66.34 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.865 0 O-C-N 121.002 -1.061 . . . . 0.0 109.222 177.721 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.034 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.3 Cg_endo -81.72 61.7 8.02 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 C-N-CA 122.129 1.886 . . . . 0.0 109.15 178.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.672 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 1.1 mp -8.81 -67.09 0.01 OUTLIER Pre-proline 0 N--CA 1.508 2.45 0 N-CA-C 113.299 0.851 . . . . 0.0 113.299 -178.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.672 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 36.3 Cg_endo -77.72 68.42 7.67 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 121.892 1.728 . . . . 0.0 111.076 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.684 HG22 ' HG2' ' A' ' 30' ' ' PRO . 3.4 t -91.22 148.06 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 120.757 -1.214 . . . . 0.0 109.875 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.9 p -114.28 -18.11 11.67 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.603 -0.686 . . . . 0.0 110.045 179.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -177.95 152.53 0.75 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.26 -0.9 . . . . 0.0 110.284 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.689 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.5 OUTLIER -140.7 140.66 34.94 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.318 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.649 ' O ' HG23 ' A' ' 69' ' ' VAL . 18.3 mtm-85 -93.74 107.35 19.24 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.101 -0.999 . . . . 0.0 109.369 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.972 ' CH2' HD11 ' A' ' 27' ' ' ILE . 22.8 m95 -90.73 179.56 5.77 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.212 -0.93 . . . . 0.0 109.502 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.421 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.95 102.3 2.96 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 177.36 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.996 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.4 m-30 -80.37 -59.66 2.61 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 118.853 -1.139 . . . . 0.0 110.086 -177.722 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 91.03 20.06 40.63 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 -179.081 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -107.15 -104.52 0.34 Allowed 'General case' 0 N--CA 1.485 1.322 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.619 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -82.91 -19.69 62.69 Favored Glycine 0 C--N 1.296 -1.67 0 N-CA-C 107.749 -2.141 . . . . 0.0 107.749 176.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 11.0 p -135.22 130.4 35.21 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.427 -1.043 . . . . 0.0 109.3 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.36 -86.65 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.115 -0.991 . . . . 0.0 109.936 -179.658 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -57.62 152.84 14.32 Favored 'General case' 0 N--CA 1.497 1.89 0 CA-C-O 121.176 0.512 . . . . 0.0 110.112 -179.618 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.996 HG21 ' CE1' ' A' ' 40' ' ' PHE . 34.3 t -140.99 126.96 19.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.416 -0.803 . . . . 0.0 111.242 -178.745 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -105.44 91.78 3.92 Favored 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 177.345 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.8 ' CB ' ' HB2' ' A' ' 54' ' ' ALA . . . -96.03 154.97 16.95 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.244 -0.91 . . . . 0.0 111.677 -177.624 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.84 153.18 19.0 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.689 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.26 -158.23 0.55 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 108.248 -1.941 . . . . 0.0 108.248 -179.229 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.402 ' HB3' HG21 ' A' ' 33' ' ' VAL . 38.2 Cg_endo -88.37 40.03 0.54 Allowed 'Trans proline' 0 C--N 1.297 -2.157 0 C-N-CA 122.029 1.819 . . . . 0.0 109.932 178.118 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.657 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -145.27 152.02 39.28 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 120.096 -1.628 . . . . 0.0 112.187 -178.651 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.8 ' HB2' ' CB ' ' A' ' 49' ' ' ALA . . . -165.12 155.91 14.15 Favored 'General case' 0 N--CA 1.498 1.941 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.654 ' HB2' HD11 ' A' ' 22' ' ' LEU . 0.2 OUTLIER -114.41 160.71 18.84 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.932 -1.105 . . . . 0.0 110.192 -179.883 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.742 ' O ' HD22 ' A' ' 22' ' ' LEU . 5.8 m80 -114.54 139.34 49.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.538 -0.726 . . . . 0.0 110.489 -179.15 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.484 HH21 HD21 ' A' ' 22' ' ' LEU . 0.7 OUTLIER -111.89 95.64 5.6 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 178.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.086 ' CE2' HG11 ' A' ' 83' ' ' VAL . 36.3 m-85 -99.02 129.86 45.32 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.161 -0.962 . . . . 0.0 109.432 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 61.7 t -117.91 -27.89 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.352 -0.842 . . . . 0.0 111.25 -178.433 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.486 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -99.51 146.39 31.71 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 120.511 -1.368 . . . . 0.0 109.596 -179.381 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.486 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 34.8 Cg_endo -77.73 124.42 6.89 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.404 2.069 . . . . 0.0 109.888 179.352 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 160.81 -151.78 22.31 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.609 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.409 ' HG2' ' HA ' ' A' ' 84' ' ' GLN . 0.0 OUTLIER -122.17 120.11 33.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.113 -1.228 . . . . 0.0 109.82 179.949 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.558 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 81.6 m-85 -103.6 153.64 20.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.353 -0.842 . . . . 0.0 109.541 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.9 t60 -107.89 132.51 53.38 Favored 'General case' 0 N--CA 1.488 1.475 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.529 ' O ' ' HA2' ' A' ' 80' ' ' GLY . 90.7 t -113.42 150.82 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.162 -0.961 . . . . 0.0 110.569 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.406 ' OG1' ' HB2' ' A' ' 39' ' ' ASP . 6.0 p -147.54 156.43 42.83 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 178.522 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.096 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -149.94 156.09 41.14 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.855 -1.153 . . . . 0.0 111.186 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.649 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.4 OUTLIER -128.49 125.82 64.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 178.502 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.999 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.2 OUTLIER -87.76 144.58 26.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 120.535 -1.353 . . . . 0.0 109.007 -178.865 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -133.21 106.7 7.72 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 118.783 -1.167 . . . . 0.0 109.627 178.445 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.562 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -103.62 -10.62 18.28 Favored 'General case' 0 C--N 1.284 -2.28 0 CA-C-N 115.317 -0.856 . . . . 0.0 108.697 179.055 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.81 -47.27 1.07 Allowed Glycine 0 N--CA 1.488 2.125 0 N-CA-C 107.627 -2.189 . . . . 0.0 107.627 -178.416 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -117.31 -5.09 11.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.741 -0.858 . . . . 0.0 109.68 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -144.55 158.4 27.52 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.726 -1.349 . . . . 0.0 109.726 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.435 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 25.7 p -148.03 -177.71 5.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.364 -1.08 . . . . 0.0 109.405 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.999 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -156.55 162.69 39.9 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.8 mp -116.8 132.38 56.71 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.065 -1.022 . . . . 0.0 109.976 -179.615 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.096 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -116.46 157.36 25.29 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.548 -0.72 . . . . 0.0 109.497 -179.752 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.529 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -168.24 96.3 0.12 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.553 HG22 HD23 ' A' ' 10' ' ' LEU . 0.7 OUTLIER -116.34 -171.74 2.05 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.044 -1.268 . . . . 0.0 109.732 179.791 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -151.55 147.63 27.03 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.408 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.086 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.3 OUTLIER -131.77 138.44 52.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 120.68 -1.262 . . . . 0.0 110.018 -179.466 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . 0.409 ' HA ' ' HG2' ' A' ' 63' ' ' ARG . 30.9 tt0 -105.22 90.47 3.44 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 178.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.781 HG21 ' HB3' ' A' ' 58' ' ' TYR . 52.9 t -76.54 130.92 35.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.307 -0.871 . . . . 0.0 109.352 -179.575 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -114.46 144.16 43.77 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.467 -0.771 . . . . 0.0 109.768 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.241 -0.912 . . . . 0.0 109.301 179.676 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.919 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.974 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.1 t -94.26 147.23 23.39 Favored 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.755 ' N ' HD12 ' A' ' 10' ' ' LEU . 5.3 mp -91.99 88.83 6.73 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.162 -178.215 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.801 HG11 ' CE1' ' A' ' 26' ' ' HIS . 22.1 t -97.76 100.15 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 120.702 -1.249 . . . . 0.0 108.561 178.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.536 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -117.96 78.73 0.3 Allowed Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.276 -179.304 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.551 ' HD3' HG12 ' A' ' 11' ' ' VAL . 34.1 Cg_endo -74.99 148.11 34.88 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.404 2.069 . . . . 0.0 111.635 179.412 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.524 ' ND1' ' HB1' ' A' ' 23' ' ' ALA . 3.3 p-80 174.35 162.01 0.19 Allowed 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.608 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.5 -130.0 1.36 Allowed Glycine 0 N--CA 1.491 2.354 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 179.354 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -78.87 147.3 21.36 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 C-N-CA 121.978 1.786 . . . . 0.0 109.145 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.767 HD13 ' HB3' ' A' ' 21' ' ' GLN . 0.4 OUTLIER -113.41 84.21 1.97 Allowed 'General case' 0 C--N 1.298 -1.671 0 O-C-N 121.194 -0.941 . . . . 0.0 109.046 -179.815 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.462 ' HB3' ' OE1' ' A' ' 21' ' ' GLN . . . -95.53 168.16 10.86 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 179.58 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 39.0 t -56.71 108.52 0.51 Allowed 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.294 -0.879 . . . . 0.0 109.521 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.94 37.67 2.49 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.767 ' HB3' HD13 ' A' ' 17' ' ' LEU . 0.1 OUTLIER -128.21 154.42 45.85 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.227 -1.161 . . . . 0.0 109.79 -179.972 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.835 HD11 ' HB2' ' A' ' 55' ' ' SER . 0.1 OUTLIER -118.66 130.01 55.61 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.118 -0.988 . . . . 0.0 109.662 -179.994 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.801 ' HB3' ' HE1' ' A' ' 25' ' ' PHE . . . -94.92 146.01 24.53 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 179.014 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.519 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -101.82 129.6 48.07 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 119.978 -1.701 . . . . 0.0 108.014 178.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.801 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 16.6 m-85 -112.22 166.39 11.31 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 121.959 0.885 . . . . 0.0 111.942 -176.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.801 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -164.5 134.41 3.92 Favored 'General case' 0 N--CA 1.485 1.287 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 178.22 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.885 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.4 OUTLIER -103.38 149.43 7.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.17 -0.956 . . . . 0.0 109.036 -178.437 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.974 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -133.73 124.31 26.44 Favored 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.545 -1.262 . . . . 0.0 112.225 -178.856 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.046 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 179.15 -66.38 0.0 OUTLIER Pre-proline 0 N--CA 1.495 1.804 0 O-C-N 121.118 -0.989 . . . . 0.0 109.199 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.046 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 36.4 Cg_endo -80.51 68.64 8.25 Favored 'Trans proline' 0 C--N 1.314 -1.281 0 C-N-CA 121.983 1.788 . . . . 0.0 109.102 178.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.679 ' CB ' ' HD3' ' A' ' 32' ' ' PRO . 0.6 OUTLIER -10.81 -66.52 0.01 OUTLIER Pre-proline 0 N--CA 1.507 2.42 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -178.664 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.679 ' HD3' ' CB ' ' A' ' 31' ' ' LEU . 37.0 Cg_endo -79.58 83.86 2.16 Favored 'Trans proline' 0 C--N 1.314 -1.257 0 C-N-CA 121.667 1.578 . . . . 0.0 111.001 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.625 HG22 ' HG2' ' A' ' 30' ' ' PRO . 6.3 t -106.12 143.22 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.836 -1.165 . . . . 0.0 109.384 179.365 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 4.5 t -118.62 -14.18 9.61 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.406 -0.809 . . . . 0.0 110.412 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -174.2 146.82 1.16 Allowed 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.898 -1.126 . . . . 0.0 110.532 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.671 HG22 ' O ' ' A' ' 51' ' ' GLY . 0.4 OUTLIER -142.96 136.94 29.02 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.69 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.573 ' HB2' HG12 ' A' ' 69' ' ' VAL . 7.5 mtm180 -94.28 112.36 24.15 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.19 -0.944 . . . . 0.0 108.872 179.448 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.727 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 18.6 m95 -94.32 -177.09 4.16 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.898 0.856 . . . . 0.0 109.079 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.442 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -151.39 103.77 3.02 Favored 'General case' 0 C--N 1.292 -1.925 0 N-CA-C 106.282 -1.748 . . . . 0.0 106.282 177.424 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 1.003 ' CE1' HG21 ' A' ' 47' ' ' VAL . 4.1 m-30 -80.04 -63.65 1.36 Allowed 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 118.822 -1.151 . . . . 0.0 110.31 -177.586 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 97.26 9.32 55.68 Favored Glycine 0 N--CA 1.486 1.974 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -178.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -93.47 -101.72 0.13 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 178.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -89.02 -28.92 19.38 Favored Glycine 0 C--N 1.293 -1.826 0 N-CA-C 107.507 -2.237 . . . . 0.0 107.507 177.056 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -118.31 130.26 55.93 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.546 -0.973 . . . . 0.0 109.38 179.438 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.442 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -81.3 -85.02 0.1 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.202 -0.936 . . . . 0.0 109.541 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -59.77 155.26 16.39 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.265 0.555 . . . . 0.0 110.065 -179.775 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 1.003 HG21 ' CE1' ' A' ' 40' ' ' PHE . 60.6 t -142.01 136.16 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.469 -0.769 . . . . 0.0 111.076 -178.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -116.16 93.2 4.14 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 177.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.672 ' HB1' ' O ' ' A' ' 53' ' ' ALA . . . -96.35 150.13 20.92 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.359 -0.838 . . . . 0.0 111.661 -177.841 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.69 146.71 27.3 Favored 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.671 ' O ' HG22 ' A' ' 36' ' ' THR . . . 47.73 -159.16 0.58 Allowed Glycine 0 N--CA 1.492 2.385 0 N-CA-C 107.91 -2.076 . . . . 0.0 107.91 -179.03 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -86.55 41.6 0.82 Allowed 'Trans proline' 0 C--N 1.299 -2.049 0 C-N-CA 121.909 1.739 . . . . 0.0 110.12 178.253 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.672 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -144.07 141.01 29.82 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.314 -1.491 . . . . 0.0 111.65 -178.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.632 ' HB2' ' HB2' ' A' ' 49' ' ' ALA . . . -146.26 -166.16 2.4 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.03 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.835 ' HB2' HD11 ' A' ' 22' ' ' LEU . 5.4 p -156.38 136.45 12.79 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.364 -0.835 . . . . 0.0 108.919 179.391 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.655 ' CE1' ' CD1' ' A' ' 40' ' ' PHE . 9.4 m80 -99.46 131.62 45.34 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.291 -0.881 . . . . 0.0 111.329 -178.26 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.404 ' H ' ' HG2' ' A' ' 57' ' ' ARG . 6.7 ptp180 -97.08 96.06 8.2 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 178.23 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.107 ' CE2' HG11 ' A' ' 83' ' ' VAL . 16.6 m-85 -100.1 105.16 16.76 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.905 -1.122 . . . . 0.0 109.547 -179.086 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 24.0 m -107.73 -9.32 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.488 -0.758 . . . . 0.0 111.292 -178.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.48 HD23 ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -105.83 145.86 31.72 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 120.46 -1.4 . . . . 0.0 109.462 -179.818 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 1.036 ' HB3' ' HB2' ' A' ' 87' ' ' ALA . 35.5 Cg_endo -77.56 123.78 6.65 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.614 2.209 . . . . 0.0 110.133 179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 150.37 -142.97 10.12 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 -179.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.26 158.54 37.87 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.204 -1.174 . . . . 0.0 109.475 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.655 ' HB2' HG13 ' A' ' 83' ' ' VAL . 92.5 m-85 -135.78 155.46 50.33 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.307 -0.87 . . . . 0.0 109.683 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.403 ' CD2' HG22 ' A' ' 67' ' ' THR . 9.8 t60 -111.46 114.31 27.33 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.034 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.648 HG13 ' NE2' ' A' ' 56' ' ' HIS . 62.7 t -95.06 150.64 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.228 -0.92 . . . . 0.0 110.527 -178.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.43 ' HA ' ' HA2' ' A' ' 80' ' ' GLY . 0.8 OUTLIER -146.42 157.96 43.83 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.388 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.018 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -156.36 164.57 38.13 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.603 -1.311 . . . . 0.0 111.224 -179.457 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.573 HG12 ' HB2' ' A' ' 37' ' ' ARG . 9.8 p -142.16 127.29 17.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 178.427 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 1.054 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.2 142.23 27.92 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.932 -1.105 . . . . 0.0 108.769 -178.471 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -131.41 106.23 8.11 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 118.551 -1.26 . . . . 0.0 109.949 178.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.638 HD21 ' O ' ' A' ' 32' ' ' PRO . 0.5 OUTLIER -104.6 -9.82 18.0 Favored 'General case' 0 C--N 1.284 -2.261 0 CA-C-N 115.218 -0.901 . . . . 0.0 108.701 178.937 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.11 -48.52 0.97 Allowed Glycine 0 N--CA 1.487 2.094 0 N-CA-C 107.776 -2.13 . . . . 0.0 107.776 -178.457 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -116.59 -5.52 11.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.633 -0.922 . . . . 0.0 109.61 179.089 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.94 156.66 26.07 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.406 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 22.0 p -150.38 -178.65 6.65 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.304 -1.115 . . . . 0.0 109.421 -179.542 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 1.054 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -158.98 141.4 14.03 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.36 -0.837 . . . . 0.0 108.744 179.577 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -99.85 135.37 41.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.984 -1.073 . . . . 0.0 110.101 -179.211 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.018 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -119.82 156.91 29.75 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.492 -0.755 . . . . 0.0 110.026 -179.569 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.52 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -166.46 89.73 0.1 Allowed Glycine 0 N--CA 1.488 2.14 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.799 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.743 HG22 HD23 ' A' ' 10' ' ' LEU . 0.1 OUTLIER -107.49 -172.7 2.12 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.991 -1.3 . . . . 0.0 110.267 -179.571 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -150.72 146.28 26.34 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.107 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -131.2 157.59 43.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.856 -1.152 . . . . 0.0 109.93 -179.702 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . 0.491 ' N ' HG23 ' A' ' 83' ' ' VAL . 8.1 mt-30 -130.45 92.14 3.21 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.595 -0.691 . . . . 0.0 109.165 179.466 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.758 HG22 ' HB3' ' A' ' 17' ' ' LEU . 40.9 t -86.58 141.92 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.253 -0.904 . . . . 0.0 109.734 -179.663 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -108.34 175.69 5.38 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.29 -0.881 . . . . 0.0 110.309 -179.29 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 1.036 ' HB2' ' HB3' ' A' ' 61' ' ' PRO . . . . . . . . 0 N--CA 1.492 1.659 0 O-C-N 121.347 -0.846 . . . . 0.0 109.693 179.5 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.714 ' HA ' ' HB2' ' A' ' 29' ' ' ALA . . . . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.943 HG22 ' HB3' ' A' ' 28' ' ' ALA . 1.6 t -74.95 150.73 38.97 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.13 -0.982 . . . . 0.0 109.408 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.753 HD23 HG22 ' A' ' 81' ' ' THR . 5.3 mp -87.15 105.6 17.31 Favored 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.977 -178.636 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.821 HG11 ' CE1' ' A' ' 26' ' ' HIS . 2.3 t -119.36 91.6 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 120.976 -1.078 . . . . 0.0 109.009 178.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.715 ' HA2' ' HA ' ' A' ' 25' ' ' PHE . . . -113.7 81.14 0.29 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.492 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.54 ' HD2' ' O ' ' A' ' 24' ' ' ALA . 34.5 Cg_endo -73.34 149.04 44.45 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.662 2.242 . . . . 0.0 111.92 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.599 ' CD2' HD22 ' A' ' 17' ' ' LEU . 45.6 t60 166.96 -39.13 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.49 -138.86 14.76 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.057 -2.017 . . . . 0.0 108.057 -178.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -77.42 147.65 25.75 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 C-N-CA 122.096 1.864 . . . . 0.0 109.043 178.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.839 HD21 ' HB2' ' A' ' 23' ' ' ALA . 0.2 OUTLIER -106.31 109.84 21.9 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.098 -1.001 . . . . 0.0 109.721 -179.285 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.602 ' HB3' ' HG3' ' A' ' 21' ' ' GLN . . . -92.34 153.35 19.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 179.269 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.0 t -59.29 111.08 1.23 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -0.875 . . . . 0.0 109.37 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 105.47 35.44 3.09 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLN . . . . . 0.602 ' HG3' ' HB3' ' A' ' 18' ' ' ALA . 13.6 mm100 -133.65 160.54 37.23 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.192 -1.181 . . . . 0.0 109.88 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.708 HD12 ' N ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -117.06 126.66 53.2 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.186 -0.946 . . . . 0.0 109.414 179.672 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.839 ' HB2' HD21 ' A' ' 17' ' ' LEU . . . -90.06 145.42 25.08 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.084 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.54 ' O ' ' HD2' ' A' ' 13' ' ' PRO . . . -99.89 129.78 46.01 Favored 'General case' 0 C--N 1.294 -1.809 0 O-C-N 119.918 -1.739 . . . . 0.0 108.165 179.111 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.816 ' HE1' ' HB3' ' A' ' 23' ' ' ALA . 16.8 m-85 -113.88 163.26 15.32 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 122.102 0.954 . . . . 0.0 111.977 -177.335 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . 0.821 ' CE1' HG11 ' A' ' 11' ' ' VAL . 0.0 OUTLIER -165.9 139.77 4.43 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.079 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.828 HD12 ' HG ' ' A' ' 79' ' ' LEU . 0.1 OUTLIER -108.31 154.69 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.868 -1.145 . . . . 0.0 108.777 -178.331 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.943 ' HB3' HG22 ' A' ' 9' ' ' THR . . . -133.87 123.43 24.73 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 120.693 -1.255 . . . . 0.0 112.732 -178.08 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 1.041 ' HB3' ' HD3' ' A' ' 30' ' ' PRO . . . 171.45 -69.22 0.0 OUTLIER Pre-proline 0 N--CA 1.496 1.874 0 O-C-N 121.399 -0.813 . . . . 0.0 109.305 177.659 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 1.041 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 34.4 Cg_endo -76.66 78.7 3.26 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 121.796 1.664 . . . . 0.0 109.486 179.198 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.709 ' HB2' ' HD3' ' A' ' 32' ' ' PRO . 6.0 mt -34.05 -53.82 0.86 Allowed Pre-proline 0 N--CA 1.504 2.251 0 O-C-N 121.944 -0.472 . . . . 0.0 111.703 -178.792 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' PRO . . . . . 0.709 ' HD3' ' HB2' ' A' ' 31' ' ' LEU . 36.8 Cg_endo -81.3 63.12 8.61 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 C-N-CA 122.077 1.851 . . . . 0.0 112.198 -179.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.918 HG23 ' O ' ' A' ' 30' ' ' PRO . 74.4 t -87.59 148.02 4.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 120.595 -1.316 . . . . 0.0 109.696 179.118 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 70.7 p -119.53 -35.82 3.47 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.422 -0.798 . . . . 0.0 109.665 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -155.13 144.37 21.04 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.461 -0.774 . . . . 0.0 109.007 179.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.929 HG23 ' HB3' ' A' ' 49' ' ' ALA . 0.5 OUTLIER -129.29 156.44 44.0 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.976 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.49 ' O ' HG23 ' A' ' 69' ' ' VAL . 49.1 mtp85 -119.51 101.06 7.67 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.31 -0.869 . . . . 0.0 109.044 179.82 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.783 ' CH2' ' HB3' ' A' ' 25' ' ' PHE . 30.3 m95 -89.24 178.77 6.27 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.123 -0.985 . . . . 0.0 109.476 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . 0.457 ' HA ' ' O ' ' A' ' 45' ' ' ALA . 0.2 OUTLIER -150.51 101.58 2.97 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 106.585 -1.635 . . . . 0.0 106.585 177.49 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 1.004 ' CE1' HG21 ' A' ' 47' ' ' VAL . 2.9 m-30 -79.75 -61.26 2.05 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.989 -177.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.77 15.86 47.68 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 -178.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.27 -104.52 0.27 Allowed 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 178.607 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.31 -20.28 59.09 Favored Glycine 0 C--N 1.296 -1.649 0 N-CA-C 107.708 -2.157 . . . . 0.0 107.708 177.028 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 m -132.58 127.59 35.35 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.432 -1.04 . . . . 0.0 109.304 179.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.457 ' O ' ' HA ' ' A' ' 39' ' ' ASP . . . -80.89 -85.96 0.09 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.17 -0.956 . . . . 0.0 109.72 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -57.73 153.37 13.69 Favored 'General case' 0 N--CA 1.495 1.816 0 CA-C-O 121.112 0.482 . . . . 0.0 109.71 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 1.004 HG21 ' CE1' ' A' ' 40' ' ' PHE . 57.7 t -140.16 124.12 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.384 -0.823 . . . . 0.0 111.1 -178.445 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -104.61 99.47 9.14 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.074 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.929 ' HB3' HG23 ' A' ' 36' ' ' THR . . . -109.91 167.8 9.9 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.203 -0.936 . . . . 0.0 111.02 -178.596 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -100.97 151.94 21.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.715 -0.615 . . . . 0.0 109.352 179.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.555 ' O ' HG22 ' A' ' 36' ' ' THR . . . 45.92 -155.2 0.58 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -89.06 41.63 0.57 Allowed 'Trans proline' 0 C--N 1.295 -2.255 0 C-N-CA 122.272 1.981 . . . . 0.0 110.515 178.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.652 ' O ' ' HB1' ' A' ' 49' ' ' ALA . . . -143.58 154.02 43.14 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 119.928 -1.733 . . . . 0.0 112.602 -178.716 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.434 ' HB3' ' CE2' ' A' ' 38' ' ' TRP . . . -166.56 -171.17 1.81 Allowed 'General case' 0 N--CA 1.496 1.831 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 179.074 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.646 ' HB3' HD11 ' A' ' 22' ' ' LEU . 0.3 OUTLIER -150.45 143.25 24.65 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.116 -0.99 . . . . 0.0 109.263 179.449 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . 0.629 ' NE2' HG22 ' A' ' 66' ' ' VAL . 7.3 m80 -102.41 134.64 45.4 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.197 -0.94 . . . . 0.0 111.515 -178.686 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.15 95.47 6.57 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.331 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 1.119 ' CE2' HG11 ' A' ' 83' ' ' VAL . 18.6 m-85 -102.58 112.84 25.77 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.079 -1.013 . . . . 0.0 109.403 -179.285 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 5.6 p -110.85 -10.56 11.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.417 -0.802 . . . . 0.0 111.525 -178.515 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.479 ' HG ' ' HD2' ' A' ' 61' ' ' PRO . 0.1 OUTLIER -114.73 146.14 35.4 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 120.478 -1.389 . . . . 0.0 109.673 -179.743 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.479 ' HD2' ' HG ' ' A' ' 60' ' ' LEU . 35.1 Cg_endo -77.06 122.85 6.41 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.403 2.069 . . . . 0.0 109.935 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 161.77 -157.05 28.73 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.251 -1.54 . . . . 0.0 109.251 -179.607 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.425 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -116.93 121.2 40.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.144 -1.21 . . . . 0.0 109.771 -179.824 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.6 ' CG ' ' CE1' ' A' ' 58' ' ' TYR . 90.3 m-85 -103.71 155.95 18.18 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.314 -0.867 . . . . 0.0 109.315 179.579 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 80.8 t60 -111.94 123.34 50.04 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.045 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.629 HG22 ' NE2' ' A' ' 56' ' ' HIS . 62.4 t -106.22 150.5 8.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.163 -0.961 . . . . 0.0 110.594 -178.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.53 159.56 44.2 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 178.664 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 1.06 ' HB3' ' HB2' ' A' ' 79' ' ' LEU . . . -151.09 154.52 37.13 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.939 -1.101 . . . . 0.0 110.921 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 37' ' ' ARG . 0.0 OUTLIER -144.75 104.3 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.102 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.821 ' HG ' ' HB3' ' A' ' 77' ' ' ALA . 0.1 OUTLIER -88.74 150.73 22.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.757 -1.215 . . . . 0.0 110.204 -178.663 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -128.99 116.16 18.91 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-O 121.826 0.822 . . . . 0.0 108.937 178.453 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.916 HD21 ' HB2' ' A' ' 30' ' ' PRO . 5.6 mp -104.36 -12.96 16.29 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-O 121.508 0.671 . . . . 0.0 109.212 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 116.74 -53.75 0.62 Allowed Glycine 0 N--CA 1.488 2.158 0 N-CA-C 108.135 -1.986 . . . . 0.0 108.135 -178.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -115.71 -5.33 12.13 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.584 -0.95 . . . . 0.0 109.777 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.43 161.4 26.95 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.419 ' HB2' ' O ' ' A' ' 70' ' ' LEU . 3.4 p -150.87 170.36 19.47 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.371 -1.076 . . . . 0.0 109.359 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.821 ' HB3' ' HG ' ' A' ' 70' ' ' LEU . . . -143.42 128.75 18.88 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.245 -0.91 . . . . 0.0 109.57 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.3 tp -95.11 140.79 29.55 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.471 -0.768 . . . . 0.0 110.029 -179.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 1.06 ' HB2' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -128.72 157.52 41.15 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.604 -0.685 . . . . 0.0 109.919 -179.464 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' A' ' 66' ' ' VAL . . . -164.88 86.48 0.1 Allowed Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 179.589 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.753 HG22 HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -104.34 -176.32 3.05 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.122 -1.222 . . . . 0.0 109.762 -179.854 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -150.76 147.53 27.42 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.119 HG11 ' CE2' ' A' ' 58' ' ' TYR . 0.4 OUTLIER -131.83 149.78 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.375 0 O-C-N 120.768 -1.208 . . . . 0.0 109.618 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -119.22 87.46 2.74 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.681 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.773 HG21 ' HB3' ' A' ' 58' ' ' TYR . 84.5 t -75.01 134.84 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.312 -0.867 . . . . 0.0 109.815 -179.55 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 -109.26 177.52 4.73 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.363 -0.835 . . . . 0.0 109.591 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.364 -0.835 . . . . 0.0 109.515 179.874 . . . . . . . . 0 0 . 1 stop_ save_